Classification of Acute Myeloid Leukemia Patent Application (2025)

U.S. patent application number 11/666648 was filed with the patent office on 2009-05-07 for classification of acute myeloid leukemia. This patent application is currently assigned to Roche Molecular Systems, Inc.. Invention is credited to Martin Dugas, Torsten Haferlach, Wolfgang Kern, Alexander Kohlmann, Susanne Schnittger, Claudia Schoch.

Classification of Acute Myeloid Leukemia

Abstract

The present invention relates to rapid and reliable approachesto leukemia prognostication. In addition to methods, the inventionalso provides related kits and systems.

 CLARK & ELBING LLP 101 FEDERAL STREET BOSTON MA 02110 US

Related U.S. Patent Documents

Claims

1. A method of classifying an acute myeloid leukemia (AML) cell,the method comprising: detecting an expression level of at leastone set of genes in or derived from at least one target AML cell;and, correlating a detected differential expression of one or moregenes selected from the markers listed in one or more of Tables1-13 relative to a corresponding expression of the genes in orderived from at least one reference AML cell having a reciprocaltranslocation with the target AML cell having a CEBPA mutation;correlating a detected substantially identical expression of one ormore genes selected from the markers listed in one or more ofTables 1-13 relative to a corresponding expression of the genes inor derived from at least one reference AML cell having a CEBPAmutation with the target AML cell having the CEBPA mutation;correlating a detected differential expression of one or more genesselected from the markers listed in one or more of Tables 1-13relative to a corresponding expression of the genes in or derivedfrom at least one reference AML cell having a CEBPA mutation withthe target AML cell having a reciprocal translocation; or,correlating a detected substantially identical expression of one ormore genes selected from the markers listed in one or more ofTables 1-13 relative to a corresponding expression of the genes inor derived from at least one reference AML cell having a reciprocaltranslocation with the target AML cell having the reciprocaltranslocation, thereby classifying the AML cell.

2. The method of claim 1, wherein the target AML cell comprises anintermediate karyotype.

3. The method of claim 1, wherein the detected differential orsubstantially identical expression expression comprises one or moreof the markers listed in Table 3 and/or Table 4 when the reciprocaltranslocation comprises a t(11q23).

4. The method of claim 1, wherein the detected differential orsubstantially identical expression expression comprises one or moreof the markers listed in Table 5 and/or Table 6 when the reciprocaltranslocation comprises an inv(16).

5. The method of claim 1, wherein the detected differential orsubstantially identical expression expression comprises one or moreof the markers listed in Table 7 and/or Table 8 when the reciprocaltranslocation comprises an inv(3).

6. The method of claim 1, wherein the detected differential orsubstantially identical expression expression comprises one or moreof the markers listed in Table 9 and/or Table 10 when thereciprocal translocation comprises a t(8;21).

7. The method of claim 1, wherein the detected differential orsubstantially identical expression expression comprises one or moreof the markers listed in Table 11 and/or Table 12 when thereciprocal translocation comprises a t(15;17).

8. The method of claim 1, comprising: correlating a detected higherexpression of an MPO gene from the target AML cell having a CEBPAmutation, and/or a detected lower expression of one or more of: aHOXA3 gene, a HOXA7 gene, a HOXA9 gene, a HOXB4 gene, a HOXB6 gene,or a PBX3 gene from the target AML cell having the CEBPA mutation,relative to at least one reference AML cell lacking the CEBPAmutation with the target AML being a group A AML cell; or,correlating a detected lower expression of an MPO gene from thetarget AML cell having a CEBPA mutation, and/or a detected higherexpression of one or more of: a HOXA3 gene, a HOXA7 gene, a HOXA9gene, a HOXB4 gene, a HOXB6 gene, and a PBX3 gene from the targetAML cell having the CEBPA mutation, relative to at least onereference AML cell lacking the CEBPA mutation with the target AMLbeing a group B AML cell.

9. The method of claim 1, wherein the set of genes in or derivedfrom the target AML cell comprises at least about 10, 100, 1000,10000, or more members.

10. The method of claim 1, wherein the target AML cell is obtainedfrom a subject.

11. The method of claim 1, wherein the detected differentialexpression of the genes comprises at least about a 5%difference.

12. The method of claim 1, wherein the detected substantiallyidentical expression of the genes comprises less than about a 5%difference.

13. The method of claim 1, wherein the expression level is detectedusing an array, a robotics system, and/or a microfluidicdevice.

14. The method of claim 1, wherein the expression level of the setof genes is detected by amplifying nucleic acid sequencesassociated with the genes to produce amplicons and detecting theamplicons.

15. The method of claim 14, wherein the amplicons are detectedusing a process that comprises one or more of: hybridizing theamplicons to an oligonucleotide array, digesting the amplicons witha restriction enzyme, or real-time polymerase chain reaction (PCR)analysis.

16. The method of claim 1, wherein detecting the expression levelof the set of genes comprises measuring quantities of transcribedpolynucleotides or portions thereof expressed or derived from thegenes.

17. The method of claim 16, wherein the transcribed polynucleotidesare mRNAs or cDNAs.

18. The method of claim 1, wherein detecting the expression levelcomprises contacting polynucleotides or polypeptides expressed fromthe genes with compounds that specifically bind the polynucleotidesor polypeptides.

19. The method of claim 18, wherein the compounds compriseaptamers, antibodies or fragments thereof.

20. A method of producing a reference data bank for classifying AMLcells, the method comprising: (a) compiling a gene expressionprofile of a patient sample by detecting the expression level ofone or more genes of at least one AML cell, which genes areselected from the markers listed in one or more of Tables 1-13,and; (b) classifying the gene expression profile using a machinelearning algorithm.

21. The reference data bank produced by the method of claim 20.

22. A kit, comprising: one or more probes that correspond to atleast portions of genes or expression products thereof, which genesare selected from the markers listed in one or more of Tables 1-13;and, instructions for correlating detected expression levels ofpolynucleotides and/or polypeptides in at least one target cellfrom a subject, which polynucleotides and/or polypeptides aretargets of one or more of the probes, with the target cell being anAML cell having a CEBPA mutation or a reciprocal translocation.

23. The kit of claim 22, wherein at least one solid supportcomprises the probes.

24. The kit of claim 22, comprising one or more additional reagentsto perform real-time PCR analyses.

25. A system, comprising: one or more probes that correspond to atleast portions of genes or expression products thereof, which genesare selected from the markers listed in one or more of Tables 1-17;and, at least one reference data bank for correlating detectedexpression levels of polynucleotides and/or polypeptides in atleast one target cell from a subject, which polynucleotides and/orpolypeptides are targets of one or more of the probes, with thetarget cell being an AML cell having a CEBPA mutation or areciprocal translocation.

26. The system of claim 25, wherein at least one solid supportcomprises the probes.

27. The system of claim 25, comprising one or more additionalreagents and/or components to perform real-time PCR analyses.

28. The system of claim 25, wherein the reference data bank isproduced by: (a) compiling a gene expression profile of a patientsample by determining the expression level at least one of thegenes, and (b) classifying the gene expression profile using amachine learning algorithm.

29. The system of claim 28, wherein the machine learning algorithmis selected from the group consisting of: a weighted votingalgorithm, a K-nearest neighbors algorithm, a decision treeinduction algorithm, a support vector machine, and a feed-forwardneural network.

30. A method of aiding in a leukemia prognosis for a subject, themethod comprising: detecting an expression level of at least oneset of genes in or derived from at least one target acute myeloidleukemia (AML) cell from the subject; and, correlating a detected ahigher expression of an MPO gene and/or an ATBF1 gene in the targetAML cell relative to a corresponding expression of the genes in orderived from an AML cell from a member of an unfavorable group withthe subject having a probable overall survival rate at three yearsof about 55% or more; or, correlating a detected a higherexpression of one or more of: an ETS2 gene, a RUNX1 gene, a TCF4gene, a FOXC1 gene, a SFRS1 gene, a TPD52 gene, a NRIP1 gene, aTFPI gene, a UBL1 gene, an REC8L1 gene, an HSF2 gene, or an ETS2gene in the target AML cell relative to a corresponding expressionof the genes in or derived from an AML cell from a member of afavorable group with the subject having a probable overall survivalrate at three years of about 25% or less, thereby aiding in theleukemia prognosis for the subject.

31-41. (canceled)

42. A method of producing a reference data bank for aiding inleukemia prognostication, the method comprising: (a) compiling agene expression profile of a patient sample by determining theexpression level at least one marker selected from: an MPO marker,an ATBF1 marker, an ETS2 marker, a RUNX1 marker, a TCF4 marker, aFOXC1 marker, a SFRS1 marker, a TPD52 marker, a NRIP1 marker, aTFPI marker, a UBL1 marker, an REC8L1 marker, an HSF2 marker, andan ETS2 marker, and; (b) classifying the gene expression profileusing a machine learning algorithm.

43. The reference data bank produced by the method of claim 42.

44. A kit, comprising: one or more markers or portions thereofselected from the group consisting of: an MPO marker, an ATBF1marker, an ETS2 marker, a RUNX1 marker, a TCF4 marker, a FOXC1marker, a SFRS1 marker, a TPD52 marker, a NRIP1 marker, a TFPImarker, a UBL1 marker, an REC8L1 marker, an HSF2 marker, and anETS2 marker; and, instructions for correlating detected expressionlevels of polynucleotides and/or polypeptides in at least onetarget AML cell from a subject, which polynucleotides and/orpolypeptides correspond to one or more of the markers, with aprobable overall survival rate for the subject.

45-48. (canceled)

49. A system, comprising: one or more markers or portions thereofselected from the group consisting of: an MPO marker, an ATBF1marker, an ETS2 marker, a RUNX1 marker, a TCF4 marker, a FOXC1marker, a SFRS1 marker, a TPD52 marker, a NRIP1 marker, a TFPImarker, a UBL1 marker, an REC8L1 marker, an HSF2 marker, and anETS2 marker; and, at least one reference data bank for correlatingdetected expression levels of polynucleotides and/or polypeptidesin target AML cells, which polynucleotides and/or polypeptidescorrespond to one or more of the markers, with a probable overallsurvival rate for a subject.

50-51. (canceled)

52. A method of detecting acute myeloid leukemia (AML) witht(8;16), the method comprising: detecting an expression level of atleast one set of genes in or derived from at least one target AMLcell; and, correlating a detected differential expression of one ormore genes of the target AML cell relative to a correspondingexpression of the genes in or derived from a reference AML cellwith t(15;17), t(8;21), inv(16), or 11q23/MLL with the target AMLcell being a target AML cell with t(8;16); or, correlating adetected substantially identical expression of one or more genes ofthe target AML cell relative to a corresponding expression of thegenes in or derived from a reference AML cell with t(8;16) with thetarget AML cell being a target AML cell with t(8;16), therebydetecting AML with t(8;16).

53-66. (canceled)

67. A method of producing a reference data bank for identifying AMLcells with t(8;16), the method comprising: (a) compiling a geneexpression profile of a patient sample by determining theexpression level of one or more genes of at least one AML cell,which genes are selected from the markers listed in Table 18, and;(b) classifying the gene expression profile using a machinelearning algorithm.

68. The reference data bank produced by the method of claim 67.

69. A kit, comprising: one or more probes that correspond to atleast portions of genes or expression products thereof, which genesare selected from the markers listed in Table 18; and, instructionsfor correlating detected expression levels of polynucleotidesand/or polypeptides in at least one target AML cell from a humansubject, which polynucleotides and/or polypeptides are targets ofone or more of the probes, with the target AML cell comprisingt(8;16).

70-71. (canceled)

72. A system, comprising: one or more probes that correspond to atleast portions of genes or expression products thereof, which genesare selected from the markers listed in Table 18; and, at least onereference data bank for correlating detected expression levels ofpolynucleotides and/or polypeptides in target human AML cells,which polynucleotides and/or polypeptides are targets of one ormore of the probes, with the target AML cells comprisingt(8;16).

73-76. (canceled)

77. A method of identifying an acute myeloid leukemia (AML) cellcomprising trisomy 8, the method comprising: (a) detecting anexpression level of at least one set of genes in or derived from atleast one target human AML cell; and, (b) correlating a detecteddifferential expression of one or more genes of the target humanAML cell relative to a corresponding expression of the genes in orderived from a human AML cell lacking trisomy 8 with the targethuman AML cell comprising trisomy 8; or, (c) correlating a detectedsubstantially identical expression of one or more genes of thetarget human AML cell relative to a corresponding expression of thegenes in or derived from a human AML cell comprising trisomy 8 withthe target human AML cell comprising trisomy 8, thereby identifyingthe AML cell comprising trisomy 8.

78-85. (canceled)

86. A method of classifying a cell, the method comprising:detecting an expression level of at least one set of genes in orderived from at least one target cell; and, correlating a detecteddifferential expression of one or more genes of the target cellrelative to a corresponding expression of the genes in or derivedfrom an acute myeloid leukemia (AML) cell with the target cellbeing a myelodysplastic syndrome (MDS) cell; or correlating adetected substantially identical expression of one or more genes ofthe target cell relative to a corresponding expression of the genesin or derived from an AML cell with the target cell being an AMLcell; or correlating a detected differential expression of one ormore genes of the target cell relative to a correspondingexpression of the genes in or derived from an MDS cell with thetarget cell being an AML cell; or correlating a detectedsubstantially identical expression of one or more genes of thetarget cell relative to a corresponding expression of the genes inor derived from an MDS cell with the target cell being an MDS cell,thereby classifying the cell.

87-97. (canceled)

98. A method of subclassifying an acute myeloid leukemia-normalkaryotype (AML-NK) cell, the method comprising: detecting anexpression level of at least one set of genes in or derived from atleast one target AML-NK cell; and, correlating: a detected higherexpression of one or more genes selected from the group listed inTable 38 and/or a detected lower expression of one or more genesselected from the group listed in Table 39 of the target AML-NKcell relative to a corresponding expression of the genes in orderived from a Group B AML-NK cell with the target AML-NK cellbeing a Group A AML-NK cell; or a detected lower expression of oneor more genes selected from the group listed in Table 38 and/or adetected higher expression of one or more genes selected from thegroup listed in Table 39 of the target AML-NK cell relative to acorresponding expression of the genes in or derived from a Group AAML-NK cell with the target AML-NK cell being a Group B AML-NKcell, thereby subclassifying the AML-NK cell.

99. A method of identifying a cell with a 5q deletion ((del)5q),the method comprising: detecting an expression level of at leastone set of genes in or derived from at least one target human cell;and, correlating a detected differential expression of one or moregenes of at least chromosome 5 of the target human cell relative toa corresponding expression of the genes in or derived from a humancell lacking a (del)5q with the target human cell comprising a(del).sub.5q; or, correlating a detected substantially identicalexpression of one or more genes of at least chromosome 5 of thetarget human cell relative to a corresponding expression of thegenes in or derived from a human cell having a (del)5q with thetarget human cell comprising a (del)5q, thereby identifying thecell with the (del)5q.

100-105. (canceled)

Description

FIELD OF THE INVENTION

[0001] The present invention relates to the detection of leukemiaand accordingly, provides diagnostic and/or prognostic informationin certain embodiments.

BACKGROUND OF THE INVENTION

[0002] Leukemias are generally classified into four differentgroups or types: acute myeloid (AML), acute lymphatic (ALL),chronic myeloid (CML) and chronic lymphatic leukemia (CLL). Withinthese groups, several subcategories or subtypes can be identifiedusing various approaches. These different subcategories of leukemiaare associated with varying clinical outcomes and therefore canserve as guides to the selection of different treatment strategies.The importance of highly specific classification may be illustratedfor AML as a very heterogeneous group of diseases. Effort has beenaimed at identifying biological entities and to distinguish andclassify subgroups of AML that are associated with, e.g.,favorable, intermediate or unfavorable prognoses. In 1976, forexample, the FAB classification was proposed by theFrench-American-British co-operative group that utilizescytomorphology and cytochemistry to separate AML subgroupsaccording to the morphological appearance of blasts in the bloodand bone marrow. In addition, genetic abnormalities occurring inleukemic blasts were recognized as having a major impact on themorphological picture and on prognosis. As a consequence, thekaryotype of leukemic blasts is commonly used as an independentprognostic factor regarding response to therapy as well assurvival.

[0003] A combination of methods is typically used to obtain thediagnostic information in leukemia. To illustrate, the analysis ofthe morphology and cytochemistry of bone marrow blasts andperipheral blood cells is commonly used to establish a diagnosis.In some cases, for example, immunophenotyping is also utilized toseparate an undifferentiated AML from acute lymphoblastic leukemiaand from CLL. In certain instances, leukemia subtypes can bediagnosed by cytomorphology alone, but this typically requires thatan expert review sample smears. However, genetic analysis based on,e.g., chromosome analysis, fluorescence in situ hybridization(FISH), or reverse transcription PCR (RT-PCR) and immunophenotypingis also generally used to accurately assign cases to the correctcategory. An aim of these techniques, aside from diagnosis, is todetermine the prognosis of the leukemia under consideration. Onedisadvantage of these methods, however, is that viable cells aregenerally necessary, as the cells used for genetic analysis need todivide in vitro in order to obtain metaphases for the analysis.Another exemplary problem is the long lag period (e.g., 72 hours)that typically occurs between the receipt of the materials to beanalyzed in the laboratory and the generation of results.Furthermore, great experience in preparing chromosomes andanalyzing karyotypes is generally needed to obtain correct resultsin most cases. Using these techniques in combination, hematologicalmalignancies can be separated into CML, CLL, ALL, and AML. Withinthe latter three disease entities, several prognostically relevantsubtypes have been identified. This further sub-classificationcommonly relies on genetic abnormalities of leukemic blasts and isassociated with different prognoses.

[0004] The sub-classification of leukemias is used increasingly asa guide to the selection of appropriate therapies. The developmentof new, specific drugs and treatment approaches often includes theidentification of specific subtypes that may benefit from adistinct therapeutic protocol and thus, improve the outcomes ofdistinct subsets of leukemia. For example, the therapeutic drug(STI571) inhibits the CML specific chimeric tyrosine kinase BCR-ABLgenerated from the genetic defect observed in CML, theBCR-ABL-rearrangement due to the translocation between chromosomes9 and 22 (t(9;22) (q34;q11)). In patients treated with this newdrug, the therapy response is dramatically higher as compared toother drugs that have previously been used. Another example is asubtype of acute myeloid leukemia, AML M3 and its variant M3v,which both include the karyotype t(15;17)(q22;q11-12). Theintroduction of all-trans retinoic acid (ATRA) has improved theoutcome in this subgroup of patient from about 50% to 85% long-termsurvivors. Accordingly, the rapid and accurate identification ofdistinct leukemia subtypes is of consequence to further drugdevelopment in addition to diagnostics and prognostics.

[0005] According to Golub et al. (Science, 1999, 286, 531-7, whichis incorporated by reference), gene expression profiles can be usedfor class prediction and discriminating AML from ALL samples.However, for the analysis of acute leukemias the selection of thetwo different subgroups was performed using exclusivelymorphologic-phenotypical criteria. This was only descriptive anddid not provide deeper insights into the pathogenesis or theunderlying biology of the leukemia. The approach reproduces onlyvery basic knowledge of cytomorphology and intends to differentiateclasses. However, the data generated via such an approach isgenerally not sufficient to predict prognostically relevantcytogenetic aberrations.

SUMMARY OF THE INVENTION

[0006] The present invention relates to rapid, cost effective, andreliable approaches to detecting and classifying leukemia. Asidefrom providing diagnostic information to patients, theseclassifications can also assist in selecting appropriate therapiesand in prognostication. In some embodiments, these methods includeprofiling the expression of selected populations of genes usingreal-time PCR analysis, oligonucleotide arrays, or the like. Inaddition to methods, the invention also provides, e.g., relatedkits and systems.

[0007] In one aspect, the invention provides a method ofclassifying an acute myeloid leukemia (AML) cell. The methodincludes detecting an expression level of at least one set of genesin or derived from at least one target AML cell. In someembodiments, the target AML cell comprises an intermediatekaryotype. The set of genes in or derived from the target AML cellgenerally comprises at least about 10, 1100, 1000, 10000, or moremembers. Typically, the target AML cell is obtained from a subject.The method also includes correlating a detected differentialexpression of one or more genes selected from the markers listed inone or more of Tables 1-13 relative to a corresponding expressionof the genes in or derived from at least one reference AML cellhaving a reciprocal translocation (e.g., a t(15;17), t(8;21),inv(16), t(11q23), inv(3), etc.) with the target AML cell having aCEBPA mutation; correlating a detected substantially identicalexpression of one or more genes selected from the markers listed inone or more of Tables 1-13 relative to a corresponding expressionof the genes in or derived from at least one reference AML cellhaving a CEBPA mutation with the target AML cell having the CEBPAmutation; correlating a detected differential expression of one ormore genes selected from the markers listed in one or more ofTables 1-13 relative to a corresponding expression of the genes inor derived from at least one reference AML cell having a CEBPAmutation with the target AML cell having a reciprocaltranslocation; or correlating a detected substantially identicalexpression of one or more genes selected from the markers listed inone or more of Tables 1-13 relative to a corresponding expressionof the genes in or derived from at least one reference AML cellhaving a reciprocal translocation with the target AML cell havingthe reciprocal translocation, thereby classifying the AML cell. Incertain embodiments, the detected differential expression of thegenes comprises at least about a 5% difference, whereas thedetected substantially identical expression of the genes comprisesless than about a 5% difference.

[0008] In some embodiments, the method also includes correlating adetected differential expression of one or more genes of the targetAML cell relative to a corresponding expression of the genes in orderived from a reference AML cell with t(15;17), t(8;21), inv(16),or 11q23/MLL with the target AML cell being a target AML cell witht(8;16); or correlating a detected substantially identicalexpression of one or more genes of the target AML cell relative toa corresponding expression of the genes in or derived from areference AML cell with t(8;16) with the target AML cell being atarget AML cell with t(8;16), thereby detecting AML with t(8;16).In some embodiments, the detected differential or substantiallyidentical expression comprises one or more markers selected fromTable 1. In certain embodiments, the expression level comprises ahigher expression of one or more markers selected from the groupconsisting of: a BCOR gene, a COXB5 gene, a CDK10 gene, a FLI1gene, a HNRPA2B1 gene, a NSEP1 gene, a PDIP38 gene, a RAD50 gene, aSUPT5H gene, a TLR2 gene, a USP33 gene, a CEBP beta gene, a DDB2gene, a HIST1H3D gene, a NSAP1 gene, a PTPNS1 gene, a RAN gene, aUSP4 gene, a TRIM8 gene, and a ZNF278 gene in the target AML cellrelative to a corresponding expression of the genes in or derivedfrom the reference AML cell with t(15;17), t(8;21), inv(16), or11q23/MLL. In certain embodiments, the expression level comprises alower expression of one or more markers selected from the groupconsisting of: an ERG gene, a GATA2 gene, a NCOR2 gene, an RPS20gene, a KIT gene, and an MBD2 gene in the target AML cell relativeto a corresponding expression of the genes in or derived from thereference AML cell with t(15;17), t(8;21), inv(16), or 11q23/MLL.Typically, the detected differential expression of the genescomprises at least about a 5% difference, whereas the detectedsubstantially identical expression of the genes comprises less thanabout a 5% difference.

[0009] To further illustrate, the detected differential orsubstantially identical expression expression comprises one or moreof the markers listed in Table 3 and/or Table 4 when the reciprocaltranslocation comprises a t(11q23) in certain embodiments. In someembodiments, the detected differential or substantially identicalexpression expression comprises one or more of the markers listedin Table 5 and/or Table 6 when the reciprocal translocationcomprises an inv(16). In certain embodiments, the detecteddifferential or substantially identical expression expressioncomprises one or more of the markers listed in Table 7 and/or Table8 when the reciprocal translocation comprises an inv(3). In someembodiments, the detected differential or substantially identicalexpression expression comprises one or more of the markers listedin Table 9 and/or Table 10 when the reciprocal translocationcomprises a t(8;21). In certain embodiments, the detecteddifferential or substantially identical expression expressioncomprises one or more of the markers listed in Table 11 and/orTable 12 when the reciprocal translocation comprises at(15;17).

[0010] In some embodiments, the method includes further classifyingtwo different subgroups of CEBPA mutations (group A and group B).Group A is defined as having mutations in the TAD2 domain of CEBPAand a high percentage of FLT3-LM in addition. In contrast, group Bhas mutations that lead to an N-terminal stop mutation and has onlya low percentage of FLT3-LM. Accordingly, in some embodiments, themethod includes correlating a detected higher expression of an MPOgene from the target AML cell having a CEBPA mutation, and/or adetected lower expression of one or more of: a HOXA3 gene, a HOXA7gene, a HOXA9 gene, a HOXB4 gene, a HOXB6 gene, or a PBX3 gene fromthe target AML cell having the CEBPA mutation, relative to at leastone reference AML cell lacking the CEBPA mutation with the targetAML being a Group A AML cell; or correlating a detected lowerexpression of an MPO gene from the target AML cell having a CEBPAmutation, and/or a detected higher expression of one or more of: aHOXA3 gene, a HOXA7 gene, a HOXA9 gene, a HOXB4 gene, a HOXB6 gene,and a PBX3 gene from the target AML cell having the CEBPA mutation,relative to at least one reference AML cell lacking the CEBPAmutation with the target AML being a Group B AML cell (see, TABLE2).

[0011] Expression levels are detected using essentially any geneexpression profiling technique. In some embodiments, for example,the expression level is detected using an array, a robotics system,and/or a microfluidic device. In certain embodiments, theexpression level of the set of genes is detected by amplifyingnucleic acid sequences associated with the genes to produceamplicons and detecting the amplicons. In these embodiments, theamplicons are generally detected using a process that comprises oneor more of: hybridizing the amplicons to an oligonucleotide array,digesting the amplicons with a restriction enzyme, or real-timepolymerase chain reaction (PCR) analysis. In certain embodiments,the expression level of the set of genes is detected by, e.g.,measuring quantities of transcribed polynucleotides (e.g., mRNAs,cDNAs, etc.) or portions thereof expressed or derived from thegenes. In some embodiments, the expression level is detected by,e.g., contacting polynucleotides or polypeptides expressed from thegenes with compounds (e.g., aptamers, antibodies or fragmentsthereof, etc.) that specifically bind the polynucleotides orpolypeptides.

[0012] Essentially any method of detecting the mutational status ofthe genes is optionally utilized. In some embodiments, for example,the mutational status is detected by sequencing the genes. Tofurther illustrate, the mutational status is optionally detected byamplifying nucleic acid sequences associated with the genes toproduce amplicons and detecting the amplicons. In theseembodiments, the amplicons are generally detected using a processthat comprises one or more of, e.g., hybridizing the amplicons toan oligonucleotide array, digesting the amplicons with arestriction enzyme, real-time polymerase chain reaction (PCR)analysis, or the like.

[0013] In another aspect, the invention provides a method ofproducing a reference data bank for classifying AML cells. Themethod includes (a) compiling a gene expression profile of apatient sample by detecting the expression level of one or moregenes of at least one AML cell, which genes are selected from themarkers listed in one or more of Tables 1-42, and (b) classifyingthe gene expression profile using a machine learning algorithm.

[0014] In another aspect, the invention provides a kit thatincludes one or more probes that correspond to at least portions ofgenes or expression products thereof, which genes are selected fromthe markers listed in one or more of Tables 1-42. In someembodiments, at least one solid support comprises the probes.Optionally, the kit also includes one or more additional reagentsto perform real-time PCR analyses. In addition, the kit alsoincludes instructions for correlating detected expression levels ofpolynucleotides and/or polypeptides in at least one target cellfrom a subject, which polynucleotides and/or polypeptides aretargets of one or more of the probes, with the target cell being anAML cell having a CEBPA mutation or a reciprocal translocation.

[0015] In another aspect, the invention provides a system thatincludes one or more probes that correspond to at least portions ofgenes or expression products thereof, which genes are selected fromthe markers listed in one or more of Tables 1-42. In someembodiments, at least one solid support comprises the probes. Incertain embodiments, the system includes one or more additionalreagents and/or components to perform real-time PCR analyses. Thesystem also includes at least one reference data bank forcorrelating detected expression levels of polynucleotides and/orpolypeptides in at least one target cell from a subject, whichpolynucleotides and/or polypeptides are targets of one or more ofthe probes, with the target cell being an AML cell having a CEBPAmutation or a reciprocal translocation. The reference data bank isgenerally produced by, e.g., (a) compiling a gene expressionprofile of a patient sample by detecting the expression level atleast one of the genes, and (b) classifying the gene expressionprofile using a machine learning algorithm. The machine learningalgorithm is generally selected from, e.g., a weighted votingalgorithm, a K-nearest neighbors algorithm, a decision treeinduction algorithm, a support vector machine, a feed-forwardneural network, etc.

[0016] In one aspect, the invention provides a method of aiding ina leukemia prognosis for a subject. The method includes detectingan expression level of at least one set of genes in or derived fromat least one target acute myeloid leukemia (AML) cell from thesubject. In some embodiments, the set of genes is selected from oneor more of: Tables 15-17. The method also includes correlating adetected a higher expression of an MPO gene and/or an ATBF1 gene inthe target AML cell relative to a corresponding expression of thegenes in or derived from an AML cell from a member of anunfavorable group with the subject having a probable overallsurvival rate at three years of about 55% or more; or correlating adetected a higher expression of one or more of: an ETS2 gene, aRUNX1 gene, a TCF4 gene, a FOXC1 gene, a SFRS1 gene, a TPD52 gene,a NRIP1 gene, a TFPI gene, a UBL1 gene, an REC8L1 gene, an HSF2gene, or an ETS2 gene in the target AML cell relative to acorresponding expression of the genes in or derived from an AMLcell from a member of a favorable group with the subject having aprobable overall survival rate at three years of about 25% or less,thereby aiding in the leukemia prognosis for the subject.Typically, the higher expression of the genes in the target AMLcell is at least 5% greater than the corresponding expression ofthe genes in or derived from the AML cell from the member of theunfavorable group or the favorable group. The unfavorable groupgenerally comprises a probable overall survival rate at three yearsof about 25% or less, whereas the favorable group typicallycomprises a probable overall survival rate at three years of about55% or more.

[0017] In another aspect, the invention provides a method ofproducing a reference data bank for aiding in leukemiaprognostication. The method includes (a) compiling a geneexpression profile of a patient sample by determining theexpression level at least one marker selected from: an MPO marker,an ATBF1 marker, an ETS2 marker, a RUNX1 marker, a TCF4 marker, aFOXC1 marker, a SFRS1 marker, a TPD52 marker, a NRIP1 marker, aTFPI marker, a UBL1 marker, an REC8L1 marker, an HSF2 marker, andan ETS2 marker. The method also includes (b) classifying the geneexpression profile using a machine learning algorithm.

[0018] In one aspect, the invention provides a method ofidentifying an acute myeloid leukemia (AML) cell comprising trisomy8. The method includes (a) detecting an expression level of atleast one set of genes in or derived from at least one target humanAML cell. The target human AML cell is generally obtained from asubject. In some embodiments, the set of genes in or derived fromthe target human AML cell comprises at least about 10, 100, 1000,10000, or more members. The method also includes (b) correlating adetected differential expression of one or more genes of chromosome8 of the target human AML cell relative to a correspondingexpression of the genes in or derived from a human AML cell lackingtrisomy 8 with the target human AML cell comprising trisomy 8; or(c) correlating a detected substantially identical expression ofone or more genes of the target human AML cell relative to acorresponding expression of the genes in or derived from a humanAML cell comprising trisomy 8 with the target human AML cellcomprising trisomy 8, thereby identifying the AML cell comprisingtrisomy 8. Typically, the human AML cell lacking trisomy 8comprises one or more of: a normal karyotype, a complex aberrantkaryotype, t(15;17), inv(16), t(8;21), 11q23/MLL, or anotherabnormality. In certain embodiments, the detected differentialexpression of the genes comprises a higher mean expression of asubstantial number of the genes of chromosome 8 of the target humanAML cell relative to the corresponding expression of the genes inor derived from the human AML cell lacking trisomy 8. Typically,the detected differential expression of the genes comprises atleast about a 5% difference, whereas the detected substantiallyidentical expression of the genes comprises less than about a 5%difference.

[0019] The methods described herein include detecting theexpression levels various sets of genes. In some embodiments, forexample, the detected differential or substantially identicalexpression comprises one or more markers selected from Table 19. Insome embodiments, the human AML cell lacking trisomy 8 comprisest(8;21) and the detected differential or substantially identicalexpression comprises one or more markers selected from Table 21. Incertain embodiments, the human AML cell lacking trisomy 8 comprisest(15;17) and the detected differential or substantially identicalexpression comprises one or more markers selected from Table 23. Insome embodiments, the human AML cell lacking trisomy 8 comprisesinv(16) and the detected differential or substantially identicalexpression comprises one or more markers selected from Table 25. Incertain embodiments, the human AML cell lacking trisomy 8 comprises11q23/MLL and the detected differential or substantially identicalexpression comprises one or more markers selected from Table 27. Insome embodiments, the human AML cell lacking trisomy 8 comprises anormal karyotype and the detected differential or substantiallyidentical expression comprises one or more markers selected fromTable 29. In certain embodiments, the human AML cell lackingtrisomy 8 comprises at least one other abnormality and the detecteddifferential or substantially identical expression comprises one ormore markers selected from Table 31. In certain embodiments, thehuman AML cell lacking trisomy 8 comprises a complex aberrantkaryotype and the detected differential or substantially identicalexpression comprises one or more markers selected from Table33.

[0020] To further illustrate, (b) comprises correlating a detecteddifferential expression of one or more genes of chromosome 8 of thetarget human AML cell relative to the corresponding expression ofthe genes in or derived from the human AML cell lacking trisomy 8with the target human AML cell comprising trisomy 8, and (c)comprises correlating a detected substantially identical expressionof one or more genes of chromosome 8 of the target human AML cellrelative to a corresponding expression of the genes in or derivedfrom a human AML cell comprising trisomy 8 with the target humanAML cell comprising trisomy 8 in certain embodiments. In some ofthese embodiments, the detected differential or substantiallyidentical expression comprises one or more markers selected fromTable 20. In certain of these embodiments, the human AML celllacking trisomy 8 comprises t(8;21) and the detected differentialor substantially identical expression comprises one or more markersselected from Table 22. In some of these embodiments, the human AMLcell lacking trisomy 8 comprises t(15;17) and the detecteddifferential or substantially identical expression comprises one ormore markers selected from Table 24. In certain of theseembodiments, the human AML cell lacking trisomy 8 comprises inv(16)and the detected differential or substantially identical expressioncomprises one or more markers selected from Table 26. In some ofthese embodiments, the human AML cell lacking trisomy 8 comprises11q23/MLL and the detected differential or substantially identicalexpression comprises one or more markers selected from Table 28. Incertain of these embodiments, wherein the human AML cell lackingtrisomy 8 comprises a normal karyotype and the detecteddifferential or substantially identical expression comprises one ormore markers selected from Table 30. In some of these embodiments,the human AML cell lacking trisomy 8 comprises at least one otherabnormality and the detected differential or substantiallyidentical expression comprises one or more markers selected fromTable 32. In certain of these embodiments, the human AML celllacking trisomy 8 comprises a complex aberrant karyotype and thedetected differential or substantially identical expressioncomprises one or more markers selected from Table 34.

[0021] In another aspect, the invention provides a kit thatincludes one or more markers or portions thereof selected from thegroup consisting of: an MPO marker, an ATBF1 marker, an ETS2marker, a RUNX1 marker, a TCF4 marker, a FOXC1 marker, a SFRS1marker, a TPD52 marker, a NRIP1 marker, a TFPI marker, a UBL1marker, an REC8L1 marker, an HSF2 marker, and an ETS2 marker. Insome embodiments, at least one solid support comprises the markersor the portions thereof. In certain embodiments, the kit includesone or more additional reagents to perform real-time PCR analyses.The kit also includes instructions for correlating detectedexpression levels of polynucleotides and/or polypeptides in atleast one target AML cell from a subject, which polynucleotidesand/or polypeptides correspond to one or more of the markers, witha probable overall survival rate for the subject. Optionally, thekit includes a reference (e.g., a sample, a data bank, etc.)corresponding to a favorable group and/or an unfavorable group.

[0022] In another aspect, the invention provides a system thatincludes one or more markers or portions thereof selected from thegroup consisting of: an MPO marker, an ATBF1 marker, an ETS2marker, a RUNX1 marker, a TCF4 marker, a FOXC1 marker, a SFRS1marker, a TPD52 marker, a NRIP1 marker, a TFPI marker, a UBL1marker, an REC8L1 marker, an HSF2 marker, and an ETS2 marker.

[0023] In some embodiments, the detected differential expression ofthe genes comprises a higher expression (e.g., positive foldchange, etc.) of a FLT3 gene of the target cell relative to thecorresponding expression of the FLT3 gene in or derived from theMDS cell. In certain embodiments, the detected differentialexpression of the genes comprises a lower expression (e.g.,negative fold change, etc.) of a FLT3 gene of the target cellrelative to the corresponding expression of the FLT3 gene in orderived from the AML cell. In some embodiments, the detectedsubstantially identical expression of the genes comprises asubstantially identical expression of a FLT3 gene of the targetcell relative to the corresponding expression of the FLT3 gene inor derived from the AML cell. See, e.g., Table 35, where the rvalues refer to MDS and AML blasts in comparison to percentage;e.g., most genes exhibit higher expression in MDS, but FTL3 isexpressed higher in AML.

[0024] In certain embodiments, the detected differential expressionof the genes comprises a higher expression of one or more of:ANXA3, ARG1, CAMP, CD24, CEACAM1, CEACAM6, CEACAM8, CRISP3,KIAA0922, LCN2, MMP9, or, STOM of the target cell relative to thecorresponding expression of the genes in or derived from the AMLcell. In some embodiments, the detected differential expression ofthe genes comprises a lower expression of one or more of: ANXA3,ARG1, CAMP, CD24, CEACAM1, CEACAM6, CEACAM8, CRISP3, KIAA0922,LCN2, MMP9, or STOM of the target cell relative to thecorresponding expression of the genes in or derived from the MDScell. In certain embodiments, the detected substantially identicalexpression of the genes comprises a substantially identicalexpression of one or more of: ANXA3, ARG1, CAMP, CD24, CEACAM1,CEACAM6, CEACAM8, CRISP3, KIAA0922, LCN2, MMP9, or STOM of thetarget cell relative to the corresponding expression of the genesin or derived from the MDS cell. See, e.g., Tables 35 and 36.

[0025] In certain embodiments, the method includes correlating adetected differential expression of one or more genes of the targetcell, which genes are selected from the markers listed in Table 37,relative to a corresponding expression of the genes in or derivedfrom an AML cell having a normal karyotype or an MDS cell having anormal karyotype with the target cell being an AML cell having acomplex aberrant karyotype or an MDS cell having a complex aberrantkaryotype. In some embodiments, the method includes correlating adetected substantially identical expression of one or more genes ofthe target cell, which genes are selected from the markers listedin Table 37, relative to a corresponding expression of the genes inor derived from an AML cell having a normal karyotype or an MDScell having a normal karyotype with the target cell being an AMLcell having a normal karyotype or an MDS cell having a normalkaryotype. In certain embodiments, the method includes correlatinga detected differential expression of one or more genes of thetarget cell, which genes are selected from the markers listed inTable 37, relative to a corresponding expression of the genes in orderived from an AML cell having a complex aberrant karyotype or anMDS cell having a complex aberrant karyotype with the target cellbeing an AML cell having a normal karyotype or an MDS cell having anormal karyotype. In some embodiments, the method includescorrelating a detected substantially identical expression of one ormore genes of the target cell, which genes are selected from themarkers listed in Table 37, relative to a corresponding expressionof the genes in or derived from an AML cell having a complexaberrant karyotype or an MDS cell having a complex aberrantkaryotype with the target cell being an AML cell having a complexaberrant karyotype or an MDS cell having a complex aberrantkaryotype.

[0026] In one aspect, the invention provides a method ofsubclassifying acute myeloid leukemia with normal karyotype(AML-NK). The method includes detecting an expression level of atleast one set of genes in or derived from at least one targetAML-NK cell. In addition, the method also includes correlating: adetected higher expression of one or more genes selected from thegroup listed in Table 38 and/or a detected lower expression of oneor more genes selected from the group listed in Table 39 of thetarget AML-NK cell relative to a corresponding expression of thegenes in or derived from a Group B AML-NK cell with the targetAML-NK cell being a Group A AML-NK cell; or a detected lowerexpression of one or more genes selected from the group listed inTable 38 and/or a detected higher expression of one or more genesselected from the group listed in Table 39 of the target AML-NKcell relative to a corresponding expression of the genes in orderived from a Group A AML-NK cell with the target AML-NK cellbeing a Group B AML-NK cell. The set of genes in or derived fromthe target AML-NK cell typically comprises at least about 10, 100,1000, 10000, or more members. Further, the set of genes is in theform of transcribed polynucleotides (e.g., mRNAs, cDNAs, etc.) orportions thereof in some embodiments. The higher expression and/orthe lower expression of the genes generally comprises at leastabout a 5% difference. The target AML-NK cell is generally obtainedfrom a subject. Moreover, a subclassification of the target AML-NKcell in Group B typically correlates with a better event-freesurvival rate and/or overall survival rate for the subject than asubclassification of the target AML-NK cell in Group A.

[0027] In one aspect, the invention provides a method ofidentifying a cell with a 5q deletion ((del)5q). The methodincludes detecting an expression level of at least one set of genesin or derived from at least one target human cell. In someembodiments, the target human cell comprises an acute myeloidleukemia (AML) cell or a myelodysplastic syndrome (MDS) cell. Thetarget human cell is generally obtained from a subject. Typically,the set of genes in or derived from the target human cell comprisesat least about 10, 100, 1000, 10000, or more members. The methodalso includes correlating a detected differential expression of oneor more genes of at least chromosome 5 of the target human cellrelative to a corresponding expression of the genes in or derivedfrom a human cell lacking a (del)5q (e.g., a myeloid cell, etc.)with the target human cell comprising a (del)5q; or correlating adetected substantially identical expression of one or more genes ofat least chromosome 5 of the target human cell relative to acorresponding expression of the genes in or derived from a humancell having a (del)5q (e.g., a myeloid cell, etc.) with the targethuman cell comprising a (del)5q, thereby identifying the cell withthe (del)5q. In some embodiments, the method include correlatingthe detected differential expression of the genes with the targethuman cell being an AML cell with a normal karyotype (AML-NK), anMDS cell with a normal karyotype (MDS-NK), or an MDS cell with acomplex aberrant karyotype. Typically, the detected differentialexpression of the genes comprises at least about a 5% difference,whereas the detected substantially identical expression of thegenes typically comprises less than about a 5% difference.

[0028] In certain embodiments, the detected differential expressionof the genes comprises a lower mean expression of a substantialnumber of the genes located on a long arm of chromosome 5 of thetarget human cell relative to the corresponding expression of thegenes in or derived from the human cell lacking the (del)5q. Insome embodiments, the detected differential expression comprises anexpression of one or more genes selected from the group consistingof: POLE, RAD21, RAD23B, ZNF75A, AF020591, MLLT3, HOXB6, UPF2,TINP1, RPL12, RPL14, RPL15, GMNN, CSPG6, PFDN1, HINT1, STK24, APP,and CAMLG. In some embodiments, the detected differentialexpression of the genes comprises a lower expression of one or moreof the genes listed in Table 41 (e.g., CSNK1A1, DAMS, HDAC3, PFDN1,CNOT8, etc.) of the target human cell relative to the correspondingexpression of the genes in or derived from the human cell lackingthe (del)5q. Table 41 lists genes located on the long (q) arm ofchromosome 5 that are downregulated or lower expressed in caseswith (del)5q compared to cases without (del)5q. In certainembodiments, the detected differential expression of the genescomprises: a higher expression of one or more of: RAD21, RAD23B,GMMN, CSPG6, APP, POLE, STK24, STAG2, H1F0, PTPN11, or TAF2 of thetarget human cell relative to the corresponding expression of thegenes in or derived from the human cell lacking the (del)5q; and/ora lower expression of one or more of: ACTA2, RPL12, DF, UBE2D2,EEF1A1, IGBP1, PPP2CA, EIF2S3, or NACA of the target human cellrelative to the corresponding expression of the genes in or derivedfrom the human cell lacking the (del)5q.

[0029] The system also includes at least one reference data bankfor correlating detected expression levels of polynucleotidesand/or polypeptides in target AML cells, which polynucleotidesand/or polypeptides correspond to one or more of the markers, witha probable overall survival rate for a subject. Typically, thereference data bank is produced by: (a) compiling a gene expressionprofile of a patient sample by determining the expression level atleast one of the markers, and (b) classifying the gene expressionprofile using a machine learning algorithm. The machine learningalgorithm is typically selected from, e.g., a weighted votingalgorithm, a K-nearest neighbors algorithm, a decision treeinduction algorithm, a support vector machine, a feed-forwardneural network, or the like.

DETAILED DESCRIPTION

Definitions

[0030] Before describing the present invention in detail, it is tobe understood that this invention is not limited to particularembodiments. It is also to be understood that the terminology usedherein is for the purpose of describing particular embodimentsonly, and is not intended to be limiting. Units, prefixes, andsymbols are denoted in the forms suggested by the InternationalSystem of Units (SI), unless specified otherwise. Numeric rangesare inclusive of the numbers defining the range. As used in thisspecification and the appended claims, the singular forms "a", "an"and "the" also include plural referents unless the context clearlydictates otherwise. To illustrate, reference to "a cell" includestwo or more cells. Further, unless defined otherwise, all technicaland scientific terms used herein have the same meaning as commonlyunderstood by one of ordinary skill in the art to which theinvention pertains. The terms defined below, and grammaticalvariants thereof, are more fully defined by reference to thespecification in its entirety.

[0031] A "5q deletion" or "(del)5q" refers to deletions (e.g.,acquired interstitial deletions) of the long arm of a humanchromosome 5.

[0032] "11q23/MLL" refers to acute myeloid leukemia with the 11q23rearrangement of the human MLL gene according to the World HealthOrganization (WHO) classification of haematologicalmalignancies.

[0033] An "antibody" refers to a polypeptide substantially encodedby at least one immunoglobulin gene or fragments of at least oneimmunoglobulin gene, which can participate in specific binding witha ligand. The term "antibody" includes polyclonal and monoclonalantibodies and biologically active fragments thereof includingamong other possibilities "univalent" antibodies (Glennie et al.(1982) Nature 295:712); Fab proteins including Fab' andF(ab').sub.2 fragments whether covalently or non-covalentlyaggregated; light or heavy chains alone, typically variable heavyand light chain regions (V.sub.H and V.sub.L regions), and moretypically including the hypervariable regions (otherwise known asthe complementarity determining regions (CDRs) of the V.sub.H andV.sub.L regions); F.sub.c proteins; "hybrid" antibodies capable ofbinding more than one antigen; constant-variable region chimeras;"composite" immunoglobulins with heavy and light chains ofdifferent origins; "altered" antibodies with improved specificityand other characteristics as prepared by standard recombinanttechniques, by mutagenic techniques, or other directed evolutionarytechniques known in the art. Derivatives of antibodies includescFvs, chimeric and humanized antibodies. See, e.g., Harlow andLane, Antibodies a laboratory manual, CSH Press (1988), which isincorporated by reference. For the detection of polypeptides usingantibodies or fragments thereof, there are a variety of methodsknown to a person skilled in the art, which are optionallyutilized. Examples include immunoprecipitations, Western blottings,Enzyme-linked immuno sorbent assays (ELISA), radioimmunoassays(RIA), dissociation-enhanced lanthanide fluoro immuno assays(DELFIA), scintillation proximity assays (SPA). To facilitatedetection, an antibody is typically labeled by one or more of thelabels described herein or otherwise known to persons skilled inthe art.

[0034] In general, an "array" or "microarray" refers to a linear ortwo- or three dimensional arrangement of preferably discretenucleic acid or polypeptide probes which comprises an intentionallycreated collection of nucleic acid or polypeptide probes of anylength spotted onto a substrate/solid support. The person skilledin the art knows a collection of nucleic acids or polypeptidespotted onto a substrate/solid support also under the term "array".As also known to the person skilled in the art, a microarrayusually refers to a miniaturized array arrangement, with the probesbeing attached to a density of at least about 10, 20, 50, 100nucleic acid molecules referring to different or the same genes percm.sup.2. Furthermore, where appropriate an array can be referredto as "gene chip". The array itself can have different formats,e.g., libraries of soluble probes or libraries of probes tetheredto resin beads, silica chips, or other solid supports.

[0035] "Complementary" and "complementarity", respectively, can bedescribed by the percentage, i.e., proportion, of nucleotides thatcan form base pairs between two polynucleotide strands or within aspecific region or domain of the two strands. Generally,complementary nucleotides are, according to the base pairing rules,adenine and thymine (or adenine and uracil), and cytosine andguanine. Complementarity may be partial, in which only some of thenucleic acids' bases are matched according to the base pairingrules. Or, there may be a complete or total complementarity betweenthe nucleic acids. The degree of complementarity between nucleicacid strands has effects on the efficiency and strength ofhybridization between nucleic acid strands.

[0036] Two nucleic acid strands are considered to be 100%complementary to each other over a defined length if in a definedregion all adenines of a first strand can pair with a thymine (oran uracil) of a second strand, all guanines of a first strand canpair with a cytosine of a second strand, all thymine (or uracils)of a first strand can pair with an adenine of a second strand, andall cytosines of a first strand can pair with a guanine of a secondstrand, and vice versa. According to the present invention, thedegree of complementarity is determined over a stretch of about 20or 25 nucleotides, i.e., a 60% complementarity means that within aregion of 20 nucleotides of two nucleic acid strands 12 nucleotidesof the first strand can base pair with 12 nucleotides of the secondstrand according to the above base pairing rules, either as astretch of 12 contiguous nucleotides or interspersed by non-pairingnucleotides, when the two strands are attached to each other overthe region of 20 nucleotides. The degree of complementarity canrange from at least about 50% to full, i.e., 100% complementarity.Two single nucleic acid strands are said to be "substantiallycomplementary" when they are at least about 80% complementary, andmore typically about 90% complementary or higher. For carrying outthe methods of present invention substantial complementarity isgenerally utilized.

[0037] Two nucleic acids "correspond" when they have substantiallyidentical or complementary sequences, when one nucleic acid is asubsequence of the other, or when one sequence is derived naturallyor artificially from the other.

[0038] The term "differential gene expression" refers to a gene orset of genes whose expression is activated to a higher or lowerlevel in a subject suffering from a disease, (e.g., cancer)relative to its expression in a normal or control subject.Differential gene expression can also occur between different typesor subtypes of diseased cells. The term also includes genes whoseexpression is activated to a higher or lower level at differentstages of the same disease. It is also understood that adifferentially expressed gene may be either activated or inhibitedat the nucleic acid level or protein level, or may be subject toalternative splicing to result in a different polypeptide product.Such differences may be evidenced by a change in mRNA levels,surface expression, secretion or other partitioning of apolypeptide, for example. Differential gene expression may includea comparison of expression between two or more genes or their geneproducts, or a comparison of the ratios of the expression betweentwo or more genes or their gene products, or even a comparison oftwo differently processed products of the same gene, which differbetween, e.g., normal subjects and subjects suffering from adisease, various stages of the same disease, different types orsubtypes of diseased cells, etc. Differential expression includesboth quantitative, as well as qualitative, differences in thetemporal or cellular expression pattern in a gene or its expressionproducts among, for example, normal and diseased cells, or amongcells which have undergone different disease events or diseasestages. In certain embodiments, "differential gene expression" isconsidered to be present when there is at least an about two-fold,typically at least about four-fold, more typically at least aboutsix-fold, most typically at least about ten-fold differencebetween, e.g., the expression of a given gene in normal anddiseased subjects, in various stages of disease development in adiseased subject, different types or subtypes of diseased cells,etc.

[0039] The term "expression" refers to the process by which mRNA ora polypeptide is produced based on the nucleic acid sequence of agene, i.e., "expression" also includes the formation of mRNA in theprocess of transcription. The term "determining the expressionlevel" refers to the determination of the level of expression ofone or more markers.

[0040] The term "genotype" refers to a description of the allelesof a gene or genes contained in an individual or a sample. As usedherein, no distinction is made between the genotype of anindividual and the genotype of a sample originating from theindividual. Although, typically, a genotype is determined fromsamples of diploid cells, a genotype can be determined from asample of haploid cells, such as a sperm cell.

[0041] The term "gene" refers to a nucleic acid sequence encoding agene product. The gene optionally comprises sequence informationrequired for expression of the gene (e.g., promoters, enhancers,etc.).

[0042] The term "gene expression data" refers to one or more setsof data that contain information regarding different aspects ofgene expression. The data set optionally includes informationregarding: the presence of target-transcripts in cell orcell-derived samples; the relative and absolute abundance levels oftarget transcripts; the ability of various treatments to induceexpression of specific genes; and the ability of various treatmentsto change expression of specific genes to different levels.

[0043] Nucleic acids "hybridize" when they associate, typically insolution. Nucleic acids hybridize due to a variety ofwell-characterized physico-chemical forces, such as hydrogenbonding, solvent exclusion, base stacking and the like. In certainembodiments, hybridization occurs under conventional hybridizationconditions, such as under stringent conditions as described, forexample, in Sambrook et al., in "Molecular Cloning: A LaboratoryManual" (1989), Eds. J. Sambrook, E. F. Fritsch and T. Maniatis,Cold Spring Harbour Laboratory Press, Cold Spring Harbour, N.Y.,which is incorporated by reference. Such conditions are, forexample, hybridization in 6.times.SSC, pH 7.0/0.1% SDS at about45.degree. C. for 18-23 hours, followed by a washing step with2.times.SSC/1% SDS at 50.degree. C. In order to select thestringency, the salt concentration in the washing step can, forexample, be chosen between 2.times.SSC/0.1% SDS at room temperaturefor low stringency and 0.2.times.SSC/0.1% SDS at 50.degree. C. forhigh stringency. In addition, the temperature of the washing stepcan be varied between room temperature (ca. 22.degree. C.), for lowstringency, and 65.degree. C. to 70.degree. C. for high stringency.Also contemplated are polynucleotides that hybridize at lowerstringency hybridization conditions. Changes in the stringency ofhybridization and signal detection are primarily accomplishedthrough the manipulation of, e.g., formamide concentration (lowerpercentages of formamide result in lowered stringency), saltconditions, or temperature. For example, lower stringencyconditions include an overnight incubation at 37.degree. C. in asolution comprising 6.times.SSPE (20.times.SSPE=3M NaCl; 0.2MNaH.sub.2PO.sub.4; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide,100 mg/mL salmon sperm blocking DNA, followed by washes at50.degree. C. with 1.times.SSPE, 0.1% SDS. In addition, to achieveeven lower stringency, washes performed following stringenthybridization can be done at higher salt concentrations (e.g.,5.times.SSC). Variations in the above conditions may beaccomplished through the inclusion and/or substitution of alternateblocking reagents used to suppress background in hybridizationexperiments. The inclusion of specific blocking reagents mayrequire modification of the hybridization conditions describedherein, due to problems with compatibility. An extensive guide tothe hybridization of nucleic acids is found in Tijssen (1993)Laboratory Techniques in Biochemistry and MolecularBiology--Hybridization with Nucleic Acid Probes part I chapter 2,"Overview of principles of hybridization and the strategy ofnucleic acid probe assays," (Elsevier, New York), as well as inAusubel (Ed.) Current Protocols in Molecular Biology, Volumes I,II, and III, (1997), which are each incorporated by reference.Hames and Higgins (1995) Gene Probes 1 IRL Press at OxfordUniversity Press, Oxford, England, (Hames and Higgins 1) and Hamesand Higgins (1995) Gene Probes 2 IRL Press at Oxford UniversityPress, Oxford, England (Hames and Higgins 2) provide details on thesynthesis; labeling, detection and quantification of DNA and RNA,including oligonucleotides. Both Hames and Higgins 1 and 2 areincorporated by reference.

[0044] "inv(3)" refers to an inversion of human chromosome 3.

[0045] "inv(16)" refers to AML with inversion 16 according to theWHO classification of haematological malignancies.

[0046] A "label" refers to a moiety attached (covalently ornon-covalently), or capable of being attached, to a molecule (e.g.,a polynucleotide, a polypeptide, etc.), which moiety provides or iscapable of providing information about the molecule (e.g.,descriptive, identifying, etc. information about the molecule) oranother molecule with which the labeled molecule interacts (e.g.,hybridizes, etc.). Exemplary labels include fluorescent labels(including, e.g., quenchers or absorbers), non-fluorescent labels,colorimetric labels, chemiluminescent labels, bioluminescentlabels, radioactive labels (such as .sup.3H, .sup.35S, .sup.32P,.sup.125I, .sup.57Co or .sup.14C), mass-modifying groups,antibodies, antigens, biotin, haptens, digoxigenin, enzymes(including, e.g., peroxidase, phosphatase, etc.), and the like. Tofurther illustrate, fluorescent labels may include dyes that arenegatively charged, such as dyes of the fluorescein family, or dyesthat are neutral in charge, such as dyes of the rhodamine family,or dyes that are positively charged, such as dyes of the cyaninefamily. Dyes of the fluorescein family include, e.g., FAM, HEX,TET, JOE, NAN and ZOE. Dyes of the rhodamine family include, e.g.,Texas Red, ROX, R110, R6G, and TAMRA. FAM, HEX, TET, JOE, NAN, ZOE,ROX, R110, R6G, and TAMRA are commercially available from, e.g.,Perkin-Elmer, Inc. (Wellesley, Mass., USA), and Texas Red iscommercially available from, e.g., Molecular Probes, Inc. (Eugene,Oreg., USA). Dyes of the cyanine family include, e.g., Cy2, Cy3,Cy3.5, Cy5, Cy5.5, and Cy7, and are commercially available from,e.g., Amersham Biosciences Corp. (Piscataway, N.J., USA). Suitablemethods include the direct labeling (incorporation) method, anamino-modified (amino-allyl) nucleotide method (available e.g. fromAmbion, Inc. (Austin, Tex., USA), and the primer tagging method(DNA dendrimer labeling, as kit available e.g. from Genisphere,Inc. (Hatfield, Pa., USA)). In some embodiments, biotin orbiotinylated nucleotides are used for labeling, with the lattergenerally being directly incorporated into, e.g., the cRNApolynucleotide by in vitro transcription.

[0047] The term "lower expression" refers an expression level ofone or more markers from a target that is less than a correspondingexpression level of the markers in a reference. In certainembodiments, "lower expression" is assigned to all by numbers andAffymetrix Id. definable polynucleotides the t-values and foldchange (fc) values of which are negative. Similarly, the term"higher expression" refers an expression level of one or moremarkers from a target that is more than a corresponding expressionlevel of the markers in a reference. In some embodiments, "higherexpression" is assigned to all by numbers and Affymetrix Id.definable polynucleotides the t-values and fold change (fc) valuesof which are positive.

[0048] A "machine learning algorithm" refers to acomputational-based prediction methodology, also known to personsskilled in the art as a "classifier", employed for characterizing agene expression profile. The signals corresponding to certainexpression levels, which are obtained by, e.g., microarray-basedhybridization assays, are typically subjected to the algorithm inorder to classify the expression profile. Supervised learninggenerally involves "training" a classifier to recognize thedistinctions among classes and then "testing" the accuracy of theclassifier on an independent test set. For new, unknown samples theclassifier can be used to predict the class in which the samplesbelong.

[0049] The term "marker" refers to a genetically controlleddifference that can be used in the genetic analysis of a test ortarget versus a control or reference sample for the purpose ofassigning the sample to a defined genotype or phenotype. In certainembodiments, for example, "markers" refer to genes,polynucleotides, polypeptides, or fragments or portions thereofthat are differentially expressed in, e.g., different leukemiatypes and/or subtypes. The markers can be defined by their genesymbol name, their encoded protein name, their transcriptidentification number (cluster identification number), the database accession number, public accession number and/or GenBankidentifier. Markers can also be defined by their Affymetrixidentification number, chromosomal location, UniGene accessionnumber and cluster type, and/or LocusLink accession number. TheAffymetrix identification number (affy id) is accessible for anyoneand the person skilled in the art by entering the "gene expressionomnibus" internet page of the National Center for BiotechnologyInformation (NCBI) on the world wide web at ncbi.nlm.nih.gov/geo/as of Nov. 4, 2004. In particular, the affy id's of thepolynucleotides used for certain embodiments of the methodsdescribed herein are derived from the so-called human genome U133chip (Affymetrix, Inc., Santa Clara, Calif., USA). The sequencedata of each identification number can be viewed on the world wideweb at, e.g., ncbi.nlm.nih.gov/projects/geo/ as of Nov. 4, 2004using the accession number GPL96 for U133A annotational data andaccession number GPL97 for U133B annotational data. In someembodiments, the expression level of a marker is determined by thedetermining the expression of its corresponding polynucleotide.

[0050] The term "normal karyotype" refers to a state of those cellslacking any visible karyotype abnormality detectable withchromosome banding analysis.

[0051] The term "nucleic acid" refers to a polymer of monomers thatcan be corresponded to a ribose nucleic acid (RNA) or deoxyribosenucleic acid (DNA) polymer, or analog thereof. This includespolymers of nucleotides such as RNA and DNA, as well as modifiedforms thereof, peptide nucleic acids (PNAs), locked nucleic acids(LNA.TM.s), and the like. In certain applications, the nucleic acidcan be a polymer that includes multiple monomer types, e.g., bothRNA and DNA subunits. A nucleic acid can be or include, e.g., achromosome or chromosomal segment, a vector (e.g., an expressionvector), an expression cassette, a naked DNA or RNA polymer, theproduct of a polymerase chain reaction (PCR) or other nucleic acidamplification reaction, an oligonucleotide, a probe, a primers,etc. A nucleic acid can be e.g., single-stranded ordouble-stranded. Unless otherwise indicated, a particular nucleicacid sequence optionally comprises or encodes complementarysequences, in addition to any sequence explicitly indicated.

[0052] Oligonucleotides (e.g., probes, primers, etc.) of a definedsequence may be produced by techniques known to those of ordinaryskill in the art, such as by chemical or biochemical synthesis, andby in vitro or in vivo expression from recombinant nucleic acidmolecules, e.g., bacterial or retroviral vectors.

[0053] Oligonucleotides which are primer and/or probe sequences, asdescribed below, may comprise DNA, RNA or nucleic acid analogs suchas uncharged nucleic acid analogs including but not limited topeptide nucleic acids (PNAs) which are disclosed in InternationalPatent Application WO 92/20702 or morpholino analogs which aredescribed in U.S. Pat. Nos. 5,185,444, 5,034,506, and 5,142,047 allof which are incorporated by reference. Such sequences canroutinely be synthesized using a variety of techniques currentlyavailable. For example, a sequence of DNA can be synthesized usingconventional nucleotide phosphoramidite chemistry and theinstruments available from Applied Biosystems, Inc, (Foster City,Calif., USA); DuPont, (Wilmington, Del., USA); or Milligen,(Bedford, Mass., USA). Similarly, and when desirable, the sequencescan be labeled using methodologies well known in the art such asdescribed in U.S. Pat. Nos. 5,464,746; 5,424,414; and 4,948,882 allof which are incorporated by reference.

[0054] A nucleic acid, nucleotide, polynucleotide oroligonucleotide can comprise the five biologically occurring bases(adenine, guanine, thymine, cytosine and uracil) and/or bases otherthan the five biologically occurring bases. These bases may serve anumber of purposes, e.g., to stabilize or destabilizehybridization; to promote or inhibit probe degradation; or asattachment points for detectable moieties or quencher moieties. Forexample, a polynucleotide of the invention can contain one or moremodified, non-standard, or derivatized base moieties, including,but not limited to, N.sup.6-methyl-adenine,N.sup.6-tert-butyl-benzyl-adenine, imidazole, substitutedimidazoles, 5-fluorouracil, 5-bromouracil, 5-chlorouracil,5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine,5-(carboxyhydroxymethyl)uracil,5-carboxymethylaminomethyl-2-thiouridine,5-carboxymethylaminomethyluracil, dihydrouracil,beta-D-galactosylqueosine, inosine, N6-isopentenyladenine,1-methylguanine, 1-methylinosine, 2,2-dimethylguanine,2-methyladenine, 2-methylguanine, 3-methylcytosine,5-methylcytosine, N6-methyladenine, 7-methylguanine,5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil,beta-D mannosylqueosine, 5'-methoxycarboxymethyluracil,5-methoxyuracil, 2-methylthio-N6-isopentenyladenine,uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine,2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil,5-methyluracil, uracil-5-oxyacetic acidmethylester,3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, 2,6-diaminopurine,and 5-propynyl pyrimidine. Other examples of modified,non-standard, or derivatized base moieties may be found in U.S.Pat. Nos. 6,001,611, 5,955,589, 5,844,106, 5,789,562, 5,750,343,5,728,525, and 5,679,785, each of which is incorporated byreference.

[0055] Furthermore, a nucleic acid, nucleotide, polynucleotide oroligonucleotide can comprise one or more modified sugar moietiesincluding, but not limited to, arabinose, 2-fluoroarabinose,xylulose, and hexose. A nucleic acid, nucleotide, polynucleotide oroligonucleotide can comprise phosphodiester linkages or modifiedlinkages including, but not limited to phosphotriester,phosphoramidate, siloxane, carbonate, carboxymethylester,acetamidate, carbamate, thioether, bridged phosphoramidate, bridgedmethylene phosphonate, phosphorothioate, methylphosphonate,phosphorodithioate, bridged phosphorothioate or sulfone linkages,and combinations of such linkages.

[0056] The term "polynucleotide" refers to a DNA, in particularcDNA, or RNA, in particular a cRNA, or a portion thereof. In thecase of RNA (or cDNA), the polynucleotide is formed upontranscription of a nucleotide sequence that is capable ofexpression. "Polynucleotide fragments" refer to fragments ofbetween at least 8, such as 10, 12, 15 or 18 nucleotides and atleast 50, such as 60, 80, 100, 200 or 300 nucleotides in length, ora complementary sequence thereto, e.g., representing a consecutivestretch of nucleotides of a gene, cDNA or mRNA. In someembodiments, polynucleotides also include any fragment (orcomplementary sequence thereto) of a sequence corresponding to orderived from any of the markers defined herein.

[0057] The term "primer" refers to an oligonucleotide having ahybridization specificity sufficient for the initiation of anenzymatic polymerization under predetermined conditions, forexample in an amplification technique such as polymerase chainreaction (PCR), in a process of sequencing, in a method of reversetranscription and the like. The term "probe" refers to anoligonucleotide having a hybridization specificity sufficient forbinding to a defined target sequence under predeterminedconditions, for example in an amplification technique such as a5'-nuclease reaction, in a hybridization-dependent detectionmethod, such as a Southern or Northern blot, and the like. Incertain embodiments, probes correspond at least in part to selectedmarkers. Primers and probes may be used in a variety of ways andmay be defined by the specific use. For example, a probe can beimmobilized on a solid support by any appropriate means, including,but not limited to: by covalent bonding, by adsorption, byhydrophobic and/or electrostatic interaction, or by directsynthesis on a solid support (see in particular patent applicationWO 92/10092). A probe may be labeled by means of a label chosen,for example, from radioactive isotopes, enzymes, in particularenzymes capable of acting on a chromogenic, fluorescent orluminescent substrate (in particular a peroxidase or an alkalinephosphatase), chromophoric chemical compounds, chromogenic,fluorigenic or luminescent compounds, analogues of nucleotidebases, and ligands such as biotin. Illustrative fluorescentcompounds include, for example, fluorescein, carboxyfluorescein,tetrachlorofluorescein, hexachlorofluorescein, Cy3,tetramethylrhodamine, Cy3.5, carboxy-x-rhodamine, Texas Red, Cy5,and Cy5.5. Illustrative luminescent compounds include, for example,luciferin and 2,3-dihydrophthalazinediones, such as luminol. Othersuitable labels are described herein or are otherwise known tothose of skill in the art.

[0058] Oligonucleotides (e.g., primers, probes, etc.), whetherhybridization assay probes, amplification primers, or helperoligonucleotides, may be modified with chemical groups to enhancetheir performance or to facilitate the characterization ofamplification products. For example, backbone-modifiedoligonucleotides such as those having phosphorothioate ormethylphosphonate groups which render the oligonucleotidesresistant to the nucleolytic activity of certain polymerases or tonuclease enzymes may allow the use of such enzymes in anamplification or other reaction. Another example of modificationinvolves using non-nucleotide linkers (e.g., Arnold, et al.,"Non-Nucleotide Linking Reagents for Nucleotide Probes", EP 0 313219, which is incorporated by reference) incorporated betweennucleotides in the nucleic acid chain which do not interfere withhybridization or the elongation of the primer. Amplificationoligonucleotides may also contain mixtures of the desired modifiedand natural nucleotides.

[0059] A "reference" in the context of gene expression profilingrefers to a cell and/or genes in or derived from the cell (or dataderived therefrom) relative to which a target is compared. In someembodiments, for example, the expression of one or more genes froma target cell is compared to a corresponding expression of thegenes in or derived from a reference cell.

[0060] A "sample" refers to any biological material containinggenetic information in the form of nucleic acids or proteinsobtainable or obtained from one or more subjects or individuals. Insome embodiments, samples are derived from subjects havingleukemia, e.g., AML. Exemplary samples include tissue samples, cellsamples, bone marrow, and/or bodily fluids such as blood, saliva,semen, urine, and the like. Methods of obtaining samples and ofisolating nucleic acids and proteins from sample are generallyknown to persons of skill in the art.

[0061] A "set" refers to a collection of one or more things. Forexample, a set may include 1, 2, 3, 4, 5, 10, 20, 50, 100, 1,000 oranother number of genes or other types of molecules.

[0062] A "solid support" refers to a solid material that can bederivatized with, or otherwise attached to, a chemical moiety, suchas an oligonucleotide probe or the like. Exemplary solid supportsinclude plates (e.g., multi-well plates, etc.), beads, microbeads,tubes, fibers, whiskers, combs, hybridization chips (includingmicroarray substrates, such as those used in GeneChip.RTM. probearrays (Affymetrix, Inc., Santa Clara, Calif., USA) and the like),membranes, single crystals, ceramic layers, self-assemblingmonolayers, and the like.

[0063] "Specifically binding" means that a compound is capable ofdiscriminating between two or more polynucleotides or polypeptides.For example, the compound binds to the desired polynucleotide orpolypeptide, but essentially does not bind to a non-targetpolynucleotide or polypeptide. The compound can be an antibody, ora fragment thereof, an enzyme, a so-called small molecule compound,a protein-scaffold (e.g., an anticalin).

[0064] A "subject" refers to an organism. Typically, the organismis a mammalian organism, particularly a human organism.

[0065] The term "substantially identical" in the context of geneexpression refers to levels of expression of genes that areapproximately equal to one another. In some embodiments, forexample, the expression levels of genes being compared aresubstantially identical to one another when they differ by lessthan about 5% (e.g., about 4%, about 3%, about 2%, about 1%,etc.).

[0066] "t(15;17)" refers to AML with translocation t(15;17)according to the WHO classification of haematologicalmalignancies.

[0067] "t(8;21)" refers to AML with translocation t(8;21) accordingto the WHO classification of haematological malignancies.

[0068] "t(9;22)" refers to translocation (9;22).

[0069] The term "target" refers to an object that is the subject ofanalysis. In some embodiments, for example, targets are specificnucleic acid sequences (e.g., mRNAs of expressed genes, etc.), thepresence, absence or abundance of which are to be determined. Incertain embodiments, targets include polypeptides (e.g., proteins,etc.) of expressed genes. Typically, the sequences subjected toanalysis are in or derived from "target cells", such as aparticular type of leukemia cell.

[0070] "Trisomy 8" refers to a condition in humans in whichchromosome 8 is triploid in one or more cells.

Introduction

[0071] The present invention provides methods, reagents, systems,and kits for classifying and prognosticating acute myeloidleukemia. In certain embodiments, for example, the methods includedetecting an expression level of a set of genes in or derived froma target AML cell (e.g., an AML cell having an intermediatekaryotype). These methods also include: [0072] (a) correlating adetected differential expression of one or more genes selected fromthe markers listed in one or more of Tables 1-13 relative to acorresponding expression of the genes in or derived from at leastone reference AML cell having a reciprocal translocation (e.g., at(15;17), t(8;21), inv(16), t(11q23), inv(3), etc.) with the targetAML cell having a CEBPA mutation; [0073] (b) correlating a detectedsubstantially identical expression of one or more genes selectedfrom the markers listed in one or more of Tables 1-13 relative to acorresponding expression of the genes in or derived from at leastone reference AML cell having a CEBPA mutation with the target AMLcell having the CEBPA mutation; [0074] (c) correlating a detecteddifferential expression of one or more genes selected from themarkers listed in one or more of Tables 1-13 relative to acorresponding expression of the genes in or derived from at leastone reference AML cell having a CEBPA mutation with the target AMLcell having a reciprocal translocation; or [0075] (d) correlating adetected substantially identical expression of one or more genesselected from the markers listed in one or more of Tables 1-13relative to a corresponding expression of the genes in or derivedfrom at least one reference AML cell having a reciprocaltranslocation with the target AML cell having the reciprocaltranslocation, thereby classifying the AML cell.

[0076] In some embodiments, the set of genes is selected from oneor more of: Table 1 (best 42 markers), Table 2 (top 100 markers todifferentiate the favorable group from the unfavorable group), orTable 3 (top 100 differentially expressed markers betweenprognostic subgroups). The methods also include: [0077] (a)correlating a detected a higher expression of an MPO gene and/or anATBF1 gene in the target AML cell relative to a correspondingexpression of the genes in or derived from an AML cell from amember of an unfavorable group with the subject having a probableoverall survival rate at three years of about 55% or more; or,[0078] (b) correlating a detected a higher expression of one ormore of: an ETS2 gene, a RUNX1 gene, a TCF4 gene, a FOXC1 gene, aSFRS1 gene, a TPD52 gene, a NRIP1 gene, a TFPI gene, a UBL1 gene,an REC8L1 gene, an HSF2 gene, or an ETS2 gene in the target AMLcell relative to a corresponding expression of the genes in orderived from an AML cell from a member of a favorable group withthe subject having a probable overall survival rate at three yearsof about 25% or less.

[0079] The use of one or more of the markers described herein,e.g., utilizing a microarray technology or other gene expressionprofiling techniques, provides various advantages, including: (1)rapid and accurate diagnoses, (2) ease of use in laboratorieswithout specialized knowledge, and (3) eliminates the need foranalyzing viable cells for chromosome analysis, thereby eliminatingcell sample transport issues. Aspects of the present invention arefurther illustrated in the examples provided below.

[0080] In practicing the present invention, many conventionaltechniques in, hematology, molecular biology and recombinant DNAare optionally used. These techniques are well known and areexplained in, for example, Current Protocols in Molecular Biology,Volumes I, II, and III, 1997 (F. M. Ausubel ed.); Sambrook et al.,Molecular Cloning: A Laboratory Manual, 3rd Ed., Cold Spring HarborLaboratory Press, Cold Spring Harbor, N.Y., 2001; Berger andKimmel, Guide to Molecular Cloning Techniques, Methods inEnzymology volume 152 Academic Press, Inc., San Diego, Calif.(Berger), DNA Cloning: A Practical Approach, Volumes I and II, 1985(D. N. Glover ed.); Oligonucleotide Synthesis, 1984 (M. L. Gaited.); Nucleic Acid Hybridization, 1985, (Hames and Higgins);Transcription and Translation, 1984 (Hames and Higgins eds.);Animal Cell Culture, 1986 (Freshney ed.); Immobilized Cells andEnzymes, 1986 (IRL Press); Perbal, 1984, A Practical Guide toMolecular Cloning; the series, Methods in Enzymology (AcademicPress, Inc.); Gene Transfer Vectors for Mammalian Cells, 1987 (J.H. Miller and M. P. Calos eds., Cold Spring Harbor Laboratory);Greer et al. (Eds.), Wintrobe's Clinical Hematology, 11.sup.th Ed.,Lippincott Williams & Wilkins (2003); Shirlyn et al., ClinicalLaboratory Hematology, Prentice Hall (2002); Lichtman et al.,Williams Manual of Hematology, 6.sup.th Ed., McGraw-HillProfessional (2002); and Methods in Enzymology Vol. 154 and Vol.155 (Wu and Grossman, and Wu, eds., respectively), all of which areincorporated by reference.

[0081] In addition to the methods of the invention, the relatedkits and systems are also described further below.

Sample Collection and Preparation

[0082] Samples are collected and prepared for analysis usingessentially any technique known to those of skill in the art. Incertain embodiments, for example, blood samples are obtained fromsubjects via venipuncture. Whole blood specimens are optionallycollected in EDTA, Heparin or ACD vacutainer tubes. In otherembodiments, the samples utilized for analysis comprise bone marrowaspirates, which are optionally processed, e.g., by erythrocytelysis techniques, Ficoll density gradient centrifugations, or thelike. Samples are typically either analyzed immediately followingacquisition or stored frozen at, e.g., -80.degree. C. until beingsubjected to analysis. Sample collection and handling are alsodescribed in, e.g., Garland et al., Handbook of Phlebotomy andPatient Service Techniques, Lippincott Williams & Wilkins(1998), and Slockbower et al. (Eds.), Collection and Handling ofLaboratory Specimens: A Practical Guide, Lippincott Williams &Wilkins (1983), which are both incorporated by reference.

[0083] Treatment of Cells

[0084] The cells lines or sources containing the target nucleicacids and/or expression products thereof, are optionally subjectedto one or more specific treatments that induce changes in geneexpression, e.g., as part of processes to identify candidatemodulators of gene expression. For example, a cell or cell line canbe treated with or exposed to one or more chemical or biochemicalconstituents, e.g., pharmaceuticals, pollutants, DNA damagingagents, oxidative stress-inducing agents, pH-altering agents,membrane-disrupting agents, metabolic blocking agent, a chemicalinhibitors, cell surface receptor ligands, antibodies,transcription promoters/enhancers/inhibitors, translationpromoters/enhancers/inhibitors, protein-stabilizing ordestabilizing agents, various toxins, carcinogens or teratogens,characterized or uncharacterized chemical libraries, proteins,lipids, or nucleic acids. Optionally, the treatment comprises anenvironmental stress, such as a change in one or more environmentalparameters including, but not limited to, temperature (e.g. heatshock or cold shock), humidity, oxygen concentration (e.g.,hypoxia), radiation exposure, culture medium composition, or growthsaturation. Responses to these treatments may be followedtemporally, and the treatment can be imposed for various times andat various concentrations. Target sequences can also be derivedfrom cells exposed to multiple specific treatments as describedabove, either concurrently or in tandem (e.g., a cancerous cell ortissue sample may be further exposed to a DNA damaging agent whilegrown in an altered medium composition).

[0085] RNA Isolation

[0086] In some embodiments, total RNA is isolated from samples foruse as target sequences. Cellular samples are lysed once culturewith or without the treatment is complete by, for example, removinggrowth medium and adding a guanidinium-based lysis buffercontaining several components to stabilize the RNA. In certainembodiments, the lysis buffer also contains purified RNAs ascontrols to monitor recovery and stability of RNA from cellcultures. Examples of such purified RNA templates include theKanamycin Positive Control RNA from Promega (Madison, Wis., USA),and 7.5 kb Poly(A)-Tailed RNA from Life Technologies (Rockville,Md., USA). Lysates may be used immediately or stored frozen at,e.g., -80.degree. C. Optionally, total RNA is purified from celllysates (or other types of samples) using silica-based isolation inan automation-compatible, 96-well format, such as the Rneasy.RTM.purification platform (Qiagen, Inc. (Valencia, Calif., USA)).Alternatively, RNA is isolated using solid-phase oligo-dT captureusing oligo-dT bound to microbeads or cellulose columns. Thismethod has the added advantage of isolating mRNA from genomic DNAand total RNA, and allowing transfer of the mRNA-capture mediumdirectly into the reverse transcriptase reaction. Other RNAisolation methods are contemplated, such as extraction withsilica-coated beads or guanidinium. Further methods for RNAisolation and preparation can be devised by one skilled in theart.

[0087] Alternatively, the methods of the present invention areperformed using crude cell lysates, eliminating the need to isolateRNA. RNAse inhibitors are optionally added to the crude samples.When using crude cellular lysates, genomic DNA could contribute oneor more copies of target sequence, depending on the sample. Insituations in which the target sequence is derived from one or morehighly expressed genes, the signal arising from genomic DNA may notbe significant. But for genes expressed at very low levels, thebackground can be eliminated by treating the samples with DNAse, orby using primers that target splice junctions. One skilled in theart can design a variety of specialized priming applications thatwould facilitate use of crude extracts as samples for the purposesof this invention.

Gene Expression Profiling

[0088] The determination of gene expression levels may be effectedat the transcriptional and/or translational level, i.e., at thelevel of mRNA or at the protein level. Essentially any method ofgene expression profiling can be used or adapted for use inperforming the methods described herein including, e.g., methodsbased on hybridization analysis of polynucleotides, and methodsbased on sequencing of polynucleotides. To illustrate, commonlyused methods for the quantification of mRNA expression in a sampleinclude northern blotting and in situ hybridization (Parker &Bames, Methods in Molecular Biology 106:247-283 (1999)), RNAseprotection assays (Hod, Biotechniques 13:852-854 (1992)), andreverse transcription polymerase chain reaction (RT-PCR) (Weis etal., Trends in Genetics 8:263-264 (1992)). Alternatively,antibodies may be employed that can recognize specific duplexes,including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexesor DNA-protein duplexes. Representative methods forsequencing-based gene expression analysis include Serial Analysisof Gene Expression (SAGE), and gene expression analysis bymassively parallel signature sequencing (MPSS). Optionally,molecular species, such as antibodies, aptamers, etc. that canspecifically bind to proteins or fragments thereof are used foranalysis (see, e.g., Beilharz et al., Brief Funct Genomic Proteomic3(2):103-111 (2004)). Some of these techniques, with a certaindegree of overlap in some cases, are described further below.

[0089] In certain embodiments, for example, the methods describedherein include determining the expression levels of transcribedpolynucleotides. In some of these embodiments, the transcribedpolynucleotide is an mRNA, a cDNA and/or a cRNA. Transcribedpolynucleotides are typically isolated from a sample, reversetranscribed and/or amplified, and labeled by techniques referred toabove or otherwise known to persons skilled in the art. In order todetermine the expression level of transcribed polynucleotides, themethods of the invention generally include hybridizing transcribedpolynucleotides to a complementary polynucleotide, or a portionthereof, under a selected hybridization condition (e.g., astringent hybridization condition), as described herein.

[0090] In some embodiments, the detection and quantification ofamounts of polynucleotides to determine the level of expression ofa marker are performed according to those described by, e.g.,Sambrook et al., supra, or real time methods known in the art as5'-nuclease methods disclosed in, e.g., WO 92/02638, U.S. Pat. No.5,210,015, U.S. Pat. No. 5,804,375, and U.S. Pat. No. 5,487,972,which are each incorporated by reference. In some embodiments, forexample, 5'-nuclease methods utilize the exonuclease activity ofcertain polymerases to generate signals. In these approaches,target nucleic acids are detected in processes that includecontacting a sample with an oligonucleotide containing a sequencecomplementary to a region of the target nucleic acid component anda labeled oligonucleotide containing a sequence complementary to asecond region of the same target nucleic acid component sequencestrand, but not including the nucleic acid sequence defined by thefirst oligonucleotide, to create a mixture of duplexes duringhybridization conditions, wherein the duplexes comprise the targetnucleic acid annealed to the first oligonucleotide and to thelabeled oligonucleotide such that the 3'-end of the firstoligonucleotide is adjacent to the 5'-end of the labeledoligonucleotide. Then this mixture is treated with atemplate-dependent nucleic acid polymerase having a 5' to 3'nuclease activity under conditions sufficient to permit the to 3'nuclease activity of the polymerase to cleave the annealed, labeledoligonucleotide and release labeled fragments. The signal generatedby the hydrolysis of the labeled oligonucleotide is detected and/ormeasured. 5'-nuclease technology eliminates the need for a solidphase bound reaction complex to be formed and made detectable.Other exemplary methods include, e.g., fluorescence resonanceenergy transfer between two adjacently hybridized probes as used inthe LightCycler.RTM. format described in, e.g., U.S. Pat. No.6,174,670, which is incorporated by reference.

[0091] In one protocol, the marker, i.e., the polynucleotide, is inform of a transcribed nucleotide, where total RNA is isolated, cDNAand, subsequently, cRNA is synthesized and biotin is incorporatedduring the transcription reaction. The purified cRNA is applied tocommercially available arrays that can be obtained from, e.g.,Affymetrix, Inc. (Santa Clara, Calif. USA). The hybridized cRNA isoptionally detected according to the methods described in theexamples provided below. The arrays are produced byphotolithography or other methods known to persons skilled in theart. Some of these techniques are also described in, e.g. U.S. Pat.No. 5,445,934, U.S. Pat. No. 5,744,305, U.S. Pat. No. 5,700,637,U.S. Pat. No. 5,945,334, EP 0 619 321, and EP 0 373 203, which areeach incorporated by reference.

[0092] In another embodiment, the polynucleotide or at least one ofthe polynucleotides is in form of a polypeptide (e.g., expressedfrom the corresponding polynucleotide). The expression level of thepolynucleotides or polypeptides is optionally detected using acompound that specifically binds to target polynucleotides ortarget polypeptides.

[0093] These and other exemplary gene expression profilingtechniques are described further below.

[0094] Blotting Techniques

[0095] Some of the earliest expression profiling methods are basedon the detection of a label in RNA hybrids or protection of RNAfrom enzymatic degradation (see, e.g., Ausubel et al., supra).Methods based on detecting hybrids include northern blots andslot/dot blots. These two techniques differ in that the componentsof the sample being analyzed are resolved by size in a northernblot prior to detection, which enables identification of more thanone species simultaneously. Slot blots are generally carried outusing unresolved mixtures or sequences, but can be easily performedin serial dilution, enabling a more quantitative analysis.

[0096] In Situ Hybridization

[0097] In situ hybridization is a technique that monitorstranscription by directly visualizing RNA hybrids in the context ofa whole cell. This method provides information regardingsubcellular localization of transcripts (see, e.g., Suzuki et al.,Pigment Cell Res. 17(1):10-4 (2004)).

[0098] Assays Based on Protection from Enzymatic Degradation

[0099] Techniques to monitor RNA that make use of protection fromenzymatic degradation include S1 analysis and RNAse protectionassays (RPAs). Both of these assays employ a labeled nucleic acidprobe, which is hybridized to the RNA species being analyzed,followed by enzymatic degradation of single-stranded regions of theprobe. Analysis of the amount and length of probe protected fromdegradation is used to determine the quantity and endpoints of thetranscripts being analyzed.

[0100] Reverse Transcriptase PCR (RT-PCR) and Real-TimeDetection

[0101] RT-PCR can be used to compare, e.g., mRNA levels indifferent sample populations, in normal and tumor tissues, with orwithout drug treatment, to characterize patterns of geneexpression, to discriminate between closely related mRNAs, and toanalyze RNA structure. These assays are derivatives of PCR in whichamplification is preceded by reverse transcription of mRNA intocDNA. Accordingly, an initial step in these processes is generallythe isolation of mRNA from a target sample (e.g., leukemia cells).The starting material is typically total RNA isolated fromcancerous tissues or cells (e.g., bone marrow, peripheral bloodaliquots, etc.), and in certain embodiments, from correspondingnormal tissues or cells.

[0102] General methods for mRNA extraction are well known in theart and are disclosed in standard textbooks of molecular biology,including Ausubel et al., supra. Methods for RNA extraction fromparaffin embedded tissues are disclosed, for example, in Rupp andLocker, Lab Invest. 56:A67 (1987), and De Andres et al.,BioTechniques 18:42044 (1995), which are each incorporated byreference. In particular, RNA isolation can be performed usingpurification kit, buffer set and protease from commercialmanufacturers, such as Qiagen, according to the manufacturer'sinstructions. For example, total RNA from cells in culture can beisolated using Qiagen Rneasy.RTM. mini-columns (referred to above).Other commercially available RNA isolation kits includeMasterPure.TM. Complete DNA and RNA Purification Kit(EPICENTRE.TM., Madison, Wis.), and Paraffin Block RNA IsolationKit (Ambion, Inc.). Total RNA from tissue samples can be isolatedusing RNA Stat-60 (Tel-Test). RNA prepared from tumor can beisolated, for example, by cesium chloride density gradientcentrifugation.

[0103] Since RNA generally cannot serve as a template for PCR, theprocess of gene expression profiling by RT-PCR typically includesthe reverse transcription of the RNA template into cDNA, followedby its exponential amplification in a PCR reaction. Two commonlyused reverse transcriptases are avilo myeloblastosis virus reversetranscriptase (AMV-RT) and Moloney murine leukemia virus reversetranscriptase (MMLV-RT). The reverse transcription-step istypically primed using specific primers, random hexamers, oroligo-dT primers, depending on the particular circumstances ofexpression profiling analysis. For example, extracted RNA can bereverse-transcribed using a GeneAmp RNA PCR kit (Perkin Elmer,Calif., USA), following the manufacturer's instructions. Thederived cDNA can then be used as a template in the subsequent PCRreaction.

[0104] Although the PCR step can use a variety of thermostableDNA-dependent DNA polymerases, it typically employs the Taq DNApolymerase, which has a 5'-3' nuclease activity but lacks a 3'-5'proofreading endonuclease activity. Thus, TaqMan.RTM. PCR typicallyutilizes the 5'-nuclease activity of Taq or Tth polymerase tohydrolyze a hybridization probe bound to its target amplicon, butany enzyme with equivalent 5' nuclease activity can be used. Pairsof primers are generally used to generate amplicons in PCRreactions. A third oligonucleotide, or probe, is designed to bindto nucleotide sequence located between PCR primer pairs. Probe aregenerally non-extendible by Taq DNA polymerase enzyme, and aretypically labeled with, e.g., a reporter fluorescent dye and aquencher fluorescent dye. Laser-induced emission from the reporterdye is quenched by the quenching dye when the two dyes are locatedclose together, such as in an intact probe. During theamplification reaction, the Taq DNA polymerase enzyme cleaves theprobe in a template-dependent manner. The resultant probe fragmentsdisassociate in solution, and signal from the released reporter dyeis free from the quenching effect of the second fluorophore. Onemolecule of reporter dye is typically liberated for each newmolecule synthesized, and detection of the unquenched reporter dyeprovides the basis for quantitative interpretation of the data.

[0105] TaqMan.RTM. RT-PCR can be performed using commerciallyavailable equipment, such as, for example, a LightCycler.RTM.system (Roche Molecular Biochemicals, Mannheim, Germany) or an ABIPRISM 7700.TM. Sequence Detection System.TM. (Perkin-Elmer-AppliedBiosystems, Foster City, Calif., USA).

[0106] To minimize errors and the effect of sample-to-samplevariation, RT-PCR is typically performed using an internalstandard. An ideal internal standard is expressed at a relativelyconstant level among different cells or tissues, and is unaffectedby the experimental treatment. Exemplary RNAs frequently used tonormalize patterns of gene expression are mRNAs transcribed fromfor the housekeeping genes glyceraldehyde-3-phosphate-dehydrogenase(GAPDH) and .beta.-actin.

[0107] Other exemplary methods for targeted mRNA analysis includedifferential display reverse transcriptase PCR (DDRT-PCR) and RNAarbitrarily primed PCR (RAP-PCR) (see, e.g., U.S. Pat. No.5,599,672; Liang and Pardee (1992) Science 257:967-971; Welsh etal. (1992) Nucleic Acids Res. 20:4965-4970, which are eachincorporated by reference). Both methods use random priming togenerate RT-PCR fingerprint profiles of transcripts in anunfractionated RNA preparation. The signal generated in these typesof analyses is a pattern of bands separated on a sequencing gel.Differentially expressed genes appear as changes in the fingerprintprofiles between two samples, which can be loaded in separate wellsof the same gel. This type of readout allows identification of bothup- and down-regulation of genes in the same reaction, appearing aseither an increase or decrease in intensity of a band from onesample to another.

[0108] Molecular beacons are oligonucleotides designed for realtime detection and quantification of target nucleic acids. The 5'and 3' termini of molecular beacons collectively comprise a pair ofmoieties, which confers the detectable properties of the molecularbeacon. One of the termini is attached to a fluorophore and theother is attached to a quencher molecule capable of quenching afluorescent emission of the fluorophore. To illustrate, one examplefluorophore-quencher pair can use a fluorophore, such as EDANS orfluorescein, e.g., on the 5'-end and a quencher, such as Dabcyl,e.g., on the 3'-end. When the molecular beacon is present free insolution, i.e., not hybridized to a second nucleic acid, the stemof the molecular beacon is stabilized by complementary basepairing. This self-complementary pairing results in a "hairpinloop" structure for the molecular beacon in which the fluorophoreand the quenching moieties are proximal to one another. In thisconfirmation, the fluorescent moiety is quenched by the quenchingmoiety. The loop of the molecular beacon typically comprises theoligonucleotide probe and is accordingly complementary to asequence to be detected in the target microbial nucleic acid, suchthat hybridization of the loop to its complementary sequence in thetarget forces disassociation of the stem, thereby distancing thefluorophore and quencher from each other. This results inunquenching of the fluorophore, causing an increase in fluorescenceof the molecular beacon.

[0109] Details regarding standard methods of making and usingmolecular beacons are well established in the literature andmolecular beacons are available from a number of commercial reagentsources. Further details regarding methods of molecular beaconmanufacture and use are found, e.g., in Leone et al. (1995)"Molecular beacon probes combined with amplification by NASBAenable homogenous real-time detection of RNA," Nucleic Acids Res.26:2150-2155; Kostrikis et al. (1998) "Molecular beacons: spectralgenotyping of human alleles" Science 279:1228-1229; Fang et al.(1999) "Designing a novel molecular beacon for surface-immobilizedDNA hybridization studies" J. Am. Chem. Soc. 121:2921-2922; andMarras et al. (1999) "Multiplex detection of single-nucleotidevariation using molecular beacons" Genet. Anal. Biomol. Eng.14:151-156, all of which are incorporated by reference. A varietyof commercial suppliers produce standard and custom molecularbeacons, including Oswel Research Products Ltd. (UK), ResearchGenetics (a division of Invitrogen, Huntsville, Ala., USA), theMidland Certified Reagent Company (Midland, Tex., USA), and GorillaGenomics, LLC (Alameda, Calif., USA). A variety of kits whichutilize molecular beacons are also commercially available, such asthe Sentinel.TM. Molecular Beacon Allelic Discrimination Kits fromStratagene (La Jolla, Calif., USA) and various kits from EurogentecSA (Belgium) and Isogen Bioscience BV (Netherlands).

[0110] Nucleic Acid Array-Based Analysis

[0111] Differential gene expression can also be identified, orconfirmed using arrayed oligonucleotides (e.g., microarrays), whichhave the benefit of assaying for sample hybridization to a largenumber of probes in a highly parallel fashion. In these approaches,polynucleotide sequences of interest (e.g., probes, such as cDNAs,mRNAs, oligonucleotides, etc.) are plated, synthesized, orotherwise disposed on a microchip substrate or other type of solidsupport (see, e.g., U.S. Pat. Nos. 5,143,854 and 5,807,522; Fodoret al. (1991) Science 251:767-773; and Schena et al. (1995) Science270:467-470, which are each incorporated by reference). Sequencesof interest can be obtained, e.g., by creating a cDNA library froman mRNA source or by using publicly available databases, such asGenBank, to annotate the sequence information of custom cDNAlibraries or to identify cDNA clones from previously preparedlibraries. The arrayed sequences are then hybridized with targetnucleic acids from cells or tissues of interest. As in the RT-PCRassays referred to above, the source of mRNA typically is total RNAisolated from a sample.

[0112] In certain embodiments, high-density oligonucleotide arraysare produced using a light-directed chemical synthesis process(i.e., photolithography). Unlike common cDNA arrays,oligonucleotide arrays (according, e.g., to the Affymetrixtechnology) typically use a single-dye technology. Given thesequence information of the probes or markers, the sequences aretypically synthesized directly onto the array, thus, bypassing theneed for physical intermediates, such as PCR products, commonlyutilized in making cDNA arrays. For this purpose, selected markers,or partial sequences thereof, can be represented by, e.g., betweenabout 14 to 20 features, typically by less then 14 features, moretypically less then about 10 features, even more typically by about6 features or less, with each feature generally being a shortsequence of nucleotides (oligonucleotide), which is typically aperfect match (PM) to a segment of the respective gene. The PMoligonucleotides are paired with mismatch (MM) oligonucleotides,which have a single mismatch at the central base of the nucleotideand are used as "controls". The chip exposure sites are typicallydefined by masks and are de-protected by the use of light, followedby a chemical coupling step resulting in the synthesis of onenucleotide. The masking, light deprotection, and coupling processcan then be repeated to synthesize the next nucleotide, until thenucleotide chain is of the specified length.

[0113] To illustrate other embodiments of microarray-based assays,PCR amplified inserts of cDNA clones are applied to a substrate ina dense array. In some embodiments, for example, at least 10,000different cDNA probe sequences are applied to a given solidsupport. Fluorescently labeled cDNA targets may be generatedthrough incorporation of fluorescent nucleotides by reversetranscription of RNA extracted from the samples of interest.Labeled cDNA targets applied to the chip hybridize withcorresponding probes on the array. After washing (e.g., understringent conditions) to remove non-specifically bound probes, thechip is typically scanned by confocal laser microscopy or byanother detection method, such as a CCD camera. Quantitation ofhybridization of each arrayed element allows for assessment ofcorresponding mRNA abundance. With dual color fluorescence, forexample, separately labeled cDNA probes generated from two sourcesof RNA can be hybridized concurrently to the arrayed probes. Therelative abundance of the transcripts from the two sourcescorresponding to each specified gene can thus be determinedsimultaneously. The miniaturized scale of the hybridization affordsa convenient and rapid evaluation of the expression pattern forlarge numbers of genes. Such methods have been shown to have thesensitivity required to detect rare transcripts, which areexpressed at a few copies per cell, and to reproducibly detect atleast approximately two-fold differences in the expression levels(Schena et al., Proc. Natl. Acad. Sci. USA 93(2):106-149 (1996),which is incorporated by reference). Other microarray-based assayformats are also optionally utilized. Microarray analysis can beperformed using commercially available equipment, followingmanufacturer's protocols, such as by using the AffymetrixGeneChip.RTM. technology, or Agilent's microarray technology.

[0114] If the polynucleotide being detected is mRNA, cDNA may beprepared into which a detectable label, as exemplified herein, isincorporated. For example, labeled cDNA, in single-stranded form,may then be hybridized (e.g., under stringent or highly stringentconditions) to a panel of single-stranded oligonucleotidesrepresenting different genes and affixed to a solid support, suchas a chip. Upon applying appropriate washing steps, those cDNAsthat have a counterpart in the oligonucleotide panel or array willbe detected (e.g., quantitatively detected). Various advantageousembodiments of this general method are feasible. For example, mRNAor cDNA may be amplified, e.g., by a polymerase chain reaction oranother nucleic acid amplification technique. In some embodiments,where quantitative assessments are sought, it is generallydesirable that the number of amplified copies corresponds to thenumber of mRNAs originally present in the cell. Optionally, cDNAsare transcribed into cRNAs prior to hybridization steps in a givenassay. In these embodiments, labels can be attached or incorporatedcRNAs during or after the transcription step.

[0115] To further illustrate, one exemplary embodiment of themethods of the invention includes, as follows (1) obtaining asample, e.g. bone marrow or peripheral blood aliquots, from apatient; (2) extracting RNA, e.g., mRNA, from the sample; (3)reverse transcribing the RNA into cDNA; (4) in vitro transcribingthe cDNA into cRNA; (5) fragmenting the cRNA; (6) hybridizing thefragmented cRNA on selected microarrays (e.g., the HG-U133microarray set available from Affymetrix, Inc. (Santa Clara, Calif.USA)); and (7) detecting hybridization.

[0116] Serical Analysis of Gene Expression (SAGE)

[0117] Serial analysis of gene expression (SAGE) is a method thatallows the simultaneous and quantitative analysis of a large numberof gene transcripts, without the need for providing an individualhybridization probe for each transcript. Initially, a shortsequence tag (e.g., about 10-14 bp) is generated that containssufficient information to uniquely identify a transcript, providedthat the tag is obtained from a unique position within eachtranscript. Then, many transcripts are linked together to form longserial molecules, that can be sequenced, revealing the identity ofthe multiple tags simultaneously. The expression pattern of anypopulation of transcripts can be quantitatively evaluated bydetermining the abundance of individual tags, and identifying thegene corresponding to each tag. SAGE-based assays are alsodescribed in, e.g. Velculescu et al., Science 270:484-487 (1995)and Velculescu et al., Cell 88:243-51 (1997), which are bothincorporated by reference.

[0118] Gene Expression Analysis by Massively Parallel SignatureSequencing (MPSS)

[0119] These sequencing approaches generally combine non-gel-basedsignature sequencing with in vitro cloning of millions of templateson separate 5 .mu.m diameter microbeads. Typically, a microbeadlibrary of DNA templates is constructed by in vitro cloning. Thisis generally followed by the assembly of a planar array of thetemplate-containing microbeads in a flow cell at a high density(typically greater than 3.times.10.sup.6 microbeads/cm.sup.2). Thefree ends of the cloned templates on each microbead are analyzedsimultaneously, using a fluorescence-based signature sequencingmethod that does not require DNA fragment separation. This methodcan be used to simultaneously and accurately provide, in a singleoperation, hundreds of thousands of gene signature sequences fromcDNA libraries. MPSS is also described in, e.g., Brenner et al.,(2000) Nature Biotechnology 18:630-634, which is incorporated byreference.

[0120] Immunoassays and Proteomics

[0121] Essentially any available technique for the detection ofproteins is optionally utilized in the methods of the invention.Exemplary protein analysis technologies include, e.g., one- andtwo-dimensional SDS-PAGE-based separation and detection,immunoassays (e.g., western blotting, etc.), aptamer-baseddetection, mass spectrometric detection, and the like. These andother techniques are generally well-known in the art.

[0122] To illustrate, immunohistochemical methods are optionallyused for detecting the expression levels of the targets describedherein. Thus, antibodies or antisera (e.g., polyclonal antisera)and in certain embodiments, monoclonal antibodies specific forparticular targets are used to detect expression. In some of theseembodiments, antibodies are directly labeled, e.g., withradioactive labels, fluorescent labels, haptens, chemiluminescentdyes, enzyme substrates or co-factors, enzyme inhibitors, freeradicals, enzymes (e.g., horseradish peroxidase or alkalinephosphatase), or the like. Such labeled reagents may be used in avariety of well known assays, such as radioimmunoassays, enzymeimmunoassays, e.g., ELISA, fluorescent immunoassays, and the like.See, e.g., U.S. Pat. Nos. 3,766,162; 3,791,932; 3,817,837; and4,233,402, which are each incorporated by reference. Additionallabels are described further herein. Alternatively, unlabeledprimary antibodies are used in conjunction with labeled secondaryantibodies, comprising antisera, polyclonal antisera or amonoclonal antibody specific for the primary antibody.Immunohistochemistry protocols and kits are well known in the artand are commercially available.

[0123] To further illustrate, proteins from a cell or tissue underinvestigation may be contacted with a panel or array of aptamers orof antibodies or fragments or derivatives thereof. Thesebiomolecules may be affixed to a solid support, such as a chip. Thebinding of proteins indicative of a given leukemia type or subtypeis optionally verified by binding to a detectably labeled secondaryantibody or aptamer. The labeling of antibodies is also describedin, e.g., Harlow and Lane, Antibodies a laboratory manual, CSHPress (1988), which is incorporated by reference. To furtherillustrate, a minimum set of proteins necessary for detectingvarious leukemia types or subtypes may be selected for the creationof a protein array for use in making diagnoses with, e.g., proteinlysates of bone marrow samples directly. Protein array systems forthe detection of specific protein expression profiles arecommercially available from various suppliers, including theBio-Plex.TM. platform available from BIO-RAD Laboratories (Munich,Germany). In some embodiments of the invention, antibodies againstthe target proteins are produced and immobilized on a solidsupport, e.g., a glass slide or a well of a microtiter plate. Theimmobilized antibodies can be labeled with a reactant that isspecific for the target proteins. These reactants can include,e.g., enzyme substrates, DNA, receptors, antigens or antibodies tocreate for example a capture sandwich immunoassay.

[0124] Target proteins can also be detected using aptamersincluding photoaptamers. Aptamers generally are single-strandedoligonucleotides (e.g., typically DNA for diagnostic applications)that assume a specific, sequence-dependent shape and binds totarget proteins based on a "lock-and-key" fit between the twomolecules. Aptamers can be identified using the SELEX process (Gold(1996) "The SELEX process: a surprising source of therapeutic anddiagnostic compounds," Harvey Lect. 91:47-57, which is incorporatedby reference). Aptamer arrays are commercially available fromvarious suppliers including, e.g., SomaLogic, Inc. (Boulder, Colo.,USA).

[0125] The detection of proteins via mass includes various formatsthat can be adapted for use in the methods of the invention.Exemplary formats include matrix assisted laserdesorption/ionization--(MALDI) and surface enhanced laserdesorption/ionization-based (SELDI) detection. MALDI- andSELDI-based detection are also described in, e.g., Weinberger etal. (2000) "Recent trends in protein biochip technology,"Pharmacogenomics 1(4):395-416, Forde et al. (2002)"Characterization of transcription factors by mass spectrometry andthe role of SELDI-MS," Mass Spectrom. Rev. 21(6):419-439, andLeushner (2001) "MALDI TOF mass spectrometry: an emerging platformfor genomics and diagnostics," Expert Rev. Mol. Diagn. 1(1): 11-18,which are each incorporated by reference. Protein chips and relatedinstrumentation are available from commercial suppliers, such asCiphergen Biosystems, Inc. (Fremont, Calif., USA).

Oligonucleotide Preparation

[0126] Various approaches can be utilized by one of skill in theart to design oligonucleotides for use as probes and/or primers. Toillustrate, the DNAstar software package available from DNASTAR,Inc. (Madison, Wis.) can be used for sequence alignments. Forexample, target nucleic acid sequences and non-target nucleic acidsequences can be uploaded into DNAstar EditSeq program asindividual files, e.g., as part of a process to identify regions inthese sequences that have low sequence similarity. To furtherillustrate, pairs of sequence files can be opened in the DNAstarMegAlign sequence alignment program and the Clustal W method ofalignment can be applied. The parameters used for Clustal Walignments are optionally the default settings in the software.MegAlign typically does not provide a summary of the percentidentity between two sequences. This is generally calculatedmanually. From the alignments, regions having, e.g., less than 85%identity with one another are typically identified andoligonucleotide sequences in these regions can be selected. Manyother sequence alignment algorithms and software packages are alsooptionally utilized. Sequence alignment algorithms are alsodescribed in, e.g., Mount, Bioinformatics: Sequence and GenomeAnalysis, Cold Spring Harbor Laboratory Press (2001), and Durbin etal., Biological Sequence Analysis: Probabilistic Models of Proteinsand Nucleic Acids, Cambridge University Press (1998), which areboth incorporated by reference.

[0127] To further illustrate, optimal alignment of sequences forcomparison can be conducted, e.g., by the local homology algorithmof Smith & Waterman (1981) Adv. Appl. Math. 2:482, by thehomology alignment algorithm of Needleman & Wunsch (1970) J.Mol. Biol. 48:443, by the search for similarity method of Pearson& Lipman (1988) Proc. Nat'l. Acad. Sci. USA 85:2444, which areeach incorporated by reference, and by computerized implementationsof these algorithms (e.g., GAP, BESTFIT, FASTA, and TFASTA in theWisconsin Genetics Software Package, Genetics Computer Group(Madison, Wis.)), or by even by visual inspection.

[0128] Another example algorithm that is suitable for determiningpercent sequence identity is the BLAST algorithm, which isdescribed in, e.g., Altschul et al. (1990) J. Mol. Biol.215:403-410, which is incorporated by reference. Software forperforming versions of BLAST analyses is publicly available throughthe National Center for Biotechnology Information on the world wideweb at ncbi.nlm.nih.gov/ as of Nov. 4, 2004.

[0129] An additional example of a useful sequence alignmentalgorithm is PILEUP. PILEUP creates a multiple sequence alignmentfrom a group of related sequences using progressive, pairwisealignments. It can also plot a tree showing the clusteringrelationships used to create the alignment. PILEUP uses asimplification of the progressive alignment method of Feng &Doolittle (1987) J. Mol. Evol. 35:351-360, which is incorporated byreference.

[0130] Oligonucleotide probes and primers are optionally preparedusing essentially any technique known in the art. In certainembodiments, for example, the oligonucleotide probes and primersare synthesized chemically using essentially any nucleic acidsynthesis method, including, e.g., according to the solid phasephosphoramidite method described by Beaucage and Caruthers (1981)Tetrahedron Letts. 22(20): 1859-1862, which is incorporated byreference. To further illustrate, oligonucleotides can also besynthesized using a triester method (see, e.g., Capaldi et al.(2000) "Highly efficient solid phase synthesis of oligonucleotideanalogs containing phosphorodithioate linkages" Nucleic Acids Res.28(9):e40 and Eldrup et al. (1994) "Preparation ofoligodeoxyribonucleoside phosphorodithioates by a triester method"Nucleic Acids Res. 22(10):1797-1804, which are both incorporated byreference). Other synthesis techniques known in the art can also beutilized, including, e.g., using an automated synthesizer, asdescribed in Needham-VanDevanter et al. (1984) Nucleic Acids Res.12:6159-6168, which is incorporated by reference. A wide variety ofequipment is commercially available for automated oligonucleotidesynthesis. Multi-nucleotide synthesis approaches (e.g.,tri-nucleotide synthesis, etc.) are also optionally utilized.Moreover, the primer nucleic acids optionally include variousmodifications. In certain embodiments, for example, primers includerestriction site linkers, e.g., to facilitate subsequent ampliconcloning or the like. To further illustrate, primers are alsooptionally modified to improve the specificity of amplificationreactions as described in, e.g., U.S. Pat. No. 6,001,611, entitled"MODIFIED NUCLEIC ACID AMPLIFICATION PRIMERS," issued Dec. 14, 1999to Will, which is incorporated by reference. Primers and probes canalso be synthesized with various other modifications as describedherein or as otherwise known in the art.

[0131] Probes and/or primers utilized in the methods and otheraspects of the invention are typically labeled to permit detectionof probe-target hybridization duplexes. In general, a label can beany moiety that can be attached to a nucleic acid and provide adetectable signal (e.g., a quantifiable signal). Labels may beattached to oligonucleotides directly or indirectly by a variety oftechniques known in the art. To illustrate, depending on the typeof label used, the label can be attached to a terminal (5' or 3'end of an oligonucleotide primer and/or probe) or a non-terminalnucleotide, and can be attached indirectly through linkers orspacer arms of various sizes and compositions. Using commerciallyavailable phosphoramidite reagents, one can produceoligonucleotides containing functional groups (e.g., thiols orprimary amines) at either the 5' or 3' terminus via anappropriately protected phosphoramidite, and can label sucholigonucleotides using protocols described in, e.g., Innis et al.(Eds.) PCR Protocols: A Guide to Methods and Applications, ElsevierScience & Technology Books (1990) (Innis), which isincorporated by reference.

[0132] Essentially any labeling moiety is optionally utilized tolabel a probe and/or primer by techniques well known in the art. Insome embodiments, for example, labels comprise a fluorescent dye(e.g., a rhodamine dye (e.g., R6G, R110, TAMRA, ROX, etc.), afluorescein dye (e.g., JOE, VIC, TET, HEX, FAM, etc.), ahalofluorescein dye, a cyanine dye (e.g., CY3, CY3.5, CY5, CY5.5,etc.), a BODIPY.RTM. dye (e.g., FL, 530/550, TR, TMR, etc.), anALEXA FLUOR.RTM. dye (e.g., 488, 532, 546, 568, 594, 555, 653, 647,660, 680, etc.), a dichlororhodamine dye, an energy transfer dye(e.g., BIGDYE.TM. v 1 dyes, BIGDYE.TM. v 2 dyes, BIGDYE.TM. v 3dyes, etc.), Lucifer dys yellow, etc.), CASCADE BLUE.RTM., OregonGreen, and the like. Additional examples of fluorescent dyes areprovided in, e.g., Haugland, Molecular Probes Handbook ofFluorescent Probes and Research Products, Ninth Ed. (2003) and theupdates thereto, which are each incorporated by reference.Fluorescent dyes are generally readily available from variouscommercial suppliers including, e.g., Molecular Probes, Inc.(Eugene, Oreg.), Amersham Biosciences Corp. (Piscataway, N.J.),Applied Biosystems (Foster City, Calif.), etc. Other labelsinclude, e.g., biotin, weakly fluorescent labels (Yin et al. (2003)Appl Environ Microbiol. 69(7):3938, Babendure et al. (2003) Anal.Biochem. 317(1):1, and Jankowiak et al. (2003) Chem Res Toxicol.16(3):304), non-fluorescent labels, colorimetric labels,chemiluminescent labels (Wilson et al. (2003) Analyst. 128(5):480and Roda et al. (2003) Luminescence 18(2):72), Raman labels,electrochemical labels, bioluminescent labels (Kitayama et al.(2003). Photochem Photobiol. 77(3):333, Arakawa et al. (2003) Anal.Biochem. 314(2):206, and Maeda (2003) J. Pharm. Biomed. Anal.30(6):1725), and an alpha-methyl-PEG labeling reagent as describedin, e.g., U.S. Provisional Patent Application No. 60/428,484, filedon Nov. 22, 2002, which references are each incorporated byreference. Nucleic acid labeling is also described further below.In some embodiments, labeling is achieved using syntheticnucleotides (e.g., synthetic ribonucleotides, etc.) and/orrecombinant phycoerythrin (PE).

[0133] In addition, whether a fluorescent dye is a label or aquencher is generally defined by its excitation and emissionspectra, and the fluorescent dye with which it is paired.Fluorescent molecules commonly used as quencher moieties in probesand primers include, e.g., fluorescein, FAM, JOE, rhodamine, R6G,TAMRA, ROX, DABCYL, and EDANS. Many of these compounds areavailable from the commercial suppliers referred to above.Exemplary non-fluorescent or dark quenchers that dissipate energyabsorbed from a fluorescent dye include the Black HoleQuenchers.TM. or BHQ.TM., which are commercially available fromBiosearch Technologies, Inc. (Novato, Calif., USA).

[0134] To further illustrate, essentially any nucleic acid (andvirtually any labeled nucleic acid, whether standard ornon-standard) can be custom or standard ordered from any of avariety of commercial sources, such as The Midland CertifiedReagent Company, The Great American Gene Company, ExpressGen Inc.,Operon Technologies Inc., Proligo LLC, and many others.

[0135] In certain embodiments, modified nucleotides are included inprobes and primers. To illustrate, the introduction of modifiednucleotide substitutions into oligonucleotide sequences can, e.g.,increase the melting temperature of the oligonucleotides. In someembodiments, this can yield greater sensitivity relative tocorresponding unmodified oligonucleotides even in the presence ofone or more mismatches in sequence between the target nucleic acidand the particular oligonucleotide. Exemplary modified nucleotidesthat can be substituted or added in oligonucleotides include, e.g.,C5-ethyl-dC, C5-methyl-dU, C5-ethyl-dU, 2,6-diaminopurines,C5-propynyl-dC, C7-propynyl-dA, C7-propynyl-dG,C5-propargylamino-dC, C5-propargylamino-dU, C7-propargylamino-dA,C7-propargylamino-dG, 7-deaza-2-deoxyxanthosine, pyrazolopyrimidineanalogs, pseudo-dU, nitro pyrrole, nitro indole, 2'-0-methylRibo-U, 2'-0-methyl Ribo-C, an 8-aza-dA, an 8-aza-dG, a 7-deaza-dA,a 7-deaza-dG, N4-ethyl-dC, N6-methyl-dA, etc. To furtherillustrate, other examples of modified oligonucleotides includethose having one or more LNA.TM. monomers. Nucleotide analogs suchas these are also described in, e.g., U.S. Pat. No. 6,639,059,entitled "SYNTHESIS OF [2.2.1]BICYCLO NUCLEOSIDES," issued Oct. 28,2003 to Kochkine et al., U.S. Pat. No. 6,303,315, entitled "ONESTEP SAMPLE PREPARATION AND DETECTION OF NUCLEIC ACIDS IN COMPLEXBIOLOGICAL SAMPLES," issued Oct. 16, 2001 to Skouv, and U.S. Pat.Application Pub. No. 2003/0092905, entitled "SYNTHESIS OF[2.2.1]BICYCLO NUCLEOSIDES," by Kochkine et al. that published May15, 2003, which are each incorporated by reference.Oligonucleotides comprising LNA.TM. monomers are commerciallyavailable through, e.g., Exiqon A/S (Vedbaek, DK). Additionaloligonucleotide modifications are referred to herein, including inthe definitions provided above.

Array Formats

[0136] In certain embodiments, oligonucleotide probes designed tohybridize with target nucleic acids are covalently or noncovalentlyattached to solid supports. In these embodiments, labeled ampliconsderived from patient samples are typically contacted with thesesolid support-bound probes to effect hybridization and detection.In other embodiments, amplicons are attached to solid supports andcontacted with labeled probes. Optionally, antibodies, aptamers, orother probe biomolecules utilized in a given assay are similarlyattached to solid supports.

[0137] Essentially any substrate material can be adapted for use asa solid support. In certain embodiments, for example, substratesare fabricated from silicon, glass, or polymeric materials (e.g.,glass or polymeric microscope slides, silicon wafers, wells ofmicrowell plates, etc.). Suitable glass or polymeric substrates,including microscope slides, are available from various commercialsuppliers, such as Fisher Scientific (Pittsburgh, Pa., USA) or thelike. In some embodiments, solid supports utilized in the inventionare membranes. Suitable membrane materials are optionally selectedfrom, e.g. polyaramide membranes, polycarbonate membranes, porousplastic matrix membranes (e.g., POREX.RTM. Porous Plastic, etc.),nylon membranes, ceramic membranes, polyester membranes,polytetrafluoroethylene (TEFLON.RTM.) membranes, nitrocellulosemembranes, or the like. Many of these membranous materials arewidely available from various commercial suppliers, such as, P. J.Cobert Associates, Inc. (St. Louis, Mo., USA), MilliporeCorporation (Bedford, Mass., USA), or the like. Other exemplarysolid supports that are optionally utilized include, e.g.,ceramics, metals, resins, gels, plates, beads (e.g., magneticmicrobeads, etc.), whiskers, fibers, combs, single crystals,self-assembling monolayers, and the like.

[0138] Nucleic acids are directly or indirectly (e.g., via linkers,such as bovine serum albumin (BSA) or the like) attached to thesupports, e.g., by any available chemical or physical method. Awide variety of linking chemistries are available for linkingmolecules to a wide variety of solid supports. More specifically,nucleic acids may be attached to the solid support by covalentbinding, such as by conjugation with a coupling agent or bynon-covalent binding, such as electrostatic interactions, hydrogenbonds or antibody-antigen coupling, or by combinations thereof.Typical coupling agents include biotin/avidin, biotin/streptavidin,Staphylococcus aureus protein A/IgG antibody F.sub.c fragment, andstreptavidin/protein A chimeras (Sano et al. (1991) Bio/Technology9:1378, which is incorporated by reference), or derivatives orcombinations of these agents. Nucleic acids may be attached to thesolid support by a photocleavable bond, an electrostatic bond, adisulfide bond, a peptide bond, a diester bond or a combination ofthese bonds. Nucleic acids are also optionally attached to solidsupports by a selectively releasable bond such as4,4'-dimethoxytrityl or its derivative.

[0139] Cleavable attachments can be created by attaching cleavablechemical moieties between the probes and the solid supportincluding, e.g., an oligopeptide, oligonucleotide, oligopolyamide,oligoacrylamide, oligoethylene glycerol, alkyl chains of betweenabout 6 to 20 carbon atoms, and combinations thereof. Thesemoieties may be cleaved with, e.g., added chemical agents,electromagnetic radiation, or enzymes. Exemplary attachmentscleavable by enzymes include peptide bonds, which can be cleaved byproteases, and phosphodiester bonds which can be cleaved bynucleases.

[0140] Chemical agents such as .beta.-mercaptoethanol,dithiothreitol (DTT) and other reducing agents cleave disulfidebonds. Other agents which may be useful include oxidizing agents,hydrating agents and other selectively active compounds.Electromagnetic radiation such as ultraviolet, infrared and visiblelight cleave photocleavable bonds. Attachments may also bereversible, e.g., using heat or enzymatic treatment, or reversiblechemical or magnetic attachments. Release and reattachment can beperformed using, e.g., magnetic or electrical fields.

[0141] A number of array systems have been described and can beadapted for use in the detection of target microbial nucleic acids.Aspects of array construction and use are also described in, e.g.,Sapolsky et al. (1999) "High-throughput polymorphism screening andgenotyping with high-density oligonucleotide arrays" GeneticAnalysis: Biomolecular Engineering 14:187-192, Lockhart (1998)"Mutant yeast on drugs" Nature Medicine 4:1235-1236, Fodor (1997)"Genes, Chips and the Human Genome" FASEB Journal 11:A879, Fodor(1997) "Massively Parallel Genomics" Science 277: 393-395, and Cheeet al. (1996) "Accessing Genetic Information with High-Density DNAArrays" Science 274:610-614, all of which are incorporated byreference.

Nucleic Acid Hybridization

[0142] The length of complementary region or sequence betweenprimer or probes and their binding partners (e.g., target nucleicacids) should generally be sufficient to allow selective orspecific hybridization of the primers or probes to the targets atthe selected annealing temperatures used for a particular nucleicacid amplification protocol, expression profiling assay, etc.Although other lengths are optionally utilized, complementaryregions of, for example, between about 10 and about 50 nucleotides(e.g., about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 or morenucleotides) are typically used in a given application.

[0143] "Stringent hybridization wash conditions" in the context ofnucleic acid hybridization experiments, such as Southern andnorthern hybridizations, are sequence dependent, and are differentunder different environmental parameters. An extensive guide to thehybridization of nucleic acids is found in Tijssen (1993), supra,and in Hames and Higgins 1 and Hames and Higgins 2, supra.

[0144] For purposes of the present invention, generally, "highlystringent" hybridization and wash conditions are selected to beabout 5.degree. C. or less lower than the thermal melting point(T.sub.m) for the specific sequence at a defined ionic strength andpH (as noted below, highly stringent conditions can also bereferred to in comparative terms). The T.sub.m is the temperature(under defined ionic strength and pH) at which 50% of the testsequence hybridizes to a perfectly matched primer or probe. Verystringent conditions are selected to be equal to the T.sub.m for aparticular primer or probe.

[0145] The T.sub.m is the temperature of the nucleic acid duplexesindicates the temperature at which the duplex is 50% denaturedunder the given conditions and its represents a direct measure ofthe stability of the nucleic acid hybrid. Thus, the T.sub.mcorresponds to the temperature corresponding to the midpoint intransition from helix to random coil; it depends on length,nucleotide composition, and ionic strength for long stretches ofnucleotides.

[0146] After hybridization, unhybridized nucleic acid material canbe removed by a series of washes, the stringency of which can beadjusted depending upon the desired results. Low stringency washingconditions (e.g., using higher salt and lower temperature) increasesensitivity, but can product nonspecific hybridization signals andhigh background signals. Higher stringency conditions (e.g., usinglower salt and higher temperature that is closer to thehybridization temperature) lowers the background signal, typicallywith only the specific signal remaining. See, e.g., Rapley et al.(Eds.), Molecular Biomethods Handbook (Humana Press, Inc. 1998),which is incorporated by reference.

[0147] Thus, one measure of stringent hybridization is the abilityof the primer or probe to hybridize to one or more of the targetnucleic acids (or complementary polynucleotide sequences thereof)under highly stringent conditions. Stringent hybridization and washconditions can easily be determined empirically for any testnucleic acid.

[0148] For example, in determining highly stringent hybridizationand wash conditions, the hybridization and wash conditions aregradually increased (e.g., by increasing temperature, decreasingsalt concentration, increasing detergent concentration and/orincreasing the concentration of organic solvents, such as formalin,in the hybridization or wash), until a selected set of criteria ismet. For example, the hybridization and wash conditions aregradually increased until a target nucleic acid, and complementarypolynucleotide sequences thereof, binds to a perfectly matchedcomplementary nucleic acid.

[0149] A target nucleic acid is said to specifically hybridize to aprimer or probe nucleic acid when it hybridizes at least as well tothe primer or probe as to a perfectly matched complementary target,i.e., with a signal to noise ratio at least 1/2 as high ashybridization of the primer or probe to the target under conditionsin which the perfectly matched primer or probe binds to theperfectly matched complementary target with a signal to noise ratiothat is at least about 2.5.times.-10.times., typically5.times.-10.times. as high as that observed for hybridization toany of the unmatched target nucleic acids.

Nucleic Acid Amplification

[0150] In some embodiments, RNA is converted to cDNA in areverse-transcription (RT) reaction using, e.g., a target-specificprimer complementary to the RNA for each gene target beingmonitored. Methods of reverse transcribing RNA into cDNA are wellknown, and described in Sambrook, supra. Alternative methods forreverse transcription utilize thermostable DNA polymerases, asdescribed in the art. As an exemplary embodiment, avianmyeloblastosis virus reverse transcriptase (AMV-RT), or Maloneymurine leukemia virus reverse transcriptase (MoMLV-RT) is used,although other enzymes are also optionally utilized. An advantageof using target-specific primers in the RT reaction is that onlythe desired sequences are converted into a PCR template.Superfluous primers or cDNA products are generally not carried intosubsequent PCR amplifications.

[0151] In another embodiment, RNA targets are reverse transcribedusing non-specific primers, such as an anchored oligo-dT primer, orrandom sequence primers. An advantage of this embodiment is thatthe "unfractionated" quality of the mRNA sample is maintainedbecause the sites of priming are non-specific, i.e., the productsof this RT reaction will serve as template for any desired targetin the subsequent PCR amplification. This allows samples to bearchived in the form of DNA, which is more stable than RNA.

[0152] In other embodiments, transcription-based amplificationsystems (TAS) are used, such as that first described by Kwoh et al.(Proc. Natl. Acad. Sci. (1989) 86(4): 1173-7), or isothermaltranscription-based systems such as 3SR (Self-Sustained SequenceReplication; Guatelli et al. (1990) Proc. Natl. Acad. Sci.87:1874-1878) or NASBA (nucleic acid sequence based amplification;Kievits et al. (1991) J Virol Methods. 35(3):273-86), which areeach incorporated by reference. In these methods, the mRNA targetof interest is copied into cDNA by a reverse transcriptase. Theprimer for cDNA synthesis includes the promoter sequence of adesignated DNA-dependent RNA polymerase 5' to the primer's regionof homology with the template. The resulting cDNA products can thenserve as templates for multiple rounds of transcription by theappropriate RNA polymerase. Transcription of the cDNA templaterapidly amplifies the signal from the original target mRNA. Theisothermal reactions bypass the need for denaturing cDNA strandsfrom their RNA templates by including RNAse H to degrade RNAhybridized to DNA.

[0153] In other exemplary embodiments, amplification isaccomplished by used of the ligase chain reaction (LCR), disclosedin European Patent Application No. 320,308 (Backman and Wang), orby the ligase detection reaction (LDR), disclosed in U.S. Pat. No.4,883,750 (Whiteley et al.), which are each incorporated byreference. In LCR, two probe pairs are typically prepared, whichare complimentary each other, and to adjacent sequences on bothstrands of the target. Each pair will bind to opposite strands ofthe target such that they abut. Each of the two probe pairs canthen be linked to form a single unit, using a thermostable ligase.By temperature cycling, as in PCR, bound ligated units dissociatefrom the target, then both molecules can serve as "targetsequences" for ligation of excess probe pairs, providing for anexponential amplification. The LDR is very similar to LCR. In thisvariation, oligonucleotides complimentary to only one strand of thetarget are used, resulting in a linear-amplification ofligation-products, since only the original target DNA can serve asa hybridization template. It is used following a PCR amplificationof the target in order to increase signal.

[0154] In further embodiments, several methods generally known inthe art would be suitable methods of amplification. Some additionalexamples include, but are not limited to, strand displacementamplification (Walker et al. (1992) Nucleic Acids Res.20:1691-1696), repair chain reaction (REF), cyclic probe reaction(REF), solid-phase amplification, including bridge amplification(Mehta and Singh (1999) BioTechniques 26(6): 1082-1086), rollingcircle amplification (Kool, U.S. Pat. No. 5,714,320), rapidamplification of cDNA ends (Frohman (1988) Proc. Natl. Acad. Sci.85: 8998-9002), and the "invader assay" (Griffin et al. (1999)Proc. Natl. Acad. Sci. 96: 6301-6306), which are each incorporatedby reference. Amplicons are optionally recovered and purified fromother reaction components by any of a number of methods well knownin the art, including electrophoresis, chromatography,precipitation, dialysis, filtration, and/or centrifugation. Aspectsof nucleic acid purification are described in, e.g., Douglas etal., DNA Chromatography, Wiley, John & Sons, Inc. (2002), andSchott, Affinity Chromatography: Template Chromatography of NucleicAcids and Proteins, Chromatographic Science Series, #27, MarcelDekker (1984), both of which are incorporated by reference. Incertain embodiments, amplicons are not purified prior to detection,such as when amplicons are detected simultaneous withamplification.

Data Collection

[0155] The number of species than can be detected within a mixturedepends primarily on the resolution capabilities of the separationplatform used, and the detection methodology employed. In someembodiments, separation steps are is based upon size-basedseparation technologies. Once separated, individual species aredetected and quantitated by either inherent physicalcharacteristics of the molecules themselves, or detection of anassociated label.

[0156] Embodiments employing other separation methods are alsodescribed. For example, certain types of labels allow resolution oftwo species of the same mass through deconvolution of the data.Non-size based differentiation methods (such as deconvolution ofdata-from-overlapping signals generated by two differentfluorophores) allow pooling of a plurality of multiplexed reactionsto further increase throughput.

[0157] Separation Methods

[0158] Certain embodiments of the invention incorporate a step ofseparating the products of a reaction based on their sizedifferences. The PCR products generated during an amplificationreaction typically range from about 50 to about 500 bases inlength, which can be resolved from one another by size. Any one ofseveral devices may be used for size separation, including massspectrometry, any of several electrophoretic devices, includingcapillary, polyacrylamide gel, or agarose gel electrophoresis, orany of several chromatographic devices, including columnchromatography, HPLC, or FPLC.

[0159] In some embodiments, sample analysis includes the use ofmass spectrometry. Several modes of separation that determine massare possible, including Time-of-Flight (TOF), Fourier TransformMass Spectrometry (FTMS), and quadruple mass spectrometry. Possiblemethods of ionization include Matrix-Assisted Laser Desorption andIonization (MALDI) or Electrospray Ionization (ESI). A preferredembodiment for the uses described in this invention is MALDI-TOF(Wu, et al. (1993) Rapid Communications in Mass Spectrometry7:142-146, which is incorporated by reference). This method may beused to provide unfragmented mass spectra of mixed-baseoligonucleotides containing between about 1 and about 1000 bases.In preparing the sample for analysis, the analyte is mixed into amatrix of molecules that resonantly absorb light at a specifiedwavelength. Pulsed laser light is then used to desorboligonucleotide molecules out of the absorbing solid matrix,creating free, charged oligomers and minimizing fragmentation. Anexemplary solid matrix material for this purpose is3-hydroxypicolinic acid (Wu, supra), although others are alsooptionally used.

[0160] In another embodiment, a microcapillary is used for analysisof nucleic acids obtained from the sample. Microcapillaryelectrophoresis generally involves the use of a thin capillary orchannel, which may optionally be filled with a particular medium toimprove separation, and employs an electric field to separatecomponents of the mixture as the sample travels through thecapillary. Samples composed of linear polymers of a fixedcharge-to-mass ratio, such as DNA or RNA, will separate based onsize. The high surface to volume ratio of these capillaries allowsapplication of very high electric fields across the capillarywithout substantial thermal variation, consequently allowing veryrapid separations. When combined with confocal imaging methods,these methods provide sensitivity in the range of attomoles,comparable to the sensitivity of radioactive sequencing methods.The use of microcapillary electrophoresis in size separation ofnucleic acids has been reported in Woolley and Mathies (Proc. Natl.Acad. Sci. USA (1994) 91:11348-11352), which is incorporated byreference. Capillaries are optionally fabricated from fused silica,or etched, machined, or molded into planar substrates. In manymicrocapillary electrophoresis methods, the capillaries are filledwith an appropriate separation/sieving matrix. Several sievingmatrices are known in the art that may be used for thisapplication, including, e.g., hydroxyethyl cellulose,polyacrylamide, agarose, and the like. Generally, the specific gelmatrix, running buffers and running conditions are selected toobtain the separation required for a particular application.Factors that are considered include, e.g., sizes of the nucleicacid fragments, level of resolution, or the presence of undenaturednucleic acid molecules. For example, running buffers may includeagents such as urea to denature double-stranded nucleic acids in asample.

[0161] Microfluidic systems for separating molecules such as DNAand RNA are commercially available and are optionally employed inthe methods of the present invention. For example, the "PersonalLaboratory System" and the "High Throughput System" have beendeveloped by Caliper Lifesciences Corp. (Mountain View, Calif.).The Agilent 2100, which uses Caliper Lifesciences' LabChip.TM.microfluidic systems, is available from Agilent Technologies (PaloAlto, Calif., USA). Currently, specialized microfluidic devices,which provide for rapid separation and analysis of both DNA and RNAare available from Caliper Lifesciences for the Agilent 2100.

[0162] Other embodiments are generally known in the art forseparating PCR amplification products by electrophoresis throughgel matrices. Examples include polyacrylamide, agarose-acrylamide,or agarose gel electrophoresis, using standard methods (Sambrook,supra).

[0163] Alternatively, chromatographic techniques may be employedfor resolving amplification products. Many types of physical orchemical characteristics may be used to effect chromatographicseparation in the present invention, including adsorption,partitioning (such as reverse phase), ion-exchange, and sizeexclusion. Many specialized techniques have been developed fortheir application including methods utilizing liquid chromatographyor HPLC (Katz and Dong (1990) BioTechniques 8(5):546-55; Gaus etal. (1993) J. Immunol. Methods 158:229-236). In yet anotherembodiment, cDNA products are captured by their affinity forcertain substrates, or other incorporated binding properties. Forexample, labeled cDNA products such as biotin or antigen can becaptured with beads bearing avidin or antibody, respectively.Affinity capture is utilized on a solid support to enable physicalseparation. Many types of solid supports are known in the art thatwould be applicable to the present invention. Examples includebeads (e.g. solid, porous, magnetic), surfaces (e.g. plates,dishes, wells, flasks, dipsticks, membranes), or chromatographicmaterials (e.g. fibers, gels, screens).

[0164] Certain separation embodiments entail the use ofmicrofluidic techniques. Technologies include separation on amicrocapillary platform, such as designed by ACLARA BioSciencesInc. (Mountain View, Calif.), or the LabChip.TM. microfluidicdevices made by Caliper Lifesciences Corp. Another technologydeveloped by Nanogen, Inc. (San Diego, Calif.), utilizesmicroelectronics to move and concentrate biological molecules on asemiconductor microchip. The microfluidics platforms developed atOrchid Biosciences, Inc. (Princeton, N.J.), including theChemtel.TM. Chip, which provides for parallel processing ofhundreds of reactions, can also be used in certain embodiments.These microfluidic platforms require only nanoliter sample volumes,in contrast to the microliter volumes required by otherconventional separation technologies.

[0165] Some of the processes usually involved in genetic analysishave been miniaturized using microfluidic devices. For example, PCTpublication WO 94/05414 reports an integrated micro-PCR apparatusfor collection and amplification of nucleic acids from a specimen.U.S. Pat. No. 5,304,487 (Wilding et al.) and U.S. Pat. No.5,296,375 (Kricka et al.) discuss devices for collection andanalysis of cell-containing samples. U.S. Pat. No. 5,856,174(Lipshutz et al.) describes an apparatus that combines the variousprocessing and analytical operations involved in nucleic acidanalysis. Each of these references is incorporated byreference.

[0166] Additional technologies are also contemplated. For example,Kasianowicz et al. (Proc. Natl. Acad. Sci. USA (1996)93:13770-13773, which is incorporated by reference) describes theuse of ion channel pores in a lipid bilayer membrane fordetermining the length of polynucleotides. In this system, anelectric field is generated by the passage of ions through thepores. Polynucleotide lengths are measured as a transient decreaseof ionic current due to blockage of ions passing through the poresby the nucleic acid. The duration of the current decrease was shownto be proportional to polymer length. Such a system can be appliedas a size separation platform in certain embodiments of the presentinvention.

[0167] Primers are useful both as reagents for hybridization insolution, such as priming PCR amplification, as well as forembodiments employing a solid phase, such as microarrays. Withmicroarrays, sample nucleic acids such as mRNA or DNA are fixed ona selected matrix or surface. PCR products may be attached to thesolid surface via one of the amplification primers, then denaturedto provide single-stranded DNA. This spatially-partitioned,single-stranded nucleic acid is then subject to hybridization withselected probes under conditions that allow a quantitativedetermination of target abundance. In this embodiment,amplification products from each individual reaction are notphysically separated, but are differentiated by hybridizing with aset of probes that are differentially labeled. Alternatively,unextended amplification primers may be physically immobilized atdiscreet positions on the solid support, then hybridized with theproducts of a nucleic acid amplification for quantitation ofdistinct species within the sample. In this embodiment,amplification products are separated by way of hybridization withprobes that are spatially separated on the solid support.

[0168] Separation platforms may optionally be coupled to utilizetwo different separation methodologies, thereby increasing themultiplexing capacity of reactions beyond that which can beobtained by separation in a single dimension. For example, some ofthe RT-PCR primers of a multiplex reaction may be coupled with amoiety that allows affinity capture, while other primers remainunmodified. Samples are then passed through an affinitychromatography column to separate PCR products arising from thesetwo classes of primers. Flow-through fractions are collected andthe bound fraction eluted. Each fraction may then be furtherseparated based on other criteria, such as size, to identifyindividual components.

[0169] Detection Methods

[0170] Following separation of the different products of amultiplex amplification, one or more of the amplicons are detectedand/or quantitated. Some embodiments of the methods of the presentinvention enable direct detection of products. Other embodimentsdetect reaction products via a label associated with one or more ofthe amplification primers. Many types of labels suitable for use inthe present invention are known in the art, includingchemiluminescent, isotopic, fluorescent, electrochemical, inferred,or mass labels, or enzyme tags. In further embodiments, separationand detection may be a multi-step process in which samples arefractionated according to more than one property of the products,and detected one or more stages during the separation process.

[0171] An exemplary embodiment of the invention that does not uselabeling or modification of the molecules being analyzed isdetection of the mass-to-charge ratio of the molecule itself. Thisdetection technique is optionally used when the separation platformis a mass spectrometer. An embodiment for increasing resolution andthroughput with mass detection is in mass-modifying theamplification products. Nucleic acids can be mass-modified througheither the amplification primer or the chain-elongating nucleosidetriphosphates. Alternatively, the product mass can be shiftedwithout modification of the individual nucleic acid components, byinstead varying the number of bases in the primers. Several typesof moieties have been shown to be compatible with analysis by massspectrometry, including polyethylene glycol, halogens, alkyl, aryl,or aralkyl moieties, peptides (described in, for example, U.S. Pat.No. 5,691,141, which is incorporated by reference). Isotopicvariants of specified atoms, such as radioisotopes or stable,higher mass isotopes, are also used to vary the mass of theamplification product. Radioisotopes can be detected based on theenergy released when they decay, and numerous applications of theiruse are generally known in the art. Stable (non-decaying) heavyisotopes can be detected based on the resulting shift in mass, andare useful for distinguishing between two amplification productsthat would otherwise have similar or equal masses. Otherembodiments of detection that make use of inherent properties ofthe molecule being analyzed include ultraviolet light absorption(UV) or electrochemical detection. Electrochemical detection isbased on oxidation or reduction of a chemical compound to which avoltage has been applied. Electrons are either donated (oxidation)or accepted (reduction), which can be monitored as current. Forboth UV absorption and electrochemical detection, sensitivity foreach individual nucleotide varies depending on the component base,but with molecules of sufficient length this bias is insignificant,and detection levels can be taken as a direct reflection of overallnucleic acid content.

[0172] Some embodiments of the invention include identifyingmolecules indirectly by detection of an associated label. A numberof labels may be employed that provide a fluorescent signal fordetection. If a sufficient quantity of a given species is generatedin a reaction, and the mode of detection has sufficientsensitivity, then some fluorescent molecules may be incorporatedinto one or more of the primers used for amplification, generatinga signal strength proportional to the concentration of DNAmolecules. Several fluorescent moieties, including Alexa 350, Alexa430, AMCA, BODIPY 630/650, BODIPY 650/665, BODIPY-FL, BODIPY-R6G,BODIPY-TMR, BODIPY-TRX, carboxyfluorescein, Cascade Blue, Cy3, Cy5,6-FAM, Fluorescein, HEX, 6-JOE, Oregon Green 488, Oregon Green 500,Oregon Green 514, Pacific Blue, REG, Rhodamine Green, RhodamineRed, ROX, TAMRA, TET, Tetramethylrhodamine, and Texas Red, aregenerally known in the art and routinely used for identification ofdiscrete nucleic acid species, such as in sequencing reactions.Many of these dyes have emission spectra distinct from one another,enabling deconvolution of data from incompletely resolved samplesinto individual signals. This allows pooling of separate reactionsthat are each labeled with a different dye, increasing thethroughput during analysis, as described in more detail below.Additional examples of suitable labels are described herein.

[0173] The signal strength obtained from fluorescent dyes can beenhanced through use of related compounds called energy transfer(ET) fluorescent dyes. After absorbing light, ET dyes have emissionspectra that allow them to serve as "donors" to a secondary"acceptor" dye that will absorb the emitted light and emit a lowerenergy fluorescent signal. Use of these coupled-dye systems cansignificantly amplify fluorescent signal. Examples of ET dyesinclude the ABI PRISM BigDye terminators, recently commercializedby Perkin-Elmer Corporation (Foster City, Calif., USA) forapplications in nucleic acid analysis. These chromophoresincorporate the donor and acceptor dyes into a single molecule andan energy transfer linker couples a donor fluorescein to adichlororhodamine acceptor dye, and the complex is attached, e.g.,to a primer.

[0174] Fluorescent signals can also be generated by non-covalentintercalation of fluorescent dyes into nucleic acids after theirsynthesis and prior to separation. This type of signal will vary inintensity as a function of the length of the species beingdetected, and thus signal intensities must be normalized based onsize. Several applicable dyes are known in the art, including, butnot limited to, ethidium bromide and Vistra Green. Someintercalating dyes, such as YOYO or TOTO, bind so strongly thatseparate DNA molecules can each be bound with a different dye andthen pooled, and the dyes will not exchange between DNA species.This enables mixing separately generated reactions in order toincrease multiplexing during analysis.

[0175] Alternatively, technologies such as the use of nanocrystalsas a fluorescent DNA label (Alivisatos, et al. (1996) Nature382:609-11, which is incorporated by reference) can be employed inthe methods of the present invention. Another method, described byMazumder, et al. (Nucleic Acids Res. (1998) 26:1996-2000, which isincorporated by reference), describes hybridization of a labeledoligonucleotide probe to its target without physical separationfrom unhybridized probe. In this method, the probe is labeled witha chemiluminescent molecule that in the unbound form is destroyedby sodium sulfite treatment, but is protected in probes that havehybridized to target sequence.

[0176] In other embodiments, both electrochemical and infraredmethods of detection can be amplified over the levels inherent tonucleic acid molecules through attachment of EC or IR labels. Theircharacteristics and use as labels are described in, for example,PCT publication WO 97/27327, which is incorporated by reference.Some preferred compounds that can serve as an IR label include anaromatic nitrile, aromatic alkynes, or aromatic azides. Numerouscompounds can serve as an EC label; many are listed in PCTpublication WO 97/27327.

[0177] Enzyme-linked reactions are also employed in the detectingstep of the methods of the present invention. Enzyme-linkedreactions theoretically yield an infinite signal, due toamplification of the signal by enzymatic activity. In thisembodiment, an enzyme is linked to a secondary group that has astrong binding affinity to the molecule of interest. Followingseparation of the nucleic acid products, enzyme is bound via thisaffinity interaction. Nucleic acids are then detected by a chemicalreaction catalyzed by the associated enzyme. Various couplingstrategies are possible utilizing well-characterized interactionsgenerally known in the art, such as those between biotin andavidin, an antibody and antigen, or a sugar and lectin. Varioustypes of enzymes can be employed, generating colorimetric,fluorescent, chemiluminescent, phosphorescent, or other types ofsignals. As an illustration, a primer may be synthesized containinga biotin molecule. After amplification, amplicons are separated bysize, and those made with the biotinylated primer are detected bybinding with streptavidin that is covalently coupled to an enzyme,such as alkaline phosphatase. A subsequent chemical reaction isconducted, detecting bound enzyme by monitoring the reactionproduct. The secondary affinity group may also be coupled to anenzymatic substrate, which is detected by incubation with unboundenzyme. One of skill in the art can conceive of many possiblevariations on the different embodiments of detection methodsdescribed above.

[0178] In some embodiments, it may be desirable prior to detectionto separate a subset of amplification products from othercomponents in the reaction, including other products. Exploitationof known high-affinity biological interactions can provide amechanism for physical capture. Some examples of high-affinityinteractions include those between a hormone with its receptor, asugar with a lectin, avidin and biotin, or an antigen with itsantibody. After affinity capture, molecules are retrieved bycleavage, denaturation, or eluting with a competitor for binding,and then detected as usual by monitoring an associated label. Insome embodiments, the binding interaction providing for capture mayalso serve as the mechanism of detection.

[0179] Furthermore, the size of an amplification product orproducts are optionally changed, or "shifted," in order to betterresolve the amplification products from other products prior todetection. For example, chemically cleavable primers can be used inthe amplification reaction. In this embodiment, one or more of theprimers used in amplification contains a chemical linkage that canbe broken, generating two separate fragments from the primer.Cleavage is performed after the amplification reaction, removing afixed number of nucleotides from the 5' end of products made fromthat primer. Design and use of such primers is described in detailin, for example, PCT publication WO 96/37630, which is incorporatedby reference.

Data Analysis

[0180] For reliably classifying AML, for example, it is generallydesirable to determine the expression of more than one of themarkers described herein. As an exemplary criterion for the choiceof markers, the statistical significance of markers as expressed inq or p values based on the concept of the false discovery rate isoptionally determined. In doing so, a measure of statisticalsignificance called the q value is associated with each testedfeature. The q value is similar to the p value, except it is ameasure of significance in terms of the false discovery rate ratherthan the false positive rate (see, e.g., Storey et al. (2003) Proc.Natl. Acad. Sci. 100:9440-5, which is incorporated byreference).

[0181] In some embodiments, the markers described herein haveq-values of less than about 3E-06, typically less than about1.5E-09, more typically less than about 1.5E-11, even moretypically less than about 0.5E-20, and still more typically lessthan about 1.5E-30.

[0182] Of the markers described or referred to herein, theexpression level of at least about two, typically of at least aboutten, more typically of at least about 25, and even more typicallyof at least about 50 of these markers is determined as describedherein or by another technique known to those of skill in the art.In some embodiments, for example, expression levels of one or moreof the genes listed in Tables 1-13 are determined in a givensample. In certain embodiments, expression levels of each of thesegenes in a sample is determined and compared with expression levelsdetected in one or more reference cells. Furthermore, theInternational Publication No. WO 03/039443, which is incorporatedby reference, discloses certain marker genes the expression levelsof which are characteristic for certain leukemia. Certain of themarkers and/or methods disclosed therein are optionally utilized inperforming the methods described herein.

[0183] The level of the expression of a marker is indicative of theclass of AML cell. The level of expression of a marker or group ofmarkers is measured and is generally compared with the level ofexpression of the same marker or the same group of markers fromother cells or samples. The comparison may be effected in an actualexperiment or in silico. There is a meaningful difference in theselevels of expression, e.g., when these expression levels (alsoreferred to as expression pattern, expression signature, orexpression profile) are measurably different. In some embodiments,the difference is typically at least about 5%, 10% or 20%, moretypically at least about 50% or may even be as high as 75% or 100%.To further illustrate, the difference in the level of expression isoptionally at least about 200%, i.e., two fold, at least about500%, i.e., five fold, or at least about 1000%, i.e., 10 fold insome embodiments.

[0184] In certain embodiments, for example, the expression level ofmarkers expressed lower in a first subtype than in at least onesecond subtype, which differs from the first subtype, is at leastabout 5%, 10% or 20%, more typically at least about 50% or may evenbe about 75% or about 100%, more typically at least about 10-fold,even more typically at least 50-fold, and still more typically atleast about 100-fold lower in the first subtype. On the other hand,the expression level of markers expressed higher in a first subtypethan in at least one second subtype, which differs from the firstsubtype, is at generally least about 5%, 10% or 20%, more generallyat least about 50% or may even be about 75% or about 100%, moregenerally at least 10-fold, still more generally at least about50-fold, and even more generally at least about 100-fold higher inthe first subtype.

[0185] The classification accuracy of a given gene list for a setof microarray experiments is preferably estimated using SupportVector Machines (SVM), because there is evidence that SVM-basedprediction slightly outperforms other classification techniques,such as k-Nearest Neighbors (k-NN). The LIBSVM software packageversion 2.36, for example, is optionally used (SVM-type: SVC,linear kernel (http://www.csie.ntu.edu.tw/-cj.1in/libsvrn/)).Machine learning algorithms are also described in, e.g., Brown etal. (2000) Proc. Natl. Acad. Sci., 97:262-267, Furey et al. (2000)Bioinformatics, 16:906-914, and Vapnik, Statistical LearningTheory, Wiley (1998), which are each incorporated by reference.

[0186] To further illustrate, the classification accuracy of agiven gene list for a set of microarray experiments can beestimated using Support Vector Machines (SVM) as supervisedlearning techniques. Generally, SVMs are trained usingdifferentially expressed genes, which were identified on a subsetof the data and then this trained model is employed to assign newsamples to those trained groups from a second and different dataset. Differentially expressed genes are optionally identified,e.g., applying analysis of variance (ANOVA) and t-test-statistics(Welch t-test). Based on identified distinct gene expressionsignatures, respective training sets consisting of, e.g., 2/3 ofcases and test sets with 1/3 of cases to assess classificationaccuracies can be designated. Assignment of cases to training andtest sets is optionally randomized and balanced by diagnosis. Basedon the training set, a Support Vector Machine (SVM) model can bebuilt using this approach.

[0187] The apparent accuracy of prediction, i.e., the overall rateof correct predictions of the complete data set can be estimatedby, e.g., 10-fold cross validation. This process typically includesdividing the data set into 10 approximately equally sized subsets,training an SVM-model for 9 subsets, and generating predictions forthe remaining subset. This training and prediction process can berepeated 10 times to include predictions for each subset.Subsequently the data set can be split into a training set,consisting of two thirds of the samples, and a test set with theremaining one third. Apparent accuracy for the training set canalso be estimated by 10fold cross validation (analogous to apparentaccuracy for complete set). An SVM-model of the training set isoptionally built to predict diagnosis in the independent test set,thereby estimating true accuracy of the prediction model. Thisprediction approach can be applied both for overall classification(multi-class) and binary classification (diagnosis X=>yes orno). For the latter, sensitivity and specificity are optionallycalculated, as follows:

Sensitivity=(number of positive samples predicted)/(number of truepositive)

Specificity=(number of negative samples predicted)/(number of truenegatives).

Systems for Gene Expression Analysis

[0188] The present invention also provides systems for analyzinggene expression. The system includes one or more probes thatcorrespond to at least portions of genes or expression productsthereof. The genes are selected from the markers listed in one ormore of Tables 1-42. In some embodiments, for example, the probesare nucleic acids (e.g., oligonucleotides, cDNAs, cRNAs, etc.),whereas in other embodiments, the probes are biomolecules (e.g.,antibodies, aptmers, etc.) designed to detect expression productsof the genes (e.g., proteins or fragments thereof). In certainembodiments, the probes are arrayed on a solid support, whereas inothers, they are provided in one or more containers, e.g., forassays performed in solution. The system also includes at least onereference data bank or database for correlating detected expressionlevels of polynucleotides and/or polypeptides in at least onetarget cell from a subject, which polynucleotides and/orpolypeptides are targets of one or more of the probes, with thetarget cell being an AML cell. In some embodiments, the referencedata bank is backed up on a computational data memory chip or othercomputer readable medium, which can be inserted in as well asremoved from system of the present invention, e.g., like aninterchangeable module, in order to use another data memory chipcontaining a different reference data bank. In certain embodiments,the systems also include detectors (e.g., spectrometers, etc.) thatdetect binding between the probes and targets. Other detectors aredescribed further below. In addition, the systems also generallyinclude at least one controller operably connected to the referencedata bank and/or to the detector. In some embodiments, for example,the controller is integral with the reference data bank.

[0189] The systems of the present invention that include a desiredreference data bank can be used in a way such that an unknownsample is, first, subjected to gene expression profiling, e.g., bymicroarray analysis in a manner as described herein or otherwiseknown to person skilled in the art, and the expression level dataobtained by the analysis are, second, fed into the system andcompared with the data of the reference data bank obtainable by theabove method. For this purpose, the apparatus suitably contains adevice for entering the expression level of the data, for example,a control panel such as a keyboard. The results, whether and howthe data of the unknown sample fit into the reference data bank canbe made visible on a monitor or display screen and, if desired,printed out on an incorporated of connected printer. Computercomponents are described further below.

[0190] In some embodiments, a system optionally further includes athermal modulator operably connected to containers to modulatetemperature in the containers (e.g., to effect thermocycling whentarget nucleic acids are amplified in the containers), and/or fluidtransfer components (e.g., automated pipettors, etc.) that transferfluid to and/or from the containers. Optionally, these systems alsoinclude robotic components for translocating solid supports,containers, and the like, and/or separation components (e.g.,microfluidic devices, chromatography columns, etc.) for separatingthe products of amplification reactions from one another.

[0191] The invention further provides a computer or computerreadable medium that includes a data set that comprises a pluralityof character strings that correspond to a plurality of sequences(or subsequences thereof) that correspond to genes selected from,e.g., the list provided in Tables 1-42. Typically, the computer orcomputer readable medium further includes an automatic synthesizercoupled to an output of the computer or computer readable medium.The automatic synthesizer accepts instructions from the computer orcomputer readable medium, which instructions direct synthesis of,e.g., one or more probe nucleic acids that correspond to one ormore character strings in the data set.

[0192] Detectors are structured to detect detectable signalsproduced, e.g., in or proximal to another component of the system(e.g., in container, on a solid support, etc.). Suitable signaldetectors that are optionally utilized, or adapted for use, inthese systems detect, e.g., fluorescence, phosphorescence,radioactivity, absorbance, refractive index, luminescence, or thelike. Detectors optionally monitor one or a plurality of signalsfrom upstream and/or downstream of the performance of, e.g., agiven assay step. For example, the detector optionally monitors aplurality of optical signals, which correspond in position to "realtime" results. Example detectors or sensors include photomultipliertubes, CCD arrays, optical sensors, temperature sensors, pressuresensors, pH sensors, conductivity sensors, scanning detectors, orthe like. Each of these as well as other types of sensors isoptionally readily incorporated into the systems described herein.Optionally, the systems of the present invention include multipledetectors.

[0193] More specific exemplary detectors that are optionallyutilized in these systems include, e.g., a resonance lightscattering detector, an emission spectroscope, a fluorescencespectroscope, a phosphorescence spectroscope, a luminescencespectroscope, a spectrophotometer, a photometer, and the like.Various synthetic components are also utilized, or adapted for, usein the systems of the invention including, e.g., automated nucleicacid synthesizers, e.g., for synthesizing the oligonucleotidesprobes described herein. Detectors and synthetic components thatare optionally included in the systems of the invention aredescribed further in, e.g., Skoog et al., Principles ofInstrumental Analysis, 5.sup.th Ed., Harcourt Brace CollegePublishers (1998) and Currell, Analytical Instrumentation:Performance Characteristics and Quality, John Wiley & Sons,Inc. (2000), both of which are incorporated by reference.

[0194] The systems of the invention also typically includecontrollers that are operably connected to one or more components(e.g., detectors, synthetic components, thermal modulator, fluidtransfer components, etc.) of the system to control operation ofthe components. More specifically, controllers are generallyincluded either as separate or integral system components that areutilized, e.g., to receive data from detectors, to effect and/orregulate temperature in the containers, to effect and/or regulatefluid flow to or from selected containers, or the like. Controllersand/or other system components is/are optionally coupled to anappropriately programmed processor, computer, digital device, orother information appliance (e.g., including an analog to digitalor digital to analog converter as needed), which functions toinstruct the operation of these instruments in accordance withpreprogrammed or user input instructions, receive data andinformation from these instruments, and interpret, manipulate andreport this information to the user. Suitable controllers aregenerally known in the art and are available from variouscommercial sources.

[0195] Any controller or computer optionally includes a monitorwhich is often a cathode ray tube ("CRT") display, a flat paneldisplay (e.g., active matrix liquid crystal display, liquid crystaldisplay, etc.), or others. Computer circuitry is often placed in abox, which includes numerous integrated circuit chips, such as amicroprocessor, memory, interface circuits, and others. The boxalso optionally includes a hard disk drive, a floppy disk drive, ahigh capacity removable drive such as a writeable CD-ROM, and othercommon peripheral elements. Inputting devices such as a keyboard ormouse optionally provide for input from a user. These componentsare illustrated further below.

[0196] The computer typically includes appropriate software forreceiving user instructions, either in the form of user input intoa set of parameter fields, e.g., in a GUI, or in the form ofpreprogrammed instructions, e.g., preprogrammed for a variety ofdifferent specific operations. The software then converts theseinstructions to appropriate language for instructing the operationof one or more controllers to carry out the desired operation. Thecomputer then receives the data from, e.g., sensors/detectorsincluded within the system, and interprets the data, eitherprovides it in a user understood format, or uses that data toinitiate further controller instructions, in accordance with theprogramming, e.g., such as controlling fluid flow regulators inresponse to fluid weight data received from weight scales or thelike.

[0197] The computer can be, e.g., a PC (Intel x86 or Pentiumchip-compatible DOS.TM., OS2.TM., WINDOWS.TM., WINDOWS NT.TM.,WINDOWS95.TM., WINDOWS98.TM., WINDOWS2000.TM., WINDOWS XP.TM.,LINUX-based machine, a MACINTOSH.TM., Power PC, or a UNIX-based(e.g., SUN.TM. work station) machine) or other common commerciallyavailable computer which is known to one of skill. Standard desktopapplications such as word processing software (e.g., MicrosoftWord.TM. or Corel WordPerfect.TM.) and database software (e.g.,spreadsheet software such as Microsoft Excel.TM., Corel QuattroPro.TM., or database programs such as Microsoft Access.TM. orParadox.TM.) can be adapted to the present invention. Software forperforming, e.g., controlling temperature modulators and fluid flowregulators is optionally constructed by one of skill using astandard programming language such as Visual basic, Fortran, Basic,Java, or the like.

[0198] Reference data banks can be produced by, e.g., (a) compilinga gene expression profile of a patient sample by determining theexpression level at least one marker selected from, e.g., thoselisted in one or more of Tables 1-42, and (b) classifying the geneexpression profile using a machine learning algorithm. Exemplarymachine learning algorithms are optionally selected from, e.g.,Weighted Voting, K-Nearest Neighbors, Decision Tree Induction,Support Vector Machines (SVM), and Feed-Forward Neural Networks. Insome embodiments, for example, the machine learning algorithm is anSVM, such as polynomial kernel, linear kernel, and Gaussian RadialBasis Function-kernel SVM models.

Kits

[0199] The present invention also provides kits that include atleast one probe as described herein for classifying AML. The kitsalso include instructions for correlating detected expressionlevels of polynucleotides and/or polypeptides in at least onetarget cell from a subject, which polynucleotides and/orpolypeptides are targets of one or more of the probes, with thetarget cell being an AML cell. The invention also provides kits forproviding prognostic information to subjects or patients diagnosedwith AML according to the related methods described herein.Typically, the kits include suitable auxiliaries, such as buffers,enzymes, labeling compounds, and/or the like. In some embodiments,probes are attached to solid supports, e.g. the wells of microtiterplates, nitrocellulose membrane surfaces, glass surfaces, toparticles in solution, etc. As another option, probes are providedfree in solution in containers, e.g., for performing the methods ofthe invention in a solution phase. In certain embodiments, kitsalso contain at least one reference cell. For example, thereference can be a sample, a database, or the like. In someembodiments, the kit includes primers and other reagents foramplifying target nucleic acids. Typically, kits also include atleast one container for packaging the probes, the set ofinstructions, and any other included components.

EXAMPLES

[0200] It is understood that the examples and embodiments describedherein are for illustrative purposes only and are not intended tolimit the scope of the claimed invention. It is also understoodthat various modifications or changes in light the examples andembodiments described herein will be suggested to persons skilledin the art and are to be included within the spirit and purview ofthis application and scope of the appended claims.

Example 1

General Experimental Design and Results

[0201] CEBPA-Mutations in AML with Prognostically IntermediateCytogenetics

[0202] Approximately 50% of acute myeloid leukemia (AML) have nokaryotype changes or those with yet unknown prognosticsignificance. They are usually pooled together into theprognostically intermediate group.

[0203] This analysis assessed the role of CEBPA mutations withinthis AML subgroup. In total, 255 AML, 237 with normal and 18 withother intermediate risk group karyotypes were screened for CEBPAmutations by sequencing. The total incidence of CEBPA mutations was51/255 (20%) ( 48/237 (20.3%) in the normal and 3/18 (16.7%) in theother karyotypes). Most of the patients showed an M1 (n=16), or M2(n=25) morphology, but there were also some with FAB M0 (n=1), M4(n=4), M5 (n=3), and M6 (n=2). CEBPA+ (i.e., having a CEBPAmutation) cases were younger as compared to the CEBPA- (i.e.,lacking a CEBPA mutation) cases (54.7 vs. 60.0, p=0.023). Leukocyteand platelet counts were similar. Clinical follow up data wereavailable for 191 (37 mutated, 154 non-mutated) patients. Overallsurvival (OS) and event-free survival (EFS) were significantlybetter in the patients with compared to those without CEBPAmutations (median 1092 vs. 259 days, p=0.0072; 375 vs. 218 days,p=0.0102, respectively). In addition, 18/42 (42.9%) of CEBPA+ caseshad an FLT3-LM, 4/40 (10%) an FLT3-TKD, 4/41 (9.8%) an MLL-PTD,3/34 (8.8%) an NRAS, 2/40 (5%) a KITD816 mutation. In four cases 2additional mutations were detected: 1.times.FLT3-LM+KITD816,1.times.FLT3-LM+FLT3-TKD, and 2.times.MLL-PTD+FLT3-LM. Thefavorable prognostic impact of CEBPA mutations was not affected byadditional mutations.

[0204] In addition, 22 of the CEBPA+ cases were analyzed bymicroarray analysis using the U133A+B array set (Affymetrix, Inc.,Santa Clara, Calif., USA) and compared to the expression profile of131 CEBPA- normal karyotype AML, as well as to 204 AMLcharacterized by the reciprocal translocations t(15;17) (n=43),t(8;21) (n=36), inv(16) (n=48), t(11q23) (n=50), inv(3) (n=27). Thediscrimination of CEBPA+ cases and reciprocal translocationsrevealed a classification accuracy of 94.7% with 75% sensitivityand 98.5% specificity. However, the CEPBA+ cases did not show aspecific expression pattern within the total group with normalkaryotype and could not be discriminated from CEBPA- cases. By useof PCA and hierarchical cluster analysis it was obvious that theCEBPA+ cases separated into two domains. One subcluster (cluster 1)was distributed among the cases with CEBPA- normal karyotype AML. Asecond cluster (cluster 2) was very close to the t(8;21) cases.Accordingly, cases of cluster 2 similar to t(8;21) and in contrastto cluster 1 highly expressed MPO and had low expression of HOXA3,HOXA7, HOXA9, HOXB4, HOXB6, and PBX3. Using the top 100differentially expressed genes and applying 100 runs of SVM with2/3 of samples being randomly selected as training set and 1/3 astest set samples, groups A and B could be classified with anoverall accuracy of 100% (sensitivity 100% and specificity 100%). Adetailed analysis of the two subclusters showed that all 8 cases ofcluster 1 revealed mutations in the TAD2 domain of CEBPA and 6 ofthese had an FLT3-LM in addition. In contrast, 12/14 cases ofcluster 2 had mutations that lead to an N-terminal stop and only 2had an FLT3-LM. Thus these two subclusters have biologicaldifferences that may explain the different gene expressionpatterns. Despite the different functional consequences of themutations in the two CEBPA-clusters no differences with respect toFAB type and prognosis were found between cluster 1 and 2.

[0205] Analysis of Molecular Markers in the PrognosticallyIntermediate Karyotype Group in AML

[0206] Acute myeloid leukemia (AML) can be divided intoprognostically different subgroups based on chromosomalaberrations. However, more than 50% of AML have no karyotypechanges or those with yet unknown prognostic significance and theyare usually pooled together into the prognostically intermediatekaryotype group (1-AML).

[0207] This analysis approached the subclassification of this largeAML group by using molecular markers. Six genes were screened formutations and analyzed for their prognostic significance incomparison to cases without the respective mutation. Results ofthis analysis are given in Table 14, below. Significant unfavorableimpact on overall survival (OS) was shown for the MLL-PTD in thetotal group and for AML1 mutations in FAB M0. Event-free survival(EFS) and relapse-free survival (RFS) was adversely affected by theFLT3-LM and EFS in AML1 mutated cases. In contrast CEBPA mutationsdisclose a favorable subgroup. Molecular mutations are not mutuallyexclusive. At least one additional mutation was observed in allpossible combinations in 1.1% to 34.7% (mean 10.9%). The mostfrequent combinations are MLL-PTD+FLT3-LM in 34.7% of all MLL-PTD+cases and CEBPA+FLT3-LM in 34.4% of all CEBPA+ cases. In contrast,double mutations of FLT3 or combinations of FLT3 or KIT with NRASare rare (1.1%-3.6%), suggesting a better cooperativity of CEBPAand MLL-PTD with FLT3-LM. For all combinations an effect onprognosis could not be shown in addition to those given in Table14. Three mutations were detected in 6 cases and again all of thepossible genes were involved at least once. In only one third ofall I-AML patients none of the analyzed mutations was detected. Atwo step hypothesis has recently been postulated for AML withfusion transcripts. The presented data support a two or maybemultistep theory for mutagenesis in AML with normal karyotype.Molecular mutations may have less transforming capacity, so thatmore than two mutations have to be accumulated. The pattern of thedetected mutations suggests CEBPA and MLL-PTD to be type IImutations (differentiation) whereas FLT3, KIT, and RAS havepreviously postulated to be type I mutations (proliferation).

[0208] In addition, gene expression studies were performed in 228I-AML positive for one or more of the mutations. All of thedifferent mutation groups did not reveal distinct individualexpression patterns. This suggests that specific pathways may beinvolved in the normal karyotype AML that are triggered redundantlyby different gene mutations.

TABLE-US-00001 TABLE 14 PROGNOSTIC SIGNIFICANCE OF GENE MUTATIONSCOMPARED TO THE GROUP TESTED NEGATIVE FOR THIS MUTATION IN THEPROGNOSTICALLY INTERMEDIATE GROUP AML1 (M0) CEBPA KIT FLT3-LMFLT-TKD MLL-PTD NRAS analyzed 80 191 676 1003 847 1024 718 +/-cases 13/67 37/154 12/664 317/686 62/785 96/928 71/647 frequency16.2% 19.4% 1.8% 31.5% 7.3% 9.4% 9.9% OS (p =) 0.0416# 0.0072*0.6229 0.1834 0.9327 0.0193# 0.4042 EFS (p =) 0.0345# 0.0102*0.3186 0.0124# 0.9898 0.1226 0.7637 RFS (p =) -- 0.0228* 0.41430.0012# 0.4074 0.6700 0.7310 *favorable, #unfavorable

[0209] Acute myeloid leukemia (AML) is a heterogeneous group ofdiseases with varying clinical outcomes. So far the karyotype ofthe leukemic blasts as well as molecular genetic abnormalities(both abnormalities on the genomic level) have been proven to bestrong prognostic markers. However, even in geneticallywell-defined subgroups clinical outcome is not uniform and a largeproportion of AML shows genetic abnormalities of yet unknownprognostic significance.

[0210] The analyses described in this example addressed thequestion whether gene expression profiles are associated withclinical outcome independent of the known genomic abnormalities.More specifically, gene expression analyses were performed usingAffymetrix U133A+B oligonucleotide microarrays in a total of 403AML treated uniformly in the AMLCG studies. This cohort was dividedrandomly into a training set (n=269) and a test set (n=134). Thetraining set included 18 cases with t(15;17), 22 cases witht(8;21), 29 cases with inv(16), 14 cases with11q23/MLL-rearrangement, 19 with complex aberrant karyotype and 167cases with normal karyotype or other chromosome aberrations. Therespective data for the test set were: 10 t(15;17), 8 t(8;21), 11inv(16), 8 11q23/MLL, 19 cases with complex aberrant karyotype and78 with normal karyotype or other chromosome aberrations. Based onthe clinical outcome the training cohort was divided into 4 equallylarge subgroups. Support vector machines (SVM) where trained withthe training set and classified the cases of the test set with therespective most discriminating genes. Next a Kaplan-Meier analysiswas performed with the test set cases assigned to prognostic groups1 to 4 according to SVM classification. Based on the expressionlevel of 100 genes group 1 showed an overall survival rate of 57%at 3 years. 31 of 134 (23%) patients were assigned to thisfavorable subgroup. They belonged to the following cytogeneticsubgroups: t(15;17) n=6, t(8;21) n=4, inv(16) n=3, 11q23/MLL n=4,complex aberrant karyotype n=1 and normal karyotype or otherchromosome aberration n=13. The overall survival rate of groups 2,3, and 4 did not differ significantly (17%, 21%, and 19% at 3years). Among the genes highly expressed in the favorable groupwere MPO and the transcription factor ATBF1, which regulates CCND1.The unfavorable groups were characterized by a higher expression ofthe transcription factors ETS2, RUNX1, TCF4, and FOXC1.Interestingly, 10 of the top 40 differentially expressed genes areinvolved in the TP53-CMYC-pathway with a higher expression of 9 ofthese in the unfavorable groups (SFRS1, TPD52, NRIP1, TFPI, UBL1,REC8L1, HSF2, ETS2 and RUNX1). See, Tables 1-3. In conclusion, geneexpression profiling leads to the identification of prognosticallyimportant alterations of molecular pathways which have not yet beenaccounted for by use of cytogenetics. This approach is can beutilized in, e.g., optimizing therapy for patients with AML.

[0211] Balanced chromosomal rearrangements leading to fusion geneson the molecular level define distinct biological subsets in AML.The four balanced rearrangements (t(15;17), t(8;21), inv(16), and11q23/MLL) show a close correlation to cytomorphology and geneexpression patterns. In this example, the focus was on seven AMLwith t(8;16) (p11;p13). This translocation is rare (7/3515 cases inown cohort). It is more frequently found in therapy-related AMLthan in de novo AML (3/258 t-AML, and 4/3287 de novo, p=0.0003).Cytomorphologically, AML with t(8;16) is characterized by strikingfeatures: in all 7 cases the positively for myeloperoxidase on bonemarrow smears was >70% and intriguingly, in parallel >80% ofblast cells stained strongly positive for non-specific esterase(NSE) in all cases. Thus, these cases could not be classifiedaccording to FAB categories. These data suggested that AML-t(8;16)arise from a very early stem cell with both myeloid and monoblasticpotential. Furthermore, erythrophagocytosis was detected in 6/7cases that was described as specific feature in AML with t(8;16).Four patients had chromosomal aberrations in addition to t(8;16), 3of these were t-AML all showing aberrations of 7q. Survival waspoor with 0, 1, 1, 2, 20 and 18+ (after alloBMT) months, one lostto follow-up, respectively. Gene expression patterns were analyzedin 4 cases (Affymetrix U133A+B). First, t(8;16) AML was comparedwith 46 AML FAB M1, 41 M4, 9 M5a, and 16 M5b, all with normalkaryotypes. Hierachical clustering and principal component analyses(PCA) revealed that t(8;16) AML were intercalating with FAB M4 andM5b and did not cluster near to M1. Thus, monocytic characteristicsinfluence the gene expression pattern stronger than myeloid. Next,the t(8;16) AML was compared with the 4 other balanced subtypesaccording to the WHO classification (t(15;17): 43; t(8;21): 40;inv(16): 49;11q23/MLL-rearrangements: 50). Using support vectormachines, the overall accuracy for correct subgroup assignment was97.3% (10-fold CV), and 96.8% (2/3 training and 1/3 test set, 100runs). In PCA and hierarchical cluster analysis, the t(8;16) wasgrouped in the vicinity of the 11q23 cases. However, in a pairwisecomparison these two subgroups could be discriminated with anaccuracy of 94.4% (10-fold CV). Genes with a specific expression inAML-t(8;16) were further investigated in pathway analyses(Ingenuity Systems (Mountain View, Calif., USA)). 15 of the top 100genes associated with AML-t(8;16) were involved in the CMYC-pathwaywith up regulation or higher expression of BCOR, COXB5, CDK10,FLI1, HNRPA2B1, NSEP1, PDIP38, RAD50, SUPT5H, TLR2 and USP33, anddown regulation or lower expression of ERG, GATA2, NCOR2 and RPS20.CEBP beta, known to play a role in myelomonocytic differentiation,was also up-regulated in t(8;16)-AML. Ten additional genes out ofthe 100 top differentially expressed genes were also involved inthis pathway with up-regulation of DDB2, HIST1H3D, NSAP1, PTPNS1,RAN, USP4, TRIM8, and ZNF278 and down regulation of KIT and MBD2.In conclusion, AML with t(8;16) is a specific subtype of AML withunique characteristics in morphology and gene expression patterns.It is more frequently found in t-AML, outcome is inferior incomparison to other AML with balanced translocations. Due to itsunique features, it is a candidate for inclusion into the WHOclassification as a specific entity.

[0212] Among the aims of this study was to analyze the impact oftrisomy 8 on the expression of genes located on chromosome 8 indifferent AML subgroups. Therefore, gene expression analyses wereperformed in a total of 567 AML cases using Affymetrix U133A+Boligonucleotide microarrays (Affymetrix, Inc., Santa Clara, Calif.,USA). The following 14 subgroups were analyzed: +8 sole (n=19), +8within a complex aberrant karyotype (n=11), +8 with t(115;17)(n=7), +8 and inv(16) (n=3), +8 with t(8;21) (n=3), +8 and11q23/MLL (n=8), and +8 with other abnormalities (n=10). These werecompared to 200 AML with normal karyotype and the followingsubgroups without trisomy 8: complex aberrant karyotype (n=73),t(15;17) (n=36), inv(16) (n=46), t(8;21) (n=37), 11q23/MLL (n=37),and other abnormalities (n=77). In total, 1188 probe sets coveredsequences located on chromosome 8 representing 580 genes. Asignificant higher mean expression of all genes located onchromosome 8 was observed in subgroups with +8 in comparison totheir respective control groups (for all comparisons, p<0.05).Significantly higher expressed genes in groups with +8 incomparison to the respective groups without +8 were identified inall comparisons. The number of identified genes ranged from 40 in11q23/MLL to 326 in trisomy 8 sole vs. normal. There was no commongene significantly overexpressed in all comparisons. Three genes(TRAM1, CHPPR, MGC40214) showed a significantly higher expressionin 5 out of 7 comparisons. Between 19 and 107 genes with anexclusive overexpression in trisomy 8 cases in only one subtypecomparison were identified.

[0213] In addition, class prediction was performed using supportvector machines (SVM) including all probe sets on the arrays. Inone approach, all 14 different subgroups were analyzed as one classeach. Only 3 out of 61 cases with trisomy 8 were assigned intotheir correct subclass, while 40 cases were assigned to theircorresponding genetic subclass without trisomy 8. In a secondapproach only two classes were defined: all cases with trisomy 8combined vs. all cases without trisomy 8. Only 26 out of 61 (42.6%)with trisomy 8 were identified correctly underlining the fact thatno distinct gene expression pattern is associated with trisomy 8 ingeneral. Performing SVM only with genes located on chromosome 8 didnot improve the correct assignment of cases with trisomy 8 overall.Only cases with trisomy 8 sole were correctly predicted in 58% ascompared to 11% in SVM using all genes.

[0214] To further illustrate, the 50 most differentially expressedgenes between AML with and without trisomy 8 are listed in Table19. The expression of genes was compared between the mentionedsubtypes characterized by a specific karyotype pattern and AML withthe same specific karyotype with trisomy 8 in addition. The mostdifferentially expressed genes are specified in Tables 21, 23, 25,27, 29, 31, and 33 (specific karyotype patterns are indicated inthe respective Tables). The most differentially genes taking intoaccount only genes located on chromosome 8 for the respectivecomparisons are listed in the respective Tables 22, 24, 26, 28, 30,32, and 34. In particular, differentially expressed genes betweent(8;21) and t(8;21) with trisomy 8 are listed in Tables 20 and 21;differentially expressed genes between t(15;17) and t(15;17) withtrisomy 8 are listed in Tables 23 and 24; differentially expressedgenes between inv(16) and inv(16) with trisomy 8 are listed inTables 25 and 26; differentially expressed genes between 11q23/MLLand 11q23/MLL with trisomy 8 are listed in Tables 27 and 28;differentially expressed genes between normal karyotype and normalkaryotype with trisomy 8 are listed in Tables 29 and 30;differentially expressed genes between other abnormalities and theother abnormalities with trisomy 8 are listed in Tables 31 and 32;and differentially expressed genes between complex aberrantkaryotype and the complex aberrant karyotype with trisomy 8 arelisted in Tables 33 and 34.

[0215] In conclusion, overall the gain of chromosome 8 leads to ahigher expression of genes located on chromosome 8. However, noconsistent pattern of genes was identified which shows a higherexpression in all AML subtypes with trisomy 8. This data suggestthat the higher expression of genes located on chromosome 8 only inpart is directly related to a gene dosage effect. Trisomy 8 mayrather provide a platform for a higher expression of chromosome 8genes which are specifically upregulated by accompanying geneticabnormalities in the respective AML subtypes (Tables IV, VI, VII,X, XII, XIV, XVI). Therefore, trisomy 8 does not seem to be anabnormality determining specific disease characteristics such asthe well known primary aberrations (t(8;21), inv(16), t(15;17),MLL/11q23) but rather a disease modulating secondary event inaddition to primary cytogenetic or molecular geneticaberrations.

[0216] MDS and AML are discriminated by percentages of blasts inthe bone marrow (BM) according to the FAB as well as to the WHOclassification. However, thresholds are arbitrary and demonstrateonly a limited reproducibility in interlaboratory testings. Thus,other parameters have been assessed to discriminate these entitieswith respect to diagnosis and prognosis. In particular, in themajority of cases common karyotype aberrations have been observedbetween MDS and AML, which have a higher prognostic impact thanblast percentages.

[0217] In this example, gene expression profiling (U133A+B,Affymetrix) was applied in 70 MDS and 238 AML cases. In accordancewith the WHO classification, cases with balanced translocations(i.e. t(8;21), t(15;17), inv(16), or 11q23), which are classifiedas AML irrespective of BM blast percentage, were excluded. First,the identity of genes of which the expression correlated to blastcount (Spearman correlation) was sought. Out of the top 50 genesthis analysis revealed only the FLT3 gene which showed a higherexpression in cases with high blast count (e.g. AML), while 12genes with a higher expression in cases with lower blast counts(e.g. MDS) were identified (ANXA3, ARG1, CAMP, CD24, CEACAM1,CEACAM6, CEACAM8, CRISP3, KIAA0922, LCN2, MMP9, STOM). Most of thelatter genes are expressed in mature granulocytes and are involvedin differentiation and apoptosis (see, e.g., more genes listed inTable 25). In a second step, class prediction was performed usingsupport vector machines (SVM) to separate MDS and AML according toblast percentages as defined in the WHO classification (<5%: RAand 5q-syndrome; 5-9%: RAEB-1;10-19%: RAEB-2; >19% AML). Using10-fold cross validation and support vector machines the overallprediction accuracy was only 80% (see, e.g., the genes listed inTable 36). More specifically, 230/238 AML cases were correctlyassigned to the AML group while 8 cases were classified as MDSRAEB-2. However, none of the RA, 5q-syndrome and RAEB-1 cases werecorrectly assigned to their groups, respectively, but were eitherclassified as AML or RAEB-2. Furthermore, only 16 of 38 RAEB-2cases were correctly predicted, while the 20 remaining cases wereassigned to the AML group. Thus, no clear gene expression patternswere identified which correlated with AML and MDS subtypesaccording to WHO classification.

[0218] Taking the common genetic background observed in MDS and AMLinto account, both entities were categorized in a third stepaccording to cytogenetics and classified based on their geneexpression profiles. In order to assess the impact of the commongenetic background, the largest cytogenetically defined subgroupswere compared to each other, i.e. AML and MDS with normal karyotypeand with complex aberrant karyotype. Intriguingly, while correctclassification of AML or MDS was found in 91%, classification intothe correct cytogenetic groups was achieved in 95%. Consequently,all cases were divided into the two groups, complex aberrantkaryotype (n=60) and other or no aberrations (n=248) irrespectiveof AML or MDS. A classification into these groups also yielded anaccuracy of 93% (see, e.g., the genes listed in Table 37).

[0219] The data from these analyses suggests that gene expressionprofiling reveals the biology of MDS or AML to highly correlatewith cytogenetics and less with the percentages of BM blasts. Theseresults strengthen the need for a revision of the current MDS andAML classification centering now genetic abnormalities, which mayalso be used for clinical decisions.

[0220] To clarify the genetic background and to improveprognostication in AML-NK, gene expression profiles in 205 patientswith untreated and newly diagnosed AML-NK were analyzed. Sampleswere comprehensively characterized by cytomorphology,immunophenotyping, cytogenetics, and molecular genetics. Forexpression profiling, samples were hybridized to both U133A andU133B microarrays (Affymetrix, Inc., Santa Clara, Calif., USA). Toidentify genetically defined subgroups, an unsupervised principalcomponent analysis (PCA) was performed applying all 34023 probesets from both arrays that were expressed in at least one of theanalyzed samples. While the majority of cases (n=162, 79%; Group A)clustered together, a subgroup comprising 43 (21%) cases wasidentified (Group B) which formed a distinct cluster. The analysisof known genetic markers (length mutations and point mutations ofFLT3, partial tandem duplications of MLL, mutations of CEBPA, NRAS,or CKIT) did not reveal differences between was performed Groups Aand B. Significant differences were found, however, in theirphenotypes. There were more cases with monocytic leukemias in groupF (84% vs. 20%, p<0.001) and the expression levels of CD4, CD56,CD65, CD15, CD14, CD64, CD11b, CD36, CD135, CD87, and CD116 werehigher while those of MPO, CD34, and CD117 were lower (p<0.05for all).

[0221] To identify the genetic background of differences, samplesfrom Groups A and B were compared using a supervised approach.Using the top 100 differentially expressed genes and applying SVMwith a 10-fold cross validation approach samples could beclassified to Groups A and B with an accuracy of 97.6% which wasconfirmed applying 100 runs of SVM with 2/3 of samples beingrandomly selected as training set and 1/3 as test set (medianaccuracy, 97.1%, range, 93.4% to 100%). Ingenuity software was usedto identify genetic pathways differentially regulated between bothgroups. Most strikingly, CD14 was higher expressed (fold-change(fc), 10.6) and WT1 and MYCN were lower expressed (fc, 3.7 and 4.4)in Group B. Also higher expressed was HCK (fc, 4.3) encoding aprotein-tyrosine kinase which phosphorylates STAT3. Sincephosphorylated STAT3 stimulates proliferation this may conferhigher chemosensitivity and result in a better prognosis. The lowerexpression of HCK in Group A cases may be due to the higherexpression of SPTBN1 (fc, 3.4) which also has been shown toincrease the transcription of C-FOS and to possibly revealantiapoptotic effects.

[0222] To assess the clinical importance of the newly identifiedsubgroups of AML-NK event-tree survival (EFS) and overall survival(OS) were compared. All patients were uniformly treated within theGerman AMLCG trials. Group B had a significantly better median EFS(13.3 vs. 7.0 months, p=0.0143) which was independent of the impactof age. In addition, there was a trend for a better OS in Group B(13.3 vs. 9.5 months, n.s.).

[0223] In conclusion, the identification of a biologically definedand clinically relevant subgroup of AML-NK has been accomplished byuse of gene expression profiling based on differences inregulations of genetic pathways involving proliferation andapoptosis.

[0224] Deletions of the long arm of chromosome 5 occur either asthe sole karyotype abnormality in MDS and AML or as part of acomplex aberrant karyotype. One objective of this study was toanalyze the impact of the 5q deletion on the expression levels ofgenes located on chromosome 5q in AML and MDS. Therefore, geneexpression analysis was performed in 344 AML and MDS cases usingAffymetrix U133A+B oligonucleotide microarrays. The followingsubgroups were analyzed: AML with sole 5q deletion (n=7), AML withcomplex aberrant karyotype (n=83), MDS with sole 5q deletion (n=9),and MDS with complex aberrant karyotype (n=9). These were comparedto 200 AML and 36 MDS with normal karyotype. In total, 1313 probesets representing 603 genes cover sequences located on the long armof chromosome 5. Overall a significant lower mean expression of allgenes located on the long arm of chromosome 5 was observed insubgroups with 5q deletion in comparison to their respectivecontrol groups (for all comparisons, p<0.05). 36 genes showed asignificantly lower expression in all comparisons. These genes areinvolved in a variety of different biological processes such assignal transduction (CSNK1A1, DAMS), cell cycle regulation (HDAC3,PFDN1) and regulation of transcription (CNOT8).

[0225] In addition, class prediction was performed using supportvector machines (SVM). In one approach, all 6 different subgroupswere analyzed as one class each. While AML and MDS with normalkaryotype as well as AML with complex aberrant karyotype werecorrectly predicted with high accuracies (97%, 81%, and 92%,respectively) AML and MDS with 5q-sole and MDS with complexaberrant karyotype were frequently misclassified as AML withcomplex aberrant karyotype. In a second approach, only two classeswere defined: all cases with 5q deletion combined vs. all caseswithout 5q deletion. 102 out of 108 cases (94%) with 5q deletionwere identified correctly supporting the fact that a distinct geneexpression pattern is associated with 5q deletion in general.Performing SVM only with genes located on the long arm ofchromosome 5 also resulted in a correct prediction of 92 of 108(85%) stressing the importance of the expression of genes locatedon chromosome 5 for these AML and MDS subtypes. The top 100differentially expressed probe sets between cases with and without5q deletion represented 74 different annotated genes of which 23are located on the long arm of chromosome 5. They are involved in avariety of different biological functions such as DNA repair (POLE,RAD21, RAD23B), regulation of transcription (ZNF75A, AF020591,MLLT3, HOXB6), protein biosynthesis (UPF2, TINP1, RPL12, RPL14,RPL15) cell cycle control (GMNN, CSPG6, PFDN1) and signaltransduction (HINT1, STK24, APP, CAMLG). 10 of the top 74 genesassociated with 5q deletion were involved in the CMYC-pathway withupregulation of RAD21, RAD23B, GMMN, CSPG6, APP, POLE STK24 andSTAG2, and downregulation of ACTA2, and RPL12. Ten other genes outof the 74 top differentially expressed genes were involved in theTP53 pathway with upregulation of H1F0, PTPN11 and TAF2 anddownregulation of DF, UBE2D2, EEF1A1, IGBP1, PPP2CA, EIF2S3, andNACA.

[0226] In conclusion, loss of parts of the long arm of chromosome 5leads to a lower expression of genes located on the long arm ofchromosome 5. A specific pattern of functionally related genes wasidentified which shows a lower expression in AML and MDS subtypeswith 5q deletion.

Example 2

General Materials, Methods and Definitions of FunctionalAnnotations

[0227] The methods section contains both information on statisticalanalyses used for identification of differentially expressed genesand detailed annotation data of identified microarray probesets.

Affymetrix Probeset Annotation

[0228] All annotation data of GeneChip.RTM. arrays are extractedfrom the NetAffx.TM. Analysis Center (internet website:www.affymetrix.com). Files for U133 set arrays, including U133A andU133B microarrays are derived from the June 2003 release. Theoriginal publication refers to: Liu et al. (2003) "NetAffx:Affymetrix probe sets and annotations," Nucleic Acids Res.31(1):82-6, which is incorporated by reference.

[0229] The sequence data are omitted due to their large size, andbecause they do not change, whereas the annotation data are updatedperiodically, for example new information on chromosomal locationand functional annotation of the respective gene products. Sequencedata are available to download in the NetAffx Download Center onthe world wide web at affymetrix.com.

Data Fields

[0230] In the following section, the content of each field of thedata files is described. Microarray probe sets, for example, foundto be differentially expressed between different types of leukemiasamples are further described by additional information. The fieldsare of the following types: [0231] 1. GeneChip Array Information[0232] 2. Probe Design Information [0233] 3. Public Domain andGenomic References

[0234] 1. GeneChip Array Information [0235] HG-U133 ProbeSet_ID:[0236] HG-U133 ProbeSet_ID describes the probe set identifier.Examples are: 200007_at 200011_s_at,200012_x_at.

[0237] Sequence Type

[0238] The Sequence Type indicates whether the sequence is anExemplar, Consensus or Control sequence. An Exemplar is a singlenucleotide sequence taken directly from a public database. Thissequence could be an mRNA or an expressed sequence tag (EST). AConsensus sequence is a nucleotide sequence assembled byAffymetrix, based on one or more sequence taken from a publicdatabase.

[0239] Transcript ID:

[0240] The cluster identification number with a sub-clusteridentifier appended.

[0241] Sequence Derived From:

[0242] The accession number of the single sequence, orrepresentative sequence on which the probe set is based. Refer tothe "Sequence Source" field to determine the database used.

[0243] Sequence ID:

[0244] For Exemplar sequences: Public accession number or GenBankidentifier. For Consensus sequences: Affymetrix identificationnumber or public accession number.

[0245] Sequence Source

[0246] The database from which the sequence used to design thisprobe set was taken. Examples are: GenBank.RTM., RefSeq, UniGene,TIGR (annotations from The Institute for Genomic Research).

[0247] 2. Public Domain and Genomic References

[0248] Most of the data in this section is from the LocusLink andUniGene databases, and are annotations of the reference sequence onwhich the probe set is modeled.

[0249] Gene Symbol and Title:

[0250] A gene symbol and a short title, when one is available. Suchsymbols are assigned by different organizations for differentspecies. Affymetrix annotational data comes from the UniGenerecord. There is no indication which species-specific databank wasused, but some of the possibilities include for example HUGO: TheHuman Genome Organization.

[0251] MapLocation:

[0252] The map location describes the chromosomal location when oneis available.

[0253] Unigene Accession:

[0254] UniGene accession number and cluster type. Cluster type canbe "full length" or "est", or "---" if unknown.

[0255] LocusLink:

[0256] This information represents the LocusLink accessionnumber.

[0257] Full Length Ref. Sequences

[0258] Indicates the references to multiple sequences in RefSeq.The field contains the ID and description for each entry, and therecan be multiple entries per probeSet.

Example 3

Sample Preparation, Processing and Data Analysis

Method 1:

[0259] Microarray analyses were performed utilizing theGeneChip.RTM. System (Affymetrix, Santa Clara, USA). Hybridizationtarget preparations were performed according to recommendedprotocols (Affymetrix Technical Manual). More specifically, at timeof diagnosis, mononuclear cells were purified by Ficoll-Hypaquedensity centrifugation. They had been lysed immediately in RLTbuffer (Qiagen, Hilden, Germany), frozen, and stored at -80.degree.C. from 1 week to 38 months. For gene expression profiling celllysates of the leukemia samples were thawed, homogenized(QIAshredder, Qiagen), and total RNA was extracted (RNeasy MiniKit, Qiagen). Subsequently, 5-10 .mu.g total RNA isolated from1.times.10.sup.7 cells was used as starting material for cDNAsynthesis with oligo[(dT).sub.24T7promotor].sub.65 primer (cDNASynthesis System, Roche Applied Science, Mannheim, Germany). cDNAproducts were purified by phenol/chloroform/IAA extraction (Ambion,Austin, Tex., USA) and acetate/ethanol-precipitated overnight. Fordetection of the hybridized target nucleic acid biotin-labeledribonucleotides were incorporated during the following in vitrotranscription reaction (Enzo BioArray HighYield RNA TranscriptLabeling Kit, Enzo Diagnostics). After quantification byspectrophotometric measurements and 260/280 absorbance valuesassessment for quality control of the purified cRNA (RNeasy MiniKit, Qiagen), 15 .mu.g cRNA was fragmented by alkaline treatment(200 mM Tris-acetate, pH 8.2/500 mM potassium acetate/150 mMmagnesium acetate) and added to the hybridization cocktailsufficient for five hybridizations on standard GeneChip.RTM.microarrays (300 .mu.L final volume). Washing and staining of theprobe arrays was performed according to the recommended FluidicsStation protocol (EukGE-WS2v4). Affymetrix Microarray Suitesoftware (version 5.0.1) extracted fluorescence signal intensitiesfrom each feature on the microarrays as detected by confocal laserscanning according to the manufacturer's recommendations.

[0260] Expression analysis quality assessment parameters includedvisual array inspection of the scanned image for the presence ofimage artifacts and correct grid alignment for the identificationof distinct probe cells as well as both low 3'/5' ratio ofhousekeeping controls (mean: 1.90 for GAPDH) and high percentage ofdetection calls (mean: 46.3% present called genes). The 3' to 5'ratio of GAPDH probesets can be used to assess RNA sample and assayquality. Signal values of the 3' probe sets for GAPDH are comparedto the Signal values of the corresponding 5' probe set. The ratioof the 3' probe set to the 5' probe set is generally no more than3.0. A high 3' to 5' ratio may indicate degraded RNA or inefficientsynthesis of ds cDNA or biotinylated cRNA (GeneChip ExpressionAnalysis Technical Manual, www.affymetrix.com). Detection calls areused to determine whether the transcript of a gene is detected(present) or undetected (absent) and were calculated using defaultparameters of the Microarray Analysis Suite MAS 5.0 softwarepackage.

[0261] Method 2:

[0262] Bone marrow (BM) aspirates are taken at the time of theinitial diagnostic biopsy and remaining material is immediatelylysed in RLT buffer (Qiagen), frozen and stored at -80.degree. C.until preparation for gene expression analysis. For microarrayanalysis the GeneChip.RTM. System (Affymetrix, Santa Clara, Calif.,USA) is used. The targets for GeneChip.RTM. analysis are preparedaccording to the current Expression Analysis. Briefly, frozenlysates of the leukemia samples are thawed, homogenized(QIAshredder, Qiagen) and total RNA extracted (RNeasy Mini Kit,Qiagen). Normally 10 .mu.g total RNA isolated from 1.times.10.sup.7cells is used as starting material in the subsequent cDNA-Synthesisusing Oligo-dT-T7-Promotor Primer (cDNA synthesis Kit, RocheMolecular Biochemicals). The cDNA is purified by phenol-chloroformextraction and precipitated with 100% Ethanol overnight. Fordetection of the hybridized target nucleic acid biotin-labeledribonucleotides are incorporated during the in vitro transcriptionreaction (Enzo BioArray.TM. High Yield RNA Transcript Labeling Kit,ENZO). After quantification of the purified cRNA (RNeasy Mini Kit,Qiagen), 15 .mu.g are fragmented by alkaline treatment (200 mMTris-acetate, pH 8.2, 500 mM potassium acetate, 150 mM magnesiumacetate) and added to the hybridization cocktail sufficient for 5hybridizations on standard GeneChip.RTM. microarrays. Beforeexpression profiling Test3 Probe Arrays (Affymetrix) are chosen formonitoring of the integrity of the cRNA. Only labeledcRNA-cocktails which show a ratio of the measured intensity of the3' to the 5' end of the GAPDH gene less than 3.0 are selected forsubsequent hybridization on HG-U133 probe arrays (Affymetrix).Washing and staining the Probe arrays is performed as described(see, Affymetrix-Original-Literature (LOCKHART und LIPSHUTZ). TheAffymetrix software (Microarray Suite, Version 4.0.1) extractedfluorescence intensities from each element on the arrays asdetected by confocal laser scanning according to the manufacturersrecommendations.

[0263] While the foregoing invention has been described in somedetail for purposes of clarity and understanding, it will be clearto one skilled in the art from a reading of this disclosure thatvarious changes in form and detail can be made without departingfrom the true scope of the invention. For example, all thetechniques and apparatus described above can be used in variouscombinations. All publications, patents, patent applications,and/or other documents cited in this application are incorporatedby reference in their entirety for all purposes to the same extentas if each individual publication, patent, patent application,and/or other document were individually indicated to beincorporated by reference for all purposes.

TABLE-US-00002 TABLE 1 genes higher expressed in CEBPA than inreciprocal Sequence Derived # affy id HUGO name Title MapLocationSequence Type Transcript ID From Sequence ID 1 232424_at PRDM16 PRdomain containing 16 1p36.23-p33 Consensussequence Hs.302022.1AI623202 Hs.302022.1.S1 2 239791_at Homo sapiens, cloneConsensussequence Hs.269918.1 AI125255 Hs.269918.1.A1 MGC: 10077IMAGE: 3896690, mRNA, complete cds 3 228904_at ESTsConsensussequence Hs.156044.0 AW510657 Hs.156044.0 4 205366_s_atHOXB6 homeo box B6 17q21.3 Exemplarsequence Hs.98428.0 NM_018952.1g9506792 5 210215_at TFR2 transferrin receptor 2 7q22Exemplarsequence Hs.63758.1 AF067864.1 g5596369 6 235438_at ESTsConsensussequence Hs.146226.0 AW162011 Hs.146226.0_RC Sequence #Source Unigene_Accession Cluster_Type LocusLinkFull_Length_Reference_Seq 1 GenBank Hs.302022 fulllength 63976NM_022114; PR domain containing 16 2 GenBank Hs.183096 fulllength 3GenBank Hs.156044 est 4 RefSeq Hs.98428 fulllength 3216 NM_018952;homeo box B6 isoform 1 NM_156036; homeo box B6 isoform 2 NM_156037;homeo box B6 isoform 1 5 GenBank Hs.63758 fulllength 7036NM_003227; transferrin receptor 2 6 GenBank Hs.445509 est

TABLE-US-00003 TABLE 2 genes lower expressed in CEBPA than inreciprocal # affy id HUGO name Title MapLocation 1 203329_at PTPRMprotein tyrosine phosphatase, receptor type, M 18p11.2 2 219892_atTM6SF1 transmembrane 6 superfamily member 1 15q24-q26 3 205076_s_atCRA cisplatin resistance associated 1q12-q21 4 204163_at EMILINelastin microfibril interface located protein 2p23.3-p23.2 5224773_at NAV1 neuron navigator 1 6 200660_at S100A11 S100 calciumbinding protein A11 1q21 (calgizzarin) 7 210992_x_at FCGR2A Fcfragment of IgG, low affinity IIa, receptor 1q23 for (CD32) 8221879_at MGC4809 serologically defined breast cancer antigen15q22.2 NY-BR-20 9 224774_s_at NAV1 neuron navigator 1 10 201666_atTIMP1 tissue inhibitor of metalloproteinase 1 Xp11.3-p11.23(erythroid potentiating activity, collagenase inhibitor) 11218831_s_at FCGRT Fc fragment of IgG, receptor, transporter,19q13.3 alpha 12 205131_x_at SCGF stem cell growth factor;lymphocyte secreted 19q13.3 C-type lectin 13 216236_s_at SLC2A3solute carrier family 2 (facilitated glucose 12p13.3 transporter),member 3 14 206580_s_at EFEMP2 EGF-containing fibulin-likeextracellular 11q13 matrix protein 2 15 208581_x_at MT1Xmetallothionein 1X 16q13 16 210783_x_at SCGF stem cell growthfactor; lymphocyte secreted 19q13.3 C-type lectin Sequence #Sequence Type Transcript ID Derived From Sequence ID 1Exemplarsequence Hs.154151.0 NM_002845.1 g4506318 2Exemplarsequence Hs.133865.0 NM_023003.1 g13194198 3Exemplarsequence Hs.166066.0 NM_006697.1 g5870890 4Exemplarsequence Hs.63348.0 NM_007046.1 g5901943 5Consensussequence Hs.6298.0 AB032977.1 Hs.6298.0 6 ExemplarsequenceHs.256290.0 NM_005620.1 g5032056 7 Exemplarsequence Hs.78864.1U90939.1 g2149627 8 Consensussequence Hs.239812.0 AA886335Hs.239812.0.S1 9 Consensussequence Hs.6298.0 AB032977.1 Hs.6298.010 Exemplarsequence Hs.5831.0 NM_003254.1 g4507508 11Exemplarsequence Hs.111903.0 NM_004107.1 g4758345 12Exemplarsequence Hs.105927.0 NM_002975.1 g4506802 13Consensussequence Hs.7594.2 AL110298.1 Hs.7594.2.A1 14Exemplarsequence Hs.6059.0 NM_016938.1 g8393298 15 ExemplarsequenceHs.278462.0 NM_005952.1 g10835231 16 Exemplarsequence Hs.105927.1D86586.1 g2257694 Sequence # Source Unigene_Accession Cluster_TypeLocusLink Full_Length_Reference_Seq 1 RefSeq Hs.154151 fulllength5797 NM_002845; protein tyrosine phosphatase, receptor type, Mprecursor 2 RefSeq Hs.341203 fulllength 53346 NM_023003;transmembrane 6 superfamily member 1 3 RefSeq Hs.166066 fulllength10903 NM_006697; cisplatin resistance associated 4 RefSeq Hs.63348fulllength 11117 NM_007046; elastin microfibril interface locatedprotein 5 GenBank Hs.6298 fulllength 89796 NM_020443; neuronnavigator 1 6 RefSeq Hs.417004 fulllength 6282 NM_005620; S100calcium binding protein A11 (calgizzarin) 7 GenBank Hs.78864fulllength 2212 NM_021642; Fc fragment of IgG, low affinity IIa,receptor for (CD32) 8 GenBank Hs.250861 fulllength 91860 9 GenBankHs.6298 fulllength 89796 NM_020443; neuron navigator 1 10 RefSeqHs.5831 fulllength 7076 NM_003254; tissue inhibitor ofmetalloproteinase 1 precursor 11 RefSeq Hs.111903 fulllength 2217NM_004107; Fc fragment of IgG, receptor, transporter, alpha 12RefSeq Hs.105927 fulllength 6320 NM_002975; stem cell growthfactor; lymphocyte secreted C-type lectin 13 GenBank Hs.7594fulllength 6515 NM_006931; solute carrier family 2 (facilitatedglucose transporter), member 3 NM_153449; glucose transporter 14 14RefSeq Hs.6059 fulllength 30008 NM_016938; EGF-containingfibulin-like extracellular matrix protein 2 15 RefSeq Hs.374950fulllength 4501 NM_005952; metallothionein 1X 16 GenBank Hs.105927fulllength 6320 NM_002975; stem cell growth factor; lymphocytesecreted C-type lectin

TABLE-US-00004 TABLE 3 genes lower expressed in CEBPA than inreciprocal # affy id HUGO name Title MapLocation 1 206761_atTACTILE T cell activation, increased late expression 3q13.13 2232424_at PRDM16 PR domain containing 16 1p36.23-p33 3 219054_atFLJ14054 hypothetical protein FLJ14054 5p13.3 4 202746_at ITM2Aintegral membrane protein 2A Xq13.3-Xq21.2 5 202747_s_at ITM2Aintegral membrane protein 2A Xq13.3-Xq21.2 6 210665_at TFPI tissuefactor pathway inhibitor (lipoprotein- 2q31-q32.1 associatedcoagulation inhibitor) 7 226751_at DKFZP566K1924 DKFZP566K1924protein 2p13.2 8 219790_s_at NPR3 natriuretic peptide receptorC/guanylate 5p14-p13 cyclase C (atrionatriuretic peptide receptorC) 9 219837_s_at C17 cytokine-like protein C17 4p16-p15 10206660_at IGLL1 immunoglobulin lambda-like polypeptide 1 22q11.2311 210762_s_at DLC1 deleted in liver cancer 1 8p22-p21.3 12209757_s_at MYCN v-myc myelocytomatosis viral related 2p24.1oncogene, neuroblastoma derived (avian) 13 219789_at NPR3natriuretic peptide receptor C/guanylate 5p14-p13 cyclase C(atrionatriuretic peptide receptor C) 15 226517_at BCAT1 branchedchain aminotransferase 1, cytosolic 12pter-q12 16 210664_s_at TFPItissue factor pathway inhibitor (lipoprotein- 2q31-q32.1 associatedcoagulation inhibitor) 17 219686_at HSA250839 gene forserine/threonine protein kinase 4p16.2 18 209160_at AKR1C3aldo-keto reductase family 1, member C3 (3- 10p15-p14 alphahydroxysteroid dehydrogenase, type II) Sequence # Sequence TypeTranscript ID Derived From Sequence ID 1 ExemplarsequenceHs.142023.0 NM_005816.1 g5032140 2 Consensussequence Hs.302022.1AI623202 Hs.302022.1.S1 3 Exemplarsequence Hs.13528.0 NM_024563.1g13375730 4 Consensussequence Hs.17109.0 AL021786 Hs.17109.0_RC 5Exemplarsequence Hs.17109.0 NM_004867.1 g4758223 6 ExemplarsequenceHs.170279.1 AF021834.1 g4103170 7 Consensussequence Hs.26358.0AW193693 Hs.26358.0.S1 8 Exemplarsequence Hs.123655.0 NM_000908.1g4505440 9 Exemplarsequence Hs.13872.0 NM_018659.1 g8922107 10Exemplarsequence Hs.288168.0 NM_020070.1 g13399297 11Exemplarsequence Hs.8700.0 AF026219.1 g2559001 12 ExemplarsequenceHs.25960.1 BC002712.1 g12803748 13 Consensussequence Hs.123655.0AI628360 Hs.123655.0 15 Consensussequence Hs.317432.0 AL390172.1Hs.317432.0.S1 16 Exemplarsequence Hs.170279.1 AF021834.1 g410317017 Exemplarsequence Hs.58241.0 NM_18401.1 g8923753 18Exemplarsequence Hs.78183.0 AB018580.1 g6624210 Sequence # SourceUnigene_Accession Cluster_Type LocusLink Full_Length_Reference_Seq1 RefSeq Hs.142023 fulllength 10225 NM_005816; T cell activation,increased late expression 2 GenBank Hs.302022 fulllength 63976NM_022114; PR domain containing 16 3 RefSeq Hs.13528 fulllength79614 NM_024563; hypothetical protein FLJ14054 4 GenBank Hs.17109fulllength 9452 NM_004867; integral membrane protein 2A 5 RefSeqHs.17109 fulllength 9452 NM_004867; integral membrane protein 2A 6GenBank Hs.170279 fulllength 7035 NM_006287; tissue factor pathwayinhibitor (lipoprotein-associated coagulation inhibitor) 7 GenBankHs.26358 fulllength 25927 NM_015463; DKFZP566K1924 protein 8 RefSeqHs.123655 fulllength 4883 NM_000908; natriuretic peptide receptorC/guanylate cyclase C (atrionatriuretic peptide receptor C) 9RefSeq Hs.13872 fulllength 54360 NM_018659; cytokine-like proteinC17 10 RefSeq Hs.348935 fulllength 3543 NM_020070; immunoglobulinlambda-like polypeptide 1 isoform a precursor NM_152855;immunoglobulin lambda-like polypeptide 1 isoform b precursor 11GenBank Hs.8700 fulllength 10395 NM_006094; deleted in liver cancer1 NM_024767; deleted in liver cancer 1 12 GenBank Hs.25960fulllength 4613 NM_005378; v-myc myelocytomatosis viral relatedoncogene, neuroblastoma derived 13 GenBank Hs.123655 fulllength4883 NM_000908; natriuretic peptide receptor C/guanylate cyclase C(atrionatriuretic peptide receptor C) 15 GenBank Hs.317432fulllength 586 NM_005504; branched chain aminotransferase 1,cytosolic 16 GenBank Hs.170279 fulllength 7035 NM_006287; tissuefactor pathway inhibitor (lipoprotein-associated coagulationinhibitor) 17 RefSeq Hs.58241 fulllength 55351 NM_018401; gene forserine/threonine protein kinase 18 GenBank Hs.78183 fulllength 8644NM_003739; aldo-keto reductase family 1, member C3

TABLE-US-00005 TABLE 4 genes lower expressed in CEBPA than int(11q23) Transcript Sequence # affy id HUGO name Title MapLocationSequence Type ID Derived From Sequence ID 1 205472_s_at DACHdachshund homolog 13q22 Exemplarsequence Hs.63931.0 NM_004392.1g4758113 (Drosophila) 2 205471_s_at DACH dachshund homolog 13q22Consensussequence Hs.63931.0 AW772082 Hs.63931.0 (Drosophila) 3225185_at MRAS muscle RAS oncogene 3q22.3 ConsensussequenceHs.7298.1 BF343625 Hs.7298.1_RC homolog 4 219360_s_at TRPM4transient receptor potential 19q13.33 Exemplarsequence Hs.31608.0NM_017636.1 g8923048 cation channel, subfamily M, member 4 5203372_s_at SOCS2 suppressor of cytokine 12q ExemplarsequenceHs.110776.0 AB004903.1 g2443360 signaling 2 6 203373_at SOCS2suppressor of cytokine 12q Exemplarsequence Hs.110776.0 NM_003877.1g4507262 signaling 2 7 228083_at CACNA2D4 calcium channel, 12p13.33Consensussequence Hs.13768.0 AI433691 Hs.13768.0 voltage-dependent,alpha 2/ delta subunit 4 8 219506_at FLJ23221 hypothetical protein1q21.2 Exemplarsequence Hs.18397.0 NM_024579.1 g13375757 FLJ23221 9200782_at ANXA5 annexin A5 4q28-q32 Exemplarsequence Hs.300711.0NM_001154.2 g4809273 10 202265_at BMI1 B lymphoma Mo-MLV 10p11.23Exemplarsequence Hs.431.0 NM_005180.1 g4885094 insertion region(mouse) 11 218376_s_at MICAL CasL interacting molecule 6q21Exemplarsequence Hs.33476.0 NM_022765.1 g12232438 12 216041_x_atGRN granulin 17q21.32 Consensussequence Hs.180577.2 AK023348.1Hs.180577.2.S1 Sequence # Source Unigene_Accession Cluster_TypeLocusLink Full_Length_Reference_Seq 1 RefSeq Hs.63931 fulllength1602 NM_004392; dachshund homolog isoform c NM_080759; dachshundhomolog isoform a NM_080760; dachshund homolog isoform b 2 GenBankHs.63931 fulllength 1602 NM_004392; dachshund homolog isoform cNM_080759; dachshund homolog isoform a NM_080760; dachshund homologisoform b 3 GenBank Hs.349227 fulllength 22808 NM_012219; muscleRAS oncogene homolog 4 RefSeq Hs.31608 fulllength 54795 NM_017636;transient receptor potential cation channel, subfamily M, member 45 GenBank Hs.405946 fulllength 8835 NM_003877; suppressor ofcytokine signaling-2 6 RefSeq Hs.405946 fulllength 8835 NM_003877;suppressor of cytokine signaling-2 7 GenBank Hs.13768 fulllength93589 NM_172364; voltage-gated calcium channel alpha(2)delta-4subunit 8 RefSeq Hs.18397 fulllength 79630 NM_024579; hypotheticalprotein FLJ23221 9 RefSeq Hs.300711 fulllength 308 NM_001154;annexin 5 10 RefSeq Hs.380403 fulllength 648 NM_005180; B lymphomaMo-MLV insertion region 11 RefSeq Hs.33476 fulllength 64780NM_022765; NEDD9 interacting protein with calponin homology and LIMdomains 12 GenBank Hs.180577 fulllength 2896 NM_002087;granulin

TABLE-US-00006 TABLE 5 genes higher expressed in CEBPA than ininv(16) HUGO Transcript Sequence # affy id name Title MapLocationSequence Type ID Derived From Sequence ID 1 235438_at ESTsConsensussequence Hs.146226.0 AW162011 Hs.146226.0_RC 2 209905_atHOXA9 homeo box A9 7p15-p14 Consensussequence Hs.127428.0 AI246769Hs.127428.0 3 235521_at HOXA3 homeo box A3 7p15-p14Consensussequence Hs.222446.0 AW137982 Hs.222446.0.A1 4 214651_s_atHOXA9 homeo box A9 7p15-p14 Consensussequence Hs.127428.2 U41813.1Hs.127428.2 5 211031_s_at CYLN2 cytoplasmic linker 2 7q11.23Exemplarsequence g13623312 BC006259.1 g13623312 6 223044_at SLC11A3solute carrier family 11 2q32 Exemplarsequence Hs.5944.0 AL136944.1g12053382 (proton-coupled divalent metal ion transporters), member3 7 230894_s_at Homo sapiens, clone Consensussequence Hs.42640.1BE672557 Hs.42640.1.A1 IMAGE: 4154313, mRNA, partial cds 8200985_s_at CD59 CD59 antigen p18-20 11p13 ExemplarsequenceHs.119663.0 NM_000611.1 g10835164 (antigen identified by monoclonalantibodies 16.3A5, EJ16, EJ30, EL32 and G344) 9 218927_s_at C4S-2chondroitin 4-O- 7p22 Exemplarsequence Hs.25204.0 NM_018641.1g8922111 sulfotransferase 2 10 201427_s_at SEPP1 selenoprotein P,plasma, 1 5q31 Exemplarsequence Hs.3314.0 NM_005410.1 g4885590 11212463_at Homo sapiens mRNA; Consensussequence Hs.99766.0 BE379006Hs.99766.0.S1 cDNA DKFZp564J0323 (from clone DKFZp564J0323) 12201669_s_at MARCKS myristoylated alanine-rich 6q22.2Exemplarsequence Hs.75607.0 NM_002356.4 g11125771 protein kinase Csubstrate 13 219218_at FLJ23058 hypothetical protein 17q25.3Exemplarsequence Hs.98968.0 NM_024696.1 g13375978 FLJ23058 14201670_s_at MARCKS myristoylated alanine-rich 6q22.2Exemplarsequence Hs.75607.0 M68956.1 g187386 protein kinase Csubstrate 15 200983_x_at CD59 CD59 antigen p18-20 11p13Consensussequence Hs.119663.0 NM_000611.1 Hs.119663.0 (antigenidentified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 andG344) 16 210215_at TFR2 transferrin receptor 2 7q22Exemplarsequence Hs.63758.1 AF067864.1 g5596369 17 235753_at Homosapiens cDNA Consensussequence Hs.196169.0 AI492051 Hs.196169.0FLJ34835 fis, clone NT2NE2010150. 18 204720_s_at DNAJC6 DnaJ(Hsp40) homolog, 1pter-q31.3 Consensussequence Hs.44896.0 AV729634Hs.44896.0 subfamily C, member 6 19 212224_at ALDH1A1 aldehydedehydrogenase 1 9q21.13 Consensussequence Hs.76392.0 NM_000689.1Hs.76392.0 family, member A1 20 243579_at MSI2 musashi homolog 217q23.1 Consensussequence Hs.173179.0 BF029215 Hs.173179.0.S1(Drosophila) 21 205830_at CLGN calmegin 4q28.3-q31.1Exemplarsequence Hs.86368.0 NM_004362.1 g4758003 22 210425_x_atGOLGIN- golgin-67 15q11.2 Exemplarsequence Hs.182982.1 AF164622.1g7211437 67 23 209691_s_at DOK4 docking protein 4 16q12.2Exemplarsequence Hs.279832.1 BC003541.1 g13097653 Sequence # SourceUnigene_Accession Cluster_Type LocusLink Full_Length_Reference_Seq1 GenBank Hs.445509 est 2 GenBank Hs.127428 fulllength 3205NM_002142; homeobox protein A9 isoform b NM_152739; homeoboxprotein A9 isoform a 3 GenBank Hs.248074 fulllength 3200 NM_030661;homeobox A3 protein isoform a NM_153631; homeobox A3 proteinisoform a NM_153632; homeobox A3 protein isoform b 4 GenBankHs.127428 fulllength 3205 NM_002142; homeobox protein A9 isoform bNM_152739; homeobox protein A9 isoform a 5 GenBank Hs.104717fulllength 7461 NM_003388; cytoplasmic linker 2 isoform 1NM_032421; cytoplasmic linker 2 isoform 2 NM_032719; 6 GenBankHs.5944 fulllength 30061 NM_014585; solute carrier family 40(iron-regulated transporter), member 1 7 GenBank Hs.173179 8 RefSeqHs.278573 fulllength 966 NM_000611; CD59 antigen p18-20 (antigenidentified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 andG344) 9 RefSeq Hs.25204 fulllength 55501 NM_018641; chondroitin4-O-sulfotransferase 2 10 RefSeq Hs.275775 fulllength 6414NM_005410; selenoprotein P precursor 11 GenBank Hs.99766 12 RefSeqHs.75607 fulllength 4082 NM_002356; myristoylated alanine-richprotein kinase C substrate 13 RefSeq Hs.98968 fulllength 79749NM_024696; hypothetical protein FLJ23058 14 GenBank Hs.75607fulllength 4082 NM_002356; myristoylated alanine-rich proteinkinase C substrate 15 GenBank Hs.278573 fulllength 966 NM_000611;CD59 antigen p18-20 (antigen identified by monoclonal antibodies16.3A5, EJ16, EJ30, EL32 and G344) 16 GenBank Hs.63758 fulllength7036 NM_003227; transferrin receptor 2 17 GenBank Hs.196169 18GenBank Hs.44896 fulllength 9829 NM_014787; DnaJ (Hsp40) homolog,subfamily C, member 6 19 GenBank Hs.76392 fulllength 216 NM_000689;aldehyde dehydrogenase 1A1 20 GenBank Hs.103512 fulllength 124540NM_138962; musashi 2 isoform a NM_170721; musashi 2 isoform b 21RefSeq Hs.86368 fulllength 1047 NM_004362; calmegin 22 GenBankHs.182982 fulllength 23015 NM_015003; golgin-67 isoform aNM_181076; golgin- 67 isoform b NM_181077; golgin-67 isoform c 23GenBank Hs.279832 fulllength 55715 NM_018110; downstream oftyrosine kinase 4

TABLE-US-00007 TABLE 6 genes lower expressed in CEBPA than ininv(16) HUGO affy id name Title MapLocation 1 204885_s_at MSLNmesothelin 16p13.3 2 201497_x_at MYH11 myosin, heavy polypeptide11, smooth muscle 16p13.13-p13.12 3 205819_at MARCO macrophagereceptor with collagenous structure 2q12-q13 4 207961_x_at MYH11myosin, heavy polypeptide 11, smooth muscle 16p13.13-p13.12 5206135_at ST18 suppression of tumorigenicity 18 (breast carcinoma)8q11.22 (zinc finger protein) 6 241525_at LOC200772 hypotheticalprotein LOC200772 2q37.3 7 212358_at CLIPR-59 CLIP-170-relatedprotein 19q13.12 8 230472_at IRX1 iroquois homeobox protein 15p15.3 9 222760_at FLJ14299 hypothetical protein FLJ14299 8p11.2210 208450_at LGALS2 lectin, galactoside-binding, soluble, 2(galectin 2) 22q13.1 11 201506_at TGFBI transforming growth factor,beta-induced, 68 kDa 5q31 12 222862_s_at AK5 adenylate kinase 51p31 13 201743_at CD14 CD14 antigen 5q31.1 14 204163_at EMILINelastin microfibril interface located protein 2p23.3-p23.2 15206682_at HML2 macrophage lectin 2 (calcium dependent) 17p13.2 16218876_at CGI-38 brain specific protein 16q21 17 203939_at NT5E5'-nucleotidase, ecto (CD73) 6q14.q21 18 203407_at PPL periplakin16p13.3 19 224724_at SULF2 similar to glucosamine-6-sulfatases20q12-13.2 20 238066_at CRBPIV retinoid binding protein 7 1p36.22Sequence Sequence Type Transcript ID Derived From Sequence ID 1Exemplarsequence Hs.155981.0 NM_005823.2 g7108357 2Exemplarsequence Hs.78344.1 NM_022844.1 g13124874 3Exemplarsequence Hs.67726.0 NM_006770.1 g5803079 4 ExemplarsequenceHs.78344.2 NM_022870.1 g13124876 5 Exemplarsequence Hs.151449.0NM_014682.1 g7662167 6 Consensussequence Hs.132051.0 AV700191Hs.132051.0.A1 7 Consensussequence Hs.7357.0 AL117468.1Hs.7357.0.S1 8 Consensussequence Hs.109525.0 AI870306Hs.109525.0.A1 9 Consensussequence Hs.288042.0 BG290193Hs.288042.0_RC 10 Exemplarsequence Hs.113987.0 NM_006498.1 g572990211 Exemplarsequence Hs.118787.0 NM_000358.1 g4507466 12Consensussequence Hs.18268.0 BG169832 Hs.18268.0 13Exemplarsequence Hs.75627.0 NM_000591.1 g4557416 14Exemplarsequence Hs.63348.0 NM_007046.1 g5901943 15Exemplarsequence Hs.54403.0 NM_006344.1 g5453683 16Exemplarsequence Hs.279772.0 NM_016140.1 g7706392 17Exemplarsequence Hs.153952.0 NM_002526.1 g4505466 18Exemplarsequence Hs.74304.0 NM_002705.1 g4505992 19Consensussequence Hs.43857.0 AL133001.1 Hs.43857.0.S1 20Consensussequence Hs.292718.0 AI733027 Hs.292718.0_RC SequenceSource Unigene_Accession Cluster_Type LocusLinkFull_Length_Reference_Seq 1 RefSeq Hs.155981 fulllength 10232NM_005823; megakaryocyte potentiating factor precursor NM_013404;mesothelin isoform 2 precursor 2 RefSeq Hs.78344 fulllength 4629NM_002474; smooth muscle myosin heavy chain 11 isoform SM1NM_022844; smooth muscle myosin heavy chain 11 isoform SM2NM_022870; 3 RefSeq Hs.67726 fulllength 8685 NM_006770; macrophagereceptor with collagenous structure 4 RefSeq Hs.78344 fulllength4629 NM_002474; smooth muscle myosin heavy chain 11 isoform SM1NM_022844; smooth muscle myosin heavy chain 11 isoform SM2NM_022870; 5 RefSeq Hs.151449 fulllength 9705 NM_014682;suppression of tumorigenicity 18 6 GenBank Hs.439538 200772 7GenBank Hs.7357 fulllength 25999 NM_015526; CLIP-170-relatedprotein 8 GenBank Hs.424156 79192 9 GenBank Hs.288042 fulllength80139 NM_025069; hypothetical protein FLJ14299 10 RefSeq Hs.113987fulllength 3957 NM_006498; lectin, galactoside-binding, soluble, 2(galectin 2) 11 RefSeq Hs.118787 fulllength 7045 NM_000358;transforming growth factor, beta-induced, 68 kDa 12 GenBankHs.18268 fulllength 26289 NM_012093; adenylate kinase 5 isoform 2NM_174858; adenylate kinase 5 isoform 1 13 RefSeq Hs.75627fulllength 929 NM_000591; CD14 antigen precursor 14 RefSeq Hs.63348fulllength 11117 NM_007046; elastin microfibril interface locatedprotein 15 RefSeq Hs.54403 fulllength 10462 NM_006344; macrophagelectin 2 (calcium dependent) 16 RefSeq Hs.279772 fulllength 51673NM_015964; CGI-38 protein NM_016140; brain specific protein 17RefSeq Hs.153952 fulllength 4907 NM_002526; 5' nucleotidase, ecto18 RefSeq Hs.74304 fulllength 5493 NM_002705; periplakin 19 GenBankHs.43857 fulllength 55959 NM_018837; similar toglucosamine-6-sulfatases 20 GenBank Hs.422688 fulllength 116362NM_052960; retinoid binding protein 7

TABLE-US-00008 TABLE 7 genes higher expressed in CEBPA than ininv(3) Sequence # affy id HUGO name Title MapLocation Sequence TypeTranscript ID Derived From 1 204561_x_at APOC2 apolipoprotein C-II19q13.2 Exemplarsequence Hs.75615.0 NM_000483.2 2 210997_at HGFhepatocyte growth factor (hepapoietin A; 7q21.1 ExemplarsequenceHs.809.1 M77227.1 scatter factor) 3 213110_s_at COL4A5 collagen,type IV, alpha 5 (Alport syndrome) Xq22 ConsensussequenceHs.169825.0 AW052179 4 206622_at TRH thyrotropin-releasing hormone3q13.3-q21 Exemplarsequence Hs.182231.0 NM_007117.1 5 210549_s_atCCL23 chemokine (C-C motif) ligand 23 17q12 ExemplarsequenceHs.169191.1 U58913.1 6 210998_s_at HGF hepatocyte growth factor(hepapoietin A; 7q21.1 Exemplarsequence Hs.809.1 M77227.1 scatterfactor) 7 236892_s_at Homo sapiens, clone MGC: 10077Consensussequence Hs.269918.0 BF590528 IMAGE: 3896690, mRNA,complete cds 8 239791_at Homo sapiens, clone MGC: 10077Consensussequence Hs.269918.1 AI125255 IMAGE: 3896690, mRNA,complete cds 9 232424_at PRDM16 PR domain containing 16 1p36.23-p33Consensussequence Hs.302022.1 AI623202 10 206210_s_at CETPcholesteryl ester transfer protein, plasma 16q21 ExemplarsequenceHs.89538.0 NM_000078.1 11 205624_at CPA3 carboxypeptidase A3 (mastcell) 3q21-q25 Exemplarsequence Hs.646.0 NM_001870.1 12 228293_atLOC91614 novel 58.3 KDA protein 11p13 Consensussequence Hs.180545.0AJ245600.1 13 206660_at IGLL1 immunoglobulin lambda-likepolypeptide 1 22q11.23 Exemplarsequence Hs.288168.0 NM_020070.1 14213844_at HOXA5 homeo box A5 7p15-p14 Consensussequence Hs.37034.0NM_019102.1 15 209960_at HGF hepatocyte growth factor (hepapoietinA; 7q21.1 Consensussequence Hs.809.0 X16323.1 scatter factor) 16210762_s_at DLC1 deleted in liver cancer 1 8p22-p21.3Exemplarsequence Hs.8700.0 AF026219.1 17 228904_at ESTsConsensussequence Hs.156044.0 AW510657 18 204082_at PBX3 pre-B-cellleukemia transcription factor 3 9q33-q34 ExemplarsequenceHs.294101.0 NM_006195.1 Sequence # Sequence ID SourceUnigene_Accession Cluster_Type LocusLink Full_Length_Reference_Seq1 g5174775 RefSeq Hs.75615 fulllength 344 NM_000483; apolipoproteinC-II precursor 2 g184029 GenBank Hs.809 fulllength 3082 NM_000601;hepatocyte growth factor precursor 3 Hs.169825.0_RC GenBankHs.169825 fulllength 1287 IV collagen isoform 2, precursorNM_033381; alpha 5 type IV collagen isoform 3, precursor 4 g6005919RefSeq Hs.182231 fulllength 7200 NM_007117; thyrotropin-releasinghormone 5 g4204907 GenBank Hs.169191 fulllength 6368 NM_005064;small inducible cytokine A23 isoform CKbeta8-1 precursor NM_145898;small inducible cytokine A23 isoform CKbeta8 precursor 6 g184029GenBank Hs.809 fulllength 3082 NM_000601; hepatocyte growth factorprecursor 7 Hs.269918.0.A1 GenBank Hs.183096 fulllength 8Hs.269918.1.A1 GenBank Hs.183096 fulllength 9 Hs.302022.1.S1GenBank Hs.302022 fulllength 63976 NM_022114; PR domain containing16 10 g4557442 RefSeq Hs.89538 fulllength 1071 NM_000078;cholesteryl ester transfer protein, plasma precursor 11 g4503000RefSeq Hs.646 fulllength 1359 NM_001870; mast cell carboxypeptidaseA3 precursor 12 Hs.180545.0 GenBank Hs.180545 fulllength 91614NM_139160; novel 58.3 KDA protein 13 g13399297 RefSeq Hs.348935fulllength 3543 NM_020070; immunoglobulin lambda-like polypeptide 1isoform a precursor NM_152855; immunoglobulin lambda-likepolypeptide 1 isoform b precursor 14 Hs.37034.0.S1 GenBank Hs.37034fulllength 3202 NM_019102; homeobox protein A5 15 Hs.809.0 GenBankHs.809 fulllength 3082 NM_000601; hepatocyte growth factorprecursor 16 g2559001 GenBank Hs.8700 fulllength 10395 NM_006094;deleted in liver cancer 1 NM_024767; deleted in liver cancer 1 17Hs.156044.0 GenBank Hs.156044 est 18 g5453851 RefSeq Hs.294101fulllength 5090 NM_006195; pre-B-cell leukemia transcription factor3

TABLE-US-00009 TABLE 8 genes lower expressed in CEBPA than ininv(3) HUGO Transcript Sequence # affy id name Title MapLocationSequence Type ID Derived From 1 221884_at EvI1 ecotropic viralintegration site 1 3q24-q28 Consensussequence Hs.234773.0 BE4665252 226420_at EVI1 ecotropic viral integration site 1 3q24-q28Consensussequence Hs.234773.0 AK025934.1 3 213201_s_at TNNT1troponin T1, skeletal, slow 19q13.4 Consensussequence Hs.73980.1AJ011712 4 202269_x_at GBP1 guanylate binding protein 1, 1p22.2Exemplarsequence Hs.62661.0 BC002666.1 interferon-inducible, 67 kDa5 231577_s_at GBP1 guanylate binding protein 1, interferon- 1p22.2Consensussequence Hs.62661.1 AW014593 inducible, 67 kDa 6209602_s_at GATA3 GATA binding protein 3 10p15 ConsensussequenceHs.169946.0 AI796169 7 226837_at SPRED1 sprouty-related, EVH1domain containing 1 15q13.3 Consensussequence Hs.94133.0 BE967019 8208820_at PTK2 PTK2 protein tyrosine kinase 2 8q24-qterConsensussequence Hs.740.1 AL037339 9 226231_at PAWR PRKC,apoptosis, WT1, regulator 12q21 Consensussequence Hs.42683.0AI189509 10 201743_at CD14 CD14 antigen 5q31.1 ExemplarsequenceHs.75627.0 NM_000591.1 11 213994_s_at SPON1 spondin 1, (f-spondin)extracellular matrix 11p15.2 Consensussequence Hs.5378.1 AI885290protein 12 207826_s_at ID3 inhibitor of DNA binding 3, dominant1p36.13-p36.12 Exemplarsequence Hs.76884.0 NM_002167.1 negativehelix-loop-helix protein 13 231947_at FLJ21269 hypothetical proteinFLJ21269 6q25.1 Consensussequence Hs.18160.0 AI242583 14 202270_atGBP1 guanylate binding protein 1, interferon- 1p22.2Exemplarsequence Hs.62661.0 NM_002053.1 inducible, 67 kDa 15203329_at PTPRM protein tyrosine phosphatase, receptor type, M18p11.2 Exemplarsequence Hs.154151.0 NM_002845.1 16 215446_s_at LOXlysyl oxidase 5q23.2 Consensussequence Hs.102267.3 L16895 17225369_at ESAM similar to endothelial cell-selective 11q24.2Consensussequence Hs.173840.0 AL573851 adhesion molecule 18204627_s_at ITGB3 integrin, beta 3 (platelet glycoprotein IIIa,17q21.32 Exemplarsequence Hs.87149.0 M35999.1 antigen CD61)Sequence # Sequence ID Source Unigene_Accession Cluster_TypeLocusLink Full_Length_Reference_Seq 1 Hs.234773.0.S1 GenBankHs.234773 2122 NM_005241; ecotropic viral integration site 1 2Hs.234773.0 GenBank Hs.234773 2122 NM_005241; ecotropic viralintegration site 1 3 Hs.73980.1.S1 GenBank Hs.73980 fulllength 7138NM_003283; troponin T1, skeletal, slow 4 g12803662 GenBank Hs.62661fulllength 2633 NM_002053; guanylate binding protein 1, interferon-inducible, 67 kD 5 Hs.62661.1.A1 GenBank Hs.62661 fulllength 2633NM_002053; guanylate binding protein 1, interferon-inducible, 67 kD6 Hs.169946.0.S3 GenBank Hs.169946 fulllength 2625 NM_002051; GATAbinding protein 3 NM_032742; 7 Hs.94133.0_RC GenBank Hs.302718fulllength 161742 NM_152594; sprouty-related protein with EVH-1domain 1 8 Hs.740.1.S2 GenBank Hs.740 fulllength 5747 NM_005607;PTK2 protein tyrosine kinase 2 isoform b NM_153831; PTK2 proteintyrosine kinase 2 isoform a 9 Hs.42683.0.A1 GenBank Hs.372504fulllength 5074 NM_002583; apoptosis response protein 10 g4557416RefSeq Hs.75627 fulllength 929 NM_000591; CD14 antigen precursor 11Hs.5378.1 GenBank Hs.5378 fulllength 10418 NM_006108; spondin 1,(f-spondin) extracellular matrix protein NM_032720; 12 g10835060RefSeq Hs.76884 fulllength 3399 NM_002167; inhibitor of DNA binding3, dominant negative helix-loop-helix protein 13 Hs.18160.0.S1GenBank Hs.18160 fulllength 80177 NM_025107; myc target in myeloidcells 1 14 g4503938 RefSeq Hs.62661 fulllength 2633 NM_002053;guanylate binding protein 1, interferon-inducible, 67 kD 15g4506318 RefSeq Hs.154151 fulllength 5797 NM_002845; proteintyrosine phosphatase, receptor type, M precursor 16 Hs.102267.3GenBank Hs.102267 fulllength 4015 NM_002317; lysyl oxidasepreproprotein 17 Hs.173840.0.S1 GenBank Hs.173840 fulllength 90952NM_138961; similar to endothelial cell-selective adhesion molecule18 g183532 GenBank Hs.87149 fulllength 3690 NM_000212; integrinbeta chain, beta 3 precursor

TABLE-US-00010 TABLE 9 genes higher expressed in CEBPA than in t(821) # affy id HUGO name Title MapLocation 1 220377_at C14orf110chromosome 14 open reading frame 110 14q32.33 2 209905_at HOXA9homeo box A9 7p15-p14 3 206310_at SPINK2 serine protease inhibitor,Kazal type, 2 (acrosin- 4q12 trypsin inhibitor) 4 214651_s_at HOXA9homeo box A9 7p15-p14 5 229461_x_at MGC46680 hypothetical proteinMGC46680 1p31.1 6 205366_s_at HOXB6 homeo box B6 17q21.3 7213150_at HOXA10 homeo box A10 7p15-p14 8 217963_s_at NGFRAP1 nervegrowth factor receptor (TNFRSF16) Xq22.1 associated protein 1 9205453_at HOXB2 homeo box B2 17q21-q22 10 204030_s_at SCHIP1schwannomin interacting protein 1 3q25.33 11 208146_s_at CPVLcarboxypeptidase, vitellogenic-like 7p15-p14 12 235521_at HOXA3homeo box A3 7p15-p14 13 236892_s_at Homo sapiens, clone MGC: 10077IMAGE: 3896690, mRNA, complete cds 14 213110_s_at COL4A5 collagen,type IV, alpha 5 (Alport syndrome) Xq22 15 204069_at MEIS1 Meis1,myeloid ecotropic viral integration site 1 2p14.p13 homolog (mouse)16 232424_at PRDM16 PR domain containing 16 1p36.23-p33 17239791_at Homo sapiens, clone MGC: 10077 IMAGE: 3896690, mRNA,complete cds 18 235438_at ESTs 19 213844_at HOXA5 homeo box A57p15-p14 20 217520_x_at LOC283683 hypothetical protein LOC28368315q11.2 21 230894_s_at Homo sapiens, clone IMAGE: 4154313, mRNA,partial cds 22 229971_at GPR114 G protein-coupled receptor 11416q12.2 23 214450_at CTSW cathepsin W (lymphopain) 11q13.1 24213147_at HOXA10 homeo box A10 7p15-p14 25 214049_x_at CD7 CD7antigen (p41) 17q25.2-q25.3 26 224595_at CDW92 CDw92 antigen 9q31.2Sequence # Sequence Type Transcript ID Derived From Sequence ID 1Exemplarsequence Hs.128155.0 NM_014151.1 g7661757 2Consensussequence Hs.127428.0 AI246769 Hs.127428.0 3Exemplarsequence Hs.98243.0 NM_021114.1 g10863910 4Consensussequence Hs.127428.2 U41813.1 Hs.127428.2 5Consensussequence Hs.296235.0 AI123532 Hs.296235.0_RC 6Exemplarsequence Hs.98428.0 NM_018952.1 g9506792 7Consensussequence Hs.110637.0 NM_018951.1 Hs.110637.0_RC 8Exemplarsequence Hs.17775.0 NM_014380.1 g7657043 9 ExemplarsequenceHs.2733.0 NM_002145.1 g4504464 10 Exemplarsequence Hs.61490.0NM_014575.1 g7657539 11 Exemplarsequence g13786124 NM_031311.1g13786124 12 Consensussequence Hs.222446.0 AW137982 Hs.222446.0.A113 Consensussequence Hs.269918.0 BF590528 Hs.269918.0.A1 14Consensussequence Hs.169825.0 AW052179 Hs.169825.0_RC 15Exemplarsequence Hs.170177.0 NM_002398.1 g4505150 16Consensussequence Hs.302022.1 AI623202 Hs.302022.1.S1 17Consensussequence Hs.269918.1 AI125255 Hs.269918.1 18Consensussequence Hs.146226.0 AW162011 Hs.146226.0_RC 19Consensussequence Hs.37034.0 NM_019102.1 Hs.37034.0.S1 20Consensussequence Hs.154999.0 BG396614 Hs.154999.0.A1 21Consensussequence Hs.42640.1 BE672557 Hs.42640.1.A1 22Consensussequence Hs.301930.0 BF057784 Hs.301930.0.A1 23Consensussequence Hs.87450.0 NM_001335.1 Hs.87450.0.S1 24Consensussequence Hs.110637.0 NM_018951.1 Hs.110637.0_RC 25Consensussequence Hs.36972.0 AI829961 Hs.36972.0.S1 26Consensussequence Hs.179902.1 NM_022109.1 Hs.179902.1 Sequence #Source Unigene_Accession Cluster_Type LocusLinkFull_length_Reference_Seq 1 RefSeq Hs.128155 fulllength 29064NM_014151; HSPC053 protein 2 GenBank Hs.127428 fulllength 3205NM_002142; homeobox protein A9 isoform b NM_152739; homeoboxprotein A9 isoform a 3 RefSeq Hs.98243 fulllength 6691 NM_021114;serine protease inhibitor, Kazal type, 2 (acrosin-trypsininhibitor) 4 GenBank Hs.127428 fulllength 3205 NM_002142; homeoboxprotein A9 isoform b NM_152739; homeobox protein A9 isoform a 5GenBank Hs.299916 fulllength 257194 NM_173808; kilon 6 RefSeqHs.98428 fulllength 3216 NM_018952; homeo box B6 isoform 1NM_156036 ; homeo box B6 isoform 2 NM_156037; homeo box B6 isoform1 7 GenBank Hs.110637 fulllength 3206 NM_018951; homeobox proteinA10 isoform a NM_153715; homeobox protein A10 isoform b 8 RefSeqHs.381039 fulllength 27018 NM_014380; nerve growth factor receptor(TNFRSF16) associated protein 1 9 RefSeq Hs.2733 fulllength 3212NM_002145; homeo box B2 10 RefSeq Hs.61490 fulllength 29970NM_014575; schwannomin interacting protein 1 11 RefSeq Hs.95594fulllength 54504 NM_019029; serine carboxypeptidasevitellogenic-like NM_031311; serine carboxypeptidasevitellogenic-like 12 GenBank Hs.248074 fulllength 3200 NM_030661;homeobox A3 protein isoform a NM_153631; homeobox A3 proteinisoform a NM_153632; homeobox A3 protein isoform b 13 GenBankHs.183096 fulllength 14 GenBank Hs.169825 fulllength 1287NM_000495; alpha 5 type IV collagen isoform 1, precursor NM_033380;alpha 5 type IV collagen isoform 2, precursor NM_033381; alpha 5type IV collagen isoform 3, precursor 15 RefSeq Hs.170177fulllength 4211 NM_002398; Meis1 homolog 16 GenBank Hs.302022fulllength 63976 NM_022114; PR domain containing 16 17 GenBankHs.183096 fulllength 18 GenBank Hs.445509 est 19 GenBank Hs.37034fulllength 3202 NM_019102; homeobox protein A5 20 GenBank Hs.433379283683 21 GenBank Hs.173179 22 GenBank Hs.301930 fulllength 221188NM_153837; G-protein coupled receptor 114 23 GenBank Hs.87450fulllength 1521 NM_001335; cathepsin W preproprotein 24 GenBankHs.110637 fulllength 3206 NM_018951; homeobox protein A10 isoform aNM_153715; homeobox protein A10 isoform b 25 GenBank Hs.36972fulllength 924 NM_006137; CD7 antigen precursor 26 GenBankHs.179902 fulllength 23446 NM_022109; CDw92 antigen NM_080546;CDw92 antigen

TABLE-US-00011 TABLE 10 genes lower expressed in CEBPA than in t(821) Sequence # affy id HUGO name Title MapLocation Sequence TypeTranscript ID Derived From 1 228827_at Homo sapiens clone 25023mRNA sequence Consensussequence Hs.90858.0 AI217416 2 203859_s_atPALM paralemmin 19p13.3 Exemplarsequence Hs.78482.0 NM_002579.1 3205528_s_at CBFA2T1 core-binding factor, runt domain, alpha sub-8q22 Consensussequence Hs.31551.0 X79990.1 unit 2; translocated to,1; cyclin D-related 4 205529_s_at CBFA2T1 core-binding factor, runtdomain, alpha sub- 8q22 Exemplarsequence Hs.31551.0 NM_004349.1unit 2; translocated to, 1; cyclin D-related 5 242845_at Homosapiens mRNA; cDNA DKFZp564B213 (from clone ConsensussequenceHs.144995.0 AI366780 DKFZp564B213) 6 202789_at ConsensussequenceHs.268177.0 AL022394 7 206940_s_at POU4F1 POU domain, class 4,transcription factor 1 13q21.1-q22 Exemplarsequence Hs.211588.0NM_006237.1 8 235468_at ESTs Consensussequence Hs.105805.0 AA5312879 233587_s_at Homo sapiens cDNA FLJ12790 fis, clone NT2RP2001985,Consensussequence Hs.18760.1 AK022852.1 weakly similar to Homosapiens high-risk human papilloma viruses E6 oncoproteins targetedprotein E6TP1 alpha mRNA. 10 219892_at TM6SF1 transmembrane 6superfamily member 1 15q24-q26 Exemplarsequence Hs.133865.0NM_023003.1 11 225056_at Homo sapiens cDNA FLJ12790 fis, cloneNT2RP2001985, Consensussequence Hs.18760.0 AB037810.1 weaklysimilar to Homo sapiens high-risk human papilloma viruses E6oncoproteins targeted protein E6TP1 alpha mRNA. 12 223046_at EGLN1egl nine homolog 1 (C. elegans) 1q42.1 Consensussequence Hs.6523.1NM_022051.1 13 221497_x_at EGLN1 egl nine homolog 1 (C. elegans)1q42.1 Exemplarsequence Hs.6523.1 BC005369.1 14 211341_at POU4F1POU domain, class 4, transcription factor 1 13q21.1-q22Exemplarsequence Hs.211588.1 L20433.1 15 210512_s_at VEGF vascularendothelial growth factor 6p12 Exemplarsequence Hs.73793.0AF022375.1 Sequence # Sequence ID Source Unigene_AccessionCluster_Type LocusLink Full_Length_Reference_Seq 1 Hs.90858.0.S1GenBank Hs.90858 2 g4557041 RefSeq Hs.78482 fulllength 5064NM_002579; paralemmin 3 Hs.31551.0 GenBank Hs.31551 fulllength 862NM_004349; acute myelogenous leukemia 1 translocation 1 proteinisoform MTG8a NM_175634; acute myelogenous leukemia 1 translocation1 protein isoform MTG8b NM_175635; acute myelogenous leukemia 1translocation 1 protein isoform MTG8c NM_175636; acute myelogenousleukemia 1 translocation 1 protein isoform MTG8c 4 g475915 RefSeqHs.31551 fulllength 862 NM_004349; acute myelogenous leukemia 1translocation 1 protein isoform MTG8a NM_175634; acute myelogenousleukemia 1 translocation 1 protein isoform MTG8b NM_175635; acutemyelogenous leukemia 1 translocation 1 protein isoform MTG8cNM_175636; acute myelogenous leukemia 1 translocation 1 proteinisoform MTG8c 5 Hs.144995.0.A1 GenBank Hs.380268 6 Hs.268177.0.S2GenBank 7 g5453937 RefSeq Hs.211588 fulllength 5457 NM_006237; POUdomain, class 4, transcription factor 1 8 Hs.105805.0_RC GenBankHs.438798 est 9 Hs.18760.1 GenBank Hs.405863 fulllength 10g13194198 RefSeq Hs.341203 fulllength 53346 NM_023003;transmembrane 6 superfamily member 1 11 Hs.18760.0 GenBankHs.405863 fulllength 12 Hs.6523.1_RC GenBank Hs.6523 fulllength54583 NM_022051; egl nine homolog 1 13 g13529208 GenBank Hs.6523fulllength 54583 NM_022051; egl nine homolog 1 14 g418015 GenBankHs.211588 fulllength 5457 NM_006237; POU domain, class 4,transcription factor 1 15 g3719220 GenBank Hs.73793 fulllength 7422NM_003376; vascular endothelial growth factor

TABLE-US-00012 TABLE 11 genes higher expressed in CEBPA than int(15 17) Transcript # affy id HUGO name Title MapLocation SequenceType ID 1 209905_at HOXA9 homeo box A9 7p15-p14 ConsensussequenceHs.127428.0 2 214651_s_at HOXA9 homeo box A9 7p15-p14Consensussequence Hs.127428.2 3 204304_s_at PROML1 prominin-like 1(mouse) 4p15.33 Exemplarsequence Hs.112360.0 4 219054_at FLJ14054hypothetical protein FLJ14054 5p13.3 Exemplarsequence Hs.13528.0 5213150_at HOXA10 homeo box A10 7p15-p14 ConsensussequenceHs.110637.0 6 204425_at ARHGAP4 Rho GTPase activating protein 4Xq28 Exemplarsequence Hs.3109.0 7 230670_at FLJ25972 hypotheticalprotein FLJ25972 3q25.1 Consensussequence Hs.88162.0 8 243618_s_atLOC152485 hypothetical protein LOC152485 4q31.1 ConsensussequenceHs.229022.0 9 202890_at MAP7 microtubule-associated protein 76q23.2 Consensussequence Hs.146388.0 10 211991_s_at HLA-DPA1 majorhistocompatibility complex, class II, DP alpha 1 6p21.3Consensussequence Hs.914.0 11 209732_at CLECSF2 C-type (calciumdependent, carbohydrate-recognition 12p13-p12 ExemplarsequenceHs.85201.0 domain) lectin, superfamily member 2(activation-induced) 12 235521_at HOXA3 homeo box A3 7p15-p14Consensussequence Hs.222446.0 13 207269_at DEFA4 defensin, alpha 4,corticostatin 8p23 Exemplarsequence Hs.2582.0 14 217388_s_at KYNUkynureninase (L-kynurenine hydrolase) 2q22.1 ConsensussequenceHs.169139.2 15 219790_s_at NPR3 natriuretic peptide receptorC/guanylate cyclase C 5p14-p13 Exemplarsequence Hs.123655.0(atrionatriuretic peptide receptor C) 16 212998_x_at HLA-DQB1 majorhistocompatibility complex, class II, DQ beta 1 6p21.3Consensussequence Hs.73931.3 17 226751_at DKFZP566K1924DKFZP566K1924 protein 2p13.2 Consensussequence Hs.26358.0 18219789_at NPR3 natriuretic peptide receptor C/guanylate cyclase C5p14-p13 Consensussequence Hs.123655.0 (atrionatriuretic peptidereceptor C) 19 213147_at HOXA10 homeo box A10 7p15-p14Consensussequence Hs.110637.0 20 201137_s_at HLA-DPB1 majorhistocompatibility complex, class II, DP beta 1 6p21.3Exemplarsequence Hs.814.0 21 213537_at HLA-DPA1 majorhistocompatibility complex, class II, DP alpha 1 6p21.3Consensussequence Hs.914.1 Sequence Derived Sequence # FromSequence ID Source Unigene_Accession Cluster_Type LocusLinkFull_Length_Reference_Seq 1 AI246769 Hs.127428.0 GenBank Hs.127428fulllength 3205 NM_002142; homeobox protein A9 isoform b NM_152739;homeobox protein A9 isoform a 2 U41813.1 Hs.127428.2 GenBankHs.127428 fulllength 3205 NM_002142; homeobox protein A9 isoform bNM_152739; homeobox protein A9 isoform a 3 NM_006017.1 g5174386RefSeq Hs.112360 fulllength 8842 NM_006017; prominin 1 4NM_024563.1 g13375730 RefSeq Hs.13528 fulllength 79614 NM_024563;hypothetical protein FLJ14054 5 NM_018951.1 Hs.110637.0_RC GenBankHs.110637 fulllength 3206 NM_018951; homeobox protein A10 isoform aNM_153715; homeobox protein A10 isoform b 6 NM_001666.1 g11386132RefSeq Hs.3109 fulllength 393 NM_001666; Rho GTPase activatingprotein 4 7 AW341661 Hs.88162.0.A1 GenBank Hs.88162 fulllength285313 NM_178822; hypothetical protein FLJ25972 8 BF678830Hs.229022.0.A1 GenBank Hs.351270 152485 NM_178835; hypotheticalprotein LOC152485 9 T62571 Hs.146388.0.S1 GenBank Hs.146388fulllength 9053 NM_003980; microtubule-associated protein 7 10M27487.1 Hs.914.0_RC GenBank Hs.914 fulllength 3113 NM_033554;major histocompatibility complex, class II, DP alpha 1 precursor 11BC005254.1 g13528920 GenBank Hs.85201 fulllength 9976 NM_005127;C-type lectin, superfamily member 2 12 AW137982 Hs.222446.0.A1GenBank Hs.248074 fulllength 3200 NM_030661; homeobox A3 proteinisoform a NM_153631; homeobox A3 protein isoform a NM_153632;homeobox A3 protein isoform b 13 NM_001925.1 g4503302 RefSeqHs.2582 fulllength 1669 NM_001925; defensin, alpha 4, preproprotein14 D55639.1 Hs.169139.2 GenBank Hs.169139 fulllength 8942NM_003937; kynureninase (L-kynurenine hydrolase) 15 NM_000908.1g4505440 RefSeq Hs.123655 fulllength 4883 NM_000908; natriureticpeptide receptor C/guanylate cyclase C (atrionatriuretic peptidereceptor C) 16 AI583173 Hs.73931.3_RC GenBank Hs.73931 fulllength3119 NM_002123; major histocompatibility complex, class II, DQ beta1 precursor 17 AW193693 Hs.26358.0.S1 GenBank Hs.26358 fulllength25927 NM_015463; DKFZP566K1924 protein 18 AI628360 Hs.123655.0GenBank Hs.123655 fulllength 4883 NM_000908; natriuretic peptidereceptor C/guanylate cyclase C (atrionatriuretic peptide receptorC) 19 NM_018951.1 Hs.110637.0_RC GenBank Hs.110637 fulllength 3206NM_018951; homeobox protein A10 isoform a NM_153715; homeoboxprotein A10 isoform b 20 NM_002121.1 g4504404 RefSeq Hs.814fulllength 3115 NM_002121; major histocompatibility complex, classII, DP beta 1 precursor 21 AI128225 Hs.914.1.A1 GenBank Hs.914fulllength 3113 NM_033554; major histocompatibility complex, classII, DP alpha 1 precursor

TABLE-US-00013 TABLE 12 genes lower expressed in CEBPA than in t(1517) Sequence # affy id HUGO name Title MapLocation Sequence TypeTranscript ID Derived From 1 38487_at STAB1 stabilin 1 3p21.31Consensussequence 4 D87433 2 212509_s_at ESTs ConsensussequenceHs.250723.2 BF968134 3 200654_at P4HB procollagen-proline,2-oxoglutarate 4- 17q25 Exemplarsequence Hs.75655.0 J02783.1dioxygenase (proline 4-hydroxylase), beta polypeptide (proteindisulfide isomerase; thyroid hormone binding protein p55) 4204150_at STAB1 stabilin 1 3p21.31 Exemplarsequence Hs.301989.0NM_015136.1 5 227326_at Homo sapiens cDNA FLJ39789 fis, cloneConsensussequence Hs.11924.0 BE966768 SPLEN2003160. 6 216320_x_atConsensussequence Hs.278657.2 U37055 7 205614_x_at MST1 macrophagestimulating 1 (hepatocyte 3p21 Exemplarsequence Hs.278657.0NM_020998.1 growth factor-like) 8 205663_at PCBP3 poly(rC) bindingprotein 3 21q22.3 Exemplarsequence Hs.121241.0 NM_020528.1 9200953_s_at CCND2 cyclin D2 12p13 Exemplarsequence Hs.75586.0NM_001759.1 10 212953_x_at CALR calreticulin 19p13.3-p13.2Consensussequence Hs.16488.2 BE251303 11 233072_at KIAA1857 netrinG2 9q34 Consensussequence Hs.163642.0 AI348745 12 200951_s_at CCND2cyclin D2 12p13 Consensussequence Hs.75586.0 NM_001759.1 13200986_at SERPING1 serine (or cysteine) proteinase inhibitor,11q12-q13.1 Exemplarsequence Hs.151242.0 NM_000062.1 clade G (C1inhibitor), member 1, (angioedema, hereditary) 14 227046_atC17orf26 chromosome 17 open reading frame 26 17q25.1Consensussequence Hs.3402.0 BF062384 15 210755_at HGF hepatocytegrowth factor (hepapoietin A; 7q21.1 Exemplarsequence Hs.809.2U46010.1 scatter factor) 16 236787_at ESTs ConsensussequenceHs.126630.0 AW591809 17 201666_at TIMP1 tissue inhibitor ofmetalloproteinase 1 Xp11.3-p11.23 Exemplarsequence Hs.5831.0NM_003254.1 (erythroid potentiating activity, collagenaseinhibitor) 18 208852_s_at CANX calnexin 5q35 ConsensussequenceHs.155560.0 AI761759 # Sequence ID Sequence SourceUnigene_Accession Cluster_Type LocusLink Full_Length_Reference_Seq1 4905477 GenBank Hs.301989 fulllength 23166 NM_015136; stabilin 12 Hs.250723.2.S1 GenBank Hs.356623 est 3 g339646 GenBank Hs.410578fulllength 5034 NM_000918; prolyl 4-hydroxylase, beta subunit 4g12225239 RefSeq Hs.301989 fulllength 23166 NM_015136; stabilin 1 5Hs.11924.0.A1 GenBank Hs.11924 6 Hs.278657.2.S1 GenBank 7 g10337614RefSeq Hs.349110 fulllength 4485 NM_020998; macrophage stimulating1 (hepatocyte growth factor-like) 8 g10092616 RefSeq Hs.121241fulllength 54039 NM_020528; poly(rC) binding protein 3 9 g4502616RefSeq Hs.75586 fulllength 894 NM_001759; cyclin D2 10Hs.16488.2_RC GenBank Hs.353170 fulllength 811 NM_004343;calreticulin precursor 11 Hs.163642.0.S1 GenBank Hs.163642fulllength 84628 NM_032536; netrin G2 12 Hs.75586.0_RC GenBankHs.75586 fulllength 894 NM_001759; cyclin D2 13 g4557378 RefSeqHs.151242 fulllength 710 NM_000062; complement component 1inhibitor precursor 14 Hs.3402.0_RC GenBank Hs.3402 fulllength201266 NM_139177; chromosome 17 open reading frame 26 15 g1378041GenBank Hs.809 fulllength 3082 NM_000601; hepatocyte growth factorprecursor 16 Hs.126630.0.A1 GenBank Hs.390407 est 17 g4507508RefSeq Hs.5831 fulllength 7076 NM_003254; tissue inhibitor ofmetalloproteinase 1 precursor 18 Hs.155560.0.S2 GenBank Hs.155560fulllength 821 NM_001746; calnexin

TABLE-US-00014 TABLE 13 Schnittger CEBPA application Sequence HUGODerived # affy id name F p q Title MapLocation Sequence TypeTranscript ID From Sequence ID 1 213147_at HOXA10 264.59 1.35E-274.13E-23 homeo box A10 7p15-p14 Consensussequence Hs.110637.0NM_018951.1 Hs.110637.0_RC 2 214651_s_at HOXA9 263.55 6.8E-271.04E-22 homeo box A9 7p15-p14 Consensussequence Hs.127428.2U41813.1 Hs.127428.2 3 205453_at HOXB2 206.96 1.82E-24 1.86E-20homeo box B2 17q21-q22 Exemplarsequence Hs.2733.0 NM_002145.1g4504464 4 235753_at 193.18 6.08E-24 4.67E-20 Homo sapiens cDNAFLJ34835 fis, clone Consensussequence Hs.196169.0 AI492051Hs.196169.0 NT2NE2010150. 5 209905_at HOXA9 177.49 4.97E-232.54E-19 homeo box A9 7p15-p14 Consensussequence Hs.127428.0AI246769 Hs.127428.0 6 221581_s_at WBSCR5 169.87 4.23E-23 2.54E-19Williams-Beuren syndrome chromosome 7q11.23 ExemplarsequenceHs.56607.1 AF257135.1 g9651998 region 5 7 213150_at HOXA10 154.572.98E-22 1.31E-18 homeo box A10 7p15-p14 ConsensussequenceHs.110637.0 NM_018951.1 Hs.110637.0_RC 8 206847_s_at HOXA7 137.232.86E-21 1.1E-17 homeo box A7 7p15-p14 Exemplarsequence Hs.70954.0AF026397.1 g2739070 9 217963_s_at NGFRAP1 136.47 1.03E-20 3.15E-17nerve growth factor receptor (TNFRSF16) Xq22.1 ExemplarsequenceHs.17775.0 NM_014380.1 g7657043 associated protein 1 10 213844_atHOXA5 133.66 7.02E-21 2.39E-17 homeo box A5 7p15-p14Consensussequence Hs.37034.0 NM_019102.1 Hs.37034.0.S1 11 227853_at115.9 2.39E-20 6.67E-17 ESTs, Weakly similar to I60307 beta-Consensussequence Hs.279860.1 AW024350 Hs.279860.1.S1galactosidase, alpha peptide - Escherichia coli [E. coli] 12235521_at HOXA3 115.62 3.73E-19 8.17E-16 homeo box A3 7p15-p14Consensussequence Hs.222446.0 AW137982 Hs.222446.0.A1 13233467_s_at PHEMX 113.32 2.43E-19 5.73E-16 pan-hematopoieticexpression 11p15.5 Consensussequence Hs.271954.2 AF176071.1Hs.271954.2 14 205366_s_at HOXB6 112.34 6.85E-19 1.11E-15 homeo boxB6 17q21.3 Exemplarsequence Hs.98428.0 NM_018952.1 g9506792 15205601_s_at HOXB5 108.77 4.84E-19 8.75E-16 homeo box B5 17q21.3Exemplarsequence Hs.22554.0 NM_002147.1 g4504468 16 243806_at108.34 4.46E-19 8.75E-16 ESTs Consensussequence Hs.161723.0AW015140 Hs.161723.0.A1 17 228827_at 107.38 4.62E-19 8.75E-16 Homosapiens clone 25023 mRNA sequence Consensussequence Hs.90858.0AI217416 Hs.90858.0.S1 18 208091_s_at DKFZP564K0822 105.18 1.69E-194.33E-16 hypothetical protein DKFZp564K0822 7p14.1 Exemplarsequenceg13540577 NM_030796.1 g13540577 19 225615_at LOC126917 104.426.23E-19 1.06E-15 hypothetical protein LOC126917 1p36.13Consensussequence Hs.13766.0 AK024480.1 Hs.13766.0 20 205600_x_atHOXB5 101.3 1.03E-18 1.51E-15 homeo box B5 17q21.3Consensussequence Hs.22554.0 AI052747 Hs.22554.0.S1 21 236892_s_at101.27 5.04E-18 5.67E-15 Homo sapiens, clone MGC: 10077Consensussequence Hs.269918.0 BF590528 Hs.269918.0.A1 IMAGE:3896690, mRNA, complete cds 22 228904_at 101.16 5.17E-18 5.67E-15ESTs Consensussequence Hs.156044.0 AW510657 Hs.156044.0 23227279_at MGC15737 100.41 8.48E-19 1.3E-15 hypothetical proteinMGC15737 Xq22.1 Consensussequence Hs.39122.0 AA847654 Hs.39122.0.S124 230894_s_at 99.92 2.89E-18 3.86E-15 Homo sapiens, clone IMAGE:4154313, Consensussequence Hs.42640.1 BE672557 Hs.42640.1.A1 mRNA,partial cds 25 215087_at 97.93 3.2E-18 4.09E-15 Homo sapiens mRNAfull length insert cDNA Consensussequence Hs.306331.0 AL109730.1Hs.306331.0 clone EUROIMAGE 68600. 26 228365_at LOC144402 97.75.75E-18 6.09E-15 copine VIII 12q11 Consensussequence Hs.71818.0AI765180 Hs.71818.0.A1 27 203949_at MPO 96.45 7E-18 7.16E-15myeloperoxidase 17q23.1 Exemplarsequence Hs.1817.0 NM_000250.1g4557758 28 203017_s_at SSX2IP 95.93 2.45E-18 3.42E-15 synovialsarcoma, X breakpoint 2 interacting Consensussequence Hs.22587.0AW136988 Hs.22587.0.S1 protein 29 239791_at 93.94 1.84E-17 1.66E-14Homo sapiens, clone MGC: 10077 Consensussequence Hs.269918.1AI125255 Hs.269918.1.A1 IMAGE: 3896690, mRNA, complete cds 30233955_x_at HSPC195 93.61 4.4E-18 5.19E-15 hypothetical proteinHSPC195 5q31.3 Consensussequence Hs.15093.1 AK001782.1 Hs.15093.131 217975_at LOC51186 92.94 1.07E-17 1.02E-14 pp21 homolog Xq22.1Exemplarsequence Hs.15984.0 NM_016303.1 g10047099 32 206310_atSPINK2 92.14 3.36E-17 2.4E-14 serine protease inhibitor, Kazaltype, 2 4q12 Exemplarsequence Hs.98243.0 NM_021114.1 g10863910(acrosin-trypsin inhibitor) 33 204069_at MEIS1 90.91 4.11E-172.81E-14 Meis1, myeloid ecotropic viral integration site 2p14-p13Exemplarsequence Hs.170177.0 NM_002398.1 g4505150 1 homolog (mouse)34 238077_at MGC27385 90.29 3.56E-18 4.37E-15 hypothetical proteinMGC27385 3p21.1 Consensussequence Hs.13982.1 T75480 Hs.13982.1_RC35 224764_at ARHGAP10 89.42 8.97E-18 8.88E-15 Rho-GTPase activatingprotein 10 10 Consensussequence Hs.11611.0 AB037845.1 Hs.11611.0.A136 216417_x_at HOXB9 87.63 3.06E-17 2.35E-14 homeo box B9 17q21.3Consensussequence Hs.287809.0 X16172 Hs.287809.0.S1 37 238012_at87.48 1.5E-17 1.39E-14 Homo sapiens, Similar to mannosidase,Consensussequence Hs.37916.0 AI620209 Hs.37916.0_RC alpha, class1B, member 1, clone IMAGE: 3623379, mRNA 38 241706_at LOC14440286.85 2.67E-17 2.1E-14 copine VIII 12q11 ConsensussequenceHs.98760.0 AA431782 Hs.98760.0.A1 39 231767_at HOXB4 84.6 5.83E-173.89E-14 homeo box B4 17q21-q22 Consensussequence Hs.126666.0AL137449.1 Hs.126666.0 40 229971_at GPR114 83.72 9.09E-17 5.81E-14G protein-coupled receptor 114 16q12.2 ConsensussequenceHs.301930.0 BF057784 Hs.301930.0.A1 41 204202_at KIAA1023 83.183.21E-17 2.4E-14 KIAA1023 protein 7p22.3 ExemplarsequenceHs.21361.0 NM_017604.1 g8922140 42 226865_at 82.7 6.24E-17 4.08E-14ESTs, Moderately similar to hypothetical ConsensussequenceHs.99472.1 AW130600 Hs.99472.1_RC protein FLJ20378 [Homo sapiens][H. sapiens] 43 201952_at ALCAM 81.76 1.93E-17 1.69E-14 activatedleukocyte cell adhesion molecule 3q13.1 ConsensussequenceHs.10247.0 NM_001627.1 Hs.10247.0 44 208146_s_at CPVL 81.1 3.11E-161.65E-13 carboxypeptidase, vitellogenic-like 7p15-p14Exemplarsequence g13786124 NM_031311.1 g13786124 45 241370_at 80.831.23E-16 7.53E-14 Homo sapiens cDNA FLJ37785 fis, cloneConsensussequence Hs.100691.0 AA278233 Hs.100691.0_RC BRHIP2028330.46 213908_at 80.82 2.17E-16 1.25E-13 Homo sapiens, clone IMAGE:4837016, Consensussequence Hs.295446.0 AI824078 Hs.295446.0.A1 mRNA47 238604_at 80.31 2.13E-17 1.82E-14 Homo sapiens cDNA FLJ25559fis, clone Consensussequence Hs.140489.0 AA768884 Hs.140489.0.A1JTH02834. 48 214450_at CTSW 79.48 2.8E-16 1.54E-13 cathepsin W(lymphopain) 11q13.1 Consensussequence Hs.87450.0 NM_001335.1Hs.87450.0.S1 49 203680_at PRKAR2B 78.35 2.02E-16 1.19E-13 proteinkinase, cAMP-dependent, regulatory, 7q22-q31.1 ExemplarsequenceHs.77439.0 NM_002736.1 g4506064 type II, beta 50 213110_s_at COL4A578.29 6.28E-16 3.16E-13 collagen, type IV, alpha 5 (Alportsyndrome) Xq22 Consensussequence Hs.169825.0 AW052179Hs.169825.0_RC 51 222996_s_at HSPC195 78.25 2E-16 1.19E-13hypothetical protein HSPC195 5q31.3 Exemplarsequence Hs.15093.0BC002490.1 g12803342 52 226134_s_at 77.62 4.23E-16 2.2E-13 Homosapiens, clone IMAGE: 4154313, Consensussequence Hs.42640.0AI978754 Hs.42640.0.A1 mRNA, partial cds 53 202732_at PKIG 77.362.48E-16 1.41E-13 protein kinase (cAMP-dependent, catalytic)20q12-q13.1 Exemplarsequence Hs.3407.0 NM_007066.1 g5902019inhibitor gamma 54 224593_at DKFZp761B128 76.84 3.78E-17 2.63E-14hypothetical protein DKFZp761B128 12q24.31 ConsensussequenceHs.61976.0 BE965646 Hs.61976.0.S1 55 240572_s_at 76.82 2.42E-172.01E-14 Homo sapiens cDNA FLJ38955 fis, clone ConsensussequenceHs.156100.1 BF436632 Hs.156100.1.A1 NT2RI2000107. 56 212895_s_atABR 76.37 1.14E-16 7.13E-14 active BCR-related gene 17p13.3Consensussequence Hs.118021.2 AL527773 Hs.118021.2_RC 57 220560_atC11orf21 75.03 2.57E-17 2.07E-14 chromosome 11 open reading frame21 11p15.5 Exemplarsequence Hs.272100.0 NM_014144.1 g7662662 58208890_s_at PLXNB2 74.34 3.3E-17 2.4E-14 plexin B2 22q13.33Exemplarsequence Hs.3989.0 BC004542.1 g13528689 59 225240_s_at73.13 1.48E-15 6.49E-13 Homo sapiens, clone IMAGE: 4154313,Consensussequence Hs.42179.0 BF435123 Hs.42179.0.A1 mRNA, partialcds 60 201951_at ALCAM 73.04 3.06E-16 1.65E-13 activated leukocytecell adhesion molecule 3q13.1 Consensussequence Hs.10247.0NM_001627.1 Hs.10247.0 61 212314_at KIAA0746 72.58 1.14E-155.29E-13 KIAA0746 protein 4p15.2 Consensussequence Hs.49500.0AB018289.1 Hs.49500.0 62 220558_x_at PHEMX 72.33 2E-15 8.18E-13pan-hematopoietic expression 11p15.5 Exemplarsequence Hs.271954.0NM_005705.1 g5032206 63 238778_at FLJ32798 72.22 1.09E-15 5.13E-13hypothetical protein FLJ32798 10p11.1 Consensussequence Hs.103296.0AI244661 Hs.103296.0 64 223398_at MGC11115 71.65 2.64E-16 1.47E-13hypothetical protein MGC11115 9q22.2 Exemplarsequence Hs.39132.0BC004500.1 g13325387 65 204495_s_at DKFZP434H132 70.9 8.45E-164.12E-13 DKFZP434H132 protein 15q22.33 Exemplarsequence Hs.17936.0NM_015492.1 g7661575 66 238756_at 70.45 1.32E-15 5.94E-13 Homosapiens cDNA FLJ35212 fis, clone Consensussequence Hs.41294.0AI860012 Hs.41294.0_RC PROST1000136. 67 212311_at KIAA0746 70.221.56E-15 6.63E-13 KIAA0746 protein 4p15.2 ConsensussequenceHs.49500.0 AB018289.1 Hs.49500.0 68 204494_s_at DKFZP434H132 70.175.14E-16 2.63E-13 DKFZP434H132 protein 15q22.33 ConsensussequenceHs.17936.0 AW516789 Hs.17936.0 69 213940_s_at FNBP1 70.17 9.37E-164.49E-13 formin binding protein 1 9q34 ConsensussequenceHs.301763.1 AU145053 Hs.301763.1.S1 70 204082_at PBX3 69.271.24E-15 5.68E-13 pre-B-cell leukemia transciption factor 39q33-q34 Exemplarsequence Hs.294101.0 NM_006195.1 g5453851 71219062_s_at FLJ20281 68.69 1.53E-15 6.61E-13 hypothetical proteinFLJ20281 18q21.32 Exemplarsequence Hs.18800.0 NM_017742.1 g892325972 201243_s_at ATP1B1 68.07 1.73E-15 7.28E-13 ATPase, Na+/K+transporting, beta 1 1q22-q25 Exemplarsequence Hs.78629.0NM_001677.1 g4502276 polypeptide 73 226206_at FLJ32205 67.954.3E-15 1.61E-12 hypothetical protein FLJ32205 7p22.3Consensussequence Hs.11607.0 BG231691 Hs.11607.0.A1 74 217226_s_atBA108L7.2 67.94 2.95E-15 1.19E-12 similar to rat tricarboxylatecarrier-like protein 10q24.31 Consensussequence Hs.155606.2M95929.1 Hs.155606.2.S1 75 218450_at HEBP1 67.86 1.89E-15 7.83E-13heme binding protein 1 12p13.2 Exemplarsequence Hs.108675.0NM_015987.1 g7705404 76 207839_s_at LOC51754 67.53 8.1E-15 2.86E-12NAG-5 protein 9p13.1 Exemplarsequence Hs.8087.0 NM_016446.1g7706546 77 215440_s_at FLJ10097 67.35 4.37E-15 1.62E-12hypothetical protein FLJ10097 Xq22.1-q22.3 ConsensussequenceHs.184736.1 AL523320 Hs.184736.1.A1 78 203741_s_at ADCY7 66.971.46E-15 6.49E-13 adenylate cyclase 7 16q12-q13 ExemplarsequenceHs.172199.0 NM_001114.1 g4557254 79 215051_x_at AIF1 66.93 7.12E-163.52E-13 allograft inflammatory factor 1 6p21.3 ConsensussequenceHs.76364.4 BF213829 Hs.76364.4 80 209500_x_at TNFSF13 66.733.51E-15 1.38E-12 tumor necrosis factor (ligand) superfamily,17p13.1 Exemplarsequence Hs.54673.2 AF114012.1 g7328555 member 1381 220974_x_at BA108L7.2 66.5 4.95E-15 1.81E-12 similar to rattricarboxylate carrier-like protein 10q24.31 Exemplarsequenceg13569945 NM_030971.1 g13569945 82 224516_s_at HSPC195 66.333.29E-15 1.31E-12 hypothetical protein HSPC195 5q31.3Exemplarsequence g13623618 BC006428.1 g13623618 83 225010_atD10S170 66.08 7.47E-15 2.67E-12 DNA segment on chromosome 10(unique) 10q21 Consensussequence Hs.288862.0 AK024913.1Hs.288862.0.A1 170 84 206289_at HOXA4 65.48 6.35E-15 2.29E-12 homeobox A4 7p15-p14 Exemplarsequence Hs.77637.0 NM_002141.1 g4504458 85204785_x_at IFNAR2 65.37 3.81E-15 1.48E-12 interferon (alpha, betaand omega) receptor 2 21q22.11 Exemplarsequence Hs.86958.0NM_000874.1 g4504600 86 243010_at MSI2 65.28 1E-14 3.38E-12 musashihomolog 2 (Drosophila) 17q23.1 Consensussequence Hs.103512.0BE000929 Hs.103512.0.A1 87 203948_s_at MPO 64.76 3.9E-14 1.12E-11myeloperoxidase 17q23.1 Exemplarsequence Hs.1817.0 J02694.1 g18903988 205518_s_at CMAH 63.14 8.5E-15 2.96E-12 cytidinemonophosphate-N-acetylneuraminic 6p21.32 ExemplarsequenceHs.24697.0 NM_003570.1 g4502908 acid hydroxylase(CMP-N-acetylneuraminate monooxygenase) 89 237189_at HOXB2 62.361.74E-14 5.62E-12 homeo box B2 17q21-q22 ConsensussequenceHs.124020.0 BF060978 Hs.124020.0.A1 90 205528_s_at CBFA2T1 62.367.36E-14 1.87E-11 core-binding factor, runt domain, alpha 8q22Consensussequence Hs.31551.0 X79990.1 Hs.31551.0 subunit 2;translocated to, 1; cyclin D-related 91 213385_at CHN2 62.321.05E-14 3.5E-12 chimerin (chimaerin) 2 7p15.3 ConsensussequenceHs.286055.2 AK026415.1 Hs.286055.2 92 238455_at 62.28 9.3E-153.21E-12 ESTs Consensussequence Hs.72639.0 AA329676 Hs.72639.0_RC93 227556_at ATP1B1 61.88 1.84E-14 5.88E-12 ATPase, Na+/K+transporting, beta 1 1q22-q25 Consensussequence Hs.78629.2 AI094580Hs.78629.2.A1 polypeptide 94 228345_at 61.07 3.69E-14 1.07E-11ESTs, Moderately similar to cystein-rich ConsensussequenceHs.34656.0 AI745136 Hs.34656.0.A1 hydrophobic domain 2;BRX-like-translocated in leukemia; BRX-like translocated inleukemia; cysteine-rich hydrophobic 2 [Homo sapiens] [H. sapiens]95 202006_at PTPN12 61.07 4.31E-15 1.61E-12 protein tyrosinephosphatase, non-receptor 7q11.23 Exemplarsequence Hs.62.0NM_002835.1 g4506286 type 12

96 213408_s_at MGC14697 60.92 9.74E-15 3.32E-12 hypotheticalprotein MGC14697 10q24.32 Consensussequence Hs.171625.3 AK024034.1Hs.171625.3 97 207081_s_at PIK4CA 60.3 1.61E-14 5.26E-12phosphatidylinositol 4-kinase, catalytic, alpha 22q11.21Exemplarsequence Hs.171625.0 NM_002650.1 g4505806 polypeptide 98235749_at UGCGL2 60.11 1.51E-14 5E-12 UDP-glucose ceramideglucosyltransferase- 13q32.1 Consensussequence Hs.133423.0 AI057619Hs.133423.0.A1 like 2 99 210314_x_at TNFSF13 60.07 2.09E-146.61E-12 tumor necrosis factor (ligand) superfamily, 17p13.1Exemplarsequence Hs.54673.1 AF114013.1 g7328557 member 13 100206940_s_at POU4F1 60.03 4.28E-12 7.02E-10 POU domain, class 4,transcription factor 1 13q21.1-q22 Exemplarsequence Hs.211588.0NM_006237.1 g5453937

TABLE-US-00015 TABLE 13 Schnittger CEBPA application SequenceLocus- # Source Unigene_Accession Cluster_Type LinkFull_Length_Reference_Seq 1 GenBank Hs.110637 fulllength 3206NM_018951; homeobox protein A10 isoform a NM_153715; homeoboxprotein A10 isoform b 2 GenBank Hs.127428 fulllength 3205NM_002142; homeobox protein A9 isoform b NM_152739; homeoboxprotein A9 isoform a 3 RefSeq Hs.2733 fulllength 3212 NM_002145;homeo box B2 4 GenBank Hs.196169 5 GenBank Hs.127428 fulllength3205 NM_002142; homeobox protein A9 isoform b NM_152739; homeoboxprotein A9 isoform a 6 GenBank Hs.56607 fulllength 7462 NM_014146;WBSCR5 protein isoform 1 NM_022040; WBSCR5 protein isoform 1NM_032463; WBSCR5 protein isoform 1 NM_032464; WBSCR5 proteinisoform 2 7 GenBank Hs.110637 fulllength 3206 NM_018951; homeoboxprotein A10 isoform a NM_153715; homeobox protein A10 isoform b 8GenBank Hs.446318 fulllength 3204 NM_006896; homeobox protein A7 9RefSeq Hs.381039 fulllength 27018 NM_014380; nerve growth factorreceptor (TNFRSF16) associated protein 1 10 GenBank Hs.37034fulllength 3202 NM_019102; homeobox protein A5 11 GenBank Hs.356538est 12 GenBank Hs.248074 fulllength 3200 NM_030661; homeobox A3protein isoform a NM_153631; homeobox A3 protein isoform aNM_153632; homeobox A3 protein isoform b 13 GenBank Hs.271954fulllength 10077 NM_005705: tumor-suppressing subtransferablecandidate 6 isoform 2 NM_139022; tumor-suppressing subtransferablecandidate 6 isoform 1 NM_139023; tumor-suppressing subtransferablecandidate 6 isoform 4 NM_139024; tumor-suppressing subtransferablecandidate 6 isoform 3 14 RefSeq Hs.98428 fulllength 3216 NM_018952;homeo box B6 isoform 1 NM_156036; homeo box B6 isoform 2 NM_156037;homeo box B6 isoform 1 15 RefSeq Hs.22554 fulllength 3215NM_002147: homeo box B5 16 GenBank Hs.443007 est 17 GenBankHs.90858 18 RefSeq Hs.4750 fulllength 81552 NM_030796; hypotheticalprotein DKFZp564K0822 19 GenBank Hs.13766 126917 20 GenBankHs.22554 fulllength 3215 NM_002147; homeo box B5 21 GenBenkHs.183096 fulllength 22 GenBank Hs.156044 est 23 GenBank Hs.39122fulllength 85012 NM_032926; hypothetical protein MGC15737 24GenBank Hs.173179 25 GenBank Hs.306331 26 GenBank Hs.71818fulllength 144402 NM_153634; copine VIII 27 RefSeq Hs.1817fulllength 4353 NM_000250; myeloperoxidase 28 GenBank Hs.22587fulllength 117178 NM_014021; synovial sarcoma, X breakpoint 2interacting protein 29 GenBank Hs.183096 fulllength 30 GenBankHs.15093 fulllength 51523 NM_016463; hypothetical protein HSPC19531 RefSeq Hs.15984 fulllength 51186 NM_016303; pp21 homolog 32RefSeq Hs.98243 fulllength 6691 NM_021114; serine proteaseinhibitor, Kazal type, 2 (acrosin-trypsin inhibitor) 33 RefSeqHs.170177 fulllength 4211 NM_002398; Meis1 homolog 34 GenBankHs.13982 fulllength 200845 NM_153331; hypothetical protein MGC2738535 GenBank Hs.11611 fulllength 57584 NM_020824; Rho-GTPaseactivating protein 10 36 GenBank Hs.86327 fulllength 3219NM_024017; homeo box B9 37 GenBank Hs.37916 38 GenBank Hs.71818fulllength 144402 NM_153634; copine VIII 39 GenBank Hs.126666fulllength 3214 NM_024015; homeo box B4 40 GenBank Hs.301930fulllength 221188 NM_153837; G-protein coupled receptor 114 41RefSeq Hs.21361 fulllength 23288 NM_017604; NM_152558; hypotheticalprotein DKFZp434I0118 42 GenBank Hs.99472 est 43 GenBank Hs.10247fulllength 214 NM_001627; activated leukocyte cell adhesionmolecule 44 RefSeq Hs.95594 fulllength 54504 NM_019029; serinecarboxypeptidase vitellogenic-like NM_031311; serinecarboxypeptidase vitellogenic-like 45 GenBank Hs.100691 46 GenBankHs.362800 47 GenBank Hs.140489 48 GenBank Hs.87450 fulllength 1521NM_001335; cathepsin W preproprotein 49 RefSeq Hs.77439 fulllength5577 NM_002736; protein kinase, cAMP-dependent, regulatory, typeII, beta 50 GenBank Hs.169825 fulllength 1287 NM_000495; alpha 5type IV collagen isoform 1, precursor NM_033380; alpha 5 type IVcollagen isoform 2, precursor NM_033381; alpha 5 type IV collagenisoform 3, precursor 51 GenBank Hs.15093 fulllength 51523NM_016463; hypothetical protein HSPC195 52 GenBank Hs.1731709 53RefSeq Hs.3407 fulllength 11142 NM_007066; protein kinase(cAMP-dependent, catalytic) inhibitor gamma 54 GenBank Hs.61976fulllength 144348 NM_152437; hypothetical protein DKFZp761B128 55GenBank Hs.156100 est 56 GenBank Hs.118021 fulllength 29 NM_001092;active breakpoint cluster region-related protein isoform bNM_021962; active breakpoint cluster region-related protein isoforma 57 RefSeq Hs.272100 fulllength 29125 NM_014144; chromosome 11open reading frame 21 58 GenBank Hs.3989 fulllength 23654NM_012401; plexin B2 59 GenBank Hs.173179 60 GenBank Hs.10247fulllength 214 NM_001627; activated leukocyte cell adhesionmolecule 61 GenBank Hs.49500 23231 62 RefSeq Hs.271954 fulllength10077 NM_005705; tumor-suppressing subtransferable candidate 6isoform 2 NM_139022; tumor-suppressing subtransferable candidate 6isoform 1 NM_139023; tumor-suppressing subtransferable candidate 6isoform 4 NM_139024; tumor-suppressing subtransferable candidate 6isoform 3 63 GenBank Hs.350684 fulllength 143098 NM_173496;hypothetical protein FLJ32798 64 GenBank Hs.39132 fulllength 84270NM_032310; hypothetical protein MGC11115 65 RefSeq Hs.17936fulllength 25958 NM_015492; DKFZP434H132 protein 66 GenBankHs.41294 67 GenBank Hs.49500 23231 68 GenBank Hs.17936 fulllength25958 NM_015492; DKFZP434H132 protein 69 GenBank Hs.301763fulllength 23048 70 RefSeq Hs.294101 fulllength 5090 NM_006195;pre-B-cell leukemia transcription factor 3 71 RefSeq Hs.18800fulllength 54877 NM_017742; hypothetical protein FLJ20281NM_032724; hypothetical protein FLJ20281 72 RefSeq Hs.78629fulllength 481 NM_001677; ATPase, Na+/K+ transporting, beta 1polypeptide 73 GenBank Hs.11607 fulllength 157254 NM_002360; v-mafmusculoaponeurotic fibrosarcoma oncogene homolog K NM_152561;hypothetical protein FLJ32205 74 GenBank Hs.283844 fulllength 81855NM_006902; paired mesoderm homeobox 1 isoform pmx-1a NM_022716;paired mesoderm homeobox 1 isoform pmx-1b NM_030971; similar to rattricarboxylate carrier-like protein 75 RefSeq Hs.294133 fulllength50865 NM_015987; heme binding protein 1 76 RefSeq Hs.8087fulllength 51754 NM_016446; NAG-5 protein 77 GenBank Hs.184736fulllength 56271 78 RefSeq Hs.172199 fulllength 113 NM_001114;adenylate cyclase 7 79 GenBank Hs.76364 fulllength 199 NM_001623;allograft inflammatory factor 1 isoform 3 NM_004847; allograftinflammatory factor 1 isoform 2 NM_032955; allograft inflammatoryfactor 1 isoform 1 80 GenBank Hs.54673 fulllength 8741 NM_003808;tumor necrosis factor ligand superfamily, member 13 isoform alphaprecursor NM_172087; tumor necrosis factor ligand superfamily,member 13 isoform beta NM_172088; tumor necrosis factor ligandsuperfamily, member 13 isoform gamma NM_172089; tumor necrosisfactor ligand superfamily, member 13 isoform delta 81 RefSeqHs.283844 fulllength 81855 NM_030971; similar to rat tricarboxylatecarrier-like protein 82 GenBank Hs.15093 fulllength 51523NM_016463; hypothetical protein HSPC195 83 GenBank Hs.288862fulllength 8030 NM_005436; DNA segment on chromosome 10 (unique)170 84 RefSeq Hs.77637 fulllength 3201 NM_002141; homeobox proteinA4 85 RefSeq Hs.86958 fulllength 3455 NM_000874; interferon (alpha,beta and omega) receptor 2 86 GenBank Hs.103512 fulllength 124540NM_138962; musashi 2 isoform a NM_170721; musashi 2 isoform b 87GenBank Hs.1817 fulllength 4353 NM_000250; myeloperoxidase 88RefSeq Hs.24697 fulllength 8418 XR_000114; 89 GenBank Hs.2733fulllength 3212 NM_002145; homeo box B2 90 GenBank Hs.31551fulllength 862 NM_004349; acute myelogenous leukemia 1translocation 1 protein isoform MTG8a NM_175634; acute myelogenousleukemia 1 translocation 1 protein isoform MTG8b NM_175635; acutemyelogenous leukemia 1 translocation 1 protein isoform MTG8cNM_175636; acute myelogenous leukemia 1 translocation 1 proteinisoform MTG8c 91 GenBank Hs.286055 fulllength 1124 NM_004067;chimerin (chimaerin) 2 92 GenBank Hs.72639 est 93 GenBank Hs.78629fulllength 481 NM_001677; ATPase, Na+/K+ transporting, beta 1polypeptide 94 GenBank Hs.34656 est 95 RefSeq Hs.62 fulllength 5782NM_002835; protein tyrosine phosphatase, non-receptor type 12 96GenBank Hs.171625 fulllength 84833 NM_002650; phosphatidylinositol4-kinase, catalytic, alpha polypeptide isoform 1 NM_032747;upregulated during skeletal muscle growth 5 NM_058004;phosphatidylinositol 4-kinase, catalytic, alpha polypeptide isoform2 97 RefSeq Hs.334874 fulllength 5297 NM_002650;phosphatidylinositol 4-kinase, catalytic, alpha polypeptide isoform1 NM_058004; phosphatidylinositol 4-kinase, catalytic, alphapolypeptide isoform 2 98 GenBank Hs.22983 fulllength 55757NM_020121; UDP-glucose:glycoprotein glucosyltransferase 2 99GenBank Hs.54673 fulllength 8741 NM_003808; tumor necrosis factorligand superfamily, member 13 isoform alpha precursor NM_172087;tumor necrosis factor ligand superfamily, member 13 isoform betaNM_172088; tumor necrosis factor ligand superfamily, member 13isoform gamma NM_172089; tumor necrosis factor ligand superfamily,member 13 isoform delta 100 RefSeq Hs.211588 fulllength 5457NM_006237; POU domain, class 4, transcription factor 1

TABLE-US-00016 TABLE 15 affy id HUGO name Title MapLocationSequence Type Go_Biological_Process 1 208268_at ADAM28 adisintegrin and 8p21.1 Exemplarsequence "GO: 7283; spermatogenesis;traceable metalloproteinase domain 28 author statement GO: 6508;proteolysis and peptidolysis; inferred from electronic annotation"2 242738_s_at ATBF1 Homo sapiens, clone Consensussequence IMAGE:5288537, mRNA 3 202946_s_at BTBD3 BTB (POZ) domain containing 320p12.1 Exemplarsequence 4 215567_at C14orf111 Homo sapiens cDNAFLJ11574 Consensussequence fis, clone HEMBA1003384. 5 209831_x_atDNASE2 deoxyribonuclease II, lysosomal 19p13.2 Exemplarsequence"GO: 6259; DNA metabolism; traceable author statement GO: 6915;apoptosis; inferred from electronic annotation" 6 203187_at DOCK1dedicator of cyto-kinesis 1 10q26.13-q26.3 Exemplarsequence "GO:7165; signal transduction; traceable author statement GO: 7229;integrin-mediated signaling pathway; traceable author statement GO:7264; small GTPase mediated signal transduction; traceable authorstatement GO: 6915; apoptosis; traceable author statement GO: 6911;phagocytosis, engulfment; traceable author statement" 7 208872_s_atDP1 likely ortholog of mouse deleted 5q22-q23 Consensussequence inpolyposis 1 8 204160_s_at ENPP4 ectonucleotide 6p12.3Consensussequence "GO: 9117; nucleotide metabolism;pyrophosphatase/phosphodiesterase inferred from electronicannotation" 4 (putative function) 9 242784_at ETS2 ESTsConsensussequence 10 219981_x_at FLJ20813 hypothetical proteinFLJ20813 19q13.43 Exemplarsequence 11 213260_at FOXC1 Homo sapienscDNA FLJ11796 Consensussequence fis, clone HEMBA1006158, highlysimilar to Homo sapiens transcription factor forkhead-like 7(FKHL7) gene. 12 202967_at GSTA4 glutathione S-transferase A46p12.1 Exemplarsequence "GO: 6950; response to stress; not recordedGO: 6803; glutathione conjugation reaction; inferred fromelectronic annotation" 13 214455_at HIST1H2BC histone 1, H2bc6p21.3 Consensussequence "GO: 6334; nucleosome assembly;non-traceable author statement GO: 7001; chromosome organizationand biogenesis (sensu Eukarya); inferred from electronicannotation" 14 211220_s_at HSF2 heat shock transcription factor 26q22.32 Exemplarsequence "GO: 6355; regulation of transcription,DNA-dependent; inferred from electronic annotation GO: 6366;transcription from Pol II promoter; traceable author statement" 15227370_at KIAA1946 KIAA1946 protein 2q32.1 Consensussequence 16208767_s_at LAPTM4B lysosomal associated protein 8q22.1Consensussequence transmembrane 4 beta 17 214039_s_at LAPTM4Blysosomal associated protein 8q22.1 Consensussequence transmembrane4 beta 18 235391_at LOC137392 similar to CG6405 gene product 8q21.3Consensussequence 19 217975_at LOC51186 pp21 homolog Xq22.1Exemplarsequence 20 208858_s_at MBC2 likely ortholog of mouse12q13.13 Exemplarsequence "GO: 7186; G-protein coupled receptormembrane bound C2 domain protein signaling pathway; inferredcontaining protein from electronic annotation" 21 201620_at MBTPS1membrane-bound transcription 16q24 Exemplarsequence "GO: 6629;lipid metabolism; inferred factor protease, site 1 from electronicannotation GO: 6508; proteolysis and peptidolysis; traceable authorstatement GO: 8203; cholesterol metabolism; inferred fromelectronic annotation" 22 203948_s_at MPO myeloperoxidase 17q23.1Exemplarsequence "GO: 6916; anti-apoptosis; traceable authorstatement GO: 6952; defense response; traceable author statementGO: 6979; response to oxidative stress; traceable author statement"23 202600_s_at NRIP1 nuclear receptor interacting 21q11.2Consensussequence "GO: 6355; regulation of transcription, protein 1DNA-dependent; inferred from electronic annotation GO: 6350;transcription; traceable author statement" 24 225864_at NSE2 Homosapiens cDNA FLJ23705 Consensussequence fis, clone HEP11066. 25217848_s_at PP pyrophosphatase (inorganic) 10q11.1-q24Exemplarsequence 26 208994_s_at PPIG peptidyl-prolyl isomerase G2q31.1 Consensussequence "GO: 6371; mRNA splicing; traceable(cyclophilin G) author statement GO: 6457; protein folding;inferred from electronic annotation" 27 218599_at REC8L1 Rec8p, ameiotic recombination 14q11.2-q12 Exemplarsequence "GO: 7126;meiosis; traceable and sister chromatid cohesion author statementGO: 7283; phosphoprotein of the rad21p spermatogenesis; traceableauthor family statement GO: 7131; meiotic recombination; traceableauthor statement GO: 7062; sister chromatid cohesion; traceableauthor statement" 28 210365_at RUNX1 runt-related transcriptionfactor 1 21q22.3 Exemplarsequence "GO: 6355; regulation oftranscription, (acute myeloid leukemia 1; aml1 DNA-dependent;non-traceable author oncogene) statement GO: 7275; development;traceable author statement GO: 8151; cell growth and/ormaintenance; inferred from electronic annotation GO: 7048;oncogenesis; traceable author statement" 29 201427_s_at SEPP1selenoprotein P, plasma, 1 5q31 Exemplarsequence "GO: 6979;response to oxidative stress; traceable author statement" 30226419_s_at SFRS1 Homo sapiens cDNA FLJ30048 Consensussequence fis,clone ADRGL1000018. 31 203753_at TCF4 transcription factor 418q21.1 Exemplarsequence "GO: 6357; regulation of transcriptionfrom Pol II promoter; traceable author statement" 32 210665_at TFPItissue factor pathway inhibitor 2q31-q32.1 Exemplarsequence "GO:7596; blood coagulation; (lipoprotein-associated traceable authorstatement" coagulation inhibitor) 33 201688_s_at TPD52 tumorprotein D52 8q21 Consensussequence "GO: 7345; embryogenesis andmorphogenesis; traceable author statement GO: 7048; oncogenesis;traceable author statement" 34 201689_s_at TPD52 tumor protein D528q21 Consensussequence "GO: 7345; embryogenesis and morphogenesis;traceable author statement GO: 7048; oncogenesis; traceable authorstatement" 35 201690_s_at TPD52 tumor protein D52 8q21Consensussequence "GO: 7345; embryogenesis and morphogenesis;traceable author statement GO: 7048; oncogenesis; traceable authorstatement" 36 208762_at UBL1 ubiquitin-like 1 (sentrin) 2q33Exemplarsequence "GO: 6281; DNA repair; traceable author statement"37 33148_at ZFR zinc finger RNA binding protein 5p13.3Consensussequence 38 214042_s_at RPL22 ribosomal protein L221p36.3-p36.2 Consensussequence "GO: 6412; protein biosynthesis;traceable author statement" 39 215447_at Homo sapiens mRNA; cDNAConsensussequence DKFZp586J0323 (from clone DKFZp586J0323) 40222380_s_at ESTs Consensussequence 41 225547_at Homo sapiens cDNAFLJ39478 Consensussequence fis, clone PROST2013605. 42 230620_atESTs Consensussequence Transcript Go_Cellular_ComponentGo_Molecular_Function ID 1 "GO: 16021; integral to membrane;inferred from "GO: 4222; metalloendopeptidase activity; inferredfrom electronic annotation Hs.174030.1 electronic annotation" GO:8270; zinc ion binding; inferred from electronic annotation GO:16787; hydrolase activity; inferred from electronic annotation" 2Hs.163208.0 3 "GO: 5515; protein binding; inferred from electronicannotation" Hs.7935.0 4 Hs.287426.0 5 "GO: 5764; lysosome;traceable author statement" "GO: 16787; hydrolase activity;inferred from electronic Hs.118243.0 annotation GO: 3677; DNAbinding; traceable author statement GO: 4519; endonucleaseactivity; inferred from electronic annotation GO: 4531;deoxyribonuclease II activity; traceable author statement" 6 "GO:5737; cytoplasm; traceable author "GO: 5524; ATP binding; inferredfrom electronic annotation GO: Hs.82295.0 statement" 5096; GTPaseactivator activity; traceable author statement" 7 "GO: 16021;integral to membrane; non-traceable Hs.178112.0 author statement" 8"GO: 16787; hydrolase activity; inferred from electronicannotation" Hs.54037.0 9 Hs.213021.0 10 Hs.306203.0 11 Hs.284186.012 "GO: 4364; glutathione transferase activity; traceable authorstatement GO: Hs.169907.0 16740; transferase activity; inferredfrom electronic annotation" 13 "GO: 5634; nucleus; inferred fromelectronic "GO: 3677; DNA binding; non-traceable author statement"Hs.239884.0 annotation GO: 786; nucleosome; non-traceable authorstatement GO: 5694; chromosome; inferred from electronicannotation" 14 "GO: 5634; nucleus; inferred from electronic "GO:3713; transcription co-activator activity; traceable authorstatement GO: Hs.158195.1 annotation" 3773; heat shock proteinactivity; inferred from electronic annotation GO: 3700;transcription factor activity; traceable author statement" 15Hs.25329.0 16 "GO: 16021; integral to membrane; inferred fromHs.296398.0 electronic annotation" 17 "GO: 16021; integral tomembrane; inferred from Hs.296398.1 electronic annotation" 18Hs.87672.0 19 Hs.15984.0 20 "GO: 16021; integral to membrane;inferred from "GO: 1584; rhodopsin-like receptor activity; inferredfrom electronic annotation" Hs.8309.0 electronic annotation" 21"GO: 5788; endoplasmic reticulum lumen; "GO: 8233; peptidaseactivity; inferred from electronic annotation GO: Hs.75890.0traceable author statement GO: 5794; Golgi 4289; subtilaseactivity; inferred from electronic annotation" apparatus; inferredfrom electronic annotation GO: 16021; integral to membrane;inferred from electronic annotation" 22 "GO: 5764; lysosome;traceable author statement "GO: 4601; An_peroxidase; peroxidaseactivity; 6.4e-161; extended: inferred Hs.1817.0 GO: 5634; nucleus;traceable author statement" from electronic annotation GO: 3682;chromatin binding; traceable author statement GO: 16687;myeloperoxidase activity; inferred from electronic annotation GO:16685; eosinophil peroxidase activity; inferred from electronicannotation GO: 5509; calcium ion binding; inferred from electronicannotation GO: 16491; oxidoreductase activity; inferred fromelectronic annotation GO: 16686; lactoperoxidase activity; inferredfrom electronic annotation" 23 "GO: 5634; nucleus; traceable authorstatement" "GO: 3713; transcription co-activator activity;traceable author statement" Hs.155017.0 24 Hs.49136.0 25 "GO: 4427;3.6.1.1; inorganic diphosphatase activity; 4.18e-116; extended:Hs.184011.0 inferred from electronic annotation GO: 16462;Pyrophosphatase; pyrophosphatase activity; 4.4e-129; extended:Unknown" 26 "GO: 5654; nucleoplasm; traceable author "GO: 16853;isomerase activity; inferred from electronic annotation GO: 30051;Hs.77965.0 statement" FK506-sensitive peptidyl-prolyl cis-transisomerase; inferred from electronic annotation GO: 4600;cyclophilin; traceable author statement GO: 8248;

pre-mRNA splicing factor activity; traceable author statement GO:42027; cyclophilin-type peptidy-prolyl cis-trans isomeraseactivity; inferred from electronic annotation" 27 "GO: 5634;nucleus; traceable author statement" Hs.4767.0 28 "GO: 5634;nucleus; non-traceable author "GO: 3700; transcription factoractivity; traceable author statement GO: 5524; Hs.129914.4statement" ATP binding; non-traceable author statement GO: 3677;Runt; DNA binding activity; 1.2e-102; extended: Unknown" 29 "GO:8430; selenium binding; traceable author statement" Hs.3314.0 30Hs.238956.1 31 "GO: 5634; nucleus; traceable author statement" "GO:3677; DNA binding; inferred from electronic annotation GO: 3702;RNA Hs.326198.0 polymerase II transcription factor activity;traceable author statement" 32 "GO: 4867; serine protease inhibitoractivity; inferred from electronic annotation Hs.170279.1 GO: 5209;plasma protein; not recorded GO: 5211; plasma glycoprotein; notrecorded" 33 "GO: 5871; kinasin complex; inferred from Hs.2384.0electronic annotation" 34 "GO: 5871; kinesin complex; inferred fromHs.2384.0 electronic annotation" 35 "GO: 5871; kinasin complax;inferred from Hs.2384.0 electronic annotation" 36 "GO: 5634;nucleus; traceable author statement" "GO: 4840; ubiquitinconjugating enzyme activity; traceable author statement" Hs.81424.0GO: 5643; nuclear pore; traceable author statement" 37 "GO: 5634;nucleus; inferred from electronic "GO: 3723; RNA binding; inferredfrom electronic annotation" 5 annotation" 38 "GO: 5840; ribosome;inferred from electronic "GO: 3723; RNA binding; traceable authorstatement GO: 8201; heparin binding; Hs.326249.0 annotation GO:5842; cytosolic large ribosomal inferred from electronic annotationGO: 3735; structural constituent of subunit (sensu Eukarya);traceable author ribosome; traceable author statement" statementGO: 5622; intracellular; inferred from electronic annotation" 39Hs.102301.0 40 Hs.124620.0 41 Hs.292815.0 42 Hs.143587.0 SequenceSequence Derived From Sequence ID Source Unigene_AccessionCluster_Type LocusLink Full_Length_Reference_Seq 1 NM_021777.1g11496993 RefSeq Hs.174030 fulllength 10863 NM_014265; adisintegrin and metalloproteinase domain 28 isoform 1 preproproteinNM_021777; a disintegrin and metalloproteinase domain 28 isoform 3preproprotein NM_021778; a disintegrin and metalloproteinase domain28 isoform 2 preproprotein 2 BG402859 Hs.163208.0.A1 GenBankHs.108806 3 NM_014962.1 g7662401 RefSeq Hs.7935 fulllength 22903NM_014982; BTB/POZ domain containing protein 3 isoform a NM_181443;BTB/POZ domain containing protein 3 isoform b 4 AU144919Hs.287426.0 GenBank Hs.287426 5 AB004574.1 g3184394 GenBankHs.118243 fulllength 1777 NM_001375; deoxyribonuclease II,lysosomal 6 NM_001380.1 g4503354 RefSeq Hs.82295 fulllength 1793NM_001380; dedicator of cyto-kinesis 1 7 AA814140 Hs.178112.0.S1GenBank Hs.178112 fulllength 7905 NM_005669; likely ortholog ofmouse deleted in polyposis 1 8 AW194947 Hs.54037.0 GenBank Hs.54037fulllength 22875 NM_014936; ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative function) 9 AV646177 Hs.213021.0.A1GenBank Hs.213021 est 10 NM_017961.1 g8923685 RefSeq Hs.288995fulllength 55044 NM_017961; hypothetical protein FLJ20813 11AU145890 Hs.284186.0.A2 GenBank Hs.284186 12 NM_001512.1 g4504172RefSeq Hs.169907 fulllength 2941 NM_001512; glutathioneS-transferase A4 13 NM_003526.1 Hs.239884.0.S1 GenBank Hs.356901fulllength 8347 NM_003526; H2B histone family, member L 14BC005329.1 g13529106 GenBank Hs.158195 fulllength 3298 NM_004506;heat shock transcription factor 2 15 AW043602 Hs.25329.0.A1 GenBankHs.172792 fulllength 165215 NM_177454; KIAA1946 protein 16 AW149681Hs.296398.0.A1 GenBank Hs.296398 fulllength 55353 NM_018407;lysosomal-associated transmembrane protein 4 beta 17 T15777Hs.296398.1.A1 GenBank Hs.296398 fulllength 55353 NM_018407;lysosomal-associated transmembrane protein 4 beta 18 AW960748Hs.87672.0_RC GenBank Hs.403869 fulllength 137392 NM_145269;similar to CG6405 gene product 19 NM_016303.1 g10047099 RefSeqHs.15984 fulllength 51186 NM_016303; pp21 homolog 20 BC004998.1g13436457 GenBank Hs.8309 fulllength 23344 NM_015292; KIAA0747protein 21 NM_003791.1 g4506774 RefSeq Hs.75890 fulllength 8720NM_003791; site-1 protease preproprotein 22 J02694.1 g189039GenBank Hs.1817 fulllength 4353 NM_000250; myeloperoxidase 23AI824012 Hs.155017.0.S1 GenBank Hs.155017 fulllength 8204NM_003489; receptor interacting protein 140 24 AL039862Hs.49136.0.A1 GenBank Hs.49136 25 NM_021129.1 g11056043 RefSeqHs.184011 fulllength 5464 NM_021129; inorganic pyrophosphatase 26NM_004792.1 Hs.77965.0_RC GenBank Hs.77965 fulllength 9360NM_004792; peptidyl-prolyl isomerase G (cyclophilin G) 27NM_005132.1 g9845292 RefSeq Hs.4767 fulllength 9985 NM_005132;Rec8p, a meiotic recombination and sister chromatid cohesion pho 28D43967.1 g966994 GenBank Hs.129914 fulllength 861 NM_001754;runt-related transcription factor 1 (acute myeloid leukemia 1; aml1oncogene) 29 NM_005410.1 g4885590 RefSeq Hs.275775 fulllength 6414NM_005410; selenoprotein P precursor 30 AA046439 Hs.238956.1.A1GenBank Hs.238956 31 NM_003199.1 g4507398 RefSeq Hs.326198fulllength 6925 NM_003199; transcription factor 4 isoform b 32AF021834.1 g4103170 GenBank Hs.170279 fulllength 7035 NM_006287;tissue factor pathway inhibitor (lipoprotein-associated coagulationinhibitor) 33 BE974098 Hs.2384.0.S2 GenBank Hs.2384 fulllength 7163NM_005079; tumor protein D52 34 BE974098 Hs.2384.0.S2 GenBankHs.2384 fulllength 7163 NM_005079; tumor protein D52 35 BE974098Hs.2384.0.S2 GenBank Hs.2384 fulllength 7163 NM_005079; tumorprotein D52 36 U83117.1 g1769601 GenBank Hs.81424 fulllength 7341NM_003352; ubiquitin-like 1 (sentrin) 37 AI459274 4923288_rcGenBank Hs.173518 fulllength 51663 NM_016107; M-phasephosphoprotein homolog 38 AW071997 Hs.326249.0.A1 GenBank Hs.326249fulllength 6146 NM_000983; ribosomal protein L22 proprotein 39AL080215.1 Hs.102301.0 GenBank Hs.102301 40 AI907083 Hs.124620.0_RCGenBank Hs.124620 est 41 BG169443 Hs.292815.0.A1 GenBank Hs.37268042 BE550967 Hs.143587.0.A1 GenBank Hs.143587 est

TABLE-US-00017 TABLE 16 affy id HUGO name fc p q stn t TitleMapLocation 1 201691_s_at TPD52 -2.11 3.69e-08 1.32e-03 -0.35 -5.70tumor protein D52 8q21 2 213217_at ADCY2 -3.18 8.65e-08 1.55e-03-0.34 -5.52 adenylate cyclase 2 (brain) 5p15.3 3 210487_at DNTT-5.47 1.75e-07 2.08e-03 -0.34 -5.39 deoxynucleotidyltransferase,terminal 10q23-q24 4 201690_s_at TPD52 -1.87 3.04e-07 2.72e-03-0.32 -5.26 tumor protein D52 8q21 5 225547_at -1.17 7.43e-073.90e-03 -0.36 -5.23 Homo sapiens cDNA FLJ39478 fis, clonePROST2013605. 6 210665_at TFPI -2.17 5.79e-07 3.90e-03 -0.33 -5.17tissue factor pathway inhibitor 2q31-q32.1 (lipoprotein-associatedcoagulation inhibitor) 7 227370_at KIAA1946 -2.22 7.62e-07 3.90e-03-0.31 -5.07 KIAA1946 protein 2q32.1 8 235721_at -1.87 9.11e-074.08e-03 -0.31 -5.03 Homo sapiens cDNA FLJ37066 fis, cloneBRACE2015132, weakly similar to Drosophila melanogaster Oregon Rcytoplasmic basic protein (deltex) mRNA. 9 224150_s_at BITE -1.493.32e-06 1.32e-02 -0.29 -4.75 p10-binding protein 3q22-q23 10224473_x_at KIAA1813 -1.24 6.36e-06 1.65e-02 -0.32 -4.71 KIAA1813protein 10q24 11 244611_at -1.58 5.33e-06 1.65e-02 -0.30 -4.69ESTs, Highly similar to thyroid hormone receptor-associatedprotein, 240 kDa subunit [Homo sapiens] [H. sapiens] 12 201689_s_atTPD52 -1.89 4.74e-06 1.65e-02 -0.29 -4.68 tumor protein D52 8q21 13220022_at ZNF334 -1.82 5.54e-06 1.65e-02 -0.29 -4.66 zinc fingerprotein 334 20q13.12 14 215567_at -1.33 6.81e-06 1.65e-02 -0.30-4.65 Homo sapiens cDNA FLJ11574 fis, clone HEMBA1003384. 15225864_at -1.64 7.38e-06 1.65e-02 -0.29 -4.61 Homo sapiens cDNAFLJ23705 fis, clone HEP11066. 16 232081_at -2.33 7.36e-06 1.65e-02-0.28 -4.58 Homo sapiens EST from clone 208499, full insert 17220602_s_at FLJ22795 -1.64 1.09e-05 2.29e-02 -0.30 -4.56hypothetical protein FLJ22795 15q24.3 18 214373_at PPP4R2 -1.281.17e-05 2.32e-02 -0.28 -4.49 protein phosphatase 4, regulatory3q29 subunit 2 19 211220_s_at HSF2 -1.28 1.37e-05 2.42e-02 -0.29-4.48 heat shock transcription factor 2 6q22.32 20 212385_at -1.711.34e-05 2.42e-02 -0.28 -4.45 Homo sapiens cDNA FLJ11918 fis, cloneHEMBB1000272. 21 208268_at ADAM28 -1.52 1.49e-05 2.42e-02 -0.28-4.43 a disintegrin and metalloproteinase 8p21.1 domain 28 22228701_at MGC33510 -1.57 1.43e-05 2.42e-02 -0.27 -4.42 hypotheticalprotein MGC33510 8q12.3 23 219981_x_at FLJ20813 -1.24 2.13e-052.63e-02 -0.30 -4.41 hypothetical protein FLJ20813 19q13.43 24237311_at -1.77 1.81e-05 2.61e-02 -0.28 -4.39 ESTs 25 230620_at-1.31 1.89e-05 2.61e-02 -0.28 -4.39 ESTs 26 209763_at NRLN1 -1.921.69e-05 2.61e-02 -0.27 -4.38 likely ortholog of mouse neuralin 1Xq22.3 27 223629_at PCDHB5 -1.72 1.89e-05 2.61e-02 -0.27 -4.36protocadherin beta 5 5q31 28 239175_at -1.74 2.08e-05 2.63e-02-0.27 -4.35 ESTs 29 233475_at SNCAIP -1.55 2.01e-05 2.63e-02 -0.27-4.35 synuclein, alpha interacting protein 5q23.1-q23.3 (synphilin)30 202946_s_at BTBD3 -1.38 3.00e-05 2.85e-02 -0.29 -4.32 BTB (POZ)domain containing 3 20p12.1 31 215447_at -1.38 2.45e-05 2.85e-02-0.27 -4.32 Homo sapiens mRNA; cDNA DKFZp586J0323 (from cloneDKFZp586J0323) 32 203753_at TCF4 -1.59 2.87e-05 2.85e-02 -0.28-4.31 transcription factor 4 18q21.1 33 203705_s_at FZD7 -1.352.82e-05 2.85e-02 -0.27 -4.30 frizzled homolog 7 (Drosophila) 2q3334 209831_x_at DNASE2 12055 4.53e-05 3.04e-02 0.32 46844deoxyribonuclease II, lysosomal 19p13.2 35 218599_at REC8 -1.343.06e-05 2.85e-02 -0.27 -4.28 Rec8p, a meiotic recombination andsister 14q11.2-q12 chromatid cohesion phosphoprotein of the rad21pfamily 36 210365_at RUNX1 -1.51 3.10e-05 2.85e-02 -0.27 -4.27runt-related transcription factor 1 (acute 21q22.3 myeloid leukemia1; aml1 oncogene) 37 230392_at -1.45 2.77e-05 2.85e-02 -0.26 -4.27Homo sapiens cDNA FLJ31096 fis, clone IMR321000207. 38 229620_atSEPP1 -1.88 2.93e-05 2.85e-02 -0.26 -4.26 selenoprotein P, plasma,1 5q31 39 222380_s_at -1.31 3.34e-05 2.85e-02 -0.27 -4.26 ESTs 40239123_at -1.52 3.11e-05 2.85e-02 -0.27 -4.25 ESTs 41 222186_at-1.34 3.32e-05 2.85e-02 -0.27 -4.24 Homo sapiens mRNA full lengthinsert cDNA clone EUROIMAGE 27080. 42 228840_at AMOTL1 -1.933.16e-05 2.85e-02 -0.26 -4.24 angiomotin like 1 11q14.3 43202967_at GSTA4 -1.28 3.42e-05 2.85e-02 -0.26 -4.23 glutathioneS-transferase A4 6p12.1 44 214378_at TFPI -1.33 4.19e-05 3.03e-02-0.28 -4.22 tissue factor pathway inhibitor (lipoprotein-associatedcoagulation 2q31-q32.1 inhibitor) 45 238154_at -1.45 3.32e-052.85e-02 -0.26 -4.22 ESTs, Highly simitar to p10-binding protein[Homo sapiens] [H. sapiens] 46 214930_at KIAA0918 -3.69 3.58e-052.91e-02 -0.27 -4.22 KIAA0918 protein 13q31.1 47 237371_at -1.933.79e-05 3.02e-02 -0.26 -4.21 ESTs 48 242549_at -1.65 4.23e-053.03e-02 -0.27 -4.20 ESTs, Highly similar to KPCN_HUMAN Proteinkinase C, nu type (nPKC-nu) (Protein kinase EPK2) [H. sapiens] 49244537_at -1.52 3.96e-05 3.03e-02 -0.26 -4.20 ESTs 50 236653_at-1.52 4.16e-05 3.03e-02 -0.26 -4.18 ESTs 51 244274_at -1.414.73e-05 3.04e-02 -0.27 -4.18 Homo sapiens, clone IMAGE: 5269446,mRNA 52 204846_at CP -1.58 4.21e-05 3.03e-02 -0.25 -4.17ceruloplasmin (ferroxidase) 3q23-q25 53 201427_s_at SEPP1 -1.885.03e-05 3.12e-02 -0.27 -4.16 selenoprotein P, plasma, 1 5q31 54227803_at ENPP5 -1.59 4.70e-05 3.04e-02 -0.26 -4.16 ectonucleotidepyrophosphatase/ 6p21.1-p11.2 phosphodiesterase 5 (putativefunction) 55 204430_s_at SLC2A5 -1.68 4.40e-05 3.03e-02 -0.25 -4.16solute carrier family 2 (facilitated glucose/ 1p36.2 fructosetransporter), member 5 56 220145_at FLJ21159 -2.43 4.38e-053.03e-02 -0.25 -4.16 hypothetical protein FLJ21159 4q31.3 57228919_at -1.59 4.75e-05 3.04e-02 -0.26 -4.15 ESTs, Highly similarto cell division cycle 2-like 1, isoform 1; Cell division cycle2-like 1; PITSLRE protein kinase alpha; p58/GTA protein kinase;galactosyltransferase associated protein kinase; CDC-relatedprotein kinase p58; PITSLRE B [Homo sapiens] [H. sapiens] 58210815_s_at CALCRL -1.54 5.12e-05 3.12e-02 -0.26 -4.14 calcitoninreceptor-like 2q32.2 59 236363_at LOC285378 -1.26 6.18e-05 3.46e-02-0.28 -4.13 hypothetical protein LOC285378 3p25.1 60 221973_atLOC150759 -1.37 6.15e-05 3.46e-02 -0.27 -4.13 hypothetical proteinLOC150759 2q11.1 61 244579_at -2.32 5.14e-05 3.12e-02 -0.26 -4.13ESTs 62 243010_at MSI2 -1.50 5.81e-05 3.46e-02 -0.26 -4.12 musashihomolog 2 (Drosophila) 17q23.1 63 223800_s_at LOC96626 -1.276.18e-05 3.46e-02 -0.27 -4.11 pinch-2 2q14-q21 64 213459_at RPL37A-1.22 6.55e-05 3.53e-02 -0.27 -4.11 ribosomal protein L37a 2q35 65220377_at C14orf110 -2.40 6.06e-05 3.46e-02 -0.26 -4.11 chromosome14 open reading frame 110 14q32.33 66 235274_at -1.35 6.75e-053.53e-02 -0.26 -4.09 ESTs, Weakly similar to hypothetical proteinFLJ20489 [Homo sapiens] [H. sapiens] 67 47560_at FLJ11939 -1.446.65e-05 3.53e-02 -0.26 -4.08 hypothetical protein FLJ1193919p13.12 68 226586_at FLJ36928 -1.39 7.66e-05 3.72e-02 -0.27 -4.06hypothetical protein FLJ36928 9q22.33 69 234996_at CALCRL -1.716.79e-05 3.53e-02 -0.25 -4.06 calcitonin receptor-like 2q32.2 70232653_at -1.83 6.57e-05 3.53e-02 -0.25 -4.06 Homo sapiens cDNAFLJ14044 fis, clone HEMBA1006124 71 221207_s_at NBEA -1.39 7.00e-053.58e-02 -0.26 -4.06 neurobeachin 13q13 72 244286_at -1.56 7.31e-053.64e-02 -0.26 -4.06 ESTs, Moderately similar to hypotheticalprotein FLJ20378 [Homo sapiens] [H. sapiens] 73 202600_s_at NRIP1-1.52 7.68e-05 3.72e-02 -0.26 -4.05 nuclear receptor interactingprotein 1 21q11.2 74 231669_at SEPP1 -1.62 7.33e-05 3.64e-02 -0.26-4.05 selenoprotein P, plasma, 1 5q31 75 217755_at HN1 467539.18e-05 4.11e-02 0.28 38111 hematological and neurological 17q25.2expressed 1 76 222999_s_at CCNL2 -1.21 8.22e-05 3.77e-02 -0.26-4.04 cyclin L2 1p36.33 77 215786_at -1.28 8.05e-05 3.77e-02 -0.26-4.03 Homo sapiens cDNA FLJ12108 fis, clone MAMMA1000009. 78243579_at MSI2 -1.73 8.09e-05 3.77e-02 -0.26 -4.03 musashi homolog2 (Drosophila) 17q23.1 79 209838_at TRIP15 -1.31 8.32e-05 3.77e-02-0.26 -4.03 thyroid receptor interacting protein 15 15q21.2 80203826_s_at PITPNM 12785 1.11e-04 4.12e-02 0.29 38021phosphatidylinositol transfer protein, 11q13 membrane-associated 81243768_at -1.27 8.06e-05 3.77e-02 -0.25 -4.02 ESTs, Weakly similarto hypothetical protein FLJ20489 [Homo sapiens] [H. sapiens] 82226043_at AGS3 -1.31 9.81e-05 4.12e-02 -0.26 -4.00 activator ofG-protein signaling 3 9q34.3 83 205251_at PER2 -1.32 9.39e-054.11e-02 -0.26 -4.00 period homolog 2 (Drosophila) 2q37.3 84208762_at UBL1 -1.31 9.52e-05 4.11e-02 -0.26 -3.99 ubiquitin-like 1(sentrin) 2q33 85 226545_at -2.14 9.48e-05 4.11e-02 -0.25 -3.99Homo sapiens mRNA; cDNA DKFZp586E1624 (from clone DKFZp586E1624) 86240824_at -1.29 1.06e-04 4.12e-02 -0.26 -3.98 ESTs 87 244740_at-1.76 9.65e-05 4.11e-02 -0.25 -3.98 Homo sapiens, clone MGC: 9913IMAGE: 3870821, mRNA, complete cds 88 210758_at PSIP1 -1.241.09e-04 4.12e-02 -0.26 -3.97 PC4 and SFRS1 interacting protein 19p22.2 89 233431_x_at -1.35 1.04e-04 4.12e-02 -0.25 -3.96 Homosapiens cDNA FLJ12393 fis, clone MAMMA1002711. 90 204160_s_at ENPP4-1.60 1.06e-04 4.12e-02 -0.25 -3.95 ectonucleotide pyrophosphatase/6p12.3 phosphodiesterase 4 (putative function) 91 226419_s_at -1.371.10e-04 4.12e-02 -0.25 -3.95 Homo sapiens cDNA FLJ30048 fis, cloneADRGL1000018. 92 219934_s_at STE -1.53 1.17e-04 4.24e-02 -0.26-3.95 sulfotransferase, estrogen-preferring 4q13.1 93 227202_atCNTN1 -2.01 9.98e-05 4.12e-02 -0.24 -3.95 contactin 1 12q11-q12 94212067_s_at C1R -1.35 1.12e-04 4.12e-02 -0.25 -3.95 complementcomponent 1, 12p13 r subcomponent 95 214043_at -1.77 1.05e-044.12e-02 -0.24 -3.94 Homo sapiens mRNA; cDNA DKFZp564P116 (fromclone DKFZp564P116) 96 214321_at NOV -2.31 1.07e-04 4.12e-02 -0.24-3.94 nephroblastoma overexpressed gene 8q24.1 97 212928_atKIAA0721 -1.22 1.36e-04 4.78e-02 -0.27 -3.94 KIAA0721 protein6q22.2 98 242064_at -2.01 1.05e-04 4.12e-02 -0.24 -3.94 Homosapiens cDNA FLJ90513 fis, clone NT2RP3004355. 99 227798_at -1.891.10e-04 4.12e-02 -0.24 -3.93 ESTs 100 239669_at HIST1H3D -2.091.17e-04 4.24e-02 -0.24 -3.91 histone 1, H3d 6p21.3 Sequence TypeGo_Biological_Process Go_Cellular_Component

1 Exemplarsequence "GO: 7345; embryogenesis and morphogenesis;traceable "GO: 5871; kinesin complex; inferred from electronicauthor statement GO: 7048; oncogenesis; traceable authorannotation" statement" 2 Consensussequence "GO: 6171; cAMPbiosynthesis; non-traceable author statement "GO: 16021; integralto membrane; non-traceable author GO: 7242; intracellular signalingcascade; inferred from statement" electronic annotation" 3Exemplarsequence "GO: 6260; DNA replication; inferred fromelectronic annotation "GO: 5634; nucleus; inferred from electronicannotation GO: 6304; DNA modification; inferred from electronic GO:5622; BRCT; intracellular; 2.4e-15; annotation GO: 6281; DNArepair; inferred from electronic extended: Unknown" annotation GO:6960; antimicrobial humoral response (sensu Invertebrata);traceable author statement" 4 Consensussequence "GO: 7345;embryogenesis and morphogenesis; traceable author "GO: 5871;kinesin complex; inferred from electronic statement GO: 7048;oncogenesis; traceable annotation" author statement" 5Consensussequence 6 Exemplarsequence "GO: 7596; blood coagulation;traceable author statement" 7 Consensussequence 8 Consensussequence9 Exemplarsequence 10 Exemplarsequence 11 Consensussequence 12Consensussequence "GO: 7345; embryogenesis and morphogenesis;traceable author "GO: 5871; kinesin complex; inferred fromelectronic statement GO: 7048; oncogenesis; traceable annotation"author statement" 13 Exemplarsequence 14 Consensussequence 15Consensussequence 16 Consensussequence 17 Exemplarsequence 18Consensussequence "GO: 6464; protein modification; traceable authorstatement" "GO: 5813; centrosome; traceable author statement" 19Exemplarsequence "GO: 6355; regulation of transcription,DNA-dependent; "GO: 5634; nucleus; inferred from electronicannotation" inferred from electronic annotation GO: 6366;transcription from Pol II promoter; traceable author statement" 20Consensussequence 21 Exemplarsequence "GO: 7283; spermatogenesis;traceable author statement "GO: 16021; integral to membrane;inferred from GO: 6508; proteolysis and peptidolysis; inferred fromelectronic annotation" electronic annotation" 22 Consensussequence23 Exemplarsequence 24 Consensussequence 25 Consensussequence 26Consensussequence "GO: 7275; development; inferred from electronicannotation" 27 Exemplarsequence "GO: 7156; homophilic celladhesion; inferred from "GO: 16021; integral to membrane;non-traceable author electronic annotation GO: 7416;synaptogenesis; statement" traceable author statement GO: 7273;regulation of synapse; traceable author statement GO: 7155; celladhesion; non-traceable author statement" 28 Consensussequence 29Consensussequence "GO: 9405; pathogenesis; traceable authorstatement" "GO: 5737; cytoplasm; traceable author statement GO:5871; kinesin complex; inferred from electronic annotation" 30Exemplarsequence 31 Consensussequence 32 Exemplarsequence "GO:6357; regulation of transcription from Pol II promoter; "GO: 5634;nucleus; traceable traceable author statement" author statement" 33Consensussequence "GO: 7222; frizzled receptor signaling pathway;experimental "GO: 16021; integral to membrane; predicted/computedevidence GO: 7048; oncogenesis; predicted/computed" GO: 5886;plasma membrane; experimental evidence" 34 Exemplarsequence "GO:6259; DNA metabolism; traceable author statement "GO: 5764;lysosome; traceable author statement" GO: 6915; apoptosis; inferredfrom electronic annotation" 35 Exemplarsequence "GO: 7126; meiosis;traceable author statement GO: 7283; "GO: 5634; nucleus; traceableauthor statement" spermatogenesis; traceable author statement GO:7131; meiotic recombination; traceable author statement GO: 7062;sister chromatid cohesion; traceable author statement" 36Exemplarsequence "GO: 6355; regulation of transcription,DNA-dependent; "GO: 5634; nucleus; non-traceable author statement"non-traceable author statement GO: 7275; development; traceableauthor statement GO: 8151; cell growth and/or maintenance; inferredfrom electronic annotation GO: 7048; oncogenesis; traceable authorstatement" 37 Consensussequence 38 Consensussequence "GO: 6979;response to oxidative stress; traceable author statement" 39Consensussequence 40 Consensussequence 41 Consensussequence 42Consensussequence 43 Exemplarsequence "GO: 6950; response tostress; not recorded GO: 6803; glutathione conjugation reaction;inferred from electronic annotation" 44 Consensussequence "GO:7596; blood coagulation; traceable author statement" 45Consensussequence 46 Consensussequence 47 Consensussequence 48Consensussequence 49 Consensussequence 50 Consensussequence 51Consensussequence 52 Exemplarsequence "GO: 6878; copper ionhomeostasis; not recorded GO: 6879; "GO: 5615; extracellular space;traceable author iron ion homeostasis; traceable author statement"statement" 53 Exemplarsequence "GO: 6979; response to oxidativestress; traceable author statement" 54 Consensussequence "GO: 9117;nucleotide metabolism; inferred from electronic annotation" 55Exemplarsequence "GO: 8643; carbohydrate transport; inferred fromelectronic "GO: 5886; plasma membrane; traceable author annotationGO: 5975; carbohydrate metabolism; traceable author statement GO:16021; integral to membrane; inferred statement GO: 15758; glucosetransport; traceable author from electronic annotation" statementGO: 15755; fructose transport; traceable author statement" 56Exemplarsequence 57 Consensussequence 58 Exemplarsequence "GO:7187; G-protein signaling, coupled to cyclic nucleotide "GO: 5887;integral to plasma membrane; traceable second messenger; traceableauthor statement" author statement" 59 Consensussequence 60Consensussequence 61 Consensussequence 62 Consensussequence 63Exemplarsequence 64 Consensussequence "GO: 6412; proteinbiosynthesis; inferred from electronic "GO: 5840; ribosome;inferred from electronic annotation annotation" GO: 5842; cytosoliclarge ribosomal subunit (sensu Eukarya); not recorded GO: 5622;intracellular; inferred from electronic annotation" 65Exemplarsequence 66 Consensussequence 67 Consensussequence 68Consensussequence 69 Consensussequence "GO: 7187; G-proteinsignaling, coupled to cyclic nucleotide "GO: 5887; integral toplasma membrane; traceable second messenger; traceable authorstatement" author statement" 70 Consensussequence 71Exemplarsequence 72 Consensussequence 73 Consensussequence "GO:6355; regulation of transcription, DNA-dependent; inferred "GO:5634; nucleus; traceable author statement" from electronicannotation GO: 6350; transcription; traceable author statement" 74Consensussequence "GO: 6979; response to oxidative stress;traceable author statement" 75 Exemplarsequence 76 Exemplarsequence77 Consensussequence 78 Consensussequence 79 Consensussequence "GO:7165; signal transduction; non-traceable author statement "GO:8180; signalosome complex; inferred from direct GO: 6366;transcription from Pol II promoter; traceable author assay GO:5737; cytoplasm; inferred from direct assay" statement" 80Exemplarsequence "GO: 6629; lipid metabolism; not recorded GO:7420; "GO: 5624; membrane fraction; traceable author braindevelopment; traceable author statement GO: 7602; statement GO:5622; intracellular; inferred from phototransduction; traceableauthor statement GO: 6810; electronic annotation" transport;inferred from electronic annotation" 81 Consensussequence 82Consensussequence 83 Exemplarsequence "GO: 7623; circadian rhythm;predicted/computed" 84 Exemplarsequence "GO: 6281; DNA repair;traceable author statement" "GO: 5634; nucleus; traceable authorstatement GO: 5643; nuclear pore; traceable author statement" 85Consensussequence 86 Consensussequence 87 Consensussequence 88Exemplarsequence 89 Consensussequence 90 Consensussequence "GO:9117; nucleotide metabolism; inferred from electronic annotation"91 Consensussequence 92 Exemplarsequence "GO: 8202; steroidmetabolism; traceable author statement" 93 Consensussequence 94Consensussequence "GO: 6958; complement activation, classicalpathway; inferred from electronic annotation GO: 6508; proteolysisand peptidolysis; inferred from electronic annotation GO: 6955;immune response; traceable author statement" 95 Consensussequence96 Consensussequence "GO: 1558; regulation of cell growth; inferredfrom electronic "GO: 5576; extracellular; inferred from electronicannotation" 97 Consensussequence "GO: 6334; nucleosome assembly;inferred from electronic "GO: 5634; nucleus; inferred fromelectronic annotation" annotation" 98 Consensussequence 99Consensussequence 100 Consensussequence "GO: 6334; nucleosomeassembly; inferred from electronic "GO: 5634; nucleus; inferredfrom electronic annotation annotation GO: 7001; chromosomeorganization and biogenesis GO: 786; nucleosome; inferred fromelectronic (sensu Eukarya); inferred from electronic annotation"annotation GO: 5694; chromosome; inferred from electronicannotation" Sequence Go_Molecular_Function Transcript ID DerivedFrom Sequence ID 1 Hs.2384.0 NM_005079.1 g4B27037 2 "GO: 4383;guanylate cyclase activity; inferred from electronic annotation GO:8294; Hs.2352.0 AU149572 Hs.2352.0.S1 calcium/calmodulin-responsive adenylate cyclase activity; inferred from electronicannotation GO: 16829; lyase activity; inferred from electronicannotation" 3 "GO: 3890; beta DNA polymerase activity; inferredfrom electronic annotation Hs.272537.0 M11722.1 g339436 GO: 3677;DNA binding; not recorded GO: 3912; DNA nucleotidylexotranseraseactivity; traceable author statement GO: 16740; transferaseactivity; inferred from electronic annotation GO: 287; magnesiumion binding; inferred from electronic annotation" 4 Hs.2384.0BE974098 Hs.2384.0.S2 5 Hs.292815.0 BG169443 Hs.292815.0.A1 6 "GO:4867; serine protease inhibitor activity; inferred from electronicannotation GO: 5209; Hs.170279.1 AF021834.1 g4103170 plasmaprotein; not recorded GO: 5211; plasma glycoprotein; not recorded"7 Hs.25329.0 AW043602 Hs.25329.0.A1 8 Hs.48461.0 N62126Hs.48461.0.A1 9 Hs.42315.1 AF289495.1 g11494382 10 g13623228BC006212.1 g13623228 11 Hs.85481.0 H38035 Hs.85481.0.A1 12Hs.2384.0 BE974098 Hs.2384.0.S2 13 "GO: 3676; KRAB; nucleic acidbinding activity: 4.4e-26; extended: inferred from Hs.192662.0NM_018102.1 g8922439 electronic annotation" 14 Hs.287426.0 AU144919Hs.287426.0 15 Hs.49136.0 AL039862 Hs.49136.0.A1 16 Hs.6655.0AL355688.1 Hs.6655.0.S1

17 Hs.330056.0 NM_025084.1 g13443001 18 Hs.125682.1 AI582773Hs.125682.1_RC 19 "GO: 3713; transcription co-activator activity;traceable author statement GO: 3773; Hs.158195.1 BC005329.1g13529106 heat shock protein activity; inferred from electronicannotation GO: 3700; transcription factor activity; traceableauthor statement" 20 Hs.289068.0 AK021980.1 Hs.289068.0 21 "GO:4222; metalloendopeptidase activity; inferred from electronicannotation GO: 8270; Hs.174030.1 NM_021777.1 g11496993 zinc ionbinding; inferred from electronic annotation GO: 16787; hydrolaseactivity; inferred from electronic annotation" 22 Hs.184261.1N22898 Hs.184261.1.A1 23 Hs.306203.0 NM_017961.1 g8923685 24Hs.161353.0 AI939580 Hs.161353.0_RC 25 Hs.143587.0 BE550967Hs.143587.0.A1 26 Hs.82223.0 AL049176 Hs.82223.0 27 "GO: 8014;calcium-dependent cell adhesion molecule activity; non-traceableauthor Hs.119693.0 BC001186.1 g12654692 statement GO: 5509; calciumion binding; inferred from electronic annotation" 28 Hs.213003.0AW203986 Hs.213003.0.A1 29 "GO: 5515; protein binding; traceableauthor statement" Hs.24948.1 AK021944.1 Hs.24948.1_RC 30 "GO: 5515;protein binding; inferred from electronic annotation" Hs.7935.0NM_014962.1 g7662401 31 Hs.102301.0 AL080215.1 Hs.102301.0 32 "GO:3677; DNA binding; inferred from electronic annotation GO: 3702;RNA polymerase Hs.326198.0 NM_003199.1 g4507398 II transcriptionfactor activity; traceable author statement" 33 "GO: 4928; frizzledreceptor activity; experimental evidence GO: 4888; Fz; Hs.173859.0AI333651 Hs.173859.0 transmembrane receptor activity; 5.3e-64;extended: Unknown" 34 "GO: 16787; hydrolase activity; inferred fromelectronic annotation GO: 3677; Hs.118243.0 AB004574.1 g3184394 DNAbinding; traceable author statement GO: 4519; endonucleaseactivity; inferred from electronic annotation GO: 4531;deoxyribonuclease II activity; traceable author statement" 35Hs.4767.0 NM_005132.1 g9845292 36 "GO: 3700; transcription factoractivity; traceable author statement GO: 5524; ATP binding;Hs.129914.4 D43967.1 g966994 non-traceable author statement GO:3677; Runt; DNA binding activity; 1.2e-102; extended: Unknown" 37Hs.157975.0 AW298141 Hs.157975.0.A1 38 "GO: 8430; selenium binding;traceable author statement" Hs.24172.0 BE856597 Hs.24172.0.A1 39Hs.124620.0 AI907083 Hs.124620.0_RC 40 Hs.78960.0 AI565177Hs.78960.0.A1 41 Hs.306329.0 AL109684.1 Hs.306329.0 42 Hs.101550.0AW451115 Hs.101550.0_RC 43 "GO: 4364; glutathione transferaseactivity; traceable author statement GO: 16740; Hs.169907.0NM_001512.1 g4504172 transferase activity; inferred from electronicannotation" 44 "GO: 4867; serine protease inhibitor activity;inferred from electronic annotation GO: 5209; Hs.170279.2 BF109662Hs.170279.2 plasma protein; not recorded GO: 5211; plasmaglycoprotein; not recorded" 45 Hs.127217.0 AI285884 Hs.127217.0_RC46 Hs.58009.0 AW449813 Hs.58009.0.S1 47 Hs.199596.0 AI671177Hs.199596.0.A1 48 Hs.270826.0 AW008270 Hs.270826.0_RC 49Hs.132879.0 R28353 Hs.132879.0_RC 50 Hs.190090.0 AA629075Hs.190090.0_RC 51 Hs.194423.0 AI005638 Hs.194423.0_RC 52 "GO: 4323;multicopper ferroxidase iron transport mediator activity; inferredfrom Hs.296634.0 NM_000096.1 g4557484 electronic annotation GO:4322; 16.3.1; ferroxidase activity; 1e-300; extended: inferredelectronic annotation GO: 16491; oxidoreductase activity; inferredfrom electronic annotation GO: 5507; copper ion binding; inferredfrom electronic annotation" 53 "GO: 8430; selenium binding;traceable author statement" Hs.3314.0 NM_005410.1 g4885590 54 "GO:16787; hydrolase activity; inferred from electronic annotation"Hs.35198.0 AA609053 Hs.35198.0.S2 55 "GO: 5351; sugar porteractivity; inferred from electronic annotation GO: 5355; Hs.33084.0NM_003039.1 g4507012 glucose transporter activity; traceable authorstatement GO: 5353; fructose transporter activity; traceable authorstatement GO: 5215; transporter activity; inferred from electronicannotation" 56 Hs.175982.0 NM_024826.1 g13376225 57 Hs.183418.17AA601031 Hs.183418.17 58 "GO: 4930; G-protein coupled receptoractivity; traceable author statement GO: 4948; Hs.152175.1 U17473.1g662328 calcitonin receptor activity; inferred from electronicannotation" 59 Hs.5020.0 AI768384 Hs.5020.0_RC 60 Hs.79732.5AI983904 Hs.79732.5.A1 61 Hs.253594.0 AI086336 Hs.253594.0_RC 62"GO: 3676; rrm; nucleic acid binding activity; 3.5e-22;extended:inferred from electronic Hs.103512.0 BE000929Hs.103512.0.A1 annotation" 63 Hs.285130.0 AF288404.1 g9800508 64"GO: 3735; structural constituent of ribosome; not recorded GO:3723; RNA binding; Hs.296290.0 AU155515 Hs.296290.0.A1 notrecorded" 65 Hs.128155.0 NM_014151.1 g7661757 66 Hs.120850.0AA740632 Hs.120850.0_RC 67 4860484_rc AI525402 4860484_rc 68Hs.24485.1 AW130559 Hs.24485.1.A1 69 "GO: 4930; G-protein coupledreceptor activity; traceable author statement GO: 4948; Hs.201591.0AI478743 Hs.201591.0_RC calcitonin receptor activity; inferred fromelectronic annotation" 70 Hs.278004.0 AW265514 Hs.278004.0.S1 71Hs.3821.0 NM_015678.1 g7657362 72 Hs.131811.0 AI017983Hs.131811.0.A1 73 "GO: 3713; transcription co-activator activity;traceable author statement" Hs.155017.0 AI824012 Hs.155017.0.S1 74"GO: 8430; selenium binding; traceable author statement" Hs.3314.1AV653290 Hs.3314.1_RC 75 Hs.109706.0 NM_016185.1 g7705876 76Hs.143601.0 AF251294.1 g12005729 77 Hs.250813.0 AK022170.1Hs.250813.0.S1 78 "GO: 3676; rrm; nucleic acid binding activity;3.5e-22; extended; inferred from Hs.173179.0 BF029215Hs.173179.0.S1 electronic annotation" 79 "GO: 5515; proteinbinding; traceable author statement GO: 4871; signal transducerHs.30212.1 AA496247 Hs.30212.1.S2 activity; non-traceable authorstatement" 80 "GO: 8526; phosphatidylinositol transporter activity;traceable author statement GO: 46872; Hs.93837.0 NM_004910.1g4758925 metal ion binding; inferred from electronic annotation" 81Hs.34244.0 AA026388 Hs.34244.0.A1 82 Hs.239370.0 AI242661Hs.239370.0.S1 83 Hs.153405.0 NM_022817.1 g12707561 84 "GO: 4840;ubiquitin conjugating enzyme activity; traceable author statement"Hs.81424.0 U83117.1 g1769601 85 Hs.94030.0 AL110152.1 Hs.94030.0.S186 Hs.134491.0 AI076185 Hs.134491.0.A1 87 Hs.23133.1 BE855713Hs.23133.1.S1 88 Hs.82110.0 AF098482.1 g4050033 89 Hs.287527.0AU148142 Hs.287527.0.S1 90 "GO: 16787; hydrolase activity; inferredfrom electronic annotation" Hs.54037.0 AW194947 Hs.54037.0 91Hs.238956.1 AA046439 Hs.238956.1.A1 92 "GO: 8146; Sulfotransfer;sulfotransferase activity; 7.8e-144; extended:inferred fromHs.54576.0 NM_005420.1 g4885616 expression pattern GO: 4304;estrone sulfotransferase activity; traceable author statement GO:5496; steroid binding; inferred from electronic annotation GO:16740; transferase activity; inferred from electronic annotation"93 Hs.143434.2 AI091445 Hs.143434.2.A1 94 "GO: 3815; complementcomponent C1r activity; traceable author statement GO: 16787;Hs.1279.1 AL573058 Hs.1279.1_RC hydrolase activity; inferred fromelectronic annotation GO: 4295; trypsin activity; inferred frometectronic annotation GO: 4263; chymotrypsin activity; inferredfrom electronic annotation GO: 5509; calcium ion binding; inferredfrom electronic annotation" 95 Hs.323079.1 BF062299 Hs.323079.1.A196 "GO: 8083; growth factor activity; inferred from electronicannotation GO: 5520; Hs.235935.1 BF440025 Hs.235935.1.S1insulin-like growth factor binding; inferred from electronicannotation" 97 "GO: 3677; DNA binding; inferred from electronicannotation" Hs.284141.0 AL050331 Hs.284141.0 98 Hs.43410.0 N23651Hs.43410.0_RC 99 Hs.322710.0 AU146891 Hs.322710.0.A1 100 "GO: 3677;DNA binding; inferred from electronic annotation" Hs.209228.0AW006409 Hs.209228.0.A1 Sequence Source Unigene_AccessionCluster_Type LocusLink Full_Length_Reference_Seq 1 RefSeq Hs.2384fulllength 7163 NM_005079; tumor protein D52 2 GenBank Hs.2352fulllength 108 NM_020546; adenylate cyclase 2 3 GenBank Hs.397294fulllength 1791 NM_004088; deoxynucleotidyltransferase, terminal 4GenBank Hs.2384 fulllength 7163 NM_005079; tumor protein D52 5GenBank Hs.372680 6 GenBank Hs.170279 fulllength 7035 NM_006287;tissue factor pathway inhibitor (lipoprotein-associated coagulationinhibitor) 7 GenBank Hs.172792 fulllength 165215 NM_177454;KIAA1946 protein 8 GenBank Hs.32374 9 GenBank Hs.42315 fulllength80321 NM_024491; p10-binding protein 10 GenBank Hs.25298 fulllength84445 11 GenBank Hs.439144 est 12 GenBank Hs.2384 fulllength 7163NM_005079; tumor protein D52 13 RefSeq Hs.192662 fulllength 55713NM_018102; zinc finger protein 334 14 GenBank Hs.287426 15 GenBankHs.49136 16 GenBank Hs.6655 17 RefSeq Hs.288390 fulllength 80154NM_025084; hypothetical protein FLJ22795 18 GenBank Hs.446494fulllength 56340 NM_019853; protein phosphatase 4 regulatorysubunit 2 19 GenBank Hs.158195 fulllength 3298 NM_004506; heatshock transcription factor 2 20 GenBank Hs.289068 21 RefSeqHs.174030 fulllength 10863 NM_014265; a disintegrin andmetalloproteinase domain 28 isoform 1 preproprotein NM_021777; adisintegrin and metalloproteinase domain 28 isoform 3 preproproteinNM_021778; a disintegrin and metalloproteinase domain 28 isoform 2preproprotein 22 GenBank Hs.184261 fulllength 254778 NM_152765;hypothetical protein MGC33510 23 RefSeq Hs.288995 fulllength 55044NM_017961; hypothetical protein FLJ20813 24 GenBank Hs.161353 est25 GenBank Hs.143587 est 26 GenBank Hs.82223 fulllength 91851NM_145234; similar to neuralin 1 27 GenBank Hs.119693 fulllength26167 NM_015669; protocadherin beta 5 precursor 28 GenBankHs.213003 est 29 GenBank Hs.24948 fulllength 9627 NM_005460;synuclein alpha interacting protein 30 RefSeq Hs.7935 fulllength22903 NM_014962; BTB/POZ domain containing protein 3 isoform aNM_181443; BTB/POZ domain containing protein 3 isoform b 31 GenBankHs.102301 32 RefSeq Hs.326198 fulllength 6925 NM_003199;transcription factor 4 isoform b 33 GenBank Hs.173859 fulllength8324 NM_003507; frizzled 7 34 GenBank Hs.118243 fulllength 1777NM_001375; deoxyribonuclease II, lysosomal 35 RefSeq Hs.4767fulllength 9985 NM_005132; Rec8p, a meiotic recombination andsister chromatid cohesion pho 36 GenBank Hs.129914 fulllength 861NM_001754; runt-related transcription factor 1 (acute myeloidleukemia 1; aml1 oncogene) 37 GenBank Hs.157975 38 GenBankHs.275775 fulllength 6414 NM_005410; selenoprotein P precursor 39GenBank Hs.124620 est 40 GenBank Hs.436383 est 41 GenBank Hs.30632942 GenBank Hs.17110 fulllength 154810 NM_130847; angiomotin like 143 RefSeq Hs.169907 fulllength 2941 NM_001512; glutathioneS-transferase A4 44 GenBank Hs.170279 fulllength 7035 NM_006287;tissue factor pathway inhibitor (lipoprotein- associatedcoagulation inhibitor) 45 GenBank Hs.127217 est 46 GenBank Hs.5800926050 47 GenBank Hs.445166 est 48 GenBank Hs.370465 est 49 GenBankHs.435763 est 50 GenBank Hs.190090 est 51 GenBank Hs.194423 52RefSeq Hs.296634 fulllength 1356 NM_000096; ceruloplasmin(ferroxidase) 53 RefSeq Hs.275775 fulllength 6414 NM_005410;selenoprotein P precursor 54 GenBank Hs.35198 fulllength 59084NM_021572; ectonucleotide pyrophosphatase/phosphodiesterase 5(putative function)

55 RefSeq Hs.33084 fulllength 6518 NM_003039; solute carrier family2 (facilitated glucose/fructose transporter), member 5 56 RefSeqHs.61271 fulllength 79884 NM_024826; hypothetical protein FLJ2115957 GenBank Hs.355702 est 58 GenBank Hs.152175 fulllength 10203NM_005795; calcitonin receptor-like 59 GenBank Hs.407068 285378 60GenBank Hs.349607 150759 NM_175853; hypothetical protein LOC15075961 GenBank Hs.253594 est 62 GenBank Hs.103512 fulllength 124540NM_138962; musashi 2 isoform a NM_170721; musashi 2 isoform b 63GenBank Hs.285130 fulllength 96626 NM_033514; pinch-2 64 GenBankHs.296290 fulllength 6168 NM_000998; ribosomal protein L37a 65RefSeq Hs.128155 fulllength 29064 NM_014151; HSPC053 protein 66GenBank Hs.120850 est 67 GenBank Hs.94229 fulllength 79732NM_024679; hypothetical protein FLJ11939 68 GenBank Hs.146662fulllength 203286 NM_173551; hypothetical protein FLJ36928 69GenBank Hs.152175 fulllength 10203 NM_005795; calcitoninreceptor-like 70 GenBank Hs.278004 71 RefSeq Hs.3821 fulllength26960 NM_015678; neurobeachin 72 GenBank Hs.131811 est 73 GenBankHs.155017 fulllength 8204 NM_003489; receptor interacting protein140 74 GenBank Hs.275775 fulllength 6414 NM_005410; selenoprotein Pprecursor 75 RefSeq Hs.109706 fulllength 51155 NM_016185;hematological and neurological expressed 1 76 GenBank Hs.143601fulllength 81669 NM_030937; cyclin L2 77 GenBank Hs.432941 78GenBank Hs.103512 fulllength 124540 NM_138962; musashi 2 isoform aNM_170721; musashi 2 isoform b 79 GenBank Hs.30212 est 9318NM_004236; thyroid receptor interacting protein 15 80 RefSeqHs.93837 fulllength 9600 NM_004910; phosphatidylinositol transferprotein, membrane-associated 81 GenBank Hs.34244 est 82 GenBankHs.239370 fulllength 26086 NM_015597; activator of G-proteinsignaling 3 83 RefSeq Hs.153405 fulllength 8864 NM_003894; period 2isoform 1 NM_022817; period 2 isoform 2 84 GenBank Hs.81424fulllength 7341 NM_003352; ubiquitin-like 1 (sentrin) 85 GenBankHs.94030 86 GenBank Hs.134491 est 87 GenBank Hs.23133 fulllength 88GenBank Hs.351305 fulllength 9090 89 GenBank Hs.287527 90 GenBankHs.54037 fulllength 22875 NM_014936; ectonucleotidepyrophosphatase/phosphodiesterase 4 (putative function) 91 GenBankHs.238956 92 RefSeq Hs.54576 fulllength 6783 NM_005420;sulfotransferase, estrogen-preferring 93 GenBank Hs.143434fulllength 1272 NM_001843; contactin 1 isoform 1 precursorNM_175038; contactin 1 isoform 2 precursor 94 GenBank Hs.1279fulllength 715 NM_001733; complement component 1, r subcomponent 95GenBank Hs.323079 96 GenBank Hs.235935 fulllength 4856 NM_002514;nov precursor 97 GenBank Hs.284141 fulllength 23270 NM_021648;KIAA0721 protein 98 GenBank Hs.43410 99 GenBank Hs.322710 est 100GenBank Hs.143042 fulllength 8351 NM_003530; H3 histone family,member B

TABLE-US-00018 TABLE 17 affy id HUGO F p q Title MapLocationSequence Type 1 201691_s_at TPD52 26999 2.11e-07 6.68e-03 tumorprotein D52 8q21 Exemplarsequence 2 242738_s_at 32782 1.73e-061.65e-02 Homo sapiens, clone IMAGE: 5288537, mRNA Consensussequence3 213217_at ADCY2 25112 2.71e-06 1.65e-02 adenylate cyclase 2(brain) 5p15.3 Consensussequence 4 208858_s_at MBC2 24016 2.36e-061.65e-02 likely ortholog of mouse membrane bound C2 domain 12q13.13Exemplarsequence containing protein 5 225547_at 14885 3.02e-061.65e-02 Homo sapiens cDNA FLJ39478 fis, clone ConsensussequencePROST2013605. 6 226705_at FGFR1 14519 3.13e-06 1.65e-02 fibroblastgrowth factor receptor 1 (fms-related tyrosine 8p11.2-p11.1Consensussequence kinase 2, Pfeiffer syndrome) 7 201690_s_at TPD5235309 5.63e-06 2.55e-02 tumor protein D52 8q21 Consensussequence 8209610_s_at SLC1A4 23621 7.88e-06 3.11e-02 solute carrier family 1(glutamate/neutral amino acid 2p15-p13 Consensussequencetransporter), member 4 9 210487_at DNTT 19968 1.11e-05 3.20e-02deoxynucleotidyltransferase, terminal 10q23-q24 Exemplarsequence 10212543_at AIM1 16316 9.63e-06 3.11e-02 absent in melanoma 1 6q21Consensussequence 11 201620_at MBTPS1 15950 9.81e-06 3.11e-02membrane-bound transcription factor protease, site 1 16q24Exemplarsequence 12 212811_x_at PSA 41883 1.42e-05 3.75e-02phosphoserine aminotransferase 9q21.2 Consensussequence 13210665_at TFPI 31260 2.02e-05 4.53e-02 tissue factor pathwayinhibitor (lipoprotein-associated 2q31-q32.1 Exemplarsequencecoagulation inhibitor) 14 227370_at KIAA1946 30895 2.34e-054.53e-02 KIAA1946 protein 2q32.1 Consensussequence 15 209190_s_atDIAPH1 29434 2.10e-05 4.53e-02 diaphanous homolog 1 (Drosophila)5q31 Exemplarsequence 16 225832_s_at LOC221955 24320 2.55e-054.53e-02 KCCR13L 7p22.2 Consensussequence 17 204499_at AGTPBP124320 2.51e-05 4.53e-02 ATP/GTP binding protein 1 9q21.33Consensussequence 18 212810_s_at PSA 23224 2.68e-05 4.53e-02phosphoserine aminotransferase 9q21.2 Consensussequence 19230263_s_at 21763 2.71e-05 4.53e-02 ESTs Consensussequence 20244399_at 17380 3.19e-05 5.05e-02 ESTs Consensussequence 21238520_at 14093 3.67e-05 5.07e-02 Homo sapiens MSTP020 (MST020)mRNA, complete cds Consensussequence 22 235721_at 12632 4.16e-055.07e-02 Homo sapiens cDNA FLJ37066 fis, clone ConsensussequenceBRACE2015132, weakly similar to Drosophila melanogaster Oregon Rcytoplasmic basic protein (deltex) mRNA. 23 232183_at FLJ1491711902 3.98e-05 5.07e-02 hypothetical protein FLJ14917 6q25.3Consensussequence 24 201689_s_at TPD52 46600 4.28e-05 5.07e-02tumor protein D52 8q21 Consensussequence 25 208872_s_at DP1 458704.14e-05 5.07e-02 likely ortholog of mouse deleted in polyposis 15q22-q23 Consensussequence 26 231874_at MGC39518 45505 4.17e-055.07e-02 hypothetical protein MGC39518 2 Consensussequence 27225864_at 45139 4.32e-05 5.07e-02 Homo sapiens cDNA FLJ23705 fis,clone HEP11066. Consensussequence 28 232081_at 43313 4.71e-055.13e-02 Homo sapiens EST from clone 208499, full insertConsensussequence 29 215567_at 42948 4.62e-05 5.13e-02 Homo sapienscDNA FLJ11574 fis, clone Consensussequence HEMBA1003384. 30212618_at KIAA0295 42583 5.07e-05 5.15e-02 KIAA0295 protein 15q22.1Consensussequence 31 220022_at ZNF334 42217 4.85e-05 5.13e-02 zincfinger protein 334 20q13.12 Exemplarsequence 32 202027_at C22orf538146 5.28e-05 5.15e-02 chromosome 22 open reading frame 5 22q12Exemplarsequence 33 236922_at 38115 5.36e-05 5.15e-02 Homo sapienscDNA FLJ38215 fis, clone Consensussequence FCBBF2000291. 34226314_at D4ST-1 38054 5.57e-05 5.19e-02dermatan-4-sulfotransferase-1 Consensussequence 35 214378_at TFPI35612 5.89e-05 5.33e-02 tissue factor pathway inhibitor(lipoprotein-associated 2q31-q32.1 Consensussequence coagulationinhibitor) 36 227367_at 34151 6.31e-05 5.56e-02 ESTsConsensussequence 37 227391_x_at 30498 6.97e-05 5.87e-02 ESTs,Weakly similar to hypothetical protein FLJ20294 Consensussequence[Homo sapiens] [H. sapiens] 38 227100_at 30133 7.04e-05 5.87e-02Homo sapiens, clone IMAGE: 4825471, mRNA Consensussequence 39222491_at FLJ32731 28672 7.43e-05 6.04e-02 hypothetical proteinFLJ32731 8p11.1 Consensussequence 40 243579_at MSI2 28307 7.64e-056.05e-02 musashi homolog 2 (Drosophila) 17q23.1 Consensussequence41 224473_x_at KIAA1813 24654 8.47e-05 6.55e-02 KIAA1813 protein10q24 Exemplarsequence 42 208873_s_at DP1 24289 8.77e-05 6.62e-02likely ortholog of mouse deleted in polyposis 1 5q22-q23Exemplarsequence 43 201894_s_at DCN 22098 9.23e-05 6.80e-02 decorin12q13.2 Exemplarsequence 44 226164_x_at 20637 9.72e-05 7.00e-02Homo sapiens mRNA; cDNA DKFZp586I0521 (from Consensussequence cloneDKFZp586I0521) 45 225589_at POSH 19906 1.08e-04 7.04e-02 likelyortholog of mouse plenty at SH3 domains 4q32.3 Consensussequence 46229969_at 18810 1.05e-04 7.04e-02 ESTs, Moderately similar toKIAA0377 gene product Consensussequence [Homo sapiens] [H. sapiens]47 244650_at 18445 1.07e-04 7.04e-02 ESTs Consensussequence 48227107_at 17349 1.11e-04 7.04e-02 ESTs Consensussequence 49211709_s_at SCGF 17349 1.09e-04 7.04e-02 stem cell growth factor;lymphocyte secreted C-type lectin 19q13.3 Exemplarsequence 50228813_at 17349 1.10e-04 7.04e-02 ESTs Consensussequence 51235016_at 16254 1.14e-04 7.08e-02 Homo sapiens, clone IMAGE:3626729, mRNA Consensussequence 52 224150_s_at BITE 15888 1.26e-047.18e-02 p10-binding protein 3q22-q23 Exemplarsequence 53 214582_atPDE3B 15523 1.19e-04 7.15e-02 phosphodiesterase 3B, cGMP-inhibited11p15.1 Consensussequence 54 208033_s_at ATBF1 15523 1.18e-047.15e-02 AT-binding transcription factor 1 16q22.3-q23.1Exemplarsequence 55 234299_s_at NIN 14062 1.24e-04 7.18e-02 ninein(GSK3B interacting protein) 14q21.3 Consensussequence 56 236497_at13697 1.34e-04 7.20e-02 ESTs, Weakly similar to cytokinereceptor-like factor 2; Consensussequence cytokine receptor CRL2precusor [Homo sapiens] [H. sapiens] 57 244611_at 13332 1.27e-047.18e-02 ESTs, Highly similar to thyroid hormone receptor-Consensussequence associated protein, 240 kDa subunit [Homosapiens] [H. sapiens] 58 226348_at 12601 1.29e-04 7.19e-02 Homosapiens cDNA: FLJ23111 fis, clone LNG07835. Consensussequence 59223342_at RRM2B 12236 1.32e-04 7.20e-02 ribonucleotide reductase M2B (TP53 inducible) 8q23.1 Exemplarsequence 60 216426_at 122361.38e-04 7.22e-02 Consensussequence 61 223046_at EGLN1 469351.39e-04 7.22e-02 egl nine homolog 1 (C. elegans) 1q42.1Consensussequence 62 204225_at HDAC4 46935 1.41e-04 7.22e-02histone deacetylase 4 2q37.2 Exemplarsequence 63 211220_s_at HSF245108 1.49e-04 7.48e-02 heat shock transcription factor 2 6q22.32Exemplarsequence 64 223629_at PCDHB5 44743 1.67e-04 8.03e-02protocadherin beta 5 5q31 Exemplarsequence 65 225462_at MGC1315944378 1.51e-04 7.50e-02 hypothetical protein MGC13159 4p16.2Consensussequence 66 212385_at 42552 1.64e-04 7.98e-02 Homo sapienscDNA FLJ11918 fis, clone Consensussequence HEMBB1000272. 67201427_s_at SEPP1 38328 1.71e-04 8.03e-02 selenoprotein P, plasma,1 5q31 Exemplarsequence 68 235476_at TSBF1 38298 1.75e-04 8.03e-02tumor suppressor TSBF1 Consensussequence 69 230836_at 382981.91e-04 8.03e-02 Homo sapiens, clone IMAGE: 4816784, mRNAConsensussequence 70 222217_s_at SLC27A3 38267 1.76e-04 8.03e-02solute carrier family 27 (fatty acid transporter), member 3 1q21.1Consensussequence 71 213119_at LOC91974 38175 1.81e-04 8.03e-02hypothetical protein LOC91974 5q33.1 Consensussequence 72202955_s_at BIG1 38175 1.83e-04 8.03e-02 brefeldin A-inhibitedguanine nucleotide-exchange protein 1 8q13 Exemplarsequence 73226367_at 38114 1.94e-04 8.03e-02 Homo sapiens mRNA; cDNADKFZp434C136 (from clone Consensussequence DKFZp434C136) 74244539_at 38084 1.90e-04 8.03e-02 ESTs Consensussequence 75226137_at 38053 1.91e-04 8.03e-02 Homo sapiens, clone IMAGE:5288537, mRNA Consensussequence 76 219934_s_at STE 38024 1.92e-048.03e-02 sulfotransferase, estrogen-preferring 4q13.1Exemplarsequence 77 235818_at 37993 1.98e-04 8.03e-02 ESTs, Weaklysimilar to T09402 immunoglobulin-like Consensussequence proteinIGSF1 - human [H. sapiens] 78 214373_at PPP4R2 7.00 2.01e-048.03e-02 protein phosphatase 4, regulatory subunit 2 3q29Consensussequence 79 225892_at 35947 2.04e-04 8.03e-02 Homo sapiensmRNA; cDNA DKFZp54D1164 (from Consensussequence cloneDKFZp564D1164) 80 203753_at TCF4 35947 2.02e-04 8.03e-02transcription factor 4 18q21.1 Exemplarsequence 81 226109_atC21orf91 35582 2.08e-04 8.03e-02 chromosome 21 open reading frame91 21q21.1 Consensussequence 82 222600_s_at FLJ10808 35217 2.07e-048.03e-02 hypothetical protein FLJ10808 4q13.2 Consensussequence 83220602_s_at FLJ22795 34486 2.13e-04 8.14e-02 hypothetical proteinFLJ22795 15q24.3 Exemplarsequence 84 225172_at CRAMP1L 326602.28e-04 8.62e-02 Crm, cramped-like (Drosophila) 16p13.3Consensussequence 85 226261_at LOC223082 32660 2.32e-04 8.66e-02LOC223082 7p15.1 Consensussequence 86 203948_s_at MPO 311992.38e-04 8.72e-02 myeloperoxidase 17q23.1 Exemplarsequence 87224716_at NFKBIE 30834 2.39e-04 8.72e-02 nuclear factor of kappalight polypeptide gene enhancer 6p21.1 Consensussequence in B-cellsinhibitor, epsilon 88 228188_at FLJ23306 30468 2.44e-04 8.80e-02hypothetical protein FLJ23306 2p23.3 Consensussequence 89216266_s_at BIG1 30103 2.50e-04 8.90e-02 brefeldin A-inhibitedguanine nucleotide-exchange protein 1 8q13 Consensussequence 90243909_x_at 29738 2.56e-04 8.93e-02 Homo sapiens cDNA FLJ13549 fis,clone Consensussequence PLACE1007097. 91 218599_at REC8 293732.56e-04 8.93e-02 Rec8p, a meiotic recombination and sisterchromatid 14q11.2-q12 Exemplarsequence cohesion phosphoprotein ofthe rad21p family 92 235516_at SLA/LP 28277 2.63e-04 9.05e-02soluble liver antigen/liver pancreas antigen 4p15.31Consensussequence 93 235391_at LOC137392 28277 2.67e-04 9.06e-02similar to CG6405 gene product 8q21.3 Consensussequence 94227489_at 27181 2.78e-04 9.06e-02 Homo sapiens cDNA FLJ11157 fis,clone Consensussequence PLACE1006961. 95 219890_at CLECSF5 264512.87e-04 9.06e-02 C-type (calcium dependent,carbohydrate-recognition 7q33 Exemplarsequence domain) lectin,superfamily member 5 96 226527_at 26085 2.83e-04 9.06e-02 ESTsConsensussequence 97 243010_at MSI2 26085 2.88e-04 9.06e-02 musashihomolog 2 (Drosophila) 17q23.1 Consensussequence 98 237311_at 253552.94e-04 9.06e-02 ESTs Consensussequence 99 210815_s_at CALCRL24990 2.97e-04 9.06e-02 calcitonin receptor-like 2q32.2Exemplarsequence 100 211547_s_at PAFAH1B1 24990 2.96e-04 9.06e-02platelet-activating factor acetylhydrolase, isoform lb, 17p13.3Exemplarsequence alpha subunit 45 kDa Go_Biological_ProcessGo_Cellular_Component Go_Molecular_Function 1 "GO: 7345;embryogenesis and morphogenesis; traceable "GO: 5871; kinesincomplex; inferred author statement GO: 7048; oncogenesis; traceableauthor from electronic annotation" statement" 2 3 "GO: 6171; cAMPbiosynthesis; non-traceable author "GO: 16021; integral tomembrane; non- "GO: 4383; guanylate cyclase activity; inferred fromelectronic statement GO: 7242; intracellular signaling cascade;inferred traceable author statement" annotation GO: 8294;calcium/calmodulin-responsive adenylate cyclase from electronicannotation" activity; inferred from electronic annotation GO:16829; lyase activity; inferred from electronic annotation" 4 "GO:7186; G-protein coupled receptor protein signaling "GO: 16021;integral to "GO: 1584; rhodopsin-like receptor activity; inferredfrom electronic pathway; inferred from electronic annotation"membrane; inferred from electronic annotation" annotation" 5 6 "GO:1501; skeletal development; experimental evidence "GO: 5887;integral to plasma "GO: 5007; fibroblast growth factor receptoractivity; experimental GO: 8543; FGF receptor signaling pathway;experimental membrane;

experimental evidence" evidence" evidence GO: 165; MAPKKK cascade;experimental evidence GO: 7048; oncogenesis; experimental evidence"7 "GO: 7345; embryogenesis and morphogenesis; traceable "GO: 5871;kinesin complex; inferred author statement GO: 7048; oncogenesis;traceable author from electronic annotation" statement" 8 "GO:6835; dicarboxylic acid transport; inferred from electronic "GO:5887; integral to plasma "GO: 5311; sodium;dicarboxylate/tricarboxylate symporter annotation GO: 15804;neutral amino acid transport; traceable membrane; traceable authorstatement activity; inferred from electronic annotation GO: 15175;neutral amino author statement GO: 6810; transport; inferred fromelectronic GO: 5624; membrane acid transporter activity; traceableauthor statement" annotation" fraction; traceable author statement"9 "GO: 6260; DNA replication; inferred from electronic "GO: 5634;nucleus; inferred from "GO: 3890; beta DNA polymerase activity;inferred from electronic annotation GO: 6304; DNA modification;inferred from electronic annotation annotation GO: 3677; DNAbinding; not recorded GO: 3912; DNA electronic annotation GO: 6281;DNA repair; inferred from GO: 5622; BRCT; intracellular; 2.4e-15;nucleotidylexotransferase activity; traceable author statementelectronic annotation GO: 6960; antimicrobial humoral extended:Unknown" GO: 16740; transferase activity; inferred from electronicannotation response (sensu invertebrata); traceable authorstatement" GO: 287; magnesium ion binding; inferred from electronicannotation" 10 "GO: 7157; heterophilic cell adhesion; inferred fromelectronic "GO: 5529; sugar binding; inferred from electronicannotation" annotation" 11 "GO: 6629; lipid metabolism; inferredfrom electronic "GO: 5788; endoplasmic reticulum "GO: 8233;peptidase activity; inferred from electronic annotation annotationGO: 6508; proteolysis and peptidolysis; traceable lumen; traceableauthor statement GO: 4289; subtilase activity; inferred fromelectronic annotation" author statement GO: 8203; cholesterolmetabolism; inferred GO: 5794; Golgi apparatus: inferred fromelectronic annotation" from electronic annotation GO: 16021;integral to membrane; inferred from electronic annotation" 12 "GO:8152; metabolism; inferred from electronic annotation "GO: 5887;integral to plasma "GO: 5311; sodium: dicarboxylate/tricarboxylatesymporter GO: 6835; dicarboxylic acid transport; inferred fromelectronic membrane; traceable author statement activity; inferredfrom electronic annotation GO: 15175; neutral amino annotation GO:15804; neutral amino acid transport; traceable GO: 5624; membraneacid transporter activity; traceable author statement authorstatement GO: 6520; amino acid metabolism; inferred fraction;traceable author statement" GO: 4648; phosphoserine transaminaseactivity; non-traceable author from electronic annotation GO: 6564;serine biosynthesis; non- statement GO: 8483; aminotran_5;transaminase activity; 3.4e-94; traceable author statement GO:8615; pyridoxine extended: inferred from electronic annotationbiosynthesis; non-traceable author statement GO: 4646; 2.6.1.52;phosphoserine aminotransferase activity; 2.71e-127; GO: 6810;transport; inferred from electronic annotation" extended: UnknownGO: 4646; 2.6.1.52; phosphoserine aminotransferase activity;4.83e-126; extended: Unknown GO: 16740; transferase activity;inferred from electronic annotation GO: 8483; aminotran_5;transaminase activity; 1.3e-127; extended: inferred from electronicannotation" 13 "GO: 7596; blood coagutation; traceable authorstatement" "GO: 4867; serine protease inhibitor activity; inferredfrom electronic annotation GO: 5209; plasma protein; not recordedGO: 5211; plasma glycoprotein; not recorded" 14 15 "GO: 7605;hearing; traceable author statement" "GO: 5871; kinesin complex;inferred "GO: 3779; actin binding; inferred from electronicannotation from electronic annotation" GO: 5102; receptor binding;not recorded GO: 5522; profilin binding; not recorded" 16 "GO:6629; lipid metabolism; inferred from electronic "GO: 4806;triacylglycerol lipase activity; inferred from electronicannotation" annotation GO: 3824; enzyme activity; inferred fromelectronic annotation" 17 18 "GO: 8152; metabolism; inferred fromelectronic annotation "GO: 5887; integral to plasma "GO: 5311;sodium: dicarboxylate/tricarboxylate symporter GO: 6835;dicarboxylic acid transport; inferred from electronic membrane;traceable author statement activity; inferred from electronicannotation GO: 15175; neutral amino annotation GO: 15804; neutralamino acid transport; traceable GO: 5624; membrane acid transporteractivity; traceable author statement author statement GO: 6520;amino acid metabolism; inferred fraction; traceable authorstatement" GO: 4648; phosphoserine transaminase activity;non-traceable author from electronic annotation GO: 6564; serinebiosynthesis; non- statement GO: 8483; aminotran_5; transaminaseactivity; 3.4e-94; traceable author statement GO: 8615; pyridoxineextended: inferred from electronic annotation biosynthesis;non-traceable author statement GO: 4646; 2.6.1.52; phosphoserineaminotransferase activity; 2.71e-127; GO: 6810; transport; inferredfrom electronic annotation" extended: Unknown GO: 4646; 2.6.1.52;phosphoserine aminotransferase activity; 4.83e-126; extended:Unknown GO: 16740; transferase activity; inferred from electronicannotation GO: 8483; aminotran_5; transaminase activity; 1.3e-127;extended: inferred from electronic annotation" 19 20 21 22 23 "GO:3824; enzyme activity; inferred from electronic annotation" 24 "GO:7345; embryogenesis and morphogenesis; traceable "GO: 5871; kinesincomplex; inferred author statement GO: 7048; oncogenesis; traceableauthor from electronic annotation" statement" 25 "GO: 16021;integral to membrane; non- traceable author statement" 26 27 28 2930 31 "GO: 3676; KRAB; nucleic acid binding activity; 4.4e-26;extended: inferred from electronic annotation" 32 "GO: 16021;integral to membrane; inferred from electronic annotation" 33 34"GO: 16740; transferase activity; inferred from electronicannotation" 35 "GO: 7596; blood coagulation; traceable authorstatement" "GO: 4867; serine protease inhibitor activity; inferredfrom electronic annotation GO: 5209; plasma protein; not recordedGO: 5211; plasma glycoprotein; not recorded" 36 37 38 39 40 "GO:3676; rrm; nucleic acid binding activity; 3.5e-22; extended:inferred from electronic annotation" 41 42 "GO: 16021; integral tomembrane; non- traceable author statement" 43 "GO: 7397;histogenesis and organogenesis; traceable author "GO: 5578;extracellular matrix; not "GO: 5205; chondroitin sulfate/dermatansulfate proteoglycan; not statement" recorded" recorded" 44 45 4647 48 49 "GO: 7267; cell-cell signaling; not recorded GO: 8284;positive "GO: 5615; extracellular "GO: 5173; stem cell factorreceptor binding; experimental evidence regulation of cellproliferation; experimental evidence" space; experimental evidence"GO: 5529; lectin_c; sugar binding activity; 3.5e-05; extended:Unknown GO: 5530; lectin; predicted/computed" 50 51 52 53 "GO:7165; signal transduction; inferred from electronic "GO: 16020;membrane; inferred from "GO: 16787; hydrolase activity; inferredfrom electronic annotation annotation" electronic annotation" GO:4119; cGMP-inhibited cyclic-nucleotide phosphodiesterase activity;traceable author statement GO: 4114; PDEase; 3',5'-cyclic-nucleotide phosphodiesterase activity; 9.5e-42; extended: Unknown"54 "GO: 6355; regulation of transcription, DNA- "GO: 5634; nucleus;traceable author "GO: 3705; RNA polymerase II transcription factoractivity, enhancer dependent; traceable author statement"statement" binding; traceable author statement" 55 "GO: 5509;ethand; calcium ion binding activity; 0.036; extended: traceableauthor statement" 56 57 58 59 "GO: 9186; deoxyribonucleosidediphosphate "GO: 4748; ribonucleoside-diphosphate reductaseactivity; inferred from metabolism; inferred from electronicannotation" electronic annotation" 60 61 "GO: 19538; proteinmatabolism; inferred from electronic "GO: 5829; cytosol; traceableauthor "GO: 16706; oxidoreductase activity, acting on paireddonors, with annotation" statement" incorporation or reduction ofmolecular oxygen, 2-oxoglutarate as one donor, and incorporation ofone atom each of oxygen into both donors; inferred from electronicannotation" 62 "GO: 7049; cell cycle; non-traceable authorstatement "GO: 5634; nucleus; non-traceable "GO: 4407; histonedeacetylase activity; non-traceable author statement GO: 6355;regulation of transcription, DNA- author statement" GO: 16787;hydrolase activity; inferred from electronic annotation dependent;traceable author statement GO: 16564; transcriptional repressoractivity; traceable author GO: 7275; development; non-traceableauthor statement" statement" 63 "GO: 6355; regulation oftranscription, DNA- "GO: 5634; nucleus; inferred from "GO: 3713;transcription co-activator activity; traceable author statementdependent; inferred from electronic annotation electronicannotation" GO: 3773; heat shock protein activity; inferred fromelectronic annotation GO: 6366; transcription from Pol II promoter;traceable author GO: 3700; transcription factor activity; traceableauthor statement" statement" 64 "GO: 7156; homophilic celladhesion; inferred from electronic "GO: 16021; integral tomembrane; non- "GO: 8014; calcium-dependent cell adhesion moleculeactivity; non- annotation GO: 7416; synaptogenesis; traceableauthor traceable author statement" traceable author statement GO:5509; calcium ion binding; inferred from statement GO: 7273;regulation of synapse; traceable author electronic annotation"statement GO: 7155; cell adhesion; non-traceable author statement"65 66 67 "GO: 6979; response to oxidative stress; traceable author"GO: 8430; selenium binding; traceable aulhor statement" statement"68 "GO: 5622; intracellular; inferred from "GO: 8270; zinc ionbinding; inferred from electronic annotation" electronicannotation" 69 70 "GO: 3824; AMP-binding; enzyme activity; 8.2e-70;extended: inferred from electronic annotation" 71 72 "GO: 6887;exocytosis; traceable author statement" "GO: 5085;guanyl-nucleotide exchange factor activity; traceable authorstatement" 73 74 75 76 "GO: 8202; steroid metabolism; traceableauthor statement" "GO: 8146; Sulfotransfer; sulfotransferaseactivity; 7.8e-144; extended: inferred from expression pattern GO:4304; estrone sulfotransferase activity; traceable author statementGO: 5496; steroid binding; inferred from electronic annotation GO:16740; transferase activity; inferred from electronic annotation"77 78 "GO: 6464; protein modification; traceable author statement""GO: 5813; centrosome; traceable author statement" 79 80 "GO: 6357;regulation of transcription from Pol II "GO: 5634; nucleus;traceable author "GO: 3677; DNA binding; inferred fromelectronic

annotation promoter; traceable author statement" statement" GO:3702; RNA polymerase II transcription factor activity; traceableauthor statement" 81 82 "GO: 6512; ubiquitin cycle; inferred fromelectronic annotation "GO: 3824; enzyme activity; inferred fromelectronic annotation GO: 6464; protein modification; inferred fromelectronic GO: 4839; ubiquitin activating enzyme activity; inferredfrom electronic annotation" annotation" 83 84 85 86 "GO: 6916;anti-apoptosis; traceable author statement "GO: 5764; lysosome;traceable author "GO: 4601; An_peroxidase; peroxidase activity;6.4e-161; GO: 6952; defense response; traceable author statementstatement GO: 5634; necleus; traceable extended: inferred fromelectronic annotation GO: 3682; chromatin GO: 6979; response tooxidative stress; traceable author author statement" binding;traceable author statement GO: 16687; myeloperoxidase statement"activity; inferred from electronic annotation GO: 16685; eosinophilperoxidase activity; inferred from electronic annotation GO: 5509;calcium ion binding; inferred from electronic annotation GO: 16491;oxidoreductase activity; inferred from electronic annotation GO:16686; lactoperoxidase activity; inferred from electronicannotation" 87 "GO: 5737; cytoplasm; experimental "GO: 3719;transcription factor binding, cytoplasmic evidence" sequestering;experimental evidence" 88 89 "GO: 6887; exocylosis; traceableauthor statement" "GO: 5085; guanyl-nucleotide exchange factoractivity; traceable author statement" 90 91 "GO: 7126; meiosis;traceable author statement "GO: 5634; nucleus; traceable author GO:7283; spermatogenesis; traceable author statement statement" GO:7131; meiotic recombination; traceable author statement GO: 7062;sister chromatid cohesion; traceable author statement" 92 "GO: 49;tRNA binding; predicted/computed" 93 94 95 "GO: 7157; heterophiliccell adhesion; inferred from electronic "GO: 5529; sugar binding;inferred from electronic annotation" 95 annotation" 96 97 "GO:3676; rrm; nucleic acid binding activity; 3.5e-22; extended:inferred from electronic annotation" 98 99 "GO: 7187; G-proteinsignaling, coupled to cyclic nucleotide "GO: 5887; integral toplasma "GO: 4930; G-protein coupled receptor activity; traceableauthor second messenger; traceable author statement" membrane;traceable author statement GO: 4948; calcitonin receptor activity;inferred from electronic statement" annotation" 100 "GO: 7165;signal transduction; traceable author statement "GO: 5737;cytoplasm: not recorded" "GO: 5209; plasma protein; not recordedGO: 16787; hydrolase GO: 7399; neurogenesis; traceable authorstatement activity; inferred from electronic annotation GO: 3847;2-acetyl-1- GO: 6928; cell motility; traceable author statementalkylglycerophosphocholine esterase activity; inferred fromelectronic GO: 6629; lipid metabolism; traceable author statement"annotation" Sequence Sequence Transcript ID Derived From SequenceID Source Unigene_Accession Cluster_Type LocusLinkFull_Length_Reference_Seq 1 Hs.2384.0 NM_005079.1 g4827037 RefSeqHs.2384 fulllength 7163 NM_005079; tumor protein D52 2 Hs.163208.0BG402859 Hs.163208.0.A1 GenBank Hs.108806 3 Hs.2352.0 AU149572Hs.2352.0.S1 GenBank Hs.2352 fulllength 108 NM_020546; adenylatecyclase 2 4 Hs.8309.0 BC004998.1 g13436457 GenBank Hs.8309fulllength 23344 NM_015292; KIAA0747 protein 5 Hs.292815.0 BG169443Hs.292815.0.A1 GenBank Hs.372680 6 Hs.748.8 BE467261 Hs.748.8.A1GenBank Hs.748 fulllength 2260 NM_000604; fibroblast growth factorreceptor 1 isoform 1 precursor NM_015850; fibroblast growth factorreceptor 1 isoform 2 precursor NM_023105; fibroblast growth factorreceptor 1 isoform 3 precursor NM_023106; fibroblast growth factorreceptor 1 isoform 4 precursor NM_023107; fibroblast growth factorreceptor 1 isoform 5 precursor NM_023108; fibroblast growth factorreceptor 1 isoform 6 precursor NM_023109; fibroblast growth factorreceptor 1 isoform 7 precursor NM_023110; fibroblast growth factorreceptor 1 isoform 8 precursor NM_023111; fibroblast growth factorreceptor 1 isoform 9 precursor 7 Hs.2384.0 BE974098 Hs.2384.0.S2GenBank Hs.2384 fulllength 7163 NM_005079; tumor protein D52 8Hs.323878.0 BF340083 Hs.323878.0 GenBank Hs.323878 fulllength 6509NM_003038; solute carrier family 1, member 4 9 Hs.272537.0 M11722.1g339436 GenBank Hs.397294 fulllength 1791 NM_004088;deoxynucleotidyltransferase, terminal 10 Hs.161002.0 U83115.1Hs.161002.0 GenBank Hs.161002 202 11 Hs.75890.0 NM_003791.1g4506774 RefSeq Hs.75890 fulllength 8720 NM_003791; site-1 proteasepreproprotein 12 Hs.286049.2 BG032165 Hs.286049.2 GenBank Hs.286049fulllength 29968 NM_003038; solute carrier family 1, member 4NM_021154; phosphoserine aminotransferase isoform 2 NM_058179;phosphoserine aminotransferase isoform 1 13 Hs.170279.1 AF021834.1g4103170 GenBank Hs.170279 fulllength 7035 NM_006287; tissue factorpathway inhibitor (lipoprotein-associated coagulation inhibitor) 14Hs.25329.0 AW043602 Hs.25329.0.A1 GenBank Hs.172792 fulllength165215 NM_177454; KIAA1946 protein 15 Hs.26584.0 AF051782.1g2947237 GenBank Hs.432623 fulllength 1729 NM_005219; diaphanous 116 Hs.131899.1 BE795104 Hs.131899.1_RC GenBank Hs.131899 fulllength221955 NM_139179; KCCR13L 17 Hs.21542.0 AB028958.1 Hs.21542.0GenBank Hs.21542 fulllength 23287 NM_015239; ATP/GTP bindingprotein 1 18 Hs.286049.2 BG032165 Hs.286049.2 GenBank Hs.286049fulllength 29968 NM_003038; solute carrier family 1, member 4NM_021154; phosphoserine aminotransferase isoform, 2 NM_058179;phosphoserine aminotransferese isoform 1 19 Hs.131705.0 BF447954Hs.131705.0.A1 GenBank Hs.131705 est 20 Hs.146119.0 BG434381Hs.146119.0_RC GenBank Hs.146119 est 21 Hs.123364.0 BF724270Hs.123364.0.A1 GenBank Hs.123364 fulllength 22 Hs.48461.0 N62126Hs.48461.0.A1 GenBank Hs.32374 23 Hs.154706.0 AA128978Hs.154706.0.S1 GenBank Hs.154706 fulllength 84947 NM_032861;hypothetical protein FLJ14917 24 Hs.2384.0 BE974098 Hs.2384.0.S2GenBank Hs.2384 fulllength 7163 NM_005079; tumor protein D52 25Hs.178112.0 AA814140 Hs.178112.0.S1 GenBenk Hs.178112 fulllength7905 NM_005669; likely ortholog of mouse deleted in polyposis 1 26Hs.115700.0 AU155930 Hs.115700.0.S1 GenBank Hs.115700 fulllength285172 NM_173822; hypothetical protein MGC39518 27 Hs.49136.0AL039862 Hs.49136.0.A1 GenBank Hs.49136 28 Hs.6655.0 AL355688.1Hs.6655.0.S1 GenBank Hs.6655 29 Hs.287426.0 AU144919 Hs.287426.0GenBank Hs.287426 30 Hs.155979.0 AB002293.1 Hs.155979.0_RC GenBankHs.155979 23060 31 Hs.192662.0 NM_018102.1 g8922439 RefSeqHs.192662 fulllength 55713 NM_018102; zinc finger protein 334 32Hs.182626.0 NM_012264.1 g7110634 RefSeq Hs.182626 fulllength 25829NM_012264; chromosome 22 open reading frame 5 33 Hs.121645.0AA772352 Hs.121645.0_RC GenBank Hs.126889 34 Hs.24947.0 AA039350Hs.24947.0_RC GenBank Hs.24947 fulllength 113189 NM_130468;dermatan-4-sulfotransferase-1 35 Hs.170279.2 BF109662 Hs.170279.2GenBank Hs.170279 fulllength 7035 NM_006287; tissue factor pathwayinhibitor (lipoprotein-associated coagulation inhibitor) 36Hs.184067.0 AW976431 Hs.184067.0 GenBank Hs.445376 est 37Hs.293327.0 BE674143 Hs.293327.0_RC GenBank Hs.293327 est 38Hs.13205.0 AI569766 Hs.13205.0.A1 GenBank Hs.13205 39 Hs.288057.0T56470 Hs.288057.0 GenBank Hs.380474 fulllength 138050 NM_152419;hypothetical protein FLJ32731 40 Hs.173179.0 BF029215Hs.173179.0.S1 GenBank Hs.103512 fulllength 124540 NM_138962;musashi 2 isoform a NM_170721; musashi 2 isoform b 41 g13623228BC006212.1 g13623228 GenBank Hs.25298 fulllength 84445 42Hs.178112.0 BC000232.1 g12652946 GenBank Hs.178112 fulllength 7905NM_005669; likely ortholog of mouse deleted in polyposis 1 43Hs.76152.0 NM_001920.1 g4503270 RefSeq Hs.433989 fulllength 1634NM_001920; decorin isoform a preproprotein NM_133503; decorinisoform a preproprotein NM_133504; decorin isoform b precursorNM_133505; decorin isoform c precursor NM_133506; decorin isoform dprecursor NM_133507; decorin isoform e precursor 44 Hs.236463.2AI760919 Hs.236463.2.S1 GenBank Hs.367803 45 Hs.301804.0 AB040927.1Hs.301804.0 GenBank Hs.301804 57630 46 Hs.26904.0 AV723931Hs.26904.0.A1 GenBank Hs.26904 est 47 Hs.152328.0 AA581439Hs.152328.0.A1 GenBank Hs.445553 est 48 Hs.24789.0 AI807404Hs.24789.0.A1 GenBank Hs.32163 est 49 g13543291 BC005810.1g13543291 GenBank Hs.105927 fulllength 6320 NM_002975; stem cellgrowth factor; lymphocyte secreted C-type lectin 50 Hs.91400.1AW206037 Hs.91400.1.S1 GenBank Hs.222874 est 51 Hs.121557.0AL118571 Hs.121557.0 GenBank Hs.121557 52 Hs.42315.1 AF289495.1g11494382 GenBank Hs.42315 fulllength 80321 NM_024491; p10-bindingprotein 53 Hs.150741.3 NM_000753.1 Hs.150741.3 GenBenk Hs.337616fulllength 5140 NM_000753; NM_000922; phosphodiesterase 3B,cGMP-inhibited 54 Hs.101842.0 NM_006885.1 g5901893 RefSeq Hs.101842fulllength 463 NM_006885; AT-binding transcription factor 1 55Hs.12772.1 AK027054.1 Hs.12772.1 GenBank Hs.44054 fulllength 51199NM_016350; ninein (GSK3B interacting protein) NM_020921; ninein(GSK3B interacting protein) 56 Hs.157489.0 AI203293 Hs.157489.0_RCGenBank Hs.157489 est 57 Hs.85481.0 H38035 Hs.85481.0.A1 GenBankHs.439144 est 58 Hs.268231.0 AK026764.1 Hs.268231.0 GenBankHs.268231 59 Hs.94262.0 AB036063.1 g7229085 GenBank Hs.94262fulllength 50484 60 Hs.287783.0 AL136318 Hs.287783.0.S1 GenBank 61Hs.6523.1 NM_022051.1 Hs.6523.1_RC GenBank Hs.6523 fulllength 54583NM_022051; egl nine homolog 1 62 Hs.91400.0 NM_006037.2 g13259519RefSeq Hs.91400 fulllength 9759 NM_006037; histone deacetylase 4 63Hs.158195.1 BC005329.1 g13529106 GenBank Hs.158195 fulllength 3298NM_004506; heat shock transcription factor 2 64 Hs.119693.0BC001186.1 g12654692 GenBank Hs.119693 fulllength 26167 NM_015669;protocadherin beta 5 precursor 65 Hs.12845.0 AV705805 Hs.12845.0.S1GenBank Hs.12845 fulllength 85013 NM_032927; hypothetical proteinMGC13159 66 Hs.289068.0 AK021980.1 Hs.289068.0 GenBank Hs.289068 67Hs.3314.0 NM_005410.1 g4885590 RefSeq Hs.275775 fulllength 6414NM_005410; selenoprotein P precursor 68 Hs.125759.0 AW182459Hs.125759.0.A1 GenBank Hs.125759 fulllength 286827 NM_173084; tumorsuppressor TSBF1 69 Hs.218289.0 AI422986 Hs.218289.0.A1 GenBankHs.152049 70 Hs.109274.1 BC003654.1 Hs.109274.1 GenBank Hs.109274fulllength 11000 NM_024330; solute carrier family 27 member 3 71Hs.18593.0 AW058600 Hs.18593.0_RC GenBank Hs.422202 91974 72Hs.94631.0 AF084520.1 g5052120 GenBank Hs.94631 fulllength 10565NM_006421; brefeldin A-inhibited guanine nucleotide-exchangeprotein 1 73 Hs.6567.1 AL133026.1 Hs.6567.1 GenBank Hs.6567 74Hs.252746.0 AW665840 Hs.252746.0_RC GenBank Hs.252746 est 75Hs.108806.0 AI288759 Hs.108806.0.S1 GenBank Hs.108806 76 Hs.54576.0NM_005420.1 g4885616 RefSeq Hs.54576 fulllength 6783 NM_005420sulfotransferase, estrogen-preferring 77 Hs.133355.0 AI498747Hs.133355.0.A1 GenBank Hs.444431 est 78 Hs.125682.1 AI582773Hs.125682.1_RC GenBank Hs.446494 fulllength 56340 NM_019853;protein phosphatase 4 regulatory subunit 2 79 Hs.295789.0 BF438417Hs.295789.0_RC GenBank Hs.295789 80 Hs.326198.0 NM_003199.1g4507398 RefSeq Hs.326198 fulllength 6925 NM_003199; transcriptionfactor 4 isoform b 81 Hs.49391.1 AK023825.1 Hs.49391.1.S2 GenBankHs.49391 fulllength 54149 NM_017447; chromosome 21 open readingframe 91 82 Hs.59838.0 NM_018227.1 Hs.59838.0 GenBank Hs.59838fulllength 55236 NM_018227; hypothetical protein FLJ10808 83Hs.330056.0 NM_025084.1 g13443001 RefSeq Hs.288390 fulllength 80154NM_025084; hypothetical protein FLJ22795 84 Hs.15441.0 AB037847.1Hs.15441.0.A1 GenBank Hs.15441 57585 85 Hs.127294.0 AI831561Hs.127294.0_RC GenBank Hs.127294 fulllength 223082 NM_147128;LOC223082 86 Hs.1817.0 J02694.1 g189039 GenBank Hs.1817 fulllength4353 NM_000250; myeloperoxidase 87 Hs.182885.0 BG163267Hs.182855.0.A1 GenBank Hs.182885 fulllength 4794 NM_004556; nuclearfactor of kappa light polypeptide gene enhancer in B-cellsinhibitor, epsilon 88 Hs.5890.0 AI860150 Hs.5890.0_RC GenBankHs.5890 fulllength 79579 NM_024530; hypothetical protein FLJ2330689 Hs.94631.1 AK025637.1 Hs.94631.1.S1 GenBank Hs.94631 fulllength10565 NM_006421; brefeldin A-inhibited guanine nucleotide-exchangeprotein 1 90 Hs.172745.0 R43205 Hs.172745.0_RC GenBank Hs.56406 91Hs.4767.0 NM_005132.1 g9845292 RefSeq Hs.4767 fulllength 9985NM_005132; Rec8p, a meiotic recombination and sister chromatidcohesion pho 92 Hs.131209.0 AI038867 Hs.131209.0_RC GenBankHs.161436 fulllength 51091 NM_016955; soluble liver antigen/liverpancreas antigen NM_153825; soluble liver antigen/liver pancreasantigen 93 Hs.87672.0 AW960748 Hs.87672.0_RC GenBank Hs.403869fulllength 137392

NM_145269; similar to CG6405 gene product 94 Hs.169872.0 BE962027Hs.169872.0.A1 GenBank Hs.323849 95 Hs.126355.0 NM_013252.1g10281668 RefSeq Hs.126355 fulllength 23601 NM_013252; C-type(calcium dependent, carbohydrate-recognition domain) lectin,superfamily member 5 96 Hs.5669.0 AI569785 Hs.5669.0_RC GenBankHs.5669 est 97 Hs.103512.0 BE000929 Hs.103512.0.A1 GenBankHs.103512 fulllength 124540 NM_138962; musashi 2 isoform aNM_170721; musashi 2 isoform b 98 Hs.161353.0 AI939580Hs.161353.0_RC GenBank Hs.161353 est 99 Hs.152175.1 U17473.1g662328 GenBank Hs.152175 fulllength 10203 NM_005795; calcitoninreceptor-like 100 Hs.77318.1 L13387.1 g349827 GenBank Hs.77318fulllength 5048 NM_000430; platelet-activating factoracetylhydrolase, isoform Ib. alpha subunit (45 kD)

TABLE-US-00019 TABLE 18 t(8;16) versus WHO 1(8;16) vere(8:16) AMLwas compared to the 4 other balanced subtypes according to the WHOclassification (t(15;17), t(8;21), inv(16), and11q23/MLL-rearrangements Top 100 differentially expressed genes:Number Affymetrix_ID HUGO name fc p q sfn t Title MapLocationSequence Type 1 223299_at LOC90701 2.21 1.27E-39 1.12E-35 1.9625.73 similar to signal peptidase complex (18 kD) 18q21.31Exemplarsequence 2 204236_at FLI1 2.34 2.39E-32 9.01E-29 1.95 25.19Friend leukemia virus integration 1 11q24.1-q24.3 Exemplarsequence3 203409_at DDB2 3.04 4.00E-07 1.58E-05 2.85 25.18 damage-specificDNA binding protein 2, 48 kDa 11p12-p11 Exemplarsequence 4223098_s_at MGC4840 2.22 1.08E-09 7.60E-08 2.09 22.04 hypotheticalprotein MGC4840 16q11.2 Consensussequence 5 214937_x_at PCM1 2.481.80E-05 0.000439408 2.74 20.23 pericentriolar material 18p22-p21.3 Consensussequence 6 212786_at KIAA0350 1.87 4.38E-082.12E-06 1.96 19.57 KIAA0350 protein 16p13.2 Consensussequence 7202174_s_at PCM1 2.40 1.90E-05 0.000457515 2.56 19.26pericentriolar material 1 8p22-p21.3 Exemplarsequence 8 229045_atMGC35578 2.75 6.63E-08 3.09E-06 1.93 19.16 hypothetical proteinMGC35578 16q11.2 Consensussequence 9 219951_s_at C20orf12 3.561.67E-05 0.000409408 2.41 18.63 chromosome 20 open reading frame 1220p11.23 Exemplarsequence 10 231982_at -85.92 1.95E-43 5.14E-39-1.37 -18.45 Homo sapiens HSPC323 mRNA, partial cdsConsensussequence 11 223000_s_at F11R -5.11 7.97E-12 8.10E-10 -1.58-18.13 F11 receptor 1q21.2-q21.3 Exemplarsequence 12 201135_atECHS1 2.43 5.14E-05 0.001083676 2.63 18.07 enoyl Coenzyme Ahydralase, short chain, 1, mitochondrial 10q26.2-q26.3Exemplarsequence 13 204924_at TLR2 2.72 1.18E-05 0.00030409 2.2418.00 toll-like receptor 2 4q32 Exemplarsequence 14 200749_at RAN2.55 1.69E-05 0.000413171 2.27 17.84 RAN, member RAS oncogenefamily 6p21 Consensussequence 15 205588_s_at FOP 2.09 4.73E-060.000137838 2.07 17.82 FGFR1 oncogene partner 6q27 Exemplarsequence16 235109_at -20.99 2.18E-40 2.87E-36 -1.27 -17.30 Homo sapienscDNA FLJ40581 fis, clone THYMU2007729. Consensussequence 17203584_at KIAA0103 2.75 4.57E-06 0.000133732 1.98 17.23 KIAA0103gene product 8q23.1 Exemplarsequence 18 217834_s_at NSAP1 3.910.000182471 0.003119077 3.16 17.19 NS1-associated protein 16q14-q15 Exemplarsequence 19 211626_x_at ERG -6.28 1.76E-111.70E-09 -1.50 -17.16 v-ets erythroblastosis virus E26 oncogenelike (avian) 21q22.3 Exemplarsequence 20 223358_s_at 3.06 1.53E-050.000378624 2.13 17.15 Homo sapiens cDNA FLJ33024 fis, cloneConsensussequence THYMU1000532, moderately similar to HIGH-AFFINITY CAMP-SPECIFIC 3',5'-CYCLIC PHOSPHODIESTERASE (EC3.1.4.17). 21 202016_at MEST -8.87 2.45E-24 2.33E-21 -1.32 -17.07mesodemn specific transcript homolog (mouse) 7q32 Exemplarsequence22 209349_at RAD50 1.85 3.61E-08 1.78E-09 1.63 16.89 RAD50 homolog(S. cerevisiae) 5q31 Exemplarsequence 23 202746_at ITM2A -28.957.47E-38 4.92E-34 -1.20 -16.41 integral membrane protein 2AXq13.3-Xq21.2 Consensussequence 24 226384_at HTPAP -4.04 4.58E-372.42E-33 -1.19 -16.23 HTPAP protein 8p11.21 Consensussequence 25232693_s_at LOC55893 -11.91 1.21E-15 2.57E-13 -1.32 -16.17papillomavirus regulatory factor PRF-1 8p21.1 Consensussequence 26226846_at LOC254295 -6.62 4.11E-21 2.35E-18 -1.25 -16.03hypothetical protein LOC254295 9q34.13 Consensussequence 27229693_at -4.06 4.36E-15 8.37E-13 -1.31 -15.98 ESTsConsensussequence 28 223132_s_at TRIMS 3.46 0.000257941 0.0041581933.03 15.94 tripartite motif-containing 8 10q24.3 Exemplarsequence29 237255_at 3.45 1.71E-05 0.000418698 1.94 15.90 ESTs. Weaklysimilar to hypothetical protein Consensussequence FLJ20489 [Homosapiens] [H. sapiens] 30 227019_at 1.94 1.26E-09 8.77E-08 1.4215.69 Homo sapiens cDNA FLJ13137 fis, clone NT2RP3003150.Consensussequence 31 218455_at NFS1 1.61 6.66E-08 3.10E-06 1.5115.59 NFS1 nitrogen fixation 1 (S. cerevisiase) 20q11.21Exemplarsequence 32 224378_x_at MAP1LC3A 2.03 1.39E-06 4.77E-051.64 15.56 microtubule-associated protein 1 light chain 3 20cen-q13alpha Exemplarsequence 33 202747_s_at ITM2A -43.58 4.71E-352.07E-31 -1.13 -15.45 integral membrane protein 2A Xq13.3-Xq21.2Exemplarsequence 34 202895_s_at PTPNS1 1.61 8.44E-08 3.86E-08 1.4915.36 protein tyrosine phosphatase, non-receptor type substrate 120p13 Exemplarsequence 35 204423_at MKLN1 2.32 5.03E-05 0.0010617422.03 15.30 muskelin 1, intracellular mediator containing 7q32Exemplarsequence kelch motifs 36 223284_at KLP1 -2.43 9.05E-271.40E-23 -1.15 -15.17 K562 cell-derived leucine-zipper-like protein1 19q13.42 Exemplarsequence 37 213206_at GOSR2 1.91 3.92E-102.98E-08 1.33 15.09 golgi SNAP receptor complex member 2 17q21Consensussequence 38 228943_at -2.20 2.60E-29 6.86E-26 -1.12 -14.97ESTs. Weakly similar to JC5963 stable tubule Consensussequence onlypolypeptide - mouse [M. musculus] 39 208628_s_at NSEP1 1.225.06E-10 3.80E-08 1.32 14.89 nuclease sensitive element bindingprotein 1 1p34 Exemplarsequence 40 208889_s_at NCOR2 -4.70 3.34E-191.35E-16 -1.16 -14.83 nuclear receptor co-repressor 2 12q24Consensussequence 41 204117_at PREP 2.19 7.21E-05 0.00144616 2.0214.83 prolyl endopeptidase 6q22 Exemplarsequence 42 200723_s_atM11S1 2.10 0.000205473 0.003445202 2.40 14.74 membrane component,chromosome 11, 11p13 Exemplarsequence surface marker 1 43 216247_atRPS20 -2.06 9.16E-32 3.01E-28 -1.09 -14.74 ribosomal protein S208q12 Consensussequence 44 203469_s_at CDK10 3.05 3.41E-050.000760347 1.80 14.47 cyclin-dependent kinase (CDC2-like) 10 16q24Exemplarsequence 45 202343_x_at COX5B 1.65 1.03E-06 3.60E-05 1.4814.42 cytochrome c oxidase subunit Vb 2cen-q13 Exemplarsequence 46212513_s_at VDU1 2.19 2.47E-05 0.00057428 1.73 14.35pVHL-interacting deubiquitinating enzyme 1 1p31.1 Consensussequence47 220218_at FLJ10058 -6.00 1.47E-24 1.62E-21 -1.08 -14.33hypothetical protein FLJ10058 9p24.1 Exemplarsequence 48 238660_at1.71 2.32E-11 2.16E-09 1.22 14.32 ESTs Consensussequence 49209036_s_at MDH2 1.58 3.22E-06 9.88E-05 1.52 14.27 malatedehydrogenase 2, NAD (mitochondrial) 7p12.3-q11.2 Exemplarsequence50 223916_s_at BCoR 3.10 0.000356085 0.005381367 2.61 14.17 BCL-6interacting corepressor Xp11.4 Exemplarsequence 51 211800_s_at USP41.98 0.000293496 0.00460455 2.44 14.13 ubiquitin specific protease4 (proto-oncogene) 3p21.3 Exemplarsequence 52 201480_s_at SUPT5H1.31 4.01E-08 1.95E-06 1.31 14.01 suppressor of Ty 5 homolog (S.cerevisiae) 19q13 Exemplarsequence 53 219143_s_at FLJ20374 2.839.96E-05 0.001900448 1.93 13.99 hypothetical protein FLJ2037415q22.33 Exemplarsequence 54 209103_s_at UFD1L 1.46 5.13E-136.59E-11 1.15 13.95 ubiquitin fusion degradation 1-like 22q11.21Exemplarsequence 55 222508_s_at FLJ10154 2.38 5.93E-06 0.0001672721.51 13.89 hypothetical protein FLJ10154 13q33.1 Consensussequence56 227629_at 4.05 0.000324762 0.004973627 2.42 13.88 Homo sapienscDNA FLJ13603 fis, clone Consensussequence PLACE1010270. 57216569_at -4.45 4.09E-28 8.29E-25 -1.03 -13.84 Consensussequence 58235154_at TAF3 1.55 2.41E-10 1.92E-08 1.20 13.83 TAF3 RHApolymerase II, TATA box binding 10p15.1 Consensussequence protein(TBP)-associated factor, 140 kDa 59 209003_at SLC25A11 1.553.53E-09 2.26E-07 1.23 13.76 solute cerrier family 25(mitochondrial carrier; 17p13.3 Exemplarsequence oxoglutaratecarrier), member 11 60 214522_x_at HIST1H2AD 4.03 4.71E-050.001004799 1.72 13.74 histone 1, H2ad 6p21.3 Consensussequence 61221942_s_at GUCY1A3 -6.55 4.16E-29 9.95E-26 -1.01 -13.70 guanylatecyclase 1, soluble. alpha 3 4q31.1-q31.2 Consensussequence 62225264_at LOC57038 1.96 0.000133494 0.002415101 1.94 13.67 similarto arginyl-tRNA synthetase 6q16.1 Consensussequence 63 243023_at-5.77 3.07E-19 1.26E-16 -1.06 -13.66 ESTs Consensussequence 64239641_at 7.93 0.000821675 0.010516972 4.94 13.65 Homo sapiens,clone IMAGE: 5173389, mRNA Consensussequence 65 227923_at SHANK3-48.32 1.19E-29 3.49E-26 -1.01 -13.65 SH3 and multiple ankyrinrepeat domains 3 22q13.3 Consensussequence 66 212501_at CEBPB 2.084.39E-05 0.000945314 1.69 13.61 CCAAT/enhancer binding protein(C/EBP), beta 20q13.1 Consensussequence 67 210465_s_at SNAPC3 2.470.000152074 0.002693897 1.95 13.53 small nuclear RNA activatingcomplex, 9p22.2 Exemplarsequence polypeptide 3, 50 kDa 68 201051_atANP32A 2.21 0.000299477 0.004670572 2.23 13.48 acidic(leucine-rich) nuclear phosphoprotein 32 15q22.3-q23Consensussequence family, member A 69 223204_at DKFZp434L142 13.190.000741924 0.009717629 3.60 13.47 hypothetical proteinDKFZp434L142 4q32.1 Exemplarsequence 70 219014_at PLAC8 2.330.000123533 0.002269182 1.86 13.43 placenta-specific 8 4q21.3Exemplarsequence 71 202896_s_at PTPNS1 3.14 0.000525082 0.0073683372.70 13.40 protein tyrosine phosphatase, non-receptor type 20p13Exemplarsequence substrate 1 72 208624_s_at EIF4G1 1.99 8.54E-050.001666663 1.76 13.34 eukaryotic translation initiation factor 4gamma, 1 3q27-qter Consensussequence 73 223162_s_at LCHN -3.407.03E-07 2.63E-05 -1.32 -13.30 LCHN protein 7q34 Exemplarsequence74 201015_s_at JUP -13.84 1.13E-17 3.46E-15 -1.04 -13.29 junctionplakoglobin 17q21 Exemplarsequence 75 228391_at 2.39 9.64E-050.001847275 1.77 13.29 Homo sapiens, Similar to expressed sequenceConsensussequence AW111961, clone IMAGE: 5268751, mRNA 76201687_s_at API5 1.58 9.82E-18 3.10E-15 1.04 13.27 apoptosisinhibitor 5 11p12-q12 Exemplarsequence 77 226452_at PDK1 -3.155.66E-13 7.16E-11 -1.09 -13.26 pyruvate dehydrogenase kinase,isoenzyme 1 2q31.1 Consensussequence 78 227600_at 2.16 1.71E-050.000416898 1.51 13.24 ESTs, Weakly similar to hypothetical proteinConsensussequence FLJ20378 [Homo sapiens] [H. sapiens] 79220690_s_at DKFZp566O084 3.44 0.000376385 0.005616049 2.30 13.24DKFZP566O084 protein 17p12 Exemplarsequence 80 209494_s_at ZNF2781.57 1.79E-05 0.000436202 1.51 13.21 zinc finger protein 27822q12.2 Consensussequence 81 208469_s_at C6orf8 -4.40 1.02E-152.22E-13 -1.05 -13.20 chromosome 6 open reading frame 8 6p21.31Exemplarsequence 82 241133_at TRB -32.67 2.41E-28 5.28E-25 -0.97-13.18 T cell receptor beta locus 7q34 Consensussequence 83222425_s_at DKFZP586F1524 2.11 3.37E-05 0.000754482 1.57 13.17DKFZP586F1524 protein 17q11.1 Consensussequence 84 224863_at 2.537.80E-05 0.001551746 1.70 13.17 Homo sapiens cDNA FLJ31057 fis,clone Consensussequence HSYRA2000787. 85 217829_s_at SAD1 1.731.69E-05 0.000413171 1.49 13.14 SnRNP assembly defective 1 homolog2p11.2 Exemplarsequence 86 243500_at -4.83 2.31E-27 4.06E-24 -0.96-13.08 ESTs Consensussequence 87 212922_s_at HSKM-B -2.88 3.41E-060.000103948 -1.36 -13.02 HSKM-B protein 1q32.3 Consensussequence 88209710_at MGC2306 -7.84 8.03E-28 1.51E-24 -0.95 -13.01 hypotheticalprotein MGC2306 3q21.3 Consensussequence 89 217803_at GOLPH3 2.420.000445393 0.006439179 2.34 12.99 golgi phosphoprotein 3(coat-protein) 5p13.3 Exemplarsequence 90 205051_s_at KIT -10.711.56E-17 4.66E-15 -1.01 -12.95 v-kit Hardy-Zuckerman 4 felinesarcoma viral 4q11-q12 Exemplarsequence oncogene homolog 91244081_at -3.25 3.64E-16 8.79E-14 -1.02 -12.93 ESTsConsensussequence 92 214396_s_at MBD2 -3.16 2.38E-18 8.03E-16 -1.00-12.93 methyl-CpG binding domain protein 2 18q21 Consensussequence93 235142_at MGC17919 -7.98 2.82E-27 4.64E-24 -0.95 -12.93hypothetical protein MGC17919 1p34.3 Consensussequence 94 233749_at-7.23 3.14E-20 1.51E-17 -0.98 -12.86 EST Consensussequence 95212380_at KIAA0082 1.44 8.52E-09 4.89E-07 1.15 12.80 KIAA0082protein 6p21.2 Consensussequence 96 215736_at -6.48 4.97E-266.88E-23 -0.95 -12.79 Homo sapiens clone 23892 mRNA sequenceConsensussequence 97 218377_s_at C21orf6 2.61 0.0004973690.007036144 2.34 12.76 chromosome 21 open reading frame 6 21q22.11Exemplarsequence 98 225932_s_at 1.41 1.09E-07 4.86E-06 1.19 12.73Homo sapiens, clone IMAGE: 4812021, mRNA Consensussequence 99222323_at -2.93 5.49E-25 7.23E-22 -0.94 -12.71 ESTs, Moderatelysimilar to crystallin, gamma Consensussequence D; gamma crystallin4 [Homo sapiens] [H. sapiens] 100 213541_s_at ERG -4.73 1.16E-239.83E-21 -0.94 -12.56 v-ets erythroblastosis virus E26 oncogenelike 21q22.3 Consensussequence (avian) Sequence Sequence NumberTranscript ID Derived From Sequence ID Source Unigene_AccessionCluster_Type LocusLink Full_Length_Reference_Seq 1 Hs.68644.0AF212233.1 g13182746 GenBank Hs.68644 fulllength 90701 NM_033280;similar to signal peptidase complex (18 kD) 2 Hs.108043.0NM_002017.2 g7110592 RefSeq Hs.108043 fulllength 2313 NM_002017;Friend leukemia virus integration 1 3 Hs.77602.0 NM_000107.1g4557514 RefSeq Hs.77602 fulllength 1643 NM_000107; damage-specificDNA binding protein 2 (48 kD) 4 Hs.301872.0 AA195024 Hs.301872.0GenBank Hs.301872 fulllength 83752 NM_031490; hypothetical proteinMGC4840 5 Hs.75737.2 AI924817 Hs.75737.2.S1 GenBank Hs.75737fulllength 5108 NM_006197; pericentriolar material 1 6 Hs.23263.1AA731693 Hs.23263.1 GenBank Hs.23263 23274 7 Hs.75737.0 NM_006197.1g5453855 RefSeq Hs.75737 fulllength 5108 NM_006197; pericentriolarmaterial 1 8 Hs.87280.0 AA521424 Hs.87280.0_RC GenBank Hs.87280fulllength 124460 NM_153337; hypothetical protein MGC35578

9 Hs.128766.0 NM_018152.1 g8922543 RefSeq Hs.128766 fulllength55184 NM_018152; chromosome 20 open reading frame 12 10 Hs.130714.0AF161441.1 Hs.130714.0 GenBank Hs.130714 11 Hs.286218.2 AF172398.2g13124448 GenBank Hs.12284 fulllength 50848 NM_016946; F11 receptorisoform a precursor NM_144501; F11 receptor isoform a precursorNM_144502; F11 receptor isoform b NM_144503; F11 receptor isoform aprecursor NM_144504; F11 receptor isoform a precursor 12 Hs.76394.0NM_004092.2 g12707569 RefSeq Hs.76394 fulllength 1892 NM_004092;mitochondrial short-chain enoyl-coenzyme A hydratase 1 precursor 13Hs.63668.0 NM_003264.1 g4507528 RefSeq Hs.63668 fulllength 7097NM_003264; toll-like receptor 2 14 Hs.10842.0 BF112006Hs.10842.0_RC GenBank Hs.10842 fulllength 5901 NM_006325;ras-related nuclear protein 15 Hs.180296.0 NM_007045.1 g5901953RefSeq Hs.180296 fulllength 11116 NM_007045; FGFR1 oncogene partner16 Hs.69560.0 AI887983 Hs.69560.0_RC GenBank Hs.355933 17Hs.154387.0 NM_014673.1 g7661909 RefSeq Hs.154387 fulllength 9694NM_014673; KIAA0103 gene product 18 Hs.155489.0 NM_006372.1g5453805 RefSeq Hs.373499 fulllength 10492 NM_006372;NS1-associated protein 1 19 g182182 M21535.1 g182182 GenBankHs.45514 fulllength 2078 NM_004449; v-ets erythroblastosis virusE26 oncogene like 20 Hs.150395.0 AW269834 Hs.150395.0 GenBankHs.401726 21 Hs.79284.0 NM_002402.1 g4505154 RefSeq Hs.79284fulllength 4232 NM_002402; mesoderm specific transcript isoform aNM_177524; mesoderm specific transcript isoform b NM_177525;mesoderm, specific transcript isoform b 22 Hs.41587.3 U63139.1g158805 GenBank Hs.41587 fulllength 10111 NM_005732; RAD50 homologisoform, 1 NM_133482; RAD50 homolog isoform 2 23 Hs.17109.0AL021786 Hs.17109.0_RC GenBank Hs.17109 fulllength 9452 NM_004867;integral membrane protein 2A 24 Hs.8841.0 BE858787 Hs.8841.0.A1GenBank Hs.406670 fulllength 84513 NM_032483; HTPAP protein 25Hs.27410.2 AK021850.1 Hs.27410.2.S1 GenBank Hs.27410 fulllength55893 NM_018660; papillomavirus regulatory factor PRF-1 26Hs.326391.0 AL545998 Hs.326391.0.A1 GenBank Hs.375767 fulllength254295 NM_174933; hypothetical protein MGC16638 27 Hs.154574.0AI952836 Hs.154574.0_RC GenBank Hs.154574 est 28 Hs.54580.0AF220034.1 g12407398 GenBank Hs.54580 fulllength 81603 NM_030912;tripartite motif-containing 8 29 Hs.58879.0 BF222867 Hs.58879.0_RCGenBank Hs.58879 est 30 Hs.288905.0 AA129774 Hs.288905.0 GenBankHs.288905 31 Hs.194692.0 NM_021100.1 g10864078 RefSeq Hs.194692fulllength 9054 NM_021100; NFS1 nitrogen fixation 1 32 g13625770AF276658.1 g13625770 GenBank Hs.134707 fulllength 84557 NM_032514;microtubule-associated protein 1 light chain 3 alpha isoform aNM_181509; microtubule-associated protein 1 light chain 3 alphaisoform b 33 Hs.17109.0 NM_004867.1 g4758223 RefSeq Hs.17109fulllength 9452 NM_004867; integral membrane protein 2A 34Hs.156114.0 D86043.1 g1864010 GenBank Hs.156114 fulllength 140885NM_004648; NM_080792; protein tyrosine phosphatase, non-receptortype substrate 1 precursor 35 Hs.288791.0 NM_013255.1 g7019458RefSeq Hs.288791 fulllength 4289 NM_013255; muskelin 1,intracellular mediator containing kelch motifs 36 Hs.31854.0AB038651.1 g9664093 GenBank Hs.31854 fulllength 57106 NM_020378;K562 cell-derived leucine-zipper-like protein 1 37 Hs.100651.2BF966558 Hs.100651.2 GenBank Hs.100651 fulllength 9570 NM_004287;golgi SNAP receptor complex member 2 isoform A NM_054022; golgiSNAP receptor complex member 2 isoform B 38 Hs.239444.0 AW003666Hs.239444.0.A1 GenBank Hs.239444 est 39 Hs.74497.1 BC002411.1g12803206 GenBank Hs.74497 fulllength 4904 NM_004559; nucleasesensitive element binding protein 1 40 Hs.287994.1 AF125672.1Hs.287994.1_RC GenBank Hs.287994 fulllength 9612 NM_006312; nuclearreceptor co-repressor 2 41 Hs.86978.0 NM_002726.1 g4506042 RefSeqHs.86978 fulllength 5550 NM_002726; prolyl endopeptidase 42Hs.278672.0 NM_005898.1 g5174502 RefSeq Hs.278672 fulllength 4076NM_005898; membrane component, chromosome 11, surface marker 1 43Hs.8102.2 AF113008.1 Hs.8102.2_RC GenBank Hs.8102 fulllength 6224NM_001023; ribosomal protein S20 44 Hs.77313.0 NM_003674.1 g4502730RefSeq Hs.77313 fulllength 8558 NM_003674; cyclin-dependent kinase10 isoform 1 NM_052987; cyclin- dependent kinase 10 isoform 2NM_052988; cyclin-dependent kinase 10 isoform 3 45 Hs.1342.0NM_001862.1 g4502982 RefSeq Hs.1342 fulllength 1329 NM_001862;cytochrome c oxidase subunit Vb precursor 46 Hs.173694.0 AB029020.1Hs.173694.0.S1 GenBank Hs.173694 fulllength 23032 NM_015017;pVHL-interacting deubiquitinating enzyme 1 47 Hs.179615.0NM_017985.1 g8922211 RefSeq Hs.179615 fulllength 55064 NM_017985;hypothetical protein FLJ10058 48 Hs.181693.0 AI732512Hs.181693.0.A1 GenBank Hs.445400 est 49 Hs.111076.0 BC001917.1g12804928 GenBank Hs.343521 fulllength 4191 NM_005918;mitochondrial malate dehydrogenase precursor 50 Hs.130732.1AF317392.1 g11907999 GenBank Hs.130732 fulllength 54880 NM_017745;BCL-6 interacting corepressor isoform 1 NM_020926; BCL-6interacting corepressor isoform 2 51 Hs.77500.1 AF017306.1 g2656142GenBank Hs.77500 fulllength 7375 NM_003363; ubiquitin specificprotease, proto-oncogene 52 Hs.70186.0 NM_003169.1 g4507312 RefSeqHs.70186 fulllength 6829 NM_003169; suppressor of Ty 5 homolog 53Hs.8562.0 NM_017793.1 g8923354 RefSeq Hs.8562 fulllength 54913NM_017793; hypothetical protein FLJ20374 54 Hs.181369.1 BC001049.1g12654446 GenBank Hs.199402 fulllength 7353 NM_005659; ubiquitinfusion degradation 1-like 55 Hs.179972.0 AU135021 Hs.179972.0GenBank Hs.179972 fulllength 55082 NM_018011; hypothetical proteinFLJ10154 56 Hs.25252.0 AA843963 Hs.25252.0 GenBank Hs.25252 57Hs.247985.0 U72237 Hs.247985.0 GenBank 58 Hs.165433.0 BG250498Hs.165433.0_RC GenBank Hs.165433 83860 59 Hs.184877.1 AF070548.1g3387910 GenBank Hs.184877 fulllength 8402 NM_003562; solutecarrier family 25 (mitochondrial carrier; oxoglutarate carrier),member 11 60 Hs.239458.0 NM_021065.1 Hs.239458.0 GenBank Hs.239458fulllength 3013 NM_021065; histone 1, H2ad 61 Hs.306079.1 AI719730Hs.306079.1.A1 GenBank Hs.75295 fulllength 2982 NM_000856;guanylate cyclase 1, soluble, alpha 3 62 Hs.15395.0 AK023550.1Hs.15395.0.S1 GenBank Hs.15395 fulllength 57038 NM_020320;arginyl-tRNA synthetase-like 63 Hs.27996.0 N34402 Hs.27996.0.A1GenBank Hs.27996 est 64 Hs.79708.0 AI860159 Hs.79708.0_RC GenBankHs.79708 65 Hs.282076.0 BF439330 Hs.282076.0 GenBank Hs.28207685358 66 Hs.99029.0 AL564683 Hs.99029.0 GenBank Hs.99029 fulllength1051 NM_005194; CCAAT/enhancer binding protein beta 67 Hs.164915.1U71300.1 g1619945 GenBank Hs.164915 fulllength 6619 NM_003084;small nuclear RNA activating complex, polypeptide 3, 50 kDa 68Hs.285013.0 BE560202 Hs.285013.0.S2 GenBank Hs.285013 est 8125NM_006305; acidic (leucine-rich) nuclear phosphoprotein 32 family,member A 69 Hs.21941.0 AF260333.1 g12005903 GenBank Hs.323583fulllength 51313 NM_016613; hypothetical protein DKFZp434L142NM_032022; 70 Hs.107139.0 NM_016619.1 g7706157 RefSeq Hs.107139fulllength 51316 NM_016619; placenta-specific 8 71 Hs.156114.0NM_004648.1 g4758977 RefSeq Hs.156114 fulllength 140885 NM_004648;NM_080792; protein tyrosine phosphatase, non-receptor typesubstrate 1 precursor 72 Hs.211568.1 BE966878 Hs.211568.1_RCGenBank Hs.433750 fulllength 1981 NM_004953; eukaryotic translationinitiation factor 4 gamma, 1 73 Hs.12461.0 AF116707.1 g7959912GenBank Hs.233044 fulllength 57189 74 Hs.2340.0 NM_021991.1g12056467 RefSeq Hs.2340 fulllength 3728 NM_002230; junctionplakoglobin NM_021991; junction plakoglobin 75 Hs.237642.1 AI916528Hs.237642.1.A1 GenBank Hs.237642 76 Hs.227913.0 NM_006595.1g5729729 RefSeq Hs.227913 fulllength 8539 NM_006595; apoptosisinhibitor 5 NM_021112; 77 Hs.61712.1 AU146532 Hs.61712.1 GenBankHs.61712 fulllength 5163 NM_002610; pyruvate dahydrogenase kinase,isoenzyme 1 78 Hs.124165.0 AW272333 Hs.124165.0_RC GenBankHs.124165 est 79 Hs.278904.0 NM_015510.1 g7661657 RefSeq Hs.11411fulllength 25979 NM_015510; DKFZP566O084 protein NM_016036; 80Hs.27801.2 AI807017 Hs.27801.2 GenBank Hs.27801 fulllength 23598NM_014323; zinc finger protein 278 long C isoform NM_032050; zincfinger protein 278 long A isoform NM_032051; zinc finger protein278 short isoform NM_032052; zinc finger protein 278 long B isoform81 Hs.332138.0 NM_030652.1 g13449286 RefSeq Hs.332138 fulllength80864 NM_030652; NG3 protein 82 Hs.127924.0 AI016855 Hs.127924.0_RCGenBank Hs.303157 fulllength 6957 NG_001333; 83 Hs.241543.0AW151250 Hs.241543.0.S1 GenBank Hs.241543 fulllength 26073NM_015584; DNA polymerase delta p38 subunit 84 Hs.5437.3 BF477658Hs.5437.3.A1 GenBank Hs.296261 85 Hs.12820.0 NM_006590.1 g5730024RefSeq Hs.12820 fulllength 10713 NM_006590; SnRNP assemblydefective 1 homolog 86 Hs.202241.0 AI697668 Hs.202241.0_RC GenBankHs.202241 est 87 Hs.66170.1 AF070592.1 Hs.66170.1_RC GenBankHs.66170 fulllength 56950 NM_020197; SET and MYND domain containing2 88 Hs.760.1 AL563460 Hs.760.1 GenBank Hs.760 fulllength 84724 89Hs.18271.0 NM_022130.1 g11545858 RefSeq Hs.18271 fulllength 64083NM_022130; golgi phosphoprotein 3 90 Hs.81665.0 NM_000222.1g4557694 RefSeq Hs.81665 fulllength 3815 NM_000222; v-kitHardy-Zuckerman 4 feline sarcoma viral oncogene homolog precursor91 Hs.191633.0 BF223154 Hs.191633.0_RC GenBank Hs.191633 est 92Hs.25674.2 AI827820 Hs.25674.2.S1 GenBank Hs.25674 fulllength 8932NM_003927; methyl-CpG binding domain protein 2 isoform 1 NM_015832;methyl-CpG binding domain protein 2 testis-specific isoform 93Hs.129837.0 AW006067 Hs.129837.0_RC GenBank Hs.129837 fulllength127557 NM_144621; hypothetical protein MGC17919 94 Hs.302098.0AW139915 Hs.302098.0.S1 GenBank Hs.437588 est 95 Hs.154045.0D43949.1 Hs.154045.0 GenBank Hs.154045 fulllength 23070 NM_015050;KIAA0082 protein 96 Hs.91916.0 AF035317.1 Hs.91916.0 GenBankHs.91916 97 Hs.34136.0 NM_016940.1 g8393017 RefSeq Hs.34136fulllength 10069 NM_016940; chromosome 21 open reading frame 6 98Hs.232400.0 AI375753 Hs.232400.0.S1 GenBank Hs.288649 99Hs.131057.0 AI742810 Hs.131057.0_RC GenBank Hs.131057 est 100Hs.279477.0 AI351043 Hs.279477.0.A1 GenBank Hs.45514 fulllength2078 NM_004449; v-ets erythroblastosis virus E26 oncogene like

TABLE-US-00020 TABLE 19 _all # affy id HUGO name F p q TitleMapLocation Sequence Type Transcript ID 1 200923_at LGALS3BP 159.329.38e-32 3.30e-27 lectin, galactoside-binding, soluble, 3 binding17q25 Exemplarsequence Hs.79339.0 protein 2 200090_at- FNTA 50.568.32e-10 1.14e-05 farnesyltransferase, CAAX box, alpha 8p22-q11Consensussequence Hs.138381.1 HG-U133B 3 201433_s_at PTDSS1 50.339.72e-10 1.14e-05 phosphatidylserine synthase 1 8q22Exemplarsequence Hs.77329.0 4 214937_x_at PCM1 49.02 1.52e-091.30e-05 pericentriolar material 1 8p22-p21.3 ConsensussequenceHs.75737.2 5 200608_s_at RAD21 46.59 2.06e-09 1.30e-05 RAD21homolog (S. pombe) 8q24 Exemplarsequence Hs.81848.0 6 205849_s_atUQCRB 45.35 2.99e-09 1.30e-05 ubiquinol-cytochrome c reductasebinding protein 8q22 Exemplarsequence Hs.131255.0 7 212250_at 45.303.44e-09 1.30e-05 Homo sapiens, Similar to LYRIC, clone MGC: 41931IMAGE: Consensussequence Hs.243901.0 5298467, mRNA, complete cds 8203534_at LSM1 45.22 4.07e-09 1.30e-05 LSM1 homolog, U6 smallnuclear RNA associated (S. cerevisiae) 8p11.2 ExemplarsequenceHs.111783.0 9 202174_s_at PCM1 45.18 4.79e-09 1.30e-05pericentriolar material 1 8p22-p21.3 Exemplarsequence Hs.75737.0 10225534_at LOC114926 44.75 15.14e-09 1.30e-05 hypothetical proteinBC013035 8p11.1 Consensussequence Hs.10018.1 11 201754_at COX6C44.51 5.18e-09 1.30e-05 cytochrome c oxidase subunit VIc 8q22-q23Exemplarsequence Hs.74649.0 12 208845_at 44.14 5.5.4e-09 1.30e-05Exemplarsequence Hs.7381.0 13 218482_at DC6 43.68 7.08e-09 143e-05DC6 protein 8q23.2 Exemplarsequence Hs.283740.0 14 200090_at- FNTA42.83 8.58e-09 1.51e-05 farnesyltransferase, CAAX box, alpha8p22-q11 Consensussequence Hs.138381.1 HG-U133A 15 217819_atLOC51125 42.35 9.39e-09 1.57e-05 HSPC041 protein 8p11.21Exemplarsequence Hs.7953.0 16 237291_at 41.07 5.91e-09 1.30e-05ESTs, Weakly similar to unknown protein [Arabidopsis thaliana]Consensussequence Hs.159362.0 [A. thaliana] 17 228366_at SID6-30640.65 4.04e-09 1.30e-05 inorganic pyrophosphatase 2 4q25Consensussequence Hs.61455.0 18 203110_at PTK2B 40.01 1.52e-082.43e-05 PTK2B protein tyrosine kinase 2 beta 8p21.1Exemplarsequence Hs.20313.0 19 225233_at 39.12 2.49e-09 1.30e-05Homo sapiens, clone IMAGE: 4154313, mRNA, partial cdsConsensussequence Hs.42179.0 20 226453_at FLJ20974 38.04 4.43e-091.30e-05 hypothetical protein FLJ20974 11q13.1 ConsensussequenceHs.6364.3 21 214118_x_at PCM1 36.86 5.16e-08 6.96e-05pericentriolar material 1 8p22-p21.3 Consensussequence Hs.75737.122 212248_at 36.32 7.65e-08 9.59e-05 Homo sapiens. Similar toLYRIC, clone MGC: 41931 IMAGE: 5298467, ConsensussequenceHs.243901.0 mRNA, complete cds 23 214089_at RPS8 35.94 7.30e-091.43e-05 ribosomal protein S8 1p34.1-p32 ConsensussequenceHs.227400.1 24 209096_at UBE2V2 35.66 9.50e-08 1.11e-04ubiquitin-conjugating enzyme E2 variant 2 8q11.1 ExemplarsequenceHs.79300.0 25 242434_at 35.60 3.12e-08 4.57e-05 Homo sapiens cDNAFLJ31093 fis, clone Consansussequence Hs.191581.0 IMR321000161. 26237108_x_at DKFZp761G0122 35.38 8.34e-09 1.51e-05 hypotheticalprotein DKFZp761G0122 1p36.32 Consensussequence Hs.198661.0 27208647_at FDFT1 34.82 1.20e-07 1.31e-04 farnesyl-diphosphatefamesyltransferase 1 8p23.1-p22 Consensussequence Hs.48876.1 2832541_at PPP3CC 34.43 1.35e-07 1.36e-04 protein phosphatase 3(formerly 2B). catalytic 8p21.2 Consensussequence 6 subunit, gammaisoform (calcineurin A gamma) 29 207000_s_at PPP3CC 34.24 1.47e-071.40e-04 protein phosphatase 3 (formerly 2B), catalytic 8p21.2Exemplarsequence Hs.75206.0 subunit, gamma isoform (calcineurin Agamma) 30 225240_s_at 34.03 4.56e-08 6.40e-05 Homo sapiens, cloneIMAGE: 4154313, mRNA, partial cds Consensussequence Hs.42179.0 31218125_s_at FLJ10853 33.69 1.87e-07 1.73e-04 hypothetical proteinFLJ10853 8p21.1 Exemplarsequence Hs.72085.0 32 202824_s_at TCEB133.30 2.00e-07 1.80e-04 transcription elongation factor B (SIII),polypeptide 6q13.3 Exemplarsequence Hs.184693.0 1 (15 kDa, elonginC) 33 201652_at COPS5 32.89 2.20e-07 1.86e-04 COP9 constitutivephotomorphogenic homolog 8q12.3 Exemplarsequence Hs.198767.0subunit 5 (Arabidopsis) 34 204278_s_at EBAG9 32.36 3.24e-0712.53e-04 estrogen receptor binding site associated, antigen, 98q23 Exemplarsequence Hs.9222.0 35 218747_s_at TAPBP-R 32.341.23e-07 1.31e-04 TAP binding protein related 12p13.31Exemplarsequence Hs.267993.0 36 204341_at TRIM16 32.13 3.06e-084.57e-05 tripartite motif-containing 16 17p11.2 ExemplarsequenceHs.241305.0 37 243579_at MSI2 32.04 9.52e-08 1.11e-04 musashihomolog 2 (Drosophila) 17q23.1 Consensussequence Hs.173179.0 38229949_at 31.88 1.19e-07 1.31e-04 Homo sapiens cDNA FLJ33372 fis,clone Consensussequence Hs.325158.0 BRACE2005981. 39 232989_s_atDKFZp434G156 31.63 5.84e-08 7.60e-05 hypothetical proteinDKFZp434G156 7q33 Consensussequence Hs.7973.2 40 202634_at POLR2K31.62 3.35e-07 2.56e-04 polymerase (RNA) II (DNA directed)polypeptide 8q22.2 Consensussequence Hs.150675.0 K, 7.0 kDa 41209471_s_at FNTA 31.32 4.25e-07 2.92e-04 farnesyltransfarase, CAAXbox, alpha 8p22-q11 Exemplarsequence Hs.138381.0 42 227943_at 30.971.42e-07 1.39e-04 ESTs Consensussequence Hs.25933.0 43 225676_s_atDKFZP564O0463 30.83 4.57e-07 3.03e-04 DKFZP564O0463 protein 8q22.3Consensussequence Hs.273344.1 44 226942_at FLJ21615 30.69 4.97e-073.24e-04 hypothetical protein FLJ21615 8q24.22 ConsensussequenceHs.44159.0 45 224836_at C20orf110 30.47 1.30e-07 1.34e-04chromosome 20 open reading frame 110 20q11.22 ConsensussequenceHs.11114.0 46 201418_s_at SOX4 30.23 2.19e-07 1.86e-04 SRY (sexdetermining region Y)-box 4 6p22.3 Exemplarsequence Hs.83484.0 47214394_x_at EEF1D 29.84 5.95e-07 3.80e-04 eukaryotic translationelongation factor 1 delta 8q24.3 Consensussequence Hs.223241.1(guanine nucleotide exchange protein) 48 213204_at KIAA0708 29.594.13e-07 2.92e-04 KIAA0708 protein 6p21.1 ConsensussequenceHs.117177.0 49 213110_s_at COL4A5 29.53 2.62e-07 2.14e-04 collagen,type IV, alpha 5 (Alport syndrome) Xq22 ConsensussequenceHs.169825.0 50 203790_s_at UK114 29.51 8.76e-07 5.40e-04translational inhibitor protein p14.5 8q22 ConsensussequenceHs.18426.0 Sequence Sequence # Derived From Sequence ID SourceUnigene_Accession Cluster_Type LocusLink Full_Length_Reference_Seq1 NM_005567.2 g6006016 RefSeq Hs.79339 fulllength 3959 NM_005567;galectin 3 binding protein 2 BG168896 Hs.138381.1A1 GenBankHs.356463 fulllength 2339 NM_002027; famesyltransferase, CAAX box,alpha 3 NM_014754.1 g7662646 RefSeq Hs.77329 fulllength 9791NM_014754; phosphatidylserine synthase 1 4 AI924817 Hs.75737.2.S1GenBank Hs.75737 fulllength 5108 NM_006197; pericentriolar material1 5 NM_006265.1 g5453993 RefSeq Hs.81848 fulllength 5885 NM_006265;RAD21 homolog 6 NM_006294.1 g5454151 RefSeq Hs.131255 fulllength7381 NM_006294; ubiquinol-cytochrome c reductase binding protein 7AI972475 Hs.243901.0.S1 GenBank Hs.243901 fulllength 8 NM_014462.1g7657312 RefSeq Hs.425311 fulllength 27257 NM014462; Lsm1 protein 9NM_006197.1 g5453855 RefSeq Hs.75737 fulllength 5108 NM_006197;pericentriolar material 1 10 AV711345 Hs.10018.1.A1 GenBankHs.10018 fulllength 114926 NM_138436; hypothetical protein BC01303511 NM_004374.1 g4758039 RefSeq Hs.351875 fulllength 1345 NM_004374;cytochrome c oxidase subunit VIc proprotein 12 BC002456.1 g12803280GenBank 13 NM_020189.1 g9910185 RefSeq Hs.283740 fulllength 56943NM_020189; DC6 protein 14 BG168896 Hs.138381.1.A1 GenBank Hs.358463fulllength 2339 NM_002027; farnesyltransferase, CAAX box, alpha 15NM_016099.1 g7705820 RefSeq Hs.7953 fulllength 51125 NM_016099;HSPC041 protein 16 AI695007 Hs.159362.0.A1 GenBank Hs.159362 est 17BF446912 Hs.61455.0.A1 GenBank Hs.5123 fulllength 27068 NM_006903;inorganic pyrophosphatase 2 isoform 2 NM_176865; inorganicpyrophosphatase 2 isoform 1 NM_176866; inorganic pyrophosphatase 2isoform 3 NM_176867; inorganic pyrophosphatase 2 isoform 4NM_176869; inorganic pyrophosphatase 2 isoform 1 18 U43522.1g1165218 GenBank Hs.20313 fulllength 2185 NM_004103; PTK2B proteintyrosine kinase 2 beta isoform a NM_173174; PTK2B protein tyrosinekinase 2 beta isoform a NM_173175; PTK2B protein tyrosine kinase 2beta isoform b NM_173176; PTK2B protein tyrosine kinase 2 betaisoform a 19 BF435123 Hs.42179.0.A1 GenBank Hs.173179 20 BF982002Hs.6364.3.A1 GenBank Hs.334800 fulllength 84153 NM_032193;hypothetical protein FLJ20974 21 AI205598 Hs.75737.1.S1 GenBankHs.75737 fulllength 5108 NM_006197; pericentriolar material 1 22AI972475 Hs.243901.0.S1 GenBank Hs.243901 fulllength 23 AA976278Hs.227400.1_RC GenBank Hs.399720 fulllength 6202 NM_001012;ribosomal protein S8 24 U62136.2 g4775663 GenBank Hs.79300fulllength 7336 NM_003350; ubiquitin-conjugating enzyme E2 variant2 25 AW771952 Hs.191581.0_RC GenBank Hs.191581 26 AW611845Hs.198661.0_RC GenBank Hs.6600 fulllength 199986 NM_152661;hypothetical protein DKFZp761G0122 27 AA872727 Hs.48876.1 GenBankHs.48876 fulllength 2222 NM_004462; farnesyl-diphosphatefarnesyltransferase 1 28 S46622 4922761 GenBank Hs.75206 fulllength5533 NM_005605; protein phosphatase 3 (formerly 2B), catalyticsubunit, gamma isoform (calcineurin A gamma) 29 NM_005605.1g5031988 RefSeq Hs.75206 fulllength 5533 NM_005605; proteinphosphatase 3 (formerly 2B), catalytic subunit, gamma isoform(calcineurin A gamma) 30 BF435123 Hs.42179.0.A1 GenBank Hs.17317931 NM_018246.1 g8922717 RefSeq Hs.72085 fulllength 55246 NM_018246;hypothetical protein FLJ10853 32 NM_005648.1 g5032160 RefSeqHs.184693 fulllength 6921 NM_005648; elongin C 33 NM_006837.1g5803045 RefSeq Hs.380969 fulllenglh 10987 NM_006837; COP9constitutive photomorphogenic homolog subunit 5 34 NM_004215.1g4758229 RefSeq Hs.9222 fulllength 9166 NM_004215; estrogenreceptor binding site associated antigen 9 35 NM_018009.1 g8922253RefSeq Hs.267993 fulllength 55080 NM_018009; TAP binding proteinrelated 36 NM_006470.1 g5453643 RefSeq Hs.241305 fulllength 10626NM_006470; tripartite motif-containing 16 37 BF029215Hs.173179.0.S1 GenBank Hs.103512 fulllength 124540 NM_138962;musashi 2 isoform a NM_170721; musashi 2 isoform b 38 AA554827Hs.325158.0_RC GenBank Hs.370705 39 AK023500.1 Hs.7973.2 GenBankHs.7973 fulllength 64753 NM_022742; hypothetical proteinDKFZp434G156 40 AL558030 Hs.150675.0 GenBank Hs.351475 fulllength5440 NM_005034; DNA directed RNA polymerase II polypeptide K 41L00634.1 g292030 GenBank Hs.356463 fulllength 2339 NM_002027;farnesyltransferase, CAAX box, alpha 42 AI798680 Hs.25933.0_RCGenBank Hs.445018 est 43 AK001693.1 Hs.273344.1 GenBank Hs.273344fulllength 25879 NM_014156; NM_015420; DKFZP564O0463 protein 44AI742668 Hs.44159.0.S1 GenBank Hs.44159 fulllength 84165 NM_032205;hypothetical protein FLJ21615 45 AL109824 Hs.11114.0.A1 GenBankHs.11114 fulllength 58476 46 NM_003107.1 g4507162 RefSeq Hs.83484fulllength 6659 NM_003107; SRY (sex determining region Y)-box 4 47AI613383 Hs.223241.1.A1 GenBank Hs.334798 fulllength 1936NM_001960; eukaryotic translation elongation factor 1 delta isoform2 NM_032378; eukaryotic translation elongation factor 1 deltaisoform 1 48 AB014608.1 Hs.117177.0 GenBank Hs.117177 fulllength23113 NM_015089; p53-associated parkin-like cytoplasmic protein 49AW052179 HS.169825.0_RC GenBank Hs.169825 fulllength 1287NM_000495; alpha 5 type IV collagen isoform 1, precursor NM_033380;alpha 5 type IV collagen isoform 2, precursor NM_033381; alpha 5type IV collagen isoform 3, precursor 50 N54448 Hs.18426.0.S1GenBank Hs.18426 fulllength 10247 NM_005836; translationalinhibitor protein p14.5

TABLE-US-00021 TABLE 20 _ALL Sequence # affy id HUGO name TitleMapLocation Sequence Type Transcript ID Derived From 1 201398_s_atTRAM translocating chain-associating membrane 8q13.1Exemplarsequence Hs.4147.0 BC000687.1 protein 2 203208_s_at CHPPRlikely ortholog of chicken chondrocyte 8q12.1 ExemplarsequenceHs.170198.0 NM_014637.1 protein with a poly-protine region 3235509_at MGC40214 hypothetical protein MGC40214 8q22.1Consensussequence Hs.98471.0 AV662196 Sequence # Sequence ID SourceUnigene_Accession Cluster_Type LocusLink Full_Length_Reference_Seq1 g12653796 GenBank Hs.4147 fulllength 23471 NM_014294;translocating chain- associating membrane protein 2 g7661853 RefSeqHs.170198 fulllength 9650 NM_014637; KIAA0009 gene product 3Hs.98471.0_RC GenBank Hs.98471 est 137682 NM_152416; hypotheticalprotein MGC40214

TABLE-US-00022 TABLE 21 _t(8; 21) # affy id HUGO name F p q Title 1218273_s_at PDP 181.63 9.58e-16 4.30e-11 pyruvate dehydrogenasephosphatase 2 220572_at DKFZp547G183 112.74 8.42e-13 1.89e-08hypothetical protein DKFZp547G183 3 219433_at BCoR 106.17 1.54e-122.30e-08 BCL-6 interacting corepressor 4 202126_at PRPF4B 92.111.61e-09 5.88e-06 PRP4 pre-mRNA processing factor 4 homolog B(yeast) 5 230541_at LOC149134 81.98 5.38e-11 6.04e-07 hypotheticalprotein LOC149134 6 201562_s_at SORD 81.30 1.51e-10 1.36e-06sorbitol dehydrogenase 7 208883_at DD5 80.56 2.10e-03 6.97e-02progestin induced protein 8 228188_at FLJ23306 79.92 4.38e-042.42e-02 hypothetical protein FLJ23306 9 225102_at LOC152009 70.051.29e-09 5.80e-06 hypothetical protein LOC152009 10 211622_s_atARF3 67.82 3.23e-09 9.67e-06 ADP-ribosylation factor 3 11200051_at- SART1 67.41 6.47e-10 4.84e-06 squamous cell carcinomaantigen HG-U133A recognised by T cells 12 203441_s_at CDH2 66.138.62e-10 4.84e-06 cadherin 2, type 1, N-cadherin (neuronal) 13239397_at 66.03 5.46e-04 2.82e-02 Homo sapiens cDNA FLJ36260 fis,clone THYMU2002548. 14 204811_s_at CACNA2D2 65.76 8.22e-10 4.84e-06calcium channel, voltage-dependent, alpha 2/delta subunit 2 15224019_at FLJ21032 65.17 1.01e-08 2.01e-05 hypothetical proteinFLJ21032 16 210465_s_at SNAPC3 64.38 1.09e-09 5.45e-06 smallnuclear RNA activating complex, polypeptide 3, 50 kDa 17 232647_atMGC39650 64.25 1.61e-09 5.88e-06 hypothetical protein MGC39650 18240178_at 64.24 3.92e-06 1.12e-03 ESTs 19 218704_at FLJ20315 63.988.61e-08 1.14e-04 hypothetical protein FLJ20315 20 204198_s_atRUNX3 62.56 1.32e-04 1.12e-02 runt-related transcription factor 321 203756_at P164RHOGEF 61.93 1.70e-09 5.88e-06 Rho-specificguanine-nucleotide exchange factor 164 kDa 22 207866_at BMP8 60.302.58e-09 8.27e-06 bone morphogenetic protein 8 (osteogenic protein2) 23 213301_x_at TIF1 59.60 2.85e-08 4.41e-05 transcriptionalintermediary factor 1 24 224855_at P5CR2 59.13 1.19e-08 2.23e-05pyrroline 5-carboxylate reductase isoform 25 213151_s_at CDC1058.86 1.77e-04 1.35e-02 CDC10 cell division cycle 10 homolog (S.cerevisiae) 26 228225_at PXMP3 58.64 4.06e-04 2.32e-02 peroxisomalmembrane protein 3, 35 kDa (Zellweger syndrome) 27 233955_x_atHSPC195 58.61 1.78e-03 6.23e-02 hypothetical protein HSPC195 28213070_at 58.02 4.65e-07 3.12e-04 Homo sapiens mRNA; cDNADKFZp564L222 (from clone DKFZp564L222) 29 224975_at NFIA 57.974.57e-09 1.28e-05 nuclear factor I/A 30 236530_at 57.20 2.19e-041.53e-02 ESTs 31 210935_s_at WDR1 56.83 5.06e-09 1.34e-05 WD repeatdomain 1 32 219461_at PAK6 56.43 2.53e-05 3.57e-03p21(CDKN1A)-activated kinase 6 33 236035_at 56.38 6.45e-09 1.52e-05ESTs 34 219075_at MGC3262 55.31 6.38e-09 1.52e-05 hypotheticalprotein MGC3262 35 237839_at 54.59 7.47e-09 1.68e-05 ESTs 36217699_at 54.59 2.05e-08 3.57e-05 ESTs, Weakly similar to cytokinereceptor- like factor 2; cytokine receptor CRL2 precusor [Homosapiens] [H. sapiens] 37 222461_s_at HERC2 53.61 9.15e-09 1.96e-05hect domain and RLD 2 38 230093_at TSGA2 53.37 1.03e-08 2.01e-05testes specific A2 homolog (mouse) 39 221502_at KPNA3 53.215.79e-04 2.92e-02 karyopherin alpha 3 (importin alpha 4) 40205977_s_at EPHA1 52.63 10.00e-08 1.18e-04 EphA1 41 205054_at NEB52.36 2.73e-05 3.74e-03 nebulin 42 236777_at LOC221584 51.921.96e-06 6.88e-04 hypothetical protein LOC221584 43 223158_s_atNEK6 51.12 1.81e-06 6.66e-04 NIMA (never in mitosis gene a)-relatedkinase 6 44 205240_at LGN 50.96 2.07e-08 3.57e-05 LGN protein 45214857_at 49.60 1.72e-04 1.33e-02 Homo sapiens mRNA; cDNADKFZp566H0124 (from clone DKFZp566H0124) 46 218199_s_at NOL6 49.566.07e-06 1.44e-03 nucleolar protein family 6 (RNA-associated) 47218620_s_at HEMK 49.50 8.03e-08 1.13e-04 HEMK homolog 7 kb 48221837_at FLJ14360 49.50 2.22e-08 3.70e-05 hypothetical proteinFLJ14360 49 217566_s_at TGM4 49.34 3.68e-07 2.71e-04transglutaminase 4 (prostate) 50 227152_at FLJ20696 49.23 4.39e-042.42e-02 hypothetical protein FLJ20696 # MapLocation Sequence TypeTranscript ID 1 8q21.3 Exemplarsequence Hs.22265.0 2 11q13.5Exemplarsequence Hs.283631.0 3 Xp11.4 Exemplarsequence Hs.278732.04 6p25.1 Consensussequence Hs.198891.0 5 1q44 ConsensussequenceHs.61829.0 6 15q15.3 Exemplarsequence Hs.878.0 7 8q22Consensussequence Hs.278428.0 8 2p23.3 Consensussequence Hs.5890.09 3q21.3 Consensussequence Hs.3964.0 10 12q13 Exemplarsequenceg178980 11 11q13.1 Exemplarsequence Hs.288319.0 12 18q11.2Exemplarsequence Hs.161.0 13 Consensussequence Hs.202402.0 143p21.3 Exemplarsequence Hs.127436.0 15 4q21.22 ExemplarsequenceHs.247474.1 16 9p22.2 Exemplarsequence Hs.164915.1 17 17q11.1Consensussequence Hs.258890.0 18 Consensussequence Hs.9451.0 1917q23.2 Exemplarsequence Hs.18457.0 20 1p36 ConsensusequenceHs.170019.0 21 11q13.2 Exemplarsequence Hs.45180.0 22 1p35-p32Exemplarsequence Hs.99948.0 23 7q32-q34 ConsensussequenceHs.183858.1 24 1q42.13 Consensussequence Hs.274287.0 257p14.3-p14.1 Consensussequence Hs.184326.1 26 8q21.1Consensussequence Hs.180612.2 27 5q31.3 ConsensussequenceHs.15093.1 28 Consensussequence Hs.5848.0 29 1p31.3-p31.2Consensussequence Hs.173933.0 30 Consensussequence Hs.288410.0 314p16.1 Exemplarsequence Hs.326791.0 32 15q14 ConsensussequenceHs.21420.0 33 Consensussequence Hs.65788.0 34 19p13.13Exemplarsequence Hs.323213.0 35 Consensussequence Hs.233301.0 36Consensussequence Hs.286243.0 37 15q13 ConsensussequenceHs.266933.0 38 21q22.3 Consensussequence Hs.7369.0 39 13q14.3Consensussequence Hs.3886.0 40 7q32-q36 Exemplarsequence Hs.89839.041 2q22 Exemplarsequence Hs.83870.0 42 6p21.33 ConsensussequenceHs.124603.0 43 9q33.3-q34.11 Consensussequence Hs.9625.2 44 1p13.2Exemplarsequence Hs.278338.0 45 Consensussequence Hs.133130.1 469p13.2 Exemplarsequence Hs.183253.0 47 3p21.3 ExemplarsequenceHs.46907.0 48 22q11.21 Consensussequence Hs.181341.1 49 3p22-p21.33Consensussequence Hs.289803.0 50 Consensussequence Hs.323822.0Sequence Sequence # Derived From Sequence ID SourceUnigene_Accession Cluster_Type LocusLink 1 NM_018444.1 g8923959RefSeq Hs.22265 fulllength 54704 2 NM_018705.1 g8922152 RefSeqHs.283631 fulllength 55525 3 NM_017745.1 g8923266 RefSeq Hs.130732fulllength 54880 4 AA156948 Hs.198891.0.S2 GenBank Hs.198891fulllength 8899 5 AU150080 Hs.61829.0 GenBank Hs.417101 149134 6NM_003104.1 g4507154 RefSeq Hs.876 fulllength 6652 7 U69567Hs.278428.0.A2 GenBank Hs.278428 fulllength 51366 8 AI860150Hs.5890.0_RC GenBank Hs.5890 fulllength 79579 9 BG168471 Hs.3964.0GenBank Hs.3964 152009 10 M33384.1 g178980 GenBank Hs.119177fulllength 377 11 NM_005146.1 g10863888 RefSeq Hs.288319 fulllength9092 12 NM_001792.1 g4502720 RefSeq Hs.161 fulllength 1000 13AW390251 Hs.202402.0_RC GenBank Hs.202402 14 NM_006030.1 g5174402RefSeq Hs.127436 fulllength 9254 15 BC004936.1 g13436280 GenBankHs.379191 fulllength 79966 16 U71300.1 g1619945 GenBank Hs.164915fulllength 6619 17 AL137531.1 Hs.258890.0 GenBank Hs.207471fulllength 147011 18 H63394 Hs.9451.0.A1 GenBank Hs.334792 est 19NM_017763.1 g8923298 RefSeq Hs.18457 fulllength 54894 20 AA541630Hs.170019.0.S1 GenBank Hs.170019 fulllength 864 21 NM_014786.1g7662063 RefSeq Hs.45180 fulllength 9828 22 NM_001720.1 g4502428RefSeq Hs.99948 fulllength 656 23 AL538264 Hs.183858.1 GenBankHs.183858 fulllength 8805 24 AL561868 Hs.274287.0 GenBank Hs.274287fulllength 29920 25 AU157515 Hs.184326.1.S1 GenBank Hs.184326fulllength 989 26 AW512586 Hs.180612.2.A1 GenBank Hs.180612fulllength 5828 27 AK001782.1 Hs.15093.1 GenBank Hs.15093fulllength 51523 28 AV682436 Hs.5848.0.S1 GenBank Hs.336446 29AK024964.1 Hs.173933.0 GenBank Hs.173933 fulllength 4774 30BF589826 Hs.288410.0_RC GenBank Hs.288410 est 31 AF274954.1g12751070 GenBank Hs.85100 fulllength 9948 32 AJ236915.1 Hs.21420.0GenBank Hs.21420 fulllength 56924 33 AW190406 Hs.65788.0.A1 GenBankHs.435027 est 34 NM_024029.1 g13128975 RefSeq Hs.323213 fulllength78992 35 BF433975 Hs.233301.0.A1 GenBank Hs.436623 est 36 AV700338Hs.286243.0 GenBank Hs.286243 est 37 BE671173 Hs.266933.0 GenBankHs.266933 fulllength 8924 38 AI683428 Hs.7369.0.A1 GenBank Hs.7369fulllength 89765 39 AL120704 Hs.3886.0.A2 GenBank Hs.3886fulllength 3839 40 NM_005232.1 g4885208 RefSeq Hs.89839 fulllength2041 41 NM_004543.2 g8400716 RefSeq Hs.83870 4703 42 AA854843Hs.124603.0_RC GenBank Hs.124603 221584 43 BE616825 Hs.9625.2.S1GenBank Hs.9625 fulllength 10783 44 NM_013296.1 g9558734 RefSeqHs.278338 fulllength 29899 45 AL050035.1 Hs.133130.1 GenBankHs.133130 46 NM_022917.1 g12597664 RefSeq Hs.183253 fulllength65083 47 AF131220.1 g4589247 GenBank Hs.46907 fulllength 51409 48BG325646 Hs.181341.1_RC GenBank Hs.347964 fulllength 84861 49BF222018 Hs.289803.0.A1 GenBank Hs.2387 est 7047 50 AI979334Hs.323822.0_RC GenBank Hs.323822 55019 # Full_Length_Reference_Seq1 NM_018444; pyruvate dehydrogenase phosphatase 2 NM_018705;hypothetical protein DKFZp547G183 3 NM_017745; BCL-6 interactingcorepressor isoform 1 NM_020926; BCL-6 interacting corepressorisoform 2 4 NM_003913; serine/threonine-protein kinase PRP4KNM_176800; serine/threonine-protein kinase PRP4K 5 6 NM_003104;sorbitol dehydrogenase 7 NM_015902; progestin induced protein 8NM_024530; hypothetical protein FLJ23306 9 10 NM_001659;ADP-ribosylation factor 3 11 NM_005146; squamous cell carcinomaantigen recognized by T cells 1 12 NM_001792; cadherin 2, type 1preproprotein 13 14 NM_006030; calcium channel, voltage-dependent,alpha 2/delta subunit 2 15 NM_024906; hypothetical protein FLJ2103216 NM_003084; small nuclear RNA activating complex, polypeptide 3,50 kDa 17 NM_152465; hypothetical protein MGC39650 18 19 NM_017763;hypothetical protein FLJ20315 20 NM_004350; runt-relatedtranscription factor 3 21 NM_014786; Rho-specificguanine-nucleotide exchange factor 164 kDa 22 NM_001720; bonemorphogenetic protein 8 preproprotein 23 NM_003852; transcriptionalintermediary factor 1 24 NM_013328; pyrroline 5-carboxylatereductase isoform 25 NM_001788; cell division cycle 10 26NM_000318; peroxisomal membrane protein 3 27 NM_016463;hypothetical protein HSPC195 28 29 NM_005595; nuclear factor I/A 3031 NM_005112; WD repeat-containing protein 1 isoform 2

NM_017491; WD repeat-containing protein 1 isoform 1 32 NM_020168;p21-activated kinase 6 33 34 NM_024029; hypothetical proteinMGC3262 35 36 37 NM_004667; hect domain and RLD 2 38 NM_080860;testes specific A2 homolog 39 NM_002267; karyopherin alpha 3 40NM_005232; EphA1 41 NM_004543; nebulin 42 43 NM_014397; putativeserine-threonine protein kinase 44 NM_013296; LGN protein 45 46NM_022917; nucleolar RNA-associated protein alpha isoformNM_130793; nucleolar RNA-associated protein beta isoform NM_139235;nucleolar RNA-associated protein gamma isoform 47 NM_016173; HEMKhomolog 7 kb 48 NM_032775; hypothetical protein FLJ14360 49NM_003241; transglutaminase 4 (prostate) 50

TABLE-US-00023 TABLE 22 _t(8; 21) # affy Id HUGO name TitleMapLocation 1 230746_s_at STC1 stanniocalcin 1 8p21-p11.2 2239860_at ESTs 3 224316_at FLJ20038 hypothetical protein FLJ200388p21.1 4 228615_at LOC286161 hypothetical protein LOC286161 8p23.35 228013_at Homo sapiens mRNA; cDNA DKFZp586F1523 (from cloneDKFZp586F1523) 6 202035_s_at SFRP1 secreted frizzled-relatedprotein 1 8p12-p11.1 7 204865_at CA3 carbonic anhydrase III, musclespecific 8q13-q22 8 230361_at ESTs, Weakly similar to innercentromere protein [Mus musculus] [M. musculus] 9 231268_at Homosapiens , clone IMAGE: 5222754, mRNA, partial cds 10 223907_s_atPINX1 PIN2-interacting protein 1 8p23 11 206574_s_at PTP4A3 proteintyrosine phosphatase type IVA, member 3 12 219060_at FLJ10204hypothetical protein FLJ10204 8q24.13 13 202873_at Homo sapienscDNA FLJ33383 fis, clone BRACE2006514. 14 238229_at ESTs 15218273_s_at PDP pyruvate dehydrogenase phosphatase 8q21.3 16222051_s_at E2F5 E2F transcription factor 5, p130-binding 8q21.1317 209928_s_at MSC musculin (activated B-cell factor-1) 8q21 18230661_at Homo sapiens mRNA; cDNA DKFZp667P166 (from cloneDKFZp667P166) 19 206222_at TNFRSF10C tumor necrosis factor receptorsuperfamily, member 10c, decoy without an intracellular domain8p22-p21 20 211489_at ADRA1A adrenergic, alpha-1A-, receptor8p21-p11.2 21 218777_at FLJ22246 hypothetical protein FLJ222468p21.2 22 212166_at XPO7 exportin 7 8p21 23 229758_at TIGD5 tiggertransposable element derived 5 8q24.3 24 219231_at NCOA6IP nuclearreceptor coactivator 6 interacting 8q11 protein 25 227017_atLOC157697 hypothetical protein LOC157697 8p23.3 26 225053_at CNOT7CCR4-NOT transcription complex, subunit 7 8p22-p21.3 27 218337_atRAI16 retinoic acid induced 16 8p21.2 28 227263_at FLJ34715hypothetical protein FLJ34715 8p21.2 29 209253_at SCAM-1 vinexinbeta (SH3-containing adaptor 8p21.2 molecule-1) 30 224413_s_at BLP1BBP-like protein 1 8p11.21 31 216865_at COL14A1 collagen, type XIV,alpha 1 (undulin) 8q23 32 205849_s_at UQCRB ubiquinol-cytochrome creductase binding 8q22 protein 33 222863_at RINZF zinc fingerprotein RINZF 8q13-q21.1 34 235210_s_at FLJ40021 hypotheticalprotein FLJ40021 8q13.2 35 220984_s_at OATPRP4 organic aniontransporter polypeptide- 8q13.1 related protein 4 36 210614_at TTPAtocopherol (alpha) transfer protein (ataxia 8q13.1-q13.3(Friedreich-like) with vitamin E deficiency) 37 238458_at LOC286097hypothetical protein LOC286097 8p22 38 241371_at ESTs 39223819_x_at HT002 HT002 protein; hypertension-relatedcalcium-regulated gene 8q24-qter 40 223687_s_at HSJ001348 cDNA fordifferentially expressed CO16 8q24.3 gene 41 227836_at 42 214708_atSNTB1 syntrophin, beta 1 (dystrophin-associated protein A1, 59 kDa,8q23-q24 basic component 1) 43 203987_at FZD6 frizzled homolog 6(Drosophila) 8q22.3-q23.1 44 221020_s_at MFTC mitochondrial folatetransporter/carrier 8q22.3 45 238807_at Homo sapiens , clone IMAGE:3957507, mRNA 46 227001_at Homo sapiens cDNA: FLJ21362 fis, cloneCOL02886. 47 222665_at CGI-90 CGI-90 protein 8q21.13 48 228225_atPXMP3 peroxisomal membrane protein 3, 35 kDa (Zellweger syndrome)8q21.1 49 205950_s_at CA1 carbonic anhydrase I 8q13-q22.1 50220405_at SNTG1 syntrophin, gamma 1 8q11-q12 51 237802_at KIAA1889KIAA1889 protein 8q11.22 52 212523_s_at KIAA0146 KIAA0146 protein8q11.21 53 230411_at UBE2V2 ubiquitin-conjugating enzyme E2 variant2 8q11.1 54 213139_at SNAI2 snail homolog 2 (Drosophila) 8q11 55236556_s_at FLJ23749 hypothetical protein FLJ23749 8p22 56216620_s_at ARHGEF10 Rho guanine nucleotide exchange factor 8p23(GEF) 10 57 218978_s_at MSCP mitochondrial solute carrier protein8p21.2 58 204505_s_at EPB49 erythrocyte membrane protein band 4.98p21.1 (dematin) 59 205574_x_at BMP1 bone morphogenetic protein 18p21 60 221805_at NEFL neurofilament, light polypeptide 68 kDa 8p2161 205667_at WRN Werner syndrome 8p12-p11.2 62 219124_at FLJ23263hypothetical protein FLJ23263 8p11.23 63 223976_at FUT10fucosyltransferase 10 (alpha (1,3) 8p11.23 fucosyltransferase) 64215404_x_at FGFR1 fibroblast growth factor receptor 1 (fms-relatedtyrosine kinase 2, Pfeiffer 8p11.2-p11.1 syndrome) 65 221814_atGPR124 G protein-coupled receptor 124 8p11.1 66 205390_s_at ANK1ankyrin 1, erythrocytic 8p11.1 67 226547_at Homo sapiens mRNA fulllength insert cDNA clone EUROIMAGE 1476475 68 209781_s_at KHDRBS3KH domain containing, RNA binding, signal transduction associated 38q24.2 69 201644_at TSTA3 tissue specific transplantation antigen8q24.3 P35B Sequence # Sequence Type Transcript ID Derived FromSequence ID 1 Consensussequence Hs.25590.1 AW003173 Hs.25590.1.A1 2Consensussequence Hs.16292.0 AI311917 Hs.16292.0.A1 3Exemplarsequence Hs.72071.1 AF130091.1 g11493486 4Consensussequence Hs.13477.0 AW291761 Hs.13477.0_RC 5Consensussequence Hs.61696.0 AV702575 Hs.61696.0_RC 6Consensussequence Hs.7306.0 AI332407 Hs.7306.0.A1 7Exemplarsequence Hs.82129.0 NM_005181.2 g6996001 8Consensussequence Hs.146109.0 AW664013 Hs.146109.0_RC 9Consensussequence Hs.144027.0 AI539459 Hs.144027.0.A1 10Exemplarsequence Hs.99829.0 AF205718.1 g10504237 11Exemplarsequence Hs.43666.0 NM_007079.1 g6857821 12Exemplarsequence Hs.18029.0 NM_018024.1 g8922280 13Consensussequence Hs.86905.0 NM_001695.1 Hs.86905.0 14Consensussequence Hs.116240.0 AI187388 Hs.116240.0.A1 15Exemplarsequence Hs.22265.0 NM_018444.1 g8923959 16Consensussequence Hs.2331.2 AW139195 Hs.2331.2 17 ExemplarsequenceHs.42474.0 AF060154.1 g3089604 18 Consensussequence Hs.194024.0AW451999 Hs.194024.0_RC 19 Exemplarsequence Hs.119684.0 NM_003841.1g10835042 20 Exemplarsequence Hs.52931.0 D32201.1 g927210 21Exemplarsequence Hs.289063.0 NM_025232.1 g13376835 22Consensussequence Hs.172685.0 H38643 Hs.172685.0 23Consensussequence Hs.71574.0 AW168771 Hs.71574.0 24Exemplarsequence Hs.179909.0 NM_024831.1 g13376235 25Consensussequence Hs.193090.0 AA767385 Hs.193090.0.A1 26Consensussequence Hs.226318.1 W94952 Hs.226318.1.A2 27Exemplarsequence Hs.299148.0 NM_022749.1 g12232410 28Consensussequence Hs.296360.0 AL519427 Hs.296360.0.S1 29Exemplarsequence Hs.33787.1 AF037261.1 g3004947 30 Exemplarsequenceg13625460 AF353991.1 g13625460 31 Consensussequence Hs.36131.2M64108.1 Hs.36131.2.S1 32 Exemplarsequence Hs.131255.0 NM_006294.1g5454151 33 Consensussequence Hs.237146.0 BG483802 Hs.237146.0.S234 Consensussequence Hs.122544.0 AW662373 Hs.122544.0_RC 35Exemplarsequence g13569931 NM_030958.1 g13569931 36Exemplarsequence Hs.69049.0 U21938.1 g726181 37 ConsensussequenceHs.131044.0 AI868167 Hs.131044.0.S1 38 Consensussequence Hs.57851.0AW451259 Hs.57851.0.A1 39 Exemplarsequence Hs.238928.0 BC003055.1g12804384 40 Consensussequence Hs.69517.0 AA723810 Hs.69517.0_RC 41Consensussequence Hs.86970.0 AI859767 Hs.86970.0.A1 42Consensussequence Hs.95011.2 BG484314 Hs.95011.2 43Exemplarsequence Hs.114218.0 NM_003506.1 g4503830 44Exemplarsequence g13540550 NM_030780.1 g13540550 45Consensussequence Hs.291531.0 AW973964 Hs.291531.0_RC 46Consensussequence Hs.167011.0 AI096706 Hs.167011.0 47Consensussequence Hs.44222.0 AK000672.1 Hs.44222.0 48Consensussequence Hs.180612.2 AW512586 Hs.180612.2.A1 49Exemplarsequence Hs.23118.0 NM_001738.1 g4502516 50Exemplarsequence Hs.167481.0 NM_018967.1 g9507162 51Consensussequence Hs.13390.0 R54212 Hs.13390.0.A1 52Consensussequence Hs.278634.0 D63480.1 Hs.278634.0_RC 53Consensussequence Hs.43569.0 AI800998 Hs.43569.0_RC 54Consensussequence Hs.93005.0 AI572079 Hs.93005.0 55Consensussequence Hs.174201.0 AV650622 Hs.174201.0_RC 56Consensussequence Hs.20695.1 AF009205.1 Hs.20695.1 57Exemplarsequence Hs.283716.0 NM_018586.1 g8924059 58Exemplarsequence Hs.274122.0 NM_001978.1 g4503580 59Exemplarsequence Hs.1274.0 NM_001199.1 g4502420 60Consensussequence Hs.211584.0 NM_006158.1 Hs.211584.0_RC 61Exemplarsequence Hs.150477.0 NM_000553.1 g5739523 62Exemplarsequence Hs.288716.0 NM_025115.1 g13376690 63Exemplarsequence Hs.326744.0 BC004884.1 g13436133 64Consensussequence Hs.306678.0 AK024388.1 Hs.306678.0.S1 65Consensussequence Hs.17270.0 BF511315 Hs.17270.0 66Exemplarsequence Hs.183805.0 NM_000037.2 g10947039 67Consensussequence Hs.93231.0 AI817830 Hs.93231.0.A1 68Exemplarsequence Hs.13565.0 AF069681.1 g3273831 69 ExemplarsequenceHs.264428.0 NM_003313.2 g6598326 Sequence # SourceUnigene_Accession Cluster_Type LocusLink Full_Length_Reterence_Seq1 GenBank Hs.25590 fulllength 6781 NM_003155; stanniocalcin 1 2GenBank Hs.16292 est 3 GenBank Hs.72071 fulllength 54793 NM_017634;hypothetical protein FLJ20038 4 GenBank Hs.13477 286161 5 GenBankHs.61696 6 GenBank Hs.7306 fulllength 6422 NM_003012; secretedfrizzled-related protein 1 7 RefSeq Hs.82129 fulllength 761NM_005181; carbonic anhydrase III 8 GenBank Hs.443139 est 9 GenBantHs.144027 10 GenBank Hs.400259 fulllength 54984 NM_017884;PIN2-interacting protein 1 11 RefSeq Hs.43666 fulllength 11156NM_007079; protein tyrosine phosphatase type IVA, member 3 isoform2 NM_032611; protein tyrosine phosphatase type IVA, member 3isoform 1 12 RefSeq Hs.18029 fulllength 55093 NM_018024;hypothetical protein FLJ10204 13 GenBank Hs.290880 14 GenBankHs.116240 est 15 RefSeq Hs.22265 fulllength 54704 NM_018444;pyruvate dehydrogenase phosphatase 16 GenBank Hs.2331 fulllength1875 NM_001951; E2F transcription factor 5 17 GenBank Hs.42474fulllength 9242 NM_005098; musculin (activated B-cell factor-1) 18GenBank Hs.407120 19 RefSeq Hs.119684 fulllength 8794 NM_003841;tumor necrosis factor receptor superfamily, member 10c precursor 20GenBank Hs.52931 fulllength 148 NM_000680; alpha-1A-adrenergicreceptor isoform 1 NM_033302; alpha-1A- adrenergic receptor isoform3 NM_033303; alpha-1A-adrenergic receptor isoform 2 NM_033304;alpha-1A-adrenergic receptor isoform 4 21 RefSeq Hs.289063fulllength 80346 NM_025232; hypothetical protein FLJ22246 22GenBank Hs.172685 fulllength 23039 NM_015024; exportin 7 23 GenBankHs.71574 fulllength 84948 NM_032862; tigger transposable elementderived 5 24 RefSeq Hs.179909 fulllength 96764 NM_024831;PRIP-interacting protein PIPMT 25 GenBank Hs.377879 fulllength157697 26 GenBank Hs.380963 fulllength 29883 NM_013354; CCR4-NOTtranscription complex, subunit 7 isoform 1 NM_054026; CCR4-NOTtranscription complex, subunit 7 isoform 2 27 RefSeq Hs.299148fulllength 64760 NM_022749; retinoic acid induced 16 28 GenBankHs.375560 fulllength 286057 NM_173686; hypothetical proteinFLJ34715 29 GenBank Hs.33787 fulllength 10174 NM_005775; vinexinbeta (SH3-containing adaptor molecule-1) 30 GenBank Hs.7471fulllength 83877 NM_031940; BBP-like protein 1 isoform b NM_078473;BBP-like protein 1 isoform a 31 GenBank Hs.403836 fulllength 737332 RefSeq Hs.131255 fulllength 7381 NM_006294; ubiquinol-cytochromec reductase binding protein 33 GenBank Hs.237146 fulllength 65986NM_023929; zinc finger protein RINZF 34 GenBank Hs.41185 fulllength157869 NM_153225; hypothetical protein FLJ40021 35 RefSeq Hs.199750fulllength 81796 NM_030958; organic anion transporterpolypeptide-related protein 4 36 GenBank Hs.69049 fulllength 7274NM_000370; tocopherol (alpha) transfer protein (ataxia(Friedreich-like) with vitamin E deficiency) 37 GenBank Hs.131044fulllength 286097 38 GenBank Hs.444578 est 39 GenBank Hs.238928fulllength 28991 NM_014066; hypertension-related

calcium-regulated gene 40 GenBank Hs.69517 fulllength 54742NM_017527; cDNA for differentially expressed CO16 gene 41 GenBank42 GenBank Hs.95011 fulllength 6641 NM_021021; basic beta 1syntrophin 43 RefSeq Hs.114218 fulllength 8323 NM_003506; frizzled6 44 RefSeq Hs.196270 fulllength 81034 NM_030780; mitochondrialfolate transporter/carrier 45 GenBank Hs.291531 46 GenBankHs.167011 47 GenBank Hs.44222 fulllength 51115 NM_016033; CGI-90protein 48 GenBank Hs.180612 fulllength 5828 NM_000318; peroxisomalmembrane protein 3 49 RefSeq Hs.23118 fulllength 759 NM_001738;carbonic anhydrase 1 50 RefSeq Hs.167481 fulllength 54212NM_018967; syntrophin, gamma 1 51 GenBank Hs.13390 114786 52GenBank Hs.278634 23514 53 GenBank Hs.79300 fulllength 7336NM_003350; ubiquitin-conjugating enzyme E2 variant 2 54 GenBankHs.93005 fulllength 6591 NM_003068; snail 2 55 GenBank Hs.180178fulllength 91694 NM_152271; hypothetical protein FLJ23749 56GenBank Hs.20695 fulllength 9639 NM_014629; Rho guanine nucleotideexchange factor 10 57 RefSeq Hs.283716 fulllength 51312 NM_016612;mitochondrial solute carrier protein NM_018579; mitochondrialsolute carrier protein 58 RefSeq Hs.274122 fulllength 2039NM_001978; erythrocyte membrane protein band 4.9 (dematin) 59RefSeq Hs.1274 fulllength 649 NM_001199; bone morphogenetic protein1 isoform 1, precursor NM_006128; bone morphogenetic protein 1isoform 2, precursor NM_006129; bone morphogenetic protein 1isoform 3, precursor NM_006130; bone morphogenetic protein 1isoform 6 precursor NM_006131; bone morphogenetic protein 1 isoform5, precursor NM_006132; bone morphogenetic protein 1 isoform 4,precursor 60 GenBank Hs.211584 fulllength 4747 NM_006158;neurofilament, light polypeptide 68 kDa 61 RefSeq Hs.150477fulllength 7486 NM_000553; Werner syndrome protein 62 RefSeqHs.288716 fulllength 80185 NM_025115; hypothetical protein FLJ2326363 GenBank Hs.326744 fulllength 84750 NM_032664; fucosyltransferase10 64 GenBank Hs.748 fulllength 2260 NM_000604; fibroblast growthfactor receptor 1 isoform 1 precursor NM_015850; fibroblast growthfactor receptor 1 isoform 2 precursor NM_023105; fibroblast growthfactor receptor 1 isoform 3 precursor NM_023106; fibroblast growthfactor receptor 1 isoform 4 precursor NM_023107; fibroblast growthfactor receptor 1 isoform 5 precursor NM_023108; fibroblast growthfactor receptor 1 isoform 6 precursor NM_023109; fibroblast growthfactor receptor 1 isoform 7 precursor NM_023110; fibroblast growthfactor receptor 1 isoform 8 precursor NM_023111; fibroblast growthfactor receptor 1 isoform 9 precursor 65 GenBank Hs.17270fulllength 25960 NM_032777; G protein-coupled receptor 124 66RefSeq Hs.183805 fulllength 286 NM_000037; ankyrin 1 isoform 3NM_020475; ankyrin 1 isoform 4 NM_020476; ankyrin 1 isoform 1NM_020477; ankyrin 1 isoform 2 NM_020478; ankyrin 1 isoform 5NM_020479; ankyrin 1 isoform 6 NM_020480; ankyrin 1 isoform 7NM_020481; ankyrin 1 isoform 8 67 GenBank Hs.93231 68 GenBankHs.13565 fulllength 10656 NM_006558; KH domain containing, RNAbinding, signal transduction associated 3 69 RefSeq Hs.404119fulllength 7264 NM_003313; tissue specific transplantation antigenP35B

TABLE-US-00024 TABLE 23 _t(15; 17) # affy id HUGO name F p q TitleMapLocation Sequence Type Transcript ID Sequence Derived From 1225032_at FAD104 66.70 3.94e-10 1.40e-05 FAD104 3q26.31Consensussequence Hs.299883.1 AI141784 2 204274_at EBAG9 55.797.06e-08 4.18e-04 estrogen receptor binding site 8q23Consensussequence Hs.9222.0 AA812215 associated, antigen, 9 3230541_at LOC149134 48.92 3.43e-08 3.05e-04 hypothetical proteinLOC149134 1q44 Consensussequence Hs.61829.0 AU150080 4 210115_atRPL39L 47.31 2.59e-08 3.05e-04 ribosomal protein L39-like 3q27Exemplarsequence Hs.132748.0 L05096.1 5 235118_at 47.06 2.60e-083.05e-04 Homo sapiens cDNA FLJ38226 fis, ConsensussequenceHs.12382.0 AV724769 clone FCBBF2004066. 6 222365_at 45.14 4.90e-083.48e-04 ESTs Consensussequence Hs.293024.0 AW974666 7 222336_at41.89 9.35e-08 4.75e-04 ESTs Consensussequence Hs.116550.0 AW9749158 207995_s_at CD209L 41.60 1.08e-07 4.79e-04 CD209 antigen-like19p13 Exemplarsequence Hs.23759.0 NM_014257.1 9 217478_s_at HLA-DMA41.33 1.44e-07 5.68e-04 major histocompatibility complex, class II,DM 6p21.3 Consensussequence Hs.77522.1 X76775 alpha 10 230747_s_at37.74 2.76e-07 9.80e-04 Homo sapiens cDNA FLJ90394 fis,Consensussequence Hs.112011.0 AA406435 clone NT2RP2005632. 11204424_s_at DAT1 37.64 3.07e-05 1.54e-02 neuronal specifictranscription factor DAT1 12p12.3 Consensussequence Hs.301914.0AL050152.1 12 235748_s_at 37.46 3.54e-07 1.14e-03 Homo sapiens,clone IMAGE: 4830703, mRNA, Consensussequence Hs.105094.0 AW969382partial cds 13 218017_s_at FLJ22242 36.67 5.88e-05 1.97e-02hypothetical protein FLJ22242 8p11.1 Exemplarsequence Hs.288057.0NM_025070.1 14 216630_at 36.34 8.81e-07 1.96e-03 Homo sapiens mRNA;cDNA Consensussequence Hs.306338.0 AL110190.1 DKFZp564J2116 (fromclone DKFZp564J2116) 15 216781_at KIAA1751 36.19 4.59e-07 1.36e-03KIAA1751 protein 1p36.33 Consensussequence Hs.307002.0 AB051538.116 211838_x_at PCDHA5 34.85 5.97e-07 1.62e-03 protocadherin alpha 55q31 Exemplarsequence Hs.167399.1 AF152483.1 17 227860_at CPXM34.64 6.39e-07 1.62e-03 carboxypeptidase X (M14 family) 20p12.3-p13Consensussequence Hs.177536.0 NM_019609.1 18 222350_at 34.431.14e-06 2.38e-03 ESTs Consensussequence Hs.105121.0 AW969913 19201240_s_at KIAA0102 34.21 7.32e-07 1.73e-03 KIAA0102 gene product11q13.3 Exemplarsequence Hs.77665.0 NM_014752.1 20 230157_at CDH2433.71 1.95e-06 3.58e-03 cadherin-like 24 14q11.2 ConsensussequenceHs.155912.0 AL137477.1 21 235429_at EIF3S6 33.32 6.51e-06 6.18e-03eukaryotic translation initiation factor 3, 8q22-q23Consensussequence Hs.161623.0 AW965494 subunit 6 48 kDa 22205674_x_at FXYD2 31.85 4.02e-06 5.49e-03 FXYD domain containingion transport 11q23 Exemplarsequence Hs.19520.1 NM_001680.2regulator 2 23 237484_at 31.72 2.12e-06 3.58e-03 Homo sapiens cDNAFLJ35318 fis, Consensussequence Hs.220931.0 BE501385 clonePROST2011410. 24 223800_s_at LOC96626 31.50 1.16e-05 8.27e-03pinch-2 2q14-q21 Exemplarsequence Hs.285130.0 AF288404.1 25230765_at KIAA1239 30.59 2.09e-06 3.58e-03 KIAA1239 protein 4p14Consensussequence Hs.4280.0 AL037517 26 210882_s_at TRO 30.442.12e-06 3.58e-03 trophinin Xp11.22-p11.21 ExemplarsequenceHs.259802.1 U04811.1 27 209810_at SFTPB 30.30 2.23e-06 3.60e-03surfactant, pulmonary-associated 2p12-p11.2 ExemplarsequenceHs.76305.0 J02761.1 protein B 28 205325_at PHYHIP 29.94 2.78e-064.30e-03 phytanoyl-CoA hydroxylase interacting 8p21.2Exemplarsequence Hs.239500.0 NM_014759.1 protein 29 231226_at CRSP229.76 7.40e-06 6.75e-03 cofactor required for Sp1 Xp11.4-p11.2Consensussequence Hs.135174.0 BF196752 transcriptional activation,subunit 2, 150 kDa 30 216278_at 29.34 2.92e-06 4.33e-03 Homosapiens mRNA full length insert Consensussequence Hs.9997.0AL109705.1 cDNA clone EUROIMAGE 73337. 31 204153_s_at MFNG 382591.96e-05 1.21e-02 manic fringe homolog (Drosophila) 22q12Exemplarsequence Hs.31939.0 NM_002405.1 32 206229_x_at PAX2 28.803.43e-06 4.87e-03 paired box gene 2 10q22.1-q24.3 ExemplarsequenceHs.155644.0 NM_003988.1 33 222692_s_at FAD104 28.73 5.34e-045.03e-02 FAD104 3q26.31 Consensussequence Hs.299883.0 BF444916 34242417_at LOC283278 28.52 1.94e-05 1.21e-02 hypothetical proteinLOC283278 11p15.1 Consensussequence Hs.201661.0 AI690465 35227757_at CUL4A 28.47 5.89e-06 6.09e-03 cullin 4A 13q34Consensussequence Hs.183874.1 AL563297 36 224629_at 38258 5.50e-066.09e-03 Homo sapiens cDNA: FLJ22120 fis, ConsensussequenceHs.5822.0 BF217539 clone HEP18874. 37 205548_s_at BTG3 381968.24e-06 7.32e-03 BTG family, member 3 21q21.1-q21.2Exemplarsequence Hs.77311.0 NM_006806.1 38 49679_s_at MMP24 28.004.37e-06 5.74e-03 matrix metalloproteinase 24 20q11.2Consensussequence 5 AA243774 (membrane-inserted) 39 241645_at 27.994.52e-06 5.74e-03 Consensussequence Hs.293467.0 AW974844 40237838_at 27.79 5.99e-06 6.09e-03 Homo sapiens, clone IMAGE:5271699, Consensussequence Hs.134004.0 AI075924 mRNA 41 234702_x_atCFTR 27.70 5.17e-06 6.09e-03 cystic fibrosis transmembrane 7q31.2Consensussequence Hs.326797.0 S64699.1 conductance regulator,ATP-binding cassette (sub-family C, member 7) 42 208011_at PTPN2227.54 5.18e-06 6.09e-03 protein tyrosine phosphatase, non-1p13.3-p13.1 Exemplarsequence Hs.87860.1 NM_012411.1 receptor type22 (lymphoid) 43 226165_at E2F5 27.51 5.15e-05 1.90e-02 E2Ftranscription factor 5, p130- 8q21.13 Consensussequence Hs.286124.2BF674436 binding 44 222579_at FLJ23251 27.34 5.67e-06 6.09e-03hypothetical protein FLJ23251 3q22.1 Consensussequence Hs.170737.0NM_024818.1 45 222632_s_at LZTFL1 27.33 6.25e-05 2.08e-02 leucinezipper transcription factor-like 1 3p21.3 ConsensussequenceHs.30824.0 AA843132 46 217170_at TRA 27.79 5.89e-06 6.09e-03 T cellreceptor alpha locus 14q11.2 Consensussequence Hs.247915.0 AE00065947 226585_at NEIL2 26.89 9.83e-04 6.70e-02 nei like 2 (E. coli)Consensussequence Hs.293818.0 BE466620 48 203139_at DAPK1 26.806.34e-06 6.18e-03 death-associated protein kinase 1 9q34.1Exemplarsequence Hs.153924.0 NM_004938.1 49 225018_at Spir-1 26.706.61e-06 6.18e-03 Spir-1 protein 18p11.1 ConsensussequenceHs.16758.0 AJ277587.1 50 214538_x_at RGS6 26.46 1.05e-04 2.54e-02regulator of G-protein signalling 6 14q24.3 ConsensussequenceHs.3221.2 AF073921.1 Sequence Sequence # ID SourceUnigene_Accession Cluster_Type LocusLink Full_Length_Reference_Seq1 Hs.299883.1.S1 GenBank Hs.299883 fulllength 64778 NM_022763;FAD104 2 Hs.9222.0 GenBank Hs.9222 fulllength 9166 NM_004215;estrogen receptor binding site associated antigen 9 3 Hs.61829.0GenBank Hs.417101 149134 4 g388035 GenBank Hs.132748 fulllength116832 NM_052969; ribosomal protein L39-like protein 5 Hs.12382.0GenBank Hs.12382 6 Hs.293024.0.A1 GenBank Hs.293024 est 7Hs.116550.0_RC GenBank Hs.430765 est 8 g7657173 RefSeq Hs.23759fulllength 10332 NM_014257; CD209 antigen-like 9 Hs.77522.1 GenBankHs.77522 fulllength 3108 NM_006120; major histocompatibilitycomplex, class II, DM alpha precursor 10 Hs.112011.0.S1 GenBankHs.112011 11 Hs.301914.0_RC GenBank Hs.301914 fulllength 55885NM_018640; neuronal specific transcription factor DAT1 12Hs.105094.0.S1 GenBank Hs.407156 13 g13376612 RefSeq Hs.288057fulllength 80140 NM_025070; hypothetical protein FLJ22242 14Hs.306338.0.A1 GenBank Hs.306338 15 Hs.307002.0.A1 GenBankHs.307002 85452 16 g5457014 GenBank Hs.167399 fulllength 56143NM_018908; protocadherin alpha 5 isoform 1 precursor NM_031501;protocadherin alpha 5 isoform 2 precursor 17 Hs.177536.0 GenBankHs.177536 fulllength 56265 NM_019609; metallocarboxypeptidase CPX-1precursor 18 Hs.105121.0 GenBank Hs.432532 est 19 g7661907 RefSeqHs.77665 fulllength 9789 NM_014752; KIAA0102 gene product 20Hs.155912.0 GenBank Hs.155912 fulllength 64403 NM_022478;cadherin-like 24 21 Hs.161623.0.A1 GenBank Hs.106673 fulllength3646 NM_001568; murine mammary tumor integration site 6 (oncogenehomolog) 22 g11125765 RefSeq Hs.19520 fulllength 486 NM_001680;FXYD domain-containing ion transport regulator 2 isoform 1NM_021603; FXYD domain-containing ion transport regulator 2 isoform2 23 Hs.220931.0_RC GenBank Hs.220931 24 g9800508 GenBank Hs.285130fulllength 96626 NM_033514; pinch-2 25 Hs.4280.0.S1 GenBank Hs.428057495 26 g905357 GenBank Hs.259802 fulllength 7216 NM_016157;trophinin isoform 2 NM_177555; trophinin isoform 1 NM_177556;trophinin isoform 2 NM_177557; trophinin isoform 4 NM_177558;trophinin isoform 3 27 g190673 GenBank Hs.76305 fulllength 6439NM_000542; surfactant, pulmonary-associated protein B 28 g7662031RefSeq Hs.334688 fulllength 9796 NM_014759; phytanoyl-CoAhydroxylase interacting protein 29 Hs.135174.0.A1 GenBank Hs.407604fulllength 9282 NM_004229; cofactor required for Sp1transcriptional activation, subunit 2, 150 kDa 30 Hs.9997.0 GenBankHs.9997 31 g4505158 RefSeq Hs.31939 fulllength 4242 NM_002405;manic fringe (Drosophila) homolog 32 g4557824 RefSeq Hs.155644fulllength 5076 NM_000278; paired box protein 2 isoform bNM_003987; paired box protein 2 isoform a NM_003988; paired boxprotein 2 isoform c NM_003989; paired box protein 2 isoform dNM_003990; paired box protein 2 isoform e 33 Hs.299883.0.S2 GenBankHs.299883 fulllength 64778 NM_022763; FAD104 34 Hs.201661.0.A1GenBank Hs.201661 283278 35 Hs.183874.1.S1 GenBank Hs.183874fulllength 8451 NM_003589; cullin 4A 36 Hs.5822.0.S1 GenBankHs.5822 37 g5802989 RefSeq Hs.77311 fulllength 10950 NM_006806;B-cell translocation gene 3 38 4921436_rc GenBank Hs.3743fulllength 10893 NM_006690; matrix metalloproteinase 24(membrane-inserted) 39 Hs.293467.0_RC GenBank 40 Hs.134004.0.A1GenBank Hs.134004 41 Hs.326797.0 GenBank Hs.426266 fulllength 1080NM_000492; cystic fibrosis transmembrane conductance regulator,ATP-binding cassette (sub-family C, member 7) 42 g6912613 RefSeqHs.87860 fulllength 26191 NM_012411; lymphoid-specific proteintyrosine phosphatase isoform 2 NM_015967; lymphoid-specific proteintyrosine phosphatase isoform 1 43 Hs.286124.2_RC GenBank Hs.2331fulllength 1875 NM_001951; E2F transcription factor 5 44Hs.170737.0_RC GenBank Hs.170737 fulllength 79876 NM_024818;hypothetical protein FLJ23251 45 Hs.30824.0.S1 GenBank Hs.30824fulllength 54585 NM_020347; leucine zipper transcriptionfactor-like 1 46 Hs.247915.0 GenBank Hs.74647 fulllength 6955 47Hs.293818.0.A1 GenBank Hs.293818 fulllength 252969 NM_145043;nei-like 2 48 g4826683 RefSeq Hs.153924 fulllength 1612 NM_004938;death-associated protein kinase 1 49 Hs.16758.0 GenBank Hs.16758fulllength 56907 50 Hs.3221.2.S1 GenBank Hs.3221 fulllength 9628NM_004296; regulator of G-protein signalling 6

TABLE-US-00025 TABLE 24 _t(15; 17) # affy Id HUGO name TitleMapLocation Sequence Type Transcript ID Sequence Derived FromSequence ID 1 230746_s_at STC1 stanniocalcin 1 8p21-p11.2Consensussequence Hs.25590.1 AW003173 Hs.25590.1.A1 2 239860_atESTs Consensussequence Hs.16292.0 AI311917 Hs.16292.0.A1 3209928_s_at MSC musculin (activated B-cell factor-1) 8q21Exemplarsequence Hs.42474.0 AF060154.1 g3089604 4 206222_atTNFRSF10C tumor necrosis factor receptor superfamily, 8p22-p21Exemplarsequence Hs.119684.0 NM_003841.1 g10835042 member 10c,decoy without an intracellular domain 5 211489_at ADRA1Aadrenergic, alpha-1A-, receptor 8p21-p11.2 ExemplarsequenceHs.52931.0 D32201.1 g927210 6 218777_at FLJ22246 hypotheticalprotein FLJ22246 8p21.2 Exemplarsequence Hs.289063.0 NM_025232.1g13376835 7 212166_at XPO7 exportin 7 8p21 ConsensussequenceHs.172685.0 H38643 Hs.172685.0 8 225053_at CNOT7 CCR4-NOTtranscription complex, subunit 7 8p22-p21.3 ConsensussequenceHs.226318.1 W94952 Hs.226318.1.A2 9 227263_at FLJ34715 hypotheticalprotein FLJ34715 8p21.2 Consensussequence Hs.296360.0 AL519427Hs.296360.0.S1 10 224413_s_at BLP1 BBP-like protein 1 8p11.21Exemplarsequence g13625460 AF353991.1 g13625460 11 205849_s_atUQCRB ubiquinol-cytochrome c reductase binding 8q22Exemplarsequence protein Hs.131255.0 NM_006294.1 g5454151 12235210_s_at FLJ40021 hypothetical protein FLJ40021 8q13.2Consensussequence Hs.122544.0 AW662373 Hs.122544.0_RC 13 227001_atHomo sapiens cDNA: FLJ21362 fis clone Consensussequence Hs.167011.0AI096706 Hs.167011.0 COL02886. 14 222665_at CGI-90 CGI-90 protein8q21.13 Consensussequence Hs.44222.0 AK000672.1 Hs.44222.0 15212523_s_at KIAA0146 KIAA0146 protein 8q11.21 ConsensussequenceHs.278634.0 D63480.1 Hs.278634.0_RC 16 230411_at UBE2V2ubiquitin-conjugating enzyme E2 variant 2 8q11.1 ConsensussequenceHs.43569.0 AI800998 Hs.43569.0_RC 17 219124_at FLJ23263hypothetical protein FLJ23263 8p11.23 Exemplarsequence Hs.288716.0NM_025115.1 g13376690 18 201644_at TSTA3 tissue specifictransplantation antigen P35B 8q24.3 Exemplarsequence Hs.264428.0NM_003313.2 g6598326 19 201398_s_at TRAM translocatingchain-associating membrane 8q13.1 Exemplarsequence Hs.4147.0BC000687.1 g12653796 protein 20 235509_at MGC40214 hypotheticalprotein MGC40214 8q22.1 Consensussequence Hs.98471.0 AV662196Hs.98471.0_RC 21 203208_s_at CHPPR likely ortholog of chickenchondrocyte 8q12.1 Exemplarsequence Hs.170198.0 NM_014637.1g7661853 protein with a poly-proline region 22 218899_s_at BAALCbrain and acute leukemia, cytoplasmic 8q22.3 ExemplarsequenceHs.169395.0 NM_024812.1 g13376199 23 230016_at Homo sapiens cDNAFLJ13277 fis, clone Consensussequence Hs.55043.0 AU155118Hs.55043.0.S1 OVARC1001044. 24 232693_s_at LOC55893 papillomavirusregulatory factor PRF-1 8p21.1 Consensussequence Hs.27410.2AK021850.1 Hs.27410.2.S1 25 203207_s_at CHPPR likely ortholog ofchicken chondrocyte 8q12.1 Consensussequence Hs.170198.0 BF214329Hs.170198.0.S1 protein with a poly-proline region 26 212248_at Homosapiens, Similar to LYRIC, clone Consensussequence Hs.243901.0AI972475 Hs.243901.0.S1 MGC: 41931 IMAGE: 5298467, mRNA, completecds 27 202680_at GTF2E2 general transcription factor IIE,polypeptide 8p21-p12 Exemplarsequence Hs.77100.0 NM_002095.1g4504194 2, beta 34 kDa 28 208791_at CLU clusterin (complementlysis inhibitor, SP- 8p21-p12 Exemplarsequence Hs.75106.0 M25915.1g180619 40,40, sulfated glycoprotein 2, testosterone- repressedprostate message 2, apolipoprotein J) 29 208792_s_at CLU clusterin(complement lysis inhibitor, SP- 8p21-p12 ExemplarsequenceHs.75106.0 M25915.1 g180619 40,40, sulfated glycoprotein 2,testosterone- repressed prostate message 2, apolipoprotein J) 30221236_s_at STMN4 stathmin-like 4 8p21.1 Exemplarsequence g13540510NM_030795.1 g13540510 31 211535_s_at FGFR1 fibroblast growth factorreceptor 1 (fms- 8p11.2-p11.1 Exemplarsequence Hs.748.6 M60485.1g182560 related tyrosine kinase 2, Pfeiffer syndrome) 32218173_s_at WHSC1L1 Wolf-Hirschhom syndrome candidate 1-like 8p11.2Exemplarsequence Hs.27721.0 NM_017778.2 g13699812 33 225676_s_atDKFZP564O0463 DKFZP564O0463 protein 8q22.3 ConsensussequenceHs.273344.1 AK001693.1 Hs.273344.1 34 218187_s_at FLJ20989hypothetical protein FLJ20989 Exemplarsequence Hs.169615.0NM_023080.1 g12751496 35 226483_at FLJ32370 hypothetical proteinFLJ32370 8q11.23 Consensussequence Hs.280858.1 AI890761Hs.280858.1.A1 36 208647_at FDFT1 farnesyl-diphosphatefarnesyltransferase 1 8p23.1-p22 Consensussequence Hs.48876.1AA872727 Hs.48876.1 37 200090_at- FNTA farnesyltransferase, CAAXbox, alpha 8p22-q11 Consensussequence Hs.138381.1 BG168896Hs.138381.1.A1 HG-U133A 38 218250_s_at CNOT7 CCR4-NOT transcriptioncomplex, subunit 7 8p22-p21.3 Exemplarsequence Hs.226318.0NM_013354.2 g10518495 39 202174_s_at PCM1 pericentriolar material 18p22-p21.3 Exemplarsequence Hs.75737.0 NM_006197.1 g5453855 40214118_x_at PCM1 pericentriolar material 1 8p22-p21.3Consensussequence Hs.75737.1 AI205598 Hs.75737.1.S1 41 214937_x_atPCM1 pericentriolar material 1 8p22-p21.3 ConsensussequenceHs.75737.2 AI924817 Hs.75737.2.S1 42 222544_s_at WHSC1L1Wolf-Hirschhorn syndrome candidate 1-like 1 8p11.2Consensussequence Hs.27721.0 AI697751 Hs.27721.0_RC 43 219819_s_atMRPS28 mitochondrial ribosomal protein S28 8q21.1-q21.2Exemplarsequence Hs.55097.0 NM_014018.1 g7661729 44 210029_at INDOindoleamine-pyrrole 2,3 dioxygenase 8p12-p11 ExemplarsequenceHs.840.0 M34455.1 g185790 45 201618_x_at GPAA1 GPAA1P anchorattachment protein 1 8q24.3 Exemplarsequence Hs.4742.0 NM_003801.2g6031166 homolog (yeast) 46 200936_at RPL8 ribosomal protein L88q24.3 Exemplarsequence Hs.178551.0 NM_000973.1 g4506662 47213072_at LOC157542 hypothetical protein BC004544 8q24.3Consensussequence Hs.331601.0 AI928387 Hs.331601.0 48 58696_atFLJ20591 exosome component Rrp41 8q24.3 Consensussequence 5AL039469 4923514_rc 49 236533_at DDEF1 development anddifferentiation enhancing 8q24.1-q24.2 ConsensussequenceHs.199057.0 AW236958 Hs.199057.0.A1 factor 1 50 238562_at ESTs,Weakly similar to hypothetical protein ConsensussequenceHs.280297.0 BE542779 Hs.280297.0.A1 FLJ20378 [Homo sapiens] [H.sapiens] 51 219548_at ZNF16 zinc finger protein 16 (KOX 9) 8q24Exemplarsequence Hs.23019.0 NM_006958.1 g11177859 52 212250_at Homosapiens, Similar to LYRIC, clone Consensussequence Hs.243901.0AI972475 Hs.243901.0.S1 MGC: 41931 IMAGE: 5298467, mRNA, completecds 53 227277_at Homo sapiens cDNA FLJ40968 fis, cloneConsensussequence Hs.33074.0 BG530089 Hs.33074.0.S1 UTERU2012615.54 235391_at LOC137392 similar to CG6405 gene product 8q21.3Consensussequence Hs.87672.0 AW960748 Hs.87672.0_RC 55 202119_s_atCPNE3 copine III 8q21.13 Exemplarsequence Hs.14158.0 NM_003909.1g4503014 56 218919_at FLJ14007 hypothetical protein FLJ140078q21.12 Exemplarsequence Hs.99519.0 NM_024699.1 g13375984 57208361_s_at BN51T BN51 (BHK21) temperature sensitivity 8q21Exemplarsequence Hs.1276.0 NM_001722.1 g4502436 complementing 58223475_at LOC83690 CocoaCrisp 8q13.3 Exemplarsequence Hs.182364.0AF142573.1 g12002310 59 202955_s_at BIG1 brefeldin A-inhibitedguanine nucleotide- 8q13 Exemplarsequence Hs.94631.0 AF084520.1g5052120 exchange protein 1 60 203448_s_at TERF1 telomeric repeatbinding factor (NIMA- 8q13 Consensussequence Hs.194562.0 AI347136Hs.194562.0.A1 interacting) 1 61 204301_at KIAA0711 KIAA0711 geneproduct 8p23.2 Exemplarsequence Hs.5333.0 NM_014867.1 g7662259 62210980_s_at ASAH1 N-acylsphingosine amidohydrolase (acid 8p22.p21.3Exemplarsequence Hs.75811.1 U47674.1 g3860239 ceramidase) 1 63209997_x_at PCM1 pericentriolar material 1 8p22-p21.3Exemplarsequence Hs.315478.0 BC000453.1 g12653366 64 208231_at NRG1neuregulin 1 8p21-p12 Exemplarsequence Hs.172816.0 NM_013960.1g7669519 65 205770_at GSR glutathione reductase 8p21.1Exemplarsequence Hs.121524.0 NM_000637.1 910835188 66 217819_atLOC51125 HSPC041 protein 8p11.21 Exemplarsequence Hs.7953.0NM_016099.1 g7705820 67 209517_s_at ASH2L ash2 (absent, small, orhomeotic)-like 8p11.2 Exemplarsequence Hs.6856.1 AB020982.1g4417209 (Drosophila) 68 216519_s_at PROSC proline synthetaseco-transcribed homolog 8p11.2 Consensussequence Hs.301959.3AK021923.1 Hs.301959.3.S1 (bacterial) 69 222551_s_at FLJ20989hypothetical protein FLJ20989 Consensussequence Hs.169615.0AI197841 Hs.169615.0 70 206573_at KCNQ3 potassium voltage-gatedchannel, KQT-like 8q24 Exemplarsequence Hs.40866.0 NM_004519.1g4758629 subfamily, member 3 71 225439_at CML66 chronic myelogenousleukemia tumor 8q23 Consensussequence Hs.195870.0 BC000967.2Hs.195870.0 antigen 66 72 200949_x_at RPS20 ribosomal protein S208q12 Exemplarsequence Hs.8102.0 NM_001023.1 g4506696 73 222525_s_atFLJ10853 hypothetical protein FLJ10853 8p21.1 ConsensussequenceHs.72085.0 AU160632 Hs.72085.0 74 222998_at MAF1 homolog of yeastMAF1 8q24.3 Exemplarsequence Hs.324157.0 AL136937.1 g12053368 75218679_s_at VPS28 vacuolar protein sorting 28 (yeast) 8q24.3Exemplarsequence Hs.293441.0 NM_016208.1 g7705884 76 223231_atCDA11 CDA11 protein 8q24.1 Exemplarsequence Hs.11810.0 AF212250.1g13182774 77 241342_at LOC157378 hypothetical protein BC0178818q24.13 Consensussequence Hs.187646.0 BG288115 Hs.187646.0.A1 78204278_s_at EBAG9 estrogen receptor binding site associated, 8q23Exemplarsequence Hs.9222.0 NM_004215.1 g4758229 antigen, 9 79218059_at LOC51123 HSPC038 protein 8q22.3 ExemplarsequenceHs.23528.0 NM_016096.1 g7705816 80 201433_s_at PTDSS1phosphatidylserine synthase 1 8q22 Exemplarsequence Hs.77329.0NM_014754.1 g7662646 81 221925_s_at FLJ22490 hypothetical proteinFLJ22490 8q12.3 Consensussequence Hs.153746.1 BE044503Hs.153746.1.S1 82 216246_at RPS20 ribosomal protein S20 8q12Consensussequence Hs.8102.2 AF113008.1 Hs.8102.2 83 224743_at Homosapiens, clone IMAGE: 3897094, Consensussequence Hs.13328.0BF965065 Hs.13328.0_RC mRNA 84 210950_s_at FDFT1farnesyl-diphosphate farnesyltransferase 1 8p23.1-p22Exemplarsequence Hs.48876.0 BC003573.1 g13097746 85 209471_s_atFNTA farnesyltransferase, CAAX box, alpha 8p22-q11 ExemplarsequenceHs.138381.0 L00634.1 g292030 86 225378_at FLJ32642 hypotheticalprotein FLJ32642 8p22 Consensussequence Hs.101617.0 AI866426Hs.101617.0_RC 87 228024_at FLJ32642 hypothetical protein FLJ326428p22 Consensussequence Hs.290855.0 AW028100 Hs.290855.0 88201985_at KIAA0196 KIAA0196 gene product 8p22 ExemplarsequenceHs.8294.0 NM_014846.1 g7661987 89 207000_s_at PPP3CC proteinphosphatase 3 (formerly 2B), 8p21.2 Exemplarsequence Hs.75206.0NM_005605.1 g5031988 catalytic subunit, gamma isoform (calcineurinA gamma) 90 227075_at ELP3 likely ortholog of mouse elongationprotein 3 8p21.1 Consensussequence Hs.267905.2 AI949204Hs.267905.2_RC homolog (S. cerevisiae) 91 221916_at NEFLneurofilament, light polypeptide 68 kDa 8p21 ConsensussequenceHs.302689.1 BF055311 Hs.302689.1.S1 92 235472_at FUT10fucosyltransferase 10 (alpha (1,3) 8p11.23 ConsensussequenceHs.132665.0 AI147738 Hs.132665.0.A1 fucosyltransferase) 93209384_at PROSC proline synthatase co-transcribed homolog 8p11.2Consensussequence Hs.301959.0 AA176833 Hs.301959.0.A2 (bacterial)94 218017_s_at FLJ22242 hypothetical protein FLJ22242 8p11.1Exemplarsequence Hs.288057.0 NM_025070.1 g13376612 95 232640_atHT002 HT002 protein; hypertension-related calcium- 8q24-qterConsensussequence Hs.238928.2 AK023070.1 Hs.238928.2.S1 regulatedgene 96 218858_at FLJ12428 hypothetical protein FLJ12428 8q24.12Exemplarsequence Hs.87729.0 NM_022783.1 g12232472 97 202872_atATP6V1C1 ATPase, H+ transporting. lysosomal 42 kDa, 8q22.3Consensussequence Hs.86905.0 NM_001695.1 Hs.86905.0 V1 subunit C,isoform 1 98 209066_x_at UQCRB ubiquinol-cytochrome c reductasebinding 8q22 Exemplarsequence Hs.131255.1 M26700.1 g190803 protein99 242338_at DKFZp762C1112 hypothetical protein DKFZp762C11128q21.3 Consensussequence Hs.330692.0 BG535396 Hs.330692.0.S1 100218549_s_at CGI-90 CGI-90 protein 8q21.13 ExemplarsequenceHs.44222.0 NM_016033.1 g7705802 101 201652_at COPS5 COP9constitutive photomorphogenic 8q12.3 Exemplarsequence Hs.198767.0NM_006837.1 g5803045

homolog subunit 5 (Arabidopsis) 102 226123_at LOC286180hypothetical protein LOC286180 8q12.1 Consensussequence Hs.60238.0AI870918 Hs.60238.0_RC 103 239877_at MTMR9 myotubularin relatedprotein 9 8p23-p22 Consensussequence Hs.128277.0 AI499833Hs.128277.0_RC 104 222714_s_at CGI-83 CGI-83 protein 8p22-q22.3Exemplarsequence Hs.118554.0 BC000878.1 g12654126 105 239303_atESTs Consensussequence Hs.97814.0 AA933717 Hs.97814.0.A1 106203941_at FLJ10871 hypothetical protein FLJ10871 8p12Exemplarsequence Hs.15562.0 NM_018250.1 g8922725 107 215983_s_atD8S2298E reproduction 8 8p12-p11.2 Consensussequence Hs.153678.1D83768.1 Hs.153678.1.S1 108 208846_s_at VDAC3 voltage-dependentanion channel 3 8p11.2 Exemplarsequence Hs.7381.0 U90943.1 g2735306109 214394_x_at EEF1D eukaryotic translation elongation factor 18q24.3 Consensussequence Hs.223241.1 AI613383 Hs.223241.1.A1 delta(guanine nucleotide exchange protein) 110 219189_at FBXL6 F-box andleucine-rich repeat protein 6 8q24.3 Exemplarsequence Hs.12271.0NM_024555.1 g13435140 111 211060_x_at GPAA1 GPAA1P anchorattachment protein 1 8q24.3 Exemplarsequence g13623546 BC006383.1g13623546 homolog (yeast) 112 212090_at VPS28 vacuolar proteinsorting 28 (yeast) 8q24.3 Consensussequence Hs.101067.2 AL571424Hs.101067.2 113 227778_at Homo sapiens cDNA FLJ35542 fis, cloneConsensussequence Hs.26563.0 H11075 Hs.26563.0_RC SPLEN2002917. 114212556_at SCRIB scribble 8q24.3 Consensussequence Hs.239784.0AI469403 Hs.239784.0.S1 115 36936_at TSTA3 tissue specifictransplantation antigen P35B 8q24.3 Consensussequence 4900667_rcU58766 4900667_rc 116 243301_at ESTs, Weakly similar to JX0369collagen Consensussequence Hs.122254.0 AW241910 Hs.122254.0.A1alpha 1(XIX) chain precursor - human [H. sapiens] 117 203113_s_atEEF1D eukaryotic translation elongation factor 1 8q24.3Exemplarsequence Hs.223241.0 NM_001960.1 g4503478 delta (guaninenucleotide exchange protein) 118 222155_s_at FLJ11856 putativeG-protein coupled receptor 8q24.3 Consensussequence Hs.6459.1AK021918.1 Hs.6459.1.S1 GPCR41 119 221629_x_at LOC51236hypothetical protein LOC51236 8q24.3 Exemplarsequence Hs.300224.1AF151022.1 g7106765 120 202145_at LY6E lymphocyte antigen 6complex, locus E 8q24.3 Exemplarsequence Hs.77667.0 NM_002346.1g4505048 121 223421_at MGC13010 hypothetical protein MGC130108q24.3 Exemplarsequence Hs.332040.0 BC005073.1 g13477216 122225203_at PPP1R16A protein phosphatase 1, regulatory (inhibitor)8q24.3 Consensussequence Hs.12185.0 AI742931 Hs.12185.0_RC subunit16A 123 222133_s_at CGI-72 CGI-72 protein 8q24.3 ConsensussequenceHs.288435.0 AK022280.1 Hs.288435.0 124 226942_at FLJ21615hypothetical protein FLJ21615 8q24.22 Consensussequence Hs.44159.0AI742668 Hs.44159.0.S1 125 227523_s_at CGI-72 CGI-72 protein 8q24.3Consensussequence Hs.318725.1 AA192936 Hs.318725.1.S1 126 226564_atZNF406 zinc finger protein 406 8q24.22 Consensussequence Hs.15611.0BF941325 Hs.15611.0 127 224790_at DDEF1 development anddifferentiation enhancing 8q24.1-q24.2 Consensussequence Hs.10669.1W03103 Hs.10669.1.S2 factor 1 128 224796_at DDEF1 development anddifferentiation enhancing 8q24.1-q24.2 Consensussequence Hs.10669.1W03103 Hs.10669.1.S2 factor 1 129 226536_at FLJ32440 hypotheticalprotein FLJ32440 8q24.13 Consensussequence Hs.58609.0 AL562908Hs.58609.0.S1 130 241370_at Homo sapiens cDNA FLJ37785 fis, cloneConsensussequence Hs.100691.0 AA278233 Hs.100691.0_RC BRHIP2028330.131 214061_at MGC21654 unknown MGC21654 product 8q24.13Consensussequence Hs.95631.0 AI017564 Hs.95631.0 132 222543_atPRO2577 hypothetical protein PRO2577 8q24.13 ConsensussequenceHs.241576.0 AF131854.1 Hs.241576.0.S2 133 225864_at Homo sapienscDNA FLJ23705 fis, clone Consensussequence Hs.49136.0 AL039862Hs.49136.0.A1 HEP11066. 134 235266_at PRO2000 PRO2000 protein8q24.13 Consensussequence Hs.222088.0 AI139629 Hs.222088.0_RC 135203556_at KIAA0854 KIAA0854 protein 8q24.13 ExemplarsequenceHs.30209.0 NM_014943.1 g7662341 136 202431_s_at MYC v-mycmyelocytomatosis viral oncogene 8q24.12-q24.13 ExemplarsequenceHs.79070.0 NM_002467.1 g12962934 homolog (avian) 137 208608_s_atSNTB1 syntrophin, beta 1 (dystrophin-associated 8q23-q24Exemplarsequence Hs.95011.0 NM_021021.1 g11321639 protein A1, 59kDa, basic component 1) 138 226438_at Homo sapiens cDNA: FLJ21447fis, clone Consensussequence Hs.44241.0 AK025100.1 Hs.44241.0COL04468. 139 218482_at DC6 DC6 protein 8q23.2 ExemplarsequenceHs.283740.0 NM_020189.1 g9910185 140 204274_at EBAG9 estrogenreceptor binding site associated, 8q23 Consensussequence Hs.9222.0AA812215 Hs.9222.0 antigen, 9 141 218197_s_at OXR1 oxidationresistance 1 8q23 Exemplarsequence Hs.169111.0 NM_018002.1 g8922240142 221266_s_at DCSTAMP DC-specific transmembrane protein 8q22Exemplarsequence g13540564 NM_030788.1 g13540564 143 222553_x_atOXR1 oxidation resistance 1 8q23 Consensussequence Hs.169111.0AL541048 Hs.169111.0.S2 144 223879_s_at OXR1 oxidation resistance 18q23 Exemplarsequence Hs.169111.1 AF309387.1 g10954045 145235429_at EIF3S6 eukaryotic translation initiation factor 3,8q22-q23 Consensussequence Hs.161623.0 AW965494 Hs.161623.0.A1subunit 6 48 kDa 146 226463_at Homo sapiens cDNA FLJ33383 fis,clone Consensussequence Hs.290880.0 AW241758 Hs.290880.0.A1BRACE2006514. 147 202635_s_at POLR2K polymerase (RNA) II (DNAdirected) 8q22.2 Exemplarsequence Hs.150675.0 NM_005034.1 g4826923polypeptide K, 7.0 kDa 148 202874_s_at ATP6V1C1 ATPase, H.sup.+transporting, lysosomal 42 kDa, 8q22.3 Exemplarsequence Hs.86905.0NM_001695.1 g4502314 V1 subunit C, isoform 1 149 231784_s_atDKFZP564O0463 DKFZP564O0463 protein 8q22.3 ConsensussequenceHs.273344.2 AK001874.1 Hs.273344.2 150 208454_s_at PGCP plasmaglutamate carboxypeptidase 8q22.2 Exemplarsequence Hs.278993.0NM_016134.1 g7706386 151 223110_at DKFZP434I116 DKFZP434I116protein 8q22.1 Exemplarsequence Hs.16621.0 BC003701.1 g13277583 152218905_at FLJ20530 hypothetical protein FLJ20530 8q22.1Exemplarsequence Hs.279521.0 NM_017864.1 g8923495 153 225600_atHomo sapiens cDNA FLJ40637 fis, clone Consensussequence Hs.6390.1AW303300 Hs.6390.1.A1 THYMU2015984. 154 225603_s_at Homo sapienscDNA FLJ40637 fis, clone Consensussequence Hs.6390.1 AW303300Hs.6390.1.A1 THYMU2015984. 155 212251_at Homo sapiens, Similar toLYRIC, clone Consensussequence Hs.243901.0 AI972475 Hs.243901.0.S1MGC: 41931 IMAGE: 5298467, mRNA, complete cds 156 222699_s_atFLJ13187 phafin 2 8q22.1 Consensussequence Hs.29724.0 BF439250Hs.29724.0.S1 157 243927_x_at ESTs, Highly similar to DKFZP434I116Consensussequence Hs.50273.0 AI636247 Hs.50273.0_RC protein [Homosapiens] [H. sapiens] 158 225599_s_at Homo sapiens cDNA FLJ40637fis, clone Consensussequence Hs.6390.1 AW303300 Hs.6390.1.A1THYMU2015984. 159 226721_at Homo sapiens, clone IMAGE: 5314143,Consensussequence Hs.165539.0 AW517711 Hs.165539.0_RC mRNA 160203790_s_at UK114 translational inhibitor protein p14.5 8q22Consensussequence Hs.18426.0 N54448 Hs.18426.0.S1 161 209065_atUQCRB ubiquinol-cytochrome c reductase binding 8q22Exemplarsequence Hs.131255.1 BC005230.1 g13528857 protein 162223085_at RNF19 ring finger protein 19 8q22 ExemplarsequenceHs.48320.1 AB029316.1 g13366023 163 202118_s_at CPNE3 copine III8q21.13 Consensussequence Hs.14158.0 AA541758 Hs.14158.0 164210296_s_at PXMP3 perosisomal membrane protein 3, 35 kDa 8q21.1Exemplarsequence Hs.180612.1 BC005375.1 g13529226 (Zellwegersyndrome) 165 202905_x_at NBS1 Nijmegen breakage syndrome 1(nibrin) 8q21-q24 Consensussequence Hs.25812.0 AI796269Hs.25812.0.S1 166 202907_s_at NBS1 Nijmegen breakage syndrome 1(nibrin) 8q21-q24 Exemplarsequence Hs.25812.0 NM_002485.2 g6996019167 208166_at MMP16 matrix metalloproteinase 16 (membrane- 8q21Exemplarsequence Hs.90800.0 NM_022564.1 g13027799 inserted) 168202906_s_at NBS1 Nijmegen breakage syndrome 1 (nibrin) 8q21-q24Consensussequence Hs.25812.0 AI796269 Hs.25812.0.S1 169 217299_s_atNBS1 Nijmegen breakage syndrome 1 (nibrin) 8q21-q24Consensussequence Hs.25812.1 AK001017.1 Hs.25812.1.S1 170 204226_atSTAU2 staufen, RNA binding protein, homolog 2 8q13-q21.1Exemplarsequence Hs.96870.0 NM_014393.1 g7657624 (Drosophila) 171219449_s_at FLJ20533 hypothetical protein FLJ20533 8q13.3Exemplarsequence Hs.106650.0 NM_017866.1 g8923499 172 226083_atFLJ20533 hypothetical protein FLJ20533 8q13.3 ConsensussequenceHs.106650.1 AA886902 Hs.106650.1_RC 173 226269_at Homo sapiensmRNA; cDNA Consensussequence Hs.168950.0 AL110252.1 Hs.168950.0DKFZp566A1046 (from clone DKFZp566A1046) 174 201399_s_at TRAMtranslocating chain-associating membrane 8q13.1 ExemplarsequenceHs.4147.0 NM_014294.1 g7657654 protein 175 202956_at BIG1 brefeldinA-inhibited guanine nucleotide- 8q13 Exemplarsequence Hs.94631.0NM_006421.2 g6715588 exchange protein 1 176 216266_s_at BIG1brefeldin A-inhibited guanine nucleotide- 8q13 ConsensussequenceHs.94631.1 AK025637.1 Hs.94631.1.S1 exchange protein 1 177224046_s_at PDE7A phosphodiesterase 7A 8q13 ExemplarsequenceHs.150395.1 U67932.1 g2306763 178 232314_at Homo sapiens cDNAFLJ14270 fis, clone Consensussequence Hs.97603.0 AU156769Hs.97603.0 PLACE1004491. 179 232149_s_at Homo sapiens cDNA FLJ11963fis, clone Consensussequence Hs.306621.0 BF056507 Hs.306621.0HEMBB1001051. 180 220038_at SGKL serum/glucocorticoid regulatedkinase-like 8q12.3-8q13.1 Exemplarsequence Hs.279696.0 NM_013257.1g7019526 181 227627_at SGKL serum/glucocorticoid regulatedkinase-like 8q12.3-8q13.1 Consensussequence Hs.24131.0 AV690866Hs.24131.0.S1 182 218185_s_at FLJ10511 hypothetical proteinFLJ10511 8q12.2 Exemplarsequence Hs.106768.0 NM_018120.1 g8922478183 222550_at FLJ10511 hypothetical protein FLJ10511 8q12.2Consensussequence Hs.106768.0 AK024053.1 Hs.106768.0 184 225008_atMGC34646 hypothetical protein MGC34646 8q12.1 ConsensussequenceHs.332422.0 AF339775.1 Hs.332422.0 185 210896_s_at ASPH aspartatebeta-hydroxylase 8q12.1 Exemplarsequence Hs.283664.4 AF306765.1g11991236 186 208731_at RAB2 RAB2, member RAS oncogene family8q12.1 Consensussequence Hs.78305.0 NM_002865.1 Hs.78305.0_RC 187208734_x_at RAB2 RAB2, member RAS oncogene family 8q12.1Exemplarsequence Hs.78305.0 M28213.1 g550061 188 222701_s_atMGC2217 hypothetical protein MGC2217 8q11.23 ConsensussequenceHs.323164.0 AA570393 Hs.323164.0 189 226119_at LOC115294 similar tohypothetical protein FLJ10883 8q11.22 Consensussequence Hs.60293.0AA453163 Hs.60293.0_RC 190 235507_at LOC115294 similar tohypothetical protein FLJ10883 8q11.22 Consensussequence Hs.99580.0AA461195 Hs.99580.0.A1 191 209096_at UBE2V2 ubiquitin-conjugatingenzyme E2 variant 2 8q11.1 Exemplarsequence Hs.79300.0 U62136.2g4775663 192 207529_at DEFA5 defensin, alpha 5, Panethcell-specific 8pter-p21 Exemplarsequence Hs.72887.0 NM_021010.1g10337584 193 219281_at MSRA methionine sulfoxide reductase A8p23.1 Exemplarsequence Hs.26458.0 NM_012331.2 g13259538 194213457_at Homo sapiens cDNA FLJ39185 fis, clone ConsensussequenceHs.24724.1 BF739959 Hs.24724.1.A2 OCBBF2004418. 195 225478_at Homosapiens cDNA FLJ39185 fis, clone Consensussequence Hs.24724.0BE783723 Hs.24724.0 OCBBF2004418. 196 221504_s_at ATP6V1H ATPase,H+ transporting, lysosomal 8p22-q22.3 Exemplarsequence Hs.19575.0AF112204.1 g6563195 50/57 kDa, V1 subunit H 197 200762_at DPYSL2dihydropyrimidinase-like 2 8p22-p21 Exemplarsequence Hs.173381.0NM_001386.1 g4503376 198 200839_s_at CTSB cathepsin B 8p22Exemplarsequence Hs.297939.0 NM_001908.1 g4503138 199 225187_atDBC-1 p30 DBC protein 8p22 Consensussequence Hs.181102.2 BC003172.1Hs.181102.2 200 210762_s_at DLC1 deleted in liver cancer 18p22-p21.3 Exemplarsequence Hs.8700.0 AF026219.1 g2559001 201224822_at DLC1 deleted in liver cancer 1 8p22-p21.3Consensussequence Hs.8700.1 AA524250 Hs.8700.1.S2 202 222730_s_atZDHHC2 zinc finger, DHHC domain containing 2 8p21.3-p22Consensussequence Hs.5943.0 AI814257 Hs.5943.0.S1 203 222731_atZDHHC2 zinc finger, DHHC domain containing 2 8p21.3-p22Consensussequence Hs.5943.0 AI814257 Hs.5943.0.S1 204 212866_atHomo sapiens, similar to hypothetical Consensussequence Hs.300861.0AI081543 Hs.300861.0 protein DKFZp564N123.1 - human (fragment),clone IMAGE: 5220614, mRNA 205 212110_at KIAA0062 KIAA0062 protein8p21.2 Consensussequence Hs.89868.0 D31887.1 Hs.89868.0_RC

206 220686_s_at PIWIL2 piwi-like 2 (Drosophila) 8p21.2Exemplarsequence Hs.274150.0 NM_018068.1 g8922369 207 221094_s_atELP3 likely ortholog of mouse elongation protein 3 8p21.1Exemplarsequence Hs.267905.0 NM_018091.1 g8922417 homolog (S.cerevisiae) 208 225609_at GSR glutathione reductase 8p21.1Consensussequence Hs.193974.0 AI888037 Hs.193974.0.S1 209 227102_atTRIM35 tripartite motif-containing 35 8p21.1 ConsensussequenceHs.137732.0 AA115933 Hs.137732.0 210 241252_at LOC157570hypothetical protein LOC157570 8p21.1 Consensussequence Hs.99480.1AI732824 Hs.99480.1_RC 211 218955_at BRF2 BRF2, subunit of RNApolymerase III 8p11.1 Exemplarsequence Hs.274136.0 NM_018310.1g8922843 transcription initiation factor, BRF1-like 212 228189_atBAG4 BCL2-associated athanogene 4 8p11.21 ConsensussequenceHs.7859.0 T32429 Hs.7859.0.A1 213 223568_s_at HTPAP HTPAP protein8p11.21 Exemplarsequence Hs.169341.0 AF212238.1 g13182756 214226384_at HTPAP HTPAP protein 8p11.21 Consensussequence Hs.8841.0BE858787 Hs.8841.0.A1 215 220985_s_at DKFZP564A022 hypotheticalprotein DKFZp564A022 8p11.1 Exemplarsequence g13569925 NM_030954.1g13569925 216 224776_at DKFZp586M1819 hypothetical proteinDKFZp586M1819 8p11.1 Consensussequence Hs.25664.1 BF513102Hs.25664.1.A1 217 226104_at DKFZP564A022 hypothetical proteinDKFZp564A022 8p11.1 Consensussequence Hs.22629.0 AI052736Hs.22629.0_RC 218 221542_s_at C8orf2 chromosome 8 open readingframe 2 8p11.2 Consensussequence Hs.125849.0 T90773 Hs.125849.0 219221543_s_at C8orf2 chromosome 8 open reading frame 2 8p11.2Exemplarsequence Hs.125849.0 AL442077.1 g10241715 220 209341_s_atIKBKB inhibitor of kappa light polypeptide gene 8p11.2Consensussequence Hs.226573.0 AU153366 Hs.226573.0 enhancer inB-cells, kinase beta 221 209385_s_at PROSC proline synthetaseco-transcribed homolog 8p11.2 Exemplarsequence Hs.301959.0AL136616.1 g12052757 (bacterial) 222 207859_s_at CHRNB3 cholinergicreceptor, nicotinic, beta 8p11.2 Exemplarsequence Hs.96094.0NM_000749.1 g4502834 polypeptide 3 223 209342_s_at IKBKB inhibitorof kappa light polypeptide gene 8p11.2 Exemplarsequence Hs.226573.0AF080158.1 g4185274 enhancer in B-cells, kinase beta 224 228790_atMGC39325 hypothetical protein MGC39325 8q11.23 ConsensussequenceHs.74280.0 AW264082 Hs.74280.0 225 222536_s_at DKFZp434K1210hypothetical protein DKFZp434K1210 8p21.1 ConsensussequenceHs.32352.0 N36098 Hs.32352.0.S1 226 229139_at Homo sapiens, cloneIMAGE: 4245141, Consensussequence Hs.293836.0 AI202201Hs.293836.0.A1 mRNA 227 207013_s_at MMP16 matrix metalloproteinase16 (membrane- 8q21 Exemplarsequence Hs.90800.1 AB009303.1 g2662305inserted) 228 219416_at SCARA3 scavenger receptor class A, member 38p21 Exemplarsequence Hs.128856.0 NM_016240.1 g7705335 # SequenceSource Unigene_Accession Cluster_Type LocusLinkFull_Length_Reference_Seq 1 GenBank Hs.25590 fulllength 6781NM_003155; stanniocalcin 1 2 GenBank Hs.16292 est 3 GenBankHs.42474 fulllength 9242 NM_005098; musculin (activated B-cellfactor-1) 4 RefSeq Hs.119684 fulllength 8794 NM_003841; tumornecrosis factor receptor superfamily, member 10c precursor 5GenBank Hs.52931 fulllength 148 NM_000680; alpha-1A-adrenergicreceptor isoform 1 NM_033302; alpha- 1A-adrenergic receptor isoform3 NM_033303; alpha-1A-adrenergic receptor isoform 2 NM_033304;alpha-1A-adrenergic receptor isoform 4 6 RefSeq Hs.289063fulllength 80346 NM_025232; hypothetical protein FLJ22246 7 GenBankHs.172685 fulllength 23039 NM_015024; exportin 7 8 GenBankHs.380963 fulllength 29883 NM_013354; CCR4-NOT transcriptioncomplex, subunit 7 isoform 1 NM_054026; CCR4-NOT transcriptioncomplex, subunit 7 isoform 2 9 GenBank Hs.375560 fulllength 286057NM_173686; hypothetical protein FLJ34715 10 GenBank Hs.7471fulllength 83877 NM_031940; BBP-like protein 1 isoform b NM_078473;BBP-like protein 1 isoform a 11 RefSeq Hs.131255 fulllength 7381NM_006294; ubiquinol-cytochrome c reductase binding protein 12GenBank Hs.41185 fulllength 157869 NM_153225; hypothetical proteinFLJ40021 13 GenBank Hs.167011 14 GenBank Hs.44222 fulllength 51115NM_016033; CGI-90 protein 15 GenBank Hs.278634 23514 16 GenBankHs.79300 fulllength 7336 NM_003350; ubiquitin-conjugating enzyme E2variant 2 17 RefSeq Hs.288716 fulllength 80185 NM_025115;hypothetical protein FLJ23263 18 RefSeq Hs.404119 fulllength 7264NM_003313; tissue specific transplantation antigen P35B 19 GenBankHs.4147 fulllength 23471 NM_014294; translocating chain-associatingmembrane protein 20 GenBank Hs.98471 est 137682 NM_152416;hypothetical protein MGC40214 21 RefSeq Hs.170198 fulllength 9650NM_014637; KIAA0009 gene product 22 RefSeq Hs.169395 fulllength79870 NM_024812; brain and acute leukemia, cytoplasmic 23 GenBankHs.55043 24 GenBank Hs.27410 fulllength 55893 NM_018660;papillomavirus regulatory factor PRF-1 25 GenBank Hs.170198fulllength 9650 NM_014637; KIAA0009 gene product 26 GenBankHs.243901 fulllength 27 RefSeq Hs.77100 fulllength 2961 NM_002095;general transcription factor IIE, polypeptide 2, beta 34 kDa 28GenBank Hs.75106 fulllength 1191 NM_001831; clusterin 29 GenBankHs.75106 fulllength 1191 NM_001831; clusterin 30 RefSeq Hs.3815fulllength 81551 NM_030795; stathmin-like-protein RB3 31 GenBankHs.748 fulllength 2260 NM_000604; fibroblast growth factor receptor1 isoform 1 precursor NM_015850; fibroblast growth factor receptor1 isoform 2 precursor NM_023105; fibroblast growth factor receptor1 isoform 3 precursor NM_023106; fibroblast growth factor receptor1 isoform 4 precursor NM_023107; fibroblast growth factor receptor1 isoform 5 precursor NM_023108; fibroblast growth factor receptor1 isoform 6 precursor NM_023109; fibroblast growth factor receptor1 isoform 7 precursor NM_023110; fibroblast growth factor receptor1 isoform 8 precursor NM_023111; fibroblast growth factor receptor1 isoform 9 precursor 32 RefSeq Hs.27721 fulllength 54904NM_017778; WHSC1L1 protein isoform short NM_023034; WHSC1L1 proteinisoform long 33 GenBank Hs.273344 fulllength 25879 NM_014156;NM_015420; DKFZP564O0463 protein 34 RefSeq Hs.169615 fulllength65265 NM_023080; hypothetical protein FLJ20989 35 GenBank Hs.406141fulllength 137695 NM_152417; hypothetical protein FLJ32370 36GenBank Hs.48876 fulllength 2222 NM_004462; farnesyl-diphosphatefarnesyltransferase 1 37 GenBank Hs.356463 fulllength 2339NM_002027; farnesyltransferase, CAAX box, alpha 38 RefSeq Hs.380963fulllength 29883 NM_013354; CCR4-NOT transcription complex, subunit7 isoform 1 NM_054026; CCR4-NOT transcription complex, subunit 7isoform 2 39 RefSeq Hs.75737 fulllength 5108 NM_006197;pericentriolar material 1 40 GenBank Hs.75737 fulllength 5108NM_006197; pericentriolar material 1 41 GenBank Hs.75737 fulllength5108 NM_006197; pericentriolar material 1 42 GenBank Hs.27721fulllength 54904 NM_017778; WHSC1L1 protein isoform shortNM_023034; WHSC1L1 protein isoform long 43 RefSeq Hs.55097fulllength 28957 NM_014018; mitochondrial ribosomal protein S28 44GenBank Hs.840 fulllength 3620 NM_002164; indoleamine-pyrrole 2,3dioxygenase 45 RefSeq Hs.4742 fulllength 8733 NM_003801; anchorattachment protein 1 46 RefSeq Hs.178551 fulllength 6132 NM_000973;ribosomal protein L8 NM_033301; ribosomal protein L8 47 GenBankHs.331601 fulllength 157542 48 GenBank Hs.343589 fulllength 54512NM_019037; exosome complex exonuclease RRP41 49 GenBank Hs.10669fulllength 50807 50 GenBank Hs.86970 est 51 RefSeq Hs.23019fulllength 7564 NM_006958; zinc finger protein 16 (KOX 9) 52GenBank Hs.243901 fulllength 53 GenBank Hs.33074 54 GenBankHs.403869 fulllength 137392 NM_145269; similar to CG6405 geneproduct 55 RefSeq Hs.14158 fulllength 8895 NM_003909; copine III 56RefSeq Hs.99519 fulllength 79752 NM_024699; hypothetical proteinFLJ14007 57 Refseq Hs.1276 fulllength 661 NM_001722; RNA polymeraseIII 53 kDa subunit RPC4 58 GenBank Hs.182364 fulllength 83690NM_031461; CocoaCrisp 59 GenBank Hs.94631 fulllength 10565NM_006421; brefeldin A-inhibited guanine nucleotide-exchangeprotein 1 60 GenBank Hs.194562 fulllength 7013 NM_003218; telomericrepeat binding factor 1 isoform 2 NM_017489; telomeric repeatbinding factor 1 isoform 1 61 RefSeq Hs.5333 fulllength 9920NM_014867; KIAA0711 gene product 62 GenBank Hs.75811 fulllength 427NM_004315; N-acylsphingosine amidohydrolase (acid ceramidase) 1isoform b NM_177924; N-acylsphingosine amidohydralase (acidceramidase) 1 preproprotein isoform a 63 GenBank Hs.75737fulllength 5108 NM_006197; pericentriolar material 1 64 RefSeqHs.172816 fulllength 3084 NM_004495; neuregulin 1 isoform HRG-gammaNM_013956; neuregulin 1 isoform NRG-beta1 NM_013957; neuregulin 1isoform HRG-beta2 NM_013958; neuregulin 1 isoform HRG-beta3NM_013959; neuregulin 1 isoform SMDF NM_013960; neuregulin 1isoform ndf43 NM_013961; neuregulin 1 isoform GGF NM_013962;neuregulin 1 isoform GGF2 NM_013964; neuregulin 1 isoform HRG-alpha65 RefSeq Hs.193974 fulllength 2936 NM_000637; glutathionereductase 66 RefSeq Hs.7953 fulllength 51125 NM_016099; NSPC041protein 67 GenBank Hs.6856 fulllength 9070 NM_004674; ash2 (absent,small, or homeotic)-like 68 GenBank Hs.301959 fulllength 11212NM_007198; proline synthetase co-transcribed homolog 69 GenBankHs.169615 fulllength 65265 NM_023080; hypothetical protein FLJ2098970 RefSeq Hs.40866 fulllength 3786 NM_004519; potassiumvoltage-gated channel KQT-like protein 3 71 GenBank Hs.195870fulllength 84955 NM_032869; chronic myelogenous leukemia tumorantigen 66 72 RefSeq Hs.8102 fulllength 6224 NM_001023; ribosomalprotein S20 73 GenBank Hs.72085 fulllength 55246 NM_018246;hypothetical protein FLJ10853 74 GenBank Hs.19673 fulllength 84232NM_032272; homolog of yeast MAF1 75 RefSeq Hs.339697 fulllength51160 NM_016208; VPS28 protein 76 GenBank Hs.11810 fulllength 83940NM_032026; CDA11 protein 77 GenBank Hs.187646 fulllength 157378 78RefSeq Hs.9222 fulllength 9166 NM_004215; estrogen receptor bindingsite associated antigen 9 79 RefSeq Hs.23528 fulllength 51123NM_016096; HSPC038 protein 80 RefSeq Hs.77329 fulllength 9791NM_014754; phosphatidylserine synthase 1 81 GenBank Hs.153746fulllength 79848 NM_024790; hypothetical protein FLJ22490 82GenBank Hs.8102 fulllength 6224 NM_001023; ribosomal protein S20 83GenBank Hs.416904 84 GenBank Hs.48876 fulllength 2222 NM_004462;farnesyl-diphosphate farnesyltransferase 1 85 GenBank Hs.356463fulllength 2339 NM_002027; farnesyltransferase, CAAX box, alpha 86GenBank Hs.101617 fulllength 137492 NM_152415; hypothetical proteinFLJ32642 87 GenBank Hs.101617 fulllength 137492 NM_152415;hypothetical protein FLJ32642 88 RefSeq Hs.8294 fulllength 9897NM_014846; KIAA0196 gene product 89 RefSeq Hs.75206 fulllength 5533NM_005605; protein phosphatase 3 (formerly 2B), catalytic subunit,gamma isoform (calcineurin A gamma) 90 GenBank Hs.267905 fulllength55140 NM_018091; elongation protein 3 homolog 91 GenBank Hs.211584fulllength 4747 NM_006158; neurofilament, light polypeptide 68 kDa92 GenBank Hs.326744 fulllength 84750 NM_032664; fucosyltransferase10 93 GenBank Hs.301959 fulllength 11212 NM_007198; prolinesynthetase co-transcribed homolog 94 RefSeq Hs.288057 fulllength80140 NM_025070; hypothetical protein FLJ22242 95 GenBank Hs.238928fulllength 28991 NM_014066; hypertension-related calcium-regulatedgene 96 RefSeq Hs.87729 fulllength 64798 NM_022783; hypotheticalprotein FLJ12428 97 GenBank Hs.86905 fulllength 528 NM_001695;ATPase, H+ transporting, lysosomal 42 kD, V1 subunit C, isoform 198 GenBank Hs.131255 fulllength 7381 NM_006294;ubiquinol-cytochrome c reductase binding protein 99 GenBankHs.88594 169200 100 RefSeq Hs.44222 fulllength 51115 NM_016033;CGI-90 protein 101 RefSeq Hs.380969 fulllength 10987 NM_006837;COP9 constitutive photomorphogenic homolog subunit 5 102 GenBankHs.397426 286180 103 GenBank Hs.48802 fulllength 66036 NM_015458;myotubularin related protein 9 104 GenBank Hs.118554 fulllength51110 NM_016027; lactamase, beta 2 105 GenBank Hs.446548 est 106RefSeq Hs.15562 fulllength 55756 NM_018250; hypothetical proteinFLJ10871 107 GenBank Hs.153678 fulllength 7993 NM_005671;reproduction 8

108 GenBank Hs.7381 fulllength 7419 NM_005662; voltage-dependentanion channel 3 109 GenBank Hs.334798 fulllength 1936 NM_001960;eukaryotic translation elongation factor 1 delta isoform 2NM_032378; eukaryotic translation elongation factor 1 delta isoform1 110 RefSeq Hs.12271 fulllength 26233 NM_012162; F-box andleucine-rich repeat protein 6 isoform 1 NM_024555; F-box andleucine-rich repeat protein 6 isoform 2 111 GenBank Hs.4742fulllength 8733 NM_003801; anchor attachment protein 1 112 GenBankHs.339697 fulllength 51160 NM_016208; VPS28 protein 113 GenBankHs.376544 114 GenBank Hs.239784 est 23513 NM_015356; scribble 115GenBank Hs.404119 fulllength 7264 NM_003313; tissue specifictransplantation antigen P35B 116 GenBank Hs.122254 est 117 RefSeqHs.334798 fulllength 1936 NM_001960; eukaryotic translationelongation factor 1 delta isoform 2 NM_032378; eukaryotictranslation elongation factor 1 delta isoform 1 118 GenBank Hs.6459fulllength 79581 NM_024531; putative G-protein coupled receptorGPCR41 119 GenBank Hs.300224 fulllength 51236 NM_016458; brainprotein 16 120 RefSeq Hs.77667 fulllength 4061 NM_002346;lymphocyte antigen 6 complex, locus E 121 GenBank Hs.332040fulllength 84773 NM_032687; hypothetical protein MGC13010 122GenBank Hs.12185 fulllength 84988 NM_032902; protein phosphatase 1,regulatory (inhibitor) subunit 16A 123 GenBank Hs.318725 fulllength51105 NM_016018; CGI-72 protein 124 GenBank Hs.44159 fulllength84165 NM_032205; hypothetical protein FLJ21615 125 GenBankHs.318725 fulllength 51105 NM_016018; CGI-72 protein 126 GenBankHs.15611 57623 127 GenBank Hs.10669 fulllength 50807 128 GenBankHs.10669 fulllength 50807 129 GenBank Hs.344478 fulllength 286053NM_173685; hypothetical protein FLJ32440 130 GenBank Hs.100691 131GenBank Hs.95631 fulllength 93594 NM_145647; unknown MGC21654product 132 GenBank Hs.241576 fulllength 55493 133 GenBank Hs.49136134 GenBank Hs.222088 fulllength 29028 NM_014109; PRO2000 proteinNM_032365; 135 RefSeq Hs.30209 fulllength 22882 NM_014943;transcription factor ZHX2 136 RefSeq Hs.79070 fulllength 4609NM_002467; v-myc myelocytomatosis viral oncogene homolog 137 RefSeqHs.95011 fulllength 6641 NM_021021; basic beta 1 syntrophin 138GenBank Hs.432544 139 RefSeq Hs.283740 fulllength 56943 NM_020189;DC6 protein 140 GenBank Hs.9222 fulllength 9166 NM_004215; estrogenreceptor binding site associated antigen 9 141 RefSeq Hs.169111fulllength 55074 NM_018002; oxidation resistance 1 142 RefSeqHs.211458 fulllength 81501 NM_030788; dendritic cell-specifictransmembrane protein 143 GenBank Hs.169111 fulllength 55074NM_018002; oxidation resistance 1 144 GenBank Hs.169111 fulllength55074 NM_018002; oxidation resistance 1 145 GenBank Hs.106673fulllength 3646 NM_001568; murine mammary tumor integration site 6(oncogene homolog) 146 GenBank Hs.290880 147 RefSeq Hs.351475fulllength 5440 NM_005034; DNA directed RNA polymerase IIpolypeptide K 148 RefSeq Hs.86905 fulllength 528 NM_001695; ATPase,H+ transporting, lysosomal 42 kD, V1 subunit C, isoform 1 149GenBank Hs.273344 fulllength 25879 NM_014156; NM_015420;DKFZP564O0463 protein 150 RefSeq Hs.197335 fulllength 10404NM_006102; NM_016134; plasma glutamate carboxypeptidase 151 GenBankHs.16621 fulllength 25962 NM_015496; DKFZP43AI116 protein 152RefSeq Hs.279521 fulllength 55656 NM_017864; hypothetical proteinFLJ20530 153 GenBank Hs.6390 fulllength 154 GenBank Hs.6390fulllength 155 GenBank Hs.243901 fulllength 156 GenBank Hs.29724fulllength 79666 NM_024613; phafin 2 157 GenBank Hs.50273 est 158GenBank Hs.6390 fulllength 159 GenBank Hs.165539 160 GenBankHs.18426 fulllength 10247 NM_005836; translational inhibitorprotein p14.5 161 GenBank Hs.131255 fulllength 7381 NM_006294;ubiquinol-cytochrome c reductase binding protein 162 GenBankHs.48320 fulllength 25897 NM_015435; ring finger protein 19 163GenBank Hs.14158 fulllength 8895 NM_003909; copine III 164 GenBankHs.180612 fulllength 5828 NM_000318; peroxisomal membrane protein 3165 GenBank Hs.25812 fulllength 4683 NM_002485; nibrin 166 RefSeqHs.25812 fulllength 4683 NM_002485; nibrin 167 RefSeq Hs.90800fulllength 4325 NM_005941; matrix metalloproteinase 16 isoform 1NM_022564; matrix metalloproteinase 16 isoform 2 168 GenBankHs.25812 fulllength 4683 NM_002485; nibrin 169 GenBank Hs.25812fulllength 4683 NM_002485; nibrin 170 RefSeq Hs.96870 fulllength27067 NM_014393; staufen homolog 2 171 RefSeq Hs.106650 fulllength54968 NM_017866; hypothetical protein FLJ20533 172 GenBankHs.106650 fulllength 54968 NM_017866; hypothetical protein FLJ20533173 GenBank Hs.168950 174 RefSeq Hs.4147 fulllength 23471NM_014294; translocating chain-associating membrane protein 175RefSeq Hs.94631 fulllength 10565 NM_006421; brefeldin A-inhibitedguanine nucleotide-exchange protein 1 176 GenBank Hs.94631fulllength 10565 NM_006421; brefeldin A-inhibited guaninenucleotide-exchange protein 1 177 GenBank Hs.406325 fulllength 5150NM_002603; phosphodiesterase 7A isoform a NM_002604;phosphodiesterase 7A isoform b 178 GenBank Hs.97603 179 GenBankHs.306621 180 RefSeq Hs.380877 fulllength 23678 NM_013257;serum/glucocorticoid regulated kinase-like isoform 1 NM_170709;serum/glucocorticoid regulated kinase-like isoform 2 181 GenBankHs.380877 fulllength 23678 NM_013257; serum/glucocorticoidregulated kinase-like isoform 1 NM_170709; serum/glucocorticoidregulated kinase-like isoform 2 182 RefSeq Hs.106768 fulllength55156 NM_018120; armadillo repeat-containing protein 183 GenBankHs.106768 fulllength 55156 NM_018120; armadillo repeat-containingprotein 184 GenBank Hs.332422 fulllength 157807 NM_173519;hypothetical protein MGC34646 185 GenBank Hs.283664 fulllength 444NM_004318; aspartate beta-hydroxylase isoform a NM_020164;aspartate beta-hydroxylase isoform e NM_032466; aspartate beta-hydroxylase isoform c NM_032467; aspartate beta-hydroxylase isoformd NM_032468; aspartate beta-hydroxylase isoform b 186 GenBankHs.78305 fulllength 5862 NM_002865; RAB2, member RAS oncogenefamily 187 GenBank Hs.78305 fulllength 5862 NM_002865; RAB2, memberRAS oncogene family 188 GenBank Hs.323164 fulllength 79145NM_024300; hypothetical protein MGC2217 189 GenBank Hs.60293fulllength 115294 NM_052937; similar to hypothetical proteinFLJ10883 190 GenBank Hs.60293 fulllength 115294 NM_052937; similarto hypothetical protein FLJ10883 191 GenBank Hs.79300 fulllength7336 NM_003350; ubiquitin-conjugating enzyme E2 variant 2 192RefSeq Hs.72887 fulllength 1670 NM_021010; defensin, alpha 5,preproprotein 193 RefSeq Hs.26458 fulllength 4482 NM_012331;methionine sulfoxide reductase A 194 GenBank Hs.24724 195 GenBankHs.24724 196 GenBank Hs.19575 fulllength 51606 NM_015941; ATPase,H+ transporting, lysosomal 50/57 kDa, V1 subunit H 197 RefSeqHs.173381 fulllength 1808 NM_001386; dihydropyrimidinase-like 2 198RefSeq Hs.297939 fulllength 1508 NM_001908; cathepsin Bpreproprotein NM_147780; cathepsin B preproprotein NM_147781;cathepsin B preproprotein NM_147782; cathepsin B preproproteinNM_147783; cathepsin B preproprotein 199 GenBank Hs.352416fulllength 57805 NM_021174; p30 DBC protein 200 GenBank Hs.8700fulllength 10395 NM_006094; deleted in liver cancer 1 NM_024767;deleted in liver cancer 1 201 GenBank Hs.8700 fulllength 10395NM_006094; deleted in liver cancer 1 NM_024767; deleted in livercancer 1 202 GenBank Hs.5943 fulllength 51201 NM_016353; rec 203GenBank Hs.5943 fulllength 51201 NM_016353; rec 204 GenBankHs.300861 205 GenBank Hs.89868 fulllength 23516 206 RefSeqHs.274150 fulllength 55124 NM_018068; piwi-like 2 207 RefSeqHs.267905 fulllength 55140 NM_018091; elongation protein 3 homolog208 GenBank Hs.193974 fulllength 2936 NM_000637; glutathionereductase 209 GenBank Hs.137732 fulllength 23087 NM_015066;tripartite motif-containing 35 isoform 1 NM_171982; tripartitemotif-containing 35 isoform 2 210 GenBank Hs.99480 157570 211RefSeq Hs.274136 fulllength 55290 NM_018310; RNA polymerase IIItranscription initiation factor BRF2 212 GenBank Hs.194726fulllength 9530 NM_004874; BCL2-associated athanogene 4 213 GenBankHs.406670 fulllength 84513 NM_032483; HTPAP protein 214 GenBankHs.406670 fulllength 84513 NM_032483; HTPAP protein 215 RefSeqHs.170822 fulllength 81790 NM_030954; hypothetical proteinDKFZp564A022 216 GenBank Hs.355753 137964 NM_178819; putativelysophosphatidic acid acyltransferase 217 GenBank Hs.170822fulllength 81790 NM_030954; hypothetical protein DKFZp564A022 218GenBank Hs.125849 fulllength 11160 NM_007175; chromosome 8 openreading frame 2 219 GenBank Hs.125849 fulllength 11160 NM_007175;chromosome 8 open reading frame 2 220 GenBank Hs.226573 fulllength3551 221 GenBank Hs.301959 fulllength 11212 NM_007198; prolinesynthetase co-transcribed homolog 222 RefSeq Hs.96094 fulllength1142 NM_000749; cholinergic receptor, nicotinic, beta polypeptide 3223 GenBank Hs.226573 fulllength 3551 224 GenBank Hs.34054fulllength 90362 NM_147189; hypothetical protein MGC39325 225GenBank Hs.32352 fulllength 54775 NM_017606; hypothetical proteinDKFZp434K1210 226 GenBank Hs.293836 227 GenBank Hs.90800 fulllength4325 NM_005941; matrix metalloproteinase 16 isoform 1 NM_022564;matrix metalloproteinase 16 isoform 2 228 RefSeq Hs.128856fulllength 51435 NM_016240; CSR1 protein

TABLE-US-00026 TABLE 25 _inv(16) # affy Id HUGO name F p q TitleMapLocation Sequence Type Transcript ID 1 218018_at C21orf97 157.772.09e-16 8.17e-12 chromosome 21 open reading frame 97 21q22.3Consensussequence Hs.4746.0 2 212608_s_at 140.44 7.66e-15 1.50e-10Homo sapiens clone 23872 mRNA sequence ConsensussequenceHs.323470.0 3 228848_at ABTB1 136.11 2.19e-14 2.85e-10 ankyrinrepeat and BTB (POZ) domain containing 1 3q21 ConsensussequenceHs.107812.1 4 221357_at CHRM4 132.03 3.41e-14 3.33e-10 cholinergicreceptor, muscarinic 4 11p12-p11.2 Exemplarsequence Hs.248100.0 5210690_at KLRC4 117.63 5.89e-05 3.37e-03 killer cell lectin-likereceptor subfamily C, member 4 12p13.2-p12.3 ExemplarsequenceHs.268510.0 6 205495_s_at GNLY 113.09 5.07e-14 3.96e-10 granulysin2p12-q11 Exemplarsequence Hs.105806.1 7 218786_at 103.51 2.65e-081.23e-05 ESTs Exemplarsequence Hs.6341.0 8 234699_at RNASE7 100.223.85e-13 2.34e-09 ribonuclease, RNase A family, 7 14q11.1Consensussequence Hs.307078.0 9 201454_s_at NPEPPS 99.82 6.90e-107.28e-07 aminopeptidase puromycin sensitive 17q21 ConsensussequenceHs.293007.0 10 231558_at INSM1 99.36 4.79e-13 2.34e-09insulinoma-associated 1 20p11.2 Consensussequence Hs.89584.1 11202174_s_at PCM1 98.55 3.22e-05 2.17e-03 pericentriolar material 18p22-p21.3 Exemplarsequence Hs.75737.0 12 230881_at FLJ32734 98.264.34e-13 2.34e-09 hypothetical protein FLJ32734 17p13.1Consensussequence Hs.121438.0 13 224755_at SMBP 97.89 4.72e-079.36e-05 SM-11044 binding protein 10q23.33 ConsensussequenceHs.8203.1 14 241623_at PTPN2 92.45 3.51e-09 2.48e-06 proteintyrosine phosphatase, non-receptor type 2 18p11.3-p11.2Consensussequence Hs.150755.0 15 211793_s_at ABI-2 92.45 3.80e-105.11e-07 abl-interactor 2 2q33 Exemplarsequence Hs.256315.3 16200779_at ATF4 91.63 8.12e-10 8.13e-07 activating transcriptionfactor 4 (tax-responsive enhancer element B67) 22q13.1Exemplarsequence Hs.181243.0 17 244777_at 89.48 1.41e-10 2.63e-07Homo sapiens, Similar to RIKEN cDNA 5730537H01 gene, cloneConsensussequence Hs.111418.0 IMAGE: 4617463, mRNA 18 209996_x_atPCM1 88.78 1.99e-09 1.65e-06 pericentriolar material 1 8p22-p21.3Consensussequence Hs.315478.0 19 221749_at FLJ31657 87.59 6.72e-082.39e-05 hypothetical protein FLJ31657 8q12.1 ConsensussequenceHs.5518.0 20 206179_s_at p25 86.81 4.14e-12 1.80e-08 brain-specificprotein p25 alpha 5p15.3 Exemplarsequence Hs.29353.0 21 215693_x_atDDX27 83.97 9.81e-07 1.63e-04 DEAD/H (Asp-Glu-Ala-Asp/His) boxpolypeptide 27 20q13.13 Consensussequence Hs.65234.2 22 209510_atTRC8 83.43 2.57e-09 2.05e-06 patched related protein translocatedin renal cancer 8q24 Exemplarsequence Hs.28285.0 23 231179_at IHPK382.29 1.13e-11 3.68e-08 inositol hexaphosphate kinase 3 6p21.31Consensussequence Hs.17253.0 24 204530_s_at TOX 80.94 3.28e-041.22e-02 thymus high mobility group box protein TOX 8q11.23Exemplarsequence Hs.184297.0 25 208617_s_at PTP4A2 80.90 1.02e-113.68e-08 protein tyrosine phosphatase type IVA, member 2 1p35Exemplarsequence Hs.82911.0 26 236296_x_at FLJ34715 80.69 2.61e-051.87e-03 hypothetical protein FLJ34715 8p21.2 ConsensussequenceHs.197445.0 27 232532_at DKFZP434P0316 80.42 4.69e-11 1.15e-07hypothetical protein DKFZp434P0316 17q25.3 ConsensussequenceHs.252739.0 28 234480_at DKFZP781C1711 80.10 1.11e-11 3.68e-08hypothetical protein DKFZp761C1711 Consensussequence Hs.285786.0 29229819_at A1BG 80.05 1.06e-07 3.21e-05 alpha-1-B glycoprotein19q13.4 Consensussequence Hs.41997.0 30 233108_at DSCR3 78.851.31e-11 3.93e-08 Down syndrome critical region gene 3 21q22.2Consensussequence Hs.296548.0 31 237314_at MGC26778 78.50 5.13e-065.52e-04 hypothetical protein MGC26778 10p12.1 ConsensussequenceHs.232407.0 32 218150_at ARL5 77.10 4.96e-10 5.77e-07ADP-ribosylation factor-like 5 2q23.3 Exemplarsequence Hs.42500.033 223921_s_at GBA2 75.40 2.50e-11 6.91e-08 glucosidase, beta (bileacid) 2 9p13.1 Exemplarsequence Hs.173422.0 34 214230_at CDC4274.64 5.35e-05 3.18e-03 cell division cycle 42 (GTP bindingprotein, 25 kDa) 1p36.1 Consensussequence Hs.146409.3 35 210022_atNSPC1 73.75 4.43e-11 1.15e-07 likely ortholog of mouse nervoussystem polycomb 1 2p12 Exemplarsequence Hs.316750.0 36 213545_x_atSNX3 73.07 5.23e-10 5.83e-07 sorting nexin 3 6q21 ConsensussequenceHs.12102.2 37 242568_s_at 72.71 5.37e-11 1.23e-07 Homo sapiens cDNAFLJ38922 fis, clone NT2NE2011691. Consensussequence Hs.97259.1 38207924_x_at PAX8 71.11 6.51e-11 1.41e-07 paired box gene 8 2q12-14Exemplarsequence Hs.73149.2 39 218121_at HMOX2 70.74 3.68e-081.55e-05 heme oxygenase (decycling) 2 16p13.3 ExemplarsequenceHs.284279.0 40 243915_at 70.48 1.08e-10 2.22e-07 ESTs, Weaklysimilar to hypothetical protein FLJ20378 [Homo sapiens]Consensussequence Hs.205853.0 [H. sapiens] 41 228786_at 69.794.52e-05 2.79e-03 Homo sapiens cDNA FLJ31518 fis, cloneNT2RI2000064. Consensussequence Hs.55962.0 42 217429_at 68.969.73e-10 9.50e-07 Homo sapiens mRNA; cDNA DKFZp564A216 (from cloneConsensussequence Hs.274505.0 DKFZp564A216) 43 229617_x_at FLJ2268868.05 1.46e-08 7.50e-06 hypothetical protein FLJ22688 19q13.33Consensussequence Hs.288800.2 44 224741_x_at 67.99 1.27e-102.49e-07 Homo sapiens mRNA; cDNA DKFZp564D0164 (from cloneConsensussequence Hs.289721.1 DKFZp564D0164) 45 244271_at 67.082.07e-10 3.11e-07 ESTs, Weakly similar 10 hypothetical proteinFLJ20378 [Homo sapiens] Consensussequence Hs.205015.0 [H. sapiens]46 232519_at 66.99 1.76e-10 2.87e-07 Homo sapiens cDNA FLJ13523fis, clone PLACE1005968. Consensussequence Hs.12865.1 47 202344_atHSF1 66.73 1.70e-10 2.87e-07 heat shock transcription factor 18q24.3 Exemplarsequence Hs.1499.0 48 203420_at FAM8A1 65.921.87e-10 2.93e-07 family with sequence similarity 8, member A16p22-p23 Exemplarsequence Hs.95260.0 49 228902_at NUP214 65.831.73e-10 2.87e-07 nucleoporin 214 kDa 9q34.1 ConsensussequenceHs.170285.2 50 242652_at 65.79 8.76e-08 2.79e-05 ESTsConsensussequence Hs.191754.0 # Sequence Derived From Sequence IDSequence Source Unigene_Accession Cluster_Type LocusLinkFull_Length_Reference_Seq 1 NM_021941.1 Hs.4746.0 GenBank Hs.4746fulllength 60683 NM_021941; chromosome 21 open reading frame 97 2W85912 Hs.323470.0.A1 GenBank Hs.188882 3 AW511257 Hs.107812.1.A1GenBank Hs.107812 fulllength 80325 NM_032548; ankyrin repeat andBTB (POZ) domain containing 1 isoform 1 NM_172027; ankyrin repeatand BTB (POZ) domain containing 1 isoform 2 NM_172028; ankyrinrepeat and BTB (POZ) domain containing 1 isoform 3 4 NM_000741.1g4502820 RefSeq Hs.248100 fulllength 1132 NM_000741; cholinergicreceptor, muscarinic 4 5 U96845.1 g2673988 GenBank Hs.268510fulllength 8302 NM_013431; killer cell lectin-like receptorsubfamily C, member 4 6 NM_006433.2 g7108343 RefSeq Hs.105806fulllength 10578 NM_006433; granulysin isoform NKG5 NM_012483;granulysin isoform 519 7 NM_016575.1 g7706748 RefSeq Hs.374350 est8 AJ131212.1 Hs.307078.0 GenBank Hs.307078 fulllength 84659NM_032572; ribonuclease 7 9 NM_006310.1 Hs.293007.0_RC GenBankHs.293007 fulllength 9520 NM_006310; aminopeptidase puromycinsensitive 10 BF108585 Hs.89584.1_RC GenBank Hs.89584 fulllength3642 NM_002196; insulinoma-associated 1 11 NM_006197.1 g5453855RefSeq Hs.75737 fulllength 5108 NM_006197; pericentriolar material1 12 AI200853 Hs.121438.0.A1 GenBank Hs.121438 fulllength 146849NM_144681; hypothetical protein FLJ32734 13 BE621524 Hs.8203.1GenBank Hs.8203 fulllength 56889 NM_020123; endomembrane proteinemp70 precursor isolog 14 AL119890 Hs.150755.0 GenBank Hs.82829fulllength 5771 NM_002828; protein tyrosine phosphatase,non-receptor type 2 isoform 1 NM_080422; protein tyrosinephosphatase, non-receptor type 2 isoform 2 NM_080423; proteintyrosine phosphatase, non-receptor type 2 15 AF260261.1 g7839523GenBank Hs.343575 fulllength 10152 NM_005759; abl-interactor 2 16NM_001675.1 g4502264 RefSeq Hs.181243 fulllength 468 NM_001675;activating transcription factor 4 17 AA504595 Hs.111418.0.A1GenBank Hs.367634 18 AA931266 Hs.315478.0 GenBank Hs.75737fulllength 5108 NM_006197; pericentriolar material 1 19 AU157915Hs.5518.0.S1 GenBank Hs.5518 fulllength 253943 NM_152758;hypothetical protein FLJ31657 20 NM_007030.1 g5902017 RefSeqHs.29353 fulllength 11076 NM_007030; brain-specific protein p25alpha 21 AL512707.1 Hs.65234.2 GenBank Hs.65234 fulllength 55661NM_017895; DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 27 22AF064801.1 g3395786 GenBank Hs.28285 fulllength 11236 NM_007218;ring finger protein 139 23 R99291 Hs.17253.0.A1 GenBank Hs.17253fulllength 117283 NM_054111; inositol hexaphosphate kinase 3 24NM_014729.1 g7662321 RefSeq Hs.184297 fulllength 9760 NM_014729;thymus high mobility group box protein TOX 25 AF208850.1 g7582287GenBank Hs.82911 fulllength 8073 NM_003479; protein tyrosinephosphatase type IVA, member 2 isoform 1 NM_080391; proteintyrosine phosphatase type IVA, member 2 isoform 1 NM_080392;protein tyrosine phosphatase type IVA, member 2 isoform 2 26AW295176 Hs.197445.0.A1 GenBank Hs.375560 fulllength 286057NM_173686; hypothetical protein FLJ34715 27 AL136774.1 Hs.252739.0GenBank Hs.252739 fulllength 84074 NM_032134; hypothetical proteinDKFZp434P0316 28 AL137340.1 Hs.285786.0 GenBank Hs.285786 57796 29AI022193 Hs.41997.0_RC GenBank Hs.373554 fulllength 1 NM_130786;alpha 1B-glycoprotein 30 AW613396 Hs.296548.0_RC GenBank Hs.26146fulllength 10311 NM_006052; Down syndrome critical region protein 331 AW119023 Hs.232407.0_RC GenBank Hs.209200 fulllength 219670NM_145010; hypothetical protein MGC26778 32 NM_012097.1 g6912243RefSeq Hs.342849 fulllength 26225 NM_012097; ADP-ribosylatlonfactor-like 5 isoform 1 NM_177985; ADP- ribosylation factor-like 5isoform 2 33 AF258662.1 g12005895 GenBank Hs.173422 fulllength57704 NM_020944; bile acid beta-glucosidase 34 R37664Hs.146409.3.S1 GenBank Hs.146409 fulllength 998 NM_001791; celldivision cycle 42 isoform 1 NM_044472; cell division cycle 42isoform 2 35 BC004952.1 g13436325 GenBank Hs.316750 fulllength84759 NM_032673; hypothetical protein MGC10882 36 BE962615Hs.12102.2_RC GenBank Hs.12102 fulllength 8724 NM_003795; sortingnexin 3 isoform a NM_152827; sorting nexin 3 isoform b NM_152828;sorting nexin 3 isoform c 37 BF995452 Hs.97259.1 GenBank Hs.43502638 NM_013992.1 g7669541 RefSeq Hs.73149 fulllength 7849 NM_003466;paired box gene 8 isoform PAX8A NM_013951; paired box gene 8isoform PAX8B NM_013952; paired box gene 8 isoform PAX8C NM_013953;paired box gene 8 isoform PAX8D NM_013992; paired box gene 8isoform PAX8E 39 NM_002134.2 g8051607 RefSeq Hs.284279 fulllength3163 NM_002134; heme oxygenase (decyclizing) 2 40 AW130385Hs.205853.0 GenBank Hs.369571 est 41 AA909523 Hs.55962.0_RC GenBankHs.433110 42 AL049307.1 Hs.274505.0.A1 GenBank Hs.274505 43AA729495 Hs.288800.2.A1 GenBank Hs.288800 fulllength 80199NM_025129; hypothetical protein FLJ22688 44 BG329175 Hs.289721.1.S1GenBank Hs.289721 45 AI697709 Hs.205015.0_RC GenBank Hs.205015 est46 AK023585.1 Hs.12865.1.A1 GenBank Hs.343962 47 NM_005526.1g5031766 RefSeq Hs.380935 fulllength 3297 NM_005526; heat shocktranscription factor 1 48 NM_016255.1 g7705267 RefSeq Hs.95260fulllength 51439 NM_016255; Autosomal Highly Conserved Protein 49AA516455 Hs.170285.2 GenBank Hs.170285 fulllength 8021 NM_005085;nucleoporin 214 kDa isoform 2 NM_153642; nucleoporin 214 kDaisoform 1 50 AI760942 Hs.191754.0_RC GenBank Hs.445968 est

TABLE-US-00027 TABLE 26 _inv(16) Sequence # affy id HUGO name TitleMapLocation Sequence Type Transcript ID Derived From Sequence ID 1225676_s_at DKFZP564O0463 DKFZP564O0463 protein 8q22.3Consensussequence Hs.273344.1 AK001693.1 Hs.273344.1 2 208423_s_atMSR1 macrophage scavenger receptor 1 8p22 Exemplarsequence Hs.49.0NM_002445.1 g4505258 3 218187_s_at FLJ20989 hypothetical proteinFLJ20989 Exemplarsequence Hs.169615.0 NM_023080.1 g12751496 4202344_at HSF1 heat shock transcription factor 1 8q24.3Exemplarsequence Hs.1499.0 NM_005526.1 g5031766 5 209899_s_atSIAHBP1 fuse-binding protein-interacting repressor 8q24.2-qtelExemplarsequence Hs.74562.0 AF217197.1 g6740005 6 33132_at CPSF1cleavage and polyadenylation specific factor 1, 160 kDa 8q24.23Consensussequence 8 U37012 4923232 7 229802_at Homo sapiens cDNAFLJ14388 fis, clone HEMBA1002716. Consensussequence Hs.9812.0AA147884 Hs.9812.0.A1 8 213122_at KIAA1750 KIAA1750 protein 8q22.1Consensussequence Hs.173094.0 AI096375 Hs.173094.0.S1 9 204865_atCA3 carbonic anhydrase III, muscle specific 8q13-q22Exemplarsequence Hs.82129.0 NM_005181.2 g6996001 10 201398_s_atTRAM translocating chain-associating membrane protein 8q13.1Exemplarsequence Hs.4147.0 BC000687.1 g12653796 11 203269_at NSMAFneutral sphingomyelinase (N-SMase) activation associated factor8q12-q13 Exemplarsequence Hs.78687.0 NM_003580.1 g4505464 12226483_at FLJ32370 hypothetical protein FLJ32370 8q11.23Consensussequence Hs.280858.1 AI890761 Hs.280858.1.A1 13 221367_atMOS v-mos Moloney murine sarcoma viral oncogene homolog 8q11Exemplarsequence Hs.248146.0 NM_005372.1 g4885488 14 233101_at Homosapiens cDNA FLJ12009 fis, clone HEMBB1001618. ConsensussequenceHs.287478.0 AK022071.1 Hs.287478.0 15 242387_at INM01 hypotheticalprotein INM01 8p23.3 Consensussequence Hs.289293.0 BF509686Hs.289293.0 16 208647_at FDFT1 farnesyl-diphosphatefarnesyltransferase 1 8p23.1-p22 Consensussequence Hs.48876.1AA872727 Hs.48876.1 17 218096_at FLJ11210 hypothetical proteinFLJ11210 8p23.1 Exemplarsequence Hs.27842.0 NM_018361.1 g8922941 18200090_at- FNTA farnesyltransferase, CAAX box, alpha 8p22-q11Consensussequence Hs.138381.1 BG168896 Hs.138381.1.A1 HG-U133A 19218250_s_at CNOT7 CCR4-NOT transcription complex, subunit 78p22-p21.3 Exemplarsequence Hs.226318.0 NM_013354.2 g10518495 20202174_s_at PCM1 pericentriolar material 1 8p22-p21.3Exemplarsequence Hs.75737.0 NM_006197.1 g5453855 21 214118_x_atPCM1 pericentriolar material 1 8p22-p21.3 ConsensussequenceHs.75737.1 AI205598 Hs.75737.1.S1 22 214937_x_at PCM1pericentriolar material 1 8p22-p21.3 Consensussequence Hs.75737.2AI924817 Hs.75737.2.S1 23 214054_at DOK2 docking protein 2, 56 kDa8p21.2 Consensussequence Hs.71215.0 AI828929 Hs.71215.0 24207595_s_at BMP1 bone morphogenetic protein 1 8p21 ExemplarsequenceHs.1274.3 NM_006132.1 g5902814 25 222544_s_at WHSC1L1Wolf-Hirschhom syndrome candidate 1-like 1 8p11.2 ConsensussequenceHs.27721.0 AI697751 Hs.27721.0_RC 26 230361_at ESTs, Weakiy similarto inner centromere protein [Mus musculus] ConsensussequenceHs.146109.0 AW664013 Hs.146109.0_RC [M. musculus] 27 219606_atCGI-72 CGI-72 protein 8q24.3 Exemplarsequence Hs.318725.0NM_016018.1 g7705782 28 225488_at MGC3067 hypothetical proteinMGC3067 8q24.13 Consensussequence Hs.323114.1 AI967978 Hs.323114.129 205608_s_at ANGPT1 angiopoietin 1 8q22.3-q23 ExemplarsequenceHs.2463.0 U83508.1 g1907326 30 205609_at ANGPT1 angiopoietin 18q22.3-q23 Exemplarsequence Hs.2463.0 NM_001146.1 g4502086 31220843_s_at DKFZP564O0463 DKFZP564O0463 protein 8q22.3Exemplarsequence Hs.273344.0 NM_014156.1 g7661767 32 235509_atMGC40214 hypothetical protein MGC40214 8q22.1 ConsensussequenceHs.98471.0 AV662196 Hs.98471.0_RC 33 231268_at Homo sapiens, cloneIMAGE: 5222754, mRNA, partial cds Consensussequence Hs.144027.0AI539459 Hs.144027.0.A1 34 213906_at MYBL1 v-myb myeloblastosisviral oncogene homolog (avian)-like 1 8q22 ConsensussequenceHs.300592.0 AW592266 Hs.300592.0.S1 35 219819_s_at MRPS28mitochondrial ribosomal protein S28 8q21.1-q21.2 ExemplarsequenceHs.55097.0 NM_014018.1 g7661729 36 203208_s_at CHPPR likelyortholog of chicken chondrocyte protein with a poly-proline region8q12.1 Exemplarsequence Hs.170198.0 NM_014637.1 g7661853 37223907_s_at PINX1 PIN2-interacting protein 1 8p23 ExemplarsequenceHs.99829.0 AF205718.1 g10504237 38 235801_at N33 Putative prostatecancer tumor suppressor 8p22 Consensussequence Hs.283526.0 AI760262Hs.283526.0_RC 39 230977_at LOC286056 hypothetical proteinLOC286056 8p21.2 Consensussequence Hs.131055.0 AI016313Hs.131055.0.A1 40 207287_at FLJ14107 hypothetical protein FLJ141078p21.2 Exemplarsequence Hs.287624.0 NM_025026.1 g13376547 41210029_at INDO indoleamine-pyrrole 2,3 dioxygenase 8p12-p11Exemplarsequence Hs.840.0 M34455.1 g185790 42 232040_at Homosapiens cDNA: FLJ22090 fis, clone Consensussequence Hs.170296.0AK025743.1 Hs.170296.0 HEP16084. 43 203534_at LSM1 LSM1 homolog, U6small nuclear RNA 8p11.2 Exemplarsequence Hs.111783.0 NM_014462.1g7657312 associated (S. cerevisiae) 44 208820_at PTK2 PTK2 proteintyrosine kinase 2 8q24-qter Consensussequence Hs.740.1 AL037339Hs.740.1.S2 45 201618_x_at GPAA1 GPAA1P anchor attachment protein 18q24.3 Exemplarsequence Hs.4742.0 NM_003801.2 g6031166 homolog(yeast) 46 200936_at RPL8 ribosomal protein L8 8q24.3Exemplarsequence Hs.178551.0 NM_000973.1 g4506662 47 213072_atLOC157542 hypothetical protein BC004544 8q24.3 ConsensussequenceHs.331601.0 AI928387 Hs.331601.0 48 58696_at FLJ20591 exosomecomponent Rrp41 8q24.3 Consensussequence 5 AL039469 4923514_rc 49218151_x_at FLJ11856 putative G-protein coupled receptor 8q24.3Exemplarsequence Hs.6459.0 NM_024531.1 g13375681 GPCR41 50206574_s_at PTP4A3 protein tyrosine phosphatase type IVA, member 3Exemplarsequence Hs.43666.0 NM_007079.1 g6857821 51 227023_at GLI4GLI-Kruppel family member GLI4 8q24.3 Consensussequence Hs.239451.0AI570458 Hs.239451.0.A1 52 213756_s_at HSF1 heat shocktranscription factor 1 8q24.3 Consensussequence Hs.1499.1 AI393937Hs.1499.1 53 228405_at RHPN1 rhophilin, Rho GTPase binding protein1 8q24.3 Consensussequence Hs.149152.0 AI917311 Hs.149152.0.A1 54236533_at DDEF1 development and differentiation enhancing8q24.1-q24.2 Consensussequence Hs.199057.0 AW236958 Hs.199057.0.A1factor 1 55 219060_at FLJ10204 hypothetical protein FLJ102048q24.13 Exemplarsequence Hs.18029.0 NM_018024.1 g8922280 56219402_s_at MGC3067 hypothetical protein MGC3067 8q24.13Exemplarsequence Hs.323114.0 NM_024295.1 g13236515 57 225801_atHomo sapiens cDNA FLJ13329 fis, clone Consensussequence Hs.61661.0BE877195 Hs.61661.0_RC OVARC1001795. 58 222740_at PRO2000 PRO2000protein 8q24.13 Consensussequence Hs.46677.0 AI925583 Hs.46677.0_RC59 238562_at ESTs, Weakly similar to hypothetical protein FLJ20378[Homo sapiens] Consensussequence Hs.280297.0 BE542779Hs.280297.0.A1 [H. sapiens] 60 201592_at EIF3S3 eukaryotictranslation initiation factor 3, subunit 3 8q23.3 ExemplarsequenceHs.58189.0 NM_003756.1 g4503514 gamma, 40 kDa 61 227786_at PFDN2prefoldin 2 1q23.1 Consensussequence Hs.298229.2 AI026938Hs.298229.2.A1 62 209510_at TRC8 patched related proteintranslocated in 8q24 Exemplarsequence Hs.28285.0 AF064801.1g3395786 renal cancer 63 219548_at ZNF16 zinc finger protein 16(KOX 9) 8q24 Exemplarsequence Hs.23019.0 NM_006958.1 911177859 64204932_at TNFRSF11B tumor necrosis factor receptor superfamily,8q24 Consensussequence Hs.81791.0 BF433902 Hs.81791.0 member 11b(osteoprotegerin) 65 240228_at KIAA1894 KIAA1894 protein 8q23.3Consensussequence Hs.21034.0 AI187364 Hs.21034.0_RC 66 226776_atDC6 DC6 protein 8q23.2 Consensussequence Hs.44243.0 BF215862Hs.44243.0_RC 67 208697_s_at EIF3S6 eukaryotic translationinitiation factor 3, 8q22-q23 Exemplarsequence Hs.106673.0BC000734.1 g12653884 subunit 6 48 kDa 68 218899_s_at BAALC brainand acute leukemia, cytoplasmic 8q22.3 Exemplarsequence Hs.169395.0NM_024812.1 g13376199 69 202873_at Homo sapiens cDNA FLJ33383 fis,clone Consensussequence Hs.86905.0 NM_001695.1 Hs.86905.0BRACE2006514. 70 219388_at FLJ13782 hypothetical protein FLJ137828q22.3 Exemplarsequence Hs.257924.0 NM_024915.1 g13376381 71203501_at PGCP plasma glutamate carboxypeptidase 8q22.2Exemplarsequence Hs.197335.0 NM_006102.1 g5174626 72 222950_atFLJ13955 hypothetical protein FLJ13955 8q22.1 ConsensussequenceHs.127331.0 NM_024759.1 Hs.127331.0_RC 73 212250_at Homo sapiens,Similar to LYRIC, clone Consensussequence Hs.243901.0 AI972475Hs.243901.0.S1 MGC: 41931 IMAGE: 5298467, mRNA, complete cds 74227277_at Homo sapiens cDNA FLJ40968 fis, clone ConsensussequenceHs.33074.0 BG530089 Hs.33074.0.S1 UTERU2012615. 75 235391_atLOC137392 similar to CG6405 gene product 8q21.3 ConsensussequenceHs.87672.0 AW960748 Hs.87672.0_RC 76 238229_at ESTsConsensussequence Hs.116240.0 AI187388 Hs.116240.0.A1 77218273_s_at PDP pyruvate dehydrogenase phosphatase 8q21.3Exemplarsequence Hs.22265.0 NM_018444.1 g8923959 78 222572_at PDPpyruvate dehydrogenase phosphatase 8q21.3 ConsensussequenceHs.22265.0 BG542521 Hs.22265.0.S2 79 220549_at FSBP fibrinogensilencer binding protein 8q22.1 Exemplarsequence Hs.241384.0NM_006550.1 g5729829 80 219494_at RAD54B RAD54B homolog 8q21.3-q22Exemplarsequence Hs.128501.0 NM_012415.1 g6912621 81 207386_atCYP7B1 cytochrome P450, family 7, subfamily B, 8q21.3Exemplarsequence Hs.144877.0 NM_004820.2 g13787190 polypeptide 1 82202119_s_at CPNE3 copine III 8q21.13 Exemplarsequence Hs.14158.0NM_003909.1 g4503014 83 222051_s_at E2F5 E2F transcription factor5, p130-binding 8q21.13 Consensussequence Hs.2331.2 AW139195Hs.2331.2 84 203011_at IMPA1 inositol(myo)-1(or 4)-monophosphatase1 8q21.13-q21.3 Exemplarsequence Hs.171776.0 NM_005536.2 g839360785 218919_at FLJ14007 hypothetical protein FLJ14007 8q21.12Exemplarsequence Hs.99519.0 NM_024699.1 g13375984 86 226803_atMGC22825 hypothetical protein MGC22825 8q21.12 ConsensussequenceHs.183861.0 AK000049.1 Hs.183861.0.S1 87 209928_s_at MSC musculin(activated B-cell factor-1) 8q21 Exemplarsequence Hs.42474.0AF060154.1 g3089604 88 208361_s_at BN51T BN51 (BHK21) temperaturesensitivity 8q21 Exemplarsequence Hs.1276.0 NM_001722.1 g4502436complementing 89 223475_at LOC83690 CocoaCrisp 8q13.3Exemplarsequence Hs.182364.0 AF142573.1 g12002310 90 230661_at Homosapiens mRNA; cDNA DKFZp667P166 (from clone ConsensussequenceHs.194024.0 AW451999 Hs.194024.0_RC DKFZp667P166) 91 200717_x_atRPL7 ribosomal protein L7 8q13.2 Exemplarsequence Hs.153.0NM_000971.1 g4506658 92 234768_at Homo sapiens cDNA: FLJ20865 fis,clone Consensussequence Hs.306681.0 AK024518.1 Hs.306681.0ADKA01850. 93 202955_s_at BIG1 brefeldin A-inhibited guaninenucleotide- 8q13 Exemplarsequence Hs.94631.0 AF084520.1 g5052120exchange protein 1 94 203448_s_at TERF1 telomeric repeat bindingfactor (NIMA- 8q13 Consensussequence Hs.194562.0 AI347136Hs.194562.0.A1 interacting) 1 95 219810_at VCIP135valosin-containing protein (p97)/p47 8q13 ExemplarsequenceHs.287727.0 NM_025054.1 g13376584 complex-interacting protein p13596 221749_at FLJ31657 hypothetical protein FLJ31657 8q12.1Consensussequence Hs.5518.0 AU157915 Hs.5518.0.S1 97 238903_atLOC137886 hypothetical protein LOC137886 8q11.23 ConsensussequenceHs.99403.0 AI636090 Hs.99403.0.A1 98 204530_s_at TOX thymus highmobility group box protein TOX 8q11.23 Exemplarsequence Hs.184297.0NM_014729.1 g7662321 99 212449_s_at LYPLA1 lysophospholipase I8q11.23 Consensussequence Hs.12540.2 BG288007 Hs.12540.2_RC 100204301_at KIAA0711 KIAA0711 gene product 8p23.2 ExemplarsequenceHs.5333.0 NM_014867.1 g7662259 101 232641_at LOC169270 hypotheticalprotein LOC169270 8p23.3 Consensussequence Hs.249181.0 AC004908Hs.249181.0.S1 102 219340_s_at CLN8 ceroid-lipofuscinosis, neuronal8 (epilepsy, 8p23 Exemplarsequence Hs.127675.0 AF123759.1 g6467264progressive with mental retardation) 103 210980_s_at ASAH1N-acylsphingosine amidohydrolase (acid ceramidase) 1 8p22-p21.3Exemplarsequence Hs.75811.1 U47674.1 g3860239 104 209997_x_at PCM1pericentriolar material 1 8p22-p21.3 Exemplarsequence Hs.315478.0BC000453.1 g12653366 105 213702_x_at ASAH1 N-acylsphingosineamidohydrolase (acid 8p22-p21.3 Consensussequence Hs.75811.3AI934569 Hs.75811.3.S1 ceramidase) 1 106 209295_at TNFRSF10B tumornecrosis factor receptor superfamily, 8p22-p21 ExemplarsequenceHs.51233.0 AF016266.1 g2529562

member 10b 107 206222_at TNFRSF10C tumor necrosis factor receptorsuperfamily, 8p22-p21 Exemplarsequence Hs.119684.0 NM_003841.1g10835042 member 10c, decoy without an intracellular domain 108212096_s_at MTSG1 transcription factor MTSG1 8p21.3Consensussequence Hs.7946.0 AL096842.1 Hs.7946.0 109 203549_s_atLPL lipoprotein lipase 8p22 Exemplarsequence Hs.180878.0NM_000237.1 g4557726 110 222107_x_at LZTS1 leucine zipper, putativetumor suppressor 1 8p22 Consensussequence Hs.93605.6 BE312985Hs.93605.6.S2 111 208231_at NRG1 neuregulin 1 8p21-p12Exemplarsequence Hs.172816.0 NM_013960.1 g7669519 112 230746_s_atSTC1 stanniocalcin 1 8p21-p11.2 Consensussequence Hs.25590.1AW003173 Hs.25590.1.A1 113 211489_at ADRA1A adrenergic, alpha-1A-,receptor 8p21-p11.2 Exemplarsequence Hs.52931.0 D32201.1 g927210114 218777_at FLJ22246 hypothetical protein FLJ22246 8p21.2Exemplarsequence Hs.289063.0 NM_025232.1 g13376835 115 205997_atADAM28 a disintegrin and metalloproteinase domain 28 8p21.1Exemplarsequence Hs.174030.0 NM_021778.1 g11496995 116 226179_atHomo sapiens, clone IMAGE: 5294823, Consensussequence Hs.34549.0N63920 Hs.34549.0.A1 mRNA 117 221123_x_at LOC55893 papillomavirusregulatory factor PRF-1 8p21.1 Exemplarsequence Hs.27410.0NM_018660.1 g8923886 118 205770_at GSR glutathione reductase 8p21.1Exemplarsequence Hs.121524.0 NM_000637.1 g10835188 119 218149_s_atDKFZp434K1210 hypothetical protein DKFZp434K1210 8p21.1Exemplarsequence Hs.32352.0 NM_017606.1 g8922146 120 235588_atLOC157570 hypothetical protein LOC157570 8p21.1 ConsensussequenceHs.99480.0 AA740849 Hs.99480.0 121 236492_at PPP2R2A proteinphosphatase 2 (formerly 2A), 8p21.1 Consensussequence Hs.132822.0AI934447 Hs.132822.0.A1 regulatory subunit B (PR 52), alpha isoform122 212166_at XPO7 exportin 7 8p21 Consensussequence Hs.172685.0H38643 Hs.172685.0 123 221478_at BNIP3L BCL2/adenovirus E1B 19 kDainteracting protein 3-like 8p21 Consensussequence Hs.132955.0AL132665.1 Hs.132955.0 124 220860_at PURG purine-rich elementbinding protein G 8p11 Exemplarsequence Hs.278953.0 NM_013357.1g7019506 125 211686_s_at LOC84549 RNA binding protein 8p11.23Exemplarsequence g13625185 AF251062.1 g13625185 126 200847_s_atMGC8721 hypothetical protein MGC8721 8p12 ExemplarsequenceHs.279921.0 NM_016127.1 g7706384 127 219897_at FLJ12526hypothetical protein FLJ12526 8p11.23 Exemplarsequence Hs.151237.0NM_024787.1 g13376151 128 231258_at MGC8721 hypothetical proteinMGC8721 8p12 Consensussequence Hs.279921.2 AV648367 Hs.279921.2.S1129 219624_at BAG4 BCL2-associated athanogene 4 8p11.21Exemplarsequence Hs.194726.0 NM_004874.1 g6631074 130 207597_atADAM18 a disintegrin and metalloproteinase domain 18 8p11.21Exemplarsequence Hs.127930.0 NM_014237.1 g7656860 131 217819_atLOC51125 HSPC041 protein 8p11.21 Exemplarsequence Hs.7953.0NM_016099.1 g7705820 132 219292_at FLJ10477 hypothetical proteinFLJ10477 8p11.1 Exemplarsequence Hs.7432.0 NM_018105.1 g8922445 133235114_x_at HOOK3 hook3 protein 8p11.1 ConsensussequenceHs.130707.0 N67300 Hs.130707.0 134 209517_s_at ASH2L ash2 (absent,small, or homeotic)-like 8p11.2 Exemplarsequance Hs.6856.1AB020982.1 g4417209 (Drosophila) 135 216519_s_at PROSC prolinesynthetase co-transcribed homolog 8p11.2 ConsensussequenceHs.301959.3 AK021923.1 Hs.301959.3.S1 (bacterial) 136 214545_s_atPROSC proline synthetase co-transcribed homolog 8p11.2Consensussequence Hs.301959.2 NM_007198.1 Hs.301959.2.S1(bacterial) 137 204817_at ESPL1 extra spindle poles like 1 (S.cerevisiae) 8 Exemplarsequence Hs.153479.0 NM_012291.1 g6912453 #Sequence Source Unigene_Accession Cluster_Type LocusLinkFull_Length_Reference_Seq 1 GenBank Hs.273344 fulllength 25879NM_014156; NM_015420; DKFZP564O0463 protein 2 RefSeq Hs.49fulllength 4481 NM_002445; macrophage scavenger receptor 1 isoformtype 2 NM_138715; macrophage scavenger receptor 1 isoform type 1NM_138716; macrophage scavenger receptor 1 isoform type 3 3 RefSeqHs.169615 fulllength 65265 NM_023080; hypothetical protein FLJ209894 RefSeq Hs.380935 fulllength 3297 NM_005526; heat shocktranscription factor 1 5 GenBank Hs.74562 fulllength 22827NM_014281; fuse-binding protein-interacting repressor isoform bNM_078480; fuse-binding protein-interacting repressor isoform a 6GenBank Hs.83727 fulllength 29894 NM_013291; cleavage andpolyadenylation specific factor 1, 160 kDa 7 GenBank Hs.9812 8GenBank Hs.173094 fulllength 85453 NM_033512; KIAA1750 protein 9RefSeq Hs.82129 fulllength 761 NM_005181; carbonic anhydrase III 10GenBank Hs.4147 fulllength 23471 NM_014294; translocatingchain-associating membrane protein 11 RefSeq Hs.78687 fulllength8439 NM_003580; neutral sphingomyelinase (N-SMase) activationassociated factor 12 GenBank Hs.406141 fulllength 137695 NM_152417;hypothetical protein FLJ32370 13 RefSeq Hs.248146 fulllength 4342NM_005372; v-mos Moloney murine sarcoma viral oncogene homolog 14GenBank Hs.287478 15 GenBank Hs.289293 fulllength 157695 NM_175075;hypothetical protein INM01 16 GenBank Hs.48876 fulllength 2222NM_004462; farnesyl-diphosphate farnesyltransferase 1 17 RefSeqHs.27842 fulllength 55326 NM_018361; acid acyltransferase-epsilon18 GenBank Hs.356463 fulllength 2339 NM_002027;farnesyltransferase, CAAX box, alpha 19 RefSeq Hs.380963 fulllength29883 NM_013354; CCR4-NOT transcription complex, subunit 7 isoform1 NM_054026; CCR4-NOT transcription complex, subunit 7 isoform 2 20RefSeq Hs.75737 fulllength 5108 NM_006197; pericentriolar material1 21 GenBank Hs.75737 fulllength 5108 NM_006197; pericentriolarmaterial 1 22 GenBank Hs.75737 fulllength 5108 NM_006197;pericentriolar material 1 23 GenBank Hs.71215 fulllength 9046NM_003974; docking protein 2, 56 kD 24 RefSeq Hs.1274 fulllength649 NM_001199; bone morphogenetic protein 1 isoform 1, precursorNM_006128; bone morphogenetic protein 1 isoform 2, precursorNM_006129; bone morphogenetic protein 1 isoform 3, precursorNM_006130; bone morphogenetic protein 1 isoform 6, precursorNM_006131; bone morphogenetic protein 1 isoform 5, precursorNM_006132; bone morphogenetic protein 1 isoform 4, precursor 25GenBank Hs.27721 fulllength 54904 NM_017778; WHSC1L1 proteinisoform short NM_023034; WHSC1L1 protein isoform long 26 GenBankHs.443139 est 27 RefSeq Hs.318725 fulllength 51105 NM_016018;CGI-72 protein 28 GenBank Hs.323114 fulllength 79139 NM_018630;NM_024295; hypothetical protein MGC3067 29 GenBank Hs.2463fulllength 284 NM_001146; angiopoietin 1 isoform a NM_139290;angiopoietin 1 isoform b 30 RefSeq Hs.2463 fulllength 284NM_001146; angiopoietin 1 isoform a NM_139290; angiopoietin 1isoform b 31 RefSeq Hs.273344 fulllength 25879 NM_014156;NM_015420; DKFZP564O0463 protein 32 GenBank Hs.98471 est 137682NM_152416; hypothetical protein MGC40214 33 GenBank Hs.144027 34GenBank Hs.300592 4603 35 RefSeq Hs.55097 fulllength 28957NM_014018; mitochondrial ribosomal protein S28 36 RefSeq Hs.170198fulllength 9650 NM_014637; KIAA0009 gene product 37 GenBankHs.400259 fulllength 54984 NM_017884; PIN2-interacting protein 1 38GenBank Hs.71119 fulllength 7991 NM_006765; Putative prostatecancer tumor suppressor isoform a NM_178234; Putative prostatecancer tumor suppressor isoform b 39 GenBank Hs.131055 286056 40RefSeq Hs.287624 fulllength 80094 NM_025026; hypothetical proteinFLJ14107 41 GenBank Hs.840 fulllength 3620 NM_002164;indoleamine-pyrrole 2,3 dioxygenase 42 GenBank Hs.170296 43 RefSeqHs.425311 fulllength 27257 NM_014462; Lsm1 protein 44 GenBankHs.740 fulllength 5747 NM_005607; PTK2 protein tyrosine kinase 2isoform b NM_153831; PTK2 protein tyrosine kinase 2 isoform a 45RefSeq Hs.4742 fulllength 8733 NM_003801; anchor attachment protein1 46 RefSeq Hs.178551 fulllength 6132 NM_000973; ribosomal proteinL8 NM_033301; ribosomal protein L8 47 GenBank Hs.331601 fulllength157542 48 GenBank Hs.343589 fulllength 54512 NM_019037; exosomecomplex exonuclease RRP41 49 RefSeq Hs.6459 fulllength 79581NM_024531; putative G-protein coupled receptor GPCR41 50 RefSeqHs.43666 fulllength 11156 NM_007079; protein tyrosine phosphatasetype IVA, member 3 isoform 2 NM_032611; protein tyrosinephosphatase type IVA, member 3 isoform 1 51 GenBank Hs.239451fulllength 2738 NM_138465; GLI-Kruppel family member GLI4 52GenBank Hs.380935 fulllength 3297 NM_005526; heat shocktranscription factor 1 53 GenBank Hs.149152 fulllength 114822NM_052924; rhophilin 1 54 GenBank Hs.10669 fulllength 50807 55RefSeq Hs.18029 fulllength 55093 NM_018024; hypothetical proteinFLJ10204 56 RefSeq Hs.323114 fulllength 79139 NM_018630; NM_024295;hypothetical protein MGC3067 57 GenBank Hs.352376 58 GenBankHs.222088 fulllength 29028 NM_014109; PRO2000 protein NM_032365; 59GenBank Hs.86970 est 60 RefSeq Hs.58189 fulllength 8667 NM_003756;eukaryotic translation initiation factor 3, subunit 3 gamma, 40 kDa61 GenBank Hs.298229 fulllength 5202 NM_012394; prefoldin 2NM_080651; TRAP/Mediator complex component TRAP25 62 GenBankHs.28285 fulllength 11236 NM_007218; ring finger protein 139 63RefSeq Hs.23019 fulllength 7564 NM_006958; zinc finger protein 16(KOX 9) 64 GenBank Hs.81791 fulllength 4982 NM_002546;osteoprotegerin precursor 65 GenBank Hs.21034 114788 66 GenBankHs.283740 fulllength 56943 NM_020189; DC6 protein 67 GenBankHs.106673 fulllength 3646 NM_001568; murine mammary tumorintegration site 6 (oncogene homolog) 68 RefSeq Hs.169395fulllength 79870 NM_024812; brain and acute leukemia, cytoplasmic69 GenBank Hs.290880 70 RefSeq Hs.257924 fulllength 79977NM_024915; hypothetical protein FLJ13782 71 RefSeq Hs.197335fulllength 10404 NM_006102; NM_016134; plasma glutamatecarboxypeptidase 72 GenBank Hs.127331 fulllength 79815 NM_024759;hypothetical protein FLJ13955 73 GenBank Hs.243901 fulllength 74GenBank Hs.33074 75 GenBank Hs.403869 fulllength 137392 NM_145269;similar to CG6405 gene product 76 GenBank Hs.116240 est 77 RefSeqHs.22265 fulllength 54704 NM_018444; pyruvate dehydrogenasephosphatase 78 GenBank Hs.22265 fulllength 54704 NM_018444;pyruvate dehydrogenase phosphatase 79 RefSeq Hs.241384 fulllength10646 NM_006550; fibrinogen silencer binding protein 80 RefSeqHs.128501 fulllength 25788 NM_012415; RAD54B homolog isoform 1NM_134434; RAD54B homolog isoform 2 81 RefSeq Hs.144877 fulllength9420 NM_004820; cytochrome P450, family 7, subfamily B, polypeptide1 82 RefSeq Hs.14158 fulllength 8895 NM_003909; copine III 83GenBank Hs.2331 fulllength 1875 NM_001951; E2F transcription factor5 84 RefSeq Hs.171776 fulllength 3612 NM_005536; inositol(myo)-1(or4)-monophosphatase 1 85 RefSeq Hs.99519 fulllength 79752 NM_024699;hypothetical protein FLJ14007 86 GenBank Hs.183861 fulllength 92421NM_152284; hypothetical protein MGC22825 87 GenBank Hs.42474fulllength 9242 NM_005098; musculin (activated B-cell factor-1) 88RefSeq Hs.1276 fulllength 661 NM_001722; RNA polymerase III 53 kDasubunit RPC4 89 GenBank Hs.182364 fulllength 83690 NM_031461;CocoaCrisp 90 GenBank Hs.407120 91 RefSeq Hs.153 fulllength 6129NM_000971; ribosomal protein L7 92 GenBank Hs.306681 93 GenBankHs.94631 fulllength 10565 NM_006421; brefeldin A-inhibited guaninenucleotide-exchange protein 1 94 GenBank Hs.194562 fulllength 7013NM_003218; telomeric repeat binding factor 1 isoform 2 NM_017489;telomeric repeat binding factor 1 isoform 1 95 RefSeq Hs.287727fulllength 80124 NM_025054; valosin-containing protein (p97)/p47complex- interacting protein p135 96 GenBank Hs.5518 fulllength253943 NM_152758; hypothetical protein

FLJ31657 97 GenBank Hs.155572 137886 98 RefSeq Hs.184297 fulllength9760 NM_014729; thymus high mobility group box protein TOX 99GenBank Hs.12540 fulllength 10434 NM_006330; lysophospholipase I100 RefSeq Hs.5333 fulllength 9920 NM_014867; KIAA0711 gene product101 GenBank Hs.249181 fulllength 169270 NM_173539; hypotheticalprotein LOC169270 102 GenBank Hs.127675 fulllength 2055 NM_018941;CLN8 protein 103 GenBank Hs.75811 fulllength 427 NM_004315;N-acylsphingosine amidohydrolase (acid ceramidase) 1 isoform bNM_177924; N-acylsphingosine amidohydrolase (acid ceramidase) 1preproprotein isoform a 104 GenBank Hs.75737 fulllength 5108NM_006197; pericentriolar material 1 105 GenBank Hs.75811fulllength 427 NM_004315; N-acylsphingosine amidohydrolase (acidceramidase) 1 isoform b NM_177924; N-acylsphingosine amidohydrolase(acid ceramidase) 1 preproprotein isoform a 106 GenBank Hs.51233fulllength 8795 NM_003842; tumor necrosis factor receptorsuperfamily, member 10b isoform 1 precursor NM_147187; tumornecrosis factor receptor superfamily, member 10b isoform 2precursor 107 RefSeq Hs.119684 fulllength 8794 NM_003841; tumornecrosis factor receptor superfamily, member 10c precursor 108GenBank Hs.7946 fulllength 57509 NM_020749; transcription factorMTSG1 109 RefSeq Hs.180878 fulllength 4023 NM_000237; lipoproteinlipase precursor 110 GenBank Hs.93605 fulllength 11178 NM_021020;leucine zipper, putative tumor suppressor 1 111 RefSeq Hs.172816fulllength 3084 NM_004495; neuregulin 1 isoform HRG-gammaNM_013956; neuregulin 1 isoform HRG-beta1 NM_013957; neuregulin 1isoform HRG-beta2 NM_013958; neuregulin 1 isoform HRG-beta3NM_013959; neuregulin 1 isoform SMDF NM_013960; neuregulin 1isoform ndf43 NM_013961; neuregulin 1 isoform GGF NM_013962;neuregulin 1 isoform GGF2 NM_013964; neuregulin 1 isoform HRG-alpha112 GenBank Hs.25590 fulllength 6781 NM_003155; stanniocalcin 1 113GenBank Hs.52931 fulllength 148 NM_000680; alpha-1A-adrenergicreceptor isoform 1 NM_033302; alpha-1A-adrenergic receptor isoform3 NM_033303; alpha-1A- adrenergic receptor isoform 2 NM_033304;alpha-1A-adrenergic receptor isoform 4 114 RefSeq Hs.289063fulllength 80346 NM_025232; hypothetical protein FLJ22246 115RefSeq Hs.174030 fulllength 10863 NM_014265; a disintegrin andmetallaproteinase domain 28 isoform 1 preproprotein NM_021777; adisintegrin and metalloproteinase domain 28 isoform 3 preproproteinNM_021778; a disintegrin and metalloproteinase domain 28 isoform 2preproprotein 116 GenBank Hs.34549 117 RefSeq Hs.27410 fulllength55893 NM_018660; papillomavirus regulatory factor PRF-1 118 RefSeqHs.193974 fulllength 2936 NM_000637; glutathione reductase 119RefSeq Hs.32352 fulllength 54775 NM_017606; hypothetical proteinDKFZp434K1210 120 GenBank Hs.99480 157570 121 GenBank Hs.179574fulllength 5520 NM_002717; protein phosphatase 2 (formerly 2A),regulatory subunit B (PR 52), alpha isoform 122 GenBank Hs.172685fulllength 23039 NM_015024; exportin 7 123 GenBank Hs.132955fulllength 665 NM_004331; BCL2/adenovirus E1B 19 kD-interactingprotein 3-like 124 RefSeq Hs.278953 fulllength 29942 NM_013357;purine-rich element binding protein G 125 GenBank Hs.77135fulllength 84549 NM_032509; RNA binding protein 126 RefSeqHs.279921 fulllength 51669 NM_016127; hypothetical protein MGC8721127 RefSeq Hs.151237 fulllength 79845 NM_024787; hypotheticalprotein FLJ12526 128 GenBank Hs.279921 fulllength 51669 NM_016127;hypothetical protein MGC8721 129 RefSeq Hs.194726 fulllength 9530NM_004874; BCL2-associated athanogene 4 130 RefSeq Hs.127930fulllength 8749 NM_014237; a disintegrin and metalloproteinasedomain 18 preproprotein 131 RefSeq Hs.7953 fulllength 51125NM_016099; HSPC041 protein 132 RefSeq Hs.7432 fulllength 55145NM_018105; hypothetical protein FLJ10477 133 GenBank Hs.130707fulllength 84376 NM_032410; hook3 protein 134 GenBank Hs.6856fulllength 9070 NM_004674; ash2 (absent, small, or homeotic)-like135 GenBank Hs.301959 fulllength 11212 NM_007198; prolinesynthetase co-transcribed homolog 136 GenBenk Hs.301959 fulllength11212 NM_007198; proline synthetase co-transcribed homolog 137RefSeq Hs.153479 fulllength 9700 NM_012291; extra spindle poleslike 1

TABLE-US-00028 TABLE 27 11q23/MLL # affy id HUGO name F p q TitleMapLocation Sequence Type 1 223503_at DKFZP566N034 78.82 2.41e-082.11e-04 hypothetical protein DKFZp566N034 2q21.2 Exemplarsequence2 202697_at CPSF5 56.52 3.27e-09 5.72e-05 cleavage andpolyadenylation specific factor 5, 25 kDa 16q12.1 Exemplarsequence3 210106_at RDH5 54.92 4.34e-09 5.72e-05 retinol dehydrogenase 5(11-cis and 9-cis) 12q13-q14 Exemplarsequence 4 218977_s_at SECP4348.90 1.01e-06 5.31e-03 tRNA selenocysteine associated protein1p35.2 Exemplarsequence 5 206290_s_at RGS7 41.72 1.65e-05 1.61e-02regulator of G-protein signalling 7 1q43 Exemplarsequence 6205257_s_at AMPH 40.30 2.99e-06 7.17e-03 amphiphysin (Stiff-Mansyndrome with breast cancer 128 kDa autoantigen) 7p14-p13Exemplarsequence 7 236200_at 37.71 7.83e-05 3.75e-02 ESTsConsensussequence 8 203345_s_at M96 36.71 2.72e-06 7.17e-03 likelyortholog of mouse metal response element binding transcriptionfactor 2 1p22.1 Consensussequence 9 202320_at GTF3C1 35.31 7.14e-074.71e-03 general transcription factor IIIC, polypeptide 1, alpha220 kDa 16p12 Exemplarsequence 10 238315_s_at MGC45586 35.214.66e-06 8.77e-03 hypothetical protein MGC45586 19q13.12Consensussequence 11 205396_at DKFZP586N0721 33.58 7.64e-061.17e-02 DKFZP586N0721 protein 15q22.2 Consensussequence 12212570_at KIAA0830 32.04 8.45e-05 3.91e-02 KIAA0830 protein 11q21Consensussequence 13 218444_at ALG12 31.97 1.79e-06 7.10e-03dolichyl-p-mannose:Man7GlcNAc2-PP-dolichyl Exemplarsequencemannosyltransferase 14 201613_s_at RUVBL1 30.44 3.84e-06 7.80e-03RuvB-like 1 (E. coli) 3q21 Exemplarsequence 15 222891_s_at BCL11A29.90 2.20e-06 7.10e-03 B-cell CLL/lymphoma 11A (zinc fingerprotein) 2p15 Consensussequence 16 225129_at CPNE2 29.81 2.32e-067.10e-03 copine II 16q12.2 Consensussequence 17 202371_at FLJ2117429.54 2.42e-06 7.10e-03 hypothetical protein FLJ21174 Xq22.1Exemplarsequence 18 215153_at CAPON 29.54 4.59e-04 8.12e-02C-terminal PDZ domain ligand of neuronal nitric oxide 1q23.1Consensussequence synthase 19 220849_at FLJ22659 29.15 5.16e-048.36e-02 hypothetical protein FLJ22659 17p11.2 Exemplarsequence 20212746_s_at KIAA0470 28.61 3.65e-06 7.80e-03 KIAA0470 gene product1q44 Consensussequence 21 217359_s_at NCAM1 38196 1.98e-04 5.68e-02neural cell adhesion molecule 1 11q23.1 Consensussequence 22227769_at GPR27 27.26 5.46e-06 9.41e-03 G protein-coupled receptor27 3p21-p14 Consensussequence 23 209620_s_at ABCB7 38287 5.71e-069.41e-03 ATP-binding cassette, sub-family B (MDR/TAP), member 7Xq12-q13 Exemplarsequence 24 204886_at STK18 26.85 1.59e-051.61e-02 serine/threonine kinase 18 4q27-q28 Consensussequence 25208519_x_at GNRH2 26.78 1.02e-04 4.01e-02 gonadotropin-releasinghormone 2 20p13 Exemplarsequence 26 221077_at FLJ10376 26.318.28e-06 1.17e-02 hypothetical protein FLJ10376 10p12.1Exemplarsequence 27 215160_x_at FRG1 38317 2.67e-05 2.19e-02 FSHDregion gene 1 4q35 Consensussequence 28 59625_at LOC283849 381949.56e-06 1.20e-02 hypothetical protein LOC283849 16q21Consensussequence 29 214743_at CUTL1 38194 8.44e-06 1.17e-02cut-like 1, CCAAT displacement protein (Drosophila) 7q22Consensussequence 30 218274_s_at FLJ10415 25.93 2.34e-05 2.06e-02hypothetical protein FLJ10415 2q36.1 Exemplarsequence 31 201578_atPODXL 25.92 2.67e-04 6.88e-02 podocalyxin-like 7q32-q33Exemplarsequence 32 206310_at SPINK2 25.68 1.02e-05 1.21e-02 serineprotease inhibitor, Kazal type, 2 (acrosin-trypsin 4q12Exemplarsequence inhibitor) 33 219555_s_at BM039 25.65 2.75e-052.19e-02 uncharacterized bone marrow protein BM039 16q23.1Exemplarsequence 34 200844_s_at AOP2 25.51 5.34e-05 3.09e-02antioxidant protein 2 1q23.3 Consensussequence 35 203484_at SEC61G25.38 9.45e-05 4.01e-02 Sec61 gamma 7p11.2 Exemplarsequence 36207185_at SLC10A1 25.31 6.43e-04 9.37e-02 solute carrier family 10(sodium/bile acid cotransporter 14q24.1 Exemplarsequence family),member 1 37 206295_at IL18 25.27 9.31e-06 1.20e-02 interleukin 18(interferon-gamma-inducing factor) 11q22.2-q22.3 Exemplarsequence38 244795_at 38255 9.52e-05 4.01e-02 ESTs Consensussequence 39201709_s_at NIPSNAP1 38224 3.67e-05 2.55e-02 nipsnap homolog 1 (C.elegans) 22q12.2 Exemplarsequence 40 201869_s_at TBL1X 24.951.08e-05 1.21e-02 transducin (beta)-like 1X-linked Xp22.3Consensussequence 41 201936_s_at EIF4G3 24.88 1.10e-05 1.21e-02eukaryotic translation initiation factor 4 gamma, 3 1p36.12Exemplarsequence 42 217081_at 24.63 4.66e-04 8.15e-02Consensussequence 43 202300_at HBXIP 24.42 1.70e-04 5.15e-02hepatitis B virus x interacting protein 1p13.1 Exemplarsequence 44206298_at LOC58504 24.13 1.58e-05 1.61e-02 hypothetical proteinfrom clones 23549 and 23762 10q11.21 Exemplarsequence 45 228113_atSTAT3 23.89 1.72e-05 1.62e-02 signal transducer and activator oftranscription 3 (acute- 17q21 Consensussequence phase responsefactor) 46 230001_at LOC92979 23.70 9.50e-04 0.11 hypotheticalprotein BC009489 12q13.13 Consensussequence 47 205374_at SLN 23.453.99e-04 7.53e-02 sarcolipin 11q22-q23 Exemplarsequence 48203938_s_at TAF1C 23.38 2.88e-04 6.88e-02 TATA box binding protein(TBP)-associated factor, RNA 16q24 Exemplarsequence polymerase I,C, 110 kDa 49 212015_x_at PTBP1 23.36 1.16e-04 4.01e-02polypyrimidine tract binding protein 1 19p13.3 Consensussequence 50211471_s_at RAB36 23.25 9.36e-04 0.11 RAB36, member RAS oncogenefamily 22q11.22 Exemplarsequence Sequence # Transcript ID DerivedFrom Sequence ID Sequence Source Unigene_Accession Cluster_TypeLocusLink Full_Length_Reference_Seq 1 Hs.331633.0 AF255647.1g12005818 GenBank Hs.331633 fulllength 81615 NM_030923;hypothetical protein DKFZp566N034 2 Hs.9605.0 NM_007006.1 g5901925RefSeq Hs.9605 fulllength 11051 NM_007006; cleavage andpolyadenylation specific factor 5, 25 kD subunit 3 Hs.172914.0U43559.1 g1616653 GenBank Hs.172914 fulllength 5959 NM_002905;retinol dehydrogenase 5 (11-cis and 9- cis) 4 Hs.266935.0NM_017846.1 g8923459 RefSeq Hs.266935 fulllength 54952 NM_017846;tRNA selenocysteine associated protein 5 Hs.79348.0 NM_002924.1g11140808 RefSeq Hs.79348 fulllength 6000 NM_002924; regulator ofG-protein signalling 7 6 Hs.173034.0 NM_001635.1 g4502080 RefSeqHs.173034 fulllength 273 NM_001635; amphiphysin isoform 1NM_139316; amphiphysin isoform 2 7 Hs.12899.0 AI698159Hs.12899.0.A1 GenBank Hs.12899 est 8 Hs.31016.0 AI566096Hs.31016.0.A1 GenBank Hs.31016 fulllength 22823 NM_007358; putativeDNA binding protein 9 Hs.3310 NM_001520.1 g4753160 RefSeq Hs.331fulllength 2975 NM_001520; general transcription factor IIIC,polypeptide 1, alpha 220 kDa 10 Hs.199359.0 BF061829 Hs.199359.0.A1GenBank Hs.145473 est 163081 NM_152603: hypothetical proteinMGC45586 11 Hs.211578.0 BF971416 Hs.211578.0 GenBank Hs.99843fulllength 25856 NM_015400; DKFZP586N0721 protein 12 Hs.167115.0AL573201 Hs.167115.0.S1 Genbank Hs.167115 fulllength 23052 13Hs.77575.0 NM_024105.1 g13129113 RefSeq Hs.77575 fulllength 79087NM_024105; dolichyl-p-mannose:Man7GlcNAc2-PP- dolichylmannosyltransferase 14 Hs.272822.0 BC000519.1 g12653494 GenBankHs.272822 fulllength 8607 NM_003707; TATA binding proteininteracting protein 49 kDa 15 Hs.130881.0 AI912275 Hs.130881.0.S2GenBank Hs.130881 fulllength 53335 NM_018014; B-cell CLL/lymphoma11A isoform 2 NM_022893; B-cell CLL/lymphoma 11A isoform 1NM_138552; B-cell CLL/lymphoma 11A isoform 4 NM_138553; B-cellCLL/lymphoma 11A isoform 5 NM_138559; B-cell CLL/lymphoma 11Aisoform 3 16 Hs.96144.0 AW170571 Hs.96144.0.A1 GenBank Hs.339809fulllength 221184 NM_152727; copine II 17 Hs.194329.0 NM_024863.1g13376293 RefSeq Hs.194329 fulllength 79921 NM_024863; hypotheticalprotein FLJ21174 18 Hs.129729.0 AF037070.1 Hs.129729.0 GenBankHs.129729 9722 NM_014697; C-terminal PDZ domain ligand of neuronalnitric oxide synthase 19 Hs.276833.0 NM_024934.1 g13376405 RefSeqHs.276833 fulllength 79999 NM_024934; hypothetical protein FLJ2265920 Hs.25132.3 AA126789 Hs.25132.3_RC GenBank Hs.25132 fulllength9859 NM_014812; KARP-1-binding protein 21 Hs.167988.3 M22094.1Hs.167988.3 GenBank Hs.167988 fulllength 4684 NM_000615; neuralcell adhesion molecule 1 22 Hs.250899.1 AI703476 Hs.250899.1.A1GenBank Hs.356084 fulllength 2850 NM_018971; G protein-coupledreceptor 27 23 Hs.125856.0 AB005289.1 g3228278 GenBank Hs.125856fulllength 22 NM_004299; ATP-binding cassette, sub-family B, member7 24 Hs.172052.0 AL043646 Hs.172052.0 GenBank Hs.172052 fulllength10733 NM_014264; serine/threonine kinase 18 25 Hs.129715.0NM_001501.1 g4504056 RefSeq Hs.129715 fulllength 2797 NM_001501;gonadotropin-releasing hormone 2 isoform a preproprotein NM_178331;gonadotropin- releasing hormone 2 isoform c preproproteinNM_178332; gonadotropin-releasing hormone 2 isoform b preproprotein26 Hs.202289.0 NM_018076.1 g8922385 RefSeq Hs.333126 fulllength55130 NM_018076; 27 Hs.203772.1 AL441988 Hs.203772.1.S1 GenBankHs.203772 fulllength 2483 NM_004477; FSHD region gene 1 284854714_rc AI912351 4854714_rc GenBank Hs.278439 fulllength 283849NM_003946; nucleolar protein 3 (apoptosis repressor with CARDdomain) NM_178516; hypothetical protein LOC283849 29 Hs.147049.1BE046521 Hs.147049.1 GenBank Hs.147049 fulllength 1523 NM_001913;cut-like 1, CCAAT displacement protein isoform b NM_181500;NM_181552; 30 Hs.23788.0 NM_018089.1 g8922412 RefSeq Hs.23788fulllength 55139 NM_018089; hypothetical protein FLJ10415 31Hs.16426.0 NM_005397.1 g4885556 RefSeq Hs.16426 fulllength 5420NM_005397; podocalyxin-like 32 Hs.98243.0 NM_021114.1 g10863910RefSeq Hs.98243 fulllength 6691 NM_021114; serine proteaseinhibitor, Kazal type, 2 (acrosin-trypsin inhibitor) 33 Hs.283532.0NM_018455.1 g8922096 RefSeq Hs.283532 fulllength 55839 NM_018455;uncharacterized bone marrow protein BM039 34 Hs.120.0 BE869583Hs.120.0_RC GenBank Hs.120 fulllength 9588 NM_004905; peroxiredoxin6 35 Hs.9950.0 NM_014302.1 g7657545 RefSeq Hs.9950 fulllength 23480NM_014302; Sec61 gamma 36 Hs.952.0 NM_003049.1 g4506970 RefSeqHs.952 fulllength 6554 NM_003049; solute carrier family 10(sodium/bile acid cotransporter family), member 1 37 Hs.83077.0NM_001562.1 g4504652 RefSeq Hs.83077 fulllength 3606 NM_001562;interleukin 18 proprotein 38 Hs.176950.0 AV693986 Hs.176950.0.A1GenBank Hs.176950 est 39 Hs.173878.0 NM_003634.1 g4505398 RefSeqHs.173878 fulllength 8508 NM_003634; NIPSNAP homolog 1 40Hs.76536.0 NM_005647.1 Hs.76536.0_RC GenBank Hs.76536 fulllength6907 NM_005647; transducin beta-like 1X 41 Hs.25732.0 NM_003760.2g10092600 RefSeq Hs.25732 fulllength 8672 NM_003760; eukaryotictranslation initiation factor 4 gamma, 3 42 Hs.194767.0 AL031983Hs.194767.0.S1 GenBank 43 Hs.80464.0 NM_006402.1 g5454169 RefSeqHs.433355 fulllength 10542 NM_006402; hepatitis B virusx-interacting protein 44 Hs.87241.0 NM_021226.1 g10864038 RefSeqHs.87241 fulllength 58504 NM_021226; hypothetical protein fromclones 23549 and 23762 45 Hs.321677.1 R62453 Hs.321677.1 GenBankHs.321677 fulllength 6774 NM_003150; signal transducer andactivator of transcription 3 isoform 2 NM_139276; signal transducerand activator of transcription 3 isoform 1 NM_175738; RAB37, memberof RAS oncogene family 46 Hs.61969.0 AI807693 Hs.61969.0.A1 GenBankHs.65377 fulllength 92979 NM_138396; hypothetical protein BC00948947 Hs.15219.0 NM_003063.1 g4507062 RefSeq Hs.334629 fulllength 6588NM_003063; sarcolipin NM_032697; 48 Hs.153022.0 NM_005679.1g5032144 RefSeq Hs.153022 fulllength 9013 NM_005679; TBP-associatedfactor 1C isoform 1 NM_139353; TBP-associated factor 1C isoform 249 Hs.172550.3 AA679988 Hs.172550.3.S1 GenBank Hs.172550 fulllength5725 NM_002819; polypyrimidine tract-binding protein 1 isoform aNM_031990; polypyrimidine tract-binding protein 1 isoform bNM_031991; polypyrimidine tract binding protein 1 isoform cNM_175847; polypyrimidine tract-binding protein 1 isoform d 50Hs.38772.1 AF133588.1 g6049163 Genbank Hs.38772 fulllength 9609NM_004914; RAB36, member RAS oncogene family

TABLE-US-00029 TABLE 28 11q23/MLL # affy id HUGO name TitleMapLocation Sequence Type Transcript ID Sequence Derived FromSequence ID 1 213122_at KIAA1750 KIAA1750 protein 8q22.1Consensussequence Hs.173094.0 AI096375 Hs.173094.0.S1 2 201398_s_atTRAM translocating chain-associating membrane protein 8q13.1Exemplarsequence Hs.4147.0 BC000687.1 g12653796 3 205608_s_atANGPT1 angiopoietin 1 8q22.3-q23 Exemplarsequence Hs.2463.0U83508.1 g1907326 4 205609_at ANGPT1 angiopoietin 1 8q22.3-q23Exemplarsequence Hs.2463.0 NM_001146.1 g4502086 5 220843_s_atDKFZP564O0463 DKFZP564O0463 protein 8q22.3 ExemplarsequenceHs.273344.0 NM_014156.1 g7661767 6 235509_at MGC40214 hypotheticalprotein MGC40214 8q22.1 Consensussequence Hs.98471.0 AV662196Hs.98471.0_RC 7 203208_s_at CHPPR likely ortholog of chickenchondrocyte protein with a poly-proline 8q12.1 ExemplarsequenceHs.170198.0 NM_014637.1 g7661853 region 8 230977_at LOC286056hypothetical protein LOC286056 8p21.2 Consensussequence Hs.131055.0AI016313 Hs.131055.0.A1 9 203534_at LSM1 LSM1 homolog, U6 smallnuclear RNA 8p11.2 Exemplarsequence Hs.111783.0 NM_014462.1g7657312 associated (S. cerevisiae) 10 209510_at TRC8 patchedrelated protein translocated in renal cancer 8q24 ExemplarsequenceHs.28285.0 AF064801.1 g3395786 11 218899_s_at BAALC brain and acuteleukemia, cytoplasmic 8q22.3 Exemplarsequence Hs.169395.0NM_024812.1 g13376199 12 220549_at FSBP fibrinogen silencer bindingprotein 8q22.1 Exemplarsequence Hs.241384.0 NM_006550.1 g5729829 13209295_at TNFRSF10B tumor necrosis factor receptor 8p22-p21Exemplarsequence Hs.51233.0 AF016266.1 g2529562 superfamily, member10b 14 212096_s_at MTSG1 transcription factor MTSG1 8p21.3Consensussequence Hs.7946.0 AL096842.1 Hs.7946.0 15 230746_s_atSTC1 stanniocalcin 1 8p21-p11.2 Consensussequence Hs.25590.1AW003173 Hs.25590.1.A1 16 205997_at ADAM28 a disintegrin andmetalloproteinase 8p21.1 Exemplarsequence Hs.174030.0 NM_021778.1g11496995 domain 28 17 221123_x_at LOC55893 papillomavirusregulatory factor PRF-1 8p21.1 Exemplarsequence Hs.27410.0NM_018660.1 g8923886 18 204817_at ESPL1 extra spindle poles like 1(S. cerevisiae) 8 Exemplarsequence Hs.153479.0 NM_012291.1 g691245319 224218_s_at TRPS1 trichorhinophalangeal syndrome I 8q24.12Exemplarsequence Hs.26102.1 AF264784.1 g10644121 20 218692_atFLJ20366 hypothetical protein FLJ20366 8q23.2 ExemplarsequenceHs.8358.0 NM_017786.1 g8923340 21 230016_at Homo sapiens cDNAFLJ13277 fis, clone Consensussequence Hs.55043.0 AU155118Hs.55043.0.S1 OVARC1001044. 22 222199_s_at BIN3 bridging integrator3 8p21.2 Consensussequence Hs.68090.1 AK001289.1 Hs.68090.1.S1 23232693_s_at LOC55893 papillomavirus regulatory factor PRF-1 8p21.1Consensussequence Hs.27410.2 AK021850.1 Hs.27410.2.S1 24223216_s_at LOC55893 papillomavirus regulatory factor PRF-1 8p21.1Exemplarsequence Hs.27410.1 BC001237.1 g12654788 25 212865_s_atCOL14A1 collagen, type XIV, alpha 1 (undulin) 8q23Consensussequence Hs.36131.0 BF449063 Hs.36131.0.S1 26 239860_atESTs Consensussequence Hs.16292.0 AI311917 Hs.16292.0.A1 27203207_s_at CHPPR likely ortholog of chicken chondrocyte 8q12.1Consensussequence Hs.170198.0 BF214329 Hs.170198.0.S1 protein witha poly-proline region 28 219665_at FLJ22494 hypothetical proteinFLJ22494 8p21.2 Exemplarsequence Hs.170132.0 NM_024815.1 g1337620529 224316_at FLJ20038 hypothetical protein FLJ20038 8p21.1Exemplarsequence Hs.72071.1 AF130091.1 g11493486 30 231764_atCHRAC1 chromatin accessibility complex 1 8q24.3 ConsensussequenceHs.279704.0 AK023537.1 Hs.279704.0 31 219071_x_at LOC51236hypothetical protein LOC51236 8q24.3 Exemplarsequence Hs.300224.0NM_016458.2 g13124772 32 226707_at PP3856 similar to CG3714 geneproduct 8q24.3 Consensussequence Hs.9614.3 BE870868 Hs.9614.3_RC 33226129_at Homo sapiens, clone IMAGE: 5455669, ConsensussequenceHs.67776.0 AI949095 Hs.67776.0.A1 mRNA, partial cds 34 212149_atKIAA0143 KIAA0143 protein 8q24.22 Consensussequence Hs.84087.0AA805651 Hs.84087.0.S1 35 212150_at KIAA0143 KIAA0143 protein8q24.22 Consensussequence Hs.84087.0 AA805651 Hs.84087.0.S1 36234351_x_at TRPS1 trichorhinophalangeal syndrome I 8q24.12Consensussequence Hs.26102.2 AK000948.1 Hs.26102.2 37 212157_atSDC2 syndecan 2 (heparan sulfate proteoglycan 8q22-q23Consensussequence Hs.1501.0 J04621.1 Hs.1501.0 1, cellsurface-associated, fibroglycan) 38 214485_at ODF1 outer densefiber of sperm tails 1 8q22.3 Consensussequence Hs.159274.0NM_024410.1 Hs.159274.0 39 220400_at FLJ20583 hypothetical proteinFLJ20583 8q22.1 Exemplarsequence Hs.158836.0 NM_017890.1 g892354440 212248_at Homo sapiens, Similar to LYRIC, cloneConsensussequence Hs.243901.0 AI972475 Hs.243901.0.S1 MGC: 41931IMAGE: 5298467, mRNA, complete cds 41 232023_at MGC26979hypothetical protein MGC26979 8q21.3 Consensussequence Hs.130554.0AL575584 Hs.130554.0 42 205529_s_at CBFA2T1 core-binding factor,runt domain, alpha 8q22 Exemplarsequence Hs.31551.0 NM_004349.1g4757915 subunit 2; translocated to, 1; cyclin D-related 43200062_s_at- RPL30 ribosomal protein L30 8q22 ExemplarsequenceHs.111222.0 L05095.1 g388034 HG-U133A 44 219793_at SNX16 sortingnexin 16 8q21.12 Exemplarsequence Hs.128645.0 NM_022133.1 g1154586445 225622_at PAG phosphoprotein associated with 8q21.11Consensussequence Hs.266175.0 NM_018440.1 Hs.266175.0glycosphingolipid-enriched microdomains 46 214161_at C8orf1chromosome 8 open reading frame 1 8q21 Consensussequence Hs.40539.1BF057458 Hs.40539.1.A1 47 44783_s_at HEY1 hairy/enhancer-of-splitrelated with YRPW 8q21 Consensussequence 4838473 R61374 4838473motif 1 48 205949_at CA1 carbonic anhydrase I 8q13-q22.1Exemplarsequence Hs.23118.0 M33987.1 g179792 49 202824_s_at TCEB1transcription elongation factor B (SIII), 8q13.3 ExemplarsequenceHs.184693.0 NM_005648.1 g5032160 polypeptide 1 (15 kDa, elongin C)50 205731_s_at NCOA2 nuclear receptor coactivator 2 8q13.1Consensussequence Hs.29131.0 AW027474 Hs.29131.0 51 230500_at PDE7Aphosphodiesterase 7A 8q13 Consensussequence Hs.150395.2 AA651933Hs.150395.2_RC 52 208730_x_at RAB2 RAB2, member RAS oncogene family8q12.1 Consensussequence Hs.78305.0 NM_002865.1 Hs.78305.0_RC 53219993_at SOX17 SRY (sex determining region Y)-box 17 8q11.22Exemplarsequence Hs.97984.0 NM_022454.1 g11967990 54 204837_atMTMR9 myotubularin related protein 9 8p23-p22 ConsensussequenceHs.27194.0 AL080178.1 Hs.27194.0.S2 55 228615_at LOC286161hypothetical protein LOC286161 8p23.3 Consensussequence Hs.13477.0AW291761 Hs.13477.0_RC 56 220512_at FLJ21120 hypothetical proteinFLJ21120 8p22 Exemplarsequence Hs.133546.0 NM_024767.1 g13376110 57203548_s_at LPL lipoprotein lipase 8p22 ConsensussequenceHs.180878.0 BF672975 Hs.180878.0_RC 58 202680_at GTF2E2 generaltranscription factor IIE, 8p21-p12 Exemplarsequence Hs.77100.0NM_002095.1 g4504194 polypeptide 2, beta 34 kDa 59 208791_at CLUclusterin (complement lysis inhibitor, SP- 8p21-p12Exemplarsequence Hs.75106.0 M25915.1 g180619 40,40, sulfatedglycoprotein 2, testosterone-repressed prostate message 2,apolipoprotein J) 60 208792_at CLU clusterin (complement lysisinhibitor, SP- 8p21-p12 Exemplarsequence Hs.75106.0 M25915.1g180619 40,40, sulfated glycoprotein 2, testosterone-repressedprostate message 2, apolipoprotein J) 61 208241_at NRG1 neuregulin1 8p21-p12 Exemplarsequence Hs.172816.4 NM_004495.1 g4758525 62228013_at Homo sapiens mRNA; cDNA Consensussequence Hs.61696.0AV702575 Hs.61696.0_RC DKFZp586F1523 (from clone DKFZp586F1523) 63221236_s_at STMN4 stathmin-like 4 8p21.1 Exemplarsequence g13540510NM_030795.1 g13540510 64 202313_at PPP2R2A protein phosphatase 2(formerly 2A), 8p21.1 Exemplarsequence Hs.179574.0 NM_002717.1g4506018 regulatory subunit B (PR 52), alpha isoform 65 202035_s_atSFRP1 secreted frizzled-related protein 1 8p12-p11.1Consensussequence Hs.7306.0 AI332407 Hs.7306.0.A1 66 211535_s_atFGFR1 fibroblast growth factor receptor 1 (fms- 8p11.2-p11.1Exemplarsequence Hs.748.6 M60485.1 g182560 related tyrosine kinase2. Pfeiffer syndrome) 67 207822_at FGFR1 fibroblast growth factorreceptor 1 (fms- 8p11.2-p11.1 Exemplarsequence Hs.748.0 NM_023107.1g13186237 related tyrosine kinase 2, Pfeiffer syndrome) 68236192_at ESTs Consensussequence Hs.124961.0 BF447112Hs.124961.0_RC 69 207568_at CHRNA6 cholinergic receptor, nicotinic,alpha 8p11.1 Exemplarsequence Hs.103128.0 NM_004198.1 g4757981polypeptide 6 70 218173_s_at WHSC1L1 Wolf-Hirschhorn syndromecandidate 1- 8p11.2 Exemplarsequence Hs.27721.0 NM_017778.2g13699812 like 1 71 217437_s_at TACC1 transforming, acidiccoiled-coil containing 8p11 Consensussequence Hs.173159.1AB029026.1 Hs.173159.1.S1 protein 1 72 38158_at ESPL1 extra spindlepoles like 1 (S. cerevisiae) 8 Consensussequence 4852842_rc D799874852842_rc # Sequence Source Unigene_Accession Cluster_TypeLocusLink Full_Length_Reference_Seq 1 GenBank Hs.173094 fulllength85453 NM_033512; KIAA1750 protein 2 GenBank Hs.4147 fulllength23471 NM_014294; translocating chain-associating membrane protein 3GenBank Hs.2463 fulllength 284 NM_001146; angiopoietin 1 isoform aNM_139290; angiopoietin 1 isoform b 4 RefSeq Hs.2463 fulllength 284NM_001146; angiopoietin 1 isoform a NM_139290; angiopoietin 1isoform b 5 RefSeq Hs.273344 fulllength 25879 NM_014156; NM_015420;DKFZP564O0463 protein 6 GenBank Hs.98471 est 137682 NM_152416;hypothetical protein MGC40214 7 RefSeq Hs.170198 fulllength 9650NM_014637; KIAA0009 gene product 8 GenBank Hs.131055 286056 9RefSeq Hs.425311 fulllength 27257 NM_014462; Lsm1 protein 10GenBank Hs.28285 fulllength 11236 NM_007218; ring finger protein139 11 RefSeq Hs.169395 fulllength 79870 NM_024812; brain and acuteleukemia, cytoplasmic 12 RefSeq Hs.241384 fulllength 10646NM_006550; fibrinogen silencer binding protein 13 GenBank Hs.51233fulllength 8795 NM_003842; tumor necrosis factor receptorsuperfamily, member 10b isoform 1 precursor NM_147187; tumornecrosis factor receptor superfamily, member 10b isoform 2precursor 14 GenBank Hs.7946 fulllength 57509 NM_020749;transcription factor MTSG1 15 GenBank Hs.25590 fulllength 6781NM_003155; stanniocalcin 1 16 RefSeq Hs.174030 fulllength 10863NM_014265; a disintegrin and metalloproteinase domain 28 isoform 1preproprotein NM_021777; a disintegrin and metalloproteinase domain28 isoform 3 preproprotein NM_021778; a disintegrin andmetalloproteinase domain 28 isoform 2 preproprotein 17 RefSeqHs.27410 fulllength 55893 NM_018660; papillomavirus regulatoryfactor PRF-1 18 RefSeq Hs.153479 fulllength 9700 NM_012291; extraspindle poles like 1 19 GenBank Hs.26102 fulllength 7227 NM_014112;zinc finger transcription factor TRPS1 20 RefSeq Hs.8358 fulllength55638 NM_017786; hypothetical protein FLJ20366 21 GenBank Hs.5504322 GenBank Hs.68090 fulllength 55909 NM_018688; bridging integrator3 23 GenBank Hs.27410 fulllength 55893 NM_018660; papillomavirusregulatory factor PRF-1 24 GenBank Hs.27410 fulllength 55893NM_018660; papillomavirus regulatory factor PRF-1 25 GenBankHs.403836 fulllength 7373 26 GenBank Hs.16292 est 27 GenBankHs.170198 fulllength 9650 NM_014637; KIAA009 gene product 28 RefSeqHs.170132 fulllength 79873 NM_024815; hypothetical protein FLJ2249429 GenBank Hs.72071 fulllength 54793 NM_017634; hypotheticalprotein FLJ20038 30 GenBank Hs.279704 fulllength 54108 NM_017444;chromatin accessibility complex 1 31 RefSeq Hs.300224 fulllength51236 NM_016458; brain protein 16 32 GenBank Hs.333388 fulllength93100 NM_145201; similar to CG3714 gene product 33 GenBank Hs.6777634 GenBank Hs.84087 23167 35 GenBank Hs.84087 23167 36 GenBankHs.26102 fulllength 7227 NM_014112; zinc finger transcriptionfactor TRPS1 37 GenBank Hs.1501 fulllength 6383 NM_002998; syndecan2 38 GenBank Hs.159274 fulllength 4956 NM_024410; outer dense fiberof sperm tails 1 39 RefSeq Hs.158836 fulllength 54990 NM_017890;hypothetical protein FLJ20583 40 GenBank Ns.243901 fulllength 41GenBank Hs.130554 fulllength 91147 NM_153704; hypothetical proteinMGC26979

42 RefSeq Hs.31551 fulllength 862 NM_004349; acute myelogenousleukemia 1 translocation 1 protein isoform MTG8a NM_175634; acutemyelogenous leukemia 1 translocation 1 protein isoform MTG8bNM_175635; acute myelogenous leukemia 1 translocation 1 proteinisoform MTG8c NM_175636; acute myelogenous leukemia 1 translocation1 protein isoform MTG8c 43 GenBank Hs.334807 fulllength 6156NM_000989; ribosomal protein L30 44 RefSeq Hs.128645 fulllength64089 NM_022133; sorting nexin 16 isoform a NM_152836; sortingnexin 16 isoform a NM_152837; sorting nexin 16 isoform b 45 GenBankHs.266175 fulllength 55824 NM_018440; phosphoprotein associatedwith glycosphingolipid-enriched microdomains 46 GenBank Hs.40539fulllength 734 NM_004337; chromosome 8 open reading frame 1 47GenBank Hs.234434 fulllength 23462 NM_012258;hairy/enhancer-of-split related with YRPW motif 1 48 GenBankHs.23118 fulllength 759 NM_001738; carbonic anhydrase I 49 RefSeqHs.184693 fulllength 6921 NM_005648; elongin C 50 GenBank Hs.404048fulllength 10499 NM_006540; nuclear receptor coactivator 2 51GenBank Hs.406325 fulllength 5150 NM_002603; phosphodiesterase 7Aisoform a NM_002604; phosphodiesterase 7A isoform b 52 GenBankHs.78305 fulllength 5862 NM_002865; RAB2, member RAS oncogenefamily 53 RefSeq Hs.97984 fulllength 64321 NM_022454; SRY-box 17 54GenBank Hs.48802 fulllength 66036 NM_015458; myotubularin relatedprotein 9 55 GenBank Hs.13477 286161 56 RefSeq Hs.133546 fulllength79824 57 GenBank Hs.180878 fulllength 4023 NM_000237; lipoproteinlipase precursor 58 RefSeq Hs.77100 fulllength 2961 NM_002095;general transcription factor IIE, polypeptide 2, beta 34 kDa 59GenBank Hs.75106 fulllength 1191 NM_001831; clusterin 60 GenBankHs.75106 fulllength 1191 NM_001831; clusterin 61 RefSeq Hs.172816fulllength 3084 NM_004495; neuregulin 1 isoform HRG-gammaNM_013956; neuregulin 1 isoform HRG-beta1 NM_013957; neuregulin 1isoform HRG-beta2 NM_013958; neuregulin 1 isoform HRG-beta3NM_013959; neuregulin 1 isoform SMDF NM_013960; neuregulin 1isoform ndf43 NM_013961; neuregulin 1 isoform GGF NM_013962;nauregulin 1 isoform GGF2 NM_013964; neuregulin 1 isoform HRG-alpha62 GenBank Hs.61696 63 RefSeq Hs.3815 fulllength 81551 NM_030795;stathmin-like-protein RB3 64 RefSeq Hs.179574 fulllength 5520NM_002717; protein phosphatase 2 (formerly 2A), regulatory subunitB (PR 52), alpha isoform 65 GenBank Hs.7306 fulllength 6422NM_003012; secreted frizzled-related protein 1 66 GenBank Hs.748fulllength 2260 NM_000604; fibroblast growth factor receptor 1isoform 1 precursor NM_015850; fibroblast growth factor receptor 1isoform 2 precursor NM_023105; fibroblast growth factor receptor 1isoform 3 precursor NM_023106; fibroblast growth factor receptor 1isoform 4 precursor NM_023107; fibroblast growth factor receptor 1isoform 5 precursor NM_023108; fibroblast growth factor receptor 1isoform 6 precursor NM_023109; fibroblast growth factor receptor 1isoform 7 precursor NM_023110; fibroblast growth factor receptor 1isoform 8 precursor NM_023111; fibroblast growth factor receptor 1isoform 9 precursor 67 RefSeq Hs.748 fulllength 2260 NM_000604;fibroblast growth factor receptor 1 isoform 1 precursor NM_015850;fibroblast growth factor receptor 1 isoform 2 precursor NM_023105;fibroblast growth factor receptor 1 isoform 3 precursor NM_023106;fibroblast growth factor receptor 1 isoform 4 precursor NM_023107;fibroblast growth factor receptor 1 isoform 5 precursor NM_023108;fibroblast growth factor receptor 1 isoform 6 precursor NM_023109;fibroblast growth factor receptor 1 isoform 7 precursor NM_023110;fibroblast growth factor receptor 1 isoform 8 precursor NM_023111;fibroblast growth factor receptor 1 isoform 9 precursor 68 GenBankHs.124961 est 69 RefSeq Hs.103128 fulllength 8973 NM_004198;cholinergic receptor, nicotinic, alpha polypeptide 6 70 RefSeqHs.27721 fulllength 54904 NM_017778; WHSC1L1 protein isoform shortNM_023034; WHSC1L1 protein isoform long 71 GenBank Hs.173159fulllength 6867 NM_006283; transforming, acidic coiled-coilcontaining protein 1 72 GenBank Hs.153479 fulllength 9700NM_012291; extra spindle poles like 1

TABLE-US-00030 TABLE 29 _normal HUGO # affy id name fc p q stn tTitle MapLocation Sequence Type Transcript ID 1 200923_at LGALS3BP-6.84 6.78e-23 2.44e-18 -0.75 -11.10 lectin, galactoside-binding,soluble, 3 binding 17q25 Exemplarsequence Hs.79339.0 protein 2212250_at 17533 1.95e-09 6.40e-06 1.00 47362 Homo sapiens, Similarto LYRIC, clone Consensussequence Hs.243901.0 MGC: 41931 IMAGE:5298467, mRNA, complete cds 3 206761_at TACTILE -5.48 7.94e-151.43e-10 -0.59 -8.53 T cell activation, increased late expression3q13.13 Exemplarsequence Hs.142023.0 4 213110_s_at COL4A5 -3.524.83e-12 3.48e-08 -0.63 -8.28 collagen, type IV, alpha 5 (AlportXq22 Consensussequence Hs.169825.0 syndrome) 5 203110_at PTK2B27030 2.85e-08 6.04e-05 0.90 41852 PTK2B protein tyrosine kinase 2beta 8p21.1 Exemplarsequence Hs.20313.0 6 225233_at -3.41 4.70e-135.64e-09 -0.54 -7.87 Homo sapiens, clone IMAGE: 4154313,Consensussequence Hs.42179.0 mRNA, partial cds 7 205910_s_at CEL-4.12 6.40e-13 5.77e-09 -0.52 -7.67 carboxyl ester lipase (bilesalt-stimulated 9q34.3 Exemplarsequence Hs.99918.0 lipase) 8225240_s_at -2.84 6.34e-10 2.86e-06 -0.62 -7.64 Homo sapiens, cloneIMAGE: 4154313, Consensussequence Hs.42179.0 mRNA, partial cds 9216412_x_at IGL -2.42 3.13e-09 8.67e-06 -0.53 -6.87 immunoglobulinlambda locus 22q11.1-q11.2 Consensussequence Hs.287815.0 10209050_s_at RALGDS -1.60 3.12e-10 1.61e-06 -0.48 -6.82 ral guaninenucleotide dissociation 9q34.3 Consensussequence Hs.106185.0stimulator 11 227943_at -1.93 2.75e-09 8.26e-06 -0.49 -6.65 ESTsConsensussequence Hs.25933.0 12 226282_at -8.88 2.44e-10 1.46e-06-0.45 -6.65 Homo sapiens cDNA FLJ32401 fis, clone ConsensussequenceHs.235857.0 SKMUS2000339. 13 219553_at NME7 -1.60 1.17e-09 4.22e-06-0.47 -6.63 non-metastatic cells 7, protein expressed 1q24Exemplarsequence Hs.274479.0 in (nucleoside-diphosphate kinase) 14236124_at LOC153546 -1.64 3.75e-08 7.12e-05 -0.54 -6.61hypothetical protein LOC153546 5p13.3 Consensussequence Hs.44104.015 240929_at 14977 7.28e-07 5.70e-04 0.64 15128 Homo sapiens cDNAFLJ25206 fis, clone Consensussequence Hs.126813.0 REC05955. 16221286_s_at PACAP -5.90 9.01e-10 3.61e-06 -0.43 -6.41 proapoptoticcaspase adaptor protein 5q23-5q31 Exemplarsequence Hs.122492.1 17225237_s_at -2.41 2.14e-07 2.57e-04 -0.56 -6.37 Homo sapiens, cloneIMAGE: 4154313, Consensussequence Hs.42179.0 mRNA, partial cds 18214029_at -2.36 1.64e-08 3.70e-05 -0.47 -6.30 Homo sapiens, cloneMGC: 26694 Consensussequence Hs.20707.0 IMAGE: 4819096, mRNA,complete cds 19 209014_at MAGED1 -1.65 8.44e-08 1.38e-04 -0.49-6.17 melanoma antigen, family D, 1 Xp11.23 ExemplarsequenceHs.177556.0 20 213185_at KIAA0556 -1.27 5.02e-07 4.86e-04 -0.53-6.08 KIAA0556 protein 16p12.1 Consensussequence Hs.30512.0 21200974_at ACTA2 -1.72 1.89e-07 2.35e-04 -0.49 -6.06 actin, alpha 2,smooth muscle, aorta 10q23.3 Exemplarsequence Hs.195851.0 22228539_at -2.56 4.38e-07 4.51e-04 -0.50 -5.98 ESTsConsensussequence Hs.296100.0 23 228598_at DPRP3 -3.05 1.08e-082.78e-05 -0.40 -5.96 dipeptidyl peptidase IV-retated protein 3 2q13Consensussequence Hs.91625.0 24 223251_s_at ANKRD10 -1.58 1.71e-061.01e-03 -0.57 -5.96 ankyrin repeat domain 10 13q33.3Exemplarsequence Hs.298998.0 25 209051_s_at RALGDS -1.73 1.77e-072.28e-04 -0.47 -5.96 ral guanine nucleotide dissociation 9q34.3Exemplarsequence Hs.106185.0 stimulator 26 225238_at -2.85 3.54e-073.98e-04 -0.49 -5.95 Homo sapiens, clone IMAGE: 4154313,Consensussequence Hs.42179.0 mRNA, partial cds 27 205801_s_at GRP3-3.12 1.17e-07 1.66e-04 -0.45 -5.94 guanine nucleotide exchangefactor for 2p25.1-p24.1 Exemplarsequence Hs.24024.0 Rap1 28202365_at MGC5139 -1.48 5.14e-07 4.86e-04 -0.50 -5.92 hypotheticalprotein MGC5139 12q24.31 Exemplarsequence Hs.127610.0 29 244533_at-3.90 1.30e-08 3.12e-05 -0.40 -5.91 ESTs, Weakly similar tohypothetical Consensussequence Hs.294079.0 protein FLJ20489 [Homosapiens] [H. sapiens] 30 226134_s_at -2.74 1.52e-06 9.78e-04 -0.54-5.89 Homo sapiens, clone IMAGE: 4154313, ConsensussequenceHs.42640.0 mRNA, partial cds 31 222742_s_at FLJ14117 -1.64 2.41e-061.31e-03 -0.57 -5.89 hypothetical protein FLJ14117 7q22.1Consensussequence Hs.61809.0 32 206506_s_at SUPT3H -1.60 1.05e-067.57e-04 -0.52 -5.89 suppressor of Ty 3 homolog (S. cerevisiae)6p21.1-p21.3 Exemplarsequence Hs.96757.0 33 229949_at -1.653.09e-07 3.59e-04 -0.46 -5.85 Homo sapiens CDNA FLJ33372 fis, cloneConsensussequence Hs.325158.0 BRACE2005981. 34 201808_s_at ENG-1.75 8.82e-07 6.62e-04 -0.50 -5.82 endoglin (Osler-Rendu-Webersyndrome 9q33-q34.1 Consensussequence Hs.76753.0 1) 35 225314_atMGC45416 -1.67 3.27e-06 1.65e-03 -0.58 -5.82 hypothetical proteinMGC45416 4p11 Consensussequence Hs.95835.0 36 219602_s_at FLJ23403-1.80 6.94e-08 1.19e-04 -0.42 -5.81 hypothetical protein FLJ2340318p11.21 Exemplarsequence Hs.293907.0 37 219218_at FLJ23058 -1.996.67e-07 5.70e-04 -0.48 -5.78 hypothetical protein FLJ23058 17q25.3Exemplarsequence Hs.98968.0 38 203007_x_at LYPLA1 18629 1.09e-054.02e-03 0.74 28246 lysophospholipase I 8q11.23 ExemplarsequenceHs.12540.0 39 201664_at SMC4L1 -1.48 3.64e-07 3.98e-04 -0.45 -5.77SMC4 structural maintenance of 3q26.1 Exemplarsequence Hs.50758.0chromosomes 4-like 1 (yeast) 40 206847_s_at HOXA7 -1.86 2.36e-061.31e-03 -0.53 -5.76 homeo box A7 7p15-p14 ExemplarsequenceHs.70954.0 41 221525_at DKFZp761I2123 -1.62 9.80e-08 1.53e-04 -0.42-5.76 hypothetical protein DKFZp761I2123 7p12.3 ExemplarsequenceHs.77978.0 42 227725_at ST6GalNAcI -6.39 3.12e-08 6.24e-05 -0.40-5.76 GalNAc alpha-2, 6-sialyltransferase I, long 17q25.3Consensussequence Hs.105352.0 form 43 239237_at -1.89 1.13e-067.96e-04 -0.49 -5.75 ESTs Consensussequence Hs.265130.0 44243579_at MSI2 -2.96 1.90e-06 1.10e-03 -0.51 -5.72 musashi homolog2 (Drosophila) 17q23.1 Consensussequence Hs.173179.0 45 230974_atDDX19 -2.27 5.13e-08 9.24e-05 -0.39 -5.71 DEAD/H(Asp-Glu-Ala-Asp/His) box 16q22.1 Consensussequence Hs.127325.0polypeptide 19 (DBP5 homolog, yeast) 46 200608_s_at RAD21 146111.21e-05 4.22e-03 0.72 25689 RAD21 homolog (S. pombe) 8q24Exemplarsequence Hs.81848.0 47 237291_at -1.78 2.71e-06 1.44e-03-0.53 -5.70 ESTs, Weakly similar to unknown proteinConsensussequence Hs.159362.0 [Arabidopsis thaliana] [A. thaliana]48 209365_s_at ECM1 -1.60 7.18e-07 5.70e-04 -0.46 -5.69extracellular matrix protein 1 1q21 Exemplarsequence Hs.81071.1 49235521_at HOXA3 -2.52 1.95e-06 1.11e-03 -0.50 -5.67 homeo box A37p15-p14 Consensussequence Hs.222446.0 50 201433_s_at PTDSS1 226471.58e-05 5.13e-03 0.78 24593 phosphatidylserine synthase 1 8q22Exemplarsequence Hs.77329.0 Sequence Sequence # Derived FromSequence ID Source Unigene_Accession Cluster_Type LocusLinkFull_Length_Reference_Seq 1 NM_005567.2 g6006016 RefSeq Hs.79339fulllength 3959 NM_005567; galectin 3 binding protein 2 AI972475Hs.243901.0.S1 GenBank Hs.243901 fulllength 3 NM_005816.1 g5032140RefSeq Hs.142023 fulllength 10225 NM_005816; T cell activation,increased late expression 4 AW052179 Hs.169825.0_RC GenBankHs.169825 fulllength 1287 NM_000495; alpha 5 type IV collagenisoform 1, precursor NM_033380; alpha 5 type IV collagen isoform 2,precursor NM_033381; alpha 5 type IV collagen isoform 3, precursor5 U43522.1 g1165218 GenBank Hs.20313 fulllength 2185 NM_004103;PTK2B protein tyrosine kinase 2 beta isoform a NM_173174; PTK2Bprotein tyrosine kinase 2 beta isoform a NM_173175; PTK2B proteintyrosine kinase 2 beta isoform b NM_173176; PTK2B protein tyrosinekinase 2 beta isoform a 6 BF435123 Hs.42179.0.A1 GenBank Hs.1731797 NM_001807.1 g4502770 RefSeq Hs.406160 fulllength 1056 NM_001807;carboxyl ester lipase precursor 8 BF435123 Hs.42179.0.A1 GenBankHs.173179 9 AF043584.1 Hs.287815.0 GenBank Hs.405944 fulllength3535 NG_000002; 10 AI421559 Hs.106185.0 GenBank Hs.106185fulllength 5900 NM_006266; ral guanine nucleotide dissociationstimulator 11 AI798680 Hs.25933.0_RC GenBank Hs.445018 est 12AW129783 Hs.235857.0_RC GenBank Hs.235857 13 NM_013330.2 g7242158RefSeq Hs.274479 fulllength 29922 NM_013330; NME7 14 AL037070Hs.44104.0_RC GenBank Hs.422878 153546 15 AW300004 Hs.126813.0_RCGenBank Hs.126813 16 NM_016459.1 g7706002 RefSeq Hs.409563fulllength 51237 NM_016459; proapoptotic caspase adaptor protein 17BF435123 Hs.42179.0.A1 GenBank Hs.173179 18 AI435954 Hs.20707.0.A1GenBank Hs.20707 fulllength 19 AF217963.1 g9963809 GenBank Hs.5258fulllength 9500 NM_006986; melanoma antigen, family D, 1 20AI758896 Hs.30512.0 GenBank Hs.30512 23247 21 NM_001613.1 g4501882RefSeq Hs.195851 fulllength 59 NM_001613; alpha 2 actin 22 AI097095Hs.296100.0_RC GenBank Hs.296100 est 23 AL538781 Hs.91625.0.S1GenBank Hs.91625 fulllength 57628 NM_020868; dipeptidyl peptidaseIV-related protein 3 24 BC001727.1 g12804610 GenBank Hs.172572fulllength 55608 NM_017664; ankyrin repeat domain 10 25 AF295773.1g9931301 GenBank Hs.106185 fulllength 5900 NM_006266; ral guaninenucleotide dissociation stimulator 26 BF435123 Hs.42179.0.A1GenBank Hs.173179 27 NM_015376.1 g7662333 RefSeq Hs.24024fulllength 25780 NM_015376; RAS guanyl releasing protein 3 (calciumand DAG-regulated) NM_170672; RAS guanyl releasing protein 3(calcium and DAG-regulated) 28 BC004815.1 g13435956 GenBankHs.127610 fulllength 84747 NM_032661; hypothetical protein MGC513929 BE617483 Hs.294079.0_RC GenBank Hs.294079 est 30 AI978754Hs.42640.0.A1 GenBank Hs.173179 31 AW026449 Hs.61809.0 GenBankHs.61809 fulllength 64792 NM_022777; hypothetical protein FLJ1411732 NM_003599.1 g4507308 RefSeq Hs.304173 fulllength 8464 NM_003599;suppressor of Ty 3 homolog 33 AA554827 Hs.325158.0_RC GenBankHs.370705 34 BE732652 Hs.76753.0 GenBank Hs.76753 fulllength 2022NM_000118; endoglin precursor 35 BG291649 Hs.95835.0.A1 GenBankHs.95835 fulllength 132299 NM_152398; hypothetical protein MGC4541636 NM_022068.1 g13384601 RefSeq Hs.293907 fulllength 63895NM_022068; hypothetical protein FLJ23403 37 NM_024696.1 g13375978RefSeq Hs.98968 fulllength 79749 NM_024696; hypothetical proteinFLJ23058 38 AF077198.1 g4679009 GenBank Hs.12540 fulllength 10434NM_006330; lysophospholipase I 39 AL136877.1 g6807670 GenBankHs.50758 fulllength 10051 NM_005496; SMC4 structural maintenance ofchromosomes 4-like 1 40 AF026397.1 g2739070 GenBank Hs.446318fulllength 3204 NM_006896; homeobox protein A7 41 AL136572.1g13276646 GenBank Hs.77978 fulllength 83637 42 Y11339.2 Hs.105352.0GenBank Hs.105352 fulllength 55808 NM_018414; GalNAc alpha-2,6-sialyltransferase I 43 AI798822 Hs.265130.0_RC GenBank Hs.265130est 44 BF029215 Hs.173179.0.S1 GenBank Hs.103512 fulllength 124540NM_138962; musashi 2 isoform a NM_170721; musashi 2 isoform b 45AA234116 Hs.127325.0_RC GenBank Hs.289097 fulllength 11269NM_007242; DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 19 46NM_006265.1 g5453993 RefSeq Hs.81848 fulllength 5885 NM_006265;RAD21 homolog 47 AI695007 Hs.159362.0.A1 GenBank Hs.159362 est 48U65932.1 g1488323 GenBank Hs.81071 fulllength 1893 NM_004425;extracellular matrix protein 1 isoform 1 precursor NM_022664;extracellular matrix protein 1 isoform 2 precursor 49 AW137982Hs.222446.0.A1 GenBank Hs.248074 fulllength 3200 NM_030661;homeobox A3 protein isoform a NM_153631; homeobox A3 proteinisoform a NM_153632; homeobox A3 protein isoform b 50 NM_014754.1g7662646 RefSeq Hs.77329 fulllength 9791 NM_014754;phosphatidylserine synthase 1

TABLE-US-00031 TABLE 30 _normal Sequence Sequence # affy Id HUGOname Title MapLocation Sequence Type Transcript ID Derived FromSequence ID Source 1 218777_at FLJ22246 hypothetical proteinFLJ22246 8p21.2 Exemplarsequence Hs.289063.0 NM_025232.1 g13376835RefSeq 2 225053_at CNOT7 CCR4-NOT transcription 8p22-p21.3Consensussequence Hs.226318.1 W94952 Hs.226318.1.A2 GenBankcomplex, subunit 7 3 224413_s_at BLP1 BBP-like protein 1 8p11.21Exemplarsequence g13625460 AF353991.1 g13625460 GenBank 4205849_s_at UQCRB ubiquinol-cytochrome c 8q22 ExemplarsequenceHs.131255.0 NM_006294.1 g5454151 RefSeq reductase binding protein 5227001_at Homo sapiens cDNA: FLJ21362 Consensussequence Hs.167011.0AI096706 Hs.167011.0 GenBank fis, clone COL02886. 6 212523_s_atKIAA0146 KIAA0146 protein 8q11.21 Consensussequence Hs.278634.0D63480.1 Hs.278634.0_RC GenBank 7 219124_at FLJ23263 hypotheticalprotein FLJ23263 8p11.23 Exemplarsequence Hs.288716.0 NM_025115.1g13376690 RefSeq 8 201398_s_at TRAM translocating chain-associating8q13.1 Exemplarsequence Hs.4147.0 BC000687.1 g12653796 GenBankmembrane protein 9 235509_at MGC40214 hypothetical protein MGC402148q22.1 Consensussequence Hs.98471.0 AV662196 Hs.98471.0_RC GenBank10 203208_s_at CHPPR likely ortholog of chicken 8q12.1Exemplarsequence Hs.170198.0 NM_014637.1 g7661853 RefSeqchondrocyte protein with a poly- proline region 11 203207_s_atCHPPR likely ortholog of chicken 8q12.1 ConsensussequenceHs.170198.0 BF214329 Hs.170198.0.S1 GenBank chondrocyte proteinwith a poly- proline region 12 212248_at Homo sapiens, Similar toLYRIC, clone MGC: 41931 Consensussequence Hs.243901.0 AI972475Hs.243901.0.S1 GenBank IMAGE: 5298467, mRNA, complete cds 13202680_at GTF2E2 general transcription factor IIE, 8p21-p12Exemplarsequence Hs.77100.0 NM_002095.1 g4504194 RefSeq polypeptide2, beta 34 kDa 14 218173_s_at WHSC1L1 Wolf-Hirschhorn syndrome8p11.2 Exemplarsequence Hs.27721.0 NM_017778.2 g13699812 RefSeqcandidate 1-like 1 15 218187_s_at FLJ20989 hypothetical proteinFLJ20989 Exemplarsequence Hs.169615.0 NM_023080.1 g12751496 RefSeq16 208647_at FDFT1 farnesyl-diphosphate 8p23.1-p22Consensussequence Hs.48876.1 AA872727 Hs.48876.1 GenBankfarnesyltransferase 1 17 200090_at- FNTA farnesyltransferase, CAAXbox, 8p22-q11 Consensussequence Hs.138381.1 BG168896 Hs.138381.1.A1GenBank HG-U133A alpha 18 218250_s_at CNOT7 CCR4-NOT transcription8p22-p21.3 Exemplarsequence Hs.226318.0 NM_013354.2 g10518495RefSeq complex, subunit 7 19 202174_s_at PCM1 pericentriolarmaterial 1 8p22-p21.3 Exemplarsequence Hs.75737.0 NM_006197.1g5453855 RefSeq 20 214118_x_at PCM1 pericentriolar material 18p22-p21.3 Consensussequence Hs.75737.1 AI205598 Hs.75737.1.S1GenBank 21 214937_x_at PCM1 pericentriolar material 1 8p22-p21.3Consensussequence Hs.75737.2 AI924817 Hs.75737.2.S1 GenBank 22222544_s_at WHSC1L1 Wolf-Hirschhom syndrome 8p11.2Consensussequence Hs.27721.0 AI697751 Hs.27721.0_RC GenBankcandidate 1-like 1 23 219819_s_at MRPS28 mitochondrial ribosomalprotein 8q21.1-q21.2 Exemplarsequence Hs.55097.0 NM_014018.1g7661729 RefSeq S28 24 201618_x_at GPAA1 GPAA1P anchor attachment8q24.3 Exemplarsequence Hs.4742.0 NM_003801.2 g6031166 RefSeqprotein 1 homolog (yeast) 25 200936_at RPL8 ribosomal protein L88q24.3 Exemplarsequence Hs.178551.0 NM_000973.1 g4506662 RefSeq 26236533_at DDEF1 development and differentiation 8q24.1-q24.2Consensussequence Hs.199057.0 AW236958 Hs.199057.0.A1 GenBankenhancing factor 1 27 238562_at ESTs, Weakly similar toConsensussequence Hs.280297.0 BE542779 Hs.280297.0.A1 GenBankhypothetical protein FLJ20378 [Homo sapiens] [H. sapiens] 28212250_at Homo sapiens, Similar to LYRIC, ConsensussequenceHs.243901.0 AI972475 Hs.243901.0.S1 GenBank clone MGC: 41931 IMAGE:5298467, mRNA, complete cds 29 227277_at Homo sapiens cDNA FLJ40968Consensussequence Hs.33074.0 BG530089 Hs.33074.0.S1 GenBank fis,clone UTERU2012615. 30 202119_s_at CPNE3 copine III 8q21.13Exemplarsequence Hs.14158.0 NM_003909.1 g4503014 RefSeq 31218919_at FLJ14007 hypothetical protein FLJ14007 8q21.12Exemplarsequence Hs.99519.0 NM_024699.1 g13375984 RefSeq 32202955_s_at BIG1 brefeldin A-inhibited guanine 8q13Exemplarsequence Hs.94631.0 AF084520.1 g5052120 GenBanknucleotide-exchange protein 1 33 203448_s_at TERF1 telomeric repeatbinding factor 8q13 Consensussequence Hs.194562.0 AI347136Hs.194562.0.A1 GenBank (NIMA-interacting) 1 34 204301_at KIAA0711KIAA0711 gene product 8p23.2 Exemplarsequence Hs.5333.0 NM_014867.1g7662259 RefSeq 35 210980_s_at ASAH1 N-acylsphingosine 8p22-p21.3Exemplarsequence Hs.75811.1 U47674.1 g3860239 GenBankamidohydrolase (acid ceramidase) 1 36 208231_at NRG1 neuregulin 18p21-p12 Exemplarsequence Hs.172816.0 NM_013960.1 g7669519 RefSeq37 205770_at GSR glutathione reductase 8p21.1 ExemplarsequenceHs.121524.0 NM_000637.1 g10835188 RefSeq 38 217819_at LOC51125HSPC041 protein 8p11.21 Exemplarsequence Hs.7953.0 NM_016099.1g7705820 RefSeq 39 209517_s_at ASH2L ash2 (absent, small, or 8p11.2Exemplarsequence Hs.6856.1 AB020982.1 g4417209 GenBankhomeotic)-like (Drosophila) 40 222525_s_at FLJ10853 hypotheticalprotein FLJ10853 8p21.1 Consensussequence Hs.72085.0 AU160632Hs.72085.0 GenBank 41 222998_at MAF1 homolog of yeast MAF1 8q24.3Exemplarsequence Hs.324157.0 AL136937.1 g12053368 GenBank 42218679_s_at VPS28 vacuolar protein sorting 28 8q24.3Exemplarsequence Hs.293441.0 NM_016208.1 g7705884 RefSeq (yeast) 43223231_at CDA11 CDA11 protein 8q24.13 Exemplarsequence Hs.11810.0AF212250.1 g13182774 GenBank 44 204278_s_at EBAG9 estrogen receptorbinding site 8q23 Exemplarsequence Hs.9222.0 NM_004215.1 g4758229RefSeq associated, antigen, 9 45 218059_at LOC51123 HSPCO38 protein8q22.3 Exemplarsequence Hs.23528.0 NM_016096.1 g7705816 RefSeq 46201433_s_at PTDSS1 phosphatidylserine synthase 1 8q22Exemplarsequence Hs.77329.0 NM_014754.1 g7662646 RefSeq 47224743_at Homo sapiens, clone Consensussequence Hs.13328.0 BF965065Hs.13328.0_RC GenBank IMAGE: 3897094, mRNA 48 210950_s_at FDFT1farnesyl-diphosphate 8p23.1-p22 Exemplarsequence Hs.48876.0BC003573.1 g13097746 GenBank farnesyltransferase 1 49 209471_s_atFNTA farnesyltransferase, CAAX box, 8p22-q11 ExemplarsequenceHs.138381.0 L00634.1 g292030 GenBank alpha 50 225378_at FLJ32642hypothetical protein FLJ32642 8p22 Consensussequence Hs.101617.0AI866426 Hs.101617.0_RC GenBank 51 228024_at FLJ32642 hypotheticalprotein FLJ32642 8p22 Consensussequence Hs.290855.0 AW028100Hs.290855.0 GenBank 52 201985_at KIAA0196 KIAA0196 gene product8p22 Exemplarsequence Hs.8294.0 NM_014846.1 g7661987 RefSeq 53207000_s_at PPP3CC protein phosphatase 3 (formerly 8p21.2Exemplarsequence Hs.75206.0 NM_005605.1 g5031988 RefSeq 2B),catalytic subunit, gamma isoform (calcineurin A gamma) 54 227075_atELP3 likely ortholog of mouse 8q21.2 Consensussequence Hs.267905.2AI949204 Hs.267905.2_RC GenBank elongation protein 3 homolog (S.cerevisiae) 55 209384_at PROSC proline synthetase co- 8p11.2Consensussequence Hs.301959.0 AA176833 Hs.301959.0.A2 GenBanktranscribed homolog (bacterial) 56 218017_s_at FLJ22242hypothetical protein FLJ22242 8p11.1 Exemplarsequence Hs.288057.0NM_025070.1 g13376612 RefSeq 57 202872_at ATP6V1C1 ATPase, H+transporting, 8q22.3 Consensussequence Hs.86905.0 NM_001695.1Hs.86905.0 GenBank lysosomal 42 kDa, V1 subunit C, isoform 1 58209066_x_at UQCRB ubiquinol-cytochrome c 8q22 ExemplarsequenceHs.131255.1 M26700.1 g190803 GenBank reductase binding protein 59218549_s_at CGI-90 CGI-90 protein 8q21.13 ExemplarsequenceHs.44222.0 NM_016033.1 g7705802 RefSeq 60 201652_at COPS5 COP9constitutive 8q12.3 Exemplarsequence Hs.198767.0 NM_006837.1g5803045 RefSeq photomorphogenic homolog subunit 5 (Arabidopsis) 61239877_at MTMR9 myotubularin related protein 9 8p23-p22Consensussequence Hs.128277.0 AI499833 Hs.128277.0_RC GenBank 62203941_at FLJ10871 hypothetical protein FLJ10871 8p12Exemplarsequence Hs.15562.0 NM_018250.1 g8922725 RefSeq 63215983_s_at D8S2298E reproduction 8 8p12-p11.2 ConsensussequenceHs.153678.1 D83768.1 Hs.153678.1.S1 GenBank 64 208846_s_at VDAC3voltage-dependent anion 8p11.2 Exemplarsequence Hs.7381.0 U90943.1g2735306 GenBank channel 3 65 214394_x_at EEF1D eukaryotictranslation elongation 8q24.3 Consensussequence Hs.223241.1AI613383 Hs.223241.1.A1 GenBank factor 1 delta (guanine nucleotideexchange protein) 66 219189_at FBXL6 F-box and leucine-rich repeat8q24.3 Exemplarsequence Hs.12271.0 NM_024555.1 g13435140 RefSeqprotein 6 67 211060_x_at GPAA1 GPAA1P anchor attachment 8q24.3Exemplarsequence g13623546 BC006383.1 g13623546 GenBank protein 1homolog (yeast) 68 212090_at VPS28 vacuolar protein sorting 288q24.3 Consensussequence Hs.101067.2 AL571424 Hs.101067.2 GenBank(yeast) 69 227778_at Homo sapiens cDNA FLJ35542 ConsensussequenceHs.26563.0 H11075 Hs.26563.0_RC GenBank fis, clone SPLEN2002917. 70212556_at SCRIB scribble 8q24.3 Consensussequence Hs.239784.0AI469403 Hs.239784.0.S1 GenBank 71 36936_at TSTA3 tissue specifictransplantation 8q24.3 Consensussequence 4900667_rc U587664900667_rc GenBank antigen P35B 72 222133_s_at CGI-72 CGI-72protein 8q24.3 Consensussequence Hs.288435.0 AK022280.1 Hs.288435.0GenBank 73 226942_at FLJ21615 hypothetical protein FLJ21615 8q24.22Consensussequence Hs.44159.0 AI742668 Hs.44159.0.S1 GenBank 74227523_s_at CGI-72 CGI-72 protein 8q24.3 ConsensussequenceHs.318725.1 AA192936 Hs.318725.1.SI GenBank 75 224790_at DDEF1development and differentiation 8q24.1-q24.2 ConsensussequenceHs.10669.1 W03103 Hs.10669.1.S2 GenBank enhancing factor 1 76224796_at DDEF1 development and differentiation 8q24.1-q24.2Consensussequence Hs.10669.1 W03103 Hs.10669.1.S2 GenBank enhancingfactor 1 77 226536_at FLJ32440 hypothetical protein FLJ324408q24.13 Consensussequence Hs.58609.0 AL562908 Hs.58609.0.S1 GenBank78 208608_s_at SNTB1 syntrophin, beta 1 (dystrophin- 8q23-q24Exemplarsequence Hs.95011.0 NM_021021.1 g11321639 RefSeq associatedprotein A1, 59 kDa, basic component 1) 79 226438_at Homo sapienscDNA: FLJ21447 Consensussequence Hs.44241.0 AK025100.1 Hs.44241.0GenBank fis, clone COL04468. 80 218482_at DC6 DC6 protein 8q23.2Exemplarsequence Hs.283740.0 NM_020189.1 g9910185 RefSeq 81204274_at EBAG9 estrogen receptor binding site 8q23Consensussequence Hs.9222.0 AA812215 Hs.9222.0 GenBank associated,antigen, 9 82 218197_s_at OXR1 oxidation resistance 1 8q23Exemplarsequence Hs.169111.0 NM_018002.1 g8922240 RefSeq 83226463_at Homo sapiens cDNA FLJ33383 Consensussequence Hs.290880.0AW241758 Hs.290880.0.A1 GenBank fis, clone BRACE2006514. 84202635_s_at POLR2K polymerase (RNA) II (DNA 8q22.2 ExemplarsequenceHs.150675.0 NM_005034.1 g4826923 RefSeq directed) polypeptide K,7.0 kDa 85 208454_s_at PGCP plasma glutamate 8q22.2Exemplarsequence Hs.278993.0 NM_016134.1 g7706386 RefSeqcarboxypeptidase 86 223110_at DKFZP434I116 DKFZP4341116 protein8q22.1 Exemplarsequence Hs.16621.0 BC003701.1 g13277583 GenBank 87218905_at FLJ20530 hypothetical protein FLJ20530 8q22.1Exemplarsequence Hs.279521.0 NM_017864.1 g8923495 RefSeq 88225600_at Homo sapiens cDNA FLJ40637 Consensussequence Hs.6390.1AW303300 Hs.6390.1.A1 GenBank fis, clone THYMU2015984. 89225603_s_at Homo sapiens cDNA FLJ40637 Consensussequence Hs.6390.1AW303300 Hs.6390.1.A1 GenBank fis, clone THYMU2015984. 90 212251_atHomo sapiens, Similar to LYRIC, Consensussequence

Hs.243901.0 AI972475 Hs.243901.0.S1 GenBank clone MGC: 41931 IMAGE:5298467, mRNA, complete cds 91 222699_s_at FLJ13187 phafin 2 8q22.1Consensussequence Hs.29724.0 BF439250 Hs.29724.0.S1 GenBank 92203790_s_at UK114 translational inhibitor protein 8q22Consensussequence Hs.18426.0 N54448 Hs.18426.0.S1 GenBank p14.5 93209065_at UQCRB ubiquinol-cytochrome c 8q22 ExemplarsequenceHs.131255.1 BC005230.1 g13528857 GenBank reductase binding protein94 202118_s_at CPNE3 copine III 8q21.13 ConsensussequenceHs.14158.0 AA541758 Hs.14158.0 GenBank 95 210296_s_at PXMP3peroxisomal membrane protein 8q21.1 Exemplarsequence Hs.180612.1BC005375.1 g13529226 GenBank 3, 35 kDa (Zellweger syndrome) 96202905_x_at NBS1 Nijmegen breakage syndrome 1 8q21-q24Consensussequence Hs.25812.0 AI796269 Hs.25812.0.S1 GenBank(nibrin) 97 202907_s_at NBS1 Nijmegen breakage syndrome 1 8q21-q24Exemplarsequence Hs.25812.0 NM_002485.2 g6996019 RefSeq (nibrin) 98204226_at STAU2 staufen, RNA binding protein, 8q13-q21.1Exemplarsequence Hs.96870.0 NM_014393.1 g7657624 RefSeq homolog 2(Drosophila) 99 219449_s_at FLJ20533 hypothetical protein FLJ205338q13.3 Exemplarsequence Hs.106650.0 NM_017866.1 g8923499 RefSeq 100201399_s_at TRAM translocating chain-associating 8q13.1Exemplarsequence Hs.4147.0 NM_014294.1 g7657654 RefSeq membraneprotein 101 202956_at BIG1 brefeldin A-inhibited guanine 8q13Exemplarsequence Hs.94631.0 NM_006421.2 g6715588 RefSeqnucleotide-exchange protein 1 102 216266_s_at BIG1 brefeldinA-inhibited guanine 8q13 Consensussequence Hs.94631.1 AK025637.1Hs.94631.1.S1 GenBank nucleotide-exchange protein 1 103 220038_atSGKL serum/glucocorticoid regulated 8q12.3-8q13.1 ExemplarsequenceHs.279696.0 NM_013257.1 g7019526 RefSeq kinase-like 104 227627_atSGKL serum/glucocorticoid regulated 8q12.3-8q13.1 ConsensussequenceHs.24131.0 AV690866 Hs.24131.0.S1 GenBank kinase-like 105218185_s_at FLJ10511 hypothetical protein FLJ10511 8q12.2Exemplarsequence Hs.106768.0 NM_018120.1 g8922478 RefSeq 106210896_s_at ASPH aspartate beta-hydroxytase 8q12.1 ExemplarsequenceHs.283664.4 AF306765.1 g11991236 GenBank 107 208731_at RAB2 RAB2,member RAS oncogene 8q12.1 Consensussequence Hs.78305.0 NM_002865.1Hs.78305.0_RC GenBank family 108 208734_x_at RAB2 RAB2, member RASoncogene 8q12.1 Exemplarsequence Hs.78305.0 M28213.1 g550061GenBank family 109 222701_s_at MGC2217 hypothetical protein MGC22178q11.23 Consensussequence Hs.323164.0 AA570393 Hs.323164.0 GenBank110 209096_at UBE2V2 ubiquitin-conjugating enzyme E2 8q11.1Exemplarsequence Hs.79300.0 U62136.2 g4775663 GenBank variant 2 111219281_at MSRA methionine sulfoxide reductase A 8p23.1Exemplarsequence Hs.26458.0 NM_012331.2 g13259538 RefSeq 112221504_s_at ATP6V1H ATPase, H+ transporting, 8p22-q22.3Exemplarsequence Hs.19576.0 AF112204.1 g6563195 GenBank lysosomal50/57 kDa, V1 subunit H 113 200762_at DPYSL2dihydropyrimidinase-like 2 8p22-p21 Exemplarsequence Hs.173381.0NM_001386.1 g4503376 RefSeq 114 212866_at Homo sapiens, simliar toConsensussequence Hs.300861.0 AI081543 Hs.300861.0 GenBankhypothetical protein DKFZp564N123.1 - human (fragment), cloneIMAGE: 5220614, mRNA 115 221094_s_at ELP3 likely ortholog of mouse8p21.1 Exemplarsequence Hs.267905.0 NM_018091.1 g8922417 RefSeqelongation protein 3 homolog (S. cerevisiae) 116 225609_at GSRglutathione reductase 8p21.1 Consensussequence Hs.193974.0 AI888037Hs.193974.0.S1 GenBank 117 227102_at TRIM35 tripartitemotif-containing 35 8p21.1 Consensussequence Hs.137732.0 AA115933Hs.137732.0 GenBank 118 218955_at BRF2 BRF2, subunit of RNA 8p11.1Exemplarsequence Hs.274136.0 NM_018310.1 g8922843 RefSeq polymeraseIII transcription initiation factor, BRF1-like 119 220985_s_atDKFZP564A022 hypothetical protein 8p11.1 Exemplarsequence g13569925NM_030954.1 g13569925 RefSeq DKFZp564A022 120 224776_atDKFZp586M1819 hypothetical protein 8p11.1 ConsensussequenceHs.25664.1 BF513102 Hs.25664.1.A1 GenBank DKFZp586M1819 121221542_s_at C8orf2 chromosome 8 open reading 8p11.2Consensussequence Hs.125849.0 T90773 Hs.125849.0 GenBank frame 2122 221543_s_at C8orf2 chromosome 8 open reading 8p11.2Exemplarsequence Hs.125849.0 AL442077.1 g10241715 GenBank frame 2123 209341_s_at IKBKB inhibitor of kappa light 8p11.2Consensussequence Hs.226573.0 AU153366 Hs.226573.0 GenBankpolypeptide gene enhancer in B- cells, kinase beta 124 209385_s_atPROSC proline synthetase co- 8p11.2 Exemplarsequence Hs.301959.0AL136616.1 g12052757 GenBank transcribed homolog (bacterial) 125219416_at SCARA3 scavenger receptor class A, 8p21 ExemplarsequenceHs.128856.0 NM_016240.1 g7705335 RefSeq member 3 126 228013_at Homosapiens mRNA; cDNA Consensussequence Hs.61696.0 AV702575Hs.61696.0_RC GenBank DKFZp586F1523 (from clone DKFZp586F1523) 127230361_at ESTs, Weakly similar to inner ConsensussequenceHs.146109.0 AW664013 Hs.146109.0_RC GenBank centromere protein [Musmusculus] [M. musculus] 128 219060_at FLJ10204 hypothetical proteinFLJ10204 8q24.13 Exemplarsequence Hs.18029.0 NM_018024.1 g8922280RefSeq 129 219231_at NCOA6IP nuclear receptor coactivator 6 8q11Exemplarsequance Hs.179909.0 NM_024831.1 g13376235 RefSeqinteracting protein 130 227017_at LOC157697 hypothetical proteinLOC157697 8p23.3 Consensussequence Hs.193090.0 AA767385Hs.193090.0.A1 GenBank 131 218337_at RAI16 retinoic acid induced 168p21.2 Exemplarsequence Hs.299148.0 NM_022749.1 g12232410 RefSeq132 209253_at SCAM-1 vinexin beta (SH3-containing 8p21.2Exemplarsequence Hs.33787.1 AF037261.1 g3004947 GenBank adaptormolecule-1) 133 227836_at Consensussequence Hs.86970.0 AI859767Hs.86970.0.A1 GenBank 134 221020_s_at MFTC mitochondrial folate8q22.3 Exemplarsequence g13540550 NM_030780.1 g13540550 RefSeqtransporter/carrier 135 228225_at PXMP3 peroxisomal membraneprotein 8q21.1 Consensussequence Hs.180612.2 AW512586Hs.180612.2.A1 GenBank 3, 35 kDa (Zellweger syndrome) 136 213139_atSNAI2 snail homolog 2 (Drosophila) 8q11 ConsensussequenceHs.93005.0 AI572079 Hs.93005.0 GenBank 137 220843_s_atDKFZP564O0463 DKFZP564O0463 protein 8q22.3 ExemplarsequenceHs.273344.0 NM_014156.1 g7661767 RefSeq 138 203534_at LSM1 LSM1homolog, U6 small 8p11.2 Exemplarsequence Hs.111783.0 NM_014462.1g7657312 RefSeq nuclear RNA associated (S. cerevisiae) 139209510_at TRC8 patched related protein 8q24 ExemplarsequenceHs.28285.0 AF064801.1 g3395786 GenBank translocated in renal cancer140 209295_at TNFRSF10B tumor necrosis factor receptor 8p22-p21Exemplarsequence Hs.51233.0 AF016266.1 g2529562 GenBanksuperfamily, member 10b 141 224218_s_at TRPS1 trichorhinophalangealsyndrome I 8q24.12 Exemplarsequence Hs.26102.1 AF264784.1 g10644121GenBank 142 231764_at CHRAC1 chromatin accessibility complex 18q24.3 Consensussequence Hs.279704.0 AK023537.1 Hs.279704.0 GenBank143 219071_x_at LOC51236 hypothetical protein LOC51236 8q24.3Exemplarsequence Hs.300224.0 NM_016458.2 g13124772 RefSeq 144226707_at PP3856 similar to CG3714 gene Product 8q24.3Consensussequence Hs.9614.3 BE870868 Hs.9614.3_RC GenBank 145212149_at KIAA0143 KIAA0143 protein 8q24.22 ConsensussequenceHs.84087.0 AA805651 Hs.84087.0.S1 GenBank 146 212150_at KIAA0143KIAA0143 protein 8q24.22 Consensussequence Hs.84087.0 AA805651Hs.84087.0.S1 GenBank 147 234351_x_at TRPS1 trichorhinophalangealsyndrome I 8q24.12 Consensussequence Hs.26102.2 AK000948.1Hs.26102.2 GenBank 148 219793_at SNX16 sorting nexin 16 8q21.12Exemplarsequence Hs.128645.0 NM_022133.1 g11545864 RefSeq 149225622_at PAG Phosphoprotein associated with 8q21.11Consensussequence Hs.266175.0 NM_018440.1 Hs.266175.0 GenBankglycosphingolipid-enriched microdomains 150 202824_s_at TCEB1transcription elongation factor B 8q13.3 ExemplarsequenceHs.184693.O NM_005648.1 g5032160 RefSeq (SIII), polypeptide 1 (15kDa, elongin C) 151 202313_at PPP2R2A protein phosphataes 2(formerly 8p21.1 Exemplarsequence Hs.179574.0 NM_002717.1 g4506018RefSeq 2A), regulatory subunit B (PR 52), alpha isoform 152236192_at ESTs Consensussequence Hs.124961.0 BF447112Hs.124961.0_RC GenBank 153 217437_s_at TACC1 transforming, acidiccoiled-coil 8p11 Consensussequence Hs.173159.1 AB029026.1Hs.173159.1.S1 GenBank containing protein 1 154 202344_at HSF1 heatshock transcription factor 1 8q24.3 Exemplarsequence Hs.1499.0NM_005526.1 g5031766 RefSeq 155 209899_s_at SIAHBP1 fuse-bindingprotein-interacting 8q24.2-qtel Exemplarsequence Hs.74562.0AF217197.1 g6740005 GenBank repressor 156 33132_at CPSF1 cleavageand polyadenylation 8q24.23 Consensussequence 8 U37012 4923232GenBank specific factor 1, 160 kDa 157 218096_at FLJ11210hypothetical protein FLJ11210 8p23.1 Exemplarsequence Hs.27842.0NM_018361.1 g8922941 RefSeq 158 214054_at DOK2 docking protein 2,56 kDa 8p21.2 Consensussequence Hs.71215.0 AI828929 Hs.71215.0GenBank 159 207287_at FLJ14107 hypotheticai protein FLJ14107 8p21.2Exemplarsequence Hs.287624.0 NM_025026.1 g13376547 RefSeq 160218151_x_at FLJ11856 putative G-protein coupled 8q24.3Exemplarsequence Hs.6459.0 NM_024531.1 g13375681 RefSeq receptorGPCR41 161 219402_s_at MGC3067 hypothetical protein MGC3067 8q24.13Exemplarsequence Hs.323114.0 NM_024295.1 g13236515 RefSeq 162201592_at EIF3S3 eukaryotic translation initiation 8q23.3Exemplarsequence Hs.58189.O NM_003756.1 g4503514 RefSeq factor 3,subunit 3 gamma. 40 kDa 163 226776_at DC6 DC6 protein 8q23.2Consensussequence Hs.44243.0 BF215862 Hs.44243.0_RC GenBank 164208697_s_at EIF3S6 eukaryotic translation initiation 8q22-q23Exemplarsequence Hs.106673.0 BC000734.1 g12653884 GenBank factor 3,subunit 6 48 kDa 165 203501_at PGCP plasma glutamate 8q22.2Exemplarsequence Hs.197335.0 NM_006102.1 g5174626 RefSeqcarboxypeptidase 166 203011_at IMPA1 inositol(myo)-1 (or 4)-8q21.13-q21.3 Exemplarsequence Hs.171776.0 NM_005536.2 g8393607RefSeq monophosphatase 1 167 219810_at VCIP135 valosin-containingprotein 8q13 Exemplarsequence Hs.287727.0 NM_025054.1 g13376584RefSeq (p97)/p47 complex-interacting protein p135 168 221749_atFLJ31657 hypothetical protein FLJ31657 8q12.1 ConsensussequenceHs.5518.0 AU157915 Hs.5518.0.S1 GenBank 169 212449_s_at LYPLA1lysophosphoilpase 1 8q11.23 Consensussequence Hs.12540.2 BG288007Hs.12540.2_RC GenBank 170 219340_s_at CLN8 ceroid-lipofuscinosis,neuronal 8 8p23 Exemplarsequence Hs.127675.0 AF123759.1 g6467264GenBank (epilepsy, progressive with mental retardation) 171213702_x_at ASAH1 N-acylsphingosine 8p22-p21.3 ConsensussequenceHs.75811.3 AI934569 Hs.75811.3.S1 GenBank amidohydrolase (acidceramidase) 1 172 211686_s_at LOC84549 RNA binding protein 8p11.23Exemplarsequence g13625185 AF251062.1 g13625185 GenBank 173200847_s_at MGC8721 hypothetical protein MGC8721 8p12Exemplarsequence Hs.279921.0 NM_016127.1 g7706384 RefSeq 174219897_at FLJ12526 hypothetical protein FLJ12526 8p11.23Exemplarsequence Hs.151237.0 NM_024787.1 g13376151 RefSeq 175219624_at BAG4 BCL2-associated athanogene 4 8p11.21Exemplarsequence Hs.194726.0 NM_004874.1 g6631074 RefSeq 176219292_at FLJ10477 hypothetical protein FLJ10477 8p11.1Exemplarsequence Hs.7432.0 NM_018105.1 g8922445 RefSeq 177205089_at ZNF7 zinc finger protein 7 (KOX 4, 8q24 ExemplarsequenceHs.2076.0 NM_003416.1 g4508034 RefSeq clone HF.16) 178 201066_atCYC1 cytochrome c-1 8q24.3 Exemplarsequence Hs.289271.0 NM_001916.1g4503184 RefSeq 179 209523_at TAF2 TAF2 RNA polymerase II, TATA8q24.12 Consensussequence Hs.122752.0 AK001618.1 Hs.122752.0GenBank box binding protein (TBP)- associated factor, 150 kDa 180200608_s_at RAD21 RAD21 homolog (S. pombe) 8q24 ExemplarsequenceHs.81848.0 NM_006265.1 g5453993 RefSeq 181 204068_at STK3serine/threonine kinase 3 8q22.1 Exemplarsequence Hs.166684.0NM_006281.1 g5454093 RefSeq

(STE20 homolog, yeast) 182 208882_s_at DD5 progestin inducedprotein 8q22 Consensussequence Hs.278428.0 U69567 Hs.278428.0.A2GenBank 183 212637_s_at WWP1 WW domain-containing protein 1 8q21Consensussequence Hs.324275.0 BF131791 Hs.324275.0.S1 GenBank 184218027_at MRPLI5 mitochondrial ribosomal protein 8q11.2-q13Exemplarsequence Hs.18349.0 NM_014175.1 g7661805 RefSeq L15 185200090_at- FNTA farnesyltransferase, CAAX box, 8p22-q11Consensussequence Hs.138381.1 BG168896 Hs.138381.1.A1 GenBankHG-U133B alpha 186 201089_at ATP6V1B2 ATPase, H+ transporting,8p22-p21 Exemplarsequence Hs.1697.0 NM_001693.1 g4502310 RefSeqlysosomal 56/58 kDa, V1 subunit B, isoform 2 187 32541_at PPP3CCprotein phosphatase 3 (formerly 8p21.2 Consensussequence 6 S466224922761 GenBank 2B), catalytic subunit, gamma isoform (calcineurinA gamma) 188 202962_at KIF13B kinesin family member 13B 8p12Exemplarsequence Hs.15711.0 NM_015254.1 g13194196 RefSeq 189201375_s_at PPP2CB protein phosphatase 2 (formerly 8p12-p11.2Exemplarsequence Hs.80350.0 NM_004156.1 g4758951 RefSeq 2A),catalytic subunit, beta isoform 190 221539_at EIF4EBP1 eukaryotictranslation initiation 8p12 Exemplarsequence Hs.71819.0 AB044548.1g11527778 GenBank factor 4E binding protein 1 191 212690_atKIAA0725 KIAA0725 protein 8p11.21 Consensussequence Hs.26450.0AB018268.1 Hs.26450.0_RC GenBank 192 225534_at LOC114926hypothetical protein BC013035 8p11.1 Consensussequence Hs.10018.1AV711345 Hs.10018.1.A1 GenBank 193 203616_at POLB polymerase (DNAdirected), beta 8p11.2 Exemplarsequence Hs.180107.0 NM_002690.1g4505930 RefSeq 194 224076_s_at WHSC1L1 Wolf-Hirschhom syndrome8p11.2 Exemplarsequence Hs.27721.1 AF255649.1 g12005822 GenBankcandidate 1-like 1 195 200632_s_at NDRG1 N-myc downstream regulated8q24 Exemplarsequence Hs.75789.0 NM_006096.1 g5174656 RefSeq gene 1196 201754_at COX6C cytochrome c oxidase subunit 8q22-q23Exemplarsequence Hs.74649.0 NM_004374.1 g4758039 RefSeq VIc 197202634_at POLR2k polymerase (RNA) II (DNA 8q22.2 ConsensussequenceHs.150675.0 AL558030 Hs.150675.0 GenBank directed) polypeptide K,7.0 kDa 198 202447_at DECR1 2,4-dienoyl CoA reductase 1, 8q21.3Exemplarsequence Hs.81548.0 NM_001359.1 g4503300 RefSeqmitochondrial 199 222036_s_at MCM4 MCM4 minichromosome 8q12-q13Consensussequence Hs.154443.1 AI859865 Hs.154443.1.S1 GenBankmaintenance deficient 4 (S. cerevisiae) 200 209294_x_at TNFRSF10Btumor necrosis factor receptor 8p22-p21 Exemplarsequence Hs.51233.0BC001281.1 g12654874 GenBank superfamily, member 10b 201 209227_atN33 Putative prostate cancer tumor 8p22 ConsensussequenceHs.71119.0 AU158251 Hs.71119.0.A2 GenBank suppressor 202203669_s_at DGAT1 diacylglycerol O-acyltransferase 8qterExemplarsequence Hs.288627.0 NM_012079.2 g7382489 RefSeq homolog 1(mouse) 203 229350_x_at FLJ14464 hypothetical protein FLJ144648q24.3 Consensussequence Hs.135106.0 AI335251 Hs.135106.0.A1GenBank 204 215690_x_at GPAA1 GPAA1P anchor attachment 8q24.3Consensussequence Hs.4742.1 AL157437.1 Hs.4742.1 GenBank protein 1homolog (yeast) 205 212975_at KIAA0870 KIAA0870 protein 8q24.3Consensussequence Hs.18166.0 AB020677.2 Hs.18166.0 GenBank 206219215_s_at SLC39A4 solute carrier family 39 (zinc 8q24.3Exemplarsequence Hs.72289.0 NM_017767.1 g8923304 RefSeqtransporter), member 4 207 221836_s_at MGC4737 KIAA1882 protein8q24.3 Consensussequence Hs.157240.1 AW291218 Hs.157240.1.S1GenBank 208 201639_s_at CPSF1 cleavage and polyadenylation 8q24.23Exemplarsequence Hs.83727.0 NM_013291.1 g9558724 RefSeq specificfactor 1, 160 kDa 209 230098_at FLJ21615 hypothetical proteinFLJ21615 8q24.22 Consensussequence Hs.170335.0 AW612407Hs.170335.0_RC GenBank 210 231967_at CGI-72 CGI-72 protein 8q24.3Consensussequence Hs.318725.2 AI913146 Hs.318725.2.S1 GenBank 211208322_s_at SIAT4A sialyltransferase 4A (beta- 8q24.22Exemplarsequence Hs.301698.0 NM_003033.1 g4506950 RefSeqgalactoside alpha-2,3- sialyltransferase) 212 217916_s_at BM-009hypothetical protein BM-009 8q24.21 Exemplarsequence Hs.92918.0NM_016623.1 g7705303 RefSeq 213 221039_s_at DDEF1 development anddifferentiation 8q24.1-q24.2 Exemplarsequence Hs.10669.0NM_018482.1 g8923867 RefSeq enhancing factor 1 214 224791_at DDEF1development and differentiation 8q24.1-q24.2 ConsensussequenceHs.10669.1 W03103 Hs.10669.1.S2 GenBank enhancing factor 1 215234305_s_at MLZE melanoma-derived leucine 8q24.1-q24.2Consensussequence Hs.133244.1 AJ245876.1 Hs.133244.1 GenBankzipper, extra-nuclear factor 216 202241_at C8FW phosphoproteinregulated by 8q24.13 Exemplarsequence Hs.7837.0 NM_025195.1g13399327 RefSeq mitogenic pathways 217 225702_at ZHX1 zinc-fingersand homeoboxes 1 8q24.13 Consensussequence Hs.12940.1 AA973041Hs.12940.1.A1 GenBank 218 218172_s_at PRO2577 hypothetical proteinPRO2577 8q24.13 Exemplarsequence Hs.241576.0 NM_018630.1 g8924181RefSeq 219 218782_s_at PRO2000 PRO2000 protein 8q24.13Exemplarsequence Hs.46677.0 NM_014109.1 g7662630 RefSeq 220223214_s_at ZHX1 zinc-fingers and homeoboxes 1 8q24.13Exemplarsequence Hs.12940.0 AF195766.1 g7012716 GenBank 221218502_s_at TRPS1 trichorhinophalangeal syndrome I 8q24.12Exemplarsequence Hs.26102.0 NM_014112.1 g7657658 RefSeq 222222651_s_at TRPS1 trichorhinophalangeal syndrome I 8q24.12Consensussequence Hs.26102.0 BF701166 Hs.26102.0_RC GenBank 223227787_s_at PFDN2 prefoldin 2 1q23.1 Consensussequence Hs.298229.2AI026938 Hs.298229.2.A1 GenBank 224 204501_at NOV nephroblastomaoverexpressed 8q24.1 Exemplarsequence Hs.235935.0 NM_002514.1g4505422 RefSeq gene 225 214321_at NOV nephroblastoma overexpressed8q24.1 Consensussequence Hs.235935.1 BF440025 Hs.235935.1.S1GenBank gene 226 200607_s_at RAD21 RAD21 homolog (S. pombe) 8q24Consensussequence Hs.81848.0 BG289967 Hs.81848.0 GenBank 227226775_at DC6 DC6 protein 8q23.2 Consensussequence Hs.44243.0BF215862 Hs.44243.0_RC GenBank 228 223342_at RRM2B ribonucleotidereductase M2 B 8q23.1 Exemplarsequence Hs.94262.0 AB036063.1g7229085 GenBank (TP53 inducible) 229 200638_s_at YWHAZ tyrosine 3-8q23.1 Exemplarsequence Hs.75103.0 BC003623.1 g13177678 GenBankmonooxygenase/tryptophan 5- monooxygenase activation protein, zetapolypeptide 230 200639_s_at YWHAZ tyrosine 3- 8q23.1Exemplarsequence Hs.75103.0 NM_003406.1 g4507952 RefSeqmonooxygenase/tryptophan 5- monooxygenase activation protein, zetapolypeptide 231 200640_at YWHAZ tyrosine 3- 8q23.1 ExemplarsequenceHs.75103.0 NM_003406.1 g4507952 RefSeq monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide 232 200641_s_atYWHAZ tyrosine 3- 8q23.1 Exemplarsequence Hs.75103.0 U28964.1g899458 GenBank monooxygenase/tryptophan 5- monooxygenaseactivation protein, zeta polypeptide 233 236989_at ESTsConsensussequence Hs.293171.0 AW293012 Hs.293171.0.A1 GenBank 234203761_at SLA Src-like-adaptor 8q24 Exemplarsequence Hs.75367.0NM_006748.1 g5803170 RefSeq 235 211445_x_at FKSG17 FKSG17 8q22.3Exemplarsequence Hs.307057.0 AF315951.1 g12276119 GenBank 236201772_at OAZIN ornithine decarboxylase 8q22.3 ExemplarsequenceHs.223014.0 NM_015878.1 g7706219 RefSeq antizyme inhibitor 237212461_at OAZIN ornithine decarboxylase 8q22.3 ConsensussequenceHs.278614.1 BF793951 Hs.278614.1_RC GenBank antizyme inhibitor 238210117_at SPAG1 sperm associated antigen 1 8q22.2 ExemplarsequenceHs.153057.0 AF311312.1 g10863767 GenBank 239 202393_s_at TIEG TGFBinducible early growth 8q22.2 Exemplarsequence Hs.82173.0NM_005655.1 g5032176 RefSeq response 240 218049_s_at MRPL13mitochondrial ribosomal protein 8q22.1-q22.3 ExemplarsequenceHs.43946.0 NM_014078.1 g7662495 RefSeq L13 241 219363_s_at CGI-12CGI-12 protein 8q22.1 Exemplarsequence Hs.46680.0 NM_015942.1g7705587 RefSeq 242 218640_s_at FLJ13187 phafin 2 8q22.1Exemplarsequence Hs.29724.0 NM_024613.1 g13375826 RefSeq 243208884_s_at DD5 progestin induced protein 8q22 ExemplarsequenceHs.278428.0 AF006010.1 g4101694 GenBank 244 226338_at DKFZp762O076hypothetical protein 8q21.3 Consensussequence Hs.21621.0 AA604382Hs.21621.0 GenBank DKFZp762O076 245 225626_at PAG phosphoproteinassociated with 8q21.11 Consensussequence Hs.266175.0 NM_018440.1Hs.266175.0 GenBank glycosphingolipid-enriched microdomains 246227354_at Homo sapiens cDNA FLJ37858 Consensussequence Hs.13256.0BF589359 Hs.13256.0.A1 GenBank fis, clone BRSSN2015238. 247209544_at RIPK2 receptor-interacting serine- 8q21 ExemplarsequenceHs.103755.0 AF027706.1 g3123886 GenBank threonine kinase 2 248209545_s_at RIPK2 receptor-interacting serine- 8q21Exemplarsequence Hs.103755.0 AF064824.1 g3290171 GenBank threoninekinase 2 249 212638_s_at WWP1 WW domain-containing protein 1 8q21Consensussequence Hs.324275.0 BF131791 Hs.3242750.S1 GenBank 250219312_s_at RiNZF zinc finger protein RINZF 8q13-q21.1Exemplarsequence Hs.237146.0 NM_023929.1 g12965200 RefSeq 251218521_s_at FLJ11011 hypothetical protein FLJ11011 8q13.2Exemplarsequence Hs.21275.0 NM_018299.1 g8922821 RefSeq 252222657_s_at FLJ11011 hypothetical protein FLJ11011 8q13.2Consensussequence Hs.21275.0 AK024050.1 Hs.21275.0.A1 GenBank 253222992_s_at NDUPB9 NADH dehydrogenase 8q13.3 ExemplarsequenceHs.15977.0 AF261090.1 g9802311 GenBank (ubiquinone) 1 betasubcomplex, 9, 22 kDa 254 202823_at TCEB1 transcription elongationfactor B 8q13.3 Consensussequence Hs.184693.0 N89607 Hs.184693.0.A2GenBank (SIII), polypeptide 1 (15 kDa, elongin C) 255 205732_s_atNCOA2 nuclear receptor coactivator 2 8q13.1 ExemplarsequenceHs.29131.0 NM_006540.1 g5729857 RefSeq 256 212867_at NCOA2 nuclearreceptor coactivator 2 8q13.1 Consensussequence Hs.29131.1 AI040324Hs.29131.1 GenBank 257 220732_at FLJ12987 hypothetical proteinFLJ12987 8q12.3 Exemplarsequence Hs.296730.0 NM_025170.2 g13489104RefSeq 258 202625_at LYN v-yes-1 Yamaguchi sarcoma 8q13Consensussequence Hs.80887.0 AI356412 Hs.80887.0_RC GenBank viralrelated oncogene homolog 259 202626_s_at LYN v-yes-1 Yamaguchisarcoma 8q13 Exemplarsequence Hs.80887.0 NM_002350.1 g4505054RefSeq viral related oncogene homolog 260 210754_s_at LYN v-yes-1Yamaguchi sarcoma 8q13 Exemplarsequence Hs.80887.1 M79321.1 g187270GenBank viral related oncogene homolog 261 203449_s_at TERF1telomeric repeat binding factor 8q13 Exemplarsequence Hs.194562.0NM_017489.1 g9257245 RefSeq (NIMA-interacting) 1 262 203560_at GGHgamma-glutamyl hydrolase 8q12.1 Exemplarsequence Hs.78619.0NM_003878.1 g4503986 RefSeq (conjugase, folylpolygammaglutamylhydrolase) 263 209135_at ASPH aspartate beta-hydroxylase 8q12.1Exemplarsequence Hs.283664.3 AF289489.1 g11878115 GenBank 264218829_s_at KIAA1416 KIAA1416 protein 8q12.1 ExemplarsequenceHs.105461.0 NM_017780.1 g8923329 RefSeq 265 212934_at LOC137886hypothetical protein LOC137886 8q11.23 ConsensussequenceHs.155572.0 AI245523 Hs.155572.0.A1 GenBank 266 208732_at RAB2RAB2, member RAS oncogene 8q12.1 Consensussequence Hs.78305.0NM_002865.1 Hs.78305.0_RC GenBank family 267 208733_at RAB2 RAB2,member RAS oncogene 8q12.1 Consensussequence Hs.78305.0 NM_002865.1Hs.78305.0_RC GenBank family 268 221960_s_at RAB2 RAB2, member RASoncogene 8q12.1 Consensussequence Hs.78305.1 AI189609 Hs.78305.1.A1GenBank family 269 205372_at PLAG1 pleiomorphic adenoma gene 1 8q12Exemplarsequence Hs.14968.0 NM_002655.1 g4505854 RefSeq 270216247_at RPS20 ribosomal protein S20 8q12 ConsensussequenceHs.8102.2 AF113008.1 Hs.8102.2_RC GenBank 271 200958_s_at SDCBPsyndecan binding protein 8q12 Exemplarsequence Hs.8180.0NM_005625.1 g5032082 RefSeq (syntenin) 272 222654_at FLJ20421hypothetical protein FLJ20421 8q11.23 Consensussequence Hs.263727.0AW295105 Hs.263727.0.A1 GenBank 273 203007_s_at LYPLA1lysophospholipase I 8q11.23 Exemplarsequence

Hs.12540.0 AF077198.1 g4679009 GenBank 274 218642_s_at MGC2217hypothetical protein MGC2217 8q11.23 Exemplarsequence Hs.323164.0NM_024300.1 g13236525 RefSeq 275 203973_s_at CEBPD CCAAT/enhancerbinding 8p11.2-p11.1 Exemplarsequence Hs.76722.0 NM_005195.1g4885130 RefSeq protein (C/EBP), delta 276 222037_at MCM4 MCM4minichromosome 8q12-q13 Consensussequence Hs.154443.1 AI859865Hs.154443.1.S1 GenBenk maintenance deficient 4 (S. cerevisiae) 277208694_at PRKDC protein kinase, DNA-activated, 8q11Exemplarsequence Hs.155637.0 U47077.5 g13570016 GenBank catalyticpolypeptide 278 210543_s_at PRKDC protein kinase, DNA-activated,8q11 Exemplarsequence Hs.155637.1 U34994.3 g13606055 GenBankcatalytic polypeptide 279 225591_at FBXO25 F-box only protein 258p23.3 Consensussequence Hs.81001.0 AA749085 Hs.81001.0.A1 GenBank280 214440_at NAT1 N-acetyltransferase 1 (arylamine 8p23.1-p21.3Consensussequence Hs.155956.0 NM_000662.1 Hs.155956.0.S1 GenBankN-acetyltransferase) 281 226038_at FLJ23749 hypothetical proteinFLJ23749 8p22 Consensussequence Hs.180178.0 BF680438 Hs.180178.0.S1GenBank 282 213902_at ASAH1 N-acylsphingosine 8p22-p21.3Consensussequence Hs.75811.2 AI379338 Hs.75811.2.S1 GenBankamidohydrolase (acid ceramidase) 1 283 228905_at ESTsConsensussequence Hs.155272.0 BE672700 Hs.155272.0_RC GenBank 284200838_at CTSB cathepsin B 8p22 Exemplarsequence Hs.297939.0NM_001908.1 g4503138 RefSeq 285 213275_x_at CTSB cathepsin B 8p22Consensussequence Hs.297939.5 BE875786 Hs.297939.5_RC GenBank 286227961_at CTSB cathepsin B 8p22 Consensussequence Hs.297939.2AA130998 Hs.297939.2.A1 GenBank 287 204596_s_at STC1 stanniocalcin1 8p21-p11.2 Exemplarsequence Hs.25590.0 U46768.1 g1199619 GenBank288 219049_at ChGn chondroitin beta1,4 N- 8p21.3 ExemplarsequenceHs.11260.0 NM_018371.1 g8922959 RefSeqacetylgalactosaminyltransferase 289 244885_at Homo sapiens cDNAFLJ36559 Consensussequence Hs.131056.0 AI016316 Hs.131056.0.A1GenBank fis, clone TRACH2009291. 290 35156_at Homo sapiens, similarto Consensussequence 4870467_rc AL050297 4870467_rc GenBankhypothetical protein DKFZp564N123.1 --human (fragment), cloneIMAGE: 5220614, mRNA 291 204076_at LYSAL1 lysosomal apyrase-like 18p21.2 Consensussequence Hs.201377.0 AB002390.1 Hs.201377.0 GenBank292 219165_at PDLIM2 PDZ and LIM domain 2 8p21.2 ExemplarsequenceHs.19447.0 NM_021630.1 g11055999 RefSeq (mystique) 293 218823_s_atFLJ20038 hypothetical protein FLJ20038 8p21.1 ExemplarsequenceHs.72071.0 NM_017634.1 g8923043 RefSeq 294 203110_at PTK2B PTK2Bprotein tyrosine kinase 2 8p21.1 Exemplarsequence Hs.20313.0U43522.1 g1165218 GenBank beta 295 203261_at DCTN6 likely orthologof mouse dynactin 6 8p12-p11 Exemplarsequence Hs.39913.0NM_006571.1 g5730115 RefSeq 296 65718_at GPR124 G protein-coupledreceptor 124 8p11.1 Consensussequence 4885918_rc AI6559034885918_rc GenBank 297 202381_at ADAM9 a disintegrin and 8p11.21Exemplarsequence Hs.2442.0 NM_003816.1 g4501914 RefSeqmetalloproteinase domain 9 (meltrin gamma) 298 225136_at Homosapiens cDNA FLJ32643 Consensussequence Hs.18585.0 BF968578Hs.18585.0_RC GenBank fis, clone SYNOV2001212. 299 238615_at C8orf2chromosome 8 open reading 8p11.2 Consensussequence Hs.143848.0AI817403 Hs.143848.0.A1 GenBank frame 2 300 202423_at RUNXBP2runt-related transcription factor 8p11 Exemplarsequence Hs.82210.0NM_006766.1 g5803097 RefSeq binding protein 2 301 200911_s_at TACC1transforming, acidic coiled-coil 8p11 Exemplarsequence Hs.173159.0NM_006283.1 g5454099 RefSeq containing protein 1 302 236034_at ESTsConsensussequence Hs.68301.0 AA083514 Hs.68301.0.A1 GenBank 303221586_s_at E2F5 E2F transcription factor 5, p130- 8q21.13Exemplarsequence Hs.2331.0 U15642.1 g758415 GenBank binding 304204597_x_at STC1 stanniocalcin 1 8p21-p11.2 ExemplarsequenceHs.25590.0 NM_003155.1 g4507264 RefSeq 305 235209_at FLJ40021hypothetical protein FLJ40021 8q13.2 Consensussequence Hs.122544.0AW662373 Hs.122544.0_RC GenBank 306 222721_at HSPC163 HSPC163protein 1q42.12 Consensussequence Hs.108854.0 AK024569.1Hs.108854.0.S2 GenBank 307 241355_at HR hairless 8p21.2Consensussequence Hs.165565.0 BF528433 Hs.165565.0_RC GenBank 308202701_at BMP1 bone morphogenetic protein 1 8p21 ExemplarsequenceHs.1274.5 NM_006129.2 g5902809 RefSeq 309 228405_at RHPN1rhophilin, Rho GTPase binding 8q24.3 Consensussequence Hs.149152.0AI917311 Hs.149152.0.A1 GenBank protein 1 310 218954_s_at BRF2BRF2, subunit of RNA 8p11.1 Exemplarsequence Hs.274136.0 AF298153.1g11096174 GenBank polymerase III transcription initiation factor,BRF1-like 311 221814_at GPR124 G protein-coupled receptor 1248p11.1 Consensussequence Hs.17270.0 BF511315 Hs.17270.0 GenBank 312223614_at DKFZp761D112 hypothetical protein 8q21.2 ExemplarsequenceHs.103849.0 AL136588.1 g13276678 GenBank DKFZp761D112 313243264_s_at FLJ11267 hypothetical protein FLJ11267 8q12.3Consensussequence Hs.160795.0 AI634652 Hs.160795.0_RC GenBank 314220511_s_at FLJ21120 hypothetical protein FLJ21120 8p22Exemplarsequence Hs.133546.0 NM_024767.1 g13376110 RefSeq 315206135_at ST18 suppression of tumorigenicity 18 8q11.22Exemplarsequence Hs.151449.0 NM_014682.1 g7662167 RefSeq (breastcarcinoma) (zinc finger protein) 316 224021_at RP1 retinitispigmentosa 1 (autosomal 8q11-q13 Exemplarsequence Hs.251687.0AF146592.1 g5678820 GenBank dominant) 317 226305_at Homo sapiensmRNA; cDNA Consensussequence Hs.6272.0 AV696976 Hs.6272.0.S1GenBank DKFZp761P0117 (from clone DKFZp761P0114) 318 243692_atGATA4 GATA binding protein 4 8p23.1-p22 ConsensussequenceHs.194114.0 AW181962 Hs.194114.0_RC GenBank 319 238460_at Homosapiens cDNA FLJ25541 Consensussequence Hs.272068.0 AI590662Hs.272068.0 GenBank fis, clone JTH00915. 320 236812_at ESTsConsensussequence Hs.223267.0 AI638208 Hs.223267.0.A1 GenBank 321207284_s_at ASPH aspartate beta-hydroxylase 8q12.1 ExemplarsequenceHs.283664.1 NM_020164.1 g9910363 RefSeq 322 237910_x_at ESTsConsensussequence Hs.87672.1 AI379467 Hs.87672.1 GenBank 323229430_at MGC33510 hypothetical protein MGC33510 8q12.3Consensussequence Hs.184261.2 AI421311 Hs.184261.2_RC GenBank 324235998_at RHPN1 rhophilin, Rho GTPase binding 8q24.3Consensussequence Hs.128081.0 AI733369 Hs.128081.0.A1 GenBankprotein 1 325 211148_s_at ANGPT2 angiopoietin 2 8p23.1Exemplarsequence Hs.115181.1 AF187858.1 g8570646 GenBank 326223843_at SCARA3 scavenger receptor class A, 8p21 ExemplarsequenceHs.128856.1 AB007830.1 g6230378 GenBank member 3 #Unigene_Accession Cluster_Type LocusLink Full_Length_Reference_Seq1 Hs.289063 fulllength 80346 NM_025232; hypothetical proteinFLJ22246 2 Hs.380963 fulllength 29883 NM_013354; CCR4-NOTtranscription complex, subunit 7 isoform 1 NM_054026; CCR4-NOTtranscription complex, subunit 7 isoform 2 3 Hs.7471 fulllength83877 NM_031940; BBP-like protein 1 isoform b NM_078473; BBP-likeprotein 1 isoform a 4 Hs.131255 fulllength 7381 NM_006294;ubiquinol-cytochrome c reductase binding protein 5 Hs.167011 6Hs.278634 23514 7 Hs.288716 fulllength 80185 NM_025115;hypothetical protein FLJ23263 8 Hs.4147 fulllength 23471 NM_014294;translocating chain-associating membrane protein 9 Hs.98471 est137682 NM_152416; hypothetical protein MGC40214 10 Hs.170198fulllength 9650 NM_014637; KIAA0009 gene product 11 Hs.170198fulllength 9650 NM_014637; KIAA0009 gene product 12 Hs.243901fulllength 13 Hs.77100 fulllength 2961 NM_002095; generaltranscription factor IIE, polypeptide 2, beta 34 kDa 14 Hs.27721fulllength 54904 NM_017778; WHSC1L1 protein isoform shortNM_023034; WHSC1L1 protein isoform long 15 Hs.169615 fulllength65265 NM_023080; hypothetical protein FLJ20989 16 Hs.48876fulllength 2222 NM_004462; farnesyl-diphosphate farnesyltransferase1 17 Hs.356463 fulllength 2339 NM_002027; farnesyltransferase, CAAXbox, alpha 18 Hs.380963 fulllength 29883 NM_013354; CCR4-NOTtranscription complex, subunit 7 isoform 1 NM_054026; CCR4-NOTtranscription complex, subunit 7 isoform 2 19 Hs.75737 fulllength5108 NM_006197; pericentriolar material 1 20 Hs.75737 fulllength5108 NM_006197; pericentriolar material 1 21 Hs.75737 fulllength5108 NM_006197; pericentriolar material 1 22 Hs.27721 fulllength54904 NM_017778; WHSC1L1 protein isoform short NM_023034; WHSC1L1protein isoform long 23 Hs.55097 fulllength 28957 NM_014018;mitochondrial ribosomal protein S28 24 Hs.4742 fulllength 8733NM_003801; anchor attachment protein 1 25 Hs.178551 fulllength 6132NM_000973; ribosomal protein L8 NM_033301; ribosomal protein L8 26Hs.10669 fulllength 50807 27 Hs.86970 est 28 Hs.243901 fulllength29 Hs.33074 30 Hs.14158 fulllength 8895 NM_003909; copine III 31Hs.99519 fulllength 79752 NM_024699; hypothetical protein FLJ1400732 Hs.94631 fulllength 10565 NM_006421; brefeldin A-inhibitedguanine nucleotide-exchange protein 1 33 Hs.194562 fulllength 7013NM_003218; telomeric repeat binding factor 1 isoform 2 NM_017489;telomeric repeat binding factor 1 isoform 1 34 Hs.5333 fulllength9920 NM_014867; KIAA0711 gene product 35 Hs.75811 fulllength 427NM_004315; N-acylsphingosine amidohydrolase (acid ceramidase) 1isoform b NM_177924; N-acylsphingosine amidohydrolase (acidceramidase) 1 preproprotein isoform a 36 Hs.172816 fulllength 3084NM_004495; neuregulin 1 isoform HRG-gamma NM_013956; neuregulin 1isoform HRG-beta1 NM_013957; neuregulin 1 isoform HRG-beta2NM_013958; neuregulin 1 isoform HRG-beta3 NM_013959; neuregulin 1isoform SMDF NM_013960; neuregulin 1 isoform ndf43 NM_013961;neuregulin 1 isoform GGF NM_013962; neuregulin 1 isoform GGF2NM_013964; neuregulin 1 isoform HRG-alpha 37 Hs.193974 fulllength2936 NM_000637; glutathione reductase 38 Hs.7953 fulllength 51125NM_016099; HSPC041 protein 39 Hs.6856 fulllength 9070 NM_004674;ash2 (absent, small, or homeotic)-like 40 Hs.72085 fulllength 55246NM_018246; hypothetical protein FLJ10853 41 Hs.19673 fulllength84232 NM_032272; homolog of yeast MAF1 42 Hs.339697 fulllength51160 NM_016208; VPS28 protein 43 Hs.11810 fulllength 83940NM_032026; CDA11 protein 44 Hs.9222 fulllength 9166 NM_004215;estrogen receptor binding site associated antigen 9 45 Hs.23528fulllength 51123 NM_016096; HSPC038 protein 46 Hs.77329 fulllength9791 NM_014754; phosphatidylserine synthase 1 47 HS.416904 48Hs.48876 fulllength 2222 NM_004462; farnesyl-diphosphatefarnesyltransferase 1 49 Hs.356463 fulllength 2339 NM_002027;farnesyltransferase, CAAX box, alpha 50 Hs.101617 fulllength 137492NM_152415; hypothetical protein FLJ32642 51 Hs.101617 fulllength137492 NM_152415; hypothetical protein FLJ32642 52 Hs.8294fulllength 9897 NM_014846; KIAA0196 gene product 53 Hs.75206fulllength 5533 NM_005605; protein phosphatase 3 (formerly 2B),catalytic subunit, gamma isoform (calcineurin A gamma) 54 Hs.267905fulllength 55140 NM_018091; elongation protein 3 homolog 55Hs.301959 fulllength 11212 NM_007198; proline synthetaseco-transcribed homolog 56 Hs.288057 fulllength 80140 NM_025070;hypothetical protein FLJ22242 57 Hs.86905 fulllength 528 NM_001695;ATPase, H+ transporting, lysosomal 42 kD, V1 subunit C, isoform 158 Hs.131255 fulllength 7381 NM_006294; ubiquinol-cytochrome creductase binding protein 59 Hs.44222 fulllength 51115 NM_016033;CGI-90 protein 60 Hs.380969 fulllength 10987 NM_006837; COP9constitutive photomorphogenic homolog subunit 5 61 Hs.48802fulllength 66036 NM_015458; myotubularin related protein 9 62Hs.15562 fulllength 55756 NM_018250; hypothetical protein FLJ1087163 Hs.153678 fulllength 7993 NM_005671; reproduction 8 64 Hs.7381fulllength 7419 NM_005662; voltage-dependent anion channel 3 65Hs.334798 fulllength 1936 NM_001960; eukaryotic translationelongation factor 1 delta isoform 2 NM_032378; eukaryotictranslation elongation factor 1 delta isoform 1

66 Hs.12271 fulllength 26233 NM_012162; F-box and leucine-richrepeat protein 6 isoform 1 NM_024555; F-box and leucine-rich repeatprotein 6 isoform 2 67 Hs.4742 fulllength 8733 NM_003801; anchorattachment protein 1 68 Hs.339697 fulllength 51160 NM_016208; VPS28protein 69 Hs.376544 70 Hs.239784 est 23513 NM_015356; scribble 71Hs.404119 fulllength 7264 NM_003313; tissue specifictransplantation antigen P35B 72 Hs.318725 fulllength 51105NM_016018; CGI-72 protein 73 Hs.44159 fulllength 84165 NM_032205;hypothetical protein FLJ21615 74 Hs.318725 fulllength 51105NM_016018; CGI-72 protein 75 Hs.10669 fulllength 50807 76 Hs.10669fulllength 50807 77 Hs.344478 fulllength 286053 NM_173685;hypothetical protein FLJ32440 78 Hs.95011 fulllength 6641NM_021021; basic beta 1 syntrophin 79 Hs.432544 80 Hs.283740fulllength 56943 NM_020189; DC6 protein 81 Hs.9222 fulllength 9166NM_004215; estrogen receptor binding site associated antigen 9 82Hs.169111 fulllength 55074 NM_018002; oxidation resistance 1 83Hs.290880 84 Hs.351475 fulllength 5440 NM_005034; DNA directed RNApolymerase II polypeptide K 85 Hs.197335 fulllength 10404NM_006102; NM_016134; plasma glutamate carboxypeptidase 86 Hs.16621fulllength 25962 NM_015496; DKFZP434I116 protein 87 Hs.279521fulllength 55656 NM_017864; hypothetical protein FLJ20530 88Hs.6390 fulllength 89 Hs.6390 fulllength 90 Hs.243901 fulllength 91Hs.29724 fulllength 79666 NM_024613; phafin 2 92 Hs.18426fulllength 10247 NM_005836; translational inhibitor protein p14.593 Hs.131255 fulllength 7381 NM_006294; ubiquinol-cytochrome creductase binding protein 94 Hs.14158 fulllength 8895 NM_003909;copine III 95 Hs.180612 fulllength 5828 NM_000318; peroxisomalmembrane protein 3 96 Hs.25812 fulllength 4683 NM_002485; nibrin 97Hs.25812 fulllength 4683 NM_002485; nibrin 98 Hs.96870 fulllength27067 NM_014393; staufen homolog 2 99 Hs.106650 fulllength 54968NM_017866; hypothetical protein FLJ20533 100 Hs.4147 fulllength23471 NM_014294; translocating chain-associating membrane protein101 Hs.94631 fulllength 10565 NM_006421; brefeldin A-inhibitedguanine nucleotide-exchange protein 1 102 Hs.94631 fulllength 10565NM_006421; brefeldin A-inhibited guanine nucleotide-exchangeprotein 1 103 Hs.380877 fulllength 23678 NM_013257;serum/glucocorticoid regulated kinase-like isoform 1 NM_170709;serum/glucocorticoid regulated kinase-like isoform 2 104 Hs.380877fulllength 23678 NM_013257; serum/glucocorticoid regulatedkinase-like isoform 1 NM_170709; serum/glucocorticoid regulatedkinase-like isoform 2 105 Hs.106768 fulllength 55156 NM_018120;armadillo repeat-containing protein 106 Hs.283664 fulllength 444NM_004318; aspartate beta-hydroxylase isoform a NM_020164;aspartate beta- hydroxylase isoform e NM_032466; aspartatebeta-hydroxylase isoform c NM_032467; aspartate beta-hydroxylaseisoform d NM_032468; aspartate beta- hydroxylase isoform b 107Hs.78305 fulllength 5862 NM_002865; RAB2, member RAS oncogenefamily 108 Hs.78305 fulllength 5862 NM_002865; RAB2, member RASoncogene family 109 Hs.323164 fulllength 79145 NM_024300;hypothetical protein MGC2217 110 Hs.79300 fulllength 7336NM_003350; ubiquitin-conjugating enzyme E2 variant 2 111 Hs.26458fulllength 4482 NM_012331; methionine sulfoxide reductase A 112Hs.19575 fulllength 51606 NM_015941; ATPase, H+ transporting,lysosomal 50/57 kDa, V1 subunit H 113 Hs.173381 fulllength 1808NM_001386; dihydropyrimidinase-like 2 114 Hs.300861 115 Hs.267905fulllength 55140 NM_018091; elongation protein 3 homolog 116Hs.193974 fulllength 2936 NM_000637; glutathione reductase 117Hs.137732 fulllength 23087 NM_015066; tripartite motif-containing35 isoform 1 NM_171982; tripartite motif- containing 35 isoform 2118 Hs.274136 fulllength 55290 NM_018310; RNA polymerase IIItranscription initiation factor BRF2 119 Hs.170822 fulllength 81790NM_030954; hypothetical protein DKFZp564A022 120 Hs.355753 137964NM_178819; putative lysophosphatidic acid acyltransferase 121Hs.125849 fulllength 11160 NM_007175; chromosome 8 open readingframe 2 122 Hs.125849 fulllength 11160 NM_007175; chromosome 8 openreading frame 2 123 Hs.226573 fulllength 3551 124 Hs.301959fulllength 11212 NM_007198; proline synthetase co-transcribedhomolog 125 Hs.128856 fulllength 51435 NM_016240; CSR1 protein 126Hs.61696 127 Hs.443139 est 128 Hs.18029 fulllength 55093 NM_018024;hypothetical protein FLJ10204 129 Hs.179909 fulllength 96764NM_024831; PRIP-interacting protein PIPMT 130 Hs.377879 fulllength157697 131 Hs.299148 fulllength 64760 NM_022749; retinoic acidinduced 16 132 Hs.33787 fulllength 10174 NM_005775; vinexin betsSH3-containing adaptor molecule-1) 133 134 Hs.196270 fulllength81034 NM_030780; mitochondrial folate transporter/carrier 135Hs.180612 fulllength 5828 NM_000318; peroxisomal membrane protein 3136 Hs.93005 fulllength 6591 NM_003068; snail 2 137 Hs.273344fulllength 25879 NM_014158; NM_015420; DKFZP564O0463 protein 138Hs.425311 fulllength 27257 NM_014462; Lsm1 protein 139 Hs.28285fulllength 11236 NM_007218; ring finger protein 139 140 Hs.51233fulllength 8795 NM_003842; tumor necrosis factor receptorsuperfamily, member 10b isoform 1 precursor NM_147187; tumornecrosis factor receptor superfamily, member 10b isoform 2precursor 141 Hs.26102 fulllength 7227 NM_014112; zinc fingertranscription factor TRPS1 142 Hs.279704 fulllength 54108NM_017444; chromatin accessibility complex 1 143 Hs.300224fulllength 51236 NM_016458; brain protein 16 144 Hs.333388fulllength 93100 NM_145201; similar to CG3714 gene product 145Hs.84087 23167 146 Hs.84087 23167 147 Hs.26102 fulllength 7227NM_014112; zinc finger transcription factor TRPS1 148 Hs.128645fulllength 64089 NM_022133; sorting nexin 16 isoform a NM_152836;sorting nexin 16 isoform a NM_152837; sorting nexin 16 isoform b149 Hs.266175 fulllength 55824 NM_018440; phosphoprotein associatedwith glycosphingolipid-enriched microdomains 150 Hs.184693fulllength 6921 NM_005648; elongin C 151 Hs.179574 fulllength 5520NM_002717; protein phosphatase 2 (formerly 2A), regulatory subunitB (PR 52), alpha isoform 152 Hs.124961 est 153 Hs.173159 fulllength6867 NM_006283; transforming, acidic coiled-coil containing protein1 154 Hs.380935 fulllengh 3297 NM_005526; heat shock transcriptionfactor 1 155 Hs.74562 fulllength 22827 NM_014281; fuse-bindingprotein-interacting repressor isoform b NM_078480; fuse- bindingprotein-interacting repressor isoform a 156 Hs.83727 fulllength29894 NM_013291; cleavage and polyadenylation specific factor 1,160 kDa 157 Hs.27842 fulllength 55326 NM_018361; acidacyltransferase-epsilon 158 Hs.71215 fulllength 9046 NM_003974;docking protein 2, 56 kD 159 Hs.287624 fulllength 80094 NM_025026;hypothetical protein FLJ14107 160 Hs.6459 fulllength 79581NM_024531; putative G-protein coupled receptor GPCR41 161 Hs.323114fulllength 79139 NM_018630; NM_024295; hypothetical protein MGC3067162 Hs.58189 fulllength 8667 NM_003756; eukaryotic translationinitiation factor 3, subunit 3 gamma, 40 kDa 163 Hs.283740fulllength 56943 NM_020189; DC6 protein 164 Hs.106673 fulllength3646 NM_001568; murine mammary tumor integration site 6 (oncogenehomolog) 165 Hs.197335 fulllength 10404 NM_006102; NM_016134;plasma glutamate carboxypeptidase 166 Hs.171776 fulllength 3612NM_005536; inositol(myo)-1(or 4)-monophosphetase 1 167 Hs.287727fulllength 80124 NM_025054; valosin-containing protein (p97)/p47complex-interacting protein p135 168 Hs.5518 fulllength 253943NM_152758; hypothetical protein FLJ31657 169 Hs.12540 fulllength10434 NM_006330; lysophospholipase I 170 Hs.127675 fulllength 2055NM_018941; CLN8 protein 171 Hs.75811 fulllength 427 NM_004315;N-acylsphingosine amidohydrolase (acid ceramidase) 1 isoform bNM_177924; N-acylsphingosine amidohydrolase (acid ceramidase) 1preproprotein isoform a 172 Hs.77135 fulllength 84549 NM_032509;RNA binding protein 173 Hs.279921 fulllength 51669 NM_016127;hypothetical protein MGC8721 174 Hs.151237 fulllength 79845NM_024787; hypothetical protein FLJ12526 175 Hs.194726 fulllength9530 NM_004874; BCL2-associated athanogene 4 176 Hs.7432 fulllength55145 NM_018105; hypothetical protein FLJ10477 177 Hs.2076fulllength 7553 NM_003416; zinc finger protein 7 (KOX 4, cloneHF.16) 178 Hs.289271 fulllength 1537 NM_001916; cytochrome c-1 179Hs.122752 fulllength 6873 NM_003184; TBP-associated factor 2 180Hs.81848 fulllength 5885 NM_006265; RAD21 homolog 181 Hs.166684fulllength 6788 NM_006281; serine/threonine kinase 3(STE20 homolog,yeast) 182 Hs.278428 fulllength 51366 NM_015902; progestin inducedprotein 183 Hs.355977 fulllength 11059 NM_007013; WWdomain-containing protein 1 184 Hs.18349 fulllength 29088NM_014175; mitochondrial ribosomal protein L15 185 Hs.356463fulllength 2339 NM_002027; famesyltransferase, CAAX box, alpha 186Hs.1697 fulllength 526 NM_001693; ATPase, H+ transporting,lysosomal 56/56 kD, V1 subunit B, isoform 2 187 Hs.75206 fulllength5533 NM_005605; protein phosphatese 3 (formerly 2B), catalyticsubunit, gamma isoform calcineurin A gamma) 188 Hs.15711 fulllength23303 NM_015254; kinesin family member 13B 189 Hs.80350 fulllength5516 NM_004156; protein phoshatase 2 (formerly 2A), catalyticsubunit, beta isoform 190 Hs.433317 fulllength 1978 NM_004095;eukaryotic translation initiation factor 4E binding protein 1 191Hs.26450 fulllength 23259 192 Hs.10018 fulllength 114926 NM_138436;hypothetical protein BC013035 193 Hs.180107 fulllength 5423NM_002690; polymerase (DNA directed), beta 194 Hs.27721 fulllength54904 NM_017778; WHSC1L1 protein isoform short NM_023034; WHSC1L1protein isoform long 195 Hs.75789 fulllength 10397 NM_006096; N-mycdownstream regulated gene 1 196 Hs.351875 fulllength 1345NM_004374; cytochrome c oxidase subunit Vic proprotein 197Hs.351475 fulllength 5440 NM_005034; DNA directed RNA polymerase IIpolypeptide K 198 Hs.81548 fulllength 1666 NM_001359; 2,4-dienoylCoA reductase 1 precursor 199 Hs.154443 fulllength 4173 200Hs.51233 fulllength 8795 NM_003842; tumor necrosis factor receptorsuperfamily, member 10b isoform 1 precursor NM_147187; tumornecrosis factor receptor superfamily, member 10b isoform 2precursor 201 Hs.71119 fulllength 7991 NM_006765; Putative prostatecancer tumor suppressor isoform a NM_178234; Putative prostatecancer tumor suppressor isoform b 202 Hs.288627 fulllength 8694NM_012079; diacylglycerol O-acyltransferase 1 203 Hs.348609fulllength 84875 NM_032789; hypothetical protein FLJ14464 204Hs.4742 fulllength 8733 NM_003801; anchor attachment protein 1 205Hs.18166 22898 206 Hs.352415 fulllength 55630 NM_017767; solutecarrier family 39 (zinc transporter), member 4 NM_130849; solutecarrier family 39 (zinc transporter), member 4 207 Hs.157240fulllength 83696 NM_031466; hypothetical protein MGC4737 208Hs.83727 fulllength 29894 NM_013291; cleavage and polyadenylationspecific factor 1, 160 kDa 209 Hs.44159 fulllength 84165 NM_032205;hypothetical protein FLJ21615 210 Hs.318725 fulllength 51105NM_016018; CGI-72 protein 211 Hs.301698 fulllength 6482 NM_003033;sialyltransferase 4A NM_173344; sialyltransferase 4A 212 Hs.92918fulllength 51571 NM_016623; hypothetical protein BM-009 213Hs.10669 fulllength 50807 214 Hs.10669 fulllength 50807 215Hs.133244 fulllength 56169 NM_031415; melanoma-derived leucinezipper, extra-nuclear factor 216 Hs.7837 fulllength 10221NM_025195; G-protein-coupled receptor induced protein 217 Hs.12940fulllength 11244 NM_007222; zinc finger and homeodomain protein 1NM_032847; hypothetical protein FLJ14825 218 Hs.241576 fulllength55493 219 Hs.222088 fulllength 29028 NM_014109; PRO2000 proteinNM_032365; 220 Hs.12940 fulllength 11244 NM_007222; zinc finger andhomeodomain protein 1 221 Hs.26102 fulllength 7227 NM_014112; zincfinger transcription factor TRPS1 222 Hs.26102 fulllength 7227NM_014112; zinc finger transcription factor

TRPS1 223 Hs.298229 fulllength 5202 NM_012394; prefoldin 2NM_080651; TRAP/Mediator complex component TRAP25 224 Hs.235935fulllength 4856 NM_002514; nov precursor 225 Hs.235935 fulllength4856 NM_002514; nov precursor 226 Hs.81848 fulllength 5885NM_006265; RAD21 homolog 227 Hs.283740 fulllength 56943 NM_020189;DC6 protein 228 Hs.94262 fulllength 50484 229 Hs.75103 fulllength7534 NM_003406; tyrosine 3/tryptophan 5-monooxygenase activationprotein, zeta polypeptide NM_145690; tyrosine 3/tryptophan5-monooxygenase activation protein, zeta polypeptide 230 Hs.75103fulllength 7534 NM_003406; tyrosine 3/tryptophan 5-monooxygenaseactivation protein, zeta polypeptide NM_145690; tyrosine3/tryptophan 5-monooxygenase activation protein, zeta polypeptide231 Hs.75103 fulllength 7534 NM_003406; tyrosine 3/tryptophan5-monooxygenase activation protein, zeta polypeptide NM_145690;tyrosine 3/tryptophan 5-monooxygenase activation protein, zetapolypeptide 232 Hs.75103 fulllength 7534 NM_003406; tyrosine3/tryptophan 5-monooxygenase activation protein, zeta polypeptideNM_145690; tyrosine 3/tryptophan 5-monooxygenase activationprotein, zeta polypeptide 233 Hs.405590 est 234 Hs.75367 fulllength6503 NM_006748; Src-like-adaptor 235 Hs.307057 fulllength 83955NM_032031; FKSG17 236 Hs.223014 fulllength 51582 NM_015878;ornithine decarboxylase antizyme inhibitor NM_148174; ornithinedecarboxylase antizyme inhibitor 237 Hs.223014 fulllength 51582NM_015878; ornithine decarboxylase antizyme inhibitor NM_148174;ornithine decarboxylase antizyme inhibitor 238 Hs.153057 fulllength6674 NM_003114; sperm associated antigen 1 NM_172218; spermassociated antigen 1 239 Hs.82173 fulllength 7071 NM_005655; TGFBinducible early growth response 240 Hs.333823 fulllength 28998NM_014078; mitochondrial ribosomal protein L13 241 Hs.46680fulllength 51001 NM_015942: CGI-12 protein 242 Hs.29724 fulllength79666 NM_024613; phafin 2 243 Hs.278428 fulllength 51366 NM_015902;progestin induced protein 244 Hs.21621 fulllength 55529 NM_018710;hypothetical protein DKFZp762O076 245 Hs.266175 fulllength 55824NM_018440; phosphoprotein associated withglycosphingolipid-enriched microdomains 246 Hs.13256 247 Hs.103755fulllength 8767 NM_003821; receptor-interacting serine-threoninekinase 2 248 Hs.103755 fulllength 8767 NM_003821;receptor-interacting serine-threonine kinase 2 249 Hs.355977fulllength 11059 NM_007013; WW domain-containing protein 1 250Hs.237146 fulllength 65986 NM_023929; zinc finger protein RINZF 251Hs.21275 fulllength 55284 NM_018299; hypothetical protein FLJ11011252 Hs.21275 fulllength 55284 NM_018299; hypothetical proteinFLJ11011 253 Hs.15977 fulllength 4715 NM_005005; NADH dehydrogenase(ubiquinone) 1 beta subcomplex, 9, 22 kDa 254 Hs.184693 fulllength6921 NM_005648; elongin C 255 Hs.404048 fulllength 10499 NM_006540;nuclear receptor coactivator 2 256 Hs.404048 fulllength 10499NM_006540; nuclear receptor coactivator 2 257 Hs.296730 fulllength80243 NM_025170; hypothetical protein FLJ12987 258 Hs.80887fulllength 4067 NM_002350; v-yes-1 Yamaguchi sarcoma viral relatedoncogene homolog 259 Hs.80887 fulllength 4067 NM_002350; v-yes-1Yamaguchi sarcoma viral related oncogene homolog 260 Hs.80887fulllength 4067 NM_002350; v-yes-1 Yamaguchi sarcoma viral relatedoncogene homolog 261 Hs.194562 fulllength 7013 NM_003218; telomericrepeat binding factor 1 isoform 2 NM_017489; telomeric repeatbinding factor 1 isoform 1 262 Hs.78619 fulllength 8836 NM_003878:gamma-glutamyl hydrolase precursor 263 Hs.283664 fulllength 444NM_004318; aspartate beta-hydroxylase isoform a NM_020164;aspartale beta- hydroxylase isoform e NM_032466; aspartatebeta-hydroxylase isoform c NM_032467; aspartate beta-hydroxylaseisoform d NM_032468; aspartate beta- hydroxylase isoform b 264Hs.105461 55636 265 Hs.155572 137886 266 Hs.78305 fulllength 5862NM_002865; RAB2, member RAS oncogene family 267 Hs.78305 fulllength5862 NM_002865; RAB2, member RAS oncogene family 268 Hs.78305fulllength 5862 NM_002865; RAB2, member RAS oncogene family 269Hs.14968 fulllength 5324 NM_002655; pleiomorphic adenoma gene 1 270Hs.8102 fulllength 6224 NM_001023; ribosomal protein S20 271Hs.8180 fulllength 6386 NM_005625; syndecan binding protein(syntenin) 272 Hs.378857 fulllength 54928 NM_017813; hypotheticalprotein FLJ20421 273 Hs.12540 fulllength 10434 NM_006330;lysophospholipase I 274 Hs.323164 fulllength 79145 NM_024300;hypothetical protein MGC2217 275 Hs.76722 fulllength 1052NM_005195; CCAAT/enhancer binding protein delta 276 Hs.154443fulllength 4173 277 Hs.155637 fulllength 5591 NM_006904; proteinkinase, DNA-activated, catalytic polypeptide 278 Hs.155637fulllength 5591 NM_006904; protein kinase, DNA-activated, catalyticpolypeptide 279 Hs.81001 fulllength 26260 NM_012173; F-box onlyprotein 25 280 Hs.155958 fulllength 9 NM_000662 N-acetyltransferase1 281 Hs.180178 fulllength 91694 NM_152271; hypothetical proteinFLJ23749 282 Hs.75811 fulllength 427 NM_004315; N-acylsphingosineamidohydrolase (acid ceramidase) 1 isoform b NM_177924;N-acylsphingosine amidohydrolase (acid ceramidase) 1 preproproteinisoform a 283 Hs.155272 est 284 Hs.297939 fulllength 1508NM_001908; cathepsin B preproprotein NM_147780; cathepsin Bpreproprotein NM_147781; cathepsin B preproprotein NM_147782;cathepsin B preproprotein NM_147783; cathepsin B preproprotein 285Hs.297939 fulllength 1508 NM_001908; cathepsin B preproproteinNM_147780; cathepsin B preproprotein NM_147781; cathepsin Bpreproprotein NM_147782; cathepsin B preproprotein NM_147783;cathepsin B preproprotein 286 Hs.297939 fulllength 1508 NM_001908;cathepsin B preproprotein NM_147780; cathepsin B preproproteinNM_147781; cathepsin B preproprotein NM_147782; cathepsin Bpreproprotein NM_147783; cathepsin B preproprotein 287 Hs.25590fulllength 6781 NM_003155; stanniocalcin 1 288 Hs.11260 fulllength55790 NM_018371; chondroitin beta1,4N-acetylgalactosaminyltransferase 289 Hs.131056 290 Hs.300861 291Hs.201377 fulllength 9583 NM_004901; lysosomal apyrase-like 1 292Hs.379109 fulllength 64236 NM_021630; PDZ and LIM domain 2NM_176871; PDZ and LIM domain 2 293 Hs.72071 fulllength 54793NM_017634; hypothetical protein FLJ20038 294 Hs.20313 fulllength2185 NM_004103; PTK2B protein tyrosine kinase 2 beta isoform aNM_173174; PTK2B protein tyrosine kinase 2 beta isoform aNM_173175; PTK2B protein tyrosine kinase 2 beta isoform bNM_173176; PTK2B protein tyrosine kinase 2 beta isoform a 295Hs.39913 fulllength 10671 NM_006571; dynactin 6 296 Hs.17270fulllength 25960 NM_032777; G protein-coupled receptor 124 297Hs.2442 fulllength 8754 NM_003816; a disintegrin andmetalloproteinase domain 9 preproprotein 298 Hs.18585 299 Hs.125849fulllength 11160 NM_007175; chromosome 8 open reading frame 2 300Hs.82210 fulllength 7994 NM_006766; MYST histone acetyltransferase(monocytic leukemia) 3 301 Hs.173159 fulllength 6867 NM_006283;transforming, acidic coiled-coil containing protein 1 302 Hs.359201est 303 Hs.2331 fulllength 1875 NM_001951; E2F transcription factor5 304 Hs.25590 fulllength 6781 NM_003155; stanniocalcin 1 305Hs.41185 fulllength 157869 NM_153225; hypothetical protein FLJ40021306 Hs.108854 fulllength 29097 NM_014184; HSPC163 protein 307Hs.272367 fulllength 55806 NM_005144; hairless protein isoform aNM_018411; hairless protein isoform b 308 Hs.1274 fulllength 649NM_001199; bone morphogenetic protein 1 isoform 1, precursorNM_006128; bone morphogenetic protein 1 isoform 2, precursorNM_006129; bone morphogenetic protein 1 isoform 3, precursorNM_006130; bone morphogenetic protein 1 isoform 6 precursorNM_006131; bone morphogenetic protein 1 isoform 5, precursorNM_006132; bone morphogenetic protein 1 isoform 4, precursor 309Hs.149152 fulllength 114822 NM_052924; rhophilin 1 310 Hs.274136fulllength 55290 NM_018310; RNA polymerase III transcriptioninitiation factor BRF2 311 Hs.17270 fulllength 25960 NM_032777; Gprotein-coupled receptor 124 312 Hs.103849 fulllength 84257NM_032297; hypothetical protein DKFZp761D112 313 Hs.165741fulllength 56260 NM_019607; hypothetical protein FLJ11267 314Hs.133546 fulllength 79824 315 Hs.151449 fulllength 9705 NM_014682;suppression of tumorigenicity 18 316 Hs.251687 fulllength 6101NM_006269; retinitis pigmentosa RP1 protein 317 Hs.6272 318Hs.243987 fulllength 2626 NM_002052; GATA binding protein 4 319Hs.379094 320 Hs.201058 est 321 Hs.283664 fulllength 444 NM_004318;aspartate beta-hydroxylase isoform a NM_020164; aspartate beta-hydroxylase isoform e NM_032466; aspartate beta-hydroxylase isoformc NM_032467; aspartate beta-hydroxylase isoform d NM_032468;aspartate beta- hydroxylase isoform b 322 Hs.445714 est 323Hs.184261 fulllength 254778 NM_152765; hypothetical proteinMGC33510 324 Hs.149152 fulllength 114822 NM_052924; rhophilin 1 325Hs.115181 fulllength 285 NM_001147; angiopoietin 2 326 Hs.128856fulllength 51435 NM_016240; CSR1 protein

TABLE-US-00032 TABLE 31 _other Sequence Derived # affy id HUGO nameF p q Title MapLocation Sequence Type Transcript ID From 1230024_at 71.32 6.16e-12 2.37e-07 ESTs ConsensussequenceHs.143698.0 AI183453 2 206207_at CLC 42.57 5.45e-09 1.05e-04Charot-Leyden crystal protein 19q13.1 Exemplarsequence Hs.889.0NM_001828.3 3 200923_at LGALS3BP 34.29 8.73e-08 1.03e-03 lectin,galactoside-binding, 17q25 Exemplarsequence Hs.79339.0 NM_005567.2soluble, 3 binding protein 4 223708_at C1QTNF4 33.73 1.07e-071.03e-03 C1q and tumor necrosis factor related protein 4 11q11Exemplarsequence Hs.119302.0 AF329838.1 5 243577_at 33.33 7.32e-074.02e-03 ESTs Consensussequence Hs.146144.0 AA643238 6 204116_atIL2RG 33.19 1.75e-07 1.35e-03 interleukin 2 receptor, gamma Xq13.1Exemplarsequence Hs.84.0 NM_000206.1 (severe combinedimmunodeficiency) 7 233452_at 32.24 5.60e-07 3.58e-03Consensussequence Hs.283931.0 AF150222 8 238502_at 29.34 1.04e-064.98e-03 ESTs Consensussequence Hs.137190.0 BE886165 9 209194_atCETN2 38195 4.96e-05 7.16e-02 centrin, EF-hand protein, 2 Xq28Exemplarsequence Hs.82794.0 BC005334.1 10 239742_at 38103 2.02e-068.63e-03 Homo sapiens full length insert cDNA clone YU79H10Consensussequence Hs.31319.0 H15278 11 228904_at 25.62 3.37e-061.29e-02 ESTS Consensussequence Hs.156044.0 AW510657 12 211743_s_atPRG2 25.27 4.54e-06 1.53e-02 proteoglycan 2, bone marrow 11q12Exemplarsequence g13543541 BC005929.1 (natural killer cellactivator, eosinophil granule major basic protein) 13 214450_atCTSW 25.19 5.18e-06 1.53e-02 cathepsin W (lymphopain) 11q13.1Consensussequence Hs.87450.0 NM_001335.1 14 205297_s_at CD79B 380712.19e-05 4.67e-02 CD79B antigen (immunoglobulin- 17q23Exemplarsequence Hs.89575.1 NM_000626.1 associated beta) 15226670_s_at C20orf119 24.48 8.88e-06 2.27e-02 chromosome 20 openreading Consensussequence Hs.251946.0 AL109839 frame 119 16214836_x_at IGKC 24.30 4.95e-06 1.53e-02 immunoglobulin kappaconstant 2p12 Consensussequence Hs.123030.0 BG536224 17 239105_at23.82 6.34e-05 7.16e-02 ESTs Consensussequence Hs.121525.0 AI68158118 214627_at EPX 23.59 5.73e-06 1.57e-02 eosinophil peroxidase17q23.1 Consensussequence Hs.46295.0 X14346.1 19 243021_at 22.751.20e-05 2.88e-02 ESTs, Weakly similar to CGHU7L ConsensussequenceHs.148652.1 AI344101 collagen alpha 1(III) chain precursor - human[H. sapiens] 20 230670_at FLJ25972 22.47 1.98e-05 4.48e-02hypothetical protein FLJ25972 3q25.1 Consensussequence Hs.88162.0AW341661 21 202044_at GRLF1 22.38 5.51e-04 0.24 glucocorticoidreceptor DNA 19q13.3 Consensussequence Hs.102548.0 NM_004491.1binding factor 1 22 213665_at SOX4 21.29 7.57e-05 7.46e-02 SRY (sexdetermining region Y)- 6p22.3 Consensussequence Hs.83484.1 AI989477box 4 23 219734_at FLJ20174 21.27 4.99e-05 7.16e-02 hypotheticalprotein FLJ20174 3q13.2 Exemplarsequence Hs.114556.0 NM_017699.1 24244043_at 21.21 1.46e-04 0.11 ESTs, Weakly similar toConsensussequence Hs.283390.0 AI049624 hypothetical proteinFLJ20378 [Homo sapiens] [H. sapiens] 25 221782_at ERdj5 20.641.31e-04 0.10 ER-resident protein ERdj5 2q32.1 ConsensussequenceHs.1098.0 AL137648.1 26 244166_at 20.60 1.17e-04 9.74e-02 ESTsConsensussequence Hs.248476.0 AI762422 27 213398_s_at KIAA032319.99 1.53e-04 0.12 KIAA0323 protein 14q11.2 ConsensussequenceHs.7911.1 AI347090 28 237422_at 19.89 2.49e-05 5.04e-02 ESTsConsensussequence Hs.190440.0 AA873726 29 209757_s_at MYCN 19.893.11e-05 5.70e-02 v-myc myelocytomatosis viral 2p24.1Exemplarsequence Hs.25960.1 BC002712.1 related oncogene,neuroblastoma derived (avian) 30 236173_s_at LRIG1 19.66 2.83e-055.43e-02 leucine-rich repeats and Consensussequence Hs.121706.0AA775396 immunoglobulin-like domains 1 31 243010_at MSI2 19.565.75e-05 7.16e-02 musashi homolog 2 (Drosophila) 17q23.1Consensussequence Hs.103512.0 BE000929 32 223723_at MFI2 19.286.65e-05 7.16e-02 antigen p97 (melanoma 3q28-q29 ExemplarsequenceHs.271966.0 BC001875.1 associated) identified by monoclonalantibodies 133.2 and 96.5 33 206998_x_at PRB3 19.22 5.85e-057.16e-02 proline-rich protein BstNI 2p13.2 ExemplarsequenceHs.73031.0 NM_006249.2 subfamily 3 34 239152_at 19.13 3.47e-056.06e-02 ESTs Consensussequence Hs.243023.0 AW263526 35 221094_s_atELP3 18.93 9.28e-04 0.31 likely ortholog of mouse 8p21.1Exemplarsequence Hs.267905.0 NM_018091.1 elongation protein 3homolog (S. cerevisiae) 36 221605_s_at PIPOX 18.78 8.74e-04 0.30pipecolic acid oxidase 17q11.1 Exemplarsequence Hs.271167.1AF136970.1 37 238152_at 18.75 5.27e-05 7.16e-02 ESTs, Weaklysimilar to collagen Consensussequence Hs.195285.0 AI683490[Caenorhabditis elegans] [C. elegans] 38 216974_at 18.68 4.35e-057.16e-02 Consensussequence Hs.123028.0 S80491.1 39 210948_s_at LEF118.60 8.72e-05 8.17e-02 lymphoid enhancer-binding factor 1 4q23-q25Exemplarsequence Hs.44865.0 AF294627.1 40 202275_at G6PD 18.566.93e-05 7.16e-02 glucose-6-phosphate Xq28 ExemplarsequenceHs.80206.0 NM_000402.1 dehydrogenase 41 231367_s_at 18.45 4.82e-040.22 ESTs Consensussequence Hs.28621.1 AW300131 42 216268_s_at JAG118.42 5.84e-05 7.16e-02 jagged 1 (Alagille syndrome) 20p12.1-p11.23Consensussequence Hs.91143.3 U77914.1 43 238418_at YEA 18.414.70e-05 7.16e-02 YEA4 protein 7q33 Consensussequence Hs.292566.0AI590926 44 206660_at IGLL1 18.36 5.03e-05 7.16e-02 immunoglobulinlambda-like 22q11.23 Exemplarsequence Hs.288168.0 NM_020070.1polypeptide 1 45 203585_at ZNF185 18.35 5.40e-04 0.24 zinc fingerprotein 185 (LIM Xq28 Exemplarsequence Hs.16622.0 NM_007150.1domain) 46 206761_at TACTILE 18.33 6.33e-05 7.16e-02 T cellactivation, increased late 3q13.13 Exemplarsequence Hs.142023.0NM_005816.1 expression 47 214819_at KIAA0522 17.78 7.09e-057.16e-02 KIAA0522 protein Xp11.22 Consensussequence Hs.129892.0BF571239 48 235818_at 17.71 8.71e-05 8.17e-02 ESTs, Weakly similarto T09402 Consensussequence Hs.133355.0 AI498747immunoglobulin-like protein IGSF1 - human [H. sapiens] 49 238709_at17.69 6.73e-05 7.16e-02 Homo sapiens cDNA FLJ38461Consensussequence Hs.170261.0 AL041747 fis, clone FEBRA2020977. 50202439_s_at IDS 17.59 6.22e-04 0.26 iduronate 2-sulfatase (HunterXq28 Exemplarsequence Hs.172458.0 NM_000202.2 syndrome) Sequence #Sequence ID Source Unigene_Accession Cluster_Type LocusLinkFull_Length_Reference_Seq 1 Hs.143698.0_RC GenBank Hs.143698 est 2g6325464 RefSeq Hs.889 fulllength 1178 NM_001828; Charot-Leydencrystal protein 3 g6006016 RefSeq Hs.79339 fulllength 3959NM_005567; galectin 3 binding protein 4 g13274521 GenBank Hs.119302fulllength 114900 NM_031909; C1q and tumor necrosis factor relatedprotein 4 5 Hs.146144.0_RC GenBank Hs.146144 est 6 g4557881 RefSeqHs.84 fulllength 3561 NM_000206; interleukin 2 receptor, gammachain, precursor 7 Hs.283931.0 GenBank 8 Hs.137190.0_RC GenBankHs.137190 est 9 g13529121 GenBank Hs.82794 fulllength 1069NM_004344; caltractin 10 Hs.31319.0.A1 GenBank Hs.406173 11Hs.156044.0 GenBank Hs.156044 est 12 g13543541 GenBank Hs.99962fulllength 5553 NM_002728; proteoglycan 2 13 Hs.87450.0.S1 GenBankHs.87450 fulllength 1521 NM_001335; cathepsin W preproprotein 14g11038673 RefSeq Hs.89575 fulllength 974 NM_000626; CD79B antigenisoform 1 precursor NM_021602; CD79B antigen isoform 2 precursor 15Hs.251946.0.S1 GenBank Hs.372714 80336 16 Hs.123030.0 GenBankHs.406565 fulllength 3514 17 Hs.121525.0.A1 GenBank Hs.121525 est18 Hs.46295.0 GenBank Hs.46295 fulllength 8288 NM_000502;eosinophil peroxidase 19 Hs.148652.1_RC GenBank Hs.445480 est 20Hs.88162.0.A1 GenBank Hs.88162 fulllength 285313 NM_178822;hypothetical protein FLJ25972 21 Hs.102548.0_RC GenBank Hs.102548fulllength 2909 NM_004491; glucocorticoid receptor DNA bindingfactor 1 isoform b NM_024342; glucocorticoid receptor DNA bindingfactor 1 isoform a 22 Hs.83484.1.A1 GenBank Hs.83484 fulllength6659 NM_003107; SRY (sex determining region Y)-box 4 23 g8923170RefSeq Hs.114556 fulllength 54847 NM_017699; hypothetical proteinFLJ20174 24 Hs.283390.0.S1 GenBank Hs.283390 est 25 Hs.1098.0_RCGenBank Hs.1098 fulllength 54431 NM_018981; ER-resident proteinERdj5 26 Hs.248476.0_RC GenBank Hs.248476 est 27 Hs.7911.1.S1GenBank Hs.7911 fulllength 23351 NM_020195; HCDI protein 28Hs.190440.0_RC GenBank Hs.190440 est 29 g12803748 GenBank Hs.25960fulllength 4613 NM_005378; v-myc myelocytomatosis viral relatedoncogene, neuroblastoma derived 30 Hs.121706.0_RC GenBank Hs.4193fulllength 26018 NM_015541; leucine-rich repeats andimmunoglobulin-like domains 1 31 Hs.103512.0.A1 GenBank Hs.103512fulllength 124540 NM_138962; musashi 2 isoform a NM_170721; musashi2 isoform b 32 g12804858 GenBank Hs.271966 fulllength 4241NM_005929; melanoma-associated antigen p97 isoform 1, precursorNM_033316; melanoma- associated antigen p97 isoform 2, precursor 33g7427520 RefSeq Hs.73031 fulllength 5544 NM_006249; proline-richprotein BstNI subfamily 3 34 Hs.243023.0_RC GenBank Hs.445903 est35 g8922417 RefSeq Hs.267905 fulllength 55140 NM_018091; elongationprotein 3 homolog 36 g12239317 GenBank Hs.271167 fulllength 51268NM_016518; L-pipecolic acid oxidase 37 Hs.195285.0_RC GenBankHs.380425 est 38 Hs.123028.0 GenBank 39 g11024343 GenBank Hs.44865fulllength 51176 NM_016269; lymphoid enhancer binding factor-1 40g4503844 RefSeq Hs.80206 fulllength 2539 NM_000402;glucose-6-phosphate dehydrogenase 41 Hs.28621.1.A1 GenBank Hs.28621est 42 Hs.91143.3 GenBank Hs.91143 fulllength 182 NM_000214; jagged1 precursor 43 Hs.292566.0.A1 GenBank Hs.292566 fulllength 84912NM_032826; YEA4 protein 44 g13399297 RefSeq Hs.348935 fulllength3543 NM_020070; immunoglobulin lambda-like polypeptide 1 isoform aprecursor NM_152855; immunoglobulin lambda-like polypeptide 1isoform b precursor 45 g6005971 RefSeq Hs.16622 fulllength 7739NM_007150; zinc finger protein 185 (LIM domain) 46 g5032140 RefSeqHs.142023 fulllength 10225 NM_005816; T cell activation, increasedlate expression 47 Hs.129892.0 GenBank Hs.129892 23096 48Hs.133355.0.A1 GenBank Hs.444431 est 49 Hs.170261.0_RC GenBankHs.170261 50 g5360215 RefSeq Hs.172458 fulllength 3423 NM_000202;iduronate-2-sulfatase isoform a precursor NM_006123;iduronate-2-sulfatase isoform b precursor

TABLE-US-00033 TABLE 32 _other # affy id HUGO name TitleMapLocation Sequence Type Transcript ID Sequence Derived FromSequence ID 1 232640_at HT002 HT002 protein; hypertension-relatedcalcium- 8q24-qter Consensussequence Hs.238928.2 AK023070.1Hs.238928.2.S1 regulated gene 2 230361_at ESTs, Weakly similar toinner centromere Consensussequence Hs.146109.0 AW664013Hs.146109.0_RC protein [Mus musculus] [M. musculus] 3 222551_s_atFLJ20989 hypothetical protein FLJ20989 ConsensussequenceHs.169615.0 AI197841 Hs.169615.0 4 200632_s_at NDRG1 N-mycdownstream regulated gene 1 8q24 Exemplarsequence Hs.75789.0NM_006096.1 g5174656 5 226754_at LOC90987 hypothetical proteinBC006258 8q24.3 Consensussequence Hs.285901.0 W93231 Hs.285901.0 6219606_at CGI-72 CGI-72 protein 8q24.3 Exemplarsequence Hs.318725.0NM_016018.1 g7705782 7 217535_at Consensussequence Hs.282721.0AV720514 Hs.282721.0_RC 8 209781_s_at KHDRBS3 KH domain containing,RNA binding, signal 8q24.2 Exemplarsequence Hs.13565.0 AF069681.1g3273831 transduction associated 3 9 225488_at MGC3067 hypotheticalprotein MGC3067 8q24.13 Consensussequence Hs.323114.1 AI967978Hs.323114.1 10 218858_at FLJ12428 hypothetical protein FL124288q24.12 Exemplarsequence Hs.87729.0 NM_022783.1 g12232472 11230555_s_at PFDN2 prefoldin 2 1q23.1 Consensussequence Hs.298229.1AA521496 Hs.298229.1.A1 12 206573_at KCNQ3 potassium voltage-gatedchannel, KQT-like 8q24 Exemplarsequence Hs.40866.0 NM_004519.1g4758629 subfamily, member 3 13 235205_at Homo sapiens, cloneIMAGE: 5726657, Consensussequence Hs.127286.0 BF109660Hs.127286.0.A1 mRNA 14 212865_s_at COL14A1 collagen, type XIV,alpha 1 (undulin) 8q23 Consensussequence Hs.36131.0 BF449063Hs.36131.0.S1 15 225439_at CML66 chronic myelogenous leukemia tumor8q23 Consensussequence Hs.195870.0 BC000967.2 Hs.195870.0 antigen66 16 216865_at COL14A1 collagen, type XIV, alpha 1 (undulin) 8q23Consensussequence Hs.36131.2 M64108.1 Hs.36131.2.S1 17 225438_atCML66 chronic myelogenous leukemia tumor 8q23 ConsensussequenceHs.195870.0 BC000967.2 Hs.195870.0 antigen 66 18 201754_at COX6Ccytochrome c oxidase subunit VIc 8q22-q23 ExemplarsequenceHs.74649.0 NM_004374.1 g4758039 19 205608_s_at ANGPT1 angiopoietin1 8q22.3-q23 Exemplarsequence Hs.2463.0 U83508.1 g1907326 20205609_at ANGPT1 angiopoietin 1 8q22.3-q23 ExemplarsequenceHs.2463.0 NM_001146.1 g4502086 21 220843_s_at DKFZP564O0463DKFZP564O0463 protein 8q22.3 Exemplarsequence Hs.273344.0NM_014156.1 g7661767 22 225676_s_at DKFZP564O0463 DKFZP564O0463protein 8q22.3 Consensussequence Hs.273344.1 AK001693.1 Hs.273344.123 202872_at ATP6V1C1 ATPase, H+ transporting, lysosomal 42 kDa,8q22.3 Consensussequence Hs.86905.0 NM_001695.1 Hs.86905.0 V1subunit C, isoform 1 24 202634_at POLR2K polymerase (RNA) II (DNAdirected) 8q22.2 Consensussequence Hs.150675.0 AL558030 Hs.150675.0polypeptide K, 7.0 kDa 25 220254_at ST7 suppression oftumorigenicity 8q22.2-q23.1 Exemplarsequence Hs.301974.0NM_013437.1 g7305524 26 220128_s_at FLJ13955 hypothetical proteinFLJ13955 8q22.1 Exemplarsequence Hs.127331.0 NM_024759.1 g1337609627 211078_s_at STK3 serine/threonine kinase 3 (STE20 homolog,8q22.1 Exemplarsequence g405722 Z25422.1 g405722 yeast) 28235509_at MGC40214 hypothetical protein MGC40214 8q22.1Consensussequence Hs.98471.0 AV662196 Hs.98471.0_RC 29 239860_atESTs Consensussequence Hs.16292.0 AI311917 Hs.16292.0.A1 30205849_s_at UQCRB ubiquinol-cytochrome c reductase binding 8q22Exemplarsequence Hs.131255.0 NM_006294.1 g5454151 protein 31209066_x_at UQCRB ubiquinol-cytochrome c reductase binding 8q22Exemplarsequence Hs.131255.1 M26700.1 g190803 protein 32 231268_atHomo sapiens, clone IMAGE: 5222754, Consensussequence Hs.144027.0AI539459 Hs.144027.0.A1 mRNA, partial cds 33 213906_at MYBL1 v-mybmyeloblastosis viral oncogene 8q22 Consensussequence Hs.300592.0AW592266 Hs.300592.0.S1 homolog (avian)-like 1 34 242338_atDKFZp762C1112 hypothetical protein DKFZp762C1112 8q21.3Consensussequence Hs.330692.0 BG535396 Hs.330692.0.S1 35 202447_atDECR1 2,4-dienoyl CoA reductase 1, mitochondrial 8q21.3Exemplarsequence Hs.81548.0 NM_001359.1 g4503300 36 218549_s_atCGI-90 CGI-90 protein 8q21.13 Exemplarsequence Hs.44222.0NM_016033.1 g7705802 37 219819_s_at MRPS28 mitochondrial ribosomalprotein S28 8q21.1-q21.2 Exemplarsequence Hs.55097.0 NM_014018.1g7661729 38 202345_s_at FABP5 fatty acid binding protein 5(psoriasis- 8q21.11 Exemplarsequence Hs.153179.0 NM_001444.1g4557580 associated) 39 205308_at CGI-62 CGI-62 protein 8q21.11Exemplarsequence Hs.118821.0 NM_016010.1 g7705774 40 226864_at PKIAprotein kinase (cAMP-dependent, catalytic) 8q21.11Consensussequence Hs.75209.1 BF245954 Hs.75209.1.S1 inhibitor alpha41 201691_s_at TPD52 tumor protein D52 8q21 ExemplarsequenceHs.2384.0 NM_005079.1 g4827037 42 222863_at RINZF zinc fingerprotein RINZF 8q13-q21.1 Consensussequence Hs.237146.0 BG483802Hs.237146.0.S2 43 229417_at STAU2 staufen, RNA binding protein,homolog 2 8q13-q21.1 Consensussequence Hs.96870.2 W46994Hs.96870.2_RC (Drosophila) 44 235210_s_at FLJ40021 hypotheticalprotein FLJ40021 8q13.2 Consensussequence Hs.122544.0 AW662373Hs.122544.0_RC 45 219448_at FLJ20533 hypothetical protein FLJ205338q13.3 Exemplarsequence Hs.106650.0 BC002748.1 g12803814 46226021_at ESTs, Weakly similar to hypothetical proteinConsensussequence Hs.106283.0 AW150720 Hs.106283.0.A1 FLJ20489[Homo sapiens] [H. sapiens] 47 239493_at RPL7 ribosomal protein L78q13.2 Consensussequence Hs.196398.0 AI984074 Hs.196398.0_RC 48220984_s_at OATPRP4 organic anion transporter polypeptide-related8q13.1 Exemplarsequence g13569931 NM_030958.1 g13569931 protein 449 210614_at TTPA tocopherol (alpha) transfer protein (ataxia8q13.1-q13.3 Exemplarsequence Hs.69049.0 U21938.1 g726181(Friedreich-like) with vitamin E deficiency) 50 201652_at COPS5COP9 constitutive photomorphogenic 8q12.3 ExemplarsequenceHs.198767.0 NM_006837.1 g5803045 homolog subunit 5 (Arabidopsis) 51203208_s_at CHPPR likely ortholog of chicken chondrocyte protein8q12.1 Exemplarsequence Hs.170198.0 NM_014637.1 g7661853 with apoly-proline region 52 203207_s_at CHPPR likely ortholog of chickenchondrocyte protein 8q12.1 Consensussequence Hs.170198.0 BF214329Hs.170198.0.S1 with a poly-proline region 53 226123_at LOC286180hypothetical protein LOC286180 8q12.1 Consensussequence Hs.60238.0AI870918 Hs.60238.0_RC 54 204529_s_at TOX thymus high mobilitygroup box protein TOX 8q11.23 Consensussequence Hs.184297.0AI961231 Hs.184297.0.S1 55 200949_x_at RPS20 ribosomal protein S208q12 Exemplarsequence Hs.8102.0 NM_001023.1 g4506696 56 234919_s_atSNTG1 syntrophin, gamma 1 8q11-q12 Consensussequence Hs.167481.1AJ003030.1 Hs.167481.1 57 228734_at ESTs ConsensussequenceHs.30662.0 BF447286 Hs.30662.0_RC 58 222036_s_at MCM4 MCM4minichromosome maintenance 8q12-q13 Consensussequence Hs.154443.1AI859865 Hs.154443.1.S1 deficient 4 (S. cerevisiae) 59 239877_atMTMR9 myotubularin related protein 9 8p23-p22 ConsensussequenceHs.128277.0 AI499833 Hs.128277.0_RC 60 226614_s_at C8orf13chromosome 8 open reading frame 13 8p23-p22 ConsensussequenceHs.35453.0 BE856336 Hs.35453.0.A1 61 229958_at Homo sapiens cDNAFLJ39417 fis, clone Consensussequence Hs.14880.0 W93695Hs.14880.0_RC PLACE6016942. 62 210397_at DEFB1 defensin, beta 18p23.2-p23.1 Exemplarsequence Hs.32949.0 U73945.1 g1755147 63243692_at GATA4 GATA binding protein 4 8p23.1-p22 ConsensussequenceHs.194114.0 AW181962 Hs.194114.0_RC 64 237261_at ESTs, Highlysimilar to hypothetical protein Consensussequence Hs.71832.0BE501356 Hs.71832.0.A1 FLJ12847 [Homo sapiens] [H. sapiens] 65223907_s_at PINX1 PIN2-interacting protein 1 8p23 ExemplarsequenceHs.99829.0 AF205718.1 g10504237 66 222714_s_at CGI-83 CGI-83protein 8p22-q22.3 Exemplarsequence Hs.118554.0 BC000878.1g12654126 67 209294_x_at TNFRSF10B tumor necrosis factor receptorsuperfamily, 8p22-p21 Exemplarsequence Hs.51233.0 BC001281.1g12654874 member 10b 68 208423_s_at MSR1 macrophage scavengerreceptor 1 8p22 Exemplarsequence Hs.49.0 NM_002445.1 g4505258 69209227_at N33 Putative prostate cancer tumor suppressor 8p22Consensussequence Hs.71119.0 AU158251 Hs.71119.0.A2 70 238458_atLOC286097 hypothetical protein LOC286097 8p22 ConsensussequenceHs.131044.0 AI868167 Hs.131044.0.S1 71 235801_at N33 Putativeprostate cancer tumor suppressor 8p22 Consensussequence Hs.283526.0AI760262 Hs.283526.0_RC 72 218613_at DKFZp761K1423 hypotheticalprotein DKFZp761K1423 8p21.3 Exemplarsequence Hs.236438.0NM_018422.1 g8922171 73 230977_at LOC286056 hypothetical proteinLOC286056 8p21.2 Consensussequence Hs.131055.0 AI016313Hs.131055.0.A1 74 219665_at FLJ22494 hypothetical protein FLJ224948p21.2 Exemplarsequence Hs.170132.0 NM_024815.1 g13376205 75207287_at FLJ14107 hypothetical protein FLJ14107 8p21.2Exemplarsequence Hs.287624.0 NM_025026.1 g13376547 76 239303_atESTs Consensussequence Hs.97814.0 AA933717 Hs.97814.0.A1 77209697_at PPP3CC protein phosphatase 3 (formerly 2B), 8p21.2Consensussequence Hs.75206.1 BC004864.1 Hs.75206.1.A1 catalyticsubunit, gamma isoform (calcineurin A gamma) 78 219921_s_atFLJ21034 hypothetical protein FLJ21034 8p21.1 ExemplarsequenceHs.282466.0 NM_024940.1 g13376416 79 224316_at FLJ20038hypothetical protein FLJ20038 8p21.1 Exemplarsequence Hs.72071.1AF130091.1 g11493486 80 222525_s_at FLJ10853 hypothetical proteinFLJ10853 8p21.1 Consensussequence Hs.72085.0 AU160632 Hs.72085.0 81203941_at FLJ10871 hypothetical protein FLJ10871 8p12Exemplarsequence Hs.15562.0 NM_018250.1 g8922725 82 241371_at ESTsConsensussequence Hs.57851.0 AW451259 Hs.57851.0.A1 83 231775_atESTs, Weakly similar to neuronal thread ConsensussequenceHs.249190.0 W65310 Hs.249190.0.S2 protein [Homo sapiens] [H.sapiens] 84 215983_s_at D8S2298E reproduction 8 8p12-p11.2Consensussequence Hs.153678.1 D83768.1 Hs.153678.1.S1 85 210029_atINDO indoleamine-pyrrole 2,3 dioxygenase 8p12-p11 ExemplarsequenceHs.840.0 M34455.1 g185790 86 231961_at Homo sapiens cDNA FLJ14130fis, clone Consensussequence Hs.112572.0 AU148114 Hs.112572.0.S1MAMMA1002618. 87 204014_at DUSP4 dual specificity phosphatase 48p12-p11 Exemplarsequence Hs.2359.0 NM_001394.2 g12707552 88207737_at 1D12A pre-T/NK cell associated protein 8p12Exemplarsequence Hs.278.0 NM_021981.1 g11415055 89 242904_x_atMGC8721 hypothetical protein MGC8721 8p12 ConsensussequenceHs.209078.0 AI351653 Hs.209078.0.A1 90 210973_s_at FGFR1 fibroblastgrowth factor receptor 1 (fms- 8p11.2-p11.1 ExemplarsequenceHs.748.7 M63889.1 g183882 related tyrosine kinase 2, Pfeiffersyndrome) 91 232040_at Homo sapiens cDNA: FLJ22090 fis, cloneConsensussequence Hs.170296.0 AK025743.1 Hs.170296.0 HEP16084. 92222760_at FLJ14299 hypothetical protein FLJ14299 8p11.22Consensussequence Hs.288042.0 BG290193 Hs.288042.0_RC 93 203534_atLSM1 LSM1 homolog, U6 small nuclear RNA associated (S. cerevisiae)8p11.2 Exemplarsequence Hs.111783.0 NM_014462.1 g7657312 94208846_s_at VDAC3 voltage-dependent anion channel 3 8p11.2Exemplarsequence Hs.7381.0 U90943.1 g2735306 95 224127_at C8orf4chromosome 8 open reading frame 4 8p11.2 ExemplarsequenceHs.31446.0 AF116660.1 g7959818_RC Sequence # SourceUnigene_Accession Cluster_Type LocusLink Full_Length_Reference_Seq1 GenBank Hs.238928 fulllength 28991 NM_014066;hypertension-related calcium-regulated gene 2 GenBank Hs.443139 est3 GenBank Hs.169615 fulllength 65265 NM_023080; hypotheticalprotein FLJ20989 4 RefSeq Hs.75789 fulllength 10397 NM_006096;N-myc downstream regulated gene 1 5 GenBank Hs.285901 90987 6RefSeq Hs.318725 fulllength 51105 NM_016018; CGI-72 protein 7GenBank 8 GenBank Hs.13565 fulllength 10656 NM_006558; KH domaincontaining, RNA binding, signal transduction associated 3 9 GenBankHs.323114 fulllength 79139 NM_018630; NM_024295; hypotheticalprotein MGC3067 10 RefSeq Hs.87729 fulllength 64798 NM_022783;hypothetical protein FLJ12428 11 GenBank Hs.298229 fulllength 5202NM_012394; prefoldin 2 NM_080651; TRAP/Mediator complex componentTRAP25 12 RefSeq Hs.40866 fulllength 3786 NM_004519; potassiumvoltage-gated

channel KQT-like protein 3 13 GenBank Hs.127286 14 GenBankHs.403836 fulllength 7373 15 GenBank Hs.195870 fulllength 84955NM_032869; chronic myelogenous leukemia tumor antigen 66 16 GenBankHs.403836 fulllength 7373 17 GenBank Hs.195870 fulllength 84955NM_032869; chronic myelogenous leukemia tumor antigen 66 18 RefSeqHs.351875 fulllength 1345 NM_004374; cytochrome c oxidase subunitVIc proprotein 19 GenBank Hs.2463 fulllength 284 NM_001146;angiopoietin 1 isoform a NM_139290; angiopoietin 1 isoform b 20RefSeq Hs.2463 fulllength 284 NM_001146; angiopoietin 1 isoform aNM_139290; angiopoietin 1 isoform b 21 RefSeq Hs.273344 fulllength25879 NM_014156; NM_015420; DKFZP564O0463 protein 22 GenBankHs.273344 fulllength 25879 NM_014156; NM_015420; DKFZP564O0463protein 23 GenBank Hs.86905 fulllength 528 NM_001695; ATPase, H+transporting, lysosomal 42 kD, V1 subunit C, isoform 1 24 GenBankHs.351475 fulllength 5440 NM_005034; DNA directed RNA polymerase IIpolypeptide K 25 RefSeq Hs.301974 fulllength 29967 NM_013437;suppression of tumorigenicity NM_024937; 26 RefSeq Hs.127331fulllength 79815 NM_024759; hypothetical protein FLJ13955 27GenBank Hs.166684 fulllength 6788 NM_006281; serine/threoninekinase 3 (STE20 homolog, yeast) 28 GenBank Hs.98471 est 137682NM_152416; hypothetical protein MGC40214 29 GenBank Hs.16292 est 30RefSeq Hs.131255 fulllength 7381 NM_006294; ubiquinol-cytochrome creductase binding protein 31 GenBank Hs.131255 fulllength 7381NM_006294; ubiquinol-cytochrome c reductase binding protein 32GenBank Hs.144027 33 GenBank Hs.300592 4603 34 GenBank Hs.88594169200 35 RefSeq Hs.81548 fulllength 1666 NM_001359; 2,4-dienoylCoA reductase 1 precursor 36 RefSeq Hs.44222 fulllength 51115NM_016033; CGI-90 protein 37 RefSeq Hs.55097 fulllength 28957NM_014018; mitochondrial ribosomal protein S28 38 RefSeq Hs.408061fulllength 2171 NM_001444; fatty acid binding protein5(psoriasis-associated) 39 RefSeq Hs.118821 fulllength 51101NM_016010; CGI-62 protein 40 GenBank Hs.433700 fulllength 5569NM_006823; protein kinase, cAMP-dependent, catalytic, inhibitoralpha 41 RefSeq Hs.2384 fulllength 7163 NM_005079; tumor proteinD52 42 GenBank Hs.237146 fulllength 65986 NM_023929; zinc fingerprotein RINZF 43 GenBank Hs.96870 fulllength 27067 NM_014393;staufen homolog 2 44 GenBank Hs.41185 fulllength 157869 NM_153225;hypothetical protein FLJ40021 45 GenBank Hs.106650 fulllength 54968NM_017866; hypothetical protein FLJ20533 46 GenBank Hs.356086 est47 GenBank Hs.153 fulllength 6129 NM_000971; ribosomal protein L748 RefSeq Hs.199750 fulllength 81796 NM_030958; organic aniontransporter polypeptide-retated protein 4 49 GenBank Hs.69049fulllength 7274 NM_000370; tocopherol (alpha) transfer protein(ataxia (Friedreich-like) with vitamin E deficiency) 50 RefSeqHs.380969 fulllength 10987 NM_006837; COP9 constitutivephotomorphogenic homolog subunit 5 51 RefSeq Hs.170198 fulllength9650 NM_014637; KIAA0009 gene product 52 GenBank Hs.170198fulllength 9650 NM_014637; KIAA0009 gene product 53 GenBankHs.397426 286180 54 GenBank Hs.184297 fulllength 9760 NM_014729;thymus high mobility group box protein TOX 55 RefSeq Hs.8102fulllength 6224 NM_001023; ribosomal protein S20 56 GenBankHs.167481 fulllength 54212 NM_018967; syntrophin, gamma 1 57GenBank Hs.371278 est 58 GenBank Hs.154443 fulllength 4173 59GenBank Hs.48802 fulllength 66036 NM_015458; myotubularin relatedprotein 9 60 GenBank Hs.35453 83648 61 GenBank Hs.14880 62 GenBankHs.32949 fulllength 1672 NM_005218; defensin, beta 1, preproprotein63 GenBank Hs.243987 fulllength 2626 NM_002052; GATA bindingprotein 4 64 GenBank Hs.71832 est 65 GenBank Hs.400259 fulllength54984 NM_017884; PIN2-interacting protein 1 66 GenBank Hs.118554fulllength 51110 NM_016027; lactamase, beta 2 67 GenBank Hs.51233fulllength 8795 NM_003842; tumor necrosis factor receptorsuperfamily, member 10b isoform 1 precursor NM_147187; tumornecrosis factor receptor superfamily, member 10b isoform 2precursor 68 RefSeq Hs.49 fulllength 4481 NM_002445; macrophagescavenger receptor 1 isoform type 2 NM_138715; macrophage scavengerreceptor 1 isoform type 1 NM_138716; macrophage scavenger receptor1 isoform type 3 69 GenBank Hs.71119 fulllength 7991 NM_006765;Putative prostate cancer tumor suppressor isoform a NM_178234;Putative prostate cancer tumor suppressor isoform b 70 GenBankHs.131044 fulllength 286097 71 GenBank Hs.71119 fulllength 7991NM_006765; Putative prostate cancer tumor suppressor isoform aNM_178234; Putative prostate cancer tumor suppressor isoform b 72RefSeq Hs.236438 fulllength 55358 NM_018422; hypothetical proteinDKFZp761K1423 73 GenBank Hs.131055 286056 74 RefSeq Hs.170132fulllength 79873 NM_024815; hypothetical protein FLJ22494 75 RefSeqHs.287624 fulllength 80094 NM_025026; hypothetical protein FLJ1410776 GenBank Hs.446548 est 77 GenBank Hs.75206 fulllength 5533NM_005605; protein phosphatase 3 (formerly 2B), catalytic subunit,gamma isoform (calcineurin A gamma) 78 RefSeq Hs.282466 fulllength80005 NM_024940; hypothetical protein FLJ21034 79 GenBank Hs.72071fulllength 54793 NM_017634; hypothetical protein FLJ20038 80GenBank Hs.72085 fulllength 55246 NM_018246; hypothetical proteinFLJ10853 81 RefSeq Hs.15562 fulllength 55756 NM_018250;hypothetical protein FLJ10871 82 GenBank Hs.444578 est 83 GenBankHs.401745 est 84 GenBank Hs.153678 fulllength 7993 NM_005671;reproduction 8 85 GenBank Hs.840 fulllength 3620 NM_002164;indoleamine-pyrrole 2,3 dioxygenase 86 GenBank Hs.112572 87 RefSeqHs.2359 fulllength 1846 NM_001394; dual specificity phosphatase 4isoform 1 NM_057158; dual specificity phosphatase 4 isoform 2 88RefSeq Hs.278 fulllength 9594 NM_021981; pre-T/NK cell associatedprotein 1D12A 89 GenBank Hs.279921 fulllength 51669 NM_016127;hypothetical protein MGC8721 90 GenBank Hs.748 fulllength 2260NM_000604; fibroblast growth factor receptor 1 isoform 1 precursorNM_015850; fibroblast growth factor receptor 1 isoform 2 precursorNM_023105; fibroblast growth factor receptor 1 isoform 3 precursorNM_023106; fibroblast growth factor receptor 1 isoform 4 precursorNM_023107; fibroblast growth factor receptor 1 isoform 5 precursorNM_023108; fibroblast growth factor receptor 1 isoform 6 precursorNM_023109; fibroblast growth factor receptor 1 isoform 7 precursorNM_023110; fibroblast growth factor receptor 1 isoform 8 precursorNM_023111; fibroblast growth factor receptor 1 isoform 9 precursor91 GenBank Hs.170296 92 GenBank Hs.288042 fulllength 80139NM_025069; hypothetical protein FLJ14299 93 RefSeq Hs.425311fulllength 27257 NM_014462; Lsm1 protein 94 GenBank Hs.7381fulllength 7419 NM_005662; voltage-dependent anion channel 3 95GenBank Hs.283683 fulllength 56892 NM_020130; chromosome 8 openreading frame 4

TABLE-US-00034 TABLE 33 _complex # affy id HUGO name F p q TitleMapLocation Sequence Type Transcript ID 1 231585_at CHAC 36.792.29e-07 5.65e-03 chorea acanthocytosis 9q21 ConsensussequenceHs.65919.1 2 231004_s_at TGM2 31.58 2.57e-07 5.65e-03transglutaminase 2 (C polypeptide, 20q12 ConsensussequenceHs.109804.1 protein-glutamine-gamma-glutamyltransferase) 3200090_at-HG-U133B FNTA 30.63 9.14e-05 0.10 famesyltransferase,CAAX box, alpha 8p22-q11 Consensussequence Hs.138381.1 4 220055_atZNF287 30.49 4.89e-07 7.16e-03 zinc finger protein 287 17p11.2Exemplarsequence Hs.99724.0 5 215052_at 28.32 9.75e-07 1.07e-02ESTs Consensussequence Hs.92025.0 6 200923_at LGALS3BP 27.201.35e-06 1.19e-02 lectin, galactoside-binding, soluble, 3 17q25Exemplarsequence Hs.79339.0 binding protein 7 238715_at 27.153.23e-06 1.77e-02 Homo sapiens; clone IMAGE: 4798235,Consensussequence Hs.117853.0 mRNA 8 244817_at ING1 26.62 2.61e-061.77e-02 inhibitor of growth family, member 1 13q34Consensussequence Hs.28714.0 9 215209_at 26.16 3.16e-06 1.77e-02Homo sapiens, clone IMAGE: 5265853, Consensussequence Hs.301645.0mRNA 10 244364_at MYO3A 25.51 1.08e-05 3.95e-02 myosin IIIA 10p11.1Consensussequence Hs.98995.0 11 240068_at 23.97 4.84e-06 2.36e-02Homo sapiens cDNA FLJ37173 fis, Consensussequence Hs.106234.0 cloneBRACE2028392. 12 241618_at 23.86 8.26e-06 3.30e-02 ESTsConsensussequence Hs.133292.0 13 226462_at STXBP6 23.34 6.31e-062.77e-02 syntaxin binding protein 6 (amisyn) 14q11.2Consensussequence Hs.99291.1 14 207552_at ATP5G2 22.48 2.62e-055.77e-02 ATP synthase, H+ transporting, 12q13.13 ExemplarsequenceHs.89399.0 mitochondrial F0 complex, subunit c (subunit 9), isoform2 15 240761_at 22.32 2.50e-05 5.77e-02 ESTs ConsensussequenceHs.147260.0 16 229023_at MGC5391 22.18 1.40e-05 4.30e-02hypothetical protein MGC5391 2q14.3 Consensussequence Hs.55256.0 17211265_at PTGER3 21.80 1.20e-05 4.05e-02 prostaglandin E receptor 3(subtype 1p31.2 Exemplarsequence Hs.170917.3 EP3) 18 214740_atPOLR2J2 21.77 2.94e-05 5.86e-02 DNA directed RNA polymerase II7q11.22 Consensussequence Hs.80475.2 polypeptide J-related gene 19242356_at 21.60 1.85e-05 4.92e-02 Homo sapiens cDNA FLJ38157 fis,Consensussequence Hs.120654.0 clone DFNES2000426. 20 201443_s_atATP6IP2 21.31 1.40e-04 0.11 ATPase, H+ transporting, lysosomal Xq21Esemplarsequence Hs.183434.0 interacting protein 2 21 204289_atALDH6A1 21.28 1.47e-05 4.30e-02 aldehyde dehydrogenase 6 family,14q24.3 Consensussequence Hs.293970.0 member A1 22 217589_at RAB40A20.70 5.89e-05 8.62e-02 RAB40A, member RAS oncogene Xq22.1Consensussequence Hs.27453.0 family 23 204013_s_at LCMT2 20.641.90e-05 4.92e-02 leucine carboxyl methyltransferase 2 15q14Exemplarsequence Hs.200596.0 24 201004_at SSR4 20.48 6.28e-058.62e-02 signal sequence receptor, delta Xq28 ExemplarsequenceHs.102135.0 (translocon-associated protein delta) 25 207067_s_atHDC 20.39 2.56e-05 5.77e-02 histidine decarboxylase 15q21-q22Exemplarsequence Hs.1481.0 26 240930_at 20.35 5.26e-05 8.56e-02ESTs Consensussequence Hs.117900.0 27 206107_at RGS11 20.112.76e-05 5.78e-02 regulator of G-protein signalling 11 16p13.3Exemplarsequence Hs.65756.0 28 206282_at NEUROD1 19.39 3.44e-056.57e-02 neurogenic differentiation 1 2q32 ExemplarsequenceHs.72981.0 29 239001_at 19.30 6.25e-05 8.62e-02 ESTsConsensussequence Hs.132678.0 30 215576_at 18.98 7.85e-05 9.37e-02Homo sapiens cDNA FLJ12004 fis, clone HEMBB1001564,Consensussequence Hs.287476.0 moderately similar to VACUOLAR ATPSYNTHASE SUBUNIT H (EC 3.6.1.34). 31 237480_at 18.77 4.51e-058.26e-02 ESTs Consensussequence Hs.213049.0 32 235586_at 18.556.25e-05 8.62e-02 ESTs Consensussequence Hs.23892.0 33 215108_x_atTNRC9 18.48 5.04e-05 8.53e-02 trinucleotide repeat containing 916q11.2 Consensussequence Hs.110826.1 34 243953_at FADS2 18.444.81e-05 8.46e-02 fatty acid desaturase 2 11q12-q13.1Consensussequence Hs.100848.0 35 239072_at 18.32 7.77e-05 9.37e-02Human S6 H-8 mRNA expressed in Consensussequence Hs.212529.0chromosome 6-suppressed melanoma cells. 36 206615_s_at ADAM22 18.301.81e-04 0.12 a disintegrin and metalloproteinase 7q21Exemplarsequence Hs.158052.1 domain 22 37 207493_x_at SSX2 18.096.05e-05 8.62e-02 synovial sarcoma, X breakpoint 2 Xp11.23-p11.22Exemplarsequence Hs.289105.0 38 239334_at 18.00 9.96e-05 0.10 ESTsConsensussequence Hs.172762.0 39 200608_s_at RAD21 18.00 2.51e-040.14 RAD21 homolog (S. pombe) 8q24 Exemplarsequence Hs.81848.0 40204739_at CENPC1 17.97 3.08e-04 0.16 centromere protein C 14q12-q13.3 Exemplarsequence Hs.154207.0 41 230210_at UNC84A 17.626.96e-05 9.27e-02 unc-84 homolog A (C. elegans) 7p22.3Consensussequence Hs.7531.3 42 241172_at GRIA2 17.55 7.27e-059.37e-02 glutamate receptor, ionotropic, AMPA 2 4q32-q33Consensussequence Hs.161378.0 43 216023_at KIAA0876 17.53 1.04e-040.10 KIAA0876 protein 19p13.3 Consensussequence Hs.306827.0 44227762_at 17.41 1.06e-03 0.24 ESTs Consensussequence Hs.22971.0 45238933_at IRS1 17.36 9.84e-05 0.10 insulin receptor substrate 12q36 Consensussequence Hs.59896.0 46 232378_at LOC200010 17.361.62e-04 0.12 hypothetical protein LOC200010 1p33 ConsensussequenceHs.37890.0 47 238358_x_at 17.28 7.88e-05 9.37e-02 ESTsConsensussequence Hs.145492.0 48 243359_at 17.13 1.16e-04 0.10 ESTsConsensussequence Hs.202388.0 49 216749_at 17.02 9.42e-05 0.10 Homosapiens cDNA: FLJ21198 fis, Consensussequence Hs.306707.0 cloneCOL00220. 50 235874_at MGC46520 17.01 1.28e-04 0.11 hypotheticalprotein MGC46520 6q14.3 Consensussequence Hs.98381.0 SequenceSequence # Derived From Sequence ID Source Unigene_AccessionCluster_Type LocusLink Full_Length_Reference_Seq 1 AI680723Hs.65919.1_RC GenBank Hs.53542 fulllength 23230 NM_015186; choreinisoform B NM_033305; chorein isoform A 2 BE219961 Hs.109804.1_RCGenBank Hs.75307 fulllength 7052 NM_004613; transglutaminase 2 (Cpolypeptide, protein-glutamine-gamma- glutamyltransferase) 3BG168896 Hs.138381.1.A1 GenBank Hs.356463 fulllength 2339NM_002027; farnesyltransferase, CAAX box, alpha 4 NM_020653.1g10190687 RefSeq Hs.99724 fulllength 57336 NM_020653; zinc fingerprotein 287 5 AW297087 Hs.92025.0 GenBank Hs.437611 est 6NM_005567.2 g6006016 RefSeq Hs.79339 fulllength 3959 NM_005567;galectin 3 binding protein 7 BF110180 Hs.117853.0 GenBank Hs.1178538 AA947302 Hs.28714.0.A1 GenBank Hs.46700 fulllength 3621NM_005537; inhibitor of growth family, member 1 9 AU143984Hs.301645.0 GenBank Hs.397840 10 AA443280 Hs.98995.0.A1 GenBankHs.279907 fulllength 53904 NM_017433; myosin IIIA 11 H08345Hs.106234.0.A1 GenBank Hs.106234 12 AI306990 Hs.133292.0 GenBankHs.432435 est 13 AW134979 Hs.99291.1.S1 GenBank Hs.99291 fulllength29091 NM_014178; amisyn 14 NM_005176.3 g6671590 RefSeq Hs.89399fulllength 517 NM_005176; ATP synthase, H+ transporting,mitochondrial F0 complex, subunit c (subunit 9), isoform 2 15AI990286 Hs.147260.0_RC GenBank Hs.147260 est 16 BF590323Hs.55256.0.A1 GenBank Hs.101660 fulllength 84826 NM_032740;hypothetical protein MGC5391 17 U13216.1 g532741 GenBank Hs.170917fulllength 5733 NM_000957; prostaglandin E receptor 3 (subtype EP3)18 BE676209 Hs.80475.2.S1 GenBank Hs.375569 fulllength 246721NM_032958; DNA directed RNA polymerase II polypeptide J-relatedgene isoform 2 NM_032959; DNA directed RNA polymerase IIpolypeptide J-related gene isoform 3 NM_145325; DNA directed RNApolymerase II polypeptide J-related gene isoform 1 19 BE613520Hs.120654.0_RC GenBank Hs.120654 20 AF248966.1 g12005668 GenBankHs.183434 fulllength 10159 NM_005765; ATPase, H+ transporting,lysosomal, membrane sector associated protein M8-9 21 BG399778Hs.293970.0.A2 GenBank Hs.293970 fulllength 4329 NM_005589;aldehyde dehydrogenase 6A1 precursor 22 AW300309 Hs.27453.0 GenBankHs.27453 fulllength 142684 NM_080879; RAB40A, member RAS oncogenefamily 23 NM_014793.1 g7662173 RefSeq Hs.200596 fulllength 9836NM_014793; p21WAF1/CIP1 promoter-interacting protein 24 NM_006280.1g5454089 RefSeq Hs.102135 fulllength 6748 NM_006280; signalsequence receptor, delta 25 NM_002112.1 g4504364 RefSeq Hs.1481fulllength 3067 NM_002112; histidine decarboxylase 26 R92115Hs.117900.0.A1 GenBank Hs.444881 est 27 NM_003834.1 g4506506 RefSeqHs.65756 fulllength 8786 NM_003834; regulator of G-proteinsignalling 11 28 NM_002500.1 g4505376 RefSeq Hs.72981 fulllength4760 NM_002500; neurogenic differentiation 1 29 AV705233Hs.132678.0.A1 GenBank Hs.132678 est 30 AU146809 Hs.287476.0GenBank Hs.355194 31 AI912612 Hs.213049.0.A1 GenBank Hs.213049 est32 W42591 Hs.23892.0.A1 GenBank Hs.436562 est 33 U80736.1Hs.110826.1 GenBank Hs.110826 27324 34 R40016 Hs.100848.0_RCGenBank Hs.184641 est 9415 NM_004265; fatty acid desaturase 2 35BE080109 Hs.212529.0.A1 GenBank Hs.446408 36 NM_021723.1 g11497046RefSeq Hs.158052 fulllength 53616 NM_004194; a disintegrin andmetalloproteinase domain 22 isoform 4 proprotein NM_016351; adisintegrin and metalloproteinase domain 22 isoform 3 proproteinNM_021721; a disintegrin and metalloproteinase domain 22 isoform 5proprotein NM_021722; a disintegrin and metalloproteinase domain 22isoform 2 proprotein NM_021723; a disintegrin and metalloproteinasedomain 22 isoform 1 proprotein 37 NM_003147.1 g10337582 RefSeqHs.446305 fulllength 6757 NM_003147; synovial sarcoma, X breakpoint2 isoform a NM_175698; synovial sarcoma, X breakpoint 2 isoform b38 AI349167 Hs.172762.0 GenBank Hs.172762 est 39 NM_006265.1g5453993 RefSeq Hs.81848 fulllength 5885 NM_006265; RAD21 homolog40 NM_001812.1 g4502778 RefSeq Hs.154207 fulllength 1060 NM_001812;centromere protein C 1 41 AW054783 Hs.7531.3.S1 GenBank Hs.381143fulllength 23353 42 AI939470 Hs.161378.0_RC GenBank Hs.89582fulllength 2891 NM_000826; glutamate receptor, ionotropic, AMPA 243 AK026040.1 Hs.306827.0 GenBank Hs.301011 23030 44 AW244016Hs.22971.0.A1 GenBank Hs.356349 est 45 AA644178 Hs.59896.0_RCGenBank Hs.96063 fulllength 3667 NM_005544; insulin receptorsubstrate 1 46 AI767388 Hs.37890.0.S1 GenBank Hs.37890 200010 47AI366965 Hs.145492.0_RC GenBank Hs.432397 est 48 AI701857Hs.202388.0_RC GenBank Hs.202388 est 49 AK024851.1 Hs.306707.0GenBank Hs.306707 50 AL574912 Hs.98381.0_RC GenBank Hs.98368fulllength 167681 NM_153362; hypothetical protein MGC46520

TABLE-US-00035 TABLE 34 _complex # affy id HUGO name TitleMapLocation Sequence Type Transcript ID 1 222551_s_at FLJ20989hypothetical protein FLJ20989 Consensussequence Hs.169615.0 2226754_at LOC90987 hypothetical protein BC006258 8q24.3Consensussequence Hs.285901.0 3 206573_at KCNQ3 potassiumvoltage-gated channel, KQT-like subfamily, member 3 8q24Exemplarsequence Hs.40866.0 4 225439_at CML66 chronic myelogenousleukemia tumor antigen 66 8q23 Consensussequence Hs.195870.0 5225676_s_at DKFZP564O0463 DKFZP564O0463 protein 8q22.3Consensussequence Hs.273344.1 6 200949_x_at RPS20 ribosomal proteinS20 8q12 Exemplarsequence Hs.8102.0 7 210397_at DEFB1 defensin,beta 1 8p23.2-p23.1 Exemplarsequence Hs.32949.0 8 208423_s_at MSR1macrophage scavenger receptor 1 8p22 Exemplarsequence Hs.49.0 9222525_s_at FLJ10853 hypothetical protein FLJ10853 8p21.1Consensussequence Hs.72085.0 10 231961_at Homo sapiens cDNAFLJ14130 fis, clone MAMMA1002618 Consensussequence Hs.112572.0 11224127_at C8orf4 chromosome 8 open reading frame 4 8p11.2Exemplarsequence Hs.31446.0 12 205089_at ZNF7 zinc finger protein 7(KOX 4, clone HF.16) 8q24 Exemplarsequence Hs.2076.0 13 224387_atHT002 HT002 protein; hypertension-related calcium-regulated gene8q24-qter Exemplarsequence g9964286 14 218187_s_at FLJ20989hypothetical protein FLJ20989 Exemplarsequence Hs.169615.0 15222998_at MAF1 homolog of yeast MAF1 8q24.3 ExemplarsequenceHs.324157.0 16 218679_s_at VPS28 vacuolar protein sorting 28(yeast) 8q24.3 Exemplarsequence Hs.293441.0 17 202344_at HSF1 heatshock transcription factor 1 8q24.3 Exemplarsequence Hs.1499.0 18201066_at CYC1 cytochrome c-1 8q24.3 Exemplarsequence Hs.289271.019 229758_at TIGD5 tigger transposable element derived 5 8q24.3Consensussequence Hs.71574.0 20 225949_at Homo sapiens mRNA; cDNADKFZp434P086 (from clone DKFZp434P086); ConsensussequenceHs.274401.0 partial cds 21 209899_s_at SIAHBP1 fuse-bindingprotein-interacting repressor 8q24.2-qtel ExemplarsequenceHs.74562.0 22 33132_at CPSF1 cleavage and polyadenylation specificfactor 1, 160 kDa 8q24.23 Consensussequence 8 23 217534_atConsensussequence Hs.282721.0 24 229802_at Homo sapiens cDNAFLJ14388 fis, clone HEMBA1002716. Consensussequence Hs.9812.0 25223231_at CDA11 CDA11 protein 8q24.13 Exemplarsequence Hs.11810.026 241342_at LOC157378 hypothetical protein BC017881 8q24.13Consensussequence Hs.187646.0 27 238741_at Homo sapiens cDNAFLJ25541 fis, clone JTH00915. Consensussequence Hs.193341.0 28224218_s_at TRPS1 trichorhinophalangeal syndrome I 8q24.12Exemplarsequence Hs.26102.1 29 209523_at TAF2 TAF2 RNA polymeraseII, TATA box binding protein (TBP)-associated factor, 8q24.12Consensussequence Hs.122752.0 150 kDa 30 227402_s_at MGC14595hypothetical protein MGC14595 8q23.3 Consensussequence Hs.323662.031 200608_s_at RAD21 RAD21 homolog (S. pombe) 8q24 ExemplarsequenceHs.81848.0 32 218692_at FLJ20366 hypothetical protein FLJ203668q23.2 Exemplarsequence Hs.8358.0 33 204278_s_at EBAG9 estrogenreceptor binding site associated, antigen, 9 8q23 ExemplarsequenceHs.9222.0 34 218059_at LOC51123 HSPC038 protein 8q22.3Exemplarsequence Hs.23528.0 35 204068_at STK3 serine/threoninekinase 3 (STE20 homolog, yeast) 8q22.1 Exemplarsequence Hs.166684.036 213243_at KIAA0532 KIAA0532 protein 8q22.2 ConsensussequenceHs.21077.1 37 230016_at Homo sapiens cDNA FLJ13277 fis, cloneOVARC1001044. Consensussequence Hs.55043.0 38 213122_at KIAA1750KIAA1750 protein 8q22.1 Consensussequence Hs.173094.0 39201433_s_at PTDSS1 phosphatidylserine synthase 1 8q22Exemplarsequence Hs.77329.0 40 208882_s_at DD5 progestin inducedprotein 8q22 Consensussequence Hs.278428.0 41 228047_at RPL30ribosomal protein L30 8q22 Consensussequence Hs.111222.1 42225912_at TP53INP1 tumor protein p53 inducible nuclear protein 18q22 Consensussequence Hs.75497.0 43 212637_s_at WWP1 WWdomain-containing protein 1 8q21 Consensussequence Hs.324275.0 44204865_at CA3 carbonic anhydrase III, muscle specific 8q13-q22Exemplarsequence Hs.82129.0 45 235491_at RINZF zinc finger proteinRINZF 8q13-q21.1 Consensussequence Hs.194136.0 46 206584_at LY96lymphocyte antigen 96 8q13.3 Exemplarsequence Hs.69328.0 47226271_at Homo sapiens mRNA; cDNA DKFZp566A1046 (from cloneConsensussequence Hs.168950.0 DKFZp566A1046) 48 201398_s_at TRAMtranslocating chain-associating membrane protein 8q13.1Exemplarsequence Hs.4147.0 49 215605_at ConsensussequenceHs.296664.0 50 221925_s_at FLJ22490 hypothetical protein FLJ224908q12.3 Consensussequence Hs.153746.1 51 227105_at FLJ22490hypothetical protein FLJ22490 8q12.3 Consensussequence Hs.153746.152 203269_at NSMAF neutral sphingomyelinase (N-SMase) activationassociated factor 8q12-q13 Exemplarsequence Hs.78687.0 53 238017_atRDH-E2 retinal short chain dehydrogenase reductase 8q12.1Consensussequence Hs.170673.0 54 220619_at KIAA1416 KIAA1416protein 8q12.1 Exemplarsequence Hs.105461.1 55 216246_at RPS20ribosomal protein S20 8q12 Consensussequence Hs.8102.2 56 218027_atMRPL15 mitochondrial ribosomal protein L15 8q11.2-q13Exemplarsequence Hs.18349.0 57 224743_at Homo sapiens, clone IMAGE:3897094, mRNA Consensussequence Hs.13328.0 58 226483_at FLJ32370hypothetical protein FLJ32370 8q11.23 Consensussequence Hs.280858.159 212142_at MCM4 MCM4 minichromosome maintenance deficient 4 (S.cerevisiae) 8q12-q13 Consensussequence Hs.154443.0 60 219231_atNCOA6IP nuclear receptor coactivator 6 interacting protein 8q11Exemplarsequence Hs.179909.0 61 221367_at MOS v-mos Moloney murinesarcoma viral oncogene homolog 8q11 Exemplarsequence Hs.248146.0 62233101_at Homo sapiens cDNA FLJ12009 fis, clone HEMBB1001618.Consensussequence Hs.287478.0 63 227017_at LOC157697 hypotheticalprotein LOC157697 8p23.3 Consensussequence Hs.193090.0 64 242387_atINM01 hypothetical protein INM01 8p23.3 ConsensussequenceHs.289293.0 65 208647_at FDFT1 farnesyl-diphosphatefarnesyltransferase 1 8p23.1-p22 Consensussequence Hs.48876.1 66210950_s_at FDFT1 farnesyl-diphosphate farnesyltransferase 18p23.1-p22 Exemplarsequence Hs.48876.0 67 218096_at FLJ11210hypothetical protein FLJ11210 8p23.1 Exemplarsequence Hs.27842.0 68236034_at ESTs Consensussequence Hs.68301.0 69 205572_at ANGPT2angiopoietin 2 8p23.1 Exemplarsequence Hs.115181.0 70 200090_at -HG-U133A FNTA farnesyltransferase, CAAX box, alpha 8p22-q11Consensussequence Hs.138381.1 71 209471_s_at FNTAfarnesyltransferase, CAAX box, alpha 8p22-q11 ExemplarsequenceHs.138381.0 72 200090_at - HG-U133B FNTA farnesyltransferase, CAAXbox, alpha 8p22-q11 Consensussequence Hs.138381.1 73 225053_atCNOT7 CCR4-NOT transcription complex, subunit 7 8p22-p21.3Consensussequence Hs.226318.1 74 218250_s_at CNOT7 CCR4-NOTtranscription complex, subunit 7 8p22-p21.3 ExemplarsequenceHs.226318.0 75 202174_s_at PCM1 pericentriolar material 18p22-p21.3 Exemplarsequence Hs.75737.0 76 214118_x_at PCM1pericentriolar material 1 8p22-p21.3 Consensussequence Hs.75737.177 214937_x_at PCM1 pericentriolar material 1 8p22-p21.3Consensussequence Hs.75737.2 78 233019_at Homo sapiens cDNAFLJ13499 fis, clone PLACE1004681. Consensussequence Hs.287574.0 79201089_at ATP6V1B2 ATPase, H+ transporting, lysosomal 56/58 kDa, V1subunit B, 8p22-p21 Exemplarsequence Hs.1697.0 isoform 2 80225378_at FLJ32642 hypothetical protein FLJ32642 8p22Consensussequence Hs.101617.0 81 228024_at FLJ32642 hypotheticalprotein FLJ32642 8p22 Consensussequence Hs.290855.0 82 201985_atKIAA0196 KIAA0196 gene product 8p22 Exemplarsequence Hs.8294.0 83209228_x_at N33 Putative prostate cancer tumor suppressor 8p22Exemplarsequence Hs.71119.0 84 218337_at RAI16 retinoic acidinduced 16 8p21.2 Exemplarsequence Hs.299148.0 85 214054_at DOK2docking protein 2, 56 kDa 8p21.2 Consensussequence Hs.71215.0 86222199_s_at BIN3 bridging integrator 3 8p21.2 ConsensussequenceHs.68090.1 87 207000_s_at PPP3CC protein phosphatase 3 (formerly2B), catalytic subunit, gamma 8p21.2 Exemplarsequence Hs.75206.0isoform (calcineurin A gamma) 88 227263_at FLJ34715 hypotheticalprotein FLJ34715 8p21.2 Consensussequence Hs.296360.0 89 209253_atSCAM-1 vinexin beta (SH3-containing adaptor molecule-1) 8p21.2Exemplarsequence Hs.33787.1 90 32541_at PPP3CC protein phosphatase3 (formerly 2B), catalytic subunit, gamma 8p21.2 Consensussequence6 isoform (calcineurin A gamma) 91 206134_at ADAMDEC1 ADAM-like,decysin 1 8p21.1 Exemplarsequence Hs.145296.0 92 232693_s_atLOC55893 papillomavirus regulatory factor PRF-1 8p21.1Consensussequence Hs.27410.2 93 223216_x_at LOC55893 papillomavirusregulatory factor PRF-1 8p21.1 Exemplarsequence Hs.27410.1 94227075_at ELP3 likely ortholog of mouse elongation protein 3homolog (S. cerevisiae) 8p21.1 Consensussequence Hs.267905.2 95202962_at KIF13B kinesin family member 13B 8p12 ExemplarsequenceHs.15711.0 96 228427_at FBX16 F-box protein 16 8p21.1Consensussequence Hs.135191.0 97 219269_at FLJ21616 hypotheticalprotein FLJ21616 8p12 Exemplarsequence Hs.14562.0 98 236812_at ESTsConsensussequence Hs.223267.0 99 221916_at NEFL neurofilament,light polypeptide 68 kDa 8p21 Consensussequence Hs.302689.1 100207595_s_at BMP1 bone morphogenetic protein 1 8p21 ExemplarsequenceHs.1274.3 101 240168_at ESTs, Moderately similar to RAN bindingprotein 16 [Homo Consensussequence Hs.308435.0 sapiens] [H.sapiens] 102 201375_s_at PPP2CB protein phosphatase 2 (formerly2A), catalytic subunit, beta isoform 8p12-p11.2 ExemplarsequenceHs.80350.0 103 204015_s_at DUSP4 dual specificity phosphatase 48p12-p11 Exemplarsequence Hs.2359.0 104 207836_s_at RBPMS RNAbinding protein with multiple splicing 8p12-p11 ExemplarsequenceHs.80248.0 105 235472_at FUT10 fucosyltransferase 10 (alpha (1,3)fucosyltransferase) 8p11.23 Consensussequence Hs.132665.0 106221539_at EIF4EBP1 eukaryotic translation initiation factor 4Ebinding protein 1 8p12 Exemplarsequence Hs.71819.0 107 207937_x_atFGFR1 fibroblast growth factor receptor 1 (fms-related tyrosinekinase 2, 8p11.2-p11.1 Exemplarsequence Hs.748.2 Pfeiffer syndrome)108 212690_at KIAA0725 KIAA0725 protein 8p11.21 ConsensussequenceHs.26450.0 109 225318_at Homo sapiens cDNA: FLJ22049 fis, cloneHEP09444. Consensussequence Hs.28274.0 110 224413_s_at BLP1BBP-like protein 1 8p11.21 Exemplarsequence g13625460 111 225534_atLOC114926 hypothetical protein BC013035 8p11.1 ConsensussequenceHs.10018.1 112 222544_s_at WHSC1L1 Wolf-Hirschhorn syndromecandidate 1-like 1 8p11.2 Consensussequence Hs.27721.0 113209384_at PROSC proline synthetase co-transcribed homolog(bacterial) 8p11.2 Consensussequence Hs.301959.0 114 203616_at POLBpolymerase (DNA directed), beta 8p11.2 Exemplarsequence Hs.180107.0115 224076_s_at WHSC1L1 Wolf-Hirschhorn syndrome candidate 1-like 18p11.2 Exemplarsequence Hs.27721.1 116 218541_s_at C8orf4chromosome 8 open reading frame 4 8p11.2 ExemplarsequenceHs.283683.0 117 218017_s_at FLJ22242 hypothetical protein FLJ222428p11.1 Exemplarsequence Hs.288057.0 118 205528_s_at CBFA2T1core-binding factor, runt domain, alpha subunit 2; translocated to,8q22 Consensussequence Hs.31551.0 1; cyclin D-related 119 228827_atHomo sapiens clone 25023 mRNA sequence Consensussequence Hs.90858.0120 213423_x_at N33 Putative prostate cancer tumor suppressor 8p22Consensussequence Hs.71119.1 # Sequence Derived From Sequence IDSequence Source Unigene_Accession Cluster_Type LocusLinkFull_Length_Reference_Seq

1 AI197841 Hs.169615.0 GenBank Hs.169615 fulllength 65265NM_023080; hypothetical protein FLJ20989 2 W93231 Hs.285901.0GenBank Hs.285901 90987 3 NM_004519.1 g4758629 RefSeq Hs.40866fulllength 3786 NM_004519; potassium voltage-gated channel KQT-likeprotein 3 4 BC000967.2 Hs.195870.0 GenBank Hs.195870 fulllength84955 NM_032869; chronic myelogenous leukemia tumor antigen 66 5AK001693.1 Hs.273344.1 GenBank Hs.273344 fulllength 25879NM_014156; NM_015420; DKFZP564O0463 protein 6 NM_001023.1 g4506696RefSeq Hs.8102 fulllength 6224 NM_001023; ribosomal protein S20 7U73945.1 g1755147 GenBank Hs.32949 fulllength 1672 NM_005218;defensin, beta 1, preproprotein 8 NM_002445.1 g4505258 RefSeq Hs.49fulllength 4481 NM_002445; macrophage scavenger receptor 1 isoformtype 2 NM_138715; macrophage scavenger receptor 1 isoform type 1NM_138716; macrophage scavenger receptor 1 isoform type 3 9AU160632 Hs.72085.0 GenBank Hs.72085 fulllength 55246 NM_018246;hypothetical protein FLJ10853 10 AU148114 Hs.112572.0.S1 GenBankHs.112572 11 AF116660.1 g7959818_RC GenBank Hs.283683 fulllength56892 NM_020130; chromosome 8 open reading frame 4 12 NM_003416.1g4508034 RefSeq Hs.2076 fulllength 7553 NM_003416; zinc fingerprotein 7 (KOX 4, clone HF.16) 13 AF290195.1 g9964286 GenBankHs.238928 fulllength 28991 NM_014066; hypertension-relatedcalcium-regulated gene 14 NM_023080.1 g12751496 RefSeq Hs.169615fulllength 65265 NM_023080; hypothetical protein FLJ20989 15AL136937.1 g12053368 GenBank Hs.19673 fulllength 84232 NM_032272;homolog of yeast MAF1 16 NM_016208.1 g7705884 RefSeq Hs.339697fulllength 51160 NM_016208; VPS28 protein 17 NM_005526.1 g5031766RefSeq Hs.380935 fulllength 3297 NM_005526; heat shocktranscription factor 1 18 NM_001916.1 g4503184 RefSeq Hs.289271fulllength 1537 NM_001916; cytochrome c-1 19 AW168771 Hs.71574.0GenBank Hs.71574 fulllength 84948 NM_032862; tigger transposableelement derived 5 20 N21030 Hs.274401.0.S1 GenBank Hs.274401fulllength 21 AF217197.1 g6740005 GenBank Hs.74562 fulllength 22827NM_014281; fuse-binding protein-interacting repressor isoform bNM_078480; fuse-binding protein-interacting repressor isoform a 22U37012 4923232 GenBank Hs.83727 fulllength 29894 NM_013291;cleavage and polyadenylation specific factor 1, 160 kDa 23 AV720514Hs.282721.0 GenBank 24 AA147884 Hs.9812.0.A1 GenBank Hs.9812 25AF212250.1 g13182774 GenBank Hs.11810 fulllength 83940 NM_032026;CDA11 protein 26 BG288115 Hs.187646.0.A1 GenBank Hs.187646fulllength 157378 27 BE157240 Hs.193341.0_RC GenBank Hs.379094 28AF264784.1 g10644121 GenBank Hs.26102 fulllength 7227 NM_014112;zinc finger transcription factor TRPS1 29 AK001618.1 Hs.122752.0GenBank Hs.122752 fulllength 6873 NM_003184; TBP-associated factor2 30 AI056895 Hs.323662.0.A1 GenBank Hs.323662 fulllength 84294NM_032334; hypothetical protein MGC14595 31 NM_006265.1 g5453993RefSeq Hs.81848 fulllength 5885 NM_006285: RAD21 homotog 32NM_017786.1 g8923340 RefSeq Hs.8358 fulllength 55638 NM_017786;hypothetical protein FLJ20366 33 NM_004215.1 g4758229 RefSeqHs.9222 fulllength 9166 NM_004215: estrogen receptor binding siteassociated antigen 9 34 NM_016096.1 g7705516 RefSeq Hs.23528fulllength 51123 NM_016096; HSPC038 protein 35 NM_006281.1 g5454093RefSeq Hs.166684 fulllength 6788 NM_006281; serine/threonine kinase3 (STE20 homolog, yeast) 36 AI052003 Hs.21077.1.A1 GenBank Hs.2107723292 37 AU155118 Hs.55043.0.S1 GenBank Hs.55043 38 AI096375Hs.173094.0.S1 GenBank Hs.173094 fulllength 85453 NM_033512;KIAA1750 protein 39 NM_014754.1 g7662646 RefSeq Hs.77329 fulllength9791 NM_014754; phosphatidylserine synthase 1 40 U69567Hs.278428.0.A2 GenBank Hs.278428 fulllength 51366 NM_015902;progestin induced protein 41 AI815001 Hs.111222.1 GenBank Hs.334807fulllength 6156 NM_000989; ribosomal protein L30 42 AW341649Hs.75497.0.A1 GenBank Hs.75497 fulllength 94241 NM_033285; tumorprotein p53 inducible nuclear protein 1 43 BF131791 Hs.324275.0.S1GenBank Hs.355977 fulllength 11059 NM_007013; WW domain-containingprotein 1 44 NM_005181.2 g6996001 RefSeq Hs.82129 fulllength 761NM_005181; carbonic anhydrase III 45 BF056208 Hs.194136.0_RCGenBank Hs.237146 fulllength 65986 NM_023929; zinc finger proteinRINZF 46 NM_015364.1 g7662503 RefSeq Hs.69328 fulllength 23643NM_015364; MD-2 protein 47 AL110252.1 Hs.168950.0 GenBank Hs.16895048 BC000687.1 g12653796 GenBank Hs.4147 fulllength 23471 NM_014294;translocating chain-associating membrane protein 49 AU145806Hs.296664.0 GenBank 50 BE044503 Hs.153746.1.S1 GenBank Hs.153746fulllength 79848 NM_024790; hypothetical protein FLJ22490 51AI400587 Hs.153746.1.S2 GenBank Hs.153746 fulllength 79848NM_024790; hypothetical protein FLJ22490 52 NM_003580.1 g4505464RefSeq Ns.78687 fulllength 8439 NM_003580; neutral sphingomyetinase(N-SMase) activation associated factor. 53 AI440266 Hs.170673.0.A1GenBank Hs.170873 fulllength 195814 NM_138969; retinal short chaindehydrogenase reductase 54 NM_017783.1 g11034826 RefSeq Hs.10546155636 55 AF113008.1 Hs.8102.2 GenBank Hs.8102 fulllength 6224NM_001023; ribosomal protein S20 56 NM_014175.1 g7661805 RefSeqHs.18349 fulllength 29088 NM_014175; mitochondrial ribosomalprotein L15 57 BF965065 Hs.13328.0_RC GenBank Hs.416904 58 AI890761Hs.280858.1.A1 GenBank Hs.406141 fulllength 137695 NM_152417;hypothetical protein FLJ32370 59 X74794.1 Hs.154443.0 GenBankHs.154443 fulllength 4173 60 NM_024831.1 p13376235 RefSeq Hs.179909fulllength 96764 NM_024831: PRIP-interacting protein PIPMT 61NM_005372.1 g4885488 RefSeq Hs.248146 fulllength 4342 NM_005372:v-mos Moloney murine sarcoma viral oncogene homolog 62 AK022071.1Hs.287478.0 GenBank Hs.287478 63 AA767385 Hs.193090.0.A1 GenBankHs.377879 fulllength 157697 64 BF509686 Hs.289293.0 GenBankHs.289293 fulllength 157695 NM_175075; hypothetical protein INM0165 AA872727 Hs.48876.1 GenBank Hs.48876 fulllength 2222 NM_004462;farnesyl-diphosphate farnesyltransferase 1 66 BC003573.1 g13097746GenBank Hs.48876 fulllength 2222 NM_004462; farnesyl-diphosphatefarnesyltransferase 1 67 NM_018361.1 g8922941 RefSeq Hs.27842fulllength 55326 NM_018361; acid acyltransferase-epsilon 68AA083514 Hs.68301.0.A1 GenBank Hs.359201 est 69 NM_001147.1g4557314 RefSeq Hs.115181 fulllength 285 NM_001147; angiopoietin 270 BG168896 Hs.138381.1.A1 GenBenk Hs.356463 fulllength 2339NM_002027; farnesyltransferase, CAAX box, alpha 71 L00634.1 g292030GenBank Hs.356463 fulllength 2339 NM_002027; farnesyltransferase,CAAX box, alpha 72 BG168896 Hs.138381.1.A1 GenBank Hs.356463fulllength 2339 NM_002027; farnesyltransferase, CAAX box, alpha 73W94952 Hs.226318.1.A2 GenBank Hs.380963 fulllength 29883 NM_013354:CCR4-NOT transcription complex, subunit 7 isoform 1 NM_054026;CCR4-NOT transcription complex, subunit 7 isoform 2 74 NM_013354.2g10518495 RefSeq Hs.380963 fulllength 29883 NM_013354: CCR4-NOTtranscription complex, subunit 7 isoform 1 NM_054026: CCR4-NOTtranscription complex, subunit 7 isoform 2 75 NM_006197.1 g5453855RefSeq Hs.75737 fulllength 5108 NM_006197; pericentriolar material1 76 AI205598 Hs.75737.1.S1 GenBank Ns.75737 fulllength 5108NM_006197; pericentriolar material 1 77 AI924817 Hs.75737.2.S1GenBank Hs.75737 fulllength 5108 NM_006197; pericentriolar material1 78 AU145061 Hs.287574.0.S1 GenBank Hs.287574 79 NM_001693.1g4502310 RefSeq Hs.1697 fulllength 526 NM_001693; ATPase, H+transporting, lysosomal 56/58 kD, V1 subunit B, isoform 2 80AI866426 Hs.101617.0_RC GenBank Hs.101617 fulllength 137492NM_152415; hypothetical protein FLJ32642 81 AW028100 Hs.290855.0GenBank Hs.101617 fulllength 137492 NM_152415; hypothetical proteinFLJ32642 82 NM_014846.1 p7661987 RefSeq Hs.8294 fulllength 9897NM_014846; KIAA0196 gene product 83 U42349.1 p1353672 GenBankHs.71119 fulllength 7991 NM_006765; Putative prostate cancer tumorsuppressor isoform a NM_178234: Putative prostate cancer tumorsuppressor isoform b 84 NM_022749.1 g12232410 RefSeq Hs.299148fulllength 64760 NM_022749: retinoic acid induced 16 85 AI828929Hs.71215.0 GenBank Hs.71215 fulllength 9046 NM_003974: dockingprotein 2, 56 kD 86 AK001289.1 Ns.68090.1.S1 GenBank Hs.68090fulllength 55909 NM_018688; bridging integrator 3 87 NM_005605.1g5031988 RefSeq Hs.75206 fulllength 5533 NM_005605; proteinphosphatase 3 (formerly 2B), catalytic subunit. gamma isoform(calcineurin A gamma) 88 AL519427 Hs.296360.0.S1 GenBank Hs.375560fulllength 286057 NM_173686; hypothetical protein FLJ34715 89AF037261.1 g3004947 GenBank Hs.33787 fulllength 10174 NM_005775;vinexin bela (SH3-containing adaptor molecule-1) 90 S46622 4922761GenBank Hs.75208 fulllength 5533 NM_005605; protein phosphatase 3(formerly 2B), catalytic subunit, gamma isoform (calcineurin Agamma) 91 NM_014479.1 g7657318 RefSeq Ns.145296 fulllength 27299NM_014479; disintegrin protease 92 AK021850.1 Hs.27410.2.S1 GenBankHs.27410 fulllength 55893 NM_018660; papillomavirus regulatoryfactor PRF-1 93 BC001237.1 g12654788 GenBank Hs.27410 fulllength55893 NM_018660; papillomavirus regulatory factor PRF-1 94 AI949204Hs.267905.2_RC GenBank Hs.267905 fulllength 55140 NM_018091;elongation protein 3 homolog 95 NM_015254.1 g13194196 RefSeqHs.15711 fulllength 23303 NM_015254; kinesin family member 13B 96BF196856 Hs.135191.0.A1 GenBank Hs.438933 fulllength 157574NM_172366; F-box only protein 16 97 NM_024567.1 g13375737 RefSeqHs.23590 fulllength 79618 NM_024567; hypothetical protein FLJ2161698 AI638208 Hs.223267.0.A1 GenBank Hs.201058 est 99 BF055311Hs.302689.1.S1 GenBank Hs.211584 fulllength 4747 NM_006158:neurofilament, light polypeptide 68 kDa 100 NM_006132.1 g5902814RefSeq Hs.1274 fulllength 649 NM_001199; bone morphogenetic protein1 isoform 1, precursor NM_006128; bone morphogenetic protein 1isoform 2, precursor NM_006129; bone morphogenetic protein 1isoform 3, precursor NM_006130; bone morphogenetic protein 1isoform 6, precursor NM_006131; bone morphogenetic protein 1isoform 5, precursor NM_006132; bone morphogenetic protein 1isoform 4, precursor 101 AA679589 Hs.308435.0.A1 GenBank Hs.308435est 102 NM_004156.1 g4758951 RefSeq Hs.80350 fulllength 5516NM_004156; protein phosphatase 2 (formerly 2A), catalytic subunit,beta isoform 103 BC002671.1 g12803670 GenBank Hs.2359 fulllength1846 NM_001394; dual specificity phosphatase 4 isoform 1 NM_057158;dual specificity phosphatase 4 isoform 2 104 NM_006867.1 g5803140RefSeq Hs.80248 fulllength 11030 NM_006867; RNA-binding proteinwith multiple splicing 105 AI147738 Hs.132665.0.A1 GenBankHs.326744 fulllength 84750 NM_032664; fucosyltransferase 10 106AB044548.1 g11527778 GenBank Hs.433317 fulllength 1978 NM_004095;eukaryotic translation initiation factor 4E binding protein 1 107NM_023110.1 g13186246 RefSeq Hs.748 fulllength 2260 NM_000604;fibroblast growth factor receptor 1 isoform 1 precursor NM_015850;fibroblast growth factor receptor 1 isoform 2 precursor NM_023105;fibroblast growth factor receptor 1 isoforrn 3 precursor NM_023106;fibroblast growth factor receptor 1 isoform 4 precursor NM_023107;fibroblast growth factor receptor 1 isoform 5 precursor NM_023108;fibroblast growth factor receptor 1 isoform 6 precursor NM_023109;fibroblast growth factor receptor 1 isoform 7 precursor NM_023110;fibroblast growth factor receptor 1 isoform 8 precursor NM_023111;fibroblast growth factor receptor 1 isoform 9 precursor 108AB018268.1 Hs.26450.0_RC GenBank Hs.26450 fulllength 23259 109AW292751 Hs.28274.0 GenBank Hs.423737 110 AF353991.1 g13625460GenBank Hs.7471 fulllength 83877 NM_031940; BBP-like protein 1isoform b NM_078473; BBP-like protein 1 isoform a 111 AV711345Hs.10018.1.A1 GenBank Hs.10018 fulllength 114926 NM_138436;hypothetical protein BC013035 112 AI697751 Hs.27721.0_RC GenBankHs.27721 fulllength 54904 NM_017778; WHSC1L1 protein isoform shortNM_023034; WHSC1L1 protein isoform long 113 AA176833 Hs.301959.0.A2GenBank Hs.301959 fulllength 11212 NM_007198; proline synthetaseco-transcribed homolog 114 NM_002690.1 g4505930 RefSeq Hs.180107fulllength 5423 NM_002690; polymerase (DNA directed), beta 115AF255649.1 g12005822 GenBenk Hs.27721 fulllength 54904 NM_017778;WHSC1L1 protein isoform short NM_023034; WHSC1L1 protein isoformlong 116 NM_020130.1 g9910147 RefSeq Hs.283683 fulllength 56892NM_020130; chromosome 8 open reading frame 4 117 NM_025070.1g13376612 RefSeq Hs.288057 fulllength 80140 NM_025070; hypotheticalprotein FLJ22242 118 X79990.1 Hs.31551.0 GenBank Hs.31551fulllength 862 NM_004349; acute myelogenous leukemia 1translocation 1 protein isoform MTG8a NM_175634; acute myelogenousleukemia 1 translocation 1 protein isoform MTG8b NM_175635; acutemyelogenous leukemia 1 translocation 1 protein isoform MTG8cNM_175636; acute myelogenous leukemia 1 translocation 1 proteinisoform MTG8c 119 AI217416 Hs.90858.0.S1 GenBank Hs.90858 120AI884858 Hs.71119.1_RC GenBank Hs.71119 fulllength 7991 NM_006765;Putative prostate cancer tumor suppressor isoform a NM_178234;Putative prostate cancer tumor suppressor isoform b

TABLE-US-00036 TABLE 35 MDS_AML_Blasten # affy id HUGO name p q rTitle MapLocation Sequence Type Transcript ID Sequence Derived From1 201061_s_at STOM 0.00e+00 0.00e+00 -0.76 stomatin 9q34.1Exemplarsequence Hs.160483.0 M81635.1 2 211883_x_at CEACAM10.00e+00 0.00e+00 -0.75 carcinoembryonic antigen-related cell19q13.2 Exemplarsequence Hs.50964.4 M76742.1 adhesion molecule 1(biliary glycoprotein) 3 202018_s_at LTF 0.00e+00 0.00e+00 -0.74lactotransferrin 3q21-q23 Exemplarsequence Hs.105938.0 NM_002343.14 206676_at CEACAM8 0.00e+00 0.00e+00 -0.74 carcinoembryonicantigen-related cell 19q13.2 Exemplarsequence Hs.41.0 M33326.1adhesion molecule 8 5 206177_s_at ARG1 0.00e+00 0.00e+00 -0.74arginasa, liver 6q23 Exemplarsequence Hs.289057.0 NM_000045.2 6211657_at CEACAM6 0.00e+00 0.00e+00 -0.73 carcinoembryonicantigen-related cell 19q13.2 Exemplarsequence g189084 M18728.1adhesion molecule 6 (non-specific cross reacting antigen) 7209369_at ANXA3 0.00e+00 0.00e+00 -0.73 annexin A3 4q13-q22Exemplarsequence Hs.1378.0 M63310.1 8 207802_at SGP28 0.00e+000.00e+00 -0.73 specific granule protein (28 kDa) 6p12.3Exemplarsequence Hs.54431.0 NM_006061.1 9 201060_x_at STOM 0.00e+000.00e+00 -0.73 stomatin 9q34.1 Consensussequence Hs.160463.0AI537887 10 212531_at LCN2 0.00e+00 0.00e+00 -0.72 lipocalin 2(oncogene 24p3) 9q34 Consensussequence Hs.204238.0 NM_005564.1 11209498_at CEACAM1 0.00e+00 0.00e+00 -0.72 carcinoembryonicantigen-related cell 19q13.2 Consensussequence Hs.50964.3 X16354.1adhesion molecule 1 (biliary glycoprotein) 12 204351_at S100P0.00e+00 0.00e+00 -0.72 S100 calcium binding protein P 4p16Exemplarsequence Hs.2962.0 NM_005980.1 13 232027_at SYNE1 0.00e+000.00e+00 -0.72 spectrin repeat containing, nuclear 6q25Consensussequence Hs.241420.0 AL049548 envelope 1 14 226726_atLOC129642 0.00e+00 0.00e+00 -0.71 hypothetical protein BC0160052p25.2 Consensussequence Hs.15641.0 W63676 15 203757_s_at CEACAM60.00e+00 0.00e+00 -0.71 carcinoembryonic antigen-related cell19q13.2 Exemplarsequence Hs.73848.0 BC005008.1 adhasion molecule 6(non-specific cross reacting antigen) 16 203936_s_at MMP9 0.00e+000.00e+00 -0.71 matrix metalloproteinase 9 (gelatinase B,20q11.2-q13.1 Exemplarsequence Hs.151738.0 NM_004994.1 92 kDagelatinase, 92 kDa type IV collagenase) 17 210244_at CAMP 0.00e+000.00e+00 -0.71 cathelicidin antimicrobial peptide 3p21.3Exemplarsequence Hs.51120.0 U19970.1 18 208650_s_at CD24 0.00e+000.00e+00 -0.71 CD24 antigen (small cell lung carcinoma 6q21Consensussequence Hs.286124.1 BG327863 cluster 4 antigen) 19206515_at CYP4F3 0.00e+00 0.00e+00 -0.71 cytochrome P450, family 4,subfamily F, 19p13.2 Exemplarsequence Hs.106242.0 NM_000896.1polypeptide 3 20 213836_s_at FLJ10055 0.00e+00 0.00e+00 -0.71hypothetical protein FLJ10055 17q24.3 Consensussequence Hs.279937.1AW052084 21 266_s_at CD24 0.00e+00 0.00e+00 -0.70 CD24 antigen(small cell lung carcinoma 6q21 Exemplarsequence L33930 L33930cluster 4 antigen) 22 209771_x_at CD24 0.00e+00 0.00e+00 -0.70 CD24antigen (small cell lung carcinoma 6q21 ConsensussequenceHs.286124.0 AA761181 cluster 4 antigen) 23 211889_x_at CEACAM10.00e+00 0.00e+00 -0.70 carcinoembryonic antigen-related cell19q13.2 Exemplarsequence Hs.50964.5 D12502.1 adhesion molecule 1(biliary glycoprotein) 24 206674_at FLT3 0.00e+00 0.00e+00 0.70fms-related tyrosine kinase 3 13q12 Exemplarsequence Hs.385.0NM_004119.1 25 207384_at PGLYRP 0.00e+00 0.00e+00 -0.70peptidoglycan recognition protein 19q13.2-q13.3 ExemplarsequenceHs.137583.0 NM_005091.1 26 226188_at HSPC159 0.00e+00 0.00e+00-0.69 HSPC159 protein 2p13.3 Consensussequence Hs.7149.0 AK025603.127 216379_x_at KIAA1919 0.00e+00 0.00e+00 -0.69 KIAA1919 protein6q22 Consensussequence Hs.332045.0 AK000168.1 28 210638_s_at FBXO90.00e+00 0.00e+00 -0.69 F-box only protein 9 6p12.3-p11.2Exemplarsequence Hs.11050.1 AF176704.1 29 207072_at IL18RAP0.00e+00 0.00e+00 -0.69 interleukin 18 receptor accessory protein2p24.3-p24.1 Exemplarsequence Hs.158315.0 NM_003853.1 30205389_s_at ANK1 0.00e+00 0.00e+00 -0.69 ankyrin 1, erythrocytic8p11.1 Consensussequence Hs.183805.0 AI659683 31 202197_at MTMR30.00e+00 0.00e+00 -0.69 myotubularin related protein 3 22q12.2Exemplarsequence Hs.63302.0 NM_021090.1 32 207674_at FCAR 0.00e+000.00e+00 -0.69 Fc fragment of IgA, receptor for 19q13.2-q13.4Exemplarsequence Hs.193122.0 NM_002000.1 33 203765_at GCA 0.00e+000.00e+00 -0.68 grancalcin, EF-hand calcium binding 2q24.3Exemplarsequence Hs.79381.0 NM_012198.1 protein 34 223423_at GPCR10.00e+00 0.00e+00 -0.68 putative G protein-coupled receptor3q26.2-q27 Exemplarsequence Hs.97101.0 BC000181.2 35 207992_s_atAMPD3 0.00e+00 0.00e+00 -0.68 adenosine monophosphate deaminase11p15 Exemplarsequence Hs.83918.0 NM_000480.1 (isoform E) 36224828_at KIAA1673 0.00e+00 0.00e+00 -0.68 KIAA1673 5q21Consensussequence Hs.301444.0 AA772278 37 208651_x_at CD24 0.00e+000.00e+00 -0.68 CD24 antigen (small cell lung carcinoma 6q21Exemplarsequence Hs.286124.1 M58664.1 cluster 4 antigen) 38207459_x_at GYPB 0.00e+00 0.00e+00 -0.68 glycophorin B (includes Ssblood group) 4q28-q31 Exemplarsequence Hs.250653.0 NM_002100.2 39221765_at UGCG 0.00e+00 0.00e+00 -0.68 UDP-glucose ceramide 9q31Consensussequence Hs.23703.0 BF970427 glucosyltransferase 40212987_at FBXO9 0.00e+00 0.00e+00 -0.68 F-box only protein 96p12.3-p11.2 Consensussequence Hs.11050.3 AL137520.1 41 205442_atKIAA0626 0.00e+00 0.00e+00 -0.68 KIAA0626 gene product 4q32.3Exemplarsequence Hs.178121.0 NM_021647.1 42 220404_at 0.00e+000.00e+00 -0.68 ESTs Exemplarsequence Hs.163833.0 NM_014076.1 43207087_x_at ANK1 0.00e+00 0.00e+00 -0.67 ankyrin 1, erythrocytic8p11.1 Exemplarsequence Hs.183805.1 NM_020478.1 44 228361_at0.00e+00 0.00e+00 -0.67 Homo sapiens, Similar to hypotheticalConsensussequence Hs.49047.0 AL561296 protein PRO1722, clone MGC:15692 IMAGE: 3351479, mRNA, complete cds 45 224967_at UGCG 0.00e+000.00e+00 -0.67 UDP-glucose ceramide 9q31 ConsensussequenceHs.23703.0 W72338 glucosyltransferase 46 221778_at KIAA17180.00e+00 0.00e+00 -0.67 KIAA1718 protein 7q33-q35 ConsensussequenceHs.222707.0 BE217882 47 208353_x_at ANK1 0.00e+00 0.00e+00 -0.67ankyrin 1, erythrocytic 8p11.1 Exemplarsequence Hs.183805.6NM_020480.1 48 205391_x_at ANK1 0.00e+00 0.00e+00 -0.67 ankyrin 1,erythrocytic 8p11.1 Exemplarsequence Hs.183805.0 M28880.1 49209760_at KIAA0922 0.00e+00 0.00e+00 -0.67 KIAA0922 protein 4q31.3Exemplarsequence Hs.37892.0 AL136932.1 50 216833_x_at GYPB 0.00e+000.00e+00 -0.67 glycophorin B (includes Ss blood group) 4q28-q31Consensussequence Hs.307185.0 U05255.1 51 207269_at DEFA4 0.00e+000.00e+00 -0.67 defensin, alpha 4, corticostatin 8p23Exemplarsequence Hs.2582.0 NM_001925.1 52 231688_at 0.00e+000.00e+00 -0.67 ESTs Consensussequence Hs.255877.0 AW337833 53205557_at BPI 0.00e+00 0.00e+00 -0.67bactericidal/permeability-increasing protein 20q11.23-q12Exemplarsequence Hs.89535.0 NM_001725.1 54 209772_s_at CD240.00e+00 0.00e+00 -0.66 CD24 antigen (small cell lung carcinoma6q21 Exemplarsequence Hs.286124.0 X69397.1 cluster 4 antigen) 55204881_s_at UGCG 0.00e+00 0.00e+00 -0.66 UDP-glucose ceramide 9q31Exemplarsequence Hs.152601.0 NM_003358.1 glucosyltransferase 56239205_s_at CR1L 0.00e+00 0.00e+00 -0.66 complement component(3b/4b) receptor 1- 1q32.1 Consensussequence Hs.89688.0 BE552138like 57 221748_s_at 0.00e+00 0.00e+00 -0.66 Homo sapiens cDNAFLJ32766 fis, clone Consensussequence Hs.9973.1 AL046979TESTI2001862. 58 206302_s_at NUDT4 0.00e+00 0.00e+00 -0.66 nudix(nucleoside diphosphate linked Exemplarsequence Hs.92381.0NM_019094.1 moiety X)-type motif 4 59 206283_s_at TAL1 0.00e+000.00e+00 -0.66 T-cell acute lymphocytic leukemia 1 1p32Exemplarsequence Hs.73828.0 NM_003189.1 60 200998_s_at CKAP40.00e+00 0.00e+00 -0.66 cytoskeleton-associated protein 4 12q24.11Consensussequence Hs.74368.0 AW029619 61 37986_at EPOR 0.00e+000.00e+00 -0.66 erythropoietin receptor 19p13.3-p13.2Consensussequence 4876922_rc M60459 62 211207_s_at FACL6 0.00e+000.00e+00 -0.66 fatty-acid-Coenzyme A ligase, long-chain 6 5q31Exemplarsequence Hs.14945.0 AF129166.1 63 211820_x_at GYPA 0.00e+000.00e+00 -0.66 glycophorin A (includes MN blood group) 4q28.2-q31.1Exemplarsequence Hs.108694.2 U00179.1 64 218853_s_at DJ473B40.00e+00 0.00e+00 -0.66 hypothetical protein dJ473B4 Xq26.3Exemplarsequence Hs.57549.0 NM_019556.1 65 209396_s_at CHI3L10.00e+00 0.00e+00 -0.66 chitinase 3-like 1 (cartilage glycoprotein-1q32.1 Exemplarsequence Hs.75184.0 M80927.1 39) 66 205513_at TCN10.00e+00 0.00e+00 -0.66 transcobalamin I (vitamin B12 binding11q11-q12 Exemplarsequence Hs.2012.0 NM_001062.1 protein, R binderfamily) 67 205592_at SLC4A1 0.00e+00 0.00e+00 -0.66 solute carrierfamily 4, anion exchanger, 17q21-q22 Consensussequence Hs.185923.0X77737.1 member 1 (erythrocyte membrane protein band 3, Diego bloodgroup) 68 236081_at 0.00e+00 0.00e+00 -0.66 ESTs ConsensussequenceHs.21374.0 AI929792 69 223894_s_at FTS 0.00e+00 0.00e+00 -0.66fused toes homolog (mouse) 16q12.1 Exemplarsequence Hs.288929.1BC001134.1 70 229889_at MGC40157 0.00e+00 0.00e+00 -0.65hypothetical protein MGC40157 17p11.2 Consensussequence Hs.295362.1AW137009 71 209212_s_at KLF5 0.00e+00 0.00e+00 -0.65 Kruppel-likefactor 5 (intestinal) 13q21.32 Exemplarsequence Hs.84728.0AB030824.1 72 239206_at CR1L 0.00e+00 0.00e+00 -0.65 complementcomponent (3b/4b) receptor 1- 1q32.1 Consensussequence Hs.89688.0BE552138 like 73 210004_at OLR1 0.00e+00 0.00e+00 -0.65 oxidisedlow density lipoprotein (lectin-like) 12p13.2-p12.3Exemplarsequence Hs.77729.0 AF035776.1 receptor 1 74 208352_x_atANK1 0.00e+00 0.00e+00 -0.65 ankyrin 1, erythrocytic 8p11.1Exemplarsequence Hs.183805.5 NM_020479.1 75 211821_x_at GYPA0.00e+00 0.00e+00 -0.65 glycophorin A (includes MN blood group)4q28.2-q31.1 Exemplarsequence Hs.108694.1 U00178.1 76 214407_x_atGYPB 0.00e+00 0.00e+00 -0.65 glycophorin B (includes Ss bloodgroup) 4q28-q31 Consensussequence Hs.250653.1 AI240545 77 214523_atCEBPE 0.00e+00 0.00e+00 -0.65 CCAAT/enhancer binding protein(C/EBP), 14q11.2 Consensussequence Hs.158323.0 NM_001805.1 epsilon78 226179_at 0.00e+00 0.00e+00 -0.65 Homo sapiens, clone IMAGE:5294823, Consensussequence Hs.34549.0 N63920 mRNA 79 203827_atFLJ10055 0.00e+00 0.00e+00 -0.65 hypothetical protein FLJ1005517q24.3 Exemplarsequence Hs.9398.0 NM_017983.1 80 208942_s_at TLOC10.00e+00 0.00e+00 -0.65 translocation protein 1 3q26.2-q27Consensussequence Hs.8146.0 BE866511 81 203845_at PCAF 0.00e+000.00e+00 -0.65 p300/CBP-associated factor 3p24 ConsensussequenceHs.199061.0 AV727449 82 209395_at CHI3L1 0.00e+00 0.00e+00 -0.65chitinase 3-like 1 (cartilage glycoprotein- 1q32.1 ExemplarsequenceHs.75184.0 M80927.1 39) 83 205837_s_at GYPA 0.00e+00 0.00e+00 -0.65glycophorin A (includes MN blood group) 4q28.2-q31.1Exemplarsequence Hs.108694.0 BC005319.1 84 216925_s_at TAL10.00e+00 0.00e+00 -0.65 T-cell acute lymphocytic leukemia 1 1p32Consensussequence Hs.73828.1 X51990.1 85 207329_at MMP8 0.00e+000.00e+00 -0.65 matrix metalloproteinase 8 (neutrophil 11q22.3Exemplarsequence Hs.73862.0 NM_002424.1 collagenase) 86 228376_ata1/3GTP 0.00e+00 0.00e+00 -0.65 alpha-1,3-galactosyltransferase9q33.3 Consensussequence Hs.97469.0 AI972498 pseudogene 87234980_at FLJ31842 0.00e+00 0.00e+00 -0.65 hypothetical proteinFLJ31842 1p21.3 Consensussequence Hs.84522.0 AI004375 88 221485_atB4GALT5 0.00e+00 0.00e+00 -0.65 UDP-Gal:betaGlcNAc beta 1,4-20q13.1-q13.2 Consensussequence Hs.107526.0 NM_004776.1galactosyltransferase, polypeptide 5 89 229610_at FLJ40629 0.00e+000.00e+00 -0.65 hypothetical protein FLJ40629 2q13 ConsensussequenceHs.99807.0 AW088063 90 220807_at HBQ1 0.00e+00 0.00e+00 -0.65hemoglobin, theta 1 16p13.3 Exemplarsequence Hs.247921.0NM_005331.2 91 210854_x_at SLC6A8 0.00e+00 0.00e+00 -0.65 solutecarrier family 6 (neurotransmitter Xq28 ExemplarsequenceHs.187958.1 U17986.1 transporter, creatine), member 8 92210746_s_at EPB42 0.00e+00 0.00e+00 -0.65 erythrocyte membraneprotein band 4.2 15q15-q21 Exemplarsequence Hs.733.1 M30646.1 93216054_x_at MYL4 0.00e+00 0.00e+00 -0.65 myosin, light polypeptide4, alkali; atrial, 17q21-qter Consensussequence Hs.298161.3 X58851embryonic 94 210395_x_at MYL4 0.00e+00 0.00e+00 -0.64 myosin, lightpolypeptide 4, alkali; atrial, 17q21-qter ConsensussequenceHs.298161.0 AF116676.1 embryonic 95 201362_at NS1-BP 0.00e+000.00e+00 -0.64 NS1-binding protein 1q25.1-q31.1 ExemplarsequenceHs.197298.0 AF205218.1 96 204467_s_at SNCA 0.00e+00 0.00e+00 -0.64synuclein, alpha (non A4 component of 4q21 EaemplarsequenceHs.76930.1 NM_000345.2 amyloid precursor) 97 206522_at MGAM0.00e+00 0.00e+00 -0.64 maltase-glucoamylase (alpha-glucosidase)7q34 Exemplarsequence Hs.122785.0 NM_004668.1 98 213805_at CGI-580.00e+00 0.00e+00 -0.64 CGI-58 protein 3p25.3-p24.3Consensussequence Hs.184019.1 AI692428 99 227309_at 0.00e+000.00e+00 -0.64 ESTs Consensussequence Hs.8688.0

AI982535 ## 219672_at ERAF 0.00e+00 0.00e+00 -0.64 erythroidassociated factor 16p11.2 Exemplarsequence Hs.274309.0 NM_016633.1# Sequence ID Sequence Source Unigene_Accession Cluster_TypeLocusLink Full_Length_Reference_Seq 1 g181183 GenBank Hs.160483fulllength 2040 NM_004099; stomatin 2 g179480 GenBank Hs.50964fulllength 634 NM_001712; carcinoembryonic antigen-related celladhesion molecule 1 (biliary glycoprotein) 3 g4505042 RefSeqHs.105938 fulllength 4057 NM_002343; lactotransferrin 4 g189101GenBank Hs.41 fulllength 1088 NM_001816; carcinoembryonicantigen-related cell adhesion molecule 8 5 g10947138 RefSeqHs.332405 fulllength 383 NM_000045; arginase, type I 6 g189084GenBank Hs.73848 fulllength 4680 NM_002483; carcinoembryonicantigen-related cell adhesion molecule 6 (non-specific crossreacting antigen) 7 g178696 GenBank Hs.1378 fulllength 306NM_005139; annexin A3 8 g5174674 RefSeq Hs.54431 fulllength 10321NM_006061; specific granule protein (28 kDa) 9 Hs.160483.0 GenBankHs.160483 fulllength 2040 NM_004099; stomatin 10 Hs.204238.0.S1GenBank Hs.204238 fulllength 3934 NM_005564; lipocalin 2 (oncogene24p3) 11 Hs.50964.3 GenBank Hs.50964 fulllength 634 NM_001712;carcinoembryonic antigen-related cell adhesion molecule 1 (biliaryglycoprotein) 12 g5174662 RefSeq Hs.2962 fulllength 6286 NM_005980;S100 calcium binding protein P 13 Hs.241420.0.S1 GenBank Hs.192102fulllength 23345 NM_015293; nesprin 1 isoform beta NM_033071;nesprin 1 isoform longest NM_133650; nesprin 1 isoform alpha 14Hs.15641.0.A1 GenBank Hs.356547 fulllength 129642 NM_138799;hypothetical protein BC016005 15 g13477106 GenBank Hs.73848fulllength 4680 NM_002483; carcinoembryonic antigen-related celladhesion molecule 6 (non-specific cross reacting antigen) 16g4826835 RefSeq Hs.151738 fulllength 4318 NM_004994; matrixmetalloproteinase 9 preproprotein 17 g643476 GenBank Hs.51120fulllength 820 NM_004345; cathelicidin antimicrobial peptide 18Hs.286124.1_RC GenBank Hs.375108 fulllength 934 NM_013230; CD24antigen (small cell lung carcinoma cluster 4 antigen) 19 24503240RefSeq Hs.106242 fulllength 4051 NM_000896; cytochrome P450, family4, subfamily F, polypeptide 3 20 Hs.279937.1_RC GenBank Hs.9398fulllength 55062 NM_014960; KIAA1001 protein NM_017983;hypothetical protein FLJ10055 21 L33930 GenBank Hs.375108fulllength 934 NM_013230; CD24 antigen (small cell lung carcinomacluster 4 antigen) 22 Hs.286124.0_RC GenBank Hs.375108 fulllength934 NM_013230; CD24 antigen (small cell lung carcinoma cluster 4antigen) 23 g219494 GenBank Hs.50964 fulllength 634 NM_001712;carcinoembryonic antigen-related cell adhesion molecule 1 (biliaryglycoprotein) 24 g4758395 RefSeq Hs.385 fulllength 2322 NM_004119;fms-related tyrosine kinase 3 25 g4827035 RefSeq Hs.137583fulllength 8993 NM_005091; peptidoglycan recognition protein 26Hs.7149.0 GenBank Hs.372208 fulllength 29094 NM_014181; HSPC159protein 27 Hs.332045.0_RC GenBank Hs.400572 fulllength 91749NM_153369; KIAA1919 protein 28 g6103646 GenBank Hs.11050 fulllength26268 NM_012347; F-box only protein 9 isoform 1 NM_033480; F-boxonly protein 9 isoform 2 NM_033481; F-box only protein 9 isoform 329 g4504656 RefSeq Hs.158315 fulllength 8807 NM_003853; Interleukin18 receptor accessory protein precursor 30 Hs.183805.0.A2 GenBankHs.183805 fulllength 286 NM_000037; ankyrin 1 isoform 3 NM_020475;ankyrin 1 isoform 4 NM_020476; ankyrin 1 isoform 1 NM_020477;ankyrin 1 isoform 2 NM_020478; ankyrin 1 isoform 5 NM_020479;ankyrin 1 isoform 6 NM_020480; ankyrin 1 isoform 7 NM_020481;ankyrin 1 isoform 8 31 g10835108 RefSeq Hs.63302 fulllength 8897NM_021090; myotubularin-related protein 3 isoform c NM_153050;myotubularin-related protein 3 isoform a NM_153051;myolubularin-related protein 3 isoform b 32 g4503672 RefSeqHs.193122 fulllength 2204 NM_002000; Fc alpha receptor isoform aprecursor NM_133269; Fc alpha receptor isoform b precursorNM_133271; Fc alpha receptor isoform c precursor NM_133272; Fcalpha receptor isoform d NM_133273; Fc alpha receptor isoform eNM_133274; Fc alpha receptor isoform f NM_133277; Fc alpha receptorisoform g NM_133278; Fc alpha receptor isoform h NM_133279; Fcalpha receptor isoform i precursor NM_133280; Fc alpha receptorisoform j 33 g6912387 RefSeq Hs.79381 fulllength 25801 NM_012198;grancalcin, EF-hand calcium binding protein 34 g13111815 GenBankHs.97101 fulllength 26996 NM_014373; putative G protein-coupledreceptor 35 g4502078 RefSeq Hs.83918 fulllength 272 NM_000480;adenosine monophosphate deaminase (isoform E) 36 Hs.301444.0.A1GenBank Hs.301444 fulllength 80315 37 g180167 GenBank Hs.375108fulllength 934 NM_013230; CD24 antigen (small cell lung carcinomacluster 4 antigen) 38 g8051603 RefSeq Hs.372513 fulllength 2994NM_002100; glycophorin B precursor 39 Hs.23703.0_RC GenBankHs.432605 fulllength 7357 NM_003358; ceramide glucosyltransferase40 Hs.11050.3_RC GenBank Hs.11050 fulllength 26268 NM_012347; F-boxonly protein 9 isoform 1 NM_033480; F-box only protein 9 isoform 2NM_033481; F-box only protein 9 isoform 3 41 g11067364 RefSeqHs.178121 fulllength 9848 NM_021647; KIAA0626 gene product 42g7662571 RefSeq Hs.383403 est 43 g10947043 RefSeq Hs.183805fulllength 286 NM_000037; ankyrin 1 isoform 3 NM_020475; ankyrin 1isoform 4 NM_020476; ankyrin 1 isoform 1 NM_020477; ankyrin 1isoform 2 NM_020478; ankyrin 1 isoform 5 NM_020479; ankyrin 1isoform 6 NM_020480; ankyrin 1 isoform 7 NM_020481; ankyrin 1isoform 8 44 Hs.49047.0.A1 GenBank Hs.231444 fulllength 45Hs.23703.0.A2 GenBank Hs.432605 fulllength 7357 NM_003358; ceramideglucosyltransferase 46 Hs.222707.0.A2 GenBank Hs.222707 80853 47g10947047 RefSeq Hs.183805 fulllength 286 NM_000037; ankyrin 1isoform 3 NM_020475; ankyrin 1 isoform 4 NM_020476; ankyrin 1isoform 1 NM_020477; ankyrin 1 isoform 2 NM_020478; ankyrin 1isoform 5 NM_020479; ankyrin 1 isoform 6 NM_020480; ankyrin 1isoform 7 NM_020481; ankyrin 1 isoform 8 48 g178645 GenBankHs.183805 fulllength 286 NM_000037; ankyrin 1 isoform 3 NM_020475;ankyrin 1 isoform 4 NM_020476; ankyrin 1 isoform 1 NM_020477;ankyrin 1 isoform 2 NM_020478; ankyrin 1 isoform 5 NM_020479;ankyrin 1 isoform 6 NM_020480; ankyrin 1 isoform 7 NM_020481;ankyrin 1 isoform 8 49 g12053358 GenBank Hs.37892 fulllength 23240NM_015196; KIAA0922 protein 50 Hs.307185.0 GenBank Hs.372513fulllength 2994 NM_002100; glycophorin B precursor 51 g4503302RefSeq Hs.2582 fulllength 1669 NM_001925; defensin, alpha 4,preproprotein 52 Hs.255877.0.A1 GenBank Hs.255877 est 53 g4502446RefSeq Hs.89535 fulllength 671 NM_001725;bactericidal/permeability-increasing protein precursor 54 g396167GenBank Hs.375108 fulllength 934 NM_013230; CD24 antigen (smallcell lung carcinoma cluster 4 antigen) 55 g4507810 RefSeq Hs.432605fulllength 7357 NM_003358; ceramide glucosyltransferase 56Hs.89688.0_RC GenBank Hs.89688 1379 57 Hs.9973.1.A1 GenBank Hs.997358 g10800135 RefSeq Hs.355399 fulllength 11163 NM_019094; nudix(nucleoside diphosphate linked moiety X)-type motif 4 59 g4507362RefSeq Hs.73828 fulllength 6886 NM_003189; T-cell acute lymphocyticleukemia 1 60 Hs.74368.0.A1 GenBank Hs.74368 fulllength 10970NM_006825; transmembrane protein (63 kD), endoplasmicreticulum/Golgi interm 61 4876922_rc GenBank Hs.127826 fulllength2057 NM_000121; erythropoietin receptor precursor 62 g5702201GenBank Hs.14945 fulllength 23305 NM_015256; fatty-acid-Coenzyme Aligase, long-chain 6 63 g392432 GenBank Hs.108694 fulllength 2993NM_002099; glycophorin A precursor 64 g9506542 RefSeq Hs.57549fulllength 56180 NM_019556; hypothetical protein dJ473B4 65 g348911GenBank Hs.75184 fulllength 1116 NM_001276; chitinase 3-like 1 66g4507406 RefSeq Hs.2012 fulllength 6947 NM_001062; transcobalamin Iprecursor 67 Hs.185923.0 GenBank Hs.185923 fulllength 6521NM_000342; solute carrier family 4, anion exchanger, member 1(erythrocyte membrane protein band 3, Diego blood group) 68Hs.21374.0_RC GenBank Hs.21374 est 69 g12654596 GenBank Hs.288929fulllength 64400 NM_022476; fused toes homolog 70 Hs.295362.1.S1GenBank Hs.295362 fulllength 125144 NM_152350; hypothetical proteinMGC40157 71 g8272417 GenBank Hs.84728 fulllength 688 NM_001730;Kruppel-like factor 5 72 Hs.89688.0_RC GenBank Hs.89688 1379 73g3941299 GenBank Hs.77729 fulllength 4973 NM_002543; oxidised lowdensity lipoprotein (lectin-like) receptor 1 74 g10947045 RefSeqHs.183805 fulllength 286 NM_000037; ankyrin 1 isoform 3 NM_020475;ankyrin 1 isoform 4 NM_020476; ankyrin 1 isoform 1 NM_020477;ankyrin 1 isoform 2 NM_020478; ankyrin 1 isoform 5 NM_020479;ankyrin 1 isoform 6 NM_020480; ankyrin 1 isoform 7 NM_020481;ankyrin 1 isoform 8 75 g392430 GenBank Hs.108694 fulllength 2993NM_002099; glycophorin A precursor 76 Hs.250653.1 GenBank Hs.372513fulllength 2994 NM_002100; glycophorin B precursor 77 Hs.158323.0GenBank Hs.158323 fulllength 1053 NM_001605; CCAAT/enhancer bindingprotein epsilon 78 Hs.34549.0.A1 GenBank Hs.34549 79 g8922207RefSeq Hs.9398 fulllength 55062 NM_017983; hypothetical proteinFLJ10055 80 Hs.8146.0_RC GenBank Hs.8146 fulllength 7095 NM_003262;translocation protein 1 81 Hs.199061.0.A2 GenBank Hs.199061fulllength 8850 NM_003884; p300/CBP-associated factor 82 g348911GenBank Hs.75184 fulllength 1116 NM_001276; chitinase 3-like 1 83g13529076 GenBank Hs.108694 fulllength 2993 NM_002099; glycophorinA precursor 84 Hs.73828.1.S1 GenBank Hs.73828 fulllength 6886NM_003189; T-cell acute lymphocytic leukemia 1 85 g4505220 RefSeqHs.73862 fulllength 4317 NM_002424; matrix metalloproteinase 8preproprotein 86 Hs.97469.0_RC GenBank Hs.97469 fulllength 13812187 Hs.84522.0.A1 GenBank Hs.84522 fulllength 148534 NM_152487;hypothetical protein FLJ31842 88 Hs.107526.0_RC GenBank Hs.107526fulllength 9334 NM_004776; UDP-Gal: betaGlcNAc beta1,4-galactosyltransferase 5 89 Hs.99807.0.A1 GenBank Hs.99807fulllength 150468 NM_152515; hypothetical protein FLJ40629 90g6633804 RefSeq Hs.247921 fulllength 3049 NM_005331; theta 1 globin91 g602433 GenBank Hs.187958 fulllength 6535 NM_005629; solutecarrier family 8 (neurotransmitter transporter, creatine), member 892 g189435 GenBank Hs.733 fulllength 2038 NM_000119; erythrocytemembrane protein band 4.2 93 Hs.298161.3 GenBank Hs.356717fulllength 4635 NM_002476; atrial/embryonic alkali myosin lightchain 94 g7959850_RC GenBank Hs.356717 fulllength 4635 NM_002476;atrial/embryonic alkali myosin light chain 95 g12003206 GenBankHs.197298 fulllength 10625 NM_006469; influenza virus NS1A bindingprotein 96 g6806896 RefSeq Hs.76930 fulllength 6622 NM_000345;alpha-synuclein isoform NACP140 NM_007308; synuclein, alpha 97g4758711 RefSeq Hs.122785 fulllength 8972 NM_004668;maltase-glucoamylase 98 Hs.184019.1.S1 GenBank Hs.19385 fulllength51099 NM_016006; CGI58 protein 99 Hs.8688.0.A1 GenBank Hs.406087est ## g7706179 RefSeq Hs.274309 fulllength 51327 NM_016633;erythroid associated factor

TABLE-US-00037 TABLE 36 MDS_AML_Blasten # affy id HUGO name F p qTitle MapLocation Sequence Type Transcript ID Sequence Derived From1 203919_at TCEA2 87.95 3.35e-15 1.26e-11 transcription elongationfactor A (SII), 2 20q13.33 Exemplarsequence Hs.80598.0 NM_003195.12 201061_s_at STOM 76.83 1.28e-12 8.01e-10 stomatin 9q34.1Exemplarsequence Hs.160483.0 M81635.1 3 206674_at FLT3 68.743.30e-16 2.47e-12 fms-related tyrosine kinase 3 13q12Exemplarsequence Hs.385.0 NM_004119.1 4 212531_at LCN2 64.931.92e-11 4.65e-09 lipocalin 2 (oncogene 24p3) 9q34Consensussequence Hs.204238.0 NM_005564.1 5 201060_x_at STOM 58.694.22e-11 6.60e-09 stomatin 9q34.1 Consensussequence Hs.160483.0AI537887 6 201416_at SOX4 58.36 1.36e-13 2.55e-10 SRY (sexdetermining region Y)-box 4 6p22.3 Consensussequence Hs.83484.0NM_003107.1 7 206676_at CEACAM8 58.30 3.04e-11 5.80e-09carcinoembryonic antigen-related cell 19q13.2 ExemplarsequenceHs.41.0 M33326.1 adhesion molecule 8 8 221517_s_at CRSP6 58.103.70e-13 3.47e-10 cofactor required for Sp1 11q14 ExemplarsequenceHs.22630.1 AF105421.1 transcriptional activation, subunit 6, 77 kDa9 201029_s_at CD99 57.51 1.83e-12 8.59e-10 CD99 antigen Xp22.32Exemplarsequence Hs.177543.0 NM_002414.1 10 207992_s_at AMPD3 56.545.83e-12 2.08e-09 adenosine monophosphate 11p15 ExemplarsequenceHs.83918.0 NM_000480.1 deaminase (isoform E) 11 201417_at 55.293.64e-13 3.47e-10 Homo sapiens mRNA full length ConsensussequenceHs.83484.0 NM_003107.1 insert cDNA clone EUROIMAGE 1977059 12209771_x_at CD24 52.97 6.51e-11 9.22e-09 CD24 antigen (small celllung 6q21 Consensussequence Hs.286124.0 AA761181 carcinoma cluster4 antigen) 13 225570_at SLC41A1 52.87 1.33e-14 3.31e-11 solutecarrier family 41, member 1 1q32.1 Consensussequence Hs.20274.0AW439816 14 203535_at S100A9 52.42 1.59e-11 4.42e-09 S100 calciumbinding protein A9 1q21 Exemplarsequence Hs.112405.0 NM_002965.2(calgranulin B) 15 216379_x_at KIAA1919 50.55 9.72e-11 1.12e-08KIAA1919 protein 6q22 Consensussequence Hs.332045.0 AK000168.1 16225605_at LOC90313 50.27 1.80e-12 8.59e-10 hypothetical proteinBC004507 17q11.1 Consensussequence Hs.97871.0 AL540867 17207721_x_at HINT1 50.26 5.33e-12 2.00e-09 histidine triadnucleotide binding 5q31.2 Exemplarsequence Hs.256697.0 NM_005340.1protein 1 18 214501_s_at H2AFY 49.78 2.02e-13 2.55e-10 H2A histonefamily, member Y 5q31.3-q32 Consensussequence Hs.75258.2 AF044286.119 202018_s_at LTF 48.30 3.50e-11 5.80e-09 lactotransferrin3q21-q23 Exemplarsequence Hs.105938.0 NM_002343.1 20 217988_atHEI10 48.15 4.48e-11 6.72e-09 enhancer of invasion 10 14q11.1Exemplarsequence Hs.107003.0 NM_021178.1 21 266_s_at CD24 47.821.99e-10 1.94e-08 CD24 antigen (small cell lung 6q21Exemplarsequence L33930 L33930 carcinoma cluster 4 antigen) 22225029_at 47.35 6.30e-12 2.15e-09 ESTs Consensussequence Hs.74111.2BE958068 23 235663_at 46.61 5.71e-11 8.40e-09 ESTsConsensussequence Hs.155780.0 AI313160 24 213666_at 38961 46.431.85e-11 4.64e-09 septin 6 Xq24 Consensussequence Hs.90998.1AK026589.1 25 204351_at S100P 46.15 2.55e-10 2.28e-08 S100 calciumbinding protein P 4p16 Exemplarsequence Hs.2962.0 NM_005980.1 26228031_at 45.40 4.54e-10 3.36e-08 Homo sapiens cDNA FLJ31616 fis,Consensussequence Hs.226666.0 AW444778 clone NT2RI2003019. 27202428_x_at DBI 45.11 3.64e-11 5.80e-09 diazepam binding inhibitor(GABA receptor modulator, acyl- 2q12-q21 ExemplarsequenceHs.78888.0 NM_020548.1 Coenzyme A binding protein) 28 223671_x_atFLJ20139 45.04 3.62e-11 5.80e-09 hypothetical protein FLJ201391p21.1 Exemplarsequence Hs.19978.3 AF248965.1 29 215501_s_at DUSP1044.96 1.25e-11 3.61e-09 dual specificity phosphatase 10 1q41Consensussequence Hs.177534.1 AK022513.1 30 201015_s_at JUP 44.569.13e-12 2.96e-09 junction plakoglobin 17q21 ExemplarsequenceHs.2340.0 NM_021991.1 31 217631_at CRFG 44.20 2.98e-11 5.80e-09 Gprotein-binding protein CRFG 10p15-p14 ConsensussequenceHs.315170.0 AI081107 32 201937_s_at DNPEP 44.12 9.48e-12 2.96e-09aspartyl aminopeptidase 2q36.1 Exemplarsequence Hs.258551.0NM_012100.1 33 210254_at MS4A3 43.88 2.50e-10 2.28e-08membrane-spanning 4-domains, 11q12 Exemplarsequence Hs.99960.0L35848.1 subfamily A, member 3 (hematopoietic cell-specific) 34213668_s_at SOX4 43.59 1.05e-11 3.14e-09 SRY (sex determiningregion Y)-box 4 6p22.3 Consensussequence Hs.83484.1 AI989477 35221563_at DUSP10 43.49 3.04e-11 5.80e-09 dual specificityphosphatase 10 1q41 Consensussequence Hs.177534.0 N36770 36228131_at ASE-1 42.97 1.10e-10 1.17e-08 CD3-epsilon-associatedprotein; 19q13.3 Consensussequence Hs.25523.0 BG111047 antisense toERCC-1 37 223446_s_at DTNBP1 42.84 2.04e-13 2.55e-10 dystrobrevinbinding protein 1 6p22.3 Exemplarsequence Hs.43481.0 AF061734.1 38205349_at GNA15 42.43 7.15e-11 9.93e-09 guanine nucleotide bindingprotein (G 19p13.3 Exemplarsequence Hs.73797.0 NM_002068.1protein), alpha 15 (Gq class) 39 224196_x_at CGI-30 42.22 6.08e-118.77e-09 CGI-30 protein 1p21.1 Exemplarsequence Hs.19978.4AF161492.1 40 204234_s_at ZNF195 41.98 2.20e-11 4.72e-09 zincfinger protein 195 11p15.5 Consensussequence Hs.104382.0 AI47626741 226043_at AGS3 41.96 8.22e-11 1.01e-08 activator of G-proteinsignaling 3 9q34.3 Consensussequence Hs.239370.0 AI242661 42228562_at RINZF 41.50 3.34e-11 5.80e-09 zinc finger protein RINZF8q13.q21.1 Consensussequence Hs.39982.0 N29918 43 216705_s_at ADA41.32 3.34e-11 5.80e-09 adenosine deaminase 20q12-q13.11Consensussequence Hs.1217.1 X02189 44 200036_s_at- RPL10A 41.316.70e-10 4.31e-08 ribosomal protein L10a 6p21.3-p21.2Exemplarsequence Hs.252574.0 NM_007104.2 HG-U133A 45 211070_x_atDBI 41.19 1.07e-10 1.17e-08 diazepam binding inhibitor (GABA2q12-q21 Exemplarsequence g13623678 BC006466.1 receptor modulator,acyl-Coenzyme A binding protein) 46 207802_at SGP28 41.18 1.88e-099.67e-08 specific granule protein (28 kDa) 6p12.3 ExemplarsequenceHs.54431.0 NM_006061.1 47 225831_at LOC148894 41.16 3.02e-115.80e-09 hypothetical protein LOC148894 1p36.11 ConsensussequenceHs.154085.0 AK025345.1 48 235753_at 41.15 3.63e-12 1.43e-09 Homosapiens cDNA FLJ34835 fis, Consensussequence Hs.196169.0 AI492051clone NT2NE2010150. 49 202391_at BASP1 40.94 6.72e-10 4.31e-08brain abundant, membrane attached 5p15.1-p14 ExemplarsequenceHs.79516.0 NM_006317.1 signal protein 1 50 219218_at FLJ23058 40.832.02e-11 4.72e-09 hypothetical protein FLJ23058 17q25.3Exemplarsequence Hs.98968.0 NM_024696.1 51 208890_s_at PLXNB2 40.292.14e-10 2.05e-08 plexin B2 22q13.33 Exemplarsequence Hs.3989.0BC004542.1 52 220974_x_at BA108L7.2 39.97 7.97e-11 1.01e-08 similarto rat tricarboxylate carrier-like 10q24.31 Exemplarsequenceg13569945 NM_030971.1 protein 53 208943_s_at TLOC1 39.80 8.11e-105.03e-08 translocation protein 1 3q26.2-q27 ExemplarsequenceHs.8146.0 U93239.1 54 212746_s_at KIAA0470 39.25 2.14e-11 4.72e-09KIAA0470 gene product 1q44 Consensussequence Hs.25132.3 AA126789 55205474_at CRLF3 39.23 1.54e-09 8.29e-08 cytokine receptor-likefactor 3 17q11.2 Exemplarsequence Hs.7120.0 NM_015986.1 56201268_at NME2 39.13 3.81e-10 3.05e-08 non-metastatic cells 2,protein 17q21.3 Exemplarsequence Hs.275163.0 NM_002512.1 (NM23B)expressed in 57 201418_s_at SOX4 38.97 3.39e-12 1.43e-09 SRY (sexdetermining region Y)-box 4 6p22.3 Exemplarsequence Hs.83484.0NM_003107.1 58 212242_at TUBA1 38.91 1.22e-09 6.91e-08 tubulin,alpha 1 (testis specific) 2q36.1 Consensussequence Hs.75318.0AL565074 59 224733_at CKLFSF3 38.62 1.09e-10 1.17e-08chemokine-like factor super family 3 16q21 ConsensussequenceHs.7773.4 AL574900 60 216650_at 38.49 9.61e-13 6.55e-10Consensussequence Hs.166181.0 AL008627 61 208650_s_at CD24 38.292.48e-09 1.19e-07 CD24 antigen (small cell lung 6q21Consensussequence Hs.286124.1 BG327863 carcinoma cluster 4 antigen)62 211657_at CEACAM6 38.13 2.37e-09 1.15e-07 carcinoembryonicantigen-related cell 19q13.2 Exemplarsequence g189084 M18728.1adhesion molecule 6 (non-specific cross reacting antigen) 63224928_at SET7 37.95 1.25e-10 1.31e-08 SET domain-containingprotein 7 4q28 Consensussequence Hs.78521.0 AK024846.1 64 225877_atMGC34695 37.93 7.41e-13 5.56e-10 hypothetical protein MGC3469510q22.1 Consensussequence Hs.15386.0 BG389635 65 211031_s_at CYLN237.76 2.32e-10 2.17e-08 cytoplasmic linker 2 7q11.23Exemplarsequence g13623312 BC006259.1 66 227056_at 37.55 1.26e-101.31e-08 ESTs Consensussequence Hs.63510.1 AA181172 67 204639_atADA 37.54 4.42e-11 6.72e-09 adenosine deaminase 20q12-q13.11Exemplarsequence Hs.1217.0 NM_000022.1 68 205997_at ADAM28 37.513.25e-10 2.80e-08 a disintegrin and metalloproteinase 8p21.1Exemplarsequence Hs.174030.0 NM_021778.1 domain 28 69 201063_atRCN1 37.32 8.07e-11 1.01e-08 reticulocalbin 1, EF-hand calcium11p13 Exemplarsequence Hs.167791.0 NM_002901.1 binding domain 70230302_at 37.26 7.93e-11 1.01e-08 Homo sapiens full length insertcDNA Consensussequence Hs.264606.0 AI741597 clone ZD68B12 71201536_at DUSP3 37.23 4.62e-10 3.37e-08 dual specificityphosphatase 3 17q21 Consensussequence Hs.181046.0 AL048503(vaccinia virus phosphatase VH1- related) 72 225510_at 37.086.56e-13 5.47e-10 Homo sapiens cDNA FLJ11658 fis, ConsensussequenceHs.22660.1 BG033561 clone HEMBA1004577. 73 219590_x_at CGI-30 36.975.57e-10 3.80e-08 CGI-30 protein 1p21.1 Exemplarsequence Hs.19978.0NM_015958.1 74 209389_x_at DBI 36.42 4.16e-10 3.15e-08 diazepambinding inhibitor (GABA 2q12-q21 Exemplarsequence Hs.78888.1M15887.1 receptor modulator, acyl-Coenzyme A binding protein) 75242051_at 36.40 1.05e-10 1.17e-08 ESTs ConsensussequenceHs.130260.0 AI695695 76 235142_at MGC17919 36.38 1.57e-10 1.57e-08hypothetical protein MGC17919 1p34.3 Consensussequence Hs.129837.0AW006067 77 209369_at ANXA3 36.27 4.25e-09 1.75e-07 annexin A34q13-q22 Exemplarsequence Hs.1378.0 M63310.1 78 221778_at KIAA171836.21 4.53e-09 1.85e-07 KIAA1718 protein 7q33-q35 ConsensussequenceHs.222707.0 BE217882 79 224916_at 36.20 2.19e-11 4.72e-09 Homosapiens cDNA FLJ38577 fis, Consensussequence Hs.86347.1 BG286973clone HCHON2007650. 80 221754_s_at CORO1B 36.18 1.82e-12 8.59e-10coronin, actin-binding protein, 1B 11q13.1 ConsensussequenceHs.6191.0 AI341234 81 221726_at RPL22 36.07 1.23e-09 6.91e-08ribosomal protein L22 1p36.3-p36.2 Consensussequence Hs.326249.1BE250348 82 207269_at DEFA4 36.02 8.40e-10 5.17e-08 defensin, alpha4, corticostatin 8p23 Exemplarsequence Hs.2582.0 NM_001925.1 83203765_at GCA 35.96 5.09e-09 1.99e-07 grancalcin, EF-hand calciumbinding 2q24.3 Exemplarsequence Hs.79381.0 NM_012198.1 protein 84208651_x_at CD24 35.93 3.83e-09 1.64e-07 CD24 antigen (small celllung 6q21 Exemplarsequence Hs.286124.1 M58664.1 carcinoma cluster 4antigen) 85 232884_s_at DKFZp434J1015 35.87 2.26e-10 2.14e-08hypothetical protein DKFZp434J1015 7p22.2 ConsensussequenceHs.283779.0 AL133055.1 86 209310_s_at CASP4 35.80 7.58e-11 1.01e-08caspase 4, apoptosis-related 11q22.2-q22.3 ExemplarsequenceHs.74122.0 U25804.1 cysteine protease 87 205863_at S100A12 35.583.98e-09 1.69e-07 S100 calcium binding protein A12 1q21Exemplarsequence Hs.19413.0 NM_005621.1 (calgranulin C) 88221781_s_at ERdj5 35.56 4.81e-10 3.43e-08 ER-resident protein ERdj52q32.1 Consensussequence Hs.1098.0 AL137648.1 89 239562_at 35.554.71e-10 3.40e-08 Homo sapiens, clone Consensussequence Hs.136330.0AW272411 IMAGE: 4830703, mRNA, partial cds 90 214298_x_at 3896135.40 3.41e-10 2.87e-08 septin 6 Xq24 Consensussequence Hs.90998.3AL568374 91 203213_at CDC2 35.37 3.87e-09 1.65e-07 cell divisioncycle 2, G1 to S and G2 10q21.1 Consensussequence Hs.184572.0AL524035 to M 92 225615_at LOC126917 35.33 7.26e-10 4.58e-08hypothetical protein LOC126917 1p36.13 Consensussequence Hs.13766.0AK024480.1 93 223276_at NID67 35.30 2.59e-10 2.29e-08 putativesmall membrane protein 5q33.1 Exemplarsequence Hs.29444.0AF313413.1 NID67 94 215116_s_at DNM1 35.19 1.33e-10 1.37e-08dynamin 1 9q34 Consensussequence Hs.166161.2 AF035321.1 95209889_at SEC31B-1 35.18 8.68e-11 1.05e-08 secretory pathwaycomponent 10q24.2 Exemplarsequence Hs.18889.0 AF274863.1 Sec31B-196 211323_s_at ITPR1 35.18 1.75e-11 4.52e-09 inositol1,4,5-triphosphate receptor, 3p26-p25 Exemplarsequence Hs.198443.1L38019.1 type 1 97 220755_s_at C6orf48 35.03 1.10e-09 6.50e-08chromosome 6 open reading frame 6p21.3 Exemplarsequence Hs.109798.0NM_016947.1 48 98 224710_at RAB34 34.95 6.64e-10 4.31e-08 RAB34,member RAS oncogene

17q11.1 Consensussequence Hs.301853.0 AF322067.1 family 99221002_s_at DC-TM4F2 34.89 5.15e-09 2.00e-07 tetraspanin similar toTM4SF9 10q22.3 Exemplarsequence g13569888 NM_030927.1 100209563_x_at CALM1 34.52 6.37e-09 2.41e-07 calmodulin 1(phosphorylase kinase, 14q24-q31 Exemplarsequence Hs.182278.1BC000454.1 delta) # Sequence ID Sequence Source Unigene_AccessionCluster_Type LocusLink Full_Length_Reference_Seq 1 g4507384 RefSeqHs.80598 fulllength 6919 NM_003195; transcription elongation factorA (SII), 2 2 g181183 GenBank Hs.160483 fulllength 2040 NM_004099;stomatin 3 g4758395 RefSeq Hs.385 fulllength 2322 NM_004119;fms-related tyrosine kinase 3 4 Hs.204238.0.S1 GenBank Hs.204238fulllength 3934 NM_005564; lipocalin 2 (oncogene 24p3) 5Hs.160483.0 GenBank Hs.160483 fulllength 2040 NM_004099; stomatin 6Hs.83484.0 GenBank Hs.83484 fulllength 6659 NM_003107; SRY (sexdetermining region Y)-box 4 7 g189101 GenBank Hs.41 fulllength 1088NM_001816; carcinoembryonic antigen-related cell adhesion molecule8 8 g4838128 GenBank Hs.22630 fulllength 9440 NM_004268; cofactorrequired for Sp1 transcriptional activation, subunit 6, 77 kDa 9g4505182 RefSeq Hs.433387 fulllength 4267 NM_002414; CD99 antigen10 g4502078 RefSeq Hs.83918 fulllength 272 NM_000480; adenosinemonophosphate deaminase (isoform E) 11 Hs.83484.0 GenBank Hs.35192812 Hs.286124.0_RC GenBank Hs.375108 fulllength 934 NM_013230; CD24antigen (small cell lung carcinoma cluster 4 antigen) 13Hs.20274.0_RC GenBank Hs.20274 fulllength 254428 NM_173854; solutecarrier family 41 member 1 14 g9845520 RefSeq Hs.112405 fulllength6280 NM_002965; S100 calcium-binding protein A9 15 Hs.332045.0_RCGenBank Hs.400572 fulllength 91749 NM_153369; KIAA1919 protein 16Hs.97871.0.S1 GenBank Hs.97871 fulllength 90313 17 g4885412 RefSeqHs.256697 fulllength 3094 NM_005340; histidine triad nucleotidebinding protein 1 18 Hs.75258.2 GenBank Hs.75258 fulllength 9555NM_004893; H2A histone family, member Y isoform 2 NM_138609; H2Ahistone family, member Y isoform 1 NM_138610; H2A histone family,member Y isoform 3 19 g4505042 RefSeq Hs.105938 fulllength 4057NM_002343; lactotransferrin 20 g10863978 RefSeq Hs.107003fulllength 57820 NM_021178; enhancer of invasion 10 21 L33930GenBank Hs.375108 fulllength 934 NM_013230; CD24 antigen (smallcell lung carcinoma cluster 4 antigen) 22 Hs.74111.2 GenBankHs.355559 est 23 Hs.155780.0.A1 GenBank Hs.436070 est 24Hs.90998.1.S1 GenBank Hs.90998 fulllength 23157 NM_015129; septin 6isoform B NM_145799; septin 6 isoform A NM_145800; septin 6 isoformA NM_145802; septin 6 isoform D 25 g5174662 RefSeq Hs.2962fulllength 6286 NM_005980; S100 calcium binding protein P 26Hs.226666.0.A1 GenBank Hs.226666 27 g10140852 RefSeq Hs.78888fulllength 1622 NM_020548; diazepam binding inhibitor 28 g12005666GenBank Hs.406051 fulllength 54833 NM_017685; hypothetical proteinFLJ20139 29 Hs.177534.1 GenBank Hs.177534 fulllength 11221NM_007207; dual specificity phosphatase 10 isoform a NM_144728;dual specificity phosphatase 10 isoform b NM_144729; dualspecificity phosphatase 10 isoform b 30 g12056467 RefSeq Hs.2340fulllength 3728 NM_002230; junction plakoglobin NM_021991; junctionplakoglobin 31 Hs.315170.0.A1 GenBank Hs.215766 fulllength 23560NM_012341; G protein-binding protein CRFG 32 g6912247 RefSeqHs.258551 fulllength 23549 NM_012100; aspartyl aminopeptidase 33g561638 GenBank Hs.99960 fulllength 932 NM_006138;membrane-spanning 4-domains, subfamily A, member 3 34 Hs.83484.1GenBank Hs.83484 fulllength 6659 NM_003107; SRY (sex determiningregion Y)-box 4 35 Hs.177534.0 GenBank Hs.177534 fulllength 11221NM_007207; dual specificity phosphatase 10 isoform a NM_144728;dual specificity phosphatase 10 isoform b NM_144729; dualspecificity phosphatase 10 isoform b 36 Hs.25523.0_RC GenBankHs.211956 fulllength 10849 NM_012099; CD3-epsilon-associatedprotein; antisense to ERCC-1 37 g12002003 GenBank Hs.43481fulllength 84062 NM_032122; dystrobrevin binding protein 1 38g4504038 RefSeq Hs.73797 fulllength 2769 NM_002068; guaninenucleotide binding protein (G protein), alpha 15 (Gq class) 39g6841507 GenBank Hs.441133 fulllength 51611 NM_015958; CGI-30protein 40 Hs.104382.0 GenBank Hs.104382 fulllength 7748 NM_007152;zinc finger protein 195 41 Hs.239370.0.S1 GenBank Hs.239370fulllength 26086 NM_015597; activator of G-protein signaling 3 42Hs.39982.0_RC GenBank Hs.237146 fulllength 65986 NM_023929; zincfinger protein RINZF 43 Hs1217.1 GenBank Hs.1217 fulllength 100NM_000022; adenosine deaminase 44 g6325471 RefSeq Hs.425293fulllength 4736 NM_007104; ribosomal protein L10a 45 g13623678GenBank Hs.78888 fulllength 1622 NM_020548; diazepam bindinginhibitor 46 g5174674 RefSeq Hs.54431 fulllength 10321 NM_006061;specific granule protein (28 kDa) 47 Hs.154085.0_RC GenBankHs.348515 fulllength 148894 48 Hs.196169.0 GenBank Hs.196169 49g5453749 RefSeq Hs.79516 fulllength 10409 NM_006317; brainabundant, membrane attached signal protein 1 50 g13375978 RefSeqHs.98968 fulllength 79749 NM_024696; hypothetical protein FLJ2305851 g13528689 GenBank Hs.3989 fulllength 23654 NM_012401; plexin B252 g13569945 RefSeq Hs.283844 fulllength 81855 NM_030971; similarto rat tricarboxylate carrier-like protein 53 g1928972 GenBankHs.8146 fulllength 7095 NM_003262; translocation protein 1 54Hs.25132.3_RC GenBank Hs.25132 fulllength 9859 NM_014812;KARP-1-binding protein 55 g7705331 RefSeq Hs.7120 fulllength 51379NM_015986; cytokine receptor-like factor 3 56 g4505408 RefSeqHs.433416 fulllength 4831 NM_002512; non-metastatic cells 2,protein (NM238) expressed in 57 g4507162 RefSeq Hs.83484 fulllength6659 NM_003107; SRY (sex determining region Y)-box 4 58 Hs.75318.0GenBank Hs.75318 fulllength 7277 NM_006000; tubulin, alpha 1 59Hs.7773.4_RC GenBank Hs.7773 fulllength 123920 NM_144601;chemokine-like factor super family 3 isoform a 60 Hs.166181.0GenBank 61 Hs.286124.1_RC GenBank Hs.375108 fulllength 934NM_013230; CD24 antigen (small cell lung carcinoma cluster 4antigen) 62 g189084 GenBank Hs.73848 fulllength 4680 NM_002483;carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) 63 Hs.78521.0.S1 GenBank Hs.78521fulllength 80854 NM_030648; SET domain-containing protein 7 64Hs.15386.0.A1 GenBank Hs.15386 fulllength 219743 NM_173555;hypothetical protein MGC34695 65 g13623312 GenBank Hs.104717fulllength 7461 NM_003388; cytoplasmic linker 2 isoform 1NM_032421; cytoplasmic linker 2 isoform 2 NM_032719; 66Hs.63510.1.A1 GenBank Hs.446502 est 67 g4557248 RefSeq Hs.1217fulllength 100 NM_000022; adenosine deaminase 68 g11496995 RefSeqHs.174030 fulllengh 10863 NM_014265; a disintegrin andmetalloproteinase domain 28 isoform 1 preproprotein NM_021777; adisintegrin and metalloproteinase domain 28 isoform 3 preproproteinNM_021778; a disintegrin and metalloproteinase domain 28 isoform 2preproprotein 69 g4506454 RefSeq Hs.167791 fulllength 5954NM_002901; reticulocalbin 1 precursor 70 Hs.264606.0_RC GenBankHs.264606 71 Hs.181046.0_RC GenBank Hs.181046 fulllength 1845NM_004090; dual specificity phosphatase 3 72 Hs.22660.1_RC GenBankHs.380824 73 g7706271 RefSeq Hs.441133 fulllength 51611 NM_015958;CGI-30 protein 74 g181960 GenBank Hs.78888 fulllength 1622NM_020548; diazepam binding inhibitor 75 Hs.130260.0_RC GenBankHs.130260 est 76 Hs.129837.0_RC GenBank Hs.129837 fulllenglh 127557NM_144621; hypothetical protein MGC17919 77 g178696 GenBank Hs.1378fulllength 306 NM_005139: annexin A3 78 Hs.222707.0.A2 GenBankHs.222707 80853 79 Hs.86347.1_RC GenBank Hs.379754 80 Hs.6191.0.S1GenBank Hs.6191 fulllength 57175 NM_020441; coronin, actin bindingprotein, 1B 81 Hs.326249.1.A2 GenBank Hs.326249 fulllength 6146NM_000983; ribosomal protein L22 proprotein 82 g4503302 RefSepHs.2582 fulllength 1669 NM_001925; defensin, alpha 4, preproprotein83 g6912387 RefSeq Hs.79381 fulllength 25801 NM_012198; grancalcin.EF-hand calcium binding protein 84 g180167 GenBank Hs.375108fulllength 934 NM_013230; CD24 antigen (small cell lung carcinomacluster 4 antigen) 85 Hs.283779.0 GenBank Hs.283779 54753 86g886049 GenBank Hs.74122 fulllength 837 NM_001225; caspase 4isoform alpha precursor NM_033306; caspase 4 isoform gammaprecursor NM_033307; caspase 4 isoform delta precursor 87 g5032058RefSeq Hs.19413 fulllength 6283 NM_005621; S100 calcium-bindingprotein A12 88 Hs.1098.0_RC GenBank Hs.1098 fulllength 54431NM_018981; ER-resident protein ERdj5 89 Hs.136330.0.A1 GenBankHs.407156 90 Hs.90998.3.S1 GenBank Hs.90998 fulllength 23157NM_015129; septin 6 isoform B NM_145799; septin 6 isoform ANM_145800; septin 6 isoform A NM_145802; septin 6 isoform D 91Hs.184572.0.S2 GenBank Hs.334562 fulllength 983 NM_001786; celldivision cycle 2 protein isoform 1 NM_033379; cell division cycle 2protein isoform 2 92 Hs.13766.0 GenBank Hs.13766 126917 93g12484085 GenBank Hs.29444 fulllength 85027 NM_032947; putativesmall membrane protein NID67 94 Hs.166161.2 GenBank Hs.166161fulllength 1759 NM_094408; dynamin 1 95 g8650513 GenBank Hs.18889fulllength 25956 NM_015490; secretory pathway component Sec31B-1 96g1464750 GenBank Hs.198443 fulllength 3708 NM_002222; inositol1,4,5-triphosphate receptor, type 1 97 g8393383 RefSeq Hs.109798fulllength 50854 NM_016947; G8 protein 98 Hs.301853.0 GenBankHs.301853 fulllength 83871 NM_031934; RAB39 99 g13569858 RefSeqHs.101395 fulllength 81619 NM_030927; tetraspanin similar to TM4SF9100 g12653368 GenBank Hs.282410 fulllength 801 NM_006888;calmodulin 1 (phosphorylase kinase, delta)

TABLE-US-00038 TABLE 37 MDS_AML_Blasten Sequence # affy id HUGOname F p q Title MapLocation Sequence Type Transcript ID DerivedFrom Sequence ID 1 223157_at MGC3232 159.61 3.40e-27 6.15e-23hypothetical protein MGC3232 4q12 Exemplarsequence Hs.8715.0BC004894.1 g13436154 2 218436_at SIL1 139.91 3.10e-24 2.80e-20endoplasmic reticulum 5q31 Exemplarsequence Hs.297875.0 NM_022464.1g11968008 chaperone SIL1, homolog of yeast 3 201922_at YR-29 127.031.09e-19 4.92e-16 hypothetical protein YR-29 5q13.2Exemplarsequence Hs.8170.0 NM_014886.1 g7662676 4 201978_s_atKIAA0141 122.17 2.45e-21 1.48e-17 KIAA0141 gene product 5q31.3Exemplarsequence Hs.63510.0 NM_014773.1 g7661939 5 227056_at 117.393.61e-19 1.31e-15 ESTs Consensussequence Hs.63510.1 AA181172Hs.63510.1.A1 6 222229_x_at 99.17 5.12e-16 9.26e-13Consensussequence Hs.272344.0 AL121871 Hs.272344.0 7 212145_atMRPS27 91.69 4.15e-17 1.07e-13 mitochondrial ribosomal protein5q13.1 Consensussequence Hs.122669.0 D87453.1 Hs.122669.0 S27 8201574_at ETF1 91.60 6.38e-17 1.28e-13 eukaryotic translation5q31.1 Exemplarsequence Hs.77324.0 NM_004730.1 g4759033 terminationfactor 1 9 224916_at 90.13 7.98e-18 2.41e-14 Homo sapiens cDNAFLJ38577 Consensussequence Hs.86347.1 BG286973 Hs.86347.1_RC fis,clone HCHON2007650. 10 222983_s_at PAIP2 88.66 7.65e-16 1.15e-12PABP-interacting protein 2 5q31.3 Exemplarsequence Hs.108548.0BC001716.1 g12804590 11 200093_s_at- HINT1 86.95 7.18e-16 1.15e-12histidine triad nucleotide binding 5q31.2 ConsensussequenceHs.256697.2 N32864 Hs.256697.2.A1 HG-U133A protein 1 12 229693_at85.38 5.56e-17 1.26e-13 ESTs Consensussequence Hs.154574.0 AI952836Hs.154574.0_RC 13 224936_at EIF2S3 83.13 1.45e-15 1.87e-12eukaryotic translation initiation Xp22.2-p22.1 ConsensussequenceHs.30376.1 BE252813 Hs.30376.1.A1 factor 2, subunit 3 gamma, 52 kDa14 214919_s_at 81.93 1.03e-15 1.43e-12 Homo sapiens, cloneConsensussequence Hs.301226.2 R39094 Hs.301226.2.A1 IMAGE: 3866125,mRNA 15 221476_s_at RPL15 81.09 4.57e-14 3.44e-11 ribosomal proteinL15 3p24.1 Exemplarsequence Hs.74267.0 AF279903.1 g12006349 16203538_at CAMLG 79.11 3.43e-15 4.13e-12 calcium modulating ligand5q23 Exemplarsequence Hs.13572.0 NM_001745.1 g4502558 17 223276_atNID67 75.50 5.70e-15 6.44e-12 putative small membrane 5q33.1Exemplarsequence Hs.29444.0 AF313413.1 g12484085 protein NID67 18223671_x_at FLJ20139 74.89 2.08e-14 1.79e-11 hypothetical proteinFLJ20139 1p21.1 Exemplarsequence Hs.19978.3 AF248965.1 g12005666 19208826_x_at HINT1 74.74 5.02e-14 3.63e-11 histidine triadnucleotide binding 5q31.2 Exemplarsequence Hs.256697.1 U27143.1g862932 protein 1 20 207721_x_at HINT1 74.67 2.83e-14 2.22e-11histidine triad nucleotide binding 5q31.2 ExemplarsequenceHs.256697.0 NM_005340.1 g4885412 protein 1 21 208646_at RPS14 74.092.75e-14 2.22e-11 ribosomal protein S14 5q31-q33 ExemplarsequenceHs.244621.0 AF116710.1 g7959918 22 200074_s_at- RPL14 74.031.06e-13 7.39e-11 ribosomal protein L14 3p22.p21.2 ExemplarsequenceHs.738.2 U16738.1 g608516 HG-U133A 23 203024_s_at HTGN29 73.898.94e-15 8.99e-12 HTGN29 protein 5q31.1 ExemplarsequenceHs.283437.0 NM_020199.1 g9910277 24 212894_at SUPV3L1 72.555.28e-13 2.89e-10 suppressor of var1, 3-like 1 (S. cerevisiae)10q22.1 Consensussequence Hs.106469.0 NM_003171.1 Hs.106469.0 2535820_at GM2A 70.44 1.65e-14 1.57e-11 GM2 ganglioside activator5q31.3-q33.1 Consensussequence 4898374 X62078 4898374 protein 26201345_s_at UBE2D2 69.89 3.17e-13 1.88e-10 ubiquitin-conjugatingenzyme 5q31.3 Exemplarsequence Hs.108332.0 NM_003339.1 g4507774 E2D2 (UBC4/5 homolog, yeast) 27 213846_at COX7C 69.81 8.70e-134.63e-10 cytochrome c oxidase subunit 5q14 ConsensussequenceHs.3462.1 AA382702 Hs.3462.1 VIIc 28 204828_at RAD9 68.11 4.20e-121.81e-09 RAD9 homolog (S. pombe) 11q13.1-q13.2 ExemplarsequenceHs.240457.0 NM_004584.1 g4759021 29 224196_x_at CGI-30 68.021.31e-13 8.75e-11 CGI-30 protein 1p21.1 Exemplarsequence Hs.19978.4AF161492.1 g6841507 30 202413_s_at USP1 67.39 1.21e-12 6.18e-10ubiquitin specific protease 1 1p32.1-p31.3 ExemplarsequenceHs.35086.0 NM_003368.1 g4507850 31 208652_at PPP2CA 67.30 3.91e-132.21e-10 protein phosphatase 2 (formerly 5q23-q31 ExemplarsequenceHs.91773.0 BC000400.1 g12653262 2A), catalytic subunit, alphaisoform 32 236892_s_at 66.64 8.65e-15 8.99e-12 Homo sapiens, cloneConsensussequence Hs.269918.0 BF590528 Hs.269918.0.A1 MGC: 10077IMAGE: 3896690, mRNA, complete cds 33 218953_s_at MGC3265 66.411.84e-14 1.66e-11 hypothetical protein MGC3265 5q32Exemplarsequence Hs.257111.0 NM_024028.1 g13128973 34 217846_atQARS 66.06 1.49e-12 7.26e-10 glutaminyl-tRNA synthetase3p21.3-p21.1 Exemplarsequence Hs.79322.0 NM_005051.1 g4826959 35200093_s_at- HINT1 65.91 1.23e-12 6.18e-10 histidine triadnucleotide binding 5q31.2 Consensussequence Hs.256697.2 N32864Hs.256697.2.A1 HG-U133B protein 1 36 214700_x_at DKFZP434D193 64.776.39e-12 2.57e-09 DKFZP434D193 protein 2q23.3 ConsensussequenceHs.225841.1 AK000323.1 Hs.225841.1.S1 37 236728_at FLJ39485 63.391.77e-13 1.15e-10 hypothetical protein FLJ39485 5q14.3Consensussequence Hs.26330.0 AW070437 Hs.26330.0.A1 38 226656_atCRTAP 62.27 2.19e-12 1.02e-09 cartilage associated protein 3p22Consensussequence Hs.155481.1 AW024741 Hs.155481.1_RC 39 212737_atGM2A 62.11 3.22e-13 1.88e-10 GM2 ganglioside activator 5q31.3-q33.1Consensussequence Hs.278242.3 AL513583 Hs.278242.3 protein 40201977_s_at KIAA0141 60.74 4.37e-12 1.84e-09 KIAA0141 gene product5q31.3 Consensussequence Hs.63510.0 AI539425 Hs.63510.0.A1 41224767_at 59.87 1.63e-12 7.76e-10 Homo sapiens mRNA; cDNAConsensussequence Hs.80545.1 AL137450.1 Hs.80545.1_RC DKFZp434J0428(from clone DKFZp434J0428) 42 208130_s_at TBXAS1 59.84 2.98e-131.86e-10 thromboxane A synthase 1 7q34-q35 Exemplarsequenceg13699839 NM_030984.1 g13699839 (platelet, cytochrome P450, family5, subfamily A) 43 238075_at 58.68 2.38e-11 7.67e-09 ESTs, Weaklysimilar to A42442 Consensussequence Hs.24529.0 AA224205Hs.24529.0.A1 integrin beta-1 chain, splice form beta-1-S - human(fragment) [H. sapiens] 44 201507_at PFDN1 58.48 1.70e-11 5.92e-09prefoldin 1 5q31 Exemplarsequence Hs.132881.0 NM_002622.2 g1240867345 226142_at GLIPR1 56.83 2.30e-12 1.04e-09 GLIpathogenesis-related 1 12q21.1 Consensussequence Hs.154762.2AV682252 Hs.154762.2.A1 (glioma) 46 211938_at PRO1843 56.741.04e-11 3.84e-09 hypothetical protein PRO1843 12q13.13Consensussequence Hs.283330.1 BF247371 Hs.283330.1 47 201568_atQP-C 56.43 1.86e-11 6.35e-09 low molecular mass ubiquinone- 5q31.1Exemplarsequence Hs.3709.0 NM_014402.1 g7657485 binding protein(9.5 kD) 48 200608_s_at RAD21 56.29 6.33e-11 1.85e-08 RAD21 homolog(S. pombe) 8q24 Exemplarsequence Hs.81848.0 NM_006265.1 g5453993 49209523_at TAF2 56.27 9.98e-11 2.65e-08 TAF2 RNA polymerase II, TATA8q24.12 Consensussequence Hs.122752.0 AK001618.1 Hs.122752.0 boxbinding protein (TBP)- associated factor, 150 kDa 50 241827_at56.18 7.16e-11 1.99e-08 Homo sapiens cDNA FLJ39372Consensussequence Hs.262036.0 AL577866 Hs.262036.0.S1 fis, clonePEBLM2007832, moderately similar to ZINC FINGER PROTEIN 84. 51206295_at IL18 55.98 4.51e-12 1.85e-09 interleukin 18 (interferon-11q22.2-q22.3 Exemplarsequence Hs.83077.0 NM_001562.1 g4504652gamma-inducing factor) 52 217751_at LOC51064 55.62 1.10e-113.97e-09 glutathione S-transferase 7q34 ExemplarsequenceHs.279952.0 NM_015917.1 g7705703 subunit 13 homolog 53 225090_atHRD1 55.32 5.10e-11 1.51e-08 HRD1 protein 11q13 ConsensussequenceHs.75859.1 AA844682 Hs.75859.1.A1 54 209303_at NDUFS4 54.572.96e-11 9.22e-09 NADH dehydrogenase 5q11.1 ExemplarsequenceHs.10758.0 BC005270.1 g13528959 (ubiquinone) Fe--S protein 4, 18kDa (NADH-coenzyme Q reductase) 55 228855_at 54.42 2.36e-121.04e-09 Homo sapiens cDNA: FLJ22816 Consensussequence Hs.115920.0AI927964 Hs.115920.0.A1 fis, clone KAIA3155. 56 222984_at PAIP254.39 2.76e-11 8.75e-09 PABP-interacting protein 2 5q31.3Exemplarsequence Hs.108548.0 AF151052.1 g7106825 57 218645_atZNF277 53.69 3.42e-11 1.03e-08 zinc finger protein (C2H2 type)7q31.1 Exemplarsequence Hs.42636.0 NM_021994.1 g11496268 277 58202659_at PSMB10 53.67 2.06e-11 6.77e-09 proteasome (prosome,16q22.1 Exemplarsequence Hs.9661.0 NM_002801.1 g4506190 macropain)subunit, beta type, 10 59 244360_at 53.28 7.87e-12 3.09e-09 ESTsConsensussequence Hs.233425.0 AW002273 Hs.233425.0.A1 60 202105_atIGBP1 53.19 6.48e-11 1.86e-08 immunoglobulin (CD79A) Xq13.1-q13.3Exemplarsequence Hs.3631.0 NM_001551.1 g4557662 binding protein 161 201377_at NICE-4 53.12 2.19e-10 5.01e-08 NICE-4 protein 1q21.3Exemplarsequence Hs.8127.0 NM_014847.1 g7661941 62 218929_at CARF52.81 2.52e-10 5.70e-08 collaborates/cooperates with 4q35.1Exemplarsequence Hs.32922.0 NM_017632.1 g8923039 ARF (alternatereading frame) protein 63 208021_s_at RFC1 52.19 1.38e-10 3.42e-08replication factor C (activator 1) 4p14-p13 Exemplarsequenceg4506484 NM_002913.1 g4506484 1, 145 kDa 64 202633_at TOPBP1 51.692.13e-10 4.94e-08 topoisomerase (DNA) II binding 3q22.1Exemplarsequence Hs.91417.0 NM_007027.1 g5902137 protein 65210314_x_at TNFSF13 51.46 1.90e-11 6.36e-09 tumor necrosis factor(ligand) 17p13.1 Exemplarsequence Hs.54673.1 AF114013.1 g7328557superfamily, member 13 66 205366_s_at HOXB6 51.24 1.17e-11 4.14e-09homeo box B6 17q21.3 Exemplarsequence Hs.98428.0 NM_018952.1g9506792 67 2174g1_x_at COX7C 51.04 2.87e-10 6.19e-08 cytochrome coxidase subunit 5q14 Consensussequence Hs.278494.0 AF042165Hs.278494.0 VIIc 68 209329_x_at MGC2198 50.98 6.71e-11 1.89e-08hypothetical protein MGC2198 5q35.3 Exemplarsequence Hs.227152.1BC000587.1 g12653618 69 224841_x_at 50.98 1.25e-10 3.22e-08 Homosapiens mRNA; cDNA Consensussequence Hs.289721.2 BF316352Hs.289721.2.S1 DKFZp564D0164 (from clone DKFZp564D0164) 70209022_at STAG2 50.79 2.59e-10 5.79e-08 stromal antigen 2 Xq25Consensussequence Hs.8217.1 AK026678.1 Hs.8217.1_RC 71 233955_x_atHSPC195 50.60 3.37e-11 1.03e-08 hypothetical protein HSPC195 5q31.3Consensussequence Hs.15093.1 AK001782.1 Hs.15093.1 72 201343_atUBE2D2 50.57 7.73e-11 2.09e-08 ubiquitin-conjugating enzyme 5q31.3Consensussequence Hs.108332.0 NM_003339.1 Hs.108332.0 E2D 2 (UBC4/5homolog, yeast) 73 239791_at 50.55 9.46e-12 3.64e-09 Homo sapiens,clone Consensussequence Hs.269918.1 AI125255 Hs.269918.1.A1 MGC:10077 IMAGE: 3896690, mRNA, complete cds 74 208697_s_at EIF3S650.28 1.66e-10 4.06e-08 eukaryotic translation initiation 8q22-q23Exemplarsequence Hs.106673.0 BC000734.1 g12653884 factor 3, subunit6 48 kDa 75 204112_s_at HNMT 50.23 9.76e-12 3.68e-09 histamineN-methyltransferase 2q21.3 Exemplarsequence Hs.81182.0 NM_006895.1g5901969 76 224915_x_at 50.16 2.00e-10 4.70e-08 Homo sapiens, cloneConsensussequence Hs.284158.1 AV756131 Hs.284158.1_RC IMAGE:5285034, mRNA 77 201696_at SFRS4 49.66 7.51e-10 1.44e-07 splicingfactor, arginine/serine- 1p35.2 Exemplarsequence Hs.76122.0NM_005626.1 g5032088 rich 4 78 209619_at CD74 49.48 7.68e-112.09e-08 CD74 antigen (invariant 5q32 Exemplarsequence Hs.84298.0K01144.1 g188469 polypeptide of major histocompatibility complex,class II antigen-associated) 79 208717_at OXA1L 49.39 1.08e-102.84e-08 oxidase (cytochrome c) 14q11.2 ExemplarsequenceHs.151134.0 BC001669.1 g12804516 assembly 1-like 80 221593_s_at VRP49.32 1.32e-10 3.36e-08 vascular Rab-GAP/TBC- 2q11.2Exemplarsequence Hs.164170.1 BC001663.1 q12804504 containing 81212038_s_at VDAC1 48.95 1.82e-10 4.40e-08 voltaga-dependent anion5q31 Consensusssequemce Hs.149155.2 AL515918 Hs.149155.2.A1 channel1 82 209259_s_at CSPG6 48.87 8.12e-10 1.55e-07 chondroitin sulfateproteoglycan 10q25 Exemplarsequence Hs.24485.0 AF020043.1 g30893676 (bamacan) 83 208635_x_at NACA 48.58 2.94e-10 6.25e-08nascent-polypeptide-associatad 12q23-q24.1 ConsensussequenceHs.158164.1 BF976260 Hs.158164.1.S1 complex alpha polypeptide 84223015_at eIF2a 48.10 2.62e-10 5.79e-08 eukaryolic translationinitiation 3q25.1 Exemplarsequence Hs.332404.0 AF212241.1 g13182760factor 2A eIF2a 85 224929_at 47.86 1.92e-10 4.56e-08 Homo sapienscDNA FLJ38577 Consensussequence Hs.86347.1 BG286973Hs.86347.1_RC

fis, clone HCHON2007650. 86 209408_at KIF2C 47.77 1.01e-09 1.89e-07kinesin family member 2C 1p34.1 Exemplarsequence Hs.69360.1U63743.1 g1695881 87 224741_x_at 47.22 4.18e-10 8.68e-08 Homosapiens mRNA; cDNA Consensussequence Hs.289721.1 BG329175Hs.289721.1.S1 DKFZp564D0164 (from clone DKFZp564D0164) 88216304_x_at YME1L1 47.17 1.48e-09 2.67e-07 YME1-like 1 (S.cerevisiae) 10p14 Consensussequence Hs.206521.1 AJ295618Hs.206521.1 89 214501_s_at H2AFY 47.15 2.75e-10 5.99e-08 H2Ahistone family, member Y 5q31.3-q32 Consensussequence Hs.75258.2AF044286.1 Hs.75258.2 90 226227_x_at 47.02 6.76e-10 1.33e-07 Homosapiens, clone Consensussequence Hs.284158.4 BF185165 Hs.284158.4IMAGE: 5285034, mRNA 91 226840_at 46.16 1.34e-10 3.36e-08 Homosapiens cDNA FLJ13771 Consensussequence Hs.288934.0 AW291297Hs.288934.0 fis, clone PLACE4000270. 92 210758_at PSIP1 45.753.08e-09 5.11e-07 PC4 and SFRS1 interacting 9p22.2 ExemplarsequenceHs.82110.0 AF098482.1 g4050033 protein 1 93 200735_x_at NACA 45.169.79e-10 1.84e-07 nascent-polypeptide-associated 12q23-q24.1Exemplarsequence Hs.32916.0 NM_005594.1 g5031930 complex alphapolypeptide 94 210844_x_at CTNNA1 45.11 5.70e-10 1.15e-07 catenin(cadherin-associated 5q31 Exemplarsequence Hs.178452.1 D14705.1g415305 protein), alpha 1, 102 kDa 95 219590_x_at CGI-30 44.955.27e-10 1.07e-07 CGI-30 protein 1p21.1 Exemplarsequence Hs.19978.0NM_015958.1 g7706271 96 218013_x_at DCTN4 44.82 6.71e-10 1.33e-07dynactin 4 (p62) 5q31-q32 Exemplarsequence Hs.180952.0 NM_016221.1g7705892 97 218735_s_at AF020591 44.59 2.81e-09 4.75e-07 zincfinger protein 19q13.43 Consensussequence Hs.142634.0 AA349848Hs.142634.0.S1 98 212018_s_at DKFZP564M182 44.11 7.48e-10 1.44e-07DKFZP564M182 protein 16p13.13 Consensussequence Hs.85963.0AK025446.1 Hs.85963.0 99 218619_s_at SUV39H1 44.08 2.41e-094.12e.07 suppressor of variegation 3-9 Xp11.23 ExemplarsequenceHs.37936.0 NM_003173.1 g4507320 homolog 1 (Drosophila) 100201352_at YME1L1 43.71 3.63e-09 5.81e-07 YME1-like 1 (S.cerevisiae) 10p14 Exemplarsequence Hs.206521.0 NM_014263.1 g7657688Sequence # Source Unigene_Accession Cluster_Type LocusLinkFull_Length_Reference_Seq 1 Genbank Hs.8715 fulllength 84273NM_032313; hypothetical protein MGC3232 2 RefSeq Hs.297875fulllength 64374 NM_022464; endoplasmic reticulum chaperone SIL1,homolog of yeast 3 RefSeq Hs.8170 fulllength 10412 NM_014886; TGFbeta-inducible nuclear protein 1 4 RefSeq Hs.63510 fulllength 9812NM_014773; KIAA0141 gene product 5 GenBank Hs.446502 est 6 GenBank7 GenBank Hs.122669 fulllength 23107 NM_015084; mitochondrialribosomal protein S27 8 RefSeq Hs.77324 fulllength 2107 NM_004730;eukaryotic translation termination factor 1 9 GenBank Hs.379754 10GenBank Hs.396644 fulllength 51247 NM_016480; polyadenylate-bindingprotein-interacting protein 2 11 GenBank Hs.256697 fulllength 3094NM_005340; histidine triad nucleotide binding protein 1 12 GenBankHs.154574 est 13 GenBank Hs.211539 fulllength 1968 NM_001415;eukaryotic translation initiation factor 2, subunit 3 gamma, 52 kDa14 GenBank Hs.301226 fulllength NM_003732; eukaryotic translationinitiation factor 4E binding protein 3 15 GenBank Hs.74267fulllength 6138 NM_002948; ribosomal protein L15 16 RefSeq Hs.13572fulllength 819 NM_001745; calcium modulating ligand 17 GenBankHs.29444 fulllength 85027 NM_032947; putative small membraneprotein NID67 18 GenBank Hs.406051 fulllength 54833 NM_017685;hypothetical protein FLJ20139 19 GenBank Hs.256697 fulllength 3094NM_005340; histidine triad nucleotide binding protein 1 20 RefSeqHs.256697 fulllength 3094 NM_005340; histidine triad nucleotidebinding protein 1 21 GenBank Hs.431584 fulllength 6208 NM_005617;ribosomal protein S14 22 GenBank Hs.235422 fulllength 9045NM_003973; ribosomal protein L14 23 RefSeq Hs.283437 fulllength56951 NM_020199; HTGN29 protein 24 GenBank Hs.106469 fulllength6832 NM_003171; suppressor of var1, 3-like 1 25 GenBank Hs.289082fulllength 2760 NM_000405; GM2 ganglioside activator proteinprecursor 26 RefSeq Hs.108332 fulllength 7322 NM_003339;ubiquitin-conjugating enzyme E2D 2 (UBC4/5 homolog, yeast) 27GenBank Hs.430075 fulllength 1350 NM_001867; cytochrome c oxidasesubunit VIIc precursor 28 RefSeq Hs.240457 fulllength 5883NM_004584; RAD9 homolog 29 GenBank Hs.441133 fulllength 51611NM_015958; CGI-30 protein 30 RefSeq Hs.35086 fulllength 7398NM_003368; ubiquitin specific protease 1 31 GenBank Hs.91773fulllength 5515 NM_002715; protein phosphatase 2 (formerly 2A),catalytic subunit, alpha isoform 32 GenBank Hs.183096 fulllength 33RefSeq Hs.257111 fulllength 78991 NM_024028; hypothetical proteinMGC3265 34 RefSeq Hs.79322 fulllength 5859 NM_005051;glutaminyl-tRNA synthetase 35 GenBank Hs.256697 fulllength 3094NM_005340; histidine triad nucleotide binding protein 1 36 GenBankHs.225841 26109 37 GenBank Hs.391318 285603 NM_175920; hypotheticalprotein FLJ39485 38 GenBank Hs.155481 fulllength 10491 NM_006371;cartilage associated protein 39 GenBank Hs.289082 fulllength 2760NM_000405; GM2 ganglioside activator protein precursor 40 GenBankHs.63510 fulllength 9812 NM_014773; KIAA0141 gene product 41GenBank Hs.80545 42 RefSeq Hs.2001 fulllength 6916 NM_001061;thromboxane A synthase 1 (platelet, cytochrome P450, family 5,subfamily A) isoform TXS-I NM_030984; thromboxane A synthase 1(platelet, cytochrome P450, family 5, subfamily A) isoform TXS-II43 GenBank Hs.24529 est 44 RefSeq Hs.132881 fulllength 5201NM_002622; prefoldin 1 45 GenBank Hs.64639 fulllength 11010NM_006851; glioma pathogenesis-related protein 46 GenBank Hs.283330fulllength 55378 NM_018507; hypothetical protein PRO1843 47 RefSeqHs.3709 fulllength 27089 NM_014402; low molecular massubiquinone-binding protein 48 RefSeq Hs.81848 fulllength 5885NM_006265; RAD21 homolog 49 GenBank Hs.122752 fulllength 6873NM_003184; TBP-associated factor 2 50 GenBank Hs.262036 51 RefSeqHs.83077 fulllength 3606 NM_001562; interleukin 18 proprotein 52RefSeq Hs.279952 fulllength 51064 NM_015917; glutathioneS-transferase subunit 13 homolog 53 GenBank Hs.334819 fulllength84447 NM_032431; HRD1 protein isoform a NM_172230; HRD1 proteinisoform b 54 GenBank Hs.10758 fulllength 4724 NM_002495; NADHdehydrogenase (ubiquinone) Fe--S protein 4, 18 kDa (NADH-coenzyme Qreductase) 55 GenBank Hs.115920 56 GenBank Hs.396644 fulllength51247 NM_016480; polyadenylate-binding protein-interacting protein2 57 RefSeq Hs.42636 fulllength 11179 NM_021994; zinc fingerprotein (C2H2 type) 277 58 RefSeq Hs.9661 fulllength 5699NM_002801; proteasome beta 10 subunit proprotein 59 GenBankHs.233425 est 60 RefSeq Hs.3631 fulllength 3476 NM_001551;immunoglobulin (CD79A) binding protein 1 61 RefSeq Hs.8127fulllength 9898 NM_014847; NICE-4 protein 62 RefSeq Hs.32922fulllength 55602 NM_017632; collaborates/cooperates with ARF(alternate reading frame) protein 63 RefSeq Hs.166563 fulllength5981 NM_002913; replication factor C large subunit NM_006081; 64RefSeq Hs.91417 fulllength 11073 NM_007027; topoisomerase (DNA) IIbinding protein 65 GenBank Hs.54673 fulllength 8741 NM_003808;tumor necrosis factor ligand superfamily, member 13 isoform alphaprecursor NM_172087; tumor necrosis factor ligand superfamily,member 13 isoform beta NM_172088; tumor necrosis factor ligandsuperfamily, member 13 isoform gamma NM_172089; tumor necrosisfactor ligand superfamily, member 13 isoform delta 66 RefSeqHs.98428 fulllength 3216 NM_018952; homeo box B6 isoform 1NM_156036; homeo box B6 isoform 2 NM_156037; homeo box B6 isoform 167 GenBank Hs.430075 fulllength 1350 NM_001867; cytochrome coxidase subunit VlIc precursor 68 GenBank Hs.433267 fulllength192286 NM_138820; hypothetical protein MGC2198 69 GenBank Hs.28972170 GenBank Hs.8217 fulllength 10735 NM_006603; stromal antigen 2 71GenBank Hs.15093 fulllength 51523 NM_016463; hypothetical proteinHSPC195 72 GenBank Hs.108332 fulllength 7322 NM_003339;ubiquitin-conjugating enzyme E2D 2 (UBC4/5 homolog, yeast) 73GenBank Hs.183096 fulllength 74 GenBank Hs.106673 fulllength 3646NM_001568; murine mammary tumor integration site 6 (oncogenehomolog) 75 RefSeq Hs.81182 fulllength 3176 NM_006895; histamineN-methyltransferase 76 GenBank Hs.356766 77 RefSeq Hs.76122fulllength 6429 NM_005626; splicing factor, arginine/serine-rich 478 GenBank Hs.84298 fulllength 972 NM_004355; invariant gamma chain79 GenBank Hs.151134 fulllength 5018 NM_005015; oxidase (cytochromec) assembly 1-like 80 GenBank Hs.164170 fulllength 11138 NM_007063;TBC1 domain family, member 8 (with GRAM domain) 81 GenBankHs.149155 fulllength 7416 NM_003374; voltage-dependent anionchannel 1 82 GenBank Hs.24485 fulllength 9126 NM_005445;chondroitin sulfate proteoglycan 6 (bamacan) 83 GenBank Hs.32916fulllength 4666 NM_005594; nascent-polypeptide-associated complexalpha polypeptide 84 GenBank Hs.332404 fulllength 83939 NM_032025;CDA02 protein 85 GenBank Hs.379754 86 GenBank Hs.69360 fulllength11004 NM_006845; kinesin family member 2C 87 GenBank Hs.289721 88GenBank Hs.206521 fulllength 10730 NM_014263; YME1-like 1 isoform 3NM_139312; YME1-like 1 isoform 1 NM_139313; YME1-like 1 isoform 289 GenBank Hs.75258 fulllength 9555 NM_004893; H2A histone family,member Y isoform 2 NM_138609; H2A histone family, member Y isoform1 NM_138610; H2A histone family, member Y isoform 3 90 GenBankHs.356766 91 GenBank Hs.288934 92 GenBank Hs.351305 fulllength 909093 RefSeq Hs.32916 fulllength 4666 NM_005594;nascent-polypeptide-aasociated complex alpha polypeptide 94 GenBankHs.177556 fulllength 1495 NM_001903; catenin (cadherin-associatedprotein), alpha 1, 102 kDa 95 RefSeq Hs.441133 fulllength 51611NM_015958; CGI-30 protein 96 RefSeq Hs.328865 fulllength 51164NM_016221; dynactin 4 (p62) 97 GenBank Hs.142634 fulllength 27300NM_014480; zinc finger protein AF020591 98 GenBank Hs.85963fulllength 26156 99 RefSeq Hs.37936 fulllength 6839 NM_003173;suppressor of variegation 3-9 homolog 1 100 RefSeq Hs.206521fulllength 10730 NM_014263; YME1-like 1 isoform 3 NM_139312;YME1-like 1 isoform 1 NM_139313; YME1-like 1 isoform 2

TABLE-US-00039 TABLE 38 Sequence HUGO Map Sequence Derived Numberaffy id name fc p q stn t Location Type Transcript ID From 74231982_at 4.69 8.4E-23 1.89E-19 0.81 11.41 Consensus Hs.130714.0AF161441.1 sequence 62 209160_at AKR1C3 3.98 4.56E-24 2.53E-20 0.8111.58 10p15-p14 Exemplar Hs.78183.0 AB018580.1 sequence 142235142_at MGC17919 3.79 1.34E-19 9.66E-17 0.71 10.13 1p34.3Consensus Hs.129837.0 AW006067 sequence 124 230460_at 3.61 2.7E-202.99E-17 0.72 10.31 Consensus Hs.79844.1 AI609804 sequence 190213258_at 3.38 4.31E-18 1.56E-15 0.68 9.68 Consensus Hs.288582.0BF511231 sequence 300 226342_at 3.38 2E-16 4.06E-14 0.63 8.97Consensus Hs.238443.0 AW593244 sequence 269 210664_s_at TFPI 3.334.86E-16 8.4E-14 0.66 9.14 2q31-q32.1 Exemplar Hs.170279.1AF021834.1 sequence 258 230894_s_at 3.27 1.73E-15 2.41E-13 0.699.19 Consensus Hs.42640.1 BE672557 sequence 140 225240_s_at 3.249.79E-19 4.62E-16 0.73 10.15 Consensus Hs.42179.0 BF435123 sequence161 202933_s_at YES1 3.04 4.16E-19 2.38E-16 0.7 9.9718p11.31-p11.21 Exemplar Hs.194148.0 NM_005433.1 sequence 218226134_s_at 3.02 1.38E-16 3.06E-14 0.69 9.42 Consensus Hs.42640.0AI978754 sequence 139 202932_at YES1 2.99 8.22E-20 6.83E-17 0.7110.15 18p11.31-p11.21 Exemplar Hs.194148.0 NM_005433.1 sequence 242227860_at CPXM 2.95 3.39E-17 8.81E-15 0.66 9.31 20p12.3-p13Consensus Hs.177536.0 NM_019609.1 sequence 163 238498_at 2.862.75E-18 1.12E-15 0.72 9.95 Consensus Hs.46922.0 AA583038 sequence138 211071_s_at AF1Q 2.81 9.98E-20 7.9E-17 0.71 10.16 1q21 Exemplarg13623686 BC006471.1 sequence 180 228046_at LOC152485 2.4 1.48E-186.45E-16 0.69 9.79 4q31.1 Consensus Hs.11325.0 AA741243 sequence196 204453_at ZNF84 2.32 1.13E-17 3.43E-15 0.69 9.65 12q24.33Exemplar Hs.9450.0 NM_003428.1 sequence 127 226043_at AGS3 2.223.82E-18 1.44E-15 0.76 10.27 9q34.3 Consensus Hs.239370.0 AI242661sequence 131 226157_at 2.22 2.55E-19 1.69E-16 0.73 10.24 ConsensusHs.19131.2 AI569747 sequence 212 242028_at FLJ38281 2.17 1.29E-173.83E-15 0.67 9.48 19p13.13 Consensus Hs.293223.0 AI800025 sequence195 227934_at 2.09 4.56E-18 1.59E-15 0.68 9.66 Consensus Hs.24252.0AI789559 sequence 271 204663_at ME3 2.06 2.27E-16 4.48E-14 0.659.14 11cen-q22.3 Exemplar Hs.2838.0 NM_006680.1 sequence 296223714_at ZNF258 2.06 2E-15 2.7E-13 0.66 8.99 19q13.43 ExemplarHs.161751.0 BC001438.1 sequence 151 209490_s_at PPT2 2.04 6.73E-192.89E-16 0.72 10.07 6p21.3 Exemplar Hs.81737.0 AF020543.1 sequence235 202732_at PKIG 2.04 3.65E-14 2.97E-12 0.77 9.36 20q12-q13.1Exemplar Hs.3407.0 NM_007066.1 sequence 63 202365_at MGC5139 1.572.9E-22 2.9E-19 0.84 11.57 12q24.31 Exemplar Hs.127610.0 BC004815.1sequence 206 228402_at MGC15435 1.88 2.19E-17 5.86E-15 0.68 9.515q13.2 Consensus Hs.152060.0 AI679968 sequence 186 37590_g_at 1.833.82E-16 7.05E-14 0.75 9.75 Consensus 4876007 AL109698 sequence 150225314_at MGC45416 1.82 3.15E-17 8.31E-15 0.78 10.08 4p11 ConsensusHs.95835.0 BG291649 sequence 225 213779_at LOC129080 1.82 8.76E-171.6E-14 0.68 9.41 22q12.1 Consensus Hs.289106.0 AL031186 sequence285 218966_at MYO5C 1.8 1.41E-16 3.09E-14 0.64 9.06 15q21 ExemplarHs.111782.0 NM_018728.1 sequence 209 213666_at 38236 1.79 6.49E-171.57E-14 0.69 9.5 Xq24 Consensus Hs.90998.1 AK026589.1 sequence 208223162_s_at LCHN 1.76 1.48E-16 3.17E-14 0.7 9.5 7q34 ExemplarHs.12461.0 AF116707.1 sequence 129 224841_x_at 1.5 1.51E-152.12E-13 0.86 10.25 Consensus Hs.289721.2 BF316352 sequence 154224741_x_at 1.5 4.27E-15 5.03E-13 0.85 10.05 Consensus Hs.289721.1BG329175 sequence Full Length Sequence Sequence Unigene ClusterLocus Reference Number ID Source Accession Type Link Seq 74Hs.130714.0 GenBank Hs.130714 62 g6624210 GenBank Hs.78183fulllength 8644 NM_003739; aldo-keto reductase family 1, member C3142 Hs.129837.0_RC GenBank Hs.129837 fulllength 127557 NM_144621;hypothetical protein MGC17919 124 Hs.79844.1.A1 GenBank Hs.433736190 Hs.288582.0_RC GenBank Hs.87980 est 300 Hs.236443.0.S1 GenBankHs.236443 269 g4103170 GenBank Hs.170279 fulllength 7035 NM_006287;tissue factor pathway inhibitor (lipoprotein-associated coagulationinhibitor) 258 Hs.42640.1.A1 GenBank Hs.173179 140 Hs.42179.0.A1GenBank Hs.173179 161 g4885660 RefSeq Hs.194148 fulllength 7525NM_005433; viral oncogene yes-1 homolog 1 218 Hs.42640.0.A1 GenBankHs.173179 139 g4885660 RefSeq Hs.194148 fulllength 7525 NM_005433;viral oncogene yes-1 homolog 1 242 Hs.177536.0 GenBank Hs.177536fulllength 56265 NM_019609; metallocarboxypeptidase CPX-1 precursor163 Hs.46922.0.A1 GenBank Hs.349207 138 g13623686 GenBank Hs.75823fulllength 10962 NM_006818; AF1Q protein 180 Hs.11325.0.A1 GenBankHs.351270 152485 NM_178835; hypothetical protein LOC152485 196g4508036 RefSeq Hs.9450 fulllength 7637 NM_003428; zinc fingerprotein 84 (HPF2) 127 Hs.239370.0.S1 GenBank Hs.239370 fulllength26086 NM_015597; activator of G-protein signaling 3 131Hs.19131.2.A1 GenBank Hs.398090 212 Hs.293223.0.A1 GenBankHs.293223 fulllength 163051 NM_152601; hypothetical proteinFLJ38281 195 Hs.24252.0_RC GenBank Hs.24252 est 271 g5729919 RefSeqHs.376590 fulllength 10873 NM_006680; malic enzyme 3,NADP(+)-dependent, mitochondrial 296 g12655164 GenBank Hs.161751fulllength 10172 NM_005773; zinc finger protein 256 151 g2501960GenBank Hs.81737 fulllength 9374 NM_005155; palmitoyl-proteinthioesterase 2 isoform a precursor NM_138717; palmitoyl-proteinthioesterase 2 isoform b precursor NM_138934; palmitoyl-proteinthioesterase 2 isoform c precursor 235 g5902019 RefSeq Hs.3407fulllength 11142 NM_007068; protein kinase (cAMP-dependent,catalytic) inhibitor gamma 63 g13435956 GenBank Hs.127610fulllength 84747 NM_032661; hypothetical protein MGC5139 206Hs.152060.0_RC GenBank Hs.152060 fulllength 84327 NM_032367; zincfinger, BED domain containing 3 186 4876007 GenBank Hs.323053 150Hs.95835.0.A1 GenBank Hs.95835 fulllength 132299 NM_152398;hypothetical protein MGC45418 225 Hs.289106.0.S1 GenBank Hs.289106fulllength 129080 NM_133455; emilin and multimerin-domaincontaining protein 1 285 g9055283 RefSeq Hs.111782 fulllength 55930NM_018728; myosin VC 209 Hs.90998.1.S1 GenBank Hs.90998 fulllength23157 NM_015129; septin 6 isoform B NM_145799; septin 6 isoform ANM_145800; septin 6 isoform A NM_145802; septin 6 isoform D 208g7959912 GenBank Hs.233044 fulllength 57189 129 Hs.289721.2.S1GenBank Hs.289721 154 Hs.289721.1.S1 GenBank Hs.289721

TABLE-US-00040 TABLE 39 Map Number affy id HUGO name fc p q stn tLocation 239 211135_x_at LILRB3 -12.15 6.41E-12 2.38E-10 -1.18-9.35 19q13.4 278 210225_x_at LILRB3 -9.8 1.21E-11 3.92E-10 -1.11-9.1 19q13.4 132 210784_x_at LILRB3 -9.47 3.39E-13 1.95E-11 -1.22-10.23 19q13.4 275 215646_s_at CSPG2 -9.47 1.07E-11 3.55E-10 -1.09-9.12 5q14.3 96 205936_s_at HK3 -8.7 4.72E-14 3.75E-12 -1.3 -10.885q35.2 89 226841_at LOC219972 -7.61 1.81E-14 1.63E-12 -1.27 -11.1111q12.1 264 205789_at CD1D -7.35 8.04E-12 2.83E-10 -1.05 -9.161q22-q23 210 210992_x_at FCGR2A -7.21 3.54E-12 1.49E-10 -1.15 -9.491q23 83 220266_s_at KLF4 -6.87 1.38E-14 1.3E-12 -1.29 -11.21 9q31299 211133_x_at LILRB3 -6.55 1.85E-11 5.67E-10 -1.1 -8.98 19q13.419 226818_at LOC219972 -6.45 9.4E-18 2.89E-15 -1.45 -13.49 11q12.135 202295_s_at CTSH -6.45 2.21E-16 4.43E-14 -1.41 -12.56 15q24-q25211 206934_at SIRP81 -6.42 3.18E-12 1.38E-10 -1.12 -9.49 20p13 259219788_at PILR -6.11 1.09E-11 3.59E-10 -1.17 -9.18 7q22 21201422_at FI30 -5.99 4.24E-18 1.56E-15 -1.34 -13.36 19p13.1 54222218_s_at PILR -5.97 4.02E-15 4.84E-13 -1.42 -11.75 7q22 76222670_s_at MAFB -5.73 3.58E-15 4.4E-13 -1.2 -11.37 20q11.2-q13.169 211429_s_at SERPINA1 -5.7 4.62E-15 5.39E-13 -1.29 -11.51 14q32.1267 212192_at LOC115207 -5.66 6E-12 2.26E-10 -0.99 -9.14 13q21.33100 209696_at FBP1 -5.57 5.12E-14 4.01E-12 -1.26 -10.82 9q22.3 202210895_s_at CD86 -5.57 1.92E-12 8.88E-11 -1.1 -9.6 3q21 44206278_at PTAFR -5.58 6.23E-16 1.01E-13 -1.34 -12.14 1p35-p34.3 224213566_at RNASE6 -5.51 2.42E-12 1.09E-10 -1.02 -9.41 14q11.1 31221731_x_at CSPG2 -5.42 1.53E-17 4.46E-15 -1.24 -12.7 5q14.3 152202878_s_at C1QR1 -5.39 4.95E-13 2.67E-11 -1.17 -10.07 20p11.21 250204961_s_at NCF1 -5.37 3.81E-12 1.57E-10 -0.98 -9.24 7q11.23 25204820_s_at CSPG2 -5.15 5.76E-18 1.91E-15 -1.25 -12.94 5q14.3 48218559_s_at MAFB -5.15 1.24E-16 2.83E-14 -1.15 -11.97 20q11.2-q13.118 218217_at RISC -5.13 5.4E-18 1.83E-15 -1.42 -13.55 17q23.1 101206380_s_at PFC -5.13 4.28E-14 3.46E-12 -1.23 -10.81 Xp11.3-p11.23256 220088_at C5R1 -5.06 5.3E-12 2.04E-10 -1.01 -9.21 19q13.3-q13.411 200782_at ANXA5 -5 3.18E-19 2.03E-16 -1.41 -14.17 4q28-q32 70203767_s_at STS -4.82 4.64E-15 5.39E-13 -1.29 -11.51 Xp22.32 34222496_s_at FLJ20273 -4.75 6.33E-17 1.57E-14 -1.29 -12.57 4p13-p12228 205237_at FCN1 -4.73 2.29E-12 1.04E-10 -1 -9.39 9p34 284205685_at CD86 -4.71 8.24E-12 2.88E-10 -1 -9.07 3p21 137 220066_atCARD15 -4.54 2.36E-13 1.46E-11 -1.11 -10.16 16p12-q21 42 209949_atNCF2 -4.48 1.99E-16 4.06E-14 -1.24 -12.17 1q25 12 204232_at FCER1G-4.33 2.66E-18 1.11E-15 -1.51 -14 1q23 4 208438_s_at FGR -1.312.39E-20 2.99E-17 -1.54 -15.23 1p36.2-p36.1 294 234985_at LOC143458-4.3 1.08E-11 3.56E-10 -1.01 -9.02 11p13 167 208983_a_at PECAM1-4.28 3.21E-13 1.87E-11 -1.03 -9.93 17q23 46 219505_at CECR1 -4.185.08E-16 8.7E-14 -1.26 -12 22q11.2 130 211661_x_at PTAFR -4.012.08E-13 1.33E-11 -1.14 -10.24 1p35-p34.3 72 211101_x_at LILRA2-3.99 3.83E-15 4.64E-13 -1.24 -11.46 19q13.4 79 204502_at SAMHD1-3.98 3.39E-15 4.24E-13 -1.15 -11.26 20pter-q12 121 204081_at NRGN-3.95 7.5E-14 5.55E-12 -1.06 -10.33 11q24 94 224356_x_at MSA4A6A-3.92 3.05E-15 3.92E-13 -1.07 -11.02 11q12.1 102 218035_s_atFLJ20273 -3.9 7.3E-15 7.73E-13 -1.05 -10.79 4p13-p12 15 211284_s_atGRN -3.87 1.64E-18 6.97E-16 -1.44 -13.89 17q21.31 90 223280_x_atMS4A6A -3.86 1.82E-15 2.5E-13 -1.06 -11.11 11q12.1 105 237255_at-3.86 1.37E-14 1.3E-12 -1.06 -10.68 220 211100_x_at LILRA2 -3.863.91E-12 1.6E-10 -1.1 -9.41 19q13.4 57 200866_s_at PSAP -3.841.89E-15 2.58E-13 -1.27 -11.7 10q21-q22 80 207270_x_at CMRF35 -3.841.56E-14 1.44E-12 -1.32 -11.23 17q25.2 64 202902_s_at CTSS -3.813.18E-15 4.04E-13 -1.26 -11.56 1q21 106 205859_at LY86 -3.731.68E-14 1.54E-12 -1.07 -10.67 6p24.3 95 207857_at LILRA2 -3.718.43E-15 8.64E-13 -1.14 -11.01 19q13.4 9 216041_x_at GRN -3.74.94E-19 2.83E-16 -1.45 -14.22 17q21.32 82 227184_at -3.68 9.52E-159.64E-13 -1.23 -1.21 243 233555_s_at SULF2 -3.68 3.48E-12 1.48E-10-1 -9.29 20q12-13.2 145 212335_at GNS -3.67 3.6E-13 2.04E-11 -1.15-10.11 12q14 65 225059_at AGTRAP -3.66 2.16E-15 2.88E-13 -1.22-11.55 1p36.21 166 209288_s_at CDC42EP3 -3.66 2.67E-13 1.63E-11-1.02 -9.93 2p21 88 203673_at GNS -3.62 1.11E-14 1.1E-12 -1.21-11.12 12q14 229 202284_s_at CDKN1A -3.62 2.53E-12 1.14E-10 -1.01-9.39 6p21.2 290 223168_at ARHU -3.61 7.66E-12 2.73E-10 -0.97 -9.041q42.11-q42.3 162 208594_x_at ILT8 -3.55 6.87E-13 3.13E-11 -1.13-9.96 19q13.4 263 202877_s_at C1QR1 -3.55 7.89E-12 2.79E-10 -1.06-9.17 20p11.21 33 204487_s_at KCNQ1 -3.54 1.9E-17 5.18E-15 -1.23-12.64 11p15.5 282 235798_at -3.53 4.73E-12 1.85E-10 -0.94 -9.09177 205839_at AOAH -3.51 5.96E-13 3.18E-11 -1.05 -9.81 7p14-p12 175200838_at CTSB -3.5 8.17E-13 4.16E-11 -1.11 -9.84 8p22 174208949_s_at LGALS3 -3.49 2.52E-13 1.55E-11 -0.98 -9.84 14q21-q22255 223922_x_at MS4A6A -3.48 3.41E-12 1.46E-10 -0.96 -9.21 11q12.114 200676_x_at GRN -3.47 1E-18 4.62E-16 -1.41 -13.92 17q21.32 30224583_at COTL1 -3.47 4.24E-17 1.08E-14 -1.33 -12.79 16q23.3 251210184_at ITGAX -3.45 1.92E-12 8.88E-11 -0.91 -9.23 16p11.2 112208981_at PECAM1 -3.41 4.6E-14 3.67E-12 -1.12 -10.58 17q23 286209286_at -3.41 3.11E-12 1.35E-10 -0.89 -9.06 17 201360_at CST3-3.34 1.33E-19 9.66E-17 -1.23 -13.56 20p11.21 84 228532_at MGC24133-3.32 6.03E-15 6.73E-13 -1.18 -11.2 1p13.1 3 221841_s_at -3.311.17E-24 9.73E-21 -1.35 -15.91 28 203973_s_at CEBPD -3.3 3.89E-192.38E-16 -1.13 -12.86 8p11.2p11.1 265 225685_at -3.25 2.93E-121.29E-10 -0.92 -9.16 246 204924_at TLR2 -3.24 3.51E-12 1.48E-10-0.99 -9.26 4q32 92 207704_s_at GAS7 -3.2 1.34E-14 127E-12 -1.2-11.07 17p 108 212334_at GNS -3.2 3.6E-14 2.96E-12 -1.12 -10.6512q14 111 217728_at S100A6 -3.18 3.58E-14 2.96E-12 -1.1 -10.58 1q21295 229041_s_at -3.16 4.73E-12 1.85E-10 -0.9 -9.01 73 221866_atTFEB -3.15 7.2E-16 1.13E-13 -1.1 -11.43 8p21 156 204254_s_at VDR-3.15 1.91E-13 1.23E-11 -1.03 -10.04 12q12-q14 36 202897_at PTPNS1-3.08 6.52E-17 1.57E-14 -1.29 -12.56 20p13 8 213503_x_at ANXA2-3.07 1.4E-20 1.93E-17 -1.31 -14.32 15q21-q22 66 221059_s_at CHST6-3.07 7.26E-16 1.13E-13 -1.13 -11.54 18q22 77 235678_at -3.068.07E-15 8.34E-13 -1.29 -11.36 10 201590_x_at ANXA2 -3.05 3.55E-203.69E-17 -1.31 -14.18 15q21-q22 41 200872_at S100A10 -3.05 7.64E-182.39E-15 -1.1 -12.22 1q21 164 210904_s_at IL13RA1 -3.03 2.59E-131.59E-11 -1.02 -9.95 Xq24 20 201944_at HEXB -3.01 3E-18 1.16E-15-1.35 -13.47 5q13 146 203300_x_at AP1S2 -3 3.76E-13 2.13E-11 -1.15-10.11 Xp22.31 197 230395_at -3 1.8E-13 1.17E-11 -0.9 -9.65 3735820_at GM2A -2.99 5.97E-17 1.5E-14 -1.26 -12.51 5q31.3-q33.1 16210427_x_at ANXA2 -2.95 6.87E-20 6E-17 -1.27 -13.58 15q21-q22 155212807_s_at SORT1 -2.92 2.27E-13 1.42E-11 -1.05 -10.04 1p21.3-p13.1227 235670_at -2.92 8.78E-13 4.41E-11 -0.91 -9.39 273 215990_s_atBCL6 -2.92 5.04E-12 1.96E-10 -0.96 -9.13 3q27 61 204057_at ICSBP1-2.9 1.2E-18 5.39E-16 -0.94 -11.6 16q24.1 200 224818_at -2.892.48E-13 1.53E-11 -0.91 -9.63 40 204122_at TYROBP -2.87 9.76E-172.28E-14 -1.22 -12.24 19q13.1 293 203769_s_at STS -2.87 8.88E-123.07E-10 -0.98 -9.02 Xp22.32 116 225373_at PP2135 -2.86 3.63E-142.97E-12 -1.07 -10.5 10q22.3 52 230264_s_at AP1S2 -2.85 6.59E-161.05E-13 -1.19 -11.76 Xp22.31 81 229101_at -2.84 1.48E-15 2.1E-13-1.08 -11.23 181 202391_at BASP1 -2.83 3.24E-14 2.73E-12 -0.86-9.79 5p15.1-p14 78 211067_s_at GAS7 -2.81 3.39E-15 4.24E-13 -1.18-11.34 17p 122 201105_at LGALS1 -2.8 6.4E-15 6.96E-13 -0.92 -10.3222q13.1 201 201531_at ZFP36 -2.8 7.68E-13 3.96E-11 -0.99 -9.6119q13.1 245 201642_at IFNGR2 -2.79 3.86E-12 1.59E-10 -1 -9.2721q22.11 169 209575_at IL10RB -2.77 4.92E-13 2.67E-11 -1.06 -9.8821q22.11 187 208982_at PECAM1 -2.77 2.23E-13 1.4E-11 -0.94 -9.7417q23 43 208683_at CAPN2 -2.76 4.59E-18 1.59E-15 -1.07 -12.161q41-q42 173 217897_at FXYD6 -2.76 2.3E-13 1.43E-11 -0.98 -9.8511q23.3 198 203388_at ARRB2 -2.75 8.21E-13 4.17E-11 -1.01 -9.6419q13 266 225604_s_at C9of19 -2.73 2.75E-12 1.23E-10 -0.91 -9.159p13-p12 168 204774_at EVI2A -2.72 4.01E-13 2.24E-11 -1.05 -9.9217q11.2 237 202426_s_at RXRA -2.71 6.78E-13 3.52E-11 -0.88 -9.359q34.3 153 206816_x_at ANXA2P2 -2.69 2.83E-13 1.68E-11 -1.08 -10.059p13 50 204158_s_at TCIRG1 -2.68 5.3E-16 8.97E-14 -1.18 -11.7611q13.4-q13.5 59 100839_s_at CTSB -2.67 3.51E-16 6.7E-14 -1.13-11.66 8p22 71 232617_at CTSS -2.67 1.04E-15 1.53E-13 -1.15 -11.511q21 53 212737_at GM2A -2.65 8.37E-16 1.26E-13 -1.21 -11.765q31.3-q33.1 193 208906_s_at CAST -2.65 5.99E-13 3.18E-11 -0.99-9.67 5q15-q21 182 228234_at -2.64 2.64E-13 1.61E-11 -0.96 -9.77 58203186_s_at S100A4 -2.62 1.72E-16 3.57E-14 -1.09 -11.67 1q21 2202803_s_at ITGB2 -2.6 9.79E-24 4.07E-20 -1.5 -16.57 21q22.3 97203140_at BCL6 -2.59 1.47E-52 2.1E-13 -0.99 -10.87 3q27 67211612_s_at IL13RA1 -2.58 5.34E-16 8.97E-14 -1.11 -11.53 Xq24 115205786_s_at ITGAM -2.58 3.17E-15 4.04E-13 -0.94 -10.52 16p11.2 280210314_x_at TNFSF13 -2.58 3.29E-12 1.41E-10 -0.91 -9.1 17p13.1 22203535_at S100A9 -2.56 9.12E-23 1.89E-19 -1.03 -13.19 1q21 135218376_s_at MICAL -2.56 2.65E-14 2.26E-12 -0.95 -10.2 6q21 277210785_s_at C10orf38 -2.58 3.24E-12 1.39E-10 -0.91 -9.11 1p35.2 179203555_at PTPN18 -2.55 4.63E-13 2.55E-11 -1.01 -9.79 2q21.1 45226276_at LOC153339 -2.53 5.97E-16 9.83E-14 -1.3 -12.06 5q14.1 185205707_at IL17R -2.53 2.19E-13 1.38E-11 -0.94 -9.75 22q11.1 241202896_s_at PTPNS1 -2.52 1.66E-12 7.8E-11 -0.93 -9.32 20p13 38214875_x_at APLP2 -2.51 1.81E-17 5.08E-15 -1.15 -12.33 11q24 217225602_at C9orf19 -2.5 8.12E-13 4.15E-11 -0.92 -9.42 9p13-p12 231204174_at ALOX5AP -2.5 3.56E-13 2.03E-11 -0.86 -9.39 13q12 110226063_at -2.48 8.09E-15 8.34E-13 -1.01 -10.62 68 225530_at moblak-2.46 7.94E-16 1.21E-13 -1.13 -11.53 19p13.3 262 228648_at LRG-2.44 9.59E-13 4.78E-11 -0.85 -9.17 19p13.3 261 203167_at TIMP2-2.43 3.42E-12 1.46E-10 -0.94 -9.17 17q25 270 206050_s_at RNH -2.436.28E-12 2.34E-10 -1 -9.14 11p15.5 133 217024_x_at -2.41 2.03E-141.8E-12 -0.95 -10.23 188 218092_s_at HRB -2.4 8.67E-13 4.37E-11-1.04 -9.7 2q36 125 227649_s_at -2.38 9.87E-15 9.94E-13 -0.93 -10.3136 224374_s_at EMILIN-2 -2.38 9.42E-14 6.6E-12 -1.03 -10.1918p11.3 143 207467_x_at CAST -2.38 8.54E-14 6.07E-12 -1 -10.125q15-q21 159 203520_s_at ZFP318 -2.38 8.02E-14 5.8E-12 -0.95 -9.986pter-p12.1 13 208702_x_at APLP2 -2.37 2.68E-20 2.99E-17 -1.26-13.98 11q24 23 220023_at APOB48R -2.37 1.45E-19 1.01E-16 -1.16-13.14 16p11 298 227276_at TEM7R -2.37 8.13E-12 2.85E-10 -0.95-8.98 10p12.1 236 203507_at CD68 -2.35 1.59E-12 7.56E-11 -0.95-9.36 17p13 1 200871_s_at PSAP -2.32 3.62E-30 6.01E-26 -1.33 -17.0110q21-q22 233 238469_at -2.32 1.23E-12 5.94E-11 -0.93 -9.37 178202670_at MAP2K1 -2.31 3.22E-13 1.87E-11 -0.99 -9.81 15q22.1-q22.33119 223502_s_at TNFSF138 -2.3 3.64E-15 4.45E-13 -0.91 -10.3813q32-34 283 203299_s_at AP1S2 -2.3 4.58E-12 1.81E-10 -0.93 -9.07Xp22.31 147 211250_s_at SH3BP2 -2.27 9.9E-14 6.88E-12 -1 -10.114p16.3 247 222774_s_at NETO2 -2.26 8.06E-13 4.13E-11 -0.87 -9.26184 202096_s_at BZRP -2.23 2.13E-13 1.35E-11 -0.94 -9.75 22q13.31 6211404_s_at APLP2 -2.22 5.83E-23 1.61E-19 -1.31 -15.14 11q24 128223376_s_at BRI3 -2.22 7.1E-14 5.32E-12 -1.03 -10.26 7q21.3 171225695_at -2.22 1.69E-14 1.54E-12 -0.86 -9.87 149 237563_s_at -2.21.06E-13 7.29E-12 -1 -10.09 86 206034_at SERPINB6 -2.18 3.88E-187.08E-14 -1.02 -11.18 18q21.3 248 217627_s_at ACP33 -2.18 3.08E-121.35E-10 -0.97 -8.25 15q21-q22 249 226140_a_at -2.19 6.33E-133.33E-11 -0.85 -9.24 51 224846_at LOC92799 -2.17 1.83E-17 5.08E-15-1.03 -11.76 19q13.13 203 212041_at ATP6V0D1 -2.16 4.8E-13 2.62E-11-0.94 -9.6 16q22 244 202192_s_at GAS7 -2.16 3.99E-13 2.24E-11 -0.84-9.27 17p 126 204971_at CSTA -2.15 4.08E-16 7.36E-14 -0.84 -10.293q21 276 200661_at PPGB -2.15 1.28E-12 6.13E-11 -0.85 -9.12 20q13.1288 214574_x_at LST1 -2.15 3.02E-12 1.33E-10 -0.88 -9.05 6p21.3 205228685_at -2.14 1.7E-13 1.12E-11 -0.86 -9.53 75 211742_s_at EVI2B-2.13 3.11E-16 6E-14 -1.06 -11.41 17q11.2 55 200701_at NPC2 -2.124.14E-16 7.4E-14 -1.15 -11.72 14q24.3 27 200742_a_at CLN2 -2.114.76E-19 2.83E-16 -1.14 -12.88 11p15 117 203185_at RASSF2 -2.111.13E-14 1.1E-12 -0.99 -10.5 20pter-p12.1 93 201201_at CSTB -2.17.72E-16 1.19E-13 -1.01 -11.06 21q22.3 24 201954_at ARPC1B -2.094.06E-19 2.38E-16 -1.17 -13.05 7q22.1 56 212501_at CEBPB -2.092.93E-18 1.16E-11 -0.98 -11.71 20q13.1 232 221875_x_at HLA-F -2.096.07E-13 3.2E-15 -0.89 -9.38 6p21.3 26 210872_x_at GAS7 -2.088.67E-19 4.24E-16 -1.17 -12.91 17p 226 202625_at LYN -2.08 4.29E-132.39E-11 -0.87 -9.4 8q13 240 225844_at POLE4 -2.08 2.8E-12 1.24E-10-0.99 -9.32 2p12 165 209901_x_at AIF1 -2.07 5.17E-14 4.04E-12 -0.92-9.95 6p21.3 160 210980_s_at ASAH1 -2.06 8.48E-14 6.05E-12 -0.95-9.98 8p22-p21.3 234 223145_a_at FLJ10342 -2.06 1.11E-12 5.4E-11-0.92 -9.36 6q15 7 200886_s_at PGAM1 -2.05 2.93E-21 4.42E-18 -1.20-14.4 10q25.3 292 202957_at HCLS1 -2.03 5.24E-12 2.02E-10 -0.92-9.03 3q13 141 200808_s_at ZYX -2.02 2.43E-14 2.11E-12 -0.93 -10.137q32 213 202484_s_at MBD2 -2.02 1.03E-12 5.09E-11 -0.96 -9.48 18q21157 226353_at SPPL2A -2 >6.1E-14 4.67E-12 -0.95 -10.03 15q15.3172 226219_at LOC257106 -2 1.46E-13 9.78E-12 -0.95 -9.85 1q23.1 5208885_at LCP1 -1.97 3.67E-23 1.22E-19 -1.31 -15.19 13q14.3 252202228_s_at SDFR1 -1.96 9.91E-13 4.92E-11 -0.87 -9.23 15q22 297204479_at OSTF1 -1.96 7.11E-12 2.58E-10 -0.93 -8.99 12q24.1-24.2260 206994_at CST4 -1.95 6.06E-12 4.66E-12 -0.75 -9.18 20p11.21 91208704_x_at APLP2 -1.93 1.52E-16 3.21E-14 -0.96 -11.09 11q24 223223058_at MGC11034 -1.93 1.04E-14 1.04E-12 -0.75 -9.41 10p13 60208248_x_at APLP2 -1.9 1.76E-17 5.05E-15 -1.01 -11.65 11q24 99203416_at CD53 -1.9 4.2E-15 5E-13 -1.03 -10.82 1p13 107 204265_a_atC6orf9 -1.9 4.21E-15 5E-13 -0.98 -10.65 6q21.3 114 221492_s_at APG3-1.89 1.83E-14 1.64E-12 -1.03 -10.54 3p13.13 214 34689_at TREX1-1.88 4.51E-13 2.5E-11 -0.9 -9.47 3p21.3-p21.2 279 202388_at RGS2-1.85 9.56E-14 6.67E-12 -0.75 -9.11 1q31 176 209166_s_at MAN2B1-1.84 3.38E-14 2.81E-12 -0.87 -9.83 19cen-q13.1 257 229860_x_at-1.84 2.75E-13 1.66E-11 -0.8 -9.19 183 210740_s_at ITPK1 -1.82.76E-13 1.66E-11 -0.96 -9.77 14q31 216 201136_at PLP2 -1.81.15E-13 7.88E-12 -0.82 -9.43 Xp11.23 85 200975_at PPT1 -1.795.87E-16 9.75E-14 -1.03 -11.19 1p32 158 225750_at -1.78 1.26E-141.21E-12 -0.88 -10.03 49 201720_s_at LAPTM5 -1.77 5.07E-19 2.63E-16-0.98 -11.94 1p34 253 200078_s_at-HG-U133A ATP6V0B -1.77 1.78E-128.29E-11 -0.91 -9.23 1p32.3 289 209073_s_at NUMB -1.77 1.98E-129.12E-11 -0.85 -9.04 14q24.3 47 201444_s_at ATP6IP2 -1.76 7.19E-182.3E-15 -1.05 -11.99 Xq21 204 211926_s_at MYH9 -1.75 1.42E-139.52E-12 -0.87 -9.58 22q13.1 134 208913_at GGA2 -1.74 9.3E-159.48E-13 -0.91 -10.21 16p12 170 203175_at ARHG -1.74 1.7E-141.54E-12 -0.86 -9.88 11p15.5-p15.4 103 223626_x_at FAM14A -1.731.33E-16 2.99E-14 -0.9 -10.77 14q32.13 113 213702_x_at AAH1 -1.734.85E-15 5.6E-13 -0.97 -10.55 8p22-p21.3 230 209393_s_at EIF4EL3-1.72 2.86E-13 1.68E-11 -0.85 -9.39 2q37.1 32 200743_s_at CLN2-1.71 4.6E-20 4.5E-17 -1.06 -12.65 11p15 104 208959_s_at TXNDC4-1.69 2.13E-15 2.86E-13 -0.96 -10.69 9q22.33 120 200625_s_at CAP-1.69 4.93E-15 5.65E-13 -0.92 -10.33 1p34.1 272 202605_at GUSB-1.69 2.84E-13 1.68E-11 -0.79 -9.13 7q21.11 39 208736_at ARPC3-1.67 6.63E-20 6E-17 -1.01 -12.33 12q24.11 148 212350_at TBC1D1-1.66 1.17E-14 1.13E-12 -0.89 -10.1 4p14 144 214665_s_at -1.641.22E-14 1.17E-12 -0.9 -10.11 98 213798_s_at CAP -1.63 3.58E-166.76E-14 -0.94 -10.84 1p34.1 281 215952_s_at -1.63 1.39E-139.38E-12 -0.76 -9.1

287 200654_at P4HB -1.61 1.47E-13 9.78E-12 -0.75 -9.06 17q25 87207988_s_at ARPC2 -1.6 1.14E-16 2.63E-14 -0.96 -11.13 2q36.1 274200055_at-HG-U133B TAF10 -1.57 8.61E-13 4.35E-11 -0.83 -9.1311p15.3 219 224573_at MGC49942 -1.54 7.53E-14 5.55E-12 -0.81 -9.4217p13.2 189 222992_s_at NDUFB9 -1.49 6.08E-15 6.73E-13 -0.79 -9.688q13.3 238 200645_at GABARAP -1.49 8.81E-14 6.23E-12 -0.8 -9.3517p13.2 207 200640_at YWHAZ -1.48 4.34E-14 3.49E-12 -0.81 -9.58q23.1 215 47105_at FLJ20399 -1.48 7.27E-14 5.42E-12 -0.81 -9.4416q22.1 191 201858_s_at PRG1 -1.46 4.4E-16 7.78E-14 -0.74 -9.6810q22.1 221 201290_at SPC18 -1.44 3.83E-14 3.1E-12 -0.79 -9.4115q24.3 291 209563_x_at CALM1 -1.44 8.11E-14 5.83E-12 -0.73 -9.0414q24-q31 29 207157_s_at GNG5 -1.42 3.92E-22 6.51E-19 -1.01 -12.851p22 123 213603_s_at RAC2 -1.39 6.11E-18 1.99E-15 -0.78 -10.3122q13.1 118 213513_x_at ARPC2 -1.38 4.84E-16 8.4E-14 -0.88 -10.42q36.1 192 223880_x_at C20orf24 -1.38 9.93E-15 9.94E-13 -0.8 -9.6720q11.22 222 224625_x_at PNN -1.38 6.37E-15 6.07E-13 -0.74 -9.4114q13.2 109 200738_s_at PGK1 -1.37 1.49E-16 3.17E-14 -0.88 -10.64Xq13 199 217835_x_at C20orf24 -1.36 1.13E-14 1.1E-12 -0.8 -9.6420q11.22 254 208612_at GRP58 -1.36 1.46E-14 1.37E-12 -0.73 -9.2315q15 194 217733_s_at TMSB10 -1.32 3.49E-15 4.33E-13 -0.78 -9.672p11.2 268 200088_s_at-HG-U133B COX4I1 -1.26 2.58E-14 2.21E-12-0.73 -9.14 16q22-qter Sequence Sequence Transcript DerivedSequence Sequence Unigene Cluster Locus Number Type ID From IDSource Accession Type Link 239 Exemplar Hs.105928.4 AF009644.1g2662447 GenBank Hs.105928 fulllength 11025 sequence 278 ExemplarHs.105928.0 AF009635.1 g2662429 GenBank Hs.105928 fulllength 11025sequence 132 Exemplar Hs.105928.2 AF009634.1 g2662427 GenBankHs.105928 fulllength 11025 sequence 275 Consensus Hs.306542.0R94644 Hs.306542.0 GenBank Hs.81800 fulllength 1462 sequence 96Exemplar Hs.159237.0 NM_002115.1 g4504394 RefSeq Hs.159237fulllength 3101 sequence 89 Consensus Hs.288581.0 T64884Hs.288581.0.S1 GenBank Hs.288581 219972 sequence 264 ExemplarHs.1799.0 NM_001766.1 g4502648 RefSeq Hs.1799 fulllength 912sequence 210 Exemplar Hs.78864.1 U90939.1 g2149627 GenBank Hs.78864fulllength 2212 sequence 83 Exemplar Hs.7934.0 NM_004235.1 g4758321RefSeq Hs.356370 fulllength 9314 sequence 299 Exemplar Hs.105928.1AF009643.1 g2662445 GenBank Hs.105928 fulllength 11025 sequence 19Consensus Hs.288581.0 T64884 Hs.288581.0.S1 GenBank Hs.288581219972 sequence 35 Exemplar Hs.288181.0 NM_004390.1 g4758095 RefSeqHs.288181 fulllength 1512 sequence 211 Exemplar Hs.194784.0NM_006065.1 g5174678 RefSeq Hs.194784 fulllength 10326 sequence 259Exemplar Hs.122591.0 NM_013439.1 g7305384 RefSeq Hs.122591fulllength 29992 sequence 21 Exemplar Hs.14623.0 NM_006332.1g5453695 RefSeq Hs.14623 fulllength 10437 sequence 54 ConsensusHs.122591.1 AJ400843.1 Hs.122591.1 GenBank Hs.122591 fulllength29992 sequence 76 Consensus Hs.16987.0 AW135013 Hs.169487.0 GenBankHs.169487 fulllength 9935 sequence 69 Exemplar Hs.297681.2AF119873.1 g770182 GenBank Hs.297681 fulllength 5265 sequence 267Consensus Hs.109438.0 AF052169.1 Hs.109438.0 GenBank Hs.109438fulllength 115207 sequence 100 Exemplar Hs.574.0 D26054.1 g439225GenBank Hs.574 fulllength 2203 sequence 202 Exemplar Hs.27954.1L25259.1 g416368 GenBank Hs.27954 fulllength 942 sequence 44Exemplar Hs.46.0 D10202.1 g219975 GenBank Hs.46 fulllength 5724sequence 224 Consensus Hs.23262.0 NM_005615.1 Hs.23262.0 GenBankHs.23262 fulllength 6039 sequence 31 Consensus Hs.81800.4 J02814.1Hs.81800.4_RC GenBank Hs.81800 fulllength 1462 sequence 152Exemplar Hs.97199.0 NM_012072.2 g11496985 RefSeq Hs.97199fulllength 22918 sequence 250 Exemplar Hs.1583.0 NM_000265.1g4557784 RefSeq Hs.1583 fulllength 4687 sequence 25 ExemplarHs.81800.0 NM_004385.1 g4758081 RefSeq Hs.81800 fulllength 1462sequence 48 Exemplar Hs.169487.0 NM_005461.1 g4885446 RefSeqHs.169487 fulllength 9935 sequence 18 Exemplar Hs.106747.0NM_021626.1 g11055991 RefSeq Hs.106747 fulllength 59342 sequence101 Exemplar Hs.53155.0 NM_002621.1 g4505736 RefSeq Hs.53155fulllength 5199 sequence 256 Exemplar Hs.2161.0 NM_001736.1g4502508 RefSeq Hs.2161 fulllength 728 sequence 11 ExemplarHs.300711.0 NM_001154.2 g4809273 RefSeq Hs.300711 fulllength 308sequence 70 Consensus Hs.79876.0 AU138166 Hs.79876.0.A2 GenBankHs.79876 fulllength 412 sequence 34 Consensus Hs.95549.0 AW241742Hs.95549.0.A1 GenBank Hs.95549 fulllength 54502 sequence 228Exemplar Hs.252136.0 NM_02003.2 g8051583 RefSeq Hs.252136fulllength 2219 sequence 284 Consensus Hs.27954.0 BG236280Hs.27954.0.S2 GenBank Hs.27954 fulllength 942 sequence 137 ExemplarHs.135201.0 NM_022162.1 g11545911 RefSeq Hs.135201 fulllength 64127sequence 42 Exemplar Hs.949.0 BC001606.1 g12804408 GenBank Hs.949fulllength 4688 sequence 12 Exemplar Hs.743.0 NM_004106.1 g4758343RefSeq Hs.433300 fulllength 2207 sequence 4 Exemplar Hs.1422.0NM_005248.1 g4885234 RefSeq Hs.1422 fulllength 2268 sequence 294Consensus Hs.293616.0 AW043782 Hs.293616.0 GenBank Hs.205865 143458sequence 167 Exemplar Hs.78146.0 M37780.1 g187239 GenBank Hs.78146fulllength 5175 sequence 46 Exemplar Hs.170310.0 NM_017424.1g8393092 RefSeq Hs.170310 fulllength 51816 sequence 130 Exemplarg189537 M80436.1 g189537 GenBank Hs.46 fulllength 5724 sequence 72Exemplar Hs.94498.2 U82276.1 g1907318 GenBank Hs.94498 fulllength11027 sequence 79 Exemplar Hs.23889.0 NM_015474.1 g7661593 RefSeqHs.23889 fulllength 25939 sequence 121 Exemplar Hs.26944.0NM_006176.1 g5453799 RefSeq Hs.26944 fulllength 4900 sequence 94Exemplar g13649404 AF237908.1 g13649404 GenBank Hs.17914 fulllength64231 sequence 102 Exemplar Hs.95549.0 NM_019027.1 g9506670 RefSeqHs.95549 fulllength 54502 sequence 15 Exemplar Hs.180577.1BC000324.1 g12653114 GenBank Hs.180577 fulllength 2896 sequence 90Exemplar Hs.17914.1 AF253977.1 g12005800 GenBank Hs.17914fulllength 64231 sequence 105 Consensus Hs.58879.0 BF222867Hs.58879.0_RC GenBank Hs.58879 est sequence 220 Exemplar Hs.94498.1U82278.1 g1907322 GenBank Hs.94498 fulllength 11027 sequence 57Exemplar Hs.78575.0 M3222.1 g337761 GenBank Hs.406455 fulllength5660 sequence 80 Exemplar Hs.2605.0 NM_006678.1 g5729775 RefSeqHs.2605 fulllength 10871 sequence 64 Exemplar Hs.181301.0NM_004079.1 g4758097 RefSeq Hs.181301 fulllength 1520 sequence 106Exemplar Hs.184018.0 NM_004271.1 g4758707 RefSeq Hs.184018fulllength 9450 sequence 95 Exemplar Hs.94498.0 NM_006866.1g5803067 RefSeq Hs.94498 fulllength 11027 sequence 9 ConsensusHs.180577.2 AK023348.1 Hs.180577.2.S1 GenBank Hs.180577 fulllength2896 sequence 82 Consensus Hs.77542.0 BF508702 Hs.77542.0_RCGenBank Hs.77542 est sequence 243 Consensus Hs.43857.1 ALD34418Hs.43857.1.S1 GenBank Hs.43857 fulllength 55959 sequence 145Consensus Hs.164036.0 AW167793 Hs.164036.0.S1 GenBank Hs.334534fulllength 2799 sequence 65 Consensus Hs.12854.0 BE875567Hs.12854.0 GenBank Hs.12854 fulllength 57085 sequence 166 ExemplarHs.260024.0 AL136842.1 g6807668 GenBank Hs.260024 fulllength 10602sequence 88 Exemplar Hs.321070.2 NM_002076.1 g4504060 RefSeqHs.334534 fulllength 2799 sequence 229 Exemplar Hs.179665.0NM_000389.1 g11386202 RefSeq Hs.179665 fulllength 1026 sequence 290Consensus Hs.20252.0 AL096776 Hs.20252.0_RC GenBank Hs.20252fulllength 58480 sequence 162 Exemplar Hs.306230.0 NM_024318.1g13324689 RefSeq Hs.306230 fulllength 79168 sequence 263 ConsensusHs.97199.0 W72082 Hs.97199.0.S2 GenBank Hs.97199 fulllength 22918sequence 33 Exemplar Hs.156115.0 NM_000218.1 g4557688 RefSeqHs.158115 fulllength 3784 sequence 282 Consensus Hs.34650.0BE671123 Hs.34650.0.A1 GenBank Hs.34650 est sequence 177 ExemplarHs.82542.0 NM_001637.1 g4502114 RefSeq Hs.82542 fulllength 313sequence 175 Exemplar Hs.297939.0 NM_001908.1 g4503138 RefSeqHs.297939 fulllength 1508 sequence 174 Exemplar Hs.621.0 BC001120.1g12654570 GenBank Hs.621 fulllength 3958 sequence 255 ExemplarHs.17914.2 AB013104.1 g11559215 GenBank Hs.17914 fulllength 64231sequence 14 Exemplar Hs.180577.0 NM_002087.1 g4504150 RefSeqHs.180577 fulllength 2898 sequence 30 Consensus Hs.289092.0AL565621 Hs.289092.0 GenBank Hs.289092 fulllength 23406 sequence251 Exemplar Hs.51077.0 M81695.1 g487829 GenBank Hs.51077fulllength 3687 sequence 112 Consensus Hs.78146.0 AW574504Hs.78146.0.S3 GenBank Hs.78146 fulllength 5175 sequence 286Consensus Hs.260024.0 AI754416 Hs.260024.0.A3 GenBank Hs.352554sequence 17 Exemplar Hs.135084.0 NM_000099.1 g4503106 RefSeqHs.304682 fulllength 1471 sequence

84 Consensus Hs.288010.0 AW662189 Hs.288010.0_RC GenBank Hs.288010fulllength 128346 sequence 3 Consensus Hs.7934.1 BF514079Hs.7934.1_RC GenBank Hs.376206 sequence 28 Exemplar Hs.76722.0NM_005195.1 g4885130 RefSeq Hs.76722 fulllength 1052 sequence 265Consensus Hs.6774.0 AI801777 Hs.6774.0.A1 GenBank Hs.352554sequence 246 Exemplar Hs.63668.0 NM_003264.1 g4507528 RefSeqHs.63658 fulllength 7097 sequence 92 Exemplar Hs.226133.1NM_003644.1 g4503920 RefSeq Hs.226133 fulllength 8522 sequence 108Consensus Hs.164036.0 AW167793 Hs.164036.0.S1 GenBank Hs.334534fulllength 2799 sequence 111 Exemplar Hs.275243.0 NM_014624.2g9845517 RefSeq Hs.275243 fulllength 6277 sequence 295 ConsensusHs.72080.0 AW303397 Hs.72080.0_RC GenBank Hs.72080 sequence 73Consensus Hs.23391.0 AL035588 Hs.23391.0 GenBank Hs.23391fulllength 7942 sequence 156 Exemplar Hs.2062.0 NM_000376.1g4507882 RefSeq Hs.2062 fulllength 7421 sequence 36 ExemplarHs.156114.0 AB023430.1 g6518912 GenBank Hs.156114 fulllength 140885sequence 8 Consensus Hs.217493.4 BE908217 Hs.217493.4.S1 GenBankHs.217493 fulllength 302 sequence 66 Exemplar Hs.157439.0NM_021615.1 g11055975 RefSeq Hs.157439 fulllength 4166 sequence 77Consensus Hs.39972.0 AI864053 Hs.39972.0_RC GenBank Hs.39972 estsequence 10 Exemplar Hs.217493.0 NM_004039.1 g4757755 RefSeqHs.217493 fulllength 302 sequence 41 Exemplar Hs.119301.0NM_002966.1 g4506760 RefSeq Hs.400250 fulllength 6281 sequence 164Exemplar Hs.285115.1 U81380.2 g5174767 GenBank Hs.285115 fulllength3597 sequence 20 Exemplar Hs.51043.0 NM_000521.2 g13128866 RefSeqHs.51043 fulllength 3074 sequence 146 Exemplar Hs.40368.0NM_003916.1 g4506956 RefSeq Hs.40368 fulllength 8905 sequence 197Consensus Hs.14411.0 AI536637 Hs.14411.0.A1 GenBank Hs.14411sequence 37 Consensus 4898374 X62078 4898374 GenBank Hs.289082fulllength 2760 sequence 16 Exemplar Hs.217493.2 BC001388.1g12655074 GenBank Hs.217493 fulllength 302 sequence 155 ConsensusHs.281706.1 BE742268 Hs.281706.1_RC GenBank Hs.351872 fulllength6272 sequence 227 Consensus Hs.28788.0 AI916948 Hs.28788.0 GenBankHs.28788 est sequence 273 Consensus Hs.155024.1 S67779.1Hs.155024.1.S1 GenBank Hs.155024 fulllength 604 sequence 61Consensus Hs.14453.0 AI073984 Hs.14453.0.S2 GenBank Hs.14453fulllength 3394 sequence 200 Consensus Hs.180372.0 BE622952Hs.180372.0 GenBank Hs.394609 sequence 40 Exemplar Hs.9963.0NM_003332.1 g4507754 RefSeq Hs.9963 fulllength 7305 sequence 293Exemplar Hs.79876.0 NM_000351.2 g13162281 RefSeq Hs.79876fulllength 412 sequence 116 Consensus Hs.132569.0 BE271644Hs.132569.0.A1 GenBank Hs.132569 fulllength 64115 sequence 52Consensus Hs.40368.3 AA551090 Hs.40368.3 GenBank Hs.40368fulllength 8905 sequence 81 Consensus Hs.177376.0 AI963142Hs.177376.0.A1 GenBank Hs.177376 est sequence 181 ExemplarHs.79516.0 NM_006317.1 g5453749 RefSeq Hs.79516 fulllength 10409sequence 78 Exemplar g13623656 BC006454.1 g13623656 GenBankHs.226133 fulllength 8522 sequence 122 Exemplar Hs.227751.0NM_002305.2 g6006015 RefSeq Hs.382367 fulllength 3956 sequence 201Exemplar Hs.1665.0 NM_003407.1 g4507960 RefSeq Hs.243586 fulllength7538 sequence 245 Exemplar Hs.177559.0 NM_005534.1 g5031782 RefSeqHs.177559 fulllength 3460 sequence 169 Exemplar Hs.173936.0BC001903.1 g12804902 GenBank Hs.173936 fulllength 3588 sequence 187Consensus Hs.78146.0 AW574504 Hs.78146.0.S3 GenBank Hs.78146fulllength 5175 sequence 43 Exemplar Hs.76288.0 M23254.1 g511636GenBank Hs.76288 fulllength 824 sequence 173 Exemplar Hs.3807.0NM_022003.1 g11612654 RefSeq Hs.3807 fulllength 53826 sequence 198Exemplar Hs.18142.0 NM_004313.1 g4757779 RefSeq Hs.18142 fulllength409 sequence 266 Consensus Hs.75544.1 AA284532 Hs.75544.1.S1GenBank Hs.302766 fulllength 152007 sequence 168 ExemplarHs.70499.0 NM_014210.1 g7657074 RefSeq Hs.70499 fulllength 2123sequence 237 Consensus Hs.20064.0 NM_002957.2 Hs.20084.0 GenBankHs.20084 fulllength 6256 sequence 153 Exemplar Hs.217493.1 M62898.1g187147 GenBank Hs.406239 fulllength 304 sequence 50 ExemplarHs.46465.1 NM_006019.1 g5174620 RefSeq Hs.46465 fulllength 10312sequence 59 Exemplar Hs.297939.0 NM_001906.1 g4503138 RefSeqHs.297939 fulllength 1508 sequence 71 Consensus Hs.181301.1AK024855.1 Hs.181301.1 GenBank Hs.181301 fulllength 1520 sequence53 Consensus Hs.278242.3 AL513583 Hs.278242.3 GenBank Hs.289082fulllength 2760 sequence 193 Exemplar Hs.279607.1 AF327443.1g12056961 GenBank Hs.359682 fulllength 831 sequence 182 ConsensusHs.114055.0 AI423165 Hs.114055.0.A1 GenBank Hs.390639 sequence 58Exemplar Hs.81256.0 NM_002961.2 g9844514 RefSeq Hs.81256 fulllength6275 sequence 2 Exemplar Hs.83968.0 NM_000211.1 g4557885 RefSeqHs.83968 fulllength 3689 sequence 97 Exemplar Hs.155024.0NM_00106.1 g4502383 RefSeq Hs.155024 fulllength 604 sequence 67Exemplar g1695875 U62858.1 g1695875 GenBank Hs.285115 fulllength3597 sequence 115 Exemplar Hs.172631.0 NM_000632.2 g6006013 RefSeqHs.172631 fulllength 3684 sequence 280 Exemplar Hs.54673.1AF114013.1 g7328557 GenBank Hs.54673 fulllength 8741 sequence 22Exemplar Hs.112405.0 NM_002965.2 g9845520 RefSeq Hs.112405fulllength 6280 sequence 135 Exemplar Hs.33476.0 NM_022765.1g12232436 RefSeq Hs.33476 fulllength 64780 sequence 277 ExemplarHs.10649.1 AB035482.1 g8272423 GenBank Hs.10649 fulllength 9473sequence 179 Exemplar Hs.278597.0 NM_014369.1 g7657483 RefSeqHs.278597 fulllength 26469 sequence 45 Consensus Hs.20183.0BF439522 Hs.20183.0.A1 GenBank Hs.374538 fulllength 153339 sequence185 Exemplar Hs.129751.0 NM_014339.1 g7657229 RefSeq Hs.129751fulllength 23765 sequence 241 Exemplar Hs.156114.0 NM_004648.1g4758977 RefSeq Hs.156114 fulllength 140885 sequence 38 ConsensusHs.279518.4 AW001847 Hs.279518.4 GenBank Hs.279518 fulllength 334sequence 217 Consensus Hs.75544.1 AA284532 Hs.75544.1.S1 GenBankHs.302766 fulllength 152007 sequence 231 Exemplar Hs.100194.0NM_001629.1 g4502058 RefSeq Hs.100194 fulllength 241 sequence 110Consensus Hs.4248.1 AA481141 Hs.4248.1.S1 GenBank Hs.4248fulllength sequence 68 Consensus Hs.180549.0 BE396735Hs.180549.0_RC GenBank Hs.180549 fulllength 125308 sequence 262Consensus Hs.10844.0 AA622495 Hs.10844.0.A1 GenBank Hs.10844fulllength 116844 sequence 261 Exemplar Hs.325495.0 NM_003255.2g9257247 RefSeq Hs.6441 fulllength 7077 sequence 270 ExemplarHs.75108.0 NM_002939.1 g4506564 RefSeq Hs.75108 fulllength 6050sequence 133 Consensus Hs.287353.0 AC004832 Hs.287353.0.S1 GenBanksequence 188 Exemplar Hs.171545.0 NM_004504.2 g7262381 RefSeqHs.171545 fulllength 3267 sequence 125 Consensus Hs.306413.0AU144000 Hs.306413.0_RC GenBank Hs.306413 sequence 136 Exemplarg13661555 AF27o513.1 g13661555 GenBank Hs.270143 fulllength 84034sequence 143 Exemplar Hs.279607.0 NM_001750.5 g5729759 RefSeqHs.359682 fulllength 831 sequence 159 Consensus Hs.48433.0 AW613549Hs.48433.0.S1 GenBank Hs.48433 fulllength 24149 sequence 13Consensus Hs.279518.1 BC000373.1 Hs.279518.1 GenBank Hs.279518fulllength 334 sequence 23 Exemplar Hs.200333.0 NM_018690.1g8922078 RefSeq Hs.200333 fulllength 55911 sequence 298 ConsensusHs.33033.0 AI264121 Hs.33033.0.A1 GenBank Hs.33033 fulllength 84898sequence 236 Exemplar Hs.246381.0 NM_001251.1 g4557434 RefSeqHs.246381 fulllength 968 sequence 1 Exemplar Hs.78575.0 NM_002778.1g11386146 RefSeq Hs.406455 fulllength 5660 sequence 233 ConsensusHs.233276.0 BE620374 Hs.233276.0.S1 GenBank Hs.405915 est sequence178 Consensus Hs.3446.0 AI571419 Hs.3446.0.A2 GenBank Hs.3446fulllength 5604 sequence 119 Exemplar Hs.270737.0 AF134715.1g7330729 GenBank Hs.270737 fulllength 10673 sequence 283 ExemplarHs.43068.0 AF251295.1 g12005731 GenBank Hs.40368 fulllength 8905sequence 147 Exemplar Hs.167679.2 AB000463.1 g1843393 GenBankHs.167679 fulllength

6452 sequence 247 Consensus Hs.6823.0 AI335263 Hs.6823.0 GenBankHs.6823 fulllength 81831 sequence 184 Exemplar Hs.202.1 NM_000714.2g6382068 RefSeq Hs.202 fulllength 706 sequence 6 ExemplarHs.279518.2 BC004371.1 g13325115 GenBank Hs.279518 fulllength 334sequence 128 Exemplar Hs.75922.0 AB055977.1 g13094234 GenBankHs.75922 fulllength 25798 sequence 171 Consensus Hs.11759.1BG497776 Hs.11759.1.A1 GenBank Hs.11759 fulllength sequence 149Consensus Hs.181156.0 AI286239 Hs.181156.0_RC GenBank Hs.181158 estsequence 86 Exemplar Hs.41726.0 NM_002640.1 g4505790 RefSeqHs.41726 fulllength 5271 sequence 248 Exemplar Hs.71475.0NM_016630.2 g13699804 RefSeq Hs.71475 fulllength 51324 sequence 249Consensus Hs.102647.0 AI934347 Hs.102647.0.A1 GenBank Hs.102647sequence 51 Consensus Hs.26506.0 AI348000 Hs.26506.0 GenBankHs.26506 fulllength 92799 sequence 203 Consensus Hs.106876.0AL566172 Hs.106876.0_RC GenBank Hs.106876 fulllength 9114 sequence244 Exemplar Hs.226133.0 NM_005890.1 g5360211 RefSeq Hs.226133fulllength 8522 sequence 126 Exemplar Hs.2621.0 NM_005213.1g4885164 RefSeq Hs.412999 fulllength 1475 sequence 276 ExemplarHs.118126.0 NM_000308.1 g450588 RefSeq Hs.118126 fulllength 5476sequence 288 Consensus Hs.88411.7 NM_007161.1 Hs.88411.7 GenBankHs.380427 fulllength 7940 sequence 205 Consensus Hs.146912.0AI990349 Hs.146912.0_RC GenBank Hs.177376 est sequence 75 Exemplarg13543535 BC005926.1 g13543535 GenBank Hs.5509 fulllength 2124sequence 55 Exemplar Hs.119529.0 NM_006432.1 g5453677 RefSeqHs.433222 fulllength 10577 sequence 27 Consensus Hs.20478.0BG231932 Hs.20478.0_RC GenBank Hs.20478 fulllength 1200 sequence117 Exemplar Hs.80905.0 NM_014737.1 g7661963 RefSeq Hs.80905fulllength 9770 sequence 93 Exemplar Hs.695.0 NM_000100.1 g4503116RefSeq Hs.695 fulllength 1476 sequence 24 Exemplar Hs.11538.0NM_005720.1 g5031600 RefSeq Hs.433506 fulllength 10095 sequence 56Consensus Hs.99029.0 AL564683 Hs.99029.0 GenBank Hs.99029fulllength 1051 sequence 232 Consensus Hs.110309.1 AW514210Hs.110309.1 GenBank Hs.110309 fulllength 3134 sequence 26 ExemplarHs.226133.2 BC001152.1 g12654630 GenBank Hs.226133 fulllength 8522sequence 226 Consensus Hs.80887.0 AI356412 Hs.80887.0_RC GenBankHs.80887 fulllength 4067 sequence 240 Consensus Hs.19980.0NM_019896.1 Hs.19980.0.S1 GenBank Hs.19980 fulllength 56655sequence 165 Exemplar Hs.76364.1 U19713.1 g1122908 GenBank Hs.76364fulllength 199 sequence 160 Exemplar Hs.75811.1 U47674.1 g3860239GenBank Hs.75811 fulllength 427 sequence 234 Exemplar Hs.101514.0BC000764.1 g12653940 GenBank Hs.101514 fulllength 55122 sequence 7Exemplar Hs.181013.0 NM_002629.1 g4505752 RefSeq Hs.181013fulllength 5223 sequence 292 Exemplar Hs.14601.0 NM_005335.1g4885404 RefSeq Hs.14601 fulllength 3059 sequence 141 ExemplarHs.75873.0 NM_003461.1 g4508046 RefSeq Hs.75873 fulllength 7791sequence 213 Exemplar Hs.25674.1 AF072242.1 g3800792 GenBankHs.25674 fulllength 8932 sequence 157 Consensus Hs.28980.0 AI674647Hs.28980.0.A1 GenBank Hs.28980 fulllength 84888 sequence 172Consensus Hs.238954.0 AW575123 Hs.238954.0.A1 GenBank Hs.238954257106 sequence 5 Exemplar Hs.76506.0 J02923.1 g189501 GenBankHs.381099 fulllength 3936 sequence 252 Exemplar Hs.6354.0NM_017455.1 g9257239 RefSeq Hs.389371 fulllength 27020 sequence 297Exemplar Hs.95821.0 NM_0012383.1 g6912563 RefSeq Hs.95821fulllength 26578 sequence 260 Exemplar Hs.56319.0 NM_001899.1g4503108 RefSeq Hs.56319 fulllength 1472 sequence 91 ExemplarHs.279518.1 BC000373.1 g12653210 GenBank Hs.279518 fulllength 334sequence 223 Exemplar Hs.103378.0 AL136885.1 g12053268 GenBankHs.103378 fulllength 83641 sequence 60 Exemplar Hs.279518.0NM_001642.1 g4502146 RefSeq Hs.279518 fulllength 334 sequence 99Exemplar Hs.82212.0 NM_000560.1 g10834971 RefSeq Hs.82212fulllength 63940 sequence 107 Exemplar Hs.288316.0 NM_022107.1g11545816 RefSeq Hs.288316 fulllength 63940 sequence 114 ExemplarHs.26367.1 AF202092.1 g11493699 GenBank Hs.26367 fulllength 64422sequence 214 Consensus 4869209_rc AJ243797 4869209_rc GenBankHs.278408 fulllength 11277 sequence 279 Exemplar Hs.78944.0NM_002923.1 g4506516 RefSeq Hs.78944 fulllength 5997 sequence 176Exemplar Hs.279854.0 U68567.1 g1658373 GenBank Hs.279854 fulllength4125 sequence 257 Consensus Hs.152932.0 AI341602 Hs.152932.0.A1GenBank Hs.446474 est sequence 183 Exemplar Hs.6453.1 AF279372.1g12006345 GenBank Hs.6453 fulllength 3705 sequence 216 ExemplarHs.77422.0 NM_002668.1 g4505892 RefSeq Hs.77422 fulllength 5355sequence 85 Exemplar Hs.3873.0 NM_000310.1 g4506030 RefSeq Hs.3873fulllength 5538 sequence 158 Consensus Hs.10949.0 BE966746Hs.10949.0.S1 GenBank Hs.10949 sequence 49 Consensus Hs.79356.0AI589086 Hs.79356.0 GenBank Hs.79356 fulllength 7805 sequence 253Exemplar g13543437 BC005876.1 g13543437 GenBank Hs.7476 fulllength533 sequence 289 Exemplar Hs.78890.1 AF015040.1 g4102704 GenBankHs.78890 fulllength 8650 sequence 47 Exemplar Hs.183434.0NM_005765.1 g5031590 RefSeq Hs.183434 fulllength 10159 sequence 204Consensus Hs.146550.0 AI827941 Hs.146550.0.A2 GenBank Hs.146550fulllength 4627 sequence 134 Consensus Hs.155546.0 NM_015044.1Hs.155546.0 GenBank Hs.155546 fulllength 23062 sequence 170Exemplar Hs.75082.0 NM_001665.1 g4502218 RefSeq Hs.75082 fulllength391 sequence 103 Exemplar Hs.94695.0 AF208232.1 g11493981 GenBankHs.94695 fulllength 83982 sequence 113 Consensus Hs.75811.3AI934569 Hs.75811.3.S1 GenBank Hs.75811 fulllength 427 sequence 230Exemplar Hs.19122.0 AF047695.1 g3172338 GenBank Hs.19122 fulllength9470 sequence 32 Exemplar Hs.20478.0 NM_000391.2 g5597012 RefSeqHs.20478 fulllength 1200 sequence 104 Exemplar Hs.154023.0BC005374.1 g13529223 GenBank Hs.154023 fulllength 23071 sequence120 Exemplar Hs.104125.0 NM_006367.2 g10938021 RefSeq Hs.104125fulllength 10487 sequence 272 Exemplar Hs.183868.0 NM_000181.1g4504222 RefSeq Hs.183868 fulllength 2990 sequence 39 ExemplarHs.6895.0 AF004561.1 g2209346 GenBank Hs.293750 fulllength 10094sequence 148 Consensus Hs.278586.1 AB029031.1 Hs.278586.1_RCGenBank Hs.278586 fulllength 23216 sequence 144 ConsensusHs.85301.3 AK000095.1 Hs.85301.3.S1 GenBank Hs.356550 fulllengthsequence 98 Consensus Hs.104125.2 AA806142 Hs.104125.2_RC GenBankHs.104125 fulllength 10487 sequence 281 Consensus Hs.125078.2AF090094.1 Hs.125078.2 GenBank Hs.405050 sequence 287 ExemplarHs.75655.0 J02783.1 g339646 GenBank Hs.410578 fulllength 5034sequence 87 Exemplar Hs.83583.0 NM_005731.1 g5031598 RefSeqHs.83583 fulllength 10109 sequence 274 Exemplar Hs.89657.0NM_006284.1 g5454105 RefSeq Hs.89657 fulllength 6881 sequence 219Consensus Hs.9408.3 BF213270 Hs.9408.3 GenBank Hs.9408 fulllength124944 sequence 189 Exemplar Hs.15977.0 AF261090.1 g9802311 GenBankHs.15977 fulllength 4715 sequence 238 Exemplar Hs.7719.0NM_007278.1 g6005763 RefSeq Hs.7719 fulllength 11337 sequence 207Exemplar Hs.75103.0 NM_003406.1 g4507952 RefSeq Hs.75103 fulllength7534 sequence 215 Consensus 4859973_rc AA886893 4859973_rc GenBankHs.8575 fulllength 54920 sequence 191 Exemplar Hs.1908.0 J03223.1g190419 GenBank Hs.1908 fulllength 5552 sequence 221 ExemplarHs.9534.0 NM_014300.1 g7657608 RefSeq Hs.9534 fulllength 23478sequence 291 Exemplar Hs.182278.1 BC000454.1 g12653368 GenBankHs.282410 fulllength 801 sequence 29 Exemplar Hs.5322.0 NM_005274.1g4885286 RefSeq Hs.424138 fulllength 2787 sequence 123 ConsensusHs.301175.1 B138888 Hs.301175.1 GenBank Hs.301175 fulllength 5880sequence 118 Consensus Hs.252280.1 BG034239 Hs.252280.1_RC GenBankHs.83583 fulllength 10109 sequence 192 Exemplar Hs.184062.2BC004446.1 g13325254 GenBank Hs.184062 fulllength

55969 sequence 222 Consensus Hs.44499.2 BE568651 Hs.44499.2_RCGenBank Hs.44499 fulllength 5411 sequence 109 Exemplar Hs.78771.0NM_000291.1 g4505762 RefSeq Hs.78771 fulllength 5230 sequence 199Exemplar Hs.184062.0 NM_018840.1 g10047115 RefSeq Hs.184062fulllength 55969 sequence 254 Exemplar Hs.289101.0 D83485.1g1208426 GenBank Hs.13751 fulllength 2923 sequence 194 ExemplarHs.76293.0 NM_021103.1 g10863894 RefSeq Hs.76293 fulllength 9168sequence 268 Consensus Hs.113205.2 AA854966 Hs.113205.S1 GenBankHs.433419 fulllength 1327 sequence Full Length Reference Number Seq239 NM_006864; leukocyte immunoglobulin-like receptor, subfamily B(with TM and ITIM domains), member 3 278 NM_006864; leukocyteimmunoglobulin-like receptor, subfamily B (with TM and ITIMdomains), member 3 132 NM_006864; leukocyte immunoglobulin-likereceptor, subfamily B (with TM and ITIM domains), member 3 275NM_004385; chondroitin sulfate proteoglycan 2 (versican) 96NM_002115; hexokinase 3 89 264 NM_001766; CD1D antigen, dpolypeptide 210 NM_021642; Fc fragment of IgG, low affinity tla,receptor for (CD32) 83 NM_004235; Kruppel-like factor 4 (gut) 299NM_006864; leukocyte immunoglobulin-like receptor, subfamily B(with TM and ITIM domains), member 3 19 35 NM_004390; cathepsin Hisoform a preproprotein NM_148979; cathepsin H isoform b precursor211 NM_006065; signal-regulatory protein beta 1 precursor 259NM_013439; paired immunoglobulin-like receptor alpha isoform 1precursor NM_178272; paired immunoglobulin-like receptor alphaisoform 2 precursor NM_178273; paired immunoglobulin-like receptoralpha isoform 3 precursor 21 NM_006332; interferon, gamma-inducibleprotein 30 preproprotein 54 NM_013439; paired immunoglobulin-likereceptor alpha isoform 1 precursor NM_178272; pairedimmunoglobulin-like receptor alpha isoform 2 precursor NM_178273;paired immunoglobulin-like receptor alpha isoform 3 precursor 76NM_005461; trasncription factor MAFB NM_152258; 69 NM_000295;serine (or cysteine) proteinase inhibitor, clade A (alpha-1antiproteinase, antitrypsin), member 1 267 NM_138444; hypotheticalprotein BC013764 100 NM_000507; fructose-1,6-bisphosphatase 1 202NM_006889; CD86 antigen isoform 2 precursor NM_175862; CD86 antigenisoform 1 44 NM_000952; platelet-activating factor receptor 224NM_005615; ribonuclease, RNAse A family, k6 31 NM_004385;chondroitin sulfate proteoglycan 2 (versican) 152 NM_012072;complement component 1, q subcomponent, receptor 1 250 NM_000265;neutrophil cytosolic factor 1 25 NM_004385; chondroitin sulfateproteoglycan 2 (versican) 48 NM_005461; transcription factor MAFBNM_152258; 18 NM_021626; serine carboxypeptidase 1 precursorprotein 101 NM_002621; properdin P factor, complement 256NM_001736; complement component 5 receptor 1 (C5a ligand) 11NM_001154; annexin 5 70 NM_000351; steroid sulfatase (microsomal),arylsulfatase C, isozyme S 34 NM_019027; RNA-binding protein 228NM_002003; ficolin 1 precursor 284 NM_006889; CD86 antigen isoform2 precursor NM_175862; CD86 antigen isoform 1 137 NM_022162; NOD2protein 42 NM_000433; neutrophil cytosolic factor 2 12 NM_004106;Fc fragment of IgE, high affinity I, receptor for, gammapolypeptide precursor 4 NM_005248; Gardner-Rasheed faline sarcomaviral (v-fgr) oncogene homolog 294 NM_174902; hypothetical proteinLOC143458 167 NM_000442; platelethendothelial cell adhesionmolecule (CD31 antigen) 46 NM_017424; cat eye symdrome criticalregion protein 1 isoform a precursor NM_177405; cat eye syndromecritical region protein 1 isoform b 130 NM_000952;platelet-activating factor receptor 72 NM_006866; leukocyteimmunoglobulin-like receptor, subfamily A (with TM domain), member2 79 NM_15474; SAM domain and HD domain 1 121 NM_006176;neurogranin 94 NM_022349; membrane-spanning 4-domains, subfamily A,member 6A isoform 2 NM_152851; membrane-spanning 4-domainssubfamily A, member 6A isoform 3 NM_152852: membrane-spanning4-domains, subfamily A, member 6A isoform 1 102 NM_019027;RNA-binding protein 15 NM_002087; granulin 90 NM_022349;membrane-spanning 4-domains, subfamily A, member 6A isoform 2NM_152851; membrane-spanning 4-domains, subfamily A, member 6Aisoform 3 NM_152852; membrane-spanning 4-domains, subfamily A,member 6A isoform 1 105 220 NM_006866; leucocyteimmunoglobulin-like receptor, subfamily A (with TM domain), member2 57 NM_002778; prosaposin (variant Gaucher disease and variantmetachromatic leukodystrophy) 80 NM_006678; CMRF35 leukocyteimmunoglobulin-like receptor 64 NM_004079; cathepsin Spreproprotein 106 NM_004271; MD-1, RP105-associated 95 NM_006866;leucocyte immunoglobulin-like receptor, subfamily A (with TMdomain), member 2 9 NM_002087; granulin 82 243 NM_018837; similarto glucosamine-6-sulfatases 145 NM_002076; glucosamine(N-acetyl)-6-sulfatase precursor 65 NM_020350; angiotensin IIreceptor-associated protein 166 NM_006449; Cdc42 effector protein 388 NM_002076; glucosamine (N-acetyl)-6-sulfatase precursor 229NM_000389; cyclin-dependent kinase inhibitor 1A NM_078467;cyclin-dependent kinase inhibitor 1A 290 NM_021205; ras homologgene family, member U 162 NM_024318; leukocyte immunoglobulin-likereceptor, subfamily B (with TM and ITIM domains), member 6 263NM_012072; complement component 1, q subcomponent, receptor 1 33NM_000218; potassium voltage-gated channel, KQT-like subfamilyprecursor, member 1 282 177 NM_001637; acyloxyacyl hydrolaseprecursor 175 NM_001908; cathepsin B preproprotein NM_147760;cathepsin B preproprotein NM_147781; cathepsin B preproproteinNM_147782; cathepsin B preproprotein NM_147783; cathepsin Bpreproprotein 174 NM_002306; lectin, galactoside-binding, soluble,3 (galactin 3) 255 NM_022349; membrane-spanning 4-domains,subfamily A, member 6A isoform 2 NM_152851; membrane-spanning4-domains, subfamily A, member 6A isoform 3 NM_152852;membrane-spanning 4-domains, subfamily A, member 6A isoform 1 14NM_002087; granulin 30 NM_021149; coactosin-like 1 251 NM_000887;integrin alpha X precursor 112 NM_00042; platelet/endothelial celladhesion molecule (CD31 antigen) 286 17 NM_000099; cystatin Cprecursor 84 NM_174896; hypothetical protein MGC24133 3 28NM_005195; CCAAT/enhancer binding protein delta 265 246 NM_003264;toll-like receptor 2 92 NM_003644; growth arrest-specific 7 isoforma NM_005890; growth arrest-specific 7 isoform b 108 NM_002076;glucosamine (N-acetyl)-8-sulfatase precursor 111 NM_014624; S100calcium-binding protein A6 295 73 NM_007162; transcription factorE8 156 NM_000376; vitamin D (1.25-dihydroxyvitamin D3) receptor 36NM_004648; NM_080792; protein tyrosine phosphatase, non-receptortype substrate 1 precursor 8 NM_004039; annexin A2 66 NM_021149;coactosin-like 1 NM_021615; carbohydrate (N-acetylglucosamine 6-O)sulfotransferase 6 77 10 NM_004039; annexin A2 41 NM_002966; S100calcium-binding protein A10 164 NM_001560; interleukin 13 receptor,alpha 1 precursor 20 NM_000521; hexosaminidase B preproprotein 146NM_003916; adaptor-related protein complex 1 sigma 2 subunit 197 37NM_000405; GM2 ganglloside activator protein precursor 16NM_004039; annexin A2 155 NM_002959; sortilin 1 preproprotein 227273 NM_001706: B-cell lymphoma 6 protein NM_138931: B-cell lymphoma6 protein 61 NM_002163; interferon consensus sequence bindingprotein 1 200 40 NM_003332; TYRO protein tyrosine kinase bindingprotein 293 NM_000351; steroid sulfatase (microsomal),arylsulfatase C, isozyme S 116 52 NM_003916; adaptor-relatedprotein complex 1 sigma 2 subunit 81 181 NM_006317; brain abundant,membrane attached signal proptein 1 78 NM_003644; growtharrest-specifuc 7 isoform a NM_005890. growth arrest-specific 7isiform b 122 NM_002305; beta-galactosidase binding lectin percusor201 NM_003407; zinc finger protein 36, C3H type, homolog 245NM_005534; interfaron gamma receptor 2 (interferon gamma transduce1) 169 NM_000628; interleukin 10 receptor, beta precursor 187NM_000442; platelet/endothelial cell adhesion molecule (CD31antigen) 43 NM_001748; capain 2, large subunit 173 NM_022003; FXYDdomain-containing ion transport regulator 6 198 NM_004313; arrestinbeta 2 266 NM_022343; chromosome 9 open reding frame 19 168NM_014210; ecotropic viral integration site 2A 237 NM_002957;retinoid X receptor, alpha 153 50 NM_006019; T-cell, immuneregulator 1, isoform a NM_006053; T-cell, immune regulator 1,isoform b 59 NM_001908; cathepsin B preproprotein NM_147780;cathepsin B preprotein NM_147781; cathapsin B preproproteinNM_147782; cathepsin B preproprotein NM_147783; cathepsin Bpreproprotein 71 NM_004079; cathepsin S preproprotein 53 NM_000405;GM2 ganglioside activator protein precursor 193 NM_001750;caloastain isoform a NM_173060; caloestain isoform b NM_173061;calpastatin isoform c NM_173062; calpastain isoform d 182 58NM_002961; S100 calcium-binding protein A4 NM_019554; S100calcium-binding protein A4 2 NM_000211; integrin beta chain, beta 2precursor 97 NM_001706; B-cell lymphoma 6 protein NM_138931; B-celllymphoma 6 protein 67 NM_001560; interleukin 13 receptor, alpha 1precursor 115 NM_000632; integrin alpha M precursor 280 NM_003808;tumor necrosis factor ligand superfamily, member 13 isoform alphaprecursor NM_172088; tumor necrosis factor ligand superfamily,member 13 isoform beta NM_172088; tumor nercrosis factor ligandsuperfamily, member 13 isoform gamma NM_172089; tumor necrosisfactor ligand superfamily, member 13 isoform delta 22 NM_002965;S100 calcium-binding protein A9 135 NM_022765; NEDD9 interactingprotein with calponin homology and LIM dimains 277 NM_004848;basement membrane-induced gene 179 NM_014369; protein tyrosinephosphatase, non-receptor type 18 45 NM_174909; hypotheticalprotein LOC153339 185 NM_014339; interleukin 17 receptor precursor241 NM_004648; NM_080792: protein tyrosine phosphatase,non-receptor type substrate 1 precursor 38 NM_001642; amyloid beta(A4) precursor-like protein 2 NM_016160; 217 NM_022343; chromosome9 open reading frame 19 231 NM_001629; arachidonate5-lipoxygenasE-activating protein 110 68 NM_130807; MOB-LAK 262NM_052972; leucine-rich alpha-2-glycoprotein 261 NM_003255; tissueinhibitor of metalloproteinase 2 precursor 270 NM_002939;ribonuclease/angiogenin inhibitor 133 188 NM_004504; HIV-1 Ravbinding protein 125 136 NM_032048; extracellular glycoproteinEMILIN-2 precursor 143 NM_001750; calpastatin isoform a NM_173060;calpastatin isoform b NM_173061; calpastatin isoform c NM_173062;calpastatin isoform d 159 NM_014345; zinc finger protein 316

13 NM_001642; amyloid beta (A4) precursor-like protein 2 NM_016160;23 NM_018690; apollpoprotein B48 receptor 298 NM_032812; tumorendothelial marker 7-related precursor 236 NM_001251; CD68 antigen1 NM_002778; prosapoain (variant Gaucher disesase and variantmetachromatic leukodystrophy) 233 178 NM_002755; mitogen-activatedprotein kinase 1 119 NM_006573; tumor necrosis factor (ligand)superfamily, member 13b 283 NM_003916; adaptor-related proteincomplex 1 sigma 2 subunit 147 NM_003023; SH3-domain binding protein2 247 NM_018092; neuropilin- and tolloid-like protein 2 precursor184 NM_000714; peripheral benzodiazapine receptor NM_007311;peripheral benzodiazapine receptor short form 6 NM_001642; amyloidbeta (A4) precursor-like protein 2 NM_016160; 128 NM_015379; brainprotein I3 171 149 86 NM_002640; serine (or cysteine) proteinaseinhibitor, clade B (ovalbumin), member B 248 NM_016630; acidcluster protein 33 249 51 NM_138392; hypothetical protein BC007653203 NM_004691; ATPase, H+ transporting, lysosomal, V0 subunit D,isoform 1 244 NM_003644; growth arrest-specific 7 isoform aNM_005890; growth arrest-specific 7 isoform b 126 NM_005213;cystatin A 276 NM_000308; protective protein for beta-galactosidase288 NM_007161; leukocyte specific transcript 1 205 75 NM_006495;ecotropic viral integration site 2B 55 NM_006432; Niemann-Pickdisease, type C2 precursor 27 NM_000391; ceroid-lipofuscinosis,neuronal 2, late infantile (Jansky-Bielschowsky disease) 117NM_014737; Ras association domain family 2 isoform 1 NM_170773; Rasassociation domain family 2 isoform 2 NM_170774; Ras associationdomain family 2 isoform 1 93 NM_000100; cystatin B 24 NM_005720;actin related protein 2/3 complex subunit 1B 56 NM_005194;CCAAT/enhancer binding protein beta 232 NM_018950; majorhistocompatibility complex, class I, F precursor 26 NM_003644;growth arrest-specific 7 isoform a NM_005890; growtharrest-specific 7 isoform b 226 NM_002350; v-yes-1 Yamaquchisarcoma viral related oncogene homolog 240 NM_019896; polymerase(DNA-directed), epsilon 4 (p12 subunit) 165 NM_001623; allograftinflammatory factor 1 isoform 3 NM_004847; allograft inflammatoryfactor 1 isoform 2 NM_032955; allograft inflammatory factor 1isoform 1 160 NM_004315; N-acylsphingosine amidohydrolase (acidcaramidase) 1 isoform b NM_177924; N-acylsphingosine amidohydrolase(acid carmidase) 1 preproprotein isoform a 234 NM_018064;hypothetical protein FLJ10342 7 NM_002629; phosphoglycerate mutase1 (brain) 292 NM_005335; hematopoletic cell-specific Lyn substrate1 141 NM_003461; zyxin 213 NM_003927; methyl-CpG binding domainprotein 2 isoform 1 NM_015832; methyl-CpG binding domain protein 2testis-specific isoform 157 NM_032802; putative intramembranecleaving protease 172 5 NM_002298; L-plastin 252 NM_012428; stromalcell derived factor receptor 1 isoform b NM_017455; stromal cellderived factor receptor 1 isoform a 297 NM_012383; osteoclaststimulating factor 1 260 NM_001899; cystatin S precursor 91NM_001642; amyloid beta (A4) precursor-like protein 2 NM_016160;223 NM_031453; hypothetical protein MGC11034 60 NM_001642; amyloidbeta (A4) precursor-like protein 2 NM_016160; 99 NM_000560; CD53antigen 107 NM_022107; chromosome 6 open reading frame 9 114NM_022488; Apg3p 214 NM_016381; three prime repair exonuclease 1isoform a NM_032166; three prime repair exonuclease 1 isoform cNM_033627; three prime repair exonuclease 1 isoform b NM_033628;three prime repair exonuclease 1 isoform b NM_033629; three primerepair exonuclease 1 isoform b NM_130384; three prime repairexonuclease 1 isoform d 279 NM_002923; regulator of G-proteinsignalling 2, 24 kDa 176 NM_000528; mannosidase, alpha, class 2B,member 1 257 183 NM_014216; inositol 1,3,4-triphosphate 5/6 kinase216 NM_002668; proteolipid protein 2 (colonic epithelium-enriched)85 NM_000310; palmitoyl-protein thioesterase 1(ceroid-lipofuscinosis, neuronal 1, infantile) 158 49 NM_006762;Lysosomal-associated multispanning membrane protein-5 253NM_004047; ATPase, H+ transporting, lysosomal, 21 kD, V0 subunit c289 NM_003744; numb homolog 47 NM_005765; ATPase, H+ transporting,lysosomal, membrane sector associated protein M8-9 204 NM_002473;myosin, heavy polypeptide 9, non-muscle 134 NM_015044;ADP-ribosylation factor binding protein 2 isoform 1 NM_138640;ADP-ribosylation factor binding protein 2 isoform 2 170 NM_001665;ras homolog gene family, member G (rho G) 103 NM_032036; TLH29protein precursor 113 NM_004315; N-acylsphingosine amidohydrolase(acid ceramidase) 1 isoform b NM_177924; N-acylsphingosineamidohydrolase (acid ceramidase) 1 preproprotein isoform a 230NM_004846; eukaryotic translation initiation factor 4E-like 3 32NM_000391; ceroid-lipofuscinosis, neuronal 2, late infantile(Jansky-Bielschowsky disease) 104 120 NM_006367; adenylylcyclase-associated protein 272 NM_000181; glucuronidase, beta 39NM_005719; actin related protein 2/3 complex subunit 3 148NM_015173; TBC1 (tre-2/USP6, BUB2, cdc16) domain family, member 1144 98 NM_006367; adenylyl cyclase-associated protein 281 287NM_000918; prolyl 4-hydroxylase, beta subunit 87 NM_005731; actinrelated protein 2/3 complex subunit 2 NM_152862; actin relatedprotein 2/3 complex subunit 2 274 NM_006284; TBP-related factor 10219 189 NM_005005; NADH dehydrogenase (ubiquinone) 1 betasubcomplex, 9, 22 kDa 238 NM_007278; GABA(A) receptor-associatdprotein 207 NM_003406; tyrosine3/tryptophan 5-monooxygenaseactivation protein, zeta polypeptide NM_145690; tyrosine3/tryptophan 5-monooxygenase activation protein, zeta polypeptide215 NM_017803; hypothetical protein FLJ20399 191 NM_002727;proteoglycan 1, secretory granule 221 NM_014300; signal peptidasecomplex (18 kD) 291 NM_006888; calmodulin 1 (phosphorylase kinase,delta) 29 NM_005274; guanine nucleotide binding protein (Gprotein), gamma 6 123 NM_002872; ras-related C3 botulinum toxinsubstrate 2 NM_014029; 118 NM_005731; actin related protein 2/3complex subunit 2 NM_152862; actin related protein 2/3 complexsubunit 2 192 NM_018840; putative Rab5-interacting protein 222NM_002687; pinin, desmosome associated protein 109 NM_000291;phosphoglycerate kinase 1 199 NM_018840; putative Rab5-interactingprotein 254 NM_005313; glucose regulated protein, 58 kDa 194NM_021103; thymosin, beta 10 268 NM_001861; cytochrome c oxidasesubunit IV isofom 1 precursor indicates data missing or illegiblewhen filed

TABLE-US-00041 TABLE 41 Downregulated or lower expressed genes incases with (del)5q compared to cases without (del)5q affy id HUGOname Title MapLocation Sequence Type Go_Biological_ProcessGo_Cellular_Component 1 203454_s_at ATOX1 ATX1 antioxidant protein1 homolog 5q32 Exemplarsequence "GO: 6878; copper ion homeostasis;traceable author statement (yeast) GO: 30001; metal ion transport;inferred from electronic annotation GO: 6825; copper ion transport;traceable author statement GO: 6979; response to oxidative stress;traceable author statement" 2 201310_s_at C5orf13 chromosome 5 openreading frame 13 5q22.1 Exemplarsequence 3 201309_x_at C5orf13chromosome 5 open reading frame 13 5q22.1 Exemplarsequence 4230424_at C5orf13 chromosome 5 open reading frame 13 5q22.1Consensussequence 5 48031_r_at C5orf4 chromosome 5 open readingframe 4 5q31-q32 Consensussequence 6 48030_i_at C5orf4 chromosome 5open reading frame 4 5q31-q32 Consensussequence 7 220751_s_atC5orf4 chromosome 5 open reading frame 4 5q31-q32 Exemplarsequence8 218518_at C5orf5 chromosome 5 open reading frame 5 5q31Exemplarsequence 9 202164_s_at CNOT8 CCR4-NOT transcriptioncomplex, 5q31-q33 Exemplarsequence "GO: 6355; regulation oftranscription, DNA-dependent; non- subunit 8 traceable authorstatement" 10 202163_s_at CNOT8 CCR4-NOT transcription complex,5q31-q33 Exemplarsequence "GO: 6355; regulation of transcription,DNA-dependent; non- subunit 8 traceable author statement" 11202162_s_at CNOT8 CCR4-NOT transcription complex, 5q31-q33Consensussequence "GO: 6355; regulation of transcription,DNA-dependent; non- subunit 8 traceable author statement" 12217491_x_at COX7C cytochrome c oxidase subunit VIIc 5q14Consensussequence "GO: 6118; electron transport; inferred fromelectronic annotation GO: 6091; energy pathways; traceable authorstatement" 13 213846_at COX7C cytochrome c oxidase subunit VIIc5q14 Consensussequence "GO: 6118; etectron transport; inferred fromelectronic annotation GO: 6091; energy pathways; traceable authorstatement" 14 201134_x_at COX7C cytochrome c oxidase subunit VIIc5q14 Exemplarsequence "GO: 6118; electron transport; inferred fromelectronic annotation GO: 6091; energy pathways; traceable authorstatement" 15 226920_at CSNK1A1 casein kinase 1, alpha 1 5q32Consensussequence "GO: 7165; signal transduction; not recorded GO:7166; cell surface receptor linked signal transduction;experimental evidence GO: 6468; protein amino acid phosphorylation;experimental evidence" 16 213086_s_at CSNK1A1 casein kinase 1,alpha 1 5q32 Consensussequence "GO: 7165; signal transduction; notrecorded GO: 7166; cell surface receptor linked signaltransduction; esperimental evidence GO: 6468; protein amino acidphosphorylation; experimental evidence" 17 208867_s_at CSNK1A1casein kinase 1, alpha 1 5q32 Exemplarsequence "GO: 7165; signaltransduction; not recorded GO: 7166; cell surface receptor linkedsignal transduction; experimental evidence GO: 6468; protein aminoacid phosphorylation; experimental evidence" 18 208866_at CSNK1A1casein kinase 1, alpha 1 5q32 Consensussequence "GO: 7165; signaltransduction; not recorded GO: 7166; cell surface receptor linkedsignal tranaduction; experimental evidence GO: 6468; protein aminoacid phosphorylation; experimental evidence" 19 208865_at CSNK1A1casein kinase 1, alpha 1 5q32 Consensussequence "GO: 7165; signaltransduction; not recorded GO: 7166; cell surface receptor linkedsignal transduction; experimental evidence GO: 6468; protein aminoacid phosphorylation; experimental evidence" 20 206562_s_at CSNK1A1casein kinase 1, alpha 1 5q32 Exemplarsequence "GO: 7165; signaltransduction: not recorded GO: 7166; cell surface receptor linkedsignal transduction; experimental evidence GO: 6468; protein aminoacid phosphorylation; experimental evidence" 21 235464_at CSNK1A1casein kinase 1, alpha 1 5q32 Consensussequence "GO: 7165; signaltransduction; not recorded GO: 7166; cell surface receptor linkedsignal transduction; experimental evidence GO: 6468; protein aminoacid phosphorylation; experimental evidence" 22 220263_at DAMS SMADin the antisense orientation 5q31.1 Exemplarsequence "GO: 7165;signal transduction; traceable author statement" 23 222488_s_atDCTN4 dynactin 4 (p62) 5q31-q32 Consensussequence 24 218013_x_atDCTN4 dynactin 4 (p62) 5q31-q32 Exemplarsequence 25 233490_at DCTN4dynactin 4 (p62) 5q31-q32 Consensussequence 26 222488_s_at DCTN4dynactin 4 (p62) 5q31-q32 Consensussequence 27 218013_x_at DCTN4dynactin 4 (p62) 5q31-q32 Exemplarsequence 28 233490_at DCTN4dynactin 4 (p62) 5q31-q32 Consensussequence 29 233087_at FBXO13F-box only protein 13 5q21.3 Consensussequence 30 223833_atFLJ20195 hypothetical protein FLJ20195 5q31.3 Exemplarsequence 3157739_at FLJ20195 hypothetical protein FLJ20195 5q31.3Consensussequence 32 222114_x_at FLJ20195 hypothetical proteinFLJ20195 5q31.3 Consensussequence 33 222070_at FLJ20195hypothetical protein FLJ20195 5q31.3 Consensussequence 34 219809_atFLJ20195 hypothetical protein FLJ20195 5q31.3 Exemplarsequence 35241734_at FLJ25286 hypothetical protein FLJ25286 5q23.1Consensussequence 36 212256_at GALNT10 UDP-N-acetyl-alpha-D- 5q33.2Consensussequence galactosamine: polypeptide N-acetytgalactosaminyltransferase 10 (GalNAc-T10) 37 207357_s_atGALNT10 UDP-N-acetyl-alpha-D- 5q33.2 Exemplarsequencegalactosamine: polypeptide N- acetylgalactosaminyltransferase 10(GalNAc-T10) 38 230906_at GALNT10 UDP-N-acetyl-alpha-D- 5q33.2Consensussequence galactosamine: polypeptide N-acetylgalactosaminyltransferase 10 (GalNAc-T10) 39 35820_at GM2AGM2 ganglioside activator protein 5q31.3-q33.1 Consensussequence"GO: 6687; glycosphingolipid metabolism; inferred from electronicannotation GO: 30149; sphingolipid catabolism; non- traceableauthor statement GO: 19377; glycolipid catabolism; non-traceableauthor statement" 40 33646_g_at GM2A GM2 ganglioside activatorprotein 5q31.3-q33.1 Consensussequence "GO: 6687; glycosphingolipidmetabolism; inferred from electronic annotation GO: 30149;sphingolipid catabolism; non- traceable author statement GO: 19377;glycolipid catabolism; non-traceable author statement" 41215891_s_at GM2A GM2 ganglioside activator protein 5q31.3-q33.1Consensussequence "GO: 6687; glycosphingolipid metabolism; inferredfrom electronic annotation GO: 30149; sphingolipid catabolism; non-traceable author statement GO: 19377; glycolipid catabolism;non-traceable author statement" 42 215890_at GM2A GM2 gangliosideactivator protein 5q31.3-q33.1 Consensussequence "GO: 6687;glycosphingolipid metabolism; inferred from electronic annotationGO: 30149; sphingolipid catabolism; non- traceable author statementGO: 19377; glycolipid catabolism; non-traceable author statement"43 212737_at GM2A GM2 ganglioside activator protein 5q31.3-q33.1Consensussequence "GO: 6687; glycosphingolipid metabolism; inferredfrom electronic annotation GO: 30149; sphingolipid catabolism; non-traceable author statement GO: 19377; glycolipid catabolism;non-traceable author statement" 44 209727_at GM2A GM2 gangliosideactivator protein 5q31.3-q33.1 Exemplarsequence "GO: 6687;glycosphingolipid metabolism; inferred from electronic annotationGO: 30149; sphingolipid catabolism; non- traceable author statementGO: 19377; glycolipid catabolism; non-traceable author statement"45 216326_s_at HDAC3 histone deacetylase 3 5q31 Consensussequence"GO: 74; regulation of cell cycle; traceabte author statement" 46202540_s_at HMGCR 3-hydroxy-3-methylglutaryl-Coenzyme A 5q13.3-q14Exemplarsequence "GO: 8406; gonad development; traceable authorstatement reductase GO: 6629; lipid metabolism; inferred fromelectronic annotation GO: 9058; biosynthesis; inferred fromelectronic annotation GO: 6695; cholesterol biosynthesis; notrecorded GO: 8354; germ-cell migration; tracesble author statement"47 202539_s_at HMGCR 3-hydroxy-3-methylglutaryl-Coenzyme A5q13.3-q14 Consensussequence "GO: 8406; gonad development;traceable author statement reductase GO: 6629; lipid metabolism;inferred from electronic annotation GO: 9058; biosynthesis;inferred from electronic annotation GO: 6695; cholesterolbiosynthesis; not recorded GO: 8354; germ-cell migration; tracesbleauthor statement" 48 200692_s_at HSPA9B heat shock 70 kDa protein9B (mortalin-2) 5q31.1 Exemplarsequence 49 200690_at HSPA9B heatshock 70 kDa protein 9B (mortalin-2) 5q31.1 Consensussequence 50200691_s_at HSPA9B heat shock 70 kDa protein 9B (mortalin-2) 5q31.1Exemplarsequence 51 200692_s_at HSPA9B heat shock 70 kDa protein 9B(mortalin-2) 5q31.1 Exemplarsequence 52 200690_at HSPA9B heat shock70 kDa protein 9B (mortalin-2) 5q31.1 Consensussequence 53200691_s_at HSPA9B heat shock 70 kDa protein 9B (mortalin-2) 5q31.1Exemplarsequence 54 211000_s_at IL6ST interleukin 6 signaltransducer (gp130, 5q11 Exemplarsequence "GO: 7166; cell surfacereceptor linked signal oncostatin M receptor) transduction;traceable author statement GO: 6955; immune response; traceableauthor statement" 55 204864_s_at IL6ST interleukin 6 signaltransducer (gp130, 5q11 Exemplarsequence "GO: 7166; cell surfacereceptor linked signal oncostatin M receptor) transduction;traceable author statement GO: 6955; immune response; traceableauthor statement" 56 204863_s_at IL6ST interleukin 6 signaltransducer (gp130, 5q11 Consensussequence "GO: 7166; cell surfacereceptor linked signal oncostatin M receptor) transduction;traceable author statement GO: 6955; immune response; traceableauthor statement" 57 234474_x_at IL6ST interleukin 6 signaltransducer (gp130, 5q11 Consensussequence "GO: 7166; cell surfacereceptor linked signal oncostatin M receptor) transduction;traceable author statement GO: 6955; immune response; traceableauthor statement" 58 234967_at IL6ST interleukin 6 signaltransducer (gp130, 5q11 Consensussequence "GO: 7166; cell surfacereceptor linked signal oncostatin M receptor) transduction;traceable author statement GO: 6955; immune response; traceableauthor statement" 59 229817_at KIAA1281 KIAA1281 protein 5q23.2Consensussequence 60 232303_at KIAA1281 KIAA1281 protein 5q23.2Consensussequence 61 225326_at KIAA1311 KIAA1311 protein 5q32Consensussequence 62 243295_at KIAA1311 KIAA1311 protein 5q32Consensussequence 63 212193_s_at LARP likely ortholog of mouse larelated protein 5q33.2 Consensussequence 64 210966_x_at LARP likelyortholog of mouse la related protein 5q33.2 Exemplarsequence 65239663_x_at LARP likely ortholog of mouse la related protein 5q33.2Consensussequence 66 205270_s_at LCP2 lymphocyte cytosolic protein2 (SH2 5q33.1-qter Exemplarsequence "GO: 7169; transmembranereceptor protein tyrosine kinase domain containing leukocyteprotein of signaling pathway; traceable author statement 76 kDa)GO: 7242; intracellular signaling cascade; inferred from electronicannotation GO: 6955; immune response; tracaable author statement"67 205269_at LCP2 lymphocyte cytosolic protein 2 (SH2 5q33.1-qterConsensussequence "GO: 7169; transmembrane receptor proteintyrosine kinase domain containing leukocyte protein of signalingpathway; traceable author statement 76 kDa) GO: 7242; intracellularsignaling cascade; inferred from electronic annotation GO: 6955;immune response; tracaable author statement" 68 244576_at LCP2lymphocyte cytosolic protein 2 (SH2 5q33.1-qter Consensussequence"GO: 7169; transmembrane receptor protein tyrosine kinase domaincontaining leukocyte protein of signaling pathway; traceable authorstatement 76 kDa) GO: 7242; intracellular signaling cascade;inferred from electronic annotation GO: 6955; immune response;tracaable author statement" 69 235208_at MGC39633 hypotheticalprotein MGC39633 5q22.2 Consensussequence 70 213550_s_at NDUFA2NADH dehydrogenase (ubiquinone) 1 5q31 Consensussequence "GO: 6091;energy pathways; not recorded" alpha subcomptes, 2, 8 kDa

71 209224_s_at NDUFA2 NADH dehydrogenase (ubiquinone) 1 5q31Exemplarsequence "GO: 6091; energy pathways; not recorded" alphasubcomplex, 2, 8 kDa 72 209223_at NDUFA2 NADH dehydrogenase(ubiquinone) 1 5q31 Consensussequence "GO: 6091; energy pathways;not recorded" alpha subcomplex, 2, 8 kDa 73 201507_at PFDN1prefoldin 1 5q31 Exemplarsequence "GO: 7049; cell cycle; traceableauthor statement" 74 220746_s_at RAP80 receptor associated protein80 5q35.3 Exemplarsequence 75 207974_s_at SKP1A S-phasekinase-associated protein 1A 5q31 Exemplarsequence (p19A) 76200719_at SKP1A S-phase kinase-associated protein 1A 5q31Consensussequence (p19A) 77 200718_s_at SKP1A S-phasekinase-associated protein 1A 5q31 Consensussequence (p19A) 78200711_s_at SKP1A S-phase kinase-associated protein 1A 5q31Exemplarsequence (p19A) 79 205097_at SLC26A2 solute carrier family26 (sulfate 5q31-q34 Consensussequence "GO: 8272; sulfatetransport; traceable author statement transporter), member 2 GO:6810; transport; inferred from electronic annotation" 80 202114_atSNX2 sorting nexin 2 5q23 Exemplarsequence "GO: 6897; endocytosis;traceable author statement GO: 6886; intracellular proteintransport; inferred from electronic annotation GO: 7242;intracellular signaling cascade; inferred from electronicannotation" 81 202113_s_at SNX2 sorting nexin 2 5q23Exemplarsequence "GO: 6897; endocytosis; traceable author statementGO: 6886; intracellular protein transport; inferred from electronicannotation GO: 7242; intracellular signaling cascade; inferred fromelectronic annotation" 82 235737_at TSLP thymic stromallymphopoietin 5q21.3 Consensussequence affy idGo_Molecular_Function Transcript ID Sequence Derived From 1 "GO:3754; chaperone activity; inferred from electronic annotation GO:46872; metal ion binding; inferred from Hs.279910.0 electronicannotation GO: 5507; copper ion binding; traceable author statementGO: 5505; HMA; heavy metal binding activity; 1.2e-11; extended:Unknown" 2 Hs.142827.0 3 Hs.142827.0 4 Hs.120969.0 5 4861120 64861120 7 Hs.10235.0 8 "GO: 5096; GTPase activator activity;inferred from electronic annotation" Hs.82035.0 9 "GO: 5634;nucleus; non-traceable author statement" "GO: 3700; transcriptionfactor activity; non-traceable author statement" Hs.26703.0 10 "GO:5634; nucleus; non-traceable author "GO: 3700; transcription factoractivity; non-traceable author statement" Hs.26703.0 statement" 11"GO: 5634; nucleus; non-traceable author statement" "GO: 3700;transcription factor activity; non-traceable author statement"Hs.26703.0 12 "GO: 5739; mitochondrion; inferred from "GO: 9482;ba3-type cytochrome c oxidase; inferred from electronic annotationGO: 9481; aa3-type Hs.278494.0 electronic annotation" cytochrome coxidase; inferred from electronic annotation GO: 9483; caa3-typecytochrome c oxidase; inferred from electronic annotation GO: 4129;cytochrome c oxidase activity; inferred from electronic annotationGO: 16491; oxidoreductase activity; inferred from electronicannotation GO: 9485; cbb3-type cytochrome c oxidase; inferred fromelectronic annotation" 13 "GO: 5739; mitochondrion; inferred from"GO: 9482; ba3-type cytochrome c oxidase; inferred from electronicannotation GO: 9481; aa3-type Hs.3462.1 electronic annotation"cytochrome c oxidase; inferred from electronic annotation GO: 9483;caa3-type cytochrome c oxidase; inferred from electronic annotationGO: 4129; cytochrome c oxidase activity; inferred from electronicannotation GO: 16491; oxidoreductase activity; inferred fromelectronic annotation GO: 9485; cbb3-type cytochrome c oxidase;inferred from electronic annotation" 14 "GO: 5739; mitochondrion;inferred from "GO: 9482; ba3-type cytochrome c oxidase; inferredfrom electronic annotation GO: 9481; aa3-type Hs.3462.0 electronicannotation" cytochrome c oxidase; inferred from electronicannotation GO: 9483; caa3-type cytochrome c oxidase; inferred fromelectronic annotation GO: 4129; cytochrome c oxidase activity;inferred from electronic annotation GO: 16491; oxidoreductaseactivity; inferred from electronic annotation GO: 9485; cbb3-typecytochrome c oxidase; inferred from electronic annotation" 15 "GO:4681; casein kinase I activity; experimental evidence GO: 4672;pkinase; protein kinase activity; 1.3e-27; Hs.283738.1 extended:inferred from electronic annotation" 16 "GO: 4681; casein kinase Iactivity; experimental evidence GO: 4672; pkinase; protein kinaseactivity; 1.3e-27; Hs.84264.3 extended: inferred from electronicannotation" 17 "GO: 4681; casein kinase I activity; experimentalevidence GO: 4672; pkinase; protein kinase activity; 1.3e-27;Hs.144477.0 extended: inferred from electronic annotation" 18 "GO:4681; casein kinase I activity; experimental evidence GO: 4672;pkinase; protein kinase activity; 1.3e-27; Hs.144477.0 extended:inferred from electronic annotation" 19 "GO: 4681; casein kinase Iactivity; experimental evidence GO: 4672; pkinase; protein kinaseactivity; 1.3e-27; Hs.144477.0 extended: inferred from electronicannotation" 20 "GO: 4681; casein kinase I activity; experimentalevidence GO: 4672; pkinase; protein kinase activity; 1.3e-27;Hs.283738.0 extended: inferred from electronic annotation" 21 "GO:4681; casein kinase I activity; experimental evidence GO: 4672;pkinase; protein kinase activity; 1.3e-27; Hs.104216.0 extended:inferred from electronic annotation" 22 Hs.59666.0 23 "GO: 5813;centrosome; predicted/computed Hs.180952.0 GO: 5869; dynactincomplex; not recorded GO: 5634; nucleus; predicted/computed GO:5737; cytoplasm; predicted/computed" 24 "GO: 5813; centrosome;predicted/computed Hs.180952.0 GO: 5869; dynactin complex; notrecorded GO: 5634; nucleus; predicted/computed GO: 5737; cytoplasm;predicted/computed" 25 "GO: 5813; centrosome; predicted/computedHs.180952.2 GO: 5869; dynactin complex; not recorded GO: 5634;nucleus; predicted/computed GO: 5737; cytoplasm;predicted/computed" 26 "GO: 5813; centrosome; predicted/computedHs.180952.0 GO: 5869; dynactin complex; not recorded GO: 5634;nucleus; predicted/computed GO: 5737; cytoplasm;predicted/computed" 27 "GO: 5813; centrosome; predicted/computedHs.180952.0 GO: 5869; dynactin complex; not recorded GO: 5634;nucleus; predicted/computed GO: 5737; cytoplasm;predicted/computed" 28 "GO: 5813; centrosome; predicted/computedHs.180952.2 GO: 5869; dynactin complex; not recorded GO: 5634;nucleus; predicted/computed GO: 5737; cytoplasm;predicted/computed" 29 Hs.272314.0 30 Hs.77798.1 31 2 32Hs.326464.1 33 Hs.326464.0 34 Hs.286261.0 35 Hs.107622.0 36Hs.107260.1 37 Hs.107260.0 38 Hs.9286.0 39 "GO: 5764; lysosome;non-traceable author "GO: 30290; sphingolipid activator proteinactivity; non-traceable author statement" 4898374 statement" 40"GO: 5764; lysosome; non-traceable author "GO: 30290; sphingolipidactivator protein activity; non-traceable author statement" 4819721statement" 41 "GO: 5764; lysosome; non-traceable author "GO: 30290;sphingolipid activator protein activity; non-traceable authorstatement" Hs.289082.1 statement" 42 "GO: 5764; lysosome;non-traceable author "GO: 30290; sphingolipid activator proteinactivity; non-traceable author statement" Hs.289082.1 statement" 43"GO: 5764; lysosome; non-traceable author "GO: 30290; sphingolipidactivator protein activity; non-traceable author statement"Hs.278242.3 statement" 44 "GO: 5764; lysosome; non-traceable author"GO: 30290; sphingolipid activator protein activity; non-traceableauthor statement" Hs.289082.0 statement" 45 "GO: 5634; nucleus;traceable author "GO: 4407; histone deacetylase activity; traceableauthor statement GO: 8189; apoptosis inhibitor Hs.279789.12statement" activity; traceable author statement GO: 16787;hydrolase activity; inferred from electronic annotation" 46 "GO:5624; membrane fraction; not "GO: 4420; hydroxymethylglutaryl-CoAreductase (NADPH) activity; inferred from electronic annotationHs.11899.0 recorded GO: 5777; peroxisome; inferred GO: 16491;oxidoreductase activity; inferred from electronic annotation" fromelectronic annotation GO: 5789; endoplasmic reticulum membrane;traceable author statement GO: 16021; integral to membrane;inferred from electronic annotation" 47 "GO: 5624; membranefraction; not "GO: 4420; hydroxymethylglutaryl-CoA reductase(NADPH) activity; inferred from electronic annotation Hs.11899.0recorded GO: 5777; peroxisome; inferred GO: 16491; oxidoreductaseactivity; inferred from electronic annotation" from electronicannotation GO: 5789; endoplasmic reticulum membrane; traceableauthor statement GO: 16021; integral to membrane; inferred fromelectronic annotation" 48 "GO: 5739; mitochondrion; traceableauthor "GO: 5524; ATP binding; inferred from electronic annotation"Hs.3069.0 statement" 49 "GO: 5739; mitochondrion; traceable author"GO: 5524; ATP binding; inferred from electronic annotation"Hs.3069.0 statement" 50 "GO: 5739; mitochondrion; traceable author"GO: 5524; ATP binding; inferred from electronic annotation"Hs.3069.0 statement" 51 "GO: 5739; mitochondrion; traceable author"GO: 5524; ATP binding; inferred from electronic annotation"Hs.3069.0 statement" 52 "GO: 5739; mitochondrion; traceable author"GO: 5524; ATP binding; inferred from electronic annotation"Hs.3069.0 statement" 53 "GO: 5739; mitochondrion; traceable author"GO: 5524; ATP binding; inferred from electronic annotation"Hs.3069.0 statement" 54 "GO: 5887; integral to plasma "GO: 4898;gp130; traceable author statement GO: 4924; oncostatin-M receptoractivity; traceable author Hs.82065.1 membrane; traceable authorstatement" statement GO: 4872; receptor activity; traceable authorstatement" 55 "GO: 5887; integral to plasma "GO: 4898; gp130;traceable author statement GO: 4924; oncostatin-M receptoractivity; traceable author Hs.82065.0 membrane; traceable authorstatement" statement GO: 4872; receptor activity; traceable authorstatement" 56 "GO: 5887; integral to plasma "GO: 4898; gp130;traceable author statement GO: 4924; oncostatin-M receptoractivity; traceable author Hs.82065.0 membrane; traceable authorstatement" statement GO: 4872; receptor activity; traceable authorstatement" 57 "GO: 5887; integral to plasma "GO: 4898; gp130;traceable author statement GO: 4924; oncostatin-M receptoractivity; traceable author Hs.283974.0 membrane; traceable authorstatement" statement GO: 4872; receptor activity; traceable authorstatement" 58 "GO: 5887; integral to plasma "GO: 4898; gp130;traceable author statement GO: 4924; oncostatin-M receptoractivity; traceable author Hs.283974.0 membrane; traceable authorstatement" statement GO: 4872; receptor activity; traceable authorstatement" 59 Hs.93738.0 60 Hs.42796.0 61 "GO: 3676; nucleic acidbinding; inferred from electronic annotation" Hs.61441.0 62 "GO:3676; nucleic acid binding; inferred from electronic annotation"Hs.183412.0 63 Hs.6214.1 64 Hs.6214.0 65 Hs.207988.0 66 "GO: 5515;protein binding; traceable author statement" Hs.2488.0

67 "GO: 5515; protein binding; traceable author statement"Hs.2488.0 68 "GO: 5515; protein binding; traceable authorstatement" Hs.260872.0 69 Hs.47534.0 70 "GO: 5739; mitochondrion;inferred from "GO: 3954; NADH dehydrogenase activity; inferred fromelectronic annotation GO: 16491; oxidoreductase Hs.163867.1electronic annotation activity; inferred from electronic annotationGO: 8137; NADH dehydrogenase (ubiquinone) activity; traceable GO:5624; membrane fraction; not author statement" recorded" 71 "GO:5739; mitochondrion; inferred from "GO: 3954; NADH dehydrogenaseactivity; inferred from electronic annotation GO: 16491;oxidoreductase Hs.163867.0 electronic annotation activity; inferredfrom electronic annotation GO: 8137; NADH dehydrogenase(ubiquinone) activity; traceable GO: 5624; membrane fraction; notauthor statement" recorded" 72 "GO: 5739; mitochondrion; inferredfrom "GO: 3954; NADH dehydrogenase activity; inferred fromelectronic annotation GO: 16491; oxidoreductase Hs.163867.0electronic annotation activity; inferred from electronic annotationGO: 8137; NADH dehydrogenase (ubiquinone) activity; traceable GO:5624; membrane fraction; not author statement" recorded" 73 "GO:3754; chaperone activity; inferred from electronic annotation GO:3700; transcription factor Hs.132881.0 activity; traceable authorstatement" 74 Hs.7889.0 75 Hs.227950.0 76 Hs.171626.0 77Hs.171626.0 78 Hs.171626.0 79 "GO: 5887; integral to plasma "GO:8271; sulfate porter activity; inferred from electronic annotation"Hs.29981.0 membrane; traceable author statement GO: 5624; membranefraction; traceable author statement" 80 "GO: 8565; proteintransporter activity; inferred from electronic annotation"Hs.11183.0 81 "GO: 8565; protein transporter activity; inferredfrom electronic annotation" Hs.11183.0 82 Hs.128051.0 affy idSequence ID Sequence Source Unigene_Accession Cluster_TypeLocusLink Full_Length_Reference_Seq 1 NM_004045.1 g4757803 RefSeqHs.279910 fulllength 475 NM_004045; antioxidant protein 1 2NM_004772.1 g4758865 RefSeq Hs.413760 fulllength 9315 NM_004772;neuronal protein 3.1 3 U36189.1 g1244509 GenBank Hs.413760fulllength 9315 NM_004772; neuronal protein 3.1 4 AU144860Hs.120969.0 GenBank Hs.413760 fulllength 9315 NM_004772; neuronalprotein 3.1 5 H93077 4861120 GenBank Hs.10235 fulllength 10826NM_016348; chromosome 5 open reading frame 4 NM_032385; chromosome5 open reading frame 4 6 H93077 4861120 GenBank Hs.10235 fulllength10826 NM_016348; chromosome 5 open reading frame 4 NM_032385;chromosome 5 open reading frame 4 7 NM_016348.1 g7705942 RefSeqHs.10235 fulllength 10826 NM_016348; chromosome 5 open readingframe 4 NM_032385; chromosome 5 open reading frame 4 8 NM_016603.1g7706136 RefSeq Hs.82035 fulllength 51306 NM_016603; chromosome 5open reading frame 5 9 AF180476.1 g6856208 GenBank Hs.26703fulllength 9337 NM_004779; CCR4-NOT transcription complex, subunit8 10 NM_004779.1 g4758945 RefSeq Hs.26703 fulllength 9337NM_004779; CCR4-NOT transcription complex, subunit 8 11 AI769416Hs.26703.0_RC GenBank Hs.26703 fulllength 9337 NM_004779; CCR4-NOTtranscription complex, subunit 8 12 AF042165 Hs.278494.0 GenBankHs.430075 fulllength 1350 NM_001867; cytochrome c oxidase subunitVIIc precursor 13 AA382702 Hs.3462.1 GenBank Hs.430075 fulllength1350 NM_001867; cytochrome c oxidase subunit VIIc precursor 14NM_001867.1 g4502992 RefSeq Hs.430075 fulllength 1350 NM_001867;cytochrome c oxidase subunit VIIc precursor 15 AW592437Hs.283738.1.A1 GenBank Hs.283738 fulllength 1452 NM_001892; caseinkinase 1, alpha 1 NM_018548; 16 BF341845 Hs.84264.3.A1 GenBankHs.283738 fulllength 1452 NM_001892; casein kinase 1, alpha 1NM_018548; 17 AF119911.1 g7770258_RC GenBank Hs.283738 fulllength1452 NM_001892; casein kinase 1, alpha 1 NM_018548; 18 BG534245Hs.144477.0.S2 GenBank Hs.283738 fulllength 1452 NM_001892; caseinkinase 1, alpha 1 NM_018548; 19 BG534245 Hs.144477.0.S2 GenBankHs.283738 fulllength 1452 NM_001892; casein kinase 1, alpha 1NM_018548; 20 NM_001892.1 g4503088 RefSeq Hs.283738 fulllength 1452NM_001892; casein kinase 1, alpha 1 NM_018548; 21 AA010757Hs.104216.0.A1 GenBank Hs.283738 fulllength 1452 NM_001892; caseinkinase 1, alpha 1 NM_018548; 22 NM_022001.1 g11545925 RefSeqHs.59666 fulllength 9597 NM_022001; SMAD in the antisenseorientation 23 BE218028 Hs.180952.0_RC GenBank Hs.328865 fulllength51164 NM_016221; dynactin 4 (p62) 24 NM_016221.1 g7705892 RefSeqHs.328865 fulllength 51164 NM_016221; dynactin 4 (P62) 25 AI985890Hs.180952.2_RC GenBank Hs.328865 fulllength 51164 NM_016221;dynactin 4 (p62) 26 BE218028 Hs.180952.0_RC GenBank Hs.328865fulllength 51164 NM_016221; dynactin 4 (p62) 27 NM_016221.1g7705892 RefSeq Hs.328865 fulllength 51164 NM_016221; dynactin 4(p62) 28 AI985890 Hs.180952.2_RC GenBank Hs.328865 fulllength 51164NM_016221; dynactin 4 (p62) 29 AL133602.1 Hs.272314.0 GenBankHs.272314 64839 30 BC002482.1 g12803328 GenBank Hs.286261fulllength 54853 NM_017706; hypothetical protein FLJ20195 31AI949010 4919314_rc GenBank Hs.286261 fulllength 54853 NM_017706;hypothetical protein FLJ20195 32 BE409994 Hs.326464.1 GenBankHs.286261 fulllength 54853 NM_017706; hypothetical protein FLJ2019533 AW090043 Hs.326464.0.A1 GenBank Hs.286261 fulllength 54853NM_017706; hypothetical protein FLJ20195 34 NM_017706.1 g8923184RefSeq Hs.286261 fulllength 54853 NM_017706; hypothetical proteinFLJ20195 35 AI391443 Hs.107622.0.A1 GenBank Hs.107622 fulllength153443 NM_152546; hypothetical protein FLJ25286 36 BE906572Hs.107260.1 GenBank Hs.107260 fulllength 55568 NM_017540;UDP-N-acetyl-alpha-D- galactosamine:polypeptide N-acetylgalactosaminyltransferase 10 (GalNAc-T10) 37 NM_017540.1g9055207 RefSeq Hs.107260 fulllength 55568 NM_017540;UDP-N-acetyl-alpha-D galactosamine:polypeptide N-acetylgalactosaminyltransferase 10 (GalNAc-T10) 38 AK024931.1Hs.9286.0.S1 GenBank Hs.107260 fulllength 55568 NM_017540;UDP-N-acetyl-alpha-D- galactosamine:polypeptide N-acetylgalactosaminyltransferase 10 (GalNAc-T10) 39 X62078 4898374GenBank Hs.289082 fulllength 2760 NM_000405; GM2 gangliosideactivator protein precursor 40 X61094 4819721 GenBank Hs.289082fulllength 2760 NM_000405; GM2 ganglioside activator proteinprecursor 41 X61094.1 Hs.289082.1 GenBank Hs.289082 fulllength 2760NM_000405; GM2 ganglioside activator protein precursor 42 X61094.1Hs.289082.1 GenBank Hs.289082 fulllength 2760 NM_000405; GM2ganglioside activator protein precursor 43 AL513583 Hs.278242.3GenBank Hs.289082 fulllength 2760 NM_000405; GM2 gangliosideactivator protein precursor 44 M76477.1 g183356 GenBank Hs.289082fulllength 2760 NM_000405; GM2 ganglioside activator proteinprecursor 45 AF059650 Hs.279789.12.S1 GenBank Hs.446552 fulllength8841 NM_003883; histone deacetylase 3 46 NM_000859.1 g4557642RefSeq Hs.11899 fulllength 3156 NM_000859;3-hydroxy-3-methylglutaryl-Coenzyme A reductase 47 AL518627Hs.11899.0 GenBank Hs.11899 fulllength 3156 NM_000859;3-hydroxy-3-methylglutaryl-Coenzyme A reductase 48 NM_004134.1g4758569 RefSeq Hs.3069 fulllength 3313 NM_004134; heat shock 70kDa protein 9B precursor 49 AA927701 Hs.3069.0_RC GenBank Hs.3069fulllength 3313 NM_004134; heat shock 70 kDa protein 9B precursor50 BC000478.1 g12653414 GenBank Hs.3069 fulllength 3313 NM_004134;heat shock 70 kDa protein 9B precursor 51 NM_004134.1 g4758569RefSeq Hs.3069 fulllength 3313 NM_004134; heat shock 70 kDa protein9B precursor 52 AA927701 Hs.3069.0_RC GenBank Hs.3069 fulllength3313 NM_004134; heat shock 70 kDa protein 9B precursor 53BC000478.1 g12653414 GenBank Hs.3069 fulllength 3313 NM_004134;heat shock 70 kDa protein 9B precursor 54 AB015706.1 g4972293GenBank Hs.82065 fulllength 3572 NM_002184; interleukin 6 signaltransducer isoform 1 precursor NM_175767; interleukin 6 signaltransducer isoform 2 precursor 55 NM_002184.1 g4504674 RefSeqHs.82065 fulllength 3572 NM_002184; interleukin 6 signal transducerisoform 1 precursor NM_175767; interleukin 6 signal transducerisoform 2 precursor 56 BE856546 Hs.82065.0_RC GenBank Hs.82065fulllength 3572 NM_002184; interleukin 6 signal transducer isoform1 precursor NM_175767; interleukin 6 signal transducer isoform 2precursor 57 U58146.1 Hs.283974.0.A1 GenBank Hs.82065 fulllength3572 NM_002184; interleukin 6 signal transducer isoform 1 precursorNM_175767; interleukin 6 signal transducer isoform 2 precursor 58U58146.1 Hs.283974.0.S1 GenBank Hs.82065 fulllength 3572 NM_002184;interleukin 6 signal transducer isoform 1 precursor NM_175767;interleukin 6 signal transducer isoform 2 precursor 59 AI452715Hs.93738.0.S1 GenBank Hs.42796 57507 60 AB033107.1 Hs.42796.0.S1GenBank Hs.42796 57507 61 AB037732.1 Hs.61441.0.S1 GenBank Hs.6144154439 62 N75450 Hs.183412.0.A1 GenBank Hs.61441 54439 63 BE881529Hs.6214.1.A1 GenBank Hs.6214 fulllength 23367 NM_015315; KIAA0731protein 64 BC001460.1 g12655204 GenBank Hs.6214 fulllength 23367NM_015315; KIAA0731 protein 65 AI768454 Hs.207988.0.A1 GenBankHs.6214 fulllength 23367 NM_015315; KIAA0731 protein 66 NM_005565.2g7382491 RefSeq Hs.2488 fulllength 3937 NM_005565; lymphocytecytosolic protein 2 67 AI123251 Hs.2488.0.S2 GenBank Hs.2488fulllength 3937 NM_005565; lymphocyte cytosolic protein 2 68AA992040 Hs.260872.0_RC GenBank Hs.2488 fulllength 3937 NM_005565;lymphocyte cytosolic protein 2 69 AW157712 Hs.47534.0.A1 GenBankHs.47534 fulllength 153733 NM_152549; hypothetical protein MGC3963370 AA993683 Hs.163867.1_RC GenBank Hs.163867 fulllength 4695NM_002488; NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 8kDa 71 BC003674.1 g13277539 GenBank Hs.163867 fulllength 4695NM_002488; NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 8kDa 72 BF434335 Hs.163867.0.S1 GenBank Hs.163867 fulllength 4695NM_002488; NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 8kDa 73 NM_002622.2 g12408673 RefSeq Hs.132881 fulllength 5201NM_002622; prefoldin 1 74 NM_016290.1 g7706482 RefSeq Hs.7889fulllength 51720 NM_016290; retinoid x receptor interacting protein75 NM_006930.1 g5902087 RefSeq Hs.171626 fulllength 6500 NM_006930;S-phase kinase-associated protein 1A isoform a NM_170679; S-phasekinase-associated protein 1A isoform b 76 NM_003197.2 Hs.171626.0GenBank Hs.171626 fulllength 6500 NM_006930; S-phasekinase-associated protein 1A isoform a NM_170679; S-phasekinase-associated protein 1A isoform b 77 NM_003197.2 Hs.171626.0GenBank Hs.171626 fulllength 6500 NM_006930; S-phasekinase-associated protein 1A isoform a NM_170679; S-phasekinase-associated protein 1A isoform b 78 NM_003197.2 g6006030RefSeq Hs.171626 fulllength 6500 NM_006930; S-phasekinase-associated protein 1A isoform a NM_170679; S-phasekinase-associated protein 1A isoform b 79 AI025519 Hs.29981.0GenBank Hs.29981 fulllength 1836 NM_000112; sulfate aniontransporter 1 80 NM_003100.1 g4507140 RefSeq Hs.11183 fulllength6643 NM_003100; sorting nexin 2 81 AF043453.1 g2827433 GenBankHs.11183 fulllength 6643 NM_003100; sorting nexin 2 82 AW118681Hs.128051.0.A1 GenBank Hs.128051 fulllength 85480 NM_033035; thymicstromal lymphopoietin isoform 1 NM_138551; thymic stromallymphopoietin isoform 2

TABLE-US-00042 TABLE 42 Top 50 differentially expressed genes insubjects with or without 5q-deletions # affy id HUGO name fc p qstn t Title 1 223157_at MGC3232 -176,840,673,711,012 1.56E-302.27E-26 -0.878761187518287 -16,290,783,098,029 hypotheticalprotein MGC3232 2 227056_at -210,270,102,717,117 4.23E-23 3.07E-20-0.835901800343154 -149,859,562,558,106 ESTs 3 222983_s_at PAIP2-152,774,472,098,093 2.60E-22 1.26E-18 -0.824763060632146-14,774,791,378,756 PABP-interacting protein 2 4 222229_x_at-138,555,045,872,062 1.32E-19 3.84E-16 -0.857704454194318-146,682,149,163,202 5 200093_s_at- HINT1 -167,652,977,392,5151.06E-19 3.84E-16 -0.775962891073544 -139,632,025,220,666 histidinetriad nucleotide binding protein 1 HG-U133B 6 208826_x_at HINT1-149,623,902,638,172 3.44E-17 7.13E-14 -0.72041319782511-131,083,164,795,885 histidine triad nucleotide binding protein 1 7200093_s_at- HINT1 -155,871,940,613,387 1.40E-16 2.54E-13-0.717122701625737 -129,921,366,659,411 histidine triad nucleotidebinding HG-U133A protein 1 8 218436_at SIL1 -227,341,823,543,5511.47E-17 3.56E-14 -0.701444914476295 -129,888,069,023,019endoplasmic reticulum chaperone SIL1, homolog of yeast 9 218645_atZNF277 -176,295,972,337,266 5.89E-16 9.50E-13 -0.710642779487633-128,442,564,651,243 zinc finger protein (C2H2 type) 277 10201922_at YR-29 -142,354,413,066,903 1.25E-15 1.51E-12-0.734143241558063 -128,308,922,616,193 hypothetical protein YR-2911 213846_at COX7C -168,767,608,406,954 6.22E-16 8.21E-12-0.719989960058898 -127,660,986,978,765 cytochrome c oxsidasesubunit VIIc 12 236892_s_at -559,327,252,933,867 1.98E-14 2.21E-11-0.715366073440501 -124,862,044,859,403 Homo sapiens, clone MGC:10077 IMAGE: 3896690, mRNA, complete cds 13 201574_at ETF1-161,004,106,965,863 2.94E-15 4.26E-12 -0.676198023006729-124,433,769,785,292 eukaryotic translation termination factor 1 14223276_at NID67 -216,267,559,712,988 3.04E-14 3.15E-11-0.656161193924451 -121,237,932,293,719 putative small membraneprotein NID67 15 239791_at -547,776,290,365,847 2.96E-13 2.86E-10-0.672006730873876 -120,352,411,255,962 Homo sapiens, clone MGC:10077 IMAGE: 3896690, mRNA, complete cds 16 205366_s_at HOXB6-44,911,335,922,303 3.49E-13 3.16E-10 -0.655406699380282-119,281,404,087,584 homeo box B6 17 201978_s_at KIAA0141-191,317,509,860,742 4.12E-13 3.51E-10 -0.639216462493315-11,812,517,148,329 KIAA0141 gene product 18 205382_s_at DF-293,432,627,776,163 1.11E-12 8.94E-10 -0.629029607893431-116,633,749,020,449 D component of complement (adipsin) 19201345_s_at UBE2D2 -148,262,114,288,443 1.26E-11 9.16E-09-0.642126647798994 -116,009,609,837,515 ubiquitin-conjugatingenzyme E2D 2 (UBC4/5 homolog, yeast) 20 202413_s_at USP115,550,121,473,553 3.10E-10 2.05E-07 0.667099477655205115,393,157,069,109 ubiquitin specific protease 1 21 217751_atLOC51064 -191,941,596,685,024 7.51E-13 5.74E-09 -0.618116585891762-11,445,907,258,588 glutathione S-transferase subunit 13 homolog 22207721_x_at HINT1 -161,968,228,706,642 2.68E-11 1.85E-08-0.628345318200291 -11,438,552,379,395 histidine triad nucleotidebinding protein 1 23 241827_at 158,826,758,599,576 3.51E-091.88E-07 0.68393425971076 114,342,004,860,552 clone PEBLM2007832,moderately similar to ZINC FINGER PROTEIN 84. 24 200608_s_at RAD21143,095,680,451,226 1.15E-08 5.56E-06 0.688201897055249113,449,542,535,785 RAD21 homolog (S. pombe) 25 201977_s_atKIAA0141 -153,332,193,867,581 5.32E-10 3.22E-07 -0.610461380259132-110,828,336,270,582 KIAA0141 gene product 26 203538_at CAMLG-151,834,530,468,475 4.42E-10 2.79E-07 -0.606086007348918-110,631,682,617,063 calcium modulating ligand 27 208646_at RPS14-173,979,392,536,201 2.34E-09 1.30E-06 -0.6127387743923-10,987,412,116,646 ribosomal protein S14 28 222902_s_at FLJ21144161,896,681,826,594 6.42E-07 2.33E-04 0.69463366257089109,496,234,449,283 hypothetical protein FLJ21144 29 226835_s_at-165,273,462,862,669 1.32E-09 7.66E-09 -0.595761971718935-109,038,850,423,911 Homo sapiens, clone IMAGE: 5285034, mRNA 30200066_at-HG- IK -143,128,055,082,803 1.30E-08 6.10E-07-0.615394465733112 -108,685,620,572,657 IK cytokine, down-regulatorof HLA II U133B 31 221476_s_at RPL15 -127,049,845,993,301 5.02E-082.14E-05 -0.63269486669309 -108,678,589,099,167 ribosomal proteinL15 32 201377_at NICE-4 156,835,350,799,393 8.81E-08 3.04E-040.664190316298723 107,661,298,383,645 NICE-4 protein 33 209523_atTAF2 170,086,707,324,231 3.53E-06 1.07E-03 0.682592061168908106,972,210,037,855 TAF2 RNA polymerase II, TATA box bindingprotein (TBP)-associated factor, 150 kDa 34 229693_at-175,675,663,418,723 4.26E-09 2.21E-06 -0.576353171339351-1,067,136,757,546 ESTs 35 200066_at-HG- IK -142,856,317,950,3393.79E-08 1.72E-05 -0.590633532411712 -10,607,405,374,437 IKcytokine, down-regulator of HLA II U133A 36 236728_at FLJ39485-200,676,202,973,617 1.03E-08 5.13E-06 -0.569259101718997-105,533,547,236,791 hypothetical protein FLJ39485 37 212894_atSUPV3L1 141,673,557,040,566 8.63E-07 3.04E-04 0.6198744425206710,523,737,772,068 suppressor of var1, 3-like 1 (S. cerevisiae) 38224936_at EIF2S3 -137,196,707,800,854 4.23E-08 1.86E-05-0.579805173176531 -105,211,684,205,005 eukaryotic translationinitiation factor 2, subunit 3 gamma, 52 kDa 39 201222_s_at RAD23B155,900,876,730,256 2.24E-06 6.92E-04 0.621845217538417104,414,587,042,546 RAD23 homolog B (S. cerevisiae) 40 228904_at-319,150,465,716,672 5.66E-09 2.34E-05 -0.573731733017053-104,305,543,620,308 ESTs 41 200023_s_at- E1F3S5-121,999,999,867,377 1.19E-06 4.02E-04 -0.592567784154637-103,262,409,439,699 eukaryotic translation initiation factorHG-U133B 3, subunit 5 epsilon, 47 kDa 42 225326_at KIAA1311-151,260,767,011,645 2.20E-07 8.64E-05 -0.569062835222392-103,129,285,547,071 KIAA1311 protein 43 224915_x_at-142,397,637,904,464 1.23E-06 4.04E-05 -0.58028667927814-1,024,454,543,165 Homo sapiens, clone IMAGE: 5285034, mRNA 44226227_x_at -139,800,457,277,837 1.43E-06 4.62E-05-0.577736346280825 -102,142,942,870,084 Homo sapiens, clone IMAGE:5285034, mRNA 45 223318_s_at MGC10974 -215,038,689,968,521 1.63E-076.58E-05 -0.550535669133841 -102,058,126,997,572 hypotheticalprotein MGC10974 46 214919_s_at -157,916,847,056,614 3.04E-071.16E-04 -0.553949943054473 -10,180,703,654,607 Homo sapiens, cloneIMAGE: 3866125, mRNA 47 222984_at PAIP2 -130,364,196,813,1781.60E-07 5.05E-04 -0.568155433373277 -101,413,895,363,391PABP-interacting protein 2 48 208855_s_at STK24 144,316,932,352,9916.36E-06 1.84E-03 0.584523623741934 101,217,526,639,216serine/threonine kinase 24 (STE20 homolog, yeast) 49 204082_at PBX3-242,166,057,961,334 3.36E-07 1.25E-04 -0.545264120738389-101,116,484,418,875 pre-B-cell leukemia transcription factor 3 50200602_at APP 258,324,086,045,963 2.23E-05 5.68E-030.604177140166656 101,105,526,849,876 amyloid beta (A4) precursorprotein (protease nexin-II, Alzheimer disease) # MapLocationSequence Type Go_Biological_Process Go_Cellular_Component 1 4q12Exemplarsequence 2 Consensussequence 3 5q31.3 Exemplarsequence 4Consensussequence 5 5q31.2 Consensussequence GO: 7165; signaltransduction; traceable author statement GO: 5634; nucleus;traceable author statement GO: 5856; cytoskeleton; traceable authorstatement 6 5q31.2 Exemplarsequence GO: 7165; signal transduction;traceable author GO: 5634; nucleus; traceable author statementstatement GO: 5856; cytoskeleton; traceable author statement 75q31.2 Consensussequence GO: 7165; signal transduction; traceableauthor statement GO: 5634; nucleus; traceable author statement GO:5856; cytoskeleton; traceable author statement 8 5q31Exemplarsequence 9 7q31.1 Exemplarsequence 10 5q13.2Exemplarsequence GO: 6412; protein biosynthesis; inferred fromelectronic GO: 5840; ribosome; inferred from electronic annotationannotation GO: 5634; nucleus; inferred from electronic annotation11 5q14 Consensussequence GO: 6118; electron transport; inferredfrom electronic GO: 5739; mitochondrion; inferred from electronicannotation annotation GO: 6091; energy pathways; traceable authorstatement 12 Consensussequence 13 5q31.1 Exemplarsequence GO: 6449;regulation of translational GO: 5737; cytoplasm; traceable authorstatement termination; traceable author statement 14 5q33.1Exemplarsequence 15 Consensussequence 16 17q21.3 ExemplarsequenceGO: 6355; regulation of transcription, DNA- GO: 5634; nucleus;non-traceable author statement dependent; non-traceable authorstatement GO: 7275; development; inferred from electronicannotation GO: 8595; determination of anterior/posterior axis,embryo; non-traceable author statement 17 5q31.3 Exemplarsequence18 19p13.3 Exemplarsequence GO: 6508; proteolysis and peptidolysis;traceable author statement GO: 6957; complement activation,alternative pathway: inferred from electronic annotation 19 5q31.3Exemplarsequence GO: 6464; protein modification; traceable authorstatement GO: 6512; ubiquitin cycle; inferred from electronicannotation GO: 7125; invasive growth; traceable author statementGO: 7048; oncogenesis; traceable author statement 20 1p32.1-p31.3Exemplarsequence GO: 6511; ubiquitin-dependent protein catabolism;inferred from electronic annotation 21 7q34 Exemplarsequence GO:5739; mitochondrion; inferred from electronic annotation GO: 30288:periplasmic space (sensu Gram-negative Becteria); inferred fromelectronic annotation 22 5q31.2 Exemplarsequence GO: 7165; signaltransduction; traceable author GO: 5634; nucleus; traceable authorstatement statement GO: 5856; cytoskeleton; traceable authorstatement 23 Consensussequence 24 8q24 Exemplarsequence GO: 6302;double-strand break repair; traceable author GO: 5634; nucleus;inferred from electronic annotation statement GO: 7131; meloticrecombination; traceable author statement GO: 7049; cell cycle;inferred from electronic annotation GO: 7067; mitosis: inferredfrom electronic annotation GO: 7059; chromosome segregation;inferred from electronic annotation GO: 6915; apoptosis; inferredfrom electronic annotation 25 5q31.3 Consensussequence 26 5q23Exemplarsequence GO: 7165; signal transduction; traceable authorGO: 16021; integral to membrane; inferred from electronic statementGO: 6952; defense response; traceable annotation author statement27 5q31-q33 Exemplarsequence GO: 6412; protein biosynthesis;predicted/computed GO: 5843; cytosolic small ribosomal subunit(sensu Eukarya); predicted/computed 28 1p34.1 Consensussequence 29Consensussequence 30 5q31.3 Exemplarsequence GO: 7267; cell-cellsignaling; traceable author statement GO: 5625; soluble fraction;traceable author statement GO: 6955; immune response; traceableauthor GO: 5615; extracellular space; traceable author statementstatement 31 3p24.1 Exemplarsequence GO: 6412; proteinbiosynthesis; traceable author GO: 5840; ribosome; traceable authorstatement statement GO: 5622; intracellular; inferred fromelectronic annotation 32 1q21.3 Exemplarsequence 33 8q24.12Consensussequence GO: 6508; proteolysis and peptidolysis; inferredfrom electronic annotation 34 Consensussequence 35 5q31.3Exemplarsequence GO: 7267; cell-cell signaling; traceable authorstatement GO: 5625; soluble fraction; traceable author statementGO: 6955; immune response; traceable author GO: 5615; extracellularspace; traceable author statement statement 36 5q14.3Consensussequence 37 10q22.1 Consensussequence 38 Xp22.2-p22.1Consensussequence GO: 6414; translational elongation; inferred fromGO: 5843; cytosolic small ribosomal subunit (sensu electronicannotation Eukarya); not recorded GO: 5850; eukaryotic translationinitiation

factor 2 complex; not recorded 39 9q31.2 Consensussequence GO:6289; nucleotide-excision repair; experimental GO: 5634; nucleus;predicted/computed evidence 40 Consensussequence 41 11p15.3Exemplarsequence GO: 6446; regulation of translational initiation;traceable GO: 5852; eukaryolic translation initiation factor 3author statement complex; traceable author statement 42 5q32Consensussequence 43 Consensussequence 44 Consensussequence 4519p13.3 Exemplarsequence 46 Consensussequence 47 5q31.3Exemplarsequence 48 13q31.2-q32.3 Exemplarsequence GO: 7165; signaltransduction; traceable author statement GO: 6468; protein aminoacid phosphorylation; inferred from electronic annotation 499q33-q34 Exemplarsequence GO: 7388; posterior compartmentspecification; predicted/computed GO: 7387; anterior compartmentspecification; predicted/computed GO: 7048; oncogenesis;predicted/computed 50 21q21.3 Exemplarsequence GO: 7165; signaltransduction; traceable author GO: 16020; A4_EXTRA; membrane;1.8e-130; extended: Unkonwn statement GO: 6897; endocytosis;inferred from GO: 5783; endoplasmic reticulum; traceable authorstatement electronic annotation GO: 6878; copper ion GO: 5576;extracellular; traceable author statement homeostasis; traceableauthor statement GO: 8219; cell GO: 5887; integral to plasmamembrane; traceable author death; traceable author statementstatement GO: 5905; coated pit; inferred from electronic GO: 6915;apoptosis; traceable author statement annotation GO: 5794; Golgaiapparatus; traceable author GO: 7155; cell adhesion; inferred fromelectronic statement annotation # Go_Molecular_Function TranscriptID Sequence Derived From Sequence ID Sequence SourceUnigene_Accession 1 Hs.8715.0 BC004894.1 g13436154 GenBank Hs.87152 Hs.63510.1 AA181172 Hs.63510.1.A1 GenBank Hs.446502 3 Hs.108548.0BC001716.1 g12804590 GenBank Hs.396644 4 Hs.272344.0 AL121871Hs.272344.0 GenBank 5 GO: 16787; hydrolase activity; inferred fromelectronic annotation GO: 5080; protein kinase C Hs.256697.2 N32864Hs.256697.2.A1 GenBank Hs.256697 binding; traceable authorstatement GO: 8270; zinc ion binding; not recorded 6 GO: 16787;hydrolase activity; inferred from electronic annotation GO: 5080;protein kinase C Hs.256697.1 U27143.1 g862932 GenBank Hs.256697binding; traceable author statement GO: 8270; zinc ion binding; notrecorded 7 GO: 16787; hydrolase activity; inferred from electronicannotation GO: 5080; protein kinase C Hs.256697.2 N32864Hs.256697.2.A1 GenBank Hs.256697 binding; traceable authorstatement GO: 8270; zinc ion binding; not recorded 8 Hs.297875.0NM_022464.1 g11968008 RefSeq Hs.297875 9 Hs.42636.0 NM_021994.1g11496268 RefSeq Hs.42636 10 GO: 3735; structural constituent ofribosome; inferred from electronic annotation Hs.8170.0 NM_014886.1g7662676 RefSeq Hs.8170 11 GO: 9482; ba3-type cytochrome c oxidase;inferred from electronic annotation GO: 9481; aa3- Hs.3462.1AA382702 Hs.3462.1 GenBank Hs.430075 type cytochrome c oxidase;inferred from electronic annotation GO: 9483; caa3-type cytochromec oxidase; inferred from electronic annotation GO: 4129; cytochromec oxidase activity; inferred from electronic annotation GO: 16491;oxidoreductase activity; inferred from electronic annotation GO:9485; cbb3-type cytochrome c oxidase; inferred from electronicannotation 12 Hs.269918.0 BF590528 Hs.269918.0.A1 GenBank Hs.18309613 GO: 16149; translation release factor activity, codon specific;inferred from electronic Hs.77324.0 NM_004730.1 g4759033 RefSeqHs.77324 annotation GO: 3723; RNA binding; traceable authorstatement 14 Hs.29444.0 AF313413.1 g12484085 GenBank Hs.29444 15Hs.269918.1 AI125255 Hs.269918.1.A1 GenBank Hs.183096 16 GO: 3700;transcription factor activity; non-traceable author statementHs.98428.0 NM_018952.1 g9506792 RefSeq Hs.98428 17 Hs.63510.0NM_014773.1 g7661939 RefSeq Hs.63510 18 GO: 3817; complement factorD activity; traceable author statement GO: 16787; hydrolaseHs.155597.0 NM_001928.1 g4503308 RefSeq Hs.155597 activity;inferred from electronic annotation GO: 4295; trypsin activity;inferred from electronic annotation GO: 4263; chymotrypsinactivity; inferred from electronic annotation 19 GO: 16874; ligaseactivity; inferred from electronic annotation GO: 4842;ubiquitin-protein Hs.108332.0 NM_003339.1 g4507774 RefSeq Hs.108332ligase activity; traceable author statement GO: 4840; ubiquitinconjugating enzyme activity, traceable author statement 20 GO:4197; cysteine-type endopeptidase activity; traceable authorstatement Hs.35086.0 NM_003368.1 g4507850 RefSeq Hs.35086 GO:16787; hydrolase activity; inferred from electronic annotation GO:4221; ubiquthin C- terminal hydrolase activity; inferred fromelectronic annotation GO: 4843; ubiquitin-specific proteaseactivity; traceable author statement 21 GO: 4364; glutathionetransferase activity; inferred from electronic annotationHs.279952.0 NM_015917.1 g7705703 RefSeq Hs.279952 GO: 16740;transferase activity; inferred from electronic annotation GO:15035; protein disulfide oxidoreductase activity; inferred fromelectronic annotation 22 GO: 16787; hydrolase activity; inferredfrom electronic annotation GO: 5080; protein kinase C Hs.256697.0NM_005340.1 g4885412 RefSeq Hs.256697 binding; traceable authorstatement GO: 8270; zinc ion binding; not recorded 23 Hs.262036.0AL577866 Hs.262036.0.S1 GenBenk Hs.262036 24 Hs.81848.0 NM_006265.1g5453993 RefSeq Hs.81848 25 Hs.63510.0 AI539425 Hs.63510.0.A1GenBank Hs.63510 26 Hs.13572.0 NM_001745.1 g4502558 RefSeq Hs.1357227 GO: 3735; structural protein of ribosome; predicted/computed GO:3723; RNA Hs.244621.0 AF116710.1 g7959918 GenBank Hs.431584binding; predicted/computed 28 Hs.59584.0 AU144258 Hs.59584.0.S1GenBank Hs.59584 29 Hs.284158.3 BG330520 Hs.284158.3 GenBankHs.356766 30 GO: 5125; cytokine activity; not recorded Hs.8024.0AF182645.1 g5901877 GenBank Hs.8024 31 GO: 3723; RNA binding;traceable author statement GO: 3735; structural constituent ofHs.74267.0 AF279903.1 g12006349 GenBank Hs.74267 ribosome;traceable author statement 32 Hs.8127.0 NM_014847.1 g7661941 RefSeqHs.8127 33 GO: 4179; membrane alanyl aminopeptidase activity;inferred from electronic annotation Hs.122752.0 AK001618.1Hs.122752.0 GenBank Hs.122752 34 Hs.154574.0 AI952836Hs.154574.0_RC GenBank Hs.154574 35 GO: 5125; cytokine activity;not recorded Hs.8024.0 AF182645.1 g5901877 GenBank Hs.8024 36Hs.26330.0 AW070437 Hs.26330.0.A1 GenBank Hs.391318 37 GO: 8026;ATP dependent helicase activity; inferred from electronicannotation Hs.106469.0 NM_003171.1 Hs.106469.0 GenBank Hs.106469GO: 3723; RNA binding; traceable author statement GO: 16787;hydrolase activity; interred from electronic annotation GO: 3676;helicase_C; nucleic acid binding activity; 7.9e-17; extended:inferred from electronic annotation GO: 5524; ATP binding; inferredfrom electronic annotation 38 GO: 3743; translation initiationfactor activity; inferred from electronic annotation Hs.30376.1BE252813 Hs.30376.1.A1 GenBank Hs.211539 GO: 3746; translationelongation factor activity; inferred from electronic annotation GO:3924; GTPase activity; traceable author statement 39 GO: 3697;single-stranded DNA binding; experimental evidence Hs.178658.0AL527365 Hs.178658.0.S1 GenBank Hs.404283 40 Hs.156044.0 AW510657Hs.156044.0 GenBank Hs.156044 41 GO: 3743; translation initiationfactor activity; traceable author statement Hs.7811.0 NM_003754.1g4503518 RefSeq Hs.7811 42 GO: 3676; nucleic acid binding; inferredfrom electronic annotation Hs.61441.0 AB037732.1 Hs.61441.0.S1GenBank Hs.61441 43 Hs.284158.1 AV756131 Hs.284158.1_RC GenBankHs.356766 44 Hs.284158.4 BF185165 Hs.284158.4 GenBank Hs.356766 45Hs.111099.0 BC004393.1 g13325151 GenBank Hs.111099 46 Hs.301226.2R39094 Hs.301226.2.A1 GenBank Hs.301226 47 Hs.108548.0 AF151052.1g7106825 GenBank Hs.396644 48 GO: 4672; pkinase; protein kinaseactivity; 5.8e-91; extended: inferred from electronic Hs.168913.1AF083420.1 g5326765 GenBank Hs.168913 annotation GO: 4691;cAMP-dependent protein kinase activity; inferred from electronicannotation GO: 4713; protein tyrosine kinase activity; inferredfrom electronic annotation GO: 16740; transferase activity;inferred from electronic annotation GO: 5524; ATP binding; inferredfrom electronic annotation GO: 4682; protein kinase CK2 activity;inferred from electronic annotation GO: 4674; proteinserine/threonine kinase activity; inferred from electronicannotation 49 GO: 3677; DNA binding; not recorded GO: 3700; PBX;transcription factor activity; 8.9e-147; Hs.294101.0 NM_006195.1g5453851 RefSeq Hs.294101 extended: inferred from electronicannotation 50 GO: 4867; serine protease inhibitor activity;traceable author statement GO: 5515; protein Hs.177486.0NM_000484.1 g4502166 RefSeq Hs.177486 binding; inferred fromphysical interaction GO: 8201; heparin binding; inferred fromelectronic annotation GO: 5194; cell adhesion molecule activity;inferred from electronic annotation # Cluster_Type LocusLinkFull_Length_Reference_Seq 1 fulllength 84273 NM_032313;hypothetical protein MGC3232 2 est 3 fulllength 51247 NM_016480;polyadenylate-binding protein- interacting protein 2 4 5 fulllength3094 NM_005340; histidine triad nucleotide binding protein 1 6fulllength 3094 NM_005340; histidine triad nucleotide bindingprotein 1 7 fulllength 3094 NM_005340; histidine triad nucleotidebinding protein 1 8 fulllength 64374 NM_022464; endoplasmicreticulum chaperone SIL1, homolog of yeast 9 fulllength 11179NM_021994; zinc finger protein (C2H2 type) 277 10 fulllength 10412NM_014886; TGF beta-inducible nuclear protein 1 11 fulllength 1350NM_001867; cytochrome c oxidase subunit VIIc precursor 12fulllength 13 fulllength 2107 NM_004730; eukaryotic translationtermination factor 1 14 fulllength 85027 NM_032947; putative smallmembrane protein NID67 15 fulllength 16 fulllength 3216 NM_018952;homeo box B6 isoform 1 NM_156036; homeo box B6 isoform 2 NM_156037;homeo box B6 isoform 1 17 fulllength 9812 NM_014773; KIAA0141 geneproduct 18 fulllength 1675 NM_001928; adipsin/complement factor Dprecursor 19 fulllength 7322 NM_003339; ubiquitin-conjugatingenzyme E2D 2 (UBC4/5 homolog, yeast) 20 fulllength 7398 NM_003368;ubiquitin specific protease 1 21 fulllength 51064 NM_015917;glutathione S-transferase subunit 13 homolog 22 fulllength 3094NM_005340; histidine triad nucleotide binding protein 1 23 24fulllength 5885 NM_006265; RAD21 homolog 25 fulllength 9812NM_014773; KIAA0141 gene product 26 fulllength 819 NM_001745;calcium modulating ligand 27 fulllength 6208 NM_005617; ribosomalprotein S14 28 fulllength 64789 NM_022774; hypothetical proteinFLJ21144 29 30 fulllength 3550 NM_004511; NM_006083; RED protein 31fulllength 6138 NM_002948; ribosomal protein L15 32 fulllength 9898NM_014847; NICE-4 protein 33 fulllength 6873 NM_003184;TBP-associated factor 2 34 est 35 fulllength 3550 NM_004511;NM_006083; RED protein 36 285603 NM_175920; hypothetical proteinFLJ39485 37 fulllength 6832 NM_003171; suppressor of var1, 3-like 138 fulllength 1968 NM_001415; eukaryotic translation initiationfactor 2, subunit 3 gamma, 52 kDa 39 fulllength 5887 NM_002874; UVexcision repair protein RAD23 homolog B 40 est 41 fulllength 8665NM_003754; eukaryotic translation initiation factor 3, subunit 5epsilon, 47 kDa 42 54439 43 44 45 fulllength 84266 NM_032306;hypothetical protein

MGC10974 46 fulllength NM_003732; eukaryotic translation initiationfactor 4E binding protein 3 47 fulllength 51247 NM_016480;polyadenylale-binding protein- interacting protein 2 48 fulllength8428 NM_003576; serine/threonine kinase 24 (STE20 homolog, yeast)49 fulllength 5090 NM_006195; pre-B-cell leukemia transcriptionfactor 3 50 fulllength 351 NM_000484; amyloid beta (A4) precursorprotein (protease nexin-II, Alzheimer disease)

* * * * *

References

• csie.ntu.edu.tw/-cj.1in/libsvrn
• affymetrix.com